ID   TSP1_HUMAN              Reviewed;        1170 AA.
AC   P07996; A8K6H4; B4E3J7; B9EGH6; Q15667; Q59E99;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   31-OCT-2006, sequence version 2.
DT   20-JAN-2016, entry version 202.
DE   RecName: Full=Thrombospondin-1;
DE   Flags: Precursor;
GN   Name=THBS1; Synonyms=TSP, TSP1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Endothelial cell;
RX   PubMed=2430973; DOI=10.1083/jcb.103.5.1635;
RA   Lawler J., Hynes R.O.;
RT   "The structure of human thrombospondin, an adhesive glycoprotein with
RT   multiple calcium-binding sites and homologies with several different
RT   proteins.";
RL   J. Cell Biol. 103:1635-1648(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ALA-523.
RX   PubMed=2918029; DOI=10.1083/jcb.108.2.729;
RA   Hennessy S.W., Frazier B.A., Kim D.D., Deckwerth T.L.,
RA   Baumgartel D.M., Rotwein P., Frazier W.A.;
RT   "Complete thrombospondin mRNA sequence includes potential regulatory
RT   sites in the 3' untranslated region.";
RL   J. Cell Biol. 108:729-736(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   ALA-523.
RC   TISSUE=Placenta, and Uterus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   SER-700.
RC   TISSUE=Aortic endothelium;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RT   "Homo sapiens protein coding cDNA.";
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16572171; DOI=10.1038/nature04601;
RA   Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K.,
RA   Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N.,
RA   Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S.,
RA   Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K.,
RA   DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R.,
RA   Fahey J., Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G.,
RA   Johnson E., Jones C., Kamat A., Kaur A., Locke D.P., Madan A.,
RA   Munson G., Jaffe D.B., Lui A., Macdonald P., Mauceli E., Naylor J.W.,
RA   Nesbitt R., Nicol R., O'Leary S.B., Ratcliffe A., Rounsley S., She X.,
RA   Sneddon K.M.B., Stewart S., Sougnez C., Stone S.M., Topham K.,
RA   Vincent D., Wang S., Zimmer A.R., Birren B.W., Hood L., Lander E.S.,
RA   Nusbaum C.;
RT   "Analysis of the DNA sequence and duplication history of human
RT   chromosome 15.";
RL   Nature 440:671-675(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-397 (ISOFORM 1).
RX   PubMed=3030396; DOI=10.1021/bi00374a014;
RA   Kobayashi S., Eden-Mccutchan F., Framson P., Bornstein P.;
RT   "Partial amino acid sequence of human thrombospondin as determined by
RT   analysis of cDNA clones: homology to malarial circumsporozoite
RT   proteins.";
RL   Biochemistry 25:8418-8425(1986).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-374 (ISOFORM 1).
RX   PubMed=3461443; DOI=10.1073/pnas.83.15.5449;
RA   Dixit V.M., Hennessy S.W., Grant G.A., Rotwein P., Frazier W.A.;
RT   "Characterization of a cDNA encoding the heparin and collagen binding
RT   domains of human thrombospondin.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:5449-5453(1986).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-166.
RX   PubMed=2544587;
RA   Laherty C.D., Gierman T.M., Dixit V.M.;
RT   "Characterization of the promoter region of the human thrombospondin
RT   gene. DNA sequences within the first intron increase transcription.";
RL   J. Biol. Chem. 264:11222-11227(1989).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1028-1170 (ISOFORM 1).
RA   la Fleur M., Jobin C., Gauthier J., Kreis C.G.;
RT   "Expression of thrombospondin in chronic inflammation: neutrophils
RT   from synovial fluids synthesize a novel 3.9 kb TSP mRNA.";
RL   Submitted (DEC-1992) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   INTERACTION WITH CD36.
RX   PubMed=1371676; DOI=10.1016/0006-291X(92)91860-S;
RA   Asch A.S., Silbiger S., Heimer E., Nachman R.L.;
RT   "Thrombospondin sequence motif (CSVTCG) is responsible for CD36
RT   binding.";
RL   Biochem. Biophys. Res. Commun. 182:1208-1217(1992).
RN   [12]
RP   GLYCOSYLATION AT TRP-385; SER-394; TRP-438; TRP-441; THR-450; TRP-498
RP   AND THR-507.
RC   TISSUE=Platelet;
RX   PubMed=11067851; DOI=10.1074/jbc.M008073200;
RA   Hofsteenge J., Huwiler K.G., Macek B., Hess D., Lawler J.,
RA   Mosher D.F., Peter-Katalinic J.;
RT   "C-mannosylation and O-fucosylation of the thrombospondin type 1
RT   module.";
RL   J. Biol. Chem. 276:6485-6498(2001).
RN   [13]
RP   INTERACTION WITH HRG, AND FUNCTION.
RX   PubMed=11134179; DOI=10.1172/JCI9061;
RA   Simantov R., Febbraio M., Crombie R., Asch A.S., Nachman R.L.,
RA   Silverstein R.L.;
RT   "Histidine-rich glycoprotein inhibits the antiangiogenic effect of
RT   thrombospondin-1.";
RL   J. Clin. Invest. 107:45-52(2001).
RN   [14]
RP   DISULFIDE BONDS IN THROMBOSPONDIN DOMAIN.
RX   PubMed=12450399; DOI=10.1021/bi026463u;
RA   Huwiler K.G., Vestling M.M., Annis D.S., Mosher D.F.;
RT   "Biophysical characterization, including disulfide bond assignments,
RT   of the anti-angiogenic type 1 domains of human thrombospondin-1.";
RL   Biochemistry 41:14329-14339(2002).
RN   [15]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-248 AND ASN-1067.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [16]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-1067.
RC   TISSUE=Saliva;
RX   PubMed=16740002; DOI=10.1021/pr050492k;
RA   Ramachandran P., Boontheung P., Xie Y., Sondej M., Wong D.T.,
RA   Loo J.A.;
RT   "Identification of N-linked glycoproteins in human saliva by
RT   glycoprotein capture and mass spectrometry.";
RL   J. Proteome Res. 5:1493-1503(2006).
RN   [17]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-248.
RC   TISSUE=Platelet;
RX   PubMed=16263699; DOI=10.1074/mcp.M500324-MCP200;
RA   Lewandrowski U., Moebius J., Walter U., Sickmann A.;
RT   "Elucidation of N-glycosylation sites on human platelet proteins: a
RT   glycoproteomic approach.";
RL   Mol. Cell. Proteomics 5:226-233(2006).
RN   [18]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-1067.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 434-546, DISULFIDE BONDS, AND
RP   GLYCOSYLATION AT THR-450 AND THR-507.
RX   PubMed=12391027; DOI=10.1083/jcb.200206062;
RA   Tan K., Duquette M., Liu J.-H., Dong Y., Zhang R., Joachimiak A.,
RA   Lawler J., Wang J.-H.;
RT   "Crystal structure of the TSP-1 type 1 repeats: a novel layered fold
RT   and its biological implication.";
RL   J. Cell Biol. 159:373-382(2002).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 834-1170 IN COMPLEX WITH
RP   CALCIUM IONS, DISULFIDE BONDS, MUTAGENESIS OF ASN-1067, GLYCOSYLATION
RP   AT ASN-1067, CELL ATTACHMENT SITE, AND FUNCTION.
RX   PubMed=15014436; DOI=10.1038/sj.emboj.7600166;
RA   Kvansakul M., Adams J.C., Hohenester E.;
RT   "Structure of a thrombospondin C-terminal fragment reveals a novel
RT   calcium core in the type 3 repeats.";
RL   EMBO J. 23:1223-1233(2004).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (1.45 ANGSTROMS) OF 19-233 IN COMPLEX WITH
RP   SYNTHETIC PENTAMERIC HEPARIN, AND DISULFIDE BOND.
RX   PubMed=16407063; DOI=10.1016/j.str.2005.09.017;
RA   Tan K., Duquette M., Liu J.-H., Zhang R., Joachimiak A., Wang J.-H.,
RA   Lawler J.;
RT   "The structures of the thrombospondin-1 N-terminal domain and its
RT   complex with a synthetic pentameric heparin.";
RL   Structure 14:33-42(2006).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 19-257 IN COMPLEXES WITH
RP   HEPARIN, IDENTIFICATION BY MASS SPECTROMETRY, AND GLYCOSYLATION AT
RP   ASN-248.
RX   PubMed=18065761; DOI=10.1074/jbc.M705203200;
RA   Tan K., Duquette M., Liu J.-H., Shanmugasundaram K., Joachimiak A.,
RA   Gallagher J.T., Rigby A.C., Wang J.-H., Lawler J.;
RT   "Heparin-induced cis- and trans-dimerization modes of the
RT   thrombospondin-1 N-terminal domain.";
RL   J. Biol. Chem. 283:3932-3941(2008).
CC   -!- FUNCTION: Adhesive glycoprotein that mediates cell-to-cell and
CC       cell-to-matrix interactions. Binds heparin. May play a role in
CC       dentinogenesis and/or maintenance of dentin and dental pulp (By
CC       similarity). Ligand for CD36 mediating antiangiogenic properties.
CC       Plays a role in ER stress response, via its interaction with the
CC       activating transcription factor 6 alpha (ATF6) which produces
CC       adaptive ER stress response factors (By similarity). {ECO:0000250,
CC       ECO:0000269|PubMed:11134179, ECO:0000269|PubMed:15014436}.
CC   -!- SUBUNIT: Homotrimer; disulfide-linked. Interacts (via the TSP type
CC       I repeats) with HRG; the interaction blocks the antiangiogenic
CC       effect of THBS1 with CD36 (By similarity). Can bind to fibrinogen,
CC       fibronectin, laminin, type V collagen and integrins alpha-V/beta-
CC       1, alpha-V/beta-3 and alpha-IIb/beta-3. Interacts (via the TSP
CC       type I repeats) with CD36; the interaction conveys an
CC       antiangiogenic effect. Interacts with ATF6 (via lumenal domain)
CC       (By similarity). {ECO:0000250}.
CC   -!- INTERACTION:
CC       Q15113:PCOLCE; NbExp=3; IntAct=EBI-2530274, EBI-8869614;
CC       P01137:TGFB1; NbExp=2; IntAct=EBI-2530274, EBI-779636;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum {ECO:0000250}.
CC       Sarcoplasmic reticulum {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P07996-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P07996-2; Sequence=VSP_055757;
CC         Note=No experimental confirmation available.;
CC   -!- SIMILARITY: Belongs to the thrombospondin family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 2 EGF-like domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00076}.
CC   -!- SIMILARITY: Contains 1 laminin G-like domain. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 TSP C-terminal (TSPC) domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00635}.
CC   -!- SIMILARITY: Contains 3 TSP type-1 domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00210}.
CC   -!- SIMILARITY: Contains 8 TSP type-3 repeats. {ECO:0000255|PROSITE-
CC       ProRule:PRU00634}.
CC   -!- SIMILARITY: Contains 1 VWFC domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00220}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAD93149.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/THBS1ID42548ch15q15.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X04665; CAA28370.1; -; mRNA.
DR   EMBL; X14787; CAA32889.1; -; mRNA.
DR   EMBL; AK291639; BAF84328.1; -; mRNA.
DR   EMBL; AK304754; BAG65509.1; -; mRNA.
DR   EMBL; AB209912; BAD93149.1; ALT_INIT; mRNA.
DR   EMBL; AC037198; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC136469; AAI36470.1; -; mRNA.
DR   EMBL; BC136470; AAI36471.1; -; mRNA.
DR   EMBL; M25631; AAA36741.1; -; mRNA.
DR   EMBL; M14326; AAA61237.1; ALT_SEQ; mRNA.
DR   EMBL; J04835; AAA61178.1; -; Genomic_DNA.
DR   EMBL; M99425; AAB59366.1; -; mRNA.
DR   CCDS; CCDS32194.1; -. [P07996-1]
DR   PIR; A26155; TSHUP1.
DR   RefSeq; NP_003237.2; NM_003246.3. [P07996-1]
DR   RefSeq; XP_011520272.1; XM_011521970.1. [P07996-1]
DR   UniGene; Hs.164226; -.
DR   UniGene; Hs.732539; -.
DR   PDB; 1LSL; X-ray; 1.90 A; A=434-546.
DR   PDB; 1UX6; X-ray; 1.90 A; A=834-1170.
DR   PDB; 1Z78; X-ray; 1.80 A; A=19-233.
DR   PDB; 1ZA4; X-ray; 1.90 A; A=19-233.
DR   PDB; 2ERF; X-ray; 1.45 A; A=25-233.
DR   PDB; 2ES3; X-ray; 1.85 A; A/B=25-233.
DR   PDB; 2OUH; X-ray; 2.40 A; A/B=19-257.
DR   PDB; 2OUJ; X-ray; 1.90 A; A=19-257.
DR   PDB; 3R6B; X-ray; 2.40 A; A=434-547.
DR   PDBsum; 1LSL; -.
DR   PDBsum; 1UX6; -.
DR   PDBsum; 1Z78; -.
DR   PDBsum; 1ZA4; -.
DR   PDBsum; 2ERF; -.
DR   PDBsum; 2ES3; -.
DR   PDBsum; 2OUH; -.
DR   PDBsum; 2OUJ; -.
DR   PDBsum; 3R6B; -.
DR   ProteinModelPortal; P07996; -.
DR   SMR; P07996; 25-233, 434-547, 549-1170.
DR   BioGrid; 112915; 34.
DR   DIP; DIP-1037N; -.
DR   IntAct; P07996; 12.
DR   MINT; MINT-6630675; -.
DR   STRING; 9606.ENSP00000260356; -.
DR   iPTMnet; P07996; -.
DR   PhosphoSite; P07996; -.
DR   UniCarbKB; P07996; -.
DR   BioMuta; THBS1; -.
DR   DMDM; 117949802; -.
DR   OGP; P07996; -.
DR   MaxQB; P07996; -.
DR   PaxDb; P07996; -.
DR   PeptideAtlas; P07996; -.
DR   PRIDE; P07996; -.
DR   Ensembl; ENST00000260356; ENSP00000260356; ENSG00000137801. [P07996-1]
DR   GeneID; 7057; -.
DR   KEGG; hsa:7057; -.
DR   UCSC; uc001zkh.3; human. [P07996-1]
DR   CTD; 7057; -.
DR   GeneCards; THBS1; -.
DR   H-InvDB; HIX0038125; -.
DR   HGNC; HGNC:11785; THBS1.
DR   HPA; CAB033678; -.
DR   MIM; 188060; gene.
DR   neXtProt; NX_P07996; -.
DR   PharmGKB; PA36497; -.
DR   eggNOG; ENOG410IFQQ; Eukaryota.
DR   eggNOG; ENOG410XQKE; LUCA.
DR   GeneTree; ENSGT00820000126982; -.
DR   HOGENOM; HOG000007542; -.
DR   HOVERGEN; HBG018006; -.
DR   InParanoid; P07996; -.
DR   KO; K16857; -.
DR   OMA; SPWDICS; -.
DR   OrthoDB; EOG76QFGD; -.
DR   PhylomeDB; P07996; -.
DR   TreeFam; TF324917; -.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   Reactome; R-HSA-186797; Signaling by PDGF.
DR   Reactome; R-HSA-216083; Integrin cell surface interactions.
DR   Reactome; R-HSA-3000170; Syndecan interactions.
DR   Reactome; R-HSA-5173214; O-glycosylation of TSR domain-containing proteins.
DR   ChiTaRS; THBS1; human.
DR   EvolutionaryTrace; P07996; -.
DR   GeneWiki; Thrombospondin_1; -.
DR   GenomeRNAi; 7057; -.
DR   NextBio; 27597; -.
DR   PMAP-CutDB; P07996; -.
DR   PRO; PR:P07996; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   Bgee; P07996; -.
DR   CleanEx; HS_THBS1; -.
DR   ExpressionAtlas; P07996; baseline and differential.
DR   Genevisible; P07996; HS.
DR   GO; GO:0009986; C:cell surface; IDA:BHF-UCL.
DR   GO; GO:0005783; C:endoplasmic reticulum; ISS:UniProtKB.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0031012; C:extracellular matrix; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005577; C:fibrinogen complex; IDA:BHF-UCL.
DR   GO; GO:0031091; C:platelet alpha granule; IDA:BHF-UCL.
DR   GO; GO:0031093; C:platelet alpha granule lumen; TAS:Reactome.
DR   GO; GO:0016529; C:sarcoplasmic reticulum; ISS:UniProtKB.
DR   GO; GO:0030141; C:secretory granule; IDA:BHF-UCL.
DR   GO; GO:0005509; F:calcium ion binding; NAS:BHF-UCL.
DR   GO; GO:0070052; F:collagen V binding; IDA:BHF-UCL.
DR   GO; GO:0070051; F:fibrinogen binding; IDA:BHF-UCL.
DR   GO; GO:0017134; F:fibroblast growth factor binding; IDA:BHF-UCL.
DR   GO; GO:0001968; F:fibronectin binding; IDA:BHF-UCL.
DR   GO; GO:0001948; F:glycoprotein binding; NAS:BHF-UCL.
DR   GO; GO:0008201; F:heparin binding; IDA:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; NAS:BHF-UCL.
DR   GO; GO:0005178; F:integrin binding; IMP:BHF-UCL.
DR   GO; GO:0043236; F:laminin binding; IDA:BHF-UCL.
DR   GO; GO:0030169; F:low-density lipoprotein particle binding; IDA:BHF-UCL.
DR   GO; GO:0001786; F:phosphatidylserine binding; IDA:UniProtKB.
DR   GO; GO:0043394; F:proteoglycan binding; TAS:BHF-UCL.
DR   GO; GO:0050431; F:transforming growth factor beta binding; ISS:BHF-UCL.
DR   GO; GO:0000187; P:activation of MAPK activity; IMP:BHF-UCL.
DR   GO; GO:0048266; P:behavioral response to pain; ISS:UniProtKB.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0007155; P:cell adhesion; NAS:BHF-UCL.
DR   GO; GO:0007050; P:cell cycle arrest; IDA:BHF-UCL.
DR   GO; GO:0016477; P:cell migration; IDA:BHF-UCL.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0034605; P:cellular response to heat; NAS:BHF-UCL.
DR   GO; GO:0071732; P:cellular response to nitric oxide; IEA:Ensembl.
DR   GO; GO:0002544; P:chronic inflammatory response; IEP:BHF-UCL.
DR   GO; GO:0003197; P:endocardial cushion development; IEA:Ensembl.
DR   GO; GO:0043652; P:engulfment of apoptotic cell; IDA:BHF-UCL.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0003417; P:growth plate cartilage development; IEA:Ensembl.
DR   GO; GO:0006955; P:immune response; IEP:BHF-UCL.
DR   GO; GO:0006954; P:inflammatory response; IDA:CACAO.
DR   GO; GO:0016525; P:negative regulation of angiogenesis; IDA:UniProtKB.
DR   GO; GO:0002581; P:negative regulation of antigen processing and presentation of peptide or polysaccharide antigen via MHC class II; IDA:BHF-UCL.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0043537; P:negative regulation of blood vessel endothelial cell migration; IDA:BHF-UCL.
DR   GO; GO:0001953; P:negative regulation of cell-matrix adhesion; IDA:BHF-UCL.
DR   GO; GO:0010754; P:negative regulation of cGMP-mediated signaling; IDA:BHF-UCL.
DR   GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; IDA:UniProtKB.
DR   GO; GO:0002605; P:negative regulation of dendritic cell antigen processing and presentation; IDA:BHF-UCL.
DR   GO; GO:2001027; P:negative regulation of endothelial cell chemotaxis; IDA:MGI.
DR   GO; GO:0010596; P:negative regulation of endothelial cell migration; IDA:BHF-UCL.
DR   GO; GO:0001937; P:negative regulation of endothelial cell proliferation; IDA:BHF-UCL.
DR   GO; GO:2001237; P:negative regulation of extrinsic apoptotic signaling pathway; TAS:BHF-UCL.
DR   GO; GO:0051918; P:negative regulation of fibrinolysis; IDA:BHF-UCL.
DR   GO; GO:0040037; P:negative regulation of fibroblast growth factor receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0051895; P:negative regulation of focal adhesion assembly; TAS:BHF-UCL.
DR   GO; GO:0032695; P:negative regulation of interleukin-12 production; IDA:BHF-UCL.
DR   GO; GO:0010751; P:negative regulation of nitric oxide mediated signal transduction; IDA:BHF-UCL.
DR   GO; GO:0010748; P:negative regulation of plasma membrane long-chain fatty acid transport; IDA:BHF-UCL.
DR   GO; GO:0010757; P:negative regulation of plasminogen activation; IDA:BHF-UCL.
DR   GO; GO:0003151; P:outflow tract morphogenesis; IEA:Ensembl.
DR   GO; GO:0018149; P:peptide cross-linking; IDA:BHF-UCL.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0002576; P:platelet degranulation; TAS:Reactome.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IMP:BHF-UCL.
DR   GO; GO:0030194; P:positive regulation of blood coagulation; IDA:BHF-UCL.
DR   GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; IDA:BHF-UCL.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:BHF-UCL.
DR   GO; GO:0010811; P:positive regulation of cell-substrate adhesion; IEA:Ensembl.
DR   GO; GO:0050921; P:positive regulation of chemotaxis; IDA:BHF-UCL.
DR   GO; GO:2000353; P:positive regulation of endothelial cell apoptotic process; IDA:UniProtKB.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; IDA:BHF-UCL.
DR   GO; GO:1902043; P:positive regulation of extrinsic apoptotic signaling pathway via death domain receptors; IDA:BHF-UCL.
DR   GO; GO:0010763; P:positive regulation of fibroblast migration; IDA:BHF-UCL.
DR   GO; GO:0043032; P:positive regulation of macrophage activation; IDA:BHF-UCL.
DR   GO; GO:0010759; P:positive regulation of macrophage chemotaxis; ISS:BHF-UCL.
DR   GO; GO:0042327; P:positive regulation of phosphorylation; IMP:BHF-UCL.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IDA:UniProtKB.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IDA:BHF-UCL.
DR   GO; GO:0030511; P:positive regulation of transforming growth factor beta receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0032914; P:positive regulation of transforming growth factor beta1 production; ISS:BHF-UCL.
DR   GO; GO:0045727; P:positive regulation of translation; IDA:BHF-UCL.
DR   GO; GO:0042535; P:positive regulation of tumor necrosis factor biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0043687; P:post-translational protein modification; TAS:Reactome.
DR   GO; GO:0036066; P:protein O-linked fucosylation; TAS:Reactome.
DR   GO; GO:0006493; P:protein O-linked glycosylation; TAS:Reactome.
DR   GO; GO:0030823; P:regulation of cGMP metabolic process; IDA:MGI.
DR   GO; GO:0051592; P:response to calcium ion; IDA:BHF-UCL.
DR   GO; GO:0042493; P:response to drug; IEP:UniProtKB.
DR   GO; GO:0034976; P:response to endoplasmic reticulum stress; ISS:UniProtKB.
DR   GO; GO:0009749; P:response to glucose; IDA:BHF-UCL.
DR   GO; GO:0001666; P:response to hypoxia; NAS:BHF-UCL.
DR   GO; GO:0032026; P:response to magnesium ion; IDA:BHF-UCL.
DR   GO; GO:0032570; P:response to progesterone; TAS:BHF-UCL.
DR   GO; GO:0006986; P:response to unfolded protein; IEA:UniProtKB-KW.
DR   GO; GO:0002040; P:sprouting angiogenesis; IMP:BHF-UCL.
DR   Gene3D; 2.60.120.200; -; 3.
DR   Gene3D; 4.10.1080.10; -; 2.
DR   InterPro; IPR013320; ConA-like_dom.
DR   InterPro; IPR013032; EGF-like_CS.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR001791; Laminin_G.
DR   InterPro; IPR028499; Thrombospondin-1.
DR   InterPro; IPR003367; Thrombospondin_3-like_rpt.
DR   InterPro; IPR017897; Thrombospondin_3_rpt.
DR   InterPro; IPR008859; Thrombospondin_C.
DR   InterPro; IPR000884; TSP1_rpt.
DR   InterPro; IPR028974; TSP_type-3_rpt.
DR   InterPro; IPR001007; VWF_dom.
DR   PANTHER; PTHR10199:SF78; PTHR10199:SF78; 1.
DR   Pfam; PF00090; TSP_1; 3.
DR   Pfam; PF02412; TSP_3; 7.
DR   Pfam; PF05735; TSP_C; 1.
DR   Pfam; PF00093; VWC; 1.
DR   SMART; SM00181; EGF; 3.
DR   SMART; SM00209; TSP1; 3.
DR   SMART; SM00210; TSPN; 1.
DR   SMART; SM00214; VWC; 1.
DR   SUPFAM; SSF103647; SSF103647; 3.
DR   SUPFAM; SSF49899; SSF49899; 2.
DR   SUPFAM; SSF82895; SSF82895; 3.
DR   PROSITE; PS01186; EGF_2; 1.
DR   PROSITE; PS50026; EGF_3; 2.
DR   PROSITE; PS50092; TSP1; 3.
DR   PROSITE; PS51234; TSP3; 8.
DR   PROSITE; PS51236; TSP_CTER; 1.
DR   PROSITE; PS01208; VWFC_1; 1.
DR   PROSITE; PS50184; VWFC_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Cell adhesion;
KW   Complete proteome; Disulfide bond; EGF-like domain;
KW   Endoplasmic reticulum; Glycoprotein; Heparin-binding; Polymorphism;
KW   Reference proteome; Repeat; Sarcoplasmic reticulum; Signal;
KW   Unfolded protein response.
FT   SIGNAL        1     18
FT   CHAIN        19   1170       Thrombospondin-1.
FT                                /FTId=PRO_0000035842.
FT   DOMAIN       65    270       Laminin G-like.
FT   DOMAIN      316    373       VWFC. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00220}.
FT   DOMAIN      379    429       TSP type-1 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00210}.
FT   DOMAIN      435    490       TSP type-1 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00210}.
FT   DOMAIN      492    547       TSP type-1 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00210}.
FT   DOMAIN      547    587       EGF-like 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      646    690       EGF-like 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   REPEAT      691    726       TSP type-3 1.
FT   REPEAT      727    762       TSP type-3 2.
FT   REPEAT      763    785       TSP type-3 3.
FT   REPEAT      786    821       TSP type-3 4.
FT   REPEAT      822    844       TSP type-3 5.
FT   REPEAT      845    882       TSP type-3 6.
FT   REPEAT      883    918       TSP type-3 7.
FT   REPEAT      919    954       TSP type-3 8.
FT   DOMAIN      958   1170       TSP C-terminal. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00635}.
FT   REGION       47     95       Heparin-binding.
FT   MOTIF       926    928       Cell attachment site. {ECO:0000305}.
FT   CARBOHYD    248    248       N-linked (GlcNAc...).
FT                                {ECO:0000305|PubMed:16263699,
FT                                ECO:0000305|PubMed:16335952,
FT                                ECO:0000305|PubMed:18065761}.
FT   CARBOHYD    360    360       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    385    385       C-linked (Man).
FT                                {ECO:0000269|PubMed:11067851}.
FT                                /FTId=CAR_000205.
FT   CARBOHYD    394    394       O-linked (Fuc...).
FT                                {ECO:0000269|PubMed:11067851}.
FT                                /FTId=CAR_000206.
FT   CARBOHYD    438    438       C-linked (Man).
FT                                {ECO:0000269|PubMed:11067851}.
FT                                /FTId=CAR_000207.
FT   CARBOHYD    441    441       C-linked (Man).
FT                                {ECO:0000269|PubMed:11067851}.
FT                                /FTId=CAR_000208.
FT   CARBOHYD    450    450       O-linked (Fuc...).
FT                                {ECO:0000269|PubMed:11067851,
FT                                ECO:0000269|PubMed:12391027}.
FT                                /FTId=CAR_000209.
FT   CARBOHYD    498    498       C-linked (Man).
FT                                {ECO:0000269|PubMed:11067851}.
FT                                /FTId=CAR_000210.
FT   CARBOHYD    507    507       O-linked (Fuc...).
FT                                {ECO:0000269|PubMed:11067851,
FT                                ECO:0000269|PubMed:12391027}.
FT                                /FTId=CAR_000211.
FT   CARBOHYD    708    708       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1067   1067       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:15014436,
FT                                ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:16740002,
FT                                ECO:0000269|PubMed:19159218}.
FT   DISULFID    171    232       {ECO:0000244|PDB:1Z78,
FT                                ECO:0000244|PDB:2ERF,
FT                                ECO:0000244|PDB:2ES3,
FT                                ECO:0000244|PDB:2OUH,
FT                                ECO:0000244|PDB:2OUJ,
FT                                ECO:0000269|PubMed:16407063,
FT                                ECO:0000269|PubMed:18065761}.
FT   DISULFID    270    270       Interchain. {ECO:0000305}.
FT   DISULFID    274    274       Interchain. {ECO:0000305}.
FT   DISULFID    391    423
FT   DISULFID    395    428
FT   DISULFID    406    413
FT   DISULFID    447    484       {ECO:0000244|PDB:1LSL,
FT                                ECO:0000269|PubMed:12391027}.
FT   DISULFID    451    489       {ECO:0000244|PDB:1LSL,
FT                                ECO:0000269|PubMed:12391027}.
FT   DISULFID    462    474       {ECO:0000244|PDB:1LSL,
FT                                ECO:0000269|PubMed:12391027}.
FT   DISULFID    504    541       {ECO:0000244|PDB:1LSL,
FT                                ECO:0000269|PubMed:12391027}.
FT   DISULFID    508    546       {ECO:0000244|PDB:1LSL,
FT                                ECO:0000269|PubMed:12391027}.
FT   DISULFID    519    531       {ECO:0000244|PDB:1LSL,
FT                                ECO:0000269|PubMed:12391027}.
FT   DISULFID    551    562       {ECO:0000250}.
FT   DISULFID    556    572       {ECO:0000250}.
FT   DISULFID    575    586       {ECO:0000250}.
FT   DISULFID    592    608       {ECO:0000250}.
FT   DISULFID    599    617       {ECO:0000250}.
FT   DISULFID    620    644       {ECO:0000250}.
FT   DISULFID    650    663       {ECO:0000250}.
FT   DISULFID    657    676       {ECO:0000250}.
FT   DISULFID    678    689       {ECO:0000250}.
FT   DISULFID    705    713       {ECO:0000250}.
FT   DISULFID    718    738       {ECO:0000250}.
FT   DISULFID    754    774       {ECO:0000250}.
FT   DISULFID    777    797       {ECO:0000250}.
FT   DISULFID    813    833       {ECO:0000250}.
FT   DISULFID    836    856       {ECO:0000244|PDB:1UX6,
FT                                ECO:0000269|PubMed:15014436}.
FT   DISULFID    874    894       {ECO:0000244|PDB:1UX6,
FT                                ECO:0000269|PubMed:15014436}.
FT   DISULFID    910    930       {ECO:0000244|PDB:1UX6,
FT                                ECO:0000269|PubMed:15014436}.
FT   DISULFID    946   1167       {ECO:0000244|PDB:1UX6,
FT                                ECO:0000269|PubMed:15014436}.
FT   VAR_SEQ      17    101       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_055757.
FT   VARIANT      24     24       S -> A (in dbSNP:rs41515347).
FT                                /FTId=VAR_052657.
FT   VARIANT     523    523       T -> A (in dbSNP:rs2292305).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:2918029}.
FT                                /FTId=VAR_028938.
FT   VARIANT     700    700       N -> S (in dbSNP:rs2228262).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_028939.
FT   MUTAGEN    1067   1067       N->K: Loss of N-glycosylation site.
FT                                {ECO:0000269|PubMed:15014436}.
FT   CONFLICT      4      4       A -> S (in Ref. 3; BAG65509).
FT                                {ECO:0000305}.
FT   CONFLICT     84     84       A -> T (in Ref. 1; CAA28370 and 9;
FT                                AAA61178). {ECO:0000305}.
FT   CONFLICT    431    431       R -> I (in Ref. 3; BAG65509).
FT                                {ECO:0000305}.
FT   CONFLICT    451    451       C -> R (in Ref. 3; BAG65509).
FT                                {ECO:0000305}.
FT   CONFLICT    546    546       C -> Y (in Ref. 3; BAF84328).
FT                                {ECO:0000305}.
FT   CONFLICT    812    812       N -> D (in Ref. 3; BAG65509).
FT                                {ECO:0000305}.
FT   CONFLICT   1008   1008       F -> S (in Ref. 3; BAF84328).
FT                                {ECO:0000305}.
FT   STRAND       30     32       {ECO:0000244|PDB:2ERF}.
FT   HELIX        33     37       {ECO:0000244|PDB:2ERF}.
FT   TURN         38     41       {ECO:0000244|PDB:2ERF}.
FT   STRAND       44     49       {ECO:0000244|PDB:2ERF}.
FT   STRAND       58     62       {ECO:0000244|PDB:2ERF}.
FT   HELIX        64     66       {ECO:0000244|PDB:2ERF}.
FT   HELIX        72     85       {ECO:0000244|PDB:2ERF}.
FT   STRAND       87     96       {ECO:0000244|PDB:2ERF}.
FT   STRAND      101    109       {ECO:0000244|PDB:2ERF}.
FT   STRAND      115    122       {ECO:0000244|PDB:2ERF}.
FT   TURN        123    126       {ECO:0000244|PDB:2ERF}.
FT   STRAND      127    134       {ECO:0000244|PDB:2ERF}.
FT   STRAND      137    145       {ECO:0000244|PDB:2ERF}.
FT   STRAND      150    161       {ECO:0000244|PDB:2ERF}.
FT   STRAND      164    169       {ECO:0000244|PDB:2ERF}.
FT   TURN        170    172       {ECO:0000244|PDB:2ERF}.
FT   STRAND      173    178       {ECO:0000244|PDB:2ERF}.
FT   HELIX       183    185       {ECO:0000244|PDB:2ERF}.
FT   HELIX       191    194       {ECO:0000244|PDB:2ERF}.
FT   STRAND      195    200       {ECO:0000244|PDB:2ERF}.
FT   TURN        203    205       {ECO:0000244|PDB:2ERF}.
FT   STRAND      210    218       {ECO:0000244|PDB:2ERF}.
FT   HELIX       223    228       {ECO:0000244|PDB:2ERF}.
FT   TURN        229    231       {ECO:0000244|PDB:2OUH}.
FT   STRAND      450    459       {ECO:0000244|PDB:1LSL}.
FT   STRAND      478    485       {ECO:0000244|PDB:1LSL}.
FT   STRAND      507    509       {ECO:0000244|PDB:1LSL}.
FT   STRAND      511    516       {ECO:0000244|PDB:1LSL}.
FT   STRAND      535    541       {ECO:0000244|PDB:1LSL}.
FT   TURN        838    840       {ECO:0000244|PDB:1UX6}.
FT   STRAND      849    852       {ECO:0000244|PDB:1UX6}.
FT   TURN        854    856       {ECO:0000244|PDB:1UX6}.
FT   STRAND      865    867       {ECO:0000244|PDB:1UX6}.
FT   HELIX       869    871       {ECO:0000244|PDB:1UX6}.
FT   STRAND      888    890       {ECO:0000244|PDB:1UX6}.
FT   HELIX       892    894       {ECO:0000244|PDB:1UX6}.
FT   STRAND      901    903       {ECO:0000244|PDB:1UX6}.
FT   HELIX       905    907       {ECO:0000244|PDB:1UX6}.
FT   TURN        909    912       {ECO:0000244|PDB:1UX6}.
FT   STRAND      924    926       {ECO:0000244|PDB:1UX6}.
FT   HELIX       928    930       {ECO:0000244|PDB:1UX6}.
FT   STRAND      937    939       {ECO:0000244|PDB:1UX6}.
FT   TURN        941    943       {ECO:0000244|PDB:1UX6}.
FT   STRAND      961    965       {ECO:0000244|PDB:1UX6}.
FT   STRAND      986    988       {ECO:0000244|PDB:1UX6}.
FT   STRAND      995   1014       {ECO:0000244|PDB:1UX6}.
FT   STRAND     1022   1031       {ECO:0000244|PDB:1UX6}.
FT   STRAND     1034   1043       {ECO:0000244|PDB:1UX6}.
FT   STRAND     1051   1053       {ECO:0000244|PDB:1UX6}.
FT   STRAND     1059   1067       {ECO:0000244|PDB:1UX6}.
FT   HELIX      1074   1081       {ECO:0000244|PDB:1UX6}.
FT   STRAND     1082   1084       {ECO:0000244|PDB:1UX6}.
FT   TURN       1087   1089       {ECO:0000244|PDB:1UX6}.
FT   STRAND     1090   1095       {ECO:0000244|PDB:1UX6}.
FT   STRAND     1107   1115       {ECO:0000244|PDB:1UX6}.
FT   TURN       1116   1119       {ECO:0000244|PDB:1UX6}.
FT   STRAND     1120   1127       {ECO:0000244|PDB:1UX6}.
FT   STRAND     1130   1134       {ECO:0000244|PDB:1UX6}.
FT   STRAND     1146   1154       {ECO:0000244|PDB:1UX6}.
FT   STRAND     1156   1167       {ECO:0000244|PDB:1UX6}.
SQ   SEQUENCE   1170 AA;  129383 MW;  74749B2418E0943B CRC64;
     MGLAWGLGVL FLMHVCGTNR IPESGGDNSV FDIFELTGAA RKGSGRRLVK GPDPSSPAFR
     IEDANLIPPV PDDKFQDLVD AVRAEKGFLL LASLRQMKKT RGTLLALERK DHSGQVFSVV
     SNGKAGTLDL SLTVQGKQHV VSVEEALLAT GQWKSITLFV QEDRAQLYID CEKMENAELD
     VPIQSVFTRD LASIARLRIA KGGVNDNFQG VLQNVRFVFG TTPEDILRNK GCSSSTSVLL
     TLDNNVVNGS SPAIRTNYIG HKTKDLQAIC GISCDELSSM VLELRGLRTI VTTLQDSIRK
     VTEENKELAN ELRRPPLCYH NGVQYRNNEE WTVDSCTECH CQNSVTICKK VSCPIMPCSN
     ATVPDGECCP RCWPSDSADD GWSPWSEWTS CSTSCGNGIQ QRGRSCDSLN NRCEGSSVQT
     RTCHIQECDK RFKQDGGWSH WSPWSSCSVT CGDGVITRIR LCNSPSPQMN GKPCEGEARE
     TKACKKDACP INGGWGPWSP WDICSVTCGG GVQKRSRLCN NPTPQFGGKD CVGDVTENQI
     CNKQDCPIDG CLSNPCFAGV KCTSYPDGSW KCGACPPGYS GNGIQCTDVD ECKEVPDACF
     NHNGEHRCEN TDPGYNCLPC PPRFTGSQPF GQGVEHATAN KQVCKPRNPC TDGTHDCNKN
     AKCNYLGHYS DPMYRCECKP GYAGNGIICG EDTDLDGWPN ENLVCVANAT YHCKKDNCPN
     LPNSGQEDYD KDGIGDACDD DDDNDKIPDD RDNCPFHYNP AQYDYDRDDV GDRCDNCPYN
     HNPDQADTDN NGEGDACAAD IDGDGILNER DNCQYVYNVD QRDTDMDGVG DQCDNCPLEH
     NPDQLDSDSD RIGDTCDNNQ DIDEDGHQNN LDNCPYVPNA NQADHDKDGK GDACDHDDDN
     DGIPDDKDNC RLVPNPDQKD SDGDGRGDAC KDDFDHDSVP DIDDICPENV DISETDFRRF
     QMIPLDPKGT SQNDPNWVVR HQGKELVQTV NCDPGLAVGY DEFNAVDFSG TFFINTERDD
     DYAGFVFGYQ SSSRFYVVMW KQVTQSYWDT NPTRAQGYSG LSVKVVNSTT GPGEHLRNAL
     WHTGNTPGQV RTLWHDPRHI GWKDFTAYRW RLSHRPKTGF IRVVMYEGKK IMADSGPIYD
     KTYAGGRLGL FVFSQEMVFF SDLKYECRDP
//
ID   WNT5A_HUMAN             Reviewed;         380 AA.
AC   P41221; A8K4A4; Q6P278;
DT   01-FEB-1995, integrated into UniProtKB/Swiss-Prot.
DT   04-NOV-2008, sequence version 2.
DT   17-FEB-2016, entry version 140.
DE   RecName: Full=Protein Wnt-5a;
DE   Flags: Precursor;
GN   Name=WNT5A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=8288227; DOI=10.1006/geno.1993.1463;
RA   Clark C.C., Cohen I.R., Eichstetter I., Cannizarro L.A.,
RA   McPherson J.D., Wasmuth J.J., Iozzo R.V.;
RT   "Molecular cloning of the human proto-oncogene Wnt-5A and mapping of
RT   the gene (WNT5A) to chromosome 3p14-p21.";
RL   Genomics 18:249-260(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Mesangial cell, and Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=15735754; DOI=10.1038/sj.onc.1208370;
RA   Kremenevskaja N., von Wasielewski R., Rao A.S., Schoefl C.,
RA   Andersson T., Brabant G.;
RT   "Wnt-5a has tumor suppressor activity in thyroid carcinoma.";
RL   Oncogene 24:2144-2154(2005).
RN   [6]
RP   FUNCTION.
RX   PubMed=17426020; DOI=10.1074/jbc.M700075200;
RA   Dissanayake S.K., Wade M., Johnson C.E., O'Connell M.P.,
RA   Leotlela P.D., French A.D., Shah K.V., Hewitt K.J., Rosenthal D.T.,
RA   Indig F.E., Jiang Y., Nickoloff B.J., Taub D.D., Trent J.M.,
RA   Moon R.T., Bittner M., Weeraratna A.T.;
RT   "The Wnt5A/protein kinase C pathway mediates motility in melanoma
RT   cells via the inhibition of metastasis suppressors and initiation of
RT   an epithelial to mesenchymal transition.";
RL   J. Biol. Chem. 282:17259-17271(2007).
RN   [7]
RP   VARIANTS DRS1 SER-83 AND ARG-182, AND CHARACTERIZATION OF VARIANTS
RP   DRS1 SER-83 AND ARG-182.
RX   PubMed=19918918; DOI=10.1002/dvdy.22156;
RA   Person A.D., Beiraghi S., Sieben C.M., Hermanson S., Neumann A.N.,
RA   Robu M.E., Schleiffarth J.R., Billington C.J. Jr., van Bokhoven H.,
RA   Hoogeboom J.M., Mazzeu J.F., Petryk A., Schimmenti L.A., Brunner H.G.,
RA   Ekker S.C., Lohr J.L.;
RT   "WNT5A mutations in patients with autosomal dominant Robinow
RT   syndrome.";
RL   Dev. Dyn. 239:327-337(2010).
CC   -!- FUNCTION: Ligand for members of the frizzled family of seven
CC       transmembrane receptors. Can activate or inhibit canonical Wnt
CC       signaling, depending on receptor context. In the presence of FZD4,
CC       activates beta-catenin signaling. In the presence of ROR2,
CC       inhibits the canonical Wnt pathway by promoting beta-catenin
CC       degradation through a GSK3-independent pathway which involves
CC       down-regulation of beta-catenin-induced reporter gene expression.
CC       Suppression of the canonical pathway allows chondrogenesis to
CC       occur and inhibits tumor formation. Stimulates cell migration.
CC       Decreases proliferation, migration, invasiveness and clonogenicity
CC       of carcinoma cells and may act as a tumor suppressor. Mediates
CC       motility of melanoma cells. Required during embryogenesis for
CC       extension of the primary anterior-posterior axis and for outgrowth
CC       of limbs and the genital tubercle. Inhibits type II collagen
CC       expression in chondrocytes. {ECO:0000269|PubMed:15735754,
CC       ECO:0000269|PubMed:17426020}.
CC   -!- SUBUNIT: Homooligomer; disulfide-linked, leading to inactivation.
CC       Interacts with PORCN. Interacts with WLS (By similarity).
CC       {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular
CC       matrix.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P41221-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P41221-2; Sequence=VSP_035594;
CC   -!- TISSUE SPECIFICITY: Expression is increased in differentiated
CC       thyroid carcinomas compared to normal thyroid tissue and
CC       anaplastic thyroid tumors where expression is low or undetectable.
CC       Expression is found in thyrocytes but not in stromal cells (at
CC       protein level). {ECO:0000269|PubMed:15735754}.
CC   -!- PTM: Glycosylation is necessary for secretion but not for
CC       activity. {ECO:0000250|UniProtKB:P22725}.
CC   -!- PTM: Palmitoleylation is required for efficient binding to
CC       frizzled receptors. Depalmitoleylation leads to Wnt signaling
CC       pathway inhibition. {ECO:0000250|UniProtKB:P27467,
CC       ECO:0000250|UniProtKB:P56704}.
CC   -!- PTM: Proteolytic processing by TIKI1 and TIKI2 promotes oxidation
CC       and formation of large disulfide-bond oligomers, leading to
CC       inactivation of WNT5A. {ECO:0000250|UniProtKB:P22725}.
CC   -!- DISEASE: Robinow syndrome, autosomal dominant 1 (DRS1)
CC       [MIM:180700]: A disease characterized by short-limb dwarfism,
CC       costovertebral segmentation defects and abnormalities of the head,
CC       face and external genitalia. The clinical signs are generally
CC       milder in dominant cases. {ECO:0000269|PubMed:19918918}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Belongs to the Wnt family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/WNT5AID42825ch3p14.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L20861; AAA16842.1; -; mRNA.
DR   EMBL; AK290375; BAF83064.1; -; mRNA.
DR   EMBL; AK290869; BAF83558.1; -; mRNA.
DR   EMBL; CH471055; EAW65310.1; -; Genomic_DNA.
DR   EMBL; BC064694; AAH64694.1; -; mRNA.
DR   CCDS; CCDS46850.1; -. [P41221-1]
DR   CCDS; CCDS58835.1; -. [P41221-2]
DR   PIR; A48914; A48914.
DR   RefSeq; NP_001243034.1; NM_001256105.1. [P41221-2]
DR   RefSeq; NP_003383.2; NM_003392.4. [P41221-1]
DR   RefSeq; XP_006713387.1; XM_006713324.1. [P41221-2]
DR   RefSeq; XP_011532383.1; XM_011534081.1. [P41221-2]
DR   RefSeq; XP_011532384.1; XM_011534082.1. [P41221-2]
DR   RefSeq; XP_011532385.1; XM_011534083.1. [P41221-2]
DR   RefSeq; XP_011532386.1; XM_011534084.1. [P41221-2]
DR   RefSeq; XP_011532387.1; XM_011534085.1. [P41221-2]
DR   RefSeq; XP_011532388.1; XM_011534086.1. [P41221-2]
DR   RefSeq; XP_011532389.1; XM_011534087.1. [P41221-2]
DR   RefSeq; XP_011532390.1; XM_011534088.1. [P41221-2]
DR   RefSeq; XP_011532391.1; XM_011534089.1. [P41221-2]
DR   UniGene; Hs.643085; -.
DR   ProteinModelPortal; P41221; -.
DR   SMR; P41221; 94-309.
DR   BioGrid; 113311; 20.
DR   DIP; DIP-29735N; -.
DR   IntAct; P41221; 1.
DR   STRING; 9606.ENSP00000264634; -.
DR   BioMuta; WNT5A; -.
DR   DMDM; 212276478; -.
DR   MaxQB; P41221; -.
DR   PaxDb; P41221; -.
DR   PRIDE; P41221; -.
DR   DNASU; 7474; -.
DR   Ensembl; ENST00000264634; ENSP00000264634; ENSG00000114251. [P41221-1]
DR   Ensembl; ENST00000474267; ENSP00000417310; ENSG00000114251. [P41221-1]
DR   Ensembl; ENST00000497027; ENSP00000420104; ENSG00000114251. [P41221-2]
DR   GeneID; 7474; -.
DR   KEGG; hsa:7474; -.
DR   UCSC; uc003dhm.3; human. [P41221-1]
DR   CTD; 7474; -.
DR   GeneCards; WNT5A; -.
DR   HGNC; HGNC:12784; WNT5A.
DR   MalaCards; WNT5A; -.
DR   MIM; 164975; gene.
DR   MIM; 180700; phenotype.
DR   neXtProt; NX_P41221; -.
DR   Orphanet; 3107; Autosomal dominant Robinow syndrome.
DR   PharmGKB; PA37385; -.
DR   eggNOG; KOG3913; Eukaryota.
DR   eggNOG; ENOG410XQZ1; LUCA.
DR   GeneTree; ENSGT00760000118943; -.
DR   HOVERGEN; HBG001595; -.
DR   InParanoid; P41221; -.
DR   KO; K00444; -.
DR   OMA; IVERCHC; -.
DR   OrthoDB; EOG7C8GJ8; -.
DR   PhylomeDB; P41221; -.
DR   TreeFam; TF105310; -.
DR   Reactome; R-HSA-201681; TCF dependent signaling in response to WNT.
DR   Reactome; R-HSA-3238698; WNT ligand biogenesis and trafficking.
DR   Reactome; R-HSA-373080; Class B/2 (Secretin family receptors).
DR   Reactome; R-HSA-3772470; Negative regulation of TCF-dependent signaling by WNT ligand antagonists.
DR   Reactome; R-HSA-4086398; Ca2+ pathway.
DR   Reactome; R-HSA-4086400; PCP/CE pathway.
DR   Reactome; R-HSA-4608870; Asymmetric localization of PCP proteins.
DR   Reactome; R-HSA-5099900; WNT5A-dependent internalization of FZD4.
DR   Reactome; R-HSA-5140745; WNT5A-dependent internalization of FZD2, FZD5 and ROR2.
DR   SignaLink; P41221; -.
DR   ChiTaRS; WNT5A; human.
DR   GeneWiki; WNT5A; -.
DR   GenomeRNAi; 7474; -.
DR   NextBio; 29276; -.
DR   PRO; PR:P41221; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; P41221; -.
DR   CleanEx; HS_WNT5A; -.
DR   ExpressionAtlas; P41221; baseline and differential.
DR   Genevisible; P41221; HS.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0030669; C:clathrin-coated endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0030666; C:endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; TAS:Reactome.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005796; C:Golgi lumen; TAS:Reactome.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005578; C:proteinaceous extracellular matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:0005109; F:frizzled binding; IPI:UniProtKB.
DR   GO; GO:0048018; F:receptor agonist activity; IC:BHF-UCL.
DR   GO; GO:0005115; F:receptor tyrosine kinase-like orphan receptor binding; IPI:UniProtKB.
DR   GO; GO:0003700; F:transcription factor activity, sequence-specific DNA binding; IMP:UniProtKB.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IDA:UniProtKB.
DR   GO; GO:0007257; P:activation of JUN kinase activity; IDA:BHF-UCL.
DR   GO; GO:0000187; P:activation of MAPK activity; IDA:BHF-UCL.
DR   GO; GO:0032148; P:activation of protein kinase B activity; IDA:BHF-UCL.
DR   GO; GO:0008595; P:anterior/posterior axis specification, embryo; IEA:Ensembl.
DR   GO; GO:0007411; P:axon guidance; ISS:UniProtKB.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:0051216; P:cartilage development; IEA:UniProtKB-KW.
DR   GO; GO:0045165; P:cell fate commitment; IBA:GO_Central.
DR   GO; GO:0034613; P:cellular protein localization; IDA:UniProtKB.
DR   GO; GO:0071277; P:cellular response to calcium ion; IEP:UniProtKB.
DR   GO; GO:0071346; P:cellular response to interferon-gamma; IEP:UniProtKB.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IEP:UniProtKB.
DR   GO; GO:0071300; P:cellular response to retinoic acid; ISS:UniProtKB.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IEP:UniProtKB.
DR   GO; GO:0060067; P:cervix development; IEA:Ensembl.
DR   GO; GO:0090103; P:cochlea morphogenesis; IEA:Ensembl.
DR   GO; GO:0060028; P:convergent extension involved in axis elongation; IEA:Ensembl.
DR   GO; GO:0060029; P:convergent extension involved in organogenesis; IEA:Ensembl.
DR   GO; GO:0071542; P:dopaminergic neuron differentiation; IEA:Ensembl.
DR   GO; GO:0009953; P:dorsal/ventral pattern formation; IEA:Ensembl.
DR   GO; GO:0042733; P:embryonic digit morphogenesis; IEA:Ensembl.
DR   GO; GO:0048706; P:embryonic skeletal system development; IMP:BHF-UCL.
DR   GO; GO:0060750; P:epithelial cell proliferation involved in mammary gland duct elongation; IEA:Ensembl.
DR   GO; GO:0001837; P:epithelial to mesenchymal transition; IEP:UniProtKB.
DR   GO; GO:0045198; P:establishment of epithelial cell apical/basal polarity; IEA:Ensembl.
DR   GO; GO:0001736; P:establishment of planar polarity; IEA:Ensembl.
DR   GO; GO:0044849; P:estrous cycle; IEA:Ensembl.
DR   GO; GO:0060324; P:face development; IMP:BHF-UCL.
DR   GO; GO:0048806; P:genitalia development; IMP:BHF-UCL.
DR   GO; GO:0001947; P:heart looping; IEA:Ensembl.
DR   GO; GO:0071425; P:hematopoietic stem cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0007442; P:hindgut morphogenesis; IEA:Ensembl.
DR   GO; GO:0048850; P:hypophysis morphogenesis; IEA:Ensembl.
DR   GO; GO:0030216; P:keratinocyte differentiation; IEP:BHF-UCL.
DR   GO; GO:0060599; P:lateral sprouting involved in mammary gland duct morphogenesis; IEA:Ensembl.
DR   GO; GO:0002088; P:lens development in camera-type eye; ISS:BHF-UCL.
DR   GO; GO:0048286; P:lung alveolus development; IEA:Ensembl.
DR   GO; GO:0008584; P:male gonad development; IEP:UniProtKB.
DR   GO; GO:0060744; P:mammary gland branching involved in thelarche; IEA:Ensembl.
DR   GO; GO:0097325; P:melanocyte proliferation; IEA:Ensembl.
DR   GO; GO:0060638; P:mesenchymal-epithelial cell signaling; IEA:Ensembl.
DR   GO; GO:0060809; P:mesodermal to mesenchymal transition involved in gastrulation; IEA:Ensembl.
DR   GO; GO:0030901; P:midbrain development; IEA:Ensembl.
DR   GO; GO:0007494; P:midgut development; IEA:Ensembl.
DR   GO; GO:0050919; P:negative chemotaxis; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0048843; P:negative regulation of axon extension involved in axon guidance; IEA:Ensembl.
DR   GO; GO:0030514; P:negative regulation of BMP signaling pathway; IEA:Ensembl.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IDA:UniProtKB.
DR   GO; GO:0050680; P:negative regulation of epithelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0045599; P:negative regulation of fat cell differentiation; IMP:BHF-UCL.
DR   GO; GO:0040037; P:negative regulation of fibroblast growth factor receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0048022; P:negative regulation of melanin biosynthetic process; IEA:Ensembl.
DR   GO; GO:0072201; P:negative regulation of mesenchymal cell proliferation; IDA:UniProtKB.
DR   GO; GO:0060686; P:negative regulation of prostatic bud formation; IEA:Ensembl.
DR   GO; GO:0051964; P:negative regulation of synapse assembly; IEA:Ensembl.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0030182; P:neuron differentiation; ISS:UniProtKB.
DR   GO; GO:0038031; P:non-canonical Wnt signaling pathway via JNK cascade; IEA:Ensembl.
DR   GO; GO:0048570; P:notochord morphogenesis; IEA:Ensembl.
DR   GO; GO:0021891; P:olfactory bulb interneuron development; ISS:UniProtKB.
DR   GO; GO:0003408; P:optic cup formation involved in camera-type eye development; ISS:BHF-UCL.
DR   GO; GO:0060021; P:palate development; IMP:BHF-UCL.
DR   GO; GO:0048341; P:paraxial mesoderm formation; IEA:Ensembl.
DR   GO; GO:0003402; P:planar cell polarity pathway involved in axis elongation; IEA:Ensembl.
DR   GO; GO:0061350; P:planar cell polarity pathway involved in cardiac muscle tissue morphogenesis; IEA:Ensembl.
DR   GO; GO:0061349; P:planar cell polarity pathway involved in cardiac right atrium morphogenesis; IEA:Ensembl.
DR   GO; GO:0060775; P:planar cell polarity pathway involved in gastrula mediolateral intercalation; IEA:Ensembl.
DR   GO; GO:0090179; P:planar cell polarity pathway involved in neural tube closure; IEA:Ensembl.
DR   GO; GO:0061347; P:planar cell polarity pathway involved in outflow tract morphogenesis; IEA:Ensembl.
DR   GO; GO:0061354; P:planar cell polarity pathway involved in pericardium morphogenesis; IEA:Ensembl.
DR   GO; GO:0061348; P:planar cell polarity pathway involved in ventricular septum morphogenesis; IEA:Ensembl.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IMP:UniProtKB.
DR   GO; GO:0061036; P:positive regulation of cartilage development; IEA:Ensembl.
DR   GO; GO:2000049; P:positive regulation of cell-cell adhesion mediated by cadherin; IEA:Ensembl.
DR   GO; GO:0030825; P:positive regulation of cGMP metabolic process; IDA:BHF-UCL.
DR   GO; GO:0045080; P:positive regulation of chemokine biosynthetic process; IMP:UniProtKB.
DR   GO; GO:0002741; P:positive regulation of cytokine secretion involved in immune response; IMP:UniProtKB.
DR   GO; GO:0045807; P:positive regulation of endocytosis; IEA:Ensembl.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; IMP:UniProtKB.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IMP:UniProtKB.
DR   GO; GO:0048146; P:positive regulation of fibroblast proliferation; IDA:UniProtKB.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; IMP:BHF-UCL.
DR   GO; GO:0032729; P:positive regulation of interferon-gamma production; IEA:Ensembl.
DR   GO; GO:0050718; P:positive regulation of interleukin-1 beta secretion; IMP:BHF-UCL.
DR   GO; GO:0032755; P:positive regulation of interleukin-6 production; IMP:BHF-UCL.
DR   GO; GO:2000484; P:positive regulation of interleukin-8 secretion; IEA:Ensembl.
DR   GO; GO:0043032; P:positive regulation of macrophage activation; IMP:BHF-UCL.
DR   GO; GO:0060907; P:positive regulation of macrophage cytokine production; IMP:UniProtKB.
DR   GO; GO:0045836; P:positive regulation of meiotic nuclear division; IEA:Ensembl.
DR   GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; IEA:Ensembl.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; ISS:UniProtKB.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IDA:UniProtKB.
DR   GO; GO:2000052; P:positive regulation of non-canonical Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:0045778; P:positive regulation of ossification; IMP:BHF-UCL.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IEA:Ensembl.
DR   GO; GO:0010800; P:positive regulation of peptidyl-threonine phosphorylation; IEA:Ensembl.
DR   GO; GO:0045732; P:positive regulation of protein catabolic process; IGI:MGI.
DR   GO; GO:1900020; P:positive regulation of protein kinase C activity; IMP:CACAO.
DR   GO; GO:0090037; P:positive regulation of protein kinase C signaling; IMP:UniProtKB.
DR   GO; GO:0060760; P:positive regulation of response to cytokine stimulus; IDA:UniProtKB.
DR   GO; GO:0010820; P:positive regulation of T cell chemotaxis; IMP:UniProtKB.
DR   GO; GO:0070245; P:positive regulation of thymocyte apoptotic process; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IMP:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IMP:UniProtKB.
DR   GO; GO:0060340; P:positive regulation of type I interferon-mediated signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0036342; P:post-anal tail morphogenesis; IEA:Ensembl.
DR   GO; GO:0090009; P:primitive streak formation; IEA:Ensembl.
DR   GO; GO:0030850; P:prostate gland development; IEA:Ensembl.
DR   GO; GO:0060762; P:regulation of branching involved in mammary gland duct morphogenesis; IEA:Ensembl.
DR   GO; GO:0032355; P:response to estradiol; IEA:Ensembl.
DR   GO; GO:0051384; P:response to glucocorticoid; IEA:Ensembl.
DR   GO; GO:0055093; P:response to hyperoxia; IEA:Ensembl.
DR   GO; GO:0010033; P:response to organic substance; IEP:UniProtKB.
DR   GO; GO:0033574; P:response to testosterone; IEA:Ensembl.
DR   GO; GO:0001756; P:somitogenesis; IEA:Ensembl.
DR   GO; GO:0003323; P:type B pancreatic cell development; IEA:Ensembl.
DR   GO; GO:0060157; P:urinary bladder development; IEA:Ensembl.
DR   GO; GO:0060065; P:uterus development; IEA:Ensembl.
DR   GO; GO:0060068; P:vagina development; IEA:Ensembl.
DR   GO; GO:0016055; P:Wnt signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0007223; P:Wnt signaling pathway, calcium modulating pathway; IMP:UniProtKB.
DR   GO; GO:0042060; P:wound healing; IDA:UniProtKB.
DR   InterPro; IPR005817; Wnt.
DR   InterPro; IPR026538; Wnt5a.
DR   InterPro; IPR018161; Wnt_CS.
DR   PANTHER; PTHR12027; PTHR12027; 1.
DR   PANTHER; PTHR12027:SF33; PTHR12027:SF33; 1.
DR   Pfam; PF00110; wnt; 1.
DR   PRINTS; PR01349; WNTPROTEIN.
DR   SMART; SM00097; WNT1; 1.
DR   PROSITE; PS00246; WNT1; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Chondrogenesis; Complete proteome;
KW   Developmental protein; Differentiation; Disease mutation;
KW   Disulfide bond; Dwarfism; Extracellular matrix; Glycoprotein;
KW   Lipoprotein; Reference proteome; Secreted; Signal;
KW   Wnt signaling pathway.
FT   SIGNAL        1     35       {ECO:0000255}.
FT   PROPEP       36     61       {ECO:0000250}.
FT                                /FTId=PRO_0000352796.
FT   CHAIN        62    380       Protein Wnt-5a.
FT                                /FTId=PRO_0000041427.
FT   LIPID       244    244       O-palmitoleyl serine; by PORCN.
FT                                {ECO:0000250|UniProtKB:P56704}.
FT   CARBOHYD    114    114       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    120    120       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    312    312       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    326    326       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID    104    115       {ECO:0000250|UniProtKB:P28026}.
FT   DISULFID    154    162       {ECO:0000250|UniProtKB:P28026}.
FT   DISULFID    164    182       {ECO:0000250|UniProtKB:P28026}.
FT   DISULFID    238    252       {ECO:0000250|UniProtKB:P28026}.
FT   DISULFID    240    247       {ECO:0000250|UniProtKB:P28026}.
FT   DISULFID    325    340       {ECO:0000250|UniProtKB:P28026}.
FT   DISULFID    355    370       {ECO:0000250|UniProtKB:P28026}.
FT   DISULFID    357    367       {ECO:0000250|UniProtKB:P28026}.
FT   DISULFID    362    363       {ECO:0000250|UniProtKB:P28026}.
FT   VAR_SEQ       1     15       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:8288227}.
FT                                /FTId=VSP_035594.
FT   VARIANT      83     83       C -> S (in DRS1; hypomorphic mutation).
FT                                {ECO:0000269|PubMed:19918918}.
FT                                /FTId=VAR_066623.
FT   VARIANT     182    182       C -> R (in DRS1; hypomorphic mutation).
FT                                {ECO:0000269|PubMed:19918918}.
FT                                /FTId=VAR_066629.
SQ   SEQUENCE   380 AA;  42339 MW;  50E73AC7FE96C7B5 CRC64;
     MKKSIGILSP GVALGMAGSA MSSKFFLVAL AIFFSFAQVV IEANSWWSLG MNNPVQMSEV
     YIIGAQPLCS QLAGLSQGQK KLCHLYQDHM QYIGEGAKTG IKECQYQFRH RRWNCSTVDN
     TSVFGRVMQI GSRETAFTYA VSAAGVVNAM SRACREGELS TCGCSRAARP KDLPRDWLWG
     GCGDNIDYGY RFAKEFVDAR ERERIHAKGS YESARILMNL HNNEAGRRTV YNLADVACKC
     HGVSGSCSLK TCWLQLADFR KVGDALKEKY DSAAAMRLNS RGKLVQVNSR FNSPTTQDLV
     YIDPSPDYCV RNESTGSLGT QGRLCNKTSE GMDGCELMCC GRGYDQFKTV QTERCHCKFH
     WCCYVKCKKC TEIVDQFVCK
//
ID   PGFRA_HUMAN             Reviewed;        1089 AA.
AC   P16234; B2RE69; E9PBH0; Q6P4H5; Q96KZ7; Q9UD28;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1990, sequence version 1.
DT   17-FEB-2016, entry version 183.
DE   RecName: Full=Platelet-derived growth factor receptor alpha;
DE            Short=PDGF-R-alpha;
DE            Short=PDGFR-alpha;
DE            EC=2.7.10.1;
DE   AltName: Full=Alpha platelet-derived growth factor receptor;
DE   AltName: Full=Alpha-type platelet-derived growth factor receptor;
DE   AltName: Full=CD140 antigen-like family member A;
DE   AltName: Full=CD140a antigen;
DE   AltName: Full=Platelet-derived growth factor alpha receptor;
DE   AltName: Full=Platelet-derived growth factor receptor 2;
DE            Short=PDGFR-2;
DE   AltName: CD_antigen=CD140a;
DE   Flags: Precursor;
GN   Name=PDGFRA; Synonyms=PDGFR2, RHEPDGFRA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH PDGFA AND
RP   PDGFB.
RC   TISSUE=Foreskin;
RX   PubMed=2544881; DOI=10.1073/pnas.86.13.4917;
RA   Claesson-Welsh L., Eriksson A., Westermark B., Heldin C.H.;
RT   "cDNA cloning and expression of the human A-type platelet-derived
RT   growth factor (PDGF) receptor establishes structural similarity to the
RT   B-type PDGF receptor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:4917-4921(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AUTOPHOSPHORYLATION, TISSUE
RP   SPECIFICITY, AND INTERACTION WITH PDGFA AND PDGFB.
RC   TISSUE=Brain;
RX   PubMed=2536956; DOI=10.1126/science.2536956;
RA   Matsui T., Heidaran M., Miki T., Popescu N., la Rochelle W., Kraus M.,
RA   Pierce J., Aaronson S.;
RT   "Isolation of a novel receptor cDNA establishes the existence of two
RT   PDGF receptor genes.";
RL   Science 243:800-804(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Blood;
RX   PubMed=8586421; DOI=10.1006/geno.1995.9883;
RA   Kawagishi J., Ku T.;
RT   "Structure, organization, and transcription units of the human alpha-
RT   platelet-derived growth factor receptor gene, PDGFRA.";
RL   Genomics 30:224-232(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   PRO-478.
RC   TISSUE=Lung, and Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3), AND VARIANT
RP   PRO-478.
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 579-1089, DISEASE, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY OF FIP1L1-PDGFRA FUSION PROTEIN.
RC   TISSUE=Eosinophil;
RX   PubMed=12808148; DOI=10.1073/pnas.0932698100;
RA   Griffin J.H., Leung J., Bruner R.J., Caligiuri M.A., Briesewitz R.;
RT   "Discovery of a fusion kinase in EOL-1 cells and idiopathic
RT   hypereosinophilic syndrome.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:7830-7835(2003).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 823-876, AND TISSUE SPECIFICITY.
RC   TISSUE=Colon tumor;
RX   PubMed=7896447; DOI=10.1002/ijc.2910600611;
RA   Craven R.J., Xu L.H., Weiner T.M., Fridell Y.-W., Dent G.A.,
RA   Srivastava S., Varnum B., Liu E.T., Cance W.G.;
RT   "Receptor tyrosine kinases expressed in metastatic colon cancer.";
RL   Int. J. Cancer 60:791-797(1995).
RN   [9]
RP   FUNCTION AS PDGFA AND PDGFB RECEPTOR IN CELL PROLIFERATION AND
RP   CHEMOTAXIS, AND SUBCELLULAR LOCATION.
RX   PubMed=2554309; DOI=10.1073/pnas.86.21.8314;
RA   Matsui T., Pierce J.H., Fleming T.P., Greenberger J.S.,
RA   LaRochelle W.J., Ruggiero M., Aaronson S.A.;
RT   "Independent expression of human alpha or beta platelet-derived growth
RT   factor receptor cDNAs in a naive hematopoietic cell leads to
RT   functional coupling with mitogenic and chemotactic signaling
RT   pathways.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:8314-8318(1989).
RN   [10]
RP   INTERACTION WITH PLCG1 AND SRC.
RX   PubMed=2173144; DOI=10.1126/science.2173144;
RA   Anderson D., Koch C.A., Grey L., Ellis C., Moran M.F., Pawson T.;
RT   "Binding of SH2 domains of phospholipase C gamma 1, GAP, and Src to
RT   activated growth factor receptors.";
RL   Science 250:979-982(1990).
RN   [11]
RP   INTERACTION WITH PDGFRA; PDGFA AND PDGFB, FUNCTION AS RECEPTOR FOR
RP   PDGFA AND PDGFB, AND AUTOPHOSPHORYLATION.
RX   PubMed=1709159;
RA   Kelly J.D., Haldeman B.A., Grant F.J., Murray M.J., Seifert R.A.,
RA   Bowen-Pope D.F., Cooper J.A., Kazlauskas A.;
RT   "Platelet-derived growth factor (PDGF) stimulates PDGF receptor
RT   subunit dimerization and intersubunit trans-phosphorylation.";
RL   J. Biol. Chem. 266:8987-8992(1991).
RN   [12]
RP   FUNCTION AS PDGFB RECEPTOR IN CHEMOTAXIS; CELL PROLIFERATION;
RP   PHOSPHORYLATION OF PLCG1; ACTIVATION OF PHOSPHATIDYLINOSITOL 3-KINASE
RP   AND REGULATION OF PHOSPHATIDYLINOSITOL METABOLISM, INTERACTION WITH
RP   PIK3R, PHOSPHORYLATION AT TYR-731 AND TYR-742, AND MUTAGENESIS OF
RP   TYR-731 AND TYR-742.
RX   PubMed=1646396;
RA   Yu J.C., Heidaran M.A., Pierce J.H., Gutkind J.S., Lombardi D.,
RA   Ruggiero M., Aaronson S.A.;
RT   "Tyrosine mutations within the alpha platelet-derived growth factor
RT   receptor kinase insert domain abrogate receptor-associated
RT   phosphatidylinositol-3 kinase activity without affecting mitogenic or
RT   chemotactic signal transduction.";
RL   Mol. Cell. Biol. 11:3780-3785(1991).
RN   [13]
RP   INTERACTION WITH PDGFA AND PDGFB.
RX   PubMed=7679113;
RA   Fretto L.J., Snape A.J., Tomlinson J.E., Seroogy J.J., Wolf D.L.,
RA   LaRochelle W.J., Giese N.A.;
RT   "Mechanism of platelet-derived growth factor (PDGF) AA, AB, and BB
RT   binding to alpha and beta PDGF receptor.";
RL   J. Biol. Chem. 268:3625-3631(1993).
RN   [14]
RP   FUNCTION AS PDGFA RECEPTOR IN REGULATION OF PLATELET ACTIVATION,
RP   SUBCELLULAR LOCATION, AUTOPHOSPHORYLATION, AND TISSUE SPECIFICITY.
RX   PubMed=8188664;
RA   Vassbotn F.S., Havnen O.K., Heldin C.H., Holmsen H.;
RT   "Negative feedback regulation of human platelets via autocrine
RT   activation of the platelet-derived growth factor alpha-receptor.";
RL   J. Biol. Chem. 269:13874-13879(1994).
RN   [15]
RP   PHOSPHORYLATION AT TYR-988 AND TYR-1018, AND INTERACTION WITH PLCG1.
RX   PubMed=7535778; DOI=10.1074/jbc.270.13.7773;
RA   Eriksson A., Naanberg E., Roennstrand L., Engstroem U., Hellman U.,
RA   Rupp E., Carpenter G., Heldin C.H., Claesson-Welsh L.;
RT   "Demonstration of functionally different interactions between
RT   phospholipase C-gamma and the two types of platelet-derived growth
RT   factor receptors.";
RL   J. Biol. Chem. 270:7773-7781(1995).
RN   [16]
RP   FUNCTION IN PROMOTING CHEMOTAXIS.
RX   PubMed=8760137;
RA   Osornio-Vargas A.R., Lindroos P.M., Coin P.G., Badgett A.,
RA   Hernandez-Rodriguez N.A., Bonner J.C.;
RT   "Maximal PDGF-induced lung fibroblast chemotaxis requires PDGF
RT   receptor-alpha.";
RL   Am. J. Physiol. 271:L93-L99(1996).
RN   [17]
RP   PHOSPHORYLATION AT TYR-768.
RX   PubMed=8617789; DOI=10.1074/jbc.271.9.5101;
RA   Yokote K., Mori S., Siegbahn A., Ronnstrand L., Wernstedt C.,
RA   Heldin C.H., Claesson-Welsh L.;
RT   "Structural determinants in the platelet-derived growth factor alpha-
RT   receptor implicated in modulation of chemotaxis.";
RL   J. Biol. Chem. 271:5101-5111(1996).
RN   [18]
RP   INTERACTION WITH GRB7 AND PIK3R1.
RX   PubMed=8940081; DOI=10.1074/jbc.271.48.30942;
RA   Yokote K., Margolis B., Heldin C.H., Claesson-Welsh L.;
RT   "Grb7 is a downstream signaling component of platelet-derived growth
RT   factor alpha- and beta-receptors.";
RL   J. Biol. Chem. 271:30942-30949(1996).
RN   [19]
RP   FUNCTION IN PHOSPHORYLATION OF PTPN11; ACTIVATION OF HRAS AND
RP   REGULATION OF CELL PROLIFERATION, PHOSPHORYLATION AT TYR-720,
RP   INTERACTION WITH GRB2; PTPN11; PLCG1 AND PIK3R1, AUTOPHOSPHORYLATION,
RP   AND MUTAGENESIS OF TYR-720.
RX   PubMed=8943348;
RA   Bazenet C.E., Gelderloos J.A., Kazlauskas A.;
RT   "Phosphorylation of tyrosine 720 in the platelet-derived growth factor
RT   alpha receptor is required for binding of Grb2 and SHP-2 but not for
RT   activation of Ras or cell proliferation.";
RL   Mol. Cell. Biol. 16:6926-6936(1996).
RN   [20]
RP   INTERACTION WITH CRK, PHOSPHORYLATION AT TYR-762, AND MUTAGENESIS OF
RP   TYR-762.
RX   PubMed=10733900; DOI=10.1006/bbrc.2000.2374;
RA   Matsumoto T., Yokote K., Take A., Takemoto M., Asaumi S.,
RA   Hashimoto Y., Matsuda M., Saito Y., Mori S.;
RT   "Differential interaction of CrkII adaptor protein with platelet-
RT   derived growth factor alpha- and beta-receptors is determined by its
RT   internal tyrosine phosphorylation.";
RL   Biochem. Biophys. Res. Commun. 270:28-33(2000).
RN   [21]
RP   INTERACTION WITH SHF, AND PHOSPHORYLATION AT TYR-720.
RX   PubMed=11095946; DOI=10.1006/bbrc.2000.3847;
RA   Lindholm C.K., Frantz J.D., Shoelson S.E., Welsh M.;
RT   "Shf, a Shb-like adapter protein, is involved in PDGF-alpha-receptor
RT   regulation of apoptosis.";
RL   Biochem. Biophys. Res. Commun. 278:537-543(2000).
RN   [22]
RP   FUNCTION IN PLATELET ACTIVATION.
RX   PubMed=10947961; DOI=10.1042/0264-6021:3500469;
RA   Selheim F., Fukami M.H., Holmsen H., Vassbotn F.S.;
RT   "Platelet-derived-growth-factor-induced signalling in human platelets:
RT   phosphoinositide-3-kinase-dependent inhibition of platelet
RT   activation.";
RL   Biochem. J. 350:469-475(2000).
RN   [23]
RP   FUNCTION IN ACTIVATION OF MAPK1/ERK2 AND/OR MAPK3/ERK1, DEGRADATION,
RP   PHOSPHORYLATION AT TYR-572 AND TYR-574, AND MUTAGENESIS OF TYR-572 AND
RP   TYR-574.
RX   PubMed=10734113; DOI=10.1074/jbc.275.13.9620;
RA   Rosenkranz S., Ikuno Y., Leong F.L., Klinghoffer R.A., Miyake S.,
RA   Band H., Kazlauskas A.;
RT   "Src family kinases negatively regulate platelet-derived growth factor
RT   alpha receptor-dependent signaling and disease progression.";
RL   J. Biol. Chem. 275:9620-9627(2000).
RN   [24]
RP   FUNCTION AS A RECEPTOR FOR PDGFC, AND INTERACTION WITH PDGFC.
RX   PubMed=11297552; DOI=10.1074/jbc.M101056200;
RA   Gilbertson D.G., Duff M.E., West J.W., Kelly J.D., Sheppard P.O.,
RA   Hofstrand P.D., Gao Z., Shoemaker K., Bukowski T.R., Moore M.,
RA   Feldhaus A.L., Humes J.M., Palmer T.E., Hart C.E.;
RT   "Platelet-derived growth factor C (PDGF-C), a novel growth factor that
RT   binds to PDGF alpha and beta receptor.";
RL   J. Biol. Chem. 276:27406-27414(2001).
RN   [25]
RP   SUBCELLULAR LOCATION, INTERACTION WITH SRC, AND MUTAGENESIS OF TYR-572
RP   AND TYR-574.
RX   PubMed=14644164; DOI=10.1016/j.yexcr.2003.08.001;
RA   Avrov K., Kazlauskas A.;
RT   "The role of c-Src in platelet-derived growth factor alpha receptor
RT   internalization.";
RL   Exp. Cell Res. 291:426-434(2003).
RN   [26]
RP   INVOLVEMENT IN HES.
RX   PubMed=12660384; DOI=10.1056/NEJMoa025217;
RA   Cools J., DeAngelo D.J., Gotlib J., Stover E.H., Legare R.D.,
RA   Cortes J., Kutok J., Clark J., Galinsky I., Griffin J.D., Cross N.C.,
RA   Tefferi A., Malone J., Alam R., Schrier S.L., Schmid J., Rose M.,
RA   Vandenberghe P., Verhoef G., Boogaerts M., Wlodarska I.,
RA   Kantarjian H., Marynen P., Coutre S.E., Stone R., Gilliland D.G.;
RT   "A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as
RT   a therapeutic target of imatinib in idiopathic hypereosinophilic
RT   syndrome.";
RL   N. Engl. J. Med. 348:1201-1214(2003).
RN   [27]
RP   FUNCTION IN PHOSPHORYLATION OF AKT1; MAP KINASES; STAT1 AND STAT3,
RP   INVOLVEMENT IN GIST, VARIANTS ASP-561; VAL-842; 842-ASP--HIS-845 DEL
RP   AND 845-HIS--PRO-448 DEL, AND CHARACTERIZATION OF VARIANTS ASP-561;
RP   VAL-842; 842-ASP--HIS-845 DEL AND 845-HIS--PRO-448 DEL.
RX   PubMed=12522257; DOI=10.1126/science.1079666;
RA   Heinrich M.C., Corless C.L., Duensing A., McGreevey L., Chen C.J.,
RA   Joseph N., Singer S., Griffith D.J., Haley A., Town A., Demetri G.D.,
RA   Fletcher C.D., Fletcher J.A.;
RT   "PDGFRA activating mutations in gastrointestinal stromal tumors.";
RL   Science 299:708-710(2003).
RN   [28]
RP   INVOLVEMENT IN GIST, VARIANTS ASP-561; LYS-659; TYR-842; VAL-842;
RP   842-ASP--HIS-845 DEL 845-HIS--PRO-448 DEL AND CYS-849,
RP   CHARACTERIZATION OF VARIANTS ASP-561; LYS-659; TYR-842; VAL-842;
RP   842-ASP--HIS-845 DEL 845-HIS--PRO-448 DEL AND CYS-849, AND ENZYME
RP   REGULATION.
RX   PubMed=15928335; DOI=10.1200/JCO.2005.14.068;
RA   Corless C.L., Schroeder A., Griffith D., Town A., McGreevey L.,
RA   Harrell P., Shiraga S., Bainbridge T., Morich J., Heinrich M.C.;
RT   "PDGFRA mutations in gastrointestinal stromal tumors: frequency,
RT   spectrum and in vitro sensitivity to imatinib.";
RL   J. Clin. Oncol. 23:5357-5364(2005).
RN   [29]
RP   FUNCTION IN CELL SURVIVAL.
RX   PubMed=17141222; DOI=10.1016/j.febslet.2006.11.034;
RA   Vantler M., Huntgeburth M., Caglayan E., Ten Freyhaus H., Schnabel P.,
RA   Rosenkranz S.;
RT   "PI3-kinase/Akt-dependent antiapoptotic signaling by the PDGF alpha
RT   receptor is negatively regulated by Src family kinases.";
RL   FEBS Lett. 580:6769-6776(2006).
RN   [30]
RP   PHOSPHORYLATION AT TYR-754.
RX   PubMed=17604334; DOI=10.1158/1535-7163.MCT-06-0720;
RA   Stock P., Monga D., Tan X., Micsenyi A., Loizos N., Monga S.P.;
RT   "Platelet-derived growth factor receptor-alpha: a novel therapeutic
RT   target in human hepatocellular cancer.";
RL   Mol. Cancer Ther. 6:1932-1941(2007).
RN   [31]
RP   INTERACTION WITH HHV-5 GB.
RX   PubMed=20660204; DOI=10.1128/JVI.00710-10;
RA   Feire A.L., Roy R.M., Manley K., Compton T.;
RT   "The glycoprotein B disintegrin-like domain binds beta 1 integrin to
RT   mediate cytomegalovirus entry.";
RL   J. Virol. 84:10026-10037(2010).
RN   [32]
RP   FUNCTION IN PHOSPHORYLATION OF STAT 5A AND/OR STAT5B, ROLE IN
RP   HYPEREOSINOPHILIC SYNDROME, VARIANTS GLY-481; PRO-507; MET-562;
RP   ARG-570; GLN-650; SER-659; PRO-705; GLY-748 AND SER-849,
RP   CHARACTERIZATION OF VARIANTS GLY-481; PRO-507; MET-562; ARG-570;
RP   GLN-650; SER-659; PRO-705; GLY-748 AND SER-849, AND ENZYME REGULATION.
RX   PubMed=21224473; DOI=10.1182/blood-2010-05-286757;
RA   Elling C., Erben P., Walz C., Frickenhaus M., Schemionek M.,
RA   Stehling M., Serve H., Cross N.C., Hochhaus A., Hofmann W.K.,
RA   Berdel W.E., Muller-Tidow C., Reiter A., Koschmieder S.;
RT   "Novel imatinib-sensitive PDGFRA-activating point mutations in
RT   hypereosinophilic syndrome induce growth factor independence and
RT   leukemia-like disease.";
RL   Blood 117:2935-2943(2011).
RN   [33]
RP   FUNCTION IN CELL DIFFERENTIATION, AND UBIQUITINATION.
RX   PubMed=21596750; DOI=10.1074/jbc.M110.197525;
RA   Severe N., Miraoui H., Marie P.J.;
RT   "The Casitas B lineage lymphoma (Cbl) mutant G306E enhances osteogenic
RT   differentiation in human mesenchymal stromal cells in part by
RT   decreased Cbl-mediated platelet-derived growth factor receptor alpha
RT   and fibroblast growth factor receptor 2 ubiquitination.";
RL   J. Biol. Chem. 286:24443-24450(2011).
RN   [34]
RP   ROLE IN DISEASE, CHARACTERIZATION OF VARIANT VAL-842, AND ENZYME
RP   REGULATION.
RX   PubMed=20972453; DOI=10.1038/onc.2010.476;
RA   von Bubnoff N., Gorantla S.P., Engh R.A., Oliveira T.M., Thone S.,
RA   Aberg E., Peschel C., Duyster J.;
RT   "The low frequency of clinical resistance to PDGFR inhibitors in
RT   myeloid neoplasms with abnormalities of PDGFRA might be related to the
RT   limited repertoire of possible PDGFRA kinase domain mutations in
RT   vitro.";
RL   Oncogene 30:933-943(2011).
RN   [35]
RP   REVIEW ON SIGNALING AND AUTOPHOSPHORYLATION.
RX   PubMed=9739761; DOI=10.1016/S0304-419X(98)00015-8;
RA   Heldin C.H., Ostman A., Ronnstrand L.;
RT   "Signal transduction via platelet-derived growth factor receptors.";
RL   Biochim. Biophys. Acta 1378:F79-113(1998).
RN   [36]
RP   REVIEW ON ROLE IN DISEASE AND ENZYME REGULATION.
RX   PubMed=15207817; DOI=10.1016/j.cytogfr.2004.03.002;
RA   Ostman A.;
RT   "PDGF receptors-mediators of autocrine tumor growth and regulators of
RT   tumor vasculature and stroma.";
RL   Cytokine Growth Factor Rev. 15:275-286(2004).
RN   [37]
RP   REVIEW ON ROLE IN DISEASE AND ENZYME REGULATION.
RX   PubMed=17419949; DOI=10.1016/S0065-230X(06)97011-0;
RA   Ostman A., Heldin C.H.;
RT   "PDGF receptors as targets in tumor treatment.";
RL   Adv. Cancer Res. 97:247-274(2007).
RN   [38]
RP   REVIEW ON FUNCTION IN DEVELOPMENT AND DISEASE; LIGANDS AND SIGNALING
RP   PATHWAYS.
RX   PubMed=18483217; DOI=10.1101/gad.1653708;
RA   Andrae J., Gallini R., Betsholtz C.;
RT   "Role of platelet-derived growth factors in physiology and medicine.";
RL   Genes Dev. 22:1276-1312(2008).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 1185-1189 IN COMPLEX WITH
RP   SLC9A3R1 AND PDGFRB.
RX   PubMed=11882663; DOI=10.1074/jbc.M201507200;
RA   Karthikeyan S., Leung T., Ladias J.A.A.;
RT   "Structural determinants of the Na+/H+ exchanger regulatory factor
RT   interaction with the beta 2 adrenergic and platelet-derived growth
RT   factor receptors.";
RL   J. Biol. Chem. 277:18973-18978(2002).
RN   [40]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASP-79; ASP-426; PRO-478; CYS-764;
RP   ARG-829; LYS-996 AND ASN-1071.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts as a cell-surface
CC       receptor for PDGFA, PDGFB and PDGFC and plays an essential role in
CC       the regulation of embryonic development, cell proliferation,
CC       survival and chemotaxis. Depending on the context, promotes or
CC       inhibits cell proliferation and cell migration. Plays an important
CC       role in the differentiation of bone marrow-derived mesenchymal
CC       stem cells. Required for normal skeleton development and cephalic
CC       closure during embryonic development. Required for normal
CC       development of the mucosa lining the gastrointestinal tract, and
CC       for recruitment of mesenchymal cells and normal development of
CC       intestinal villi. Plays a role in cell migration and chemotaxis in
CC       wound healing. Plays a role in platelet activation, secretion of
CC       agonists from platelet granules, and in thrombin-induced platelet
CC       aggregation. Binding of its cognate ligands - homodimeric PDGFA,
CC       homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or
CC       homodimeric PDGFC -leads to the activation of several signaling
CC       cascades; the response depends on the nature of the bound ligand
CC       and is modulated by the formation of heterodimers between PDGFRA
CC       and PDGFRB. Phosphorylates PIK3R1, PLCG1, and PTPN11. Activation
CC       of PLCG1 leads to the production of the cellular signaling
CC       molecules diacylglycerol and inositol 1,4,5-trisphosphate,
CC       mobilization of cytosolic Ca(2+) and the activation of protein
CC       kinase C. Phosphorylates PIK3R1, the regulatory subunit of
CC       phosphatidylinositol 3-kinase, and thereby mediates activation of
CC       the AKT1 signaling pathway. Mediates activation of HRAS and of the
CC       MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. Promotes activation of
CC       STAT family members STAT1, STAT3 and STAT5A and/or STAT5B.
CC       Receptor signaling is down-regulated by protein phosphatases that
CC       dephosphorylate the receptor and its down-stream effectors, and by
CC       rapid internalization of the activated receptor.
CC       {ECO:0000269|PubMed:10734113, ECO:0000269|PubMed:10947961,
CC       ECO:0000269|PubMed:11297552, ECO:0000269|PubMed:12522257,
CC       ECO:0000269|PubMed:1646396, ECO:0000269|PubMed:1709159,
CC       ECO:0000269|PubMed:17141222, ECO:0000269|PubMed:20972453,
CC       ECO:0000269|PubMed:21224473, ECO:0000269|PubMed:21596750,
CC       ECO:0000269|PubMed:2554309, ECO:0000269|PubMed:8188664,
CC       ECO:0000269|PubMed:8760137, ECO:0000269|PubMed:8943348}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- ENZYME REGULATION: Present in an inactive conformation in the
CC       absence of bound ligand. Binding of PDGFA and/or PDGFB leads to
CC       dimerization and activation by autophosphorylation on tyrosine
CC       residues. Inhibited by imatinib, nilotinib and sorafenib.
CC       {ECO:0000269|PubMed:15928335, ECO:0000269|PubMed:20972453,
CC       ECO:0000269|PubMed:21224473}.
CC   -!- SUBUNIT: Interacts with homodimeric PDGFA, PDGFB and PDGFC, and
CC       with heterodimers formed by PDGFA and PDGFB. Monomer in the
CC       absence of bound ligand. Interaction with dimeric PDGFA, PDGFB
CC       and/or PDGFC leads to receptor dimerization, where both PDGFRA
CC       homodimers and heterodimers with PDGFRB are observed. Interacts
CC       (tyrosine phosphorylated) with SHB (via SH2 domain) (By
CC       similarity). Interacts (tyrosine phosphorylated) with SHF (via SH2
CC       domain). Interacts (tyrosine phosphorylated) with SRC (via SH2
CC       domain). Interacts (tyrosine phosphorylated) with PIK3R1.
CC       Interacts (tyrosine phosphorylated) with PLCG1 (via SH2 domain).
CC       Interacts (tyrosine phosphorylated) with CRK, GRB2 and GRB7.
CC       Interacts with human cytomegalovirus/HHV-5 envelop glycoprotein
CC       B/gB. {ECO:0000250, ECO:0000269|PubMed:10733900,
CC       ECO:0000269|PubMed:11095946, ECO:0000269|PubMed:11297552,
CC       ECO:0000269|PubMed:11882663, ECO:0000269|PubMed:14644164,
CC       ECO:0000269|PubMed:1646396, ECO:0000269|PubMed:1709159,
CC       ECO:0000269|PubMed:20660204, ECO:0000269|PubMed:2173144,
CC       ECO:0000269|PubMed:2536956, ECO:0000269|PubMed:2544881,
CC       ECO:0000269|PubMed:7535778, ECO:0000269|PubMed:7679113,
CC       ECO:0000269|PubMed:8940081, ECO:0000269|PubMed:8943348}.
CC   -!- INTERACTION:
CC       Q8N6L0:CCDC155; NbExp=3; IntAct=EBI-2861522, EBI-749265;
CC       P46108:CRK; NbExp=4; IntAct=EBI-2861522, EBI-886;
CC       P46109:CRKL; NbExp=3; IntAct=EBI-2861522, EBI-910;
CC       P00533:EGFR; NbExp=3; IntAct=EBI-2861522, EBI-297353;
CC       P04085:PDGFA; NbExp=6; IntAct=EBI-2861522, EBI-2881386;
CC       P01127:PDGFB; NbExp=11; IntAct=EBI-2861522, EBI-1554925;
CC       Q9NRA1:PDGFC; NbExp=2; IntAct=EBI-2861522, EBI-8833587;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:14644164,
CC       ECO:0000269|PubMed:2554309, ECO:0000269|PubMed:8188664}; Single-
CC       pass type I membrane protein {ECO:0000269|PubMed:14644164,
CC       ECO:0000269|PubMed:2554309, ECO:0000269|PubMed:8188664}. Note=The
CC       activated receptor is rapidly internalized and degraded.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P16234-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P16234-2; Sequence=VSP_007833, VSP_007834;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=P16234-3; Sequence=VSP_042015, VSP_042016;
CC   -!- TISSUE SPECIFICITY: Detected in platelets (at protein level).
CC       Widely expressed. Detected in brain, fibroblasts, smooth muscle,
CC       heart, and embryo. Expressed in primary and metastatic colon
CC       tumors and in normal colon tissue. {ECO:0000269|PubMed:2536956,
CC       ECO:0000269|PubMed:7896447, ECO:0000269|PubMed:8188664}.
CC   -!- PTM: N-glycosylated.
CC   -!- PTM: Ubiquitinated, leading to its degradation.
CC       {ECO:0000305|PubMed:21596750}.
CC   -!- PTM: Autophosphorylated on tyrosine residues upon ligand binding.
CC       Autophosphorylation occurs in trans, i.e. one subunit of the
CC       dimeric receptor phosphorylates tyrosine residues on the other
CC       subunit. Phosphorylation at Tyr-731 and Tyr-742 is important for
CC       interaction with PIK3R1. Phosphorylation at Tyr-720 and Tyr-754 is
CC       important for interaction with PTPN11. Phosphorylation at Tyr-762
CC       is important for interaction with CRK. Phosphorylation at Tyr-572
CC       and Tyr-574 is important for interaction with SRC and SRC family
CC       members. Phosphorylation at Tyr-988 and Tyr-1018 is important for
CC       interaction with PLCG1. {ECO:0000269|PubMed:10733900,
CC       ECO:0000269|PubMed:10734113, ECO:0000269|PubMed:11095946,
CC       ECO:0000269|PubMed:1646396, ECO:0000269|PubMed:7535778,
CC       ECO:0000269|PubMed:8943348}.
CC   -!- DISEASE: Note=A chromosomal aberration involving PDGFRA is found
CC       in some cases of hypereosinophilic syndrome. Interstitial
CC       chromosomal deletion del(4)(q12q12) causes the fusion of FIP1L1
CC       and PDGFRA (FIP1L1-PDGFRA). Mutations that cause overexpression
CC       and/or constitutive activation of PDGFRA may be a cause of
CC       hypereosinophilic syndrome. {ECO:0000269|PubMed:12808148}.
CC   -!- DISEASE: Gastrointestinal stromal tumor (GIST) [MIM:606764]:
CC       Common mesenchymal neoplasms arising in the gastrointestinal
CC       tract, most often in the stomach. They are histologically,
CC       immunohistochemically, and genetically different from typical
CC       leiomyomas, leiomyosarcomas, and schwannomas. Most GISTs are
CC       composed of a fairly uniform population of spindle-shaped cells.
CC       Some tumors are dominated by epithelioid cells or contain a
CC       mixture of spindle and epithelioid morphologies. Primary GISTs in
CC       the gastrointestinal tract commonly metastasize in the omentum and
CC       mesenteries, often as multiple nodules. However, primary tumors
CC       may also occur outside of the gastrointestinal tract, in other
CC       intra-abdominal locations, especially in the omentum and
CC       mesentery. {ECO:0000269|PubMed:12522257,
CC       ECO:0000269|PubMed:15928335}. Note=The gene represented in this
CC       entry may be involved in disease pathogenesis. Mutations causing
CC       PDGFRA constitutive activation have been found in gastrointestinal
CC       stromal tumors lacking KIT mutations (PubMed:12522257).
CC       {ECO:0000269|PubMed:12522257}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. CSF-1/PDGF receptor subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 5 Ig-like C2-type (immunoglobulin-like)
CC       domains. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAP69563.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M22734; AAA60048.1; -; mRNA.
DR   EMBL; M21574; AAA96715.1; -; mRNA.
DR   EMBL; D50017; BAA08742.1; -; Genomic_DNA.
DR   EMBL; AK316578; BAG38166.1; -; mRNA.
DR   EMBL; AC098587; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC138779; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC015186; AAH15186.1; -; mRNA.
DR   EMBL; BC063414; AAH63414.1; -; mRNA.
DR   EMBL; AY229892; AAP69563.1; ALT_INIT; mRNA.
DR   CCDS; CCDS3495.1; -. [P16234-1]
DR   PIR; A40162; PFHUGA.
DR   RefSeq; NP_006197.1; NM_006206.4. [P16234-1]
DR   RefSeq; XP_005265800.1; XM_005265743.1. [P16234-1]
DR   RefSeq; XP_011532687.1; XM_011534385.1. [P16234-1]
DR   RefSeq; XP_011532688.1; XM_011534386.1. [P16234-1]
DR   UniGene; Hs.74615; -.
DR   PDB; 1GQ5; X-ray; 2.20 A; -.
DR   PDBsum; 1GQ5; -.
DR   ProteinModelPortal; P16234; -.
DR   SMR; P16234; 26-509, 551-997.
DR   BioGrid; 111182; 28.
DR   DIP; DIP-5736N; -.
DR   IntAct; P16234; 37.
DR   MINT; MINT-4529366; -.
DR   STRING; 9606.ENSP00000257290; -.
DR   BindingDB; P16234; -.
DR   ChEMBL; CHEMBL2095189; -.
DR   DrugBank; DB00102; Becaplermin.
DR   DrugBank; DB00619; Imatinib.
DR   DrugBank; DB06589; Pazopanib.
DR   DrugBank; DB08901; Ponatinib.
DR   DrugBank; DB08896; Regorafenib.
DR   DrugBank; DB01268; Sunitinib.
DR   GuidetoPHARMACOLOGY; 1803; -.
DR   iPTMnet; P16234; -.
DR   PhosphoSite; P16234; -.
DR   BioMuta; PDGFRA; -.
DR   DMDM; 129892; -.
DR   MaxQB; P16234; -.
DR   PaxDb; P16234; -.
DR   PRIDE; P16234; -.
DR   DNASU; 5156; -.
DR   Ensembl; ENST00000257290; ENSP00000257290; ENSG00000134853. [P16234-1]
DR   Ensembl; ENST00000508170; ENSP00000425648; ENSG00000134853. [P16234-2]
DR   Ensembl; ENST00000509490; ENSP00000424218; ENSG00000134853. [P16234-3]
DR   GeneID; 5156; -.
DR   KEGG; hsa:5156; -.
DR   UCSC; uc003hal.3; human. [P16234-2]
DR   UCSC; uc003han.4; human. [P16234-1]
DR   CTD; 5156; -.
DR   GeneCards; PDGFRA; -.
DR   HGNC; HGNC:8803; PDGFRA.
DR   HPA; CAB018143; -.
DR   MalaCards; PDGFRA; -.
DR   MIM; 173490; gene.
DR   MIM; 606764; phenotype.
DR   MIM; 607685; phenotype.
DR   neXtProt; NX_P16234; -.
DR   Orphanet; 44890; Gastrointestinal stromal tumor.
DR   Orphanet; 168947; Myeloid neoplasm associated with PDGFRA rearrangement.
DR   Orphanet; 99860; Precursor B-cell acute lymphoblastic leukemia.
DR   Orphanet; 314950; Primary hypereosinophilic syndrome.
DR   PharmGKB; PA33147; -.
DR   eggNOG; KOG0200; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118923; -.
DR   HOGENOM; HOG000112009; -.
DR   HOVERGEN; HBG004335; -.
DR   InParanoid; P16234; -.
DR   KO; K04363; -.
DR   OMA; DSAIIPC; -.
DR   OrthoDB; EOG71G9T1; -.
DR   PhylomeDB; P16234; -.
DR   TreeFam; TF325768; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-186763; Downstream signal transduction.
DR   Reactome; R-HSA-186797; Signaling by PDGF.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   SignaLink; P16234; -.
DR   ChiTaRS; PDGFRA; human.
DR   EvolutionaryTrace; P16234; -.
DR   GeneWiki; PDGFRA; -.
DR   GenomeRNAi; 5156; -.
DR   NextBio; 19946; -.
DR   PRO; PR:P16234; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   Bgee; P16234; -.
DR   CleanEx; HS_PDGFRA; -.
DR   ExpressionAtlas; P16234; baseline and differential.
DR   Genevisible; P16234; HS.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IMP:GOC.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0031226; C:intrinsic component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0043234; C:protein complex; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005018; F:platelet-derived growth factor alpha-receptor activity; IDA:UniProtKB.
DR   GO; GO:0048407; F:platelet-derived growth factor binding; IDA:UniProtKB.
DR   GO; GO:0005161; F:platelet-derived growth factor receptor binding; IPI:BHF-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:BHF-UCL.
DR   GO; GO:0004672; F:protein kinase activity; IDA:MGI.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0038085; F:vascular endothelial growth factor binding; IPI:BHF-UCL.
DR   GO; GO:0005021; F:vascular endothelial growth factor-activated receptor activity; IDA:BHF-UCL.
DR   GO; GO:0000186; P:activation of MAPKK activity; TAS:Reactome.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0055003; P:cardiac myofibril assembly; ISS:UniProtKB.
DR   GO; GO:0001775; P:cell activation; TAS:BHF-UCL.
DR   GO; GO:0060326; P:cell chemotaxis; IMP:UniProtKB.
DR   GO; GO:0034614; P:cellular response to reactive oxygen species; IDA:MGI.
DR   GO; GO:0048701; P:embryonic cranial skeleton morphogenesis; ISS:UniProtKB.
DR   GO; GO:0048557; P:embryonic digestive tract morphogenesis; ISS:UniProtKB.
DR   GO; GO:0048704; P:embryonic skeletal system morphogenesis; ISS:UniProtKB.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0045087; P:innate immune response; TAS:Reactome.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0001553; P:luteinization; ISS:UniProtKB.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0072277; P:metanephric glomerular capillary formation; ISS:UniProtKB.
DR   GO; GO:0010544; P:negative regulation of platelet activation; IDA:UniProtKB.
DR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; IMP:UniProtKB.
DR   GO; GO:0070527; P:platelet aggregation; IMP:UniProtKB.
DR   GO; GO:0048008; P:platelet-derived growth factor receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0035790; P:platelet-derived growth factor receptor-alpha signaling pathway; IMP:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; IMP:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IMP:UniProtKB.
DR   GO; GO:0038091; P:positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IMP:UniProtKB.
DR   GO; GO:0045740; P:positive regulation of DNA replication; IDA:BHF-UCL.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:0048146; P:positive regulation of fibroblast proliferation; IDA:BHF-UCL.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; IMP:UniProtKB.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; TAS:UniProtKB.
DR   GO; GO:0010863; P:positive regulation of phospholipase C activity; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0007265; P:Ras protein signal transduction; TAS:Reactome.
DR   GO; GO:2000249; P:regulation of actin cytoskeleton reorganization; TAS:UniProtKB.
DR   GO; GO:0050920; P:regulation of chemotaxis; IMP:UniProtKB.
DR   GO; GO:2000739; P:regulation of mesenchymal stem cell differentiation; IMP:UniProtKB.
DR   GO; GO:0061298; P:retina vasculature development in camera-type eye; ISS:UniProtKB.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; TAS:Reactome.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   GO; GO:0042060; P:wound healing; ISS:UniProtKB.
DR   Gene3D; 2.60.40.10; -; 4.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR027290; PDGFRA.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016243; Tyr_kinase_CSF1/PDGF_rcpt.
DR   InterPro; IPR001824; Tyr_kinase_rcpt_3_CS.
DR   PANTHER; PTHR24416:SF52; PTHR24416:SF52; 3.
DR   Pfam; PF07679; I-set; 2.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PIRSF; PIRSF500950; Alpha-PDGF_receptor; 1.
DR   PIRSF; PIRSF000615; TyrPK_CSF1-R; 1.
DR   SMART; SM00409; IG; 2.
DR   SMART; SM00408; IGc2; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 4.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS50835; IG_LIKE; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00240; RECEPTOR_TYR_KIN_III; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Chemotaxis; Complete proteome; Developmental protein; Disulfide bond;
KW   Glycoprotein; Host-virus interaction; Immunoglobulin domain; Kinase;
KW   Membrane; Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Proto-oncogene; Receptor; Reference proteome; Repeat; Signal;
KW   Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL        1     23
FT   CHAIN        24   1089       Platelet-derived growth factor receptor
FT                                alpha.
FT                                /FTId=PRO_0000016760.
FT   TOPO_DOM     24    528       Extracellular. {ECO:0000255}.
FT   TRANSMEM    529    549       Helical. {ECO:0000255}.
FT   TOPO_DOM    550   1089       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       24    113       Ig-like C2-type 1.
FT   DOMAIN      117    201       Ig-like C2-type 2.
FT   DOMAIN      202    306       Ig-like C2-type 3.
FT   DOMAIN      319    410       Ig-like C2-type 4.
FT   DOMAIN      414    517       Ig-like C2-type 5.
FT   DOMAIN      593    954       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     599    607       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   COMPBIAS   1041   1087       Ser-rich.
FT   ACT_SITE    818    818       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     627    627       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   SITE        578    579       Breakpoint for interstitial deletion to
FT                                form the FIP1L1-PDGFRA fusion protein.
FT   MOD_RES     572    572       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:10734113}.
FT   MOD_RES     574    574       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:10734113}.
FT   MOD_RES     720    720       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:11095946,
FT                                ECO:0000269|PubMed:8943348}.
FT   MOD_RES     731    731       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:1646396}.
FT   MOD_RES     742    742       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:1646396}.
FT   MOD_RES     754    754       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:17604334}.
FT   MOD_RES     762    762       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:10733900}.
FT   MOD_RES     768    768       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:8617789}.
FT   MOD_RES     849    849       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     988    988       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:7535778}.
FT   MOD_RES    1018   1018       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:7535778}.
FT   CARBOHYD     42     42       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD     76     76       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    103    103       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    179    179       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    353    353       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    359    359       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    458    458       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    468    468       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     49    100       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    150    189       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    235    290       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    435    501       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   VAR_SEQ     210    218       ATSELDLEM -> GTCIISFLL (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_007833.
FT   VAR_SEQ     219   1089       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_007834.
FT   VAR_SEQ     720    743       YVILSFENNGDYMDMKQADTTQYV -> SGQGCLSSGTLQE
FT                                LSVDLQARGPC (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_042015.
FT   VAR_SEQ     744   1089       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_042016.
FT   VARIANT      79     79       G -> D (in dbSNP:rs36035373).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042032.
FT   VARIANT     426    426       G -> D (in dbSNP:rs55865821).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042033.
FT   VARIANT     478    478       S -> P (in dbSNP:rs35597368).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_034378.
FT   VARIANT     481    481       R -> G (in a hypereosinophilic syndrome
FT                                sample; does not lead to constitutive
FT                                kinase activation).
FT                                {ECO:0000269|PubMed:21224473}.
FT                                /FTId=VAR_066460.
FT   VARIANT     507    507       L -> P (in a hypereosinophilic syndrome
FT                                sample; does not lead to constitutive
FT                                kinase activation).
FT                                {ECO:0000269|PubMed:21224473}.
FT                                /FTId=VAR_066461.
FT   VARIANT     561    561       V -> D (in a GIST sample; constitutively
FT                                activated kinase).
FT                                {ECO:0000269|PubMed:12522257,
FT                                ECO:0000269|PubMed:15928335}.
FT                                /FTId=VAR_066462.
FT   VARIANT     562    562       I -> M (in a hypereosinophilic syndrome
FT                                sample; does not lead to constitutive
FT                                kinase activation).
FT                                {ECO:0000269|PubMed:21224473}.
FT                                /FTId=VAR_066463.
FT   VARIANT     570    570       H -> R (in a hypereosinophilic syndrome
FT                                sample; does not lead to constitutive
FT                                kinase activation).
FT                                {ECO:0000269|PubMed:21224473}.
FT                                /FTId=VAR_066464.
FT   VARIANT     650    650       H -> Q (in a hypereosinophilic syndrome
FT                                sample; constitutively activated kinase).
FT                                {ECO:0000269|PubMed:21224473}.
FT                                /FTId=VAR_066465.
FT   VARIANT     659    659       N -> K (in GIST sample; constitutively
FT                                activated kinase).
FT                                {ECO:0000269|PubMed:15928335}.
FT                                /FTId=VAR_066466.
FT   VARIANT     659    659       N -> S (in a hypereosinophilic syndrome
FT                                sample; constitutively activated kinase).
FT                                {ECO:0000269|PubMed:21224473}.
FT                                /FTId=VAR_066467.
FT   VARIANT     705    705       L -> P (in a hypereosinophilic syndrome
FT                                sample; does not lead to constitutive
FT                                kinase activation).
FT                                {ECO:0000269|PubMed:21224473}.
FT                                /FTId=VAR_066468.
FT   VARIANT     748    748       R -> G (in a hypereosinophilic syndrome
FT                                sample; constitutively activated kinase).
FT                                {ECO:0000269|PubMed:21224473}.
FT                                /FTId=VAR_066469.
FT   VARIANT     764    764       R -> C (in dbSNP:rs34392012).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042034.
FT   VARIANT     829    829       G -> R (in a glioblastoma multiforme
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042035.
FT   VARIANT     842    845       Missing (in a GIST sample; constitutively
FT                                activated kinase).
FT                                {ECO:0000269|PubMed:12522257,
FT                                ECO:0000269|PubMed:15928335}.
FT                                /FTId=VAR_066470.
FT   VARIANT     842    842       D -> V (in a GIST sample; imatinib
FT                                resistant, constitutively activated
FT                                kinase). {ECO:0000269|PubMed:12522257,
FT                                ECO:0000269|PubMed:15928335,
FT                                ECO:0000269|PubMed:20972453}.
FT                                /FTId=VAR_066471.
FT   VARIANT     842    842       D -> Y (in a GIST sample; imatinib
FT                                sensitive, constitutively activated
FT                                kinase). {ECO:0000269|PubMed:15928335}.
FT                                /FTId=VAR_066472.
FT   VARIANT     845    848       Missing (in a GIST sample; constitutively
FT                                activated kinase).
FT                                {ECO:0000269|PubMed:12522257,
FT                                ECO:0000269|PubMed:15928335}.
FT                                /FTId=VAR_066473.
FT   VARIANT     849    849       Y -> C (in GIST).
FT                                {ECO:0000269|PubMed:15928335}.
FT                                /FTId=VAR_066474.
FT   VARIANT     849    849       Y -> S (in a hypereosinophilic syndrome
FT                                sample; constitutively activated kinase).
FT                                {ECO:0000269|PubMed:21224473}.
FT                                /FTId=VAR_066475.
FT   VARIANT     996    996       E -> K (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042036.
FT   VARIANT    1071   1071       D -> N (in a lung neuroendocrine
FT                                carcinoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042037.
FT   MUTAGEN     572    572       Y->F: Abolishes interaction with SRC-
FT                                family members and impairs
FT                                internalization of the activated
FT                                receptor; when associated with F-574.
FT                                {ECO:0000269|PubMed:10734113,
FT                                ECO:0000269|PubMed:14644164}.
FT   MUTAGEN     574    574       Y->F: Abolishes interaction with SRC-
FT                                family members and impairs
FT                                internalization of the activated
FT                                receptor; when associated with F-572.
FT                                {ECO:0000269|PubMed:10734113,
FT                                ECO:0000269|PubMed:14644164}.
FT   MUTAGEN     720    720       Y->F: Strongly reduced interaction with
FT                                PTPN11 and GRB2.
FT                                {ECO:0000269|PubMed:8943348}.
FT   MUTAGEN     731    731       Y->F: No effect on autophosphorylation
FT                                and phosphorylation of PLCG1. Abolishes
FT                                activation of phosphatidylinositol 3-
FT                                kinase. {ECO:0000269|PubMed:1646396}.
FT   MUTAGEN     742    742       Y->F: No effect on autophosphorylation
FT                                and phosphorylation of PLCG1. Abolishes
FT                                activation of phosphatidylinositol 3-
FT                                kinase. {ECO:0000269|PubMed:1646396}.
FT   MUTAGEN     762    762       Y->F: Abolishes interaction with CRK.
FT                                {ECO:0000269|PubMed:10733900}.
SQ   SEQUENCE   1089 AA;  122670 MW;  5E3FB9940ACD1BE8 CRC64;
     MGTSHPAFLV LGCLLTGLSL ILCQLSLPSI LPNENEKVVQ LNSSFSLRCF GESEVSWQYP
     MSEEESSDVE IRNEENNSGL FVTVLEVSSA SAAHTGLYTC YYNHTQTEEN ELEGRHIYIY
     VPDPDVAFVP LGMTDYLVIV EDDDSAIIPC RTTDPETPVT LHNSEGVVPA SYDSRQGFNG
     TFTVGPYICE ATVKGKKFQT IPFNVYALKA TSELDLEMEA LKTVYKSGET IVVTCAVFNN
     EVVDLQWTYP GEVKGKGITM LEEIKVPSIK LVYTLTVPEA TVKDSGDYEC AARQATREVK
     EMKKVTISVH EKGFIEIKPT FSQLEAVNLH EVKHFVVEVR AYPPPRISWL KNNLTLIENL
     TEITTDVEKI QEIRYRSKLK LIRAKEEDSG HYTIVAQNED AVKSYTFELL TQVPSSILDL
     VDDHHGSTGG QTVRCTAEGT PLPDIEWMIC KDIKKCNNET SWTILANNVS NIITEIHSRD
     RSTVEGRVTF AKVEETIAVR CLAKNLLGAE NRELKLVAPT LRSELTVAAA VLVLLVIVII
     SLIVLVVIWK QKPRYEIRWR VIESISPDGH EYIYVDPMQL PYDSRWEFPR DGLVLGRVLG
     SGAFGKVVEG TAYGLSRSQP VMKVAVKMLK PTARSSEKQA LMSELKIMTH LGPHLNIVNL
     LGACTKSGPI YIITEYCFYG DLVNYLHKNR DSFLSHHPEK PKKELDIFGL NPADESTRSY
     VILSFENNGD YMDMKQADTT QYVPMLERKE VSKYSDIQRS LYDRPASYKK KSMLDSEVKN
     LLSDDNSEGL TLLDLLSFTY QVARGMEFLA SKNCVHRDLA ARNVLLAQGK IVKICDFGLA
     RDIMHDSNYV SKGSTFLPVK WMAPESIFDN LYTTLSDVWS YGILLWEIFS LGGTPYPGMM
     VDSTFYNKIK SGYRMAKPDH ATSEVYEIMV KCWNSEPEKR PSFYHLSEIV ENLLPGQYKK
     SYEKIHLDFL KSDHPAVARM RVDSDNAYIG VTYKNEEDKL KDWEGGLDEQ RLSADSGYII
     PLPDIDPVPE EEDLGKRNRH SSQTSEESAI ETGSSSSTFI KREDETIEDI DMMDDIGIDS
     SDLVEDSFL
//
ID   ACVL1_HUMAN             Reviewed;         503 AA.
AC   P37023; A6NGA8;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   15-DEC-1998, sequence version 2.
DT   17-FEB-2016, entry version 180.
DE   RecName: Full=Serine/threonine-protein kinase receptor R3;
DE            Short=SKR3;
DE            EC=2.7.11.30;
DE   AltName: Full=Activin receptor-like kinase 1;
DE            Short=ALK-1;
DE   AltName: Full=TGF-B superfamily receptor type I;
DE            Short=TSR-I;
DE   Flags: Precursor;
GN   Name=ACVRL1; Synonyms=ACVRLK1, ALK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Placenta;
RX   PubMed=8397373;
RA   ten Dijke P., Ichijo H., Franzen P., Schulz P., Saras J.,
RA   Toyoshima H., Heldin C.-H., Miyazono K.;
RT   "Activin receptor-like kinases: a novel subclass of cell-surface
RT   receptors with predicted serine/threonine kinase activity.";
RL   Oncogene 8:2879-2887(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8242742; DOI=10.1016/0092-8674(93)90488-C;
RA   Attisano L., Carcamo J., Ventura F., Weis F.M., Massague J.,
RA   Wrana J.L.;
RT   "Identification of human activin and TGF beta type I receptors that
RT   form heteromeric kinase complexes with type II receptors.";
RL   Cell 75:671-680(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS HHT2 CYS-50; GLN-67;
RP   ILE-333; TRP-374 AND THR-424.
RX   PubMed=9245985; DOI=10.1086/513903;
RA   Berg J.N., Gallione C.J., Stenzel T.T., Johnson D.W., Allen W.P.,
RA   Schwartz C.E., Jackson C.E., Porteous M.E.M., Marchuk D.A.;
RT   "The activin receptor-like kinase 1 gene: genomic structure and
RT   mutations in hereditary hemorrhagic telangiectasia type 2.";
RL   Am. J. Hum. Genet. 61:60-67(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M.,
RA   Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Montgomery K.T., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D.,
RA   Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., Zhang Z.,
RA   Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., Draper H.,
RA   Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., Kelly S.H.,
RA   Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V.,
RA   Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., Santibanez J.,
RA   Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., Williams G.A.,
RA   Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., Bailey M.,
RA   Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., Burkett C.E.,
RA   Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M.,
RA   Dathorne S.R., David R., Davis C.M., Davy-Carroll L., Deshazo D.R.,
RA   Donlin J.E., D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J.,
RA   Escotto M., Flagg N., Forbes L.D., Gabisi A.M., Garza M., Hamilton C.,
RA   Henderson N., Hernandez O., Hines S., Hogues M.E., Huang M.,
RA   Idlebird D.G., Johnson R., Jolivet A., Jones S., Kagan R., King L.M.,
RA   Leal B., Lebow H., Lee S., LeVan J.M., Lewis L.C., London P.,
RA   Lorensuhewa L.M., Loulseged H., Lovett D.A., Lucier A., Lucier R.L.,
RA   Ma J., Madu R.C., Mapua P., Martindale A.D., Martinez E., Massey E.,
RA   Mawhiney S., Meador M.G., Mendez S., Mercado C., Mercado I.C.,
RA   Merritt C.E., Miner Z.L., Minja E., Mitchell T., Mohabbat F.,
RA   Mohabbat K., Montgomery B., Moore N., Morris S., Munidasa M.,
RA   Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., Nwokenkwo S.,
RA   Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D.,
RA   Trejos Z.Y., Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I.,
RA   Vera V.A., Villasana D.M., Wang L., Ward-Moore S., Warren J.T.,
RA   Wei X., White F., Williamson A.L., Wleczyk R., Wooden H.S.,
RA   Wooden S.H., Yen J., Yoon L., Yoon V., Zorrilla S.E., Nelson D.,
RA   Kucherlapati R., Weinstock G., Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   STRUCTURE BY NMR OF 19-118, FUNCTION AS BMP9 RECEPTOR, DISULFIDE
RP   BONDS, AND MUTAGENESIS OF 74-ARG--LEU-76.
RX   PubMed=22799562; DOI=10.1021/bi300942x;
RA   Mahlawat P., Ilangovan U., Biswas T., Sun L.Z., Hinck A.P.;
RT   "Structure of the Alk1 extracellular domain and characterization of
RT   its bone morphogenetic protein (BMP) binding properties.";
RL   Biochemistry 51:6328-6341(2012).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (3.36 ANGSTROMS) OF 22-118 IN COMPLEX WITH BMP9
RP   AND ACVR2B, FUNCTION AS BMP9 AND BMP10 RECEPTOR, AND DISULFIDE BONDS.
RX   PubMed=22718755; DOI=10.1074/jbc.M112.377960;
RA   Townson S.A., Martinez-Hackert E., Greppi C., Lowden P., Sako D.,
RA   Liu J., Ucran J.A., Liharska K., Underwood K.W., Seehra J., Kumar R.,
RA   Grinberg A.V.;
RT   "Specificity and structure of a high affinity activin receptor-like
RT   kinase 1 (ALK1) signaling complex.";
RL   J. Biol. Chem. 287:27313-27325(2012).
RN   [9]
RP   VARIANTS HHT2 SER-232 DEL; ARG-376 AND GLN-411.
RX   PubMed=8640225; DOI=10.1038/ng0696-189;
RA   Johnson D.W., Berg J.N., Baldwin M.A., Gallione C.J., Marondel I.,
RA   Yoon S.-J., Stenzel T.T., Speer M., Pericak-Vance M.A., Diamond A.,
RA   Guttmacher A.E., Jackson C.E., Attisano L., Kucherlapati R.,
RA   Porteous M.E.M., Marchuk D.A.;
RT   "Mutations in the activin receptor-like kinase 1 gene in hereditary
RT   haemorrhagic telangiectasia type 2.";
RL   Nat. Genet. 13:189-194(1996).
RN   [10]
RP   VARIANTS HHT2 TYR-51; TRP-77 AND ASP-96.
RX   PubMed=10694922;
RX   DOI=10.1002/(SICI)1098-1004(1998)12:2<137::AID-HUMU15>3.0.CO;2-M;
RA   Klaus D.J., Gallione C.J., Anthony K., Yeh E.Y., Yu J., Lux A.,
RA   Johnson D.W., Marchuk D.A.;
RT   "Novel missense and frameshift mutations in the activin receptor-like
RT   kinase-1 gene in hereditary hemorrhagic telangiectasia.";
RL   Hum. Mutat. 12:137-137(1998).
RN   [11]
RP   VARIANTS HHT2 GLY-48-49-ALA DELINS EP; CYS-50; SER-232 DEL; ILE-333;
RP   TYR-344 AND ASP-407.
RX   PubMed=10767348; DOI=10.1093/hmg/9.8.1227;
RA   Abdalla S.A., Pece-Barbara N., Vera S., Tapia E., Paez E.,
RA   Bernabeu C., Letarte M.;
RT   "Analysis of ALK-1 and endoglin in newborns from families with
RT   hereditary hemorrhagic telangiectasia type 2.";
RL   Hum. Mol. Genet. 9:1227-1237(2000).
RN   [12]
RP   VARIANTS HHT2 TRP-374 AND ASN-398.
RX   PubMed=11170071;
RX   DOI=10.1002/1096-8628(20010201)98:4<298::AID-AJMG1093>3.0.CO;2-K;
RA   Kjeldsen A.D., Brusgaard K., Poulsen L., Kruse T., Rasmussen K.,
RA   Green A., Vase P.;
RT   "Mutations in the ALK-1 gene and the phenotype of hereditary
RT   hemorrhagic telangiectasia in two large Danish families.";
RL   Am. J. Med. Genet. 98:298-302(2001).
RN   [13]
RP   VARIANTS HHT2 ASP-254 DEL; TRP-411 AND TRP-484.
RX   PubMed=11484689; DOI=10.1056/NEJM200108023450503;
RA   Trembath R.C., Thomson J.R., Machado R.D., Morgan N.V., Atkinson C.,
RA   Winship I., Simonneau G., Galie N., Loyd J.E., Humbert M.,
RA   Nichols W.C., Berg J., Manes A., McGaughran J., Pauciulo M.,
RA   Wheeler L., Morrell N.W.;
RT   "Clinical and molecular genetic features of pulmonary hypertension in
RT   patients with hereditary hemorrhagic telangiectasia.";
RL   N. Engl. J. Med. 345:325-334(2001).
RN   [14]
RP   VARIANTS HHT2 ALA-179; ASP-211; TYR-344; TRP-374; GLN-374; SER-399;
RP   GLN-411 AND THR-487, AND CHARACTERIZATION OF VARIANTS HHT2 CYS-50;
RP   GLN-67; TRP-77; ALA-179; ASP-211; SER-232 DEL; ASP-254 DEL; ILE-333;
RP   TYR-344; GLN-374; LEU-378; GLN-411 AND THR-487.
RX   PubMed=14684682; DOI=10.1136/jmg.40.12.865;
RA   Harrison R.E., Flanagan J.A., Sankelo M., Abdalla S.A., Rowell J.,
RA   Machado R.D., Elliott C.G., Robbins I.M., Olschewski H.,
RA   McLaughlin V., Gruenig E., Kermeen F., Halme M.,
RA   Raeisaenen-Sokolowski A., Laitinen T., Morrell N.W., Trembath R.C.;
RT   "Molecular and functional analysis identifies ALK-1 as the predominant
RT   cause of pulmonary hypertension related to hereditary haemorrhagic
RT   telangiectasia.";
RL   J. Med. Genet. 40:865-871(2003).
RN   [15]
RP   ERRATUM.
RA   Harrison R.E., Flanagan J.A., Sankelo M., Abdalla S.A., Rowell J.,
RA   Machado R.D., Elliott C.G., Robbins I.M., Olschewski H.,
RA   McLaughlin V., Gruenig E., Kermeen F., Halme M.,
RA   Raeisaenen-Sokolowski A., Laitinen T., Morrell N.W., Trembath R.C.;
RL   J. Med. Genet. 41:576-576(2004).
RN   [16]
RP   VARIANTS HHT2 ARG-48; LYS-215; ARG-223; ARG-229; SER-233 DEL; PHE-285;
RP   PRO-306; TYR-314; PRO-337; PRO-347; GLN-374; VAL-376; LYS-379;
RP   GLY-397; TRP-411; PRO-411; GLN-411; LEU-425; LEU-479; VAL-482 AND
RP   TRP-484.
RX   PubMed=15024723; DOI=10.1002/humu.20017;
RG   French Rendu-Osler network;
RA   Lesca G., Plauchu H., Coulet F., Lefebvre S., Plessis G., Odent S.,
RA   Riviere S., Leheup B., Goizet C., Carette M.-F., Cordier J.-F.,
RA   Pinson S., Soubrier F., Calender A., Giraud S.;
RT   "Molecular screening of ALK1/ACVRL1 and ENG genes in hereditary
RT   hemorrhagic telangiectasia in France.";
RL   Hum. Mutat. 23:289-299(2004).
RN   [17]
RP   VARIANTS HHT2 TRP-67; TRP-374; LYS-379; ASP-407; TRP-411; VAL-425 AND
RP   PHE-425 DEL.
RX   PubMed=15712270; DOI=10.1002/humu.9311;
RA   Kuehl H.K.A., Caselitz M., Hasenkamp S., Wagner S., El-Harith E.-H.A.,
RA   Manns M.P., Stuhrmann M.;
RT   "Hepatic manifestation is associated with ALK1 in hereditary
RT   hemorrhagic telangiectasia: identification of five novel ALK1 and one
RT   novel ENG mutations.";
RL   Hum. Mutat. 25:320-320(2005).
RN   [18]
RP   VARIANT SER-30, AND VARIANTS HHT2 TYR-34; ALA-52; ILE-197; ASP-219;
RP   LYS-237; LEU-260; PRO-289; ARG-344; CYS-426 AND ARG-433.
RX   PubMed=16752392; DOI=10.1002/humu.20342;
RA   Bossler A.D., Richards J., George C., Godmilow L., Ganguly A.;
RT   "Novel mutations in ENG and ACVRL1 identified in a series of 200
RT   individuals undergoing clinical genetic testing for hereditary
RT   hemorrhagic telangiectasia (HHT): correlation of genotype with
RT   phenotype.";
RL   Hum. Mutat. 27:667-675(2006).
RN   [19]
RP   VARIANTS HHT2 GLY-50; PRO-66; ARG-69; TYR-176; LEU-233; PRO-265;
RP   PRO-403 AND SER-416.
RX   PubMed=16525724;
RA   Argyriou L., Twelkemeyer S., Panchulidze I., Wehner L.E., Teske U.,
RA   Engel W., Nayernia K.;
RT   "Novel mutations in the ENG and ACVRL1 genes causing hereditary
RT   hemorrhagic teleangiectasia.";
RL   Int. J. Mol. Med. 17:655-659(2006).
RN   [20]
RP   VARIANTS CYS-38; PRO-138; LYS-277; PRO-342; THR-400 AND GLU-486, AND
RP   VARIANTS HHT2 SER-96; GLY-217; GLU-226; ARG-280; ARG-294; GLN-328;
RP   HIS-335; ASP-347; SER-378; ARG-424; SER-449 AND PRO-479.
RX   PubMed=20414677; DOI=10.1007/s00439-010-0825-4;
RA   Richards-Yutz J., Grant K., Chao E.C., Walther S.E., Ganguly A.;
RT   "Update on molecular diagnosis of hereditary hemorrhagic
RT   telangiectasia.";
RL   Hum. Genet. 128:61-77(2010).
CC   -!- FUNCTION: Type I receptor for TGF-beta family ligands BMP9/GDF2
CC       and BMP10 and important regulator of normal blood vessel
CC       development. On ligand binding, forms a receptor complex
CC       consisting of two type II and two type I transmembrane
CC       serine/threonine kinases. Type II receptors phosphorylate and
CC       activate type I receptors which autophosphorylate, then bind and
CC       activate SMAD transcriptional regulators. May bind activin as
CC       well. {ECO:0000269|PubMed:22718755, ECO:0000269|PubMed:22799562}.
CC   -!- CATALYTIC ACTIVITY: ATP + [receptor-protein] = ADP + [receptor-
CC       protein] phosphate.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250};
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- DISEASE: Telangiectasia, hereditary hemorrhagic, 2 (HHT2)
CC       [MIM:600376]: A multisystemic vascular dysplasia leading to
CC       dilation of permanent blood vessels and arteriovenous
CC       malformations of skin, mucosa, and viscera. The disease is
CC       characterized by recurrent epistaxis and gastro-intestinal
CC       hemorrhage. Visceral involvement includes arteriovenous
CC       malformations of the lung, liver, and brain.
CC       {ECO:0000269|PubMed:10694922, ECO:0000269|PubMed:10767348,
CC       ECO:0000269|PubMed:11170071, ECO:0000269|PubMed:11484689,
CC       ECO:0000269|PubMed:14684682, ECO:0000269|PubMed:15024723,
CC       ECO:0000269|PubMed:15712270, ECO:0000269|PubMed:16525724,
CC       ECO:0000269|PubMed:16752392, ECO:0000269|PubMed:20414677,
CC       ECO:0000269|PubMed:8640225, ECO:0000269|PubMed:9245985}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. TGFB receptor subfamily. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 GS domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00585}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Hereditary Hemorrhagic Telangiectasia and ENG;
CC       URL="http://arup.utah.edu/database/ACVRL1/ACVRL1_welcome.php";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Z22533; CAA80255.1; -; mRNA.
DR   EMBL; L17075; AAA16160.1; -; mRNA.
DR   EMBL; U77713; AAB61900.1; -; Genomic_DNA.
DR   EMBL; U77707; AAB61900.1; JOINED; Genomic_DNA.
DR   EMBL; U77708; AAB61900.1; JOINED; Genomic_DNA.
DR   EMBL; U77709; AAB61900.1; JOINED; Genomic_DNA.
DR   EMBL; U77710; AAB61900.1; JOINED; Genomic_DNA.
DR   EMBL; U77711; AAB61900.1; JOINED; Genomic_DNA.
DR   EMBL; U77712; AAB61900.1; JOINED; Genomic_DNA.
DR   EMBL; AC025259; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471111; EAW58213.1; -; Genomic_DNA.
DR   EMBL; BC042637; AAH42637.1; -; mRNA.
DR   CCDS; CCDS31804.1; -.
DR   PIR; A49431; A49431.
DR   RefSeq; NP_000011.2; NM_000020.2.
DR   RefSeq; NP_001070869.1; NM_001077401.1.
DR   RefSeq; XP_005269292.1; XM_005269235.2.
DR   UniGene; Hs.591026; -.
DR   PDB; 2LCR; NMR; -; A=22-118.
DR   PDB; 3MY0; X-ray; 2.65 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U/V/W/X=195-497.
DR   PDB; 4FAO; X-ray; 3.36 A; C/D/I/J/O/P/U/V/c/d/i/j=22-118.
DR   PDBsum; 2LCR; -.
DR   PDBsum; 3MY0; -.
DR   PDBsum; 4FAO; -.
DR   ProteinModelPortal; P37023; -.
DR   SMR; P37023; 22-118, 172-493.
DR   BioGrid; 106609; 18.
DR   DIP; DIP-5938N; -.
DR   IntAct; P37023; 1.
DR   STRING; 9606.ENSP00000373574; -.
DR   BindingDB; P37023; -.
DR   ChEMBL; CHEMBL5311; -.
DR   DrugBank; DB00171; Adenosine triphosphate.
DR   GuidetoPHARMACOLOGY; 1784; -.
DR   iPTMnet; P37023; -.
DR   PhosphoSite; P37023; -.
DR   BioMuta; ACVRL1; -.
DR   DMDM; 3915750; -.
DR   PaxDb; P37023; -.
DR   PRIDE; P37023; -.
DR   DNASU; 94; -.
DR   Ensembl; ENST00000388922; ENSP00000373574; ENSG00000139567.
DR   GeneID; 94; -.
DR   KEGG; hsa:94; -.
DR   UCSC; uc001rzj.3; human.
DR   CTD; 94; -.
DR   GeneCards; ACVRL1; -.
DR   GeneReviews; ACVRL1; -.
DR   HGNC; HGNC:175; ACVRL1.
DR   HPA; HPA007041; -.
DR   MalaCards; ACVRL1; -.
DR   MIM; 600376; phenotype.
DR   MIM; 601284; gene.
DR   neXtProt; NX_P37023; -.
DR   Orphanet; 774; Hereditary hemorrhagic telangiectasia.
DR   Orphanet; 275777; Heritable pulmonary arterial hypertension.
DR   PharmGKB; PA24496; -.
DR   eggNOG; KOG2052; Eukaryota.
DR   eggNOG; ENOG410XQT0; LUCA.
DR   GeneTree; ENSGT00760000118876; -.
DR   HOGENOM; HOG000230587; -.
DR   HOVERGEN; HBG054502; -.
DR   InParanoid; P37023; -.
DR   KO; K13594; -.
DR   PhylomeDB; P37023; -.
DR   TreeFam; TF314724; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   BRENDA; 2.7.11.30; 2681.
DR   SignaLink; P37023; -.
DR   ChiTaRS; ACVRL1; human.
DR   GeneWiki; ACVRL1; -.
DR   GenomeRNAi; 94; -.
DR   NextBio; 355; -.
DR   PRO; PR:P37023; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   Bgee; P37023; -.
DR   CleanEx; HS_ACVRL1; -.
DR   ExpressionAtlas; P37023; baseline and differential.
DR   Genevisible; P37023; HS.
DR   GO; GO:0009986; C:cell surface; IDA:MGI.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0048185; F:activin binding; IDA:UniProtKB.
DR   GO; GO:0016361; F:activin receptor activity, type I; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IDA:HGNC.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0019901; F:protein kinase binding; IPI:BHF-UCL.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:HGNC.
DR   GO; GO:0004702; F:receptor signaling protein serine/threonine kinase activity; IEA:Ensembl.
DR   GO; GO:0046332; F:SMAD binding; IDA:HGNC.
DR   GO; GO:0050431; F:transforming growth factor beta binding; IPI:UniProtKB.
DR   GO; GO:0005025; F:transforming growth factor beta receptor activity, type I; IEA:Ensembl.
DR   GO; GO:0005024; F:transforming growth factor beta-activated receptor activity; IDA:MGI.
DR   GO; GO:0004675; F:transmembrane receptor protein serine/threonine kinase activity; NAS:UniProtKB.
DR   GO; GO:0032924; P:activin receptor signaling pathway; IDA:GOC.
DR   GO; GO:0001525; P:angiogenesis; IMP:HGNC.
DR   GO; GO:0060840; P:artery development; ISS:BHF-UCL.
DR   GO; GO:0008015; P:blood circulation; IMP:HGNC.
DR   GO; GO:0002043; P:blood vessel endothelial cell proliferation involved in sprouting angiogenesis; TAS:DFLAT.
DR   GO; GO:0001955; P:blood vessel maturation; TAS:DFLAT.
DR   GO; GO:0001974; P:blood vessel remodeling; ISS:BHF-UCL.
DR   GO; GO:0030509; P:BMP signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0071773; P:cellular response to BMP stimulus; IMP:BHF-UCL.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IDA:BHF-UCL.
DR   GO; GO:0061154; P:endothelial tube morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0001946; P:lymphangiogenesis; ISS:BHF-UCL.
DR   GO; GO:0060836; P:lymphatic endothelial cell differentiation; IMP:BHF-UCL.
DR   GO; GO:0043537; P:negative regulation of blood vessel endothelial cell migration; IMP:BHF-UCL.
DR   GO; GO:0007162; P:negative regulation of cell adhesion; IMP:HGNC.
DR   GO; GO:0030308; P:negative regulation of cell growth; IDA:BHF-UCL.
DR   GO; GO:0030336; P:negative regulation of cell migration; IMP:HGNC.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IMP:HGNC.
DR   GO; GO:2000279; P:negative regulation of DNA biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0045602; P:negative regulation of endothelial cell differentiation; IEA:Ensembl.
DR   GO; GO:0010596; P:negative regulation of endothelial cell migration; IDA:BHF-UCL.
DR   GO; GO:0001937; P:negative regulation of endothelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0051895; P:negative regulation of focal adhesion assembly; IMP:HGNC.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IEA:Ensembl.
DR   GO; GO:0030513; P:positive regulation of BMP signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0032332; P:positive regulation of chondrocyte differentiation; TAS:BHF-UCL.
DR   GO; GO:0045603; P:positive regulation of endothelial cell differentiation; IEA:Ensembl.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0010862; P:positive regulation of pathway-restricted SMAD protein phosphorylation; IMP:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:HGNC.
DR   GO; GO:0051291; P:protein heterooligomerization; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:HGNC.
DR   GO; GO:0008217; P:regulation of blood pressure; IMP:HGNC.
DR   GO; GO:0043535; P:regulation of blood vessel endothelial cell migration; TAS:DFLAT.
DR   GO; GO:0006275; P:regulation of DNA replication; TAS:DFLAT.
DR   GO; GO:0001936; P:regulation of endothelial cell proliferation; TAS:DFLAT.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IMP:HGNC.
DR   GO; GO:0061298; P:retina vasculature development in camera-type eye; ISS:BHF-UCL.
DR   GO; GO:0007165; P:signal transduction; IDA:HGNC.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IDA:HGNC.
DR   GO; GO:0060841; P:venous blood vessel development; ISS:BHF-UCL.
DR   GO; GO:0035313; P:wound healing, spreading of epidermal cells; IMP:HGNC.
DR   InterPro; IPR003605; GS_dom.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR000333; TGFB_receptor.
DR   PANTHER; PTHR23255; PTHR23255; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF08515; TGF_beta_GS; 1.
DR   PRINTS; PR00653; ACTIVIN2R.
DR   SMART; SM00467; GS; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51256; GS; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Angiogenesis; ATP-binding; Complete proteome;
KW   Disease mutation; Disulfide bond; Glycoprotein; Kinase; Magnesium;
KW   Manganese; Membrane; Metal-binding; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Receptor; Reference proteome;
KW   Serine/threonine-protein kinase; Signal; Transferase; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL        1     21       {ECO:0000255}.
FT   CHAIN        22    503       Serine/threonine-protein kinase receptor
FT                                R3.
FT                                /FTId=PRO_0000024420.
FT   TOPO_DOM     22    118       Extracellular. {ECO:0000255}.
FT   TRANSMEM    119    141       Helical. {ECO:0000255}.
FT   TOPO_DOM    142    503       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      172    201       GS. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00585}.
FT   DOMAIN      202    492       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     208    216       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION       73     76       Mediates specificity for BMP ligand.
FT   ACT_SITE    330    330       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     229    229       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     155    155       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q61288}.
FT   MOD_RES     160    160       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q61288}.
FT   MOD_RES     161    161       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q61288}.
FT   MOD_RES     495    495       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q04771}.
FT   CARBOHYD     98     98       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     34     51       {ECO:0000244|PDB:2LCR,
FT                                ECO:0000244|PDB:4FAO,
FT                                ECO:0000269|PubMed:22718755,
FT                                ECO:0000269|PubMed:22799562}.
FT   DISULFID     36     41       {ECO:0000244|PDB:2LCR,
FT                                ECO:0000244|PDB:4FAO,
FT                                ECO:0000269|PubMed:22718755,
FT                                ECO:0000269|PubMed:22799562}.
FT   DISULFID     46     69       {ECO:0000244|PDB:2LCR,
FT                                ECO:0000244|PDB:4FAO,
FT                                ECO:0000269|PubMed:22718755,
FT                                ECO:0000269|PubMed:22799562}.
FT   DISULFID     77     89       {ECO:0000244|PDB:2LCR,
FT                                ECO:0000244|PDB:4FAO,
FT                                ECO:0000269|PubMed:22718755,
FT                                ECO:0000269|PubMed:22799562}.
FT   DISULFID     90     95       {ECO:0000244|PDB:2LCR,
FT                                ECO:0000244|PDB:4FAO,
FT                                ECO:0000269|PubMed:22718755,
FT                                ECO:0000269|PubMed:22799562}.
FT   VARIANT      30     30       P -> S (found in a patient with
FT                                hereditary hemorrhagic talagiectasia;
FT                                unknown pathological significance;
FT                                dbSNP:rs149664056).
FT                                {ECO:0000269|PubMed:16752392}.
FT                                /FTId=VAR_070308.
FT   VARIANT      34     34       C -> Y (in HHT2).
FT                                {ECO:0000269|PubMed:16752392}.
FT                                /FTId=VAR_070309.
FT   VARIANT      38     38       S -> C. {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070310.
FT   VARIANT      48     49       GA -> EP (in HHT2).
FT                                /FTId=VAR_026784.
FT   VARIANT      48     48       G -> R (in HHT2).
FT                                {ECO:0000269|PubMed:15024723}.
FT                                /FTId=VAR_026785.
FT   VARIANT      50     50       W -> C (in HHT2; retained in the
FT                                endoplasmic reticulum).
FT                                {ECO:0000269|PubMed:10767348,
FT                                ECO:0000269|PubMed:14684682,
FT                                ECO:0000269|PubMed:9245985}.
FT                                /FTId=VAR_006204.
FT   VARIANT      50     50       W -> G (in HHT2).
FT                                {ECO:0000269|PubMed:16525724}.
FT                                /FTId=VAR_070311.
FT   VARIANT      51     51       C -> Y (in HHT2).
FT                                {ECO:0000269|PubMed:10694922}.
FT                                /FTId=VAR_006205.
FT   VARIANT      52     52       T -> A (in HHT2).
FT                                {ECO:0000269|PubMed:16752392}.
FT                                /FTId=VAR_070312.
FT   VARIANT      66     66       H -> P (in HHT2).
FT                                {ECO:0000269|PubMed:16525724}.
FT                                /FTId=VAR_070313.
FT   VARIANT      67     67       R -> Q (in HHT2; retained in the
FT                                endoplasmic reticulum).
FT                                {ECO:0000269|PubMed:14684682,
FT                                ECO:0000269|PubMed:9245985}.
FT                                /FTId=VAR_006206.
FT   VARIANT      67     67       R -> W (in HHT2).
FT                                {ECO:0000269|PubMed:15712270}.
FT                                /FTId=VAR_026786.
FT   VARIANT      69     69       C -> R (in HHT2).
FT                                {ECO:0000269|PubMed:16525724}.
FT                                /FTId=VAR_070314.
FT   VARIANT      77     77       C -> W (in HHT2; retained in the
FT                                endoplasmic reticulum).
FT                                {ECO:0000269|PubMed:10694922,
FT                                ECO:0000269|PubMed:14684682}.
FT                                /FTId=VAR_006207.
FT   VARIANT      96     96       N -> D (in HHT2).
FT                                {ECO:0000269|PubMed:10694922}.
FT                                /FTId=VAR_006208.
FT   VARIANT      96     96       N -> S (in HHT2).
FT                                {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070315.
FT   VARIANT     138    138       L -> P. {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070316.
FT   VARIANT     176    176       D -> Y (in HHT2).
FT                                {ECO:0000269|PubMed:16525724}.
FT                                /FTId=VAR_070317.
FT   VARIANT     179    179       D -> A (in HHT2; mutant protein is
FT                                capable of targeting the cell surface
FT                                appropriately).
FT                                {ECO:0000269|PubMed:14684682}.
FT                                /FTId=VAR_026787.
FT   VARIANT     197    197       T -> I (in HHT2).
FT                                {ECO:0000269|PubMed:16752392}.
FT                                /FTId=VAR_070318.
FT   VARIANT     211    211       G -> D (in HHT2; retained in the
FT                                endoplasmic reticulum; dbSNP:rs28936687).
FT                                {ECO:0000269|PubMed:14684682}.
FT                                /FTId=VAR_026788.
FT   VARIANT     215    215       E -> K (in HHT2).
FT                                {ECO:0000269|PubMed:15024723}.
FT                                /FTId=VAR_026789.
FT   VARIANT     217    217       W -> G (in HHT2).
FT                                {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070319.
FT   VARIANT     219    219       G -> D (in HHT2).
FT                                {ECO:0000269|PubMed:16752392}.
FT                                /FTId=VAR_070320.
FT   VARIANT     223    223       G -> R (in HHT2).
FT                                {ECO:0000269|PubMed:15024723}.
FT                                /FTId=VAR_026790.
FT   VARIANT     226    226       V -> E (in HHT2).
FT                                {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070321.
FT   VARIANT     229    229       K -> R (in HHT2).
FT                                {ECO:0000269|PubMed:15024723}.
FT                                /FTId=VAR_026791.
FT   VARIANT     232    232       Missing (in HHT2; mutant protein is
FT                                capable of targeting the cell surface
FT                                appropriately).
FT                                {ECO:0000269|PubMed:10767348,
FT                                ECO:0000269|PubMed:14684682,
FT                                ECO:0000269|PubMed:8640225}.
FT                                /FTId=VAR_006209.
FT   VARIANT     233    233       S -> L (in HHT2).
FT                                {ECO:0000269|PubMed:16525724}.
FT                                /FTId=VAR_070322.
FT   VARIANT     233    233       Missing (in HHT2).
FT                                {ECO:0000269|PubMed:15024723}.
FT                                /FTId=VAR_026792.
FT   VARIANT     237    237       Q -> K (in HHT2).
FT                                {ECO:0000269|PubMed:16752392}.
FT                                /FTId=VAR_070323.
FT   VARIANT     245    245       I -> N (in dbSNP:rs1804508).
FT                                /FTId=VAR_011717.
FT   VARIANT     254    254       Missing (in HHT2; retained in the
FT                                endoplasmic reticulum).
FT                                {ECO:0000269|PubMed:11484689,
FT                                ECO:0000269|PubMed:14684682}.
FT                                /FTId=VAR_026793.
FT   VARIANT     260    260       I -> L (in HHT2).
FT                                {ECO:0000269|PubMed:16752392}.
FT                                /FTId=VAR_070324.
FT   VARIANT     265    265       T -> P (in HHT2).
FT                                {ECO:0000269|PubMed:16525724}.
FT                                /FTId=VAR_070325.
FT   VARIANT     277    277       T -> K (found in a patient with
FT                                hereditary hemorrhagic talagiectasia;
FT                                unknown pathological significance).
FT                                {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070326.
FT   VARIANT     280    280       H -> R (in HHT2).
FT                                {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070327.
FT   VARIANT     285    285       L -> F (in HHT2).
FT                                {ECO:0000269|PubMed:15024723}.
FT                                /FTId=VAR_026794.
FT   VARIANT     289    289       L -> P (in HHT2).
FT                                {ECO:0000269|PubMed:16752392}.
FT                                /FTId=VAR_070328.
FT   VARIANT     294    294       L -> R (in HHT2).
FT                                {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070329.
FT   VARIANT     306    306       A -> P (in HHT2).
FT                                {ECO:0000269|PubMed:15024723}.
FT                                /FTId=VAR_026795.
FT   VARIANT     314    314       H -> Y (in HHT2).
FT                                {ECO:0000269|PubMed:15024723}.
FT                                /FTId=VAR_026796.
FT   VARIANT     328    328       H -> Q (in HHT2).
FT                                {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070330.
FT   VARIANT     333    333       S -> I (in HHT2; retained in the
FT                                endoplasmic reticulum).
FT                                {ECO:0000269|PubMed:10767348,
FT                                ECO:0000269|PubMed:14684682,
FT                                ECO:0000269|PubMed:9245985}.
FT                                /FTId=VAR_006210.
FT   VARIANT     335    335       N -> H (in HHT2).
FT                                {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070331.
FT   VARIANT     337    337       L -> P (in HHT2).
FT                                {ECO:0000269|PubMed:15024723}.
FT                                /FTId=VAR_026797.
FT   VARIANT     342    342       L -> P. {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070332.
FT   VARIANT     344    344       C -> R (in HHT2).
FT                                {ECO:0000269|PubMed:16752392}.
FT                                /FTId=VAR_070333.
FT   VARIANT     344    344       C -> Y (in HHT2; retained in the
FT                                endoplasmic reticulum; dbSNP:rs28936688).
FT                                {ECO:0000269|PubMed:10767348,
FT                                ECO:0000269|PubMed:14684682}.
FT                                /FTId=VAR_026798.
FT   VARIANT     347    347       A -> D (in HHT2).
FT                                {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070334.
FT   VARIANT     347    347       A -> P (in HHT2).
FT                                {ECO:0000269|PubMed:15024723}.
FT                                /FTId=VAR_026799.
FT   VARIANT     374    374       R -> Q (in HHT2; retained in the
FT                                endoplasmic reticulum).
FT                                {ECO:0000269|PubMed:14684682,
FT                                ECO:0000269|PubMed:15024723}.
FT                                /FTId=VAR_026800.
FT   VARIANT     374    374       R -> W (in HHT2; dbSNP:rs28936401).
FT                                {ECO:0000269|PubMed:11170071,
FT                                ECO:0000269|PubMed:14684682,
FT                                ECO:0000269|PubMed:15712270,
FT                                ECO:0000269|PubMed:9245985}.
FT                                /FTId=VAR_006211.
FT   VARIANT     376    376       M -> R (in HHT2; dbSNP:rs28936399).
FT                                {ECO:0000269|PubMed:8640225}.
FT                                /FTId=VAR_006212.
FT   VARIANT     376    376       M -> V (in HHT2).
FT                                {ECO:0000269|PubMed:15024723}.
FT                                /FTId=VAR_026801.
FT   VARIANT     378    378       P -> L (in HHT2; retained in the
FT                                endoplasmic reticulum).
FT                                {ECO:0000269|PubMed:14684682}.
FT                                /FTId=VAR_026802.
FT   VARIANT     378    378       P -> S (in HHT2).
FT                                {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070335.
FT   VARIANT     379    379       E -> K (in HHT2).
FT                                {ECO:0000269|PubMed:15024723,
FT                                ECO:0000269|PubMed:15712270}.
FT                                /FTId=VAR_026803.
FT   VARIANT     397    397       D -> G (in HHT2).
FT                                {ECO:0000269|PubMed:15024723}.
FT                                /FTId=VAR_026804.
FT   VARIANT     398    398       I -> N (in HHT2; dbSNP:rs28936400).
FT                                {ECO:0000269|PubMed:11170071}.
FT                                /FTId=VAR_026805.
FT   VARIANT     399    399       W -> S (in HHT2; dbSNP:rs28936402).
FT                                {ECO:0000269|PubMed:14684682}.
FT                                /FTId=VAR_026806.
FT   VARIANT     400    400       A -> T (found in a patient with
FT                                hereditary hemorrhagic talagiectasia;
FT                                unknown pathological significance).
FT                                {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070336.
FT   VARIANT     403    403       L -> P (in HHT2).
FT                                {ECO:0000269|PubMed:16525724}.
FT                                /FTId=VAR_070337.
FT   VARIANT     407    407       E -> D (in HHT2).
FT                                {ECO:0000269|PubMed:10767348,
FT                                ECO:0000269|PubMed:15712270}.
FT                                /FTId=VAR_026807.
FT   VARIANT     411    411       R -> P (in HHT2).
FT                                {ECO:0000269|PubMed:15024723}.
FT                                /FTId=VAR_026808.
FT   VARIANT     411    411       R -> Q (in HHT2; retained in the
FT                                endoplasmic reticulum; dbSNP:rs28936398).
FT                                {ECO:0000269|PubMed:14684682,
FT                                ECO:0000269|PubMed:15024723,
FT                                ECO:0000269|PubMed:8640225}.
FT                                /FTId=VAR_006213.
FT   VARIANT     411    411       R -> W (in HHT2).
FT                                {ECO:0000269|PubMed:11484689,
FT                                ECO:0000269|PubMed:15024723,
FT                                ECO:0000269|PubMed:15712270}.
FT                                /FTId=VAR_026809.
FT   VARIANT     416    416       G -> S (in HHT2).
FT                                {ECO:0000269|PubMed:16525724}.
FT                                /FTId=VAR_070338.
FT   VARIANT     424    424       P -> R (in HHT2).
FT                                {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070339.
FT   VARIANT     424    424       P -> T (in HHT2).
FT                                {ECO:0000269|PubMed:9245985}.
FT                                /FTId=VAR_006214.
FT   VARIANT     425    425       F -> L (in HHT2).
FT                                {ECO:0000269|PubMed:15024723}.
FT                                /FTId=VAR_026810.
FT   VARIANT     425    425       F -> V (in HHT2).
FT                                {ECO:0000269|PubMed:15712270}.
FT                                /FTId=VAR_026811.
FT   VARIANT     425    425       Missing (in HHT2).
FT                                {ECO:0000269|PubMed:15712270}.
FT                                /FTId=VAR_026812.
FT   VARIANT     426    426       Y -> C (in HHT2).
FT                                {ECO:0000269|PubMed:16752392}.
FT                                /FTId=VAR_070340.
FT   VARIANT     433    433       P -> R (in HHT2).
FT                                {ECO:0000269|PubMed:16752392}.
FT                                /FTId=VAR_070341.
FT   VARIANT     449    449       P -> S (in HHT2).
FT                                {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070342.
FT   VARIANT     479    479       R -> L (in HHT2).
FT                                {ECO:0000269|PubMed:15024723}.
FT                                /FTId=VAR_026813.
FT   VARIANT     479    479       R -> P (in HHT2).
FT                                {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070343.
FT   VARIANT     482    482       A -> V (in HHT2; dbSNP:rs139142865).
FT                                {ECO:0000269|PubMed:15024723}.
FT                                /FTId=VAR_026814.
FT   VARIANT     484    484       R -> W (in HHT2).
FT                                {ECO:0000269|PubMed:11484689,
FT                                ECO:0000269|PubMed:15024723}.
FT                                /FTId=VAR_026815.
FT   VARIANT     486    486       K -> E (found in a patient with
FT                                hereditary hemorrhagic talagiectasia;
FT                                unknown pathological significance).
FT                                {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070344.
FT   VARIANT     487    487       K -> T (in HHT2; mutant protein is
FT                                capable of targeting the cell surface
FT                                appropriately).
FT                                {ECO:0000269|PubMed:14684682}.
FT                                /FTId=VAR_026816.
FT   MUTAGEN      74     76       REL->DFQ: Affinity for BMP9 decreased by
FT                                200-fold. {ECO:0000269|PubMed:22799562}.
FT   CONFLICT    172    172       S -> T (in Ref. 1; CAA80255).
FT                                {ECO:0000305}.
FT   HELIX        26     28       {ECO:0000244|PDB:2LCR}.
FT   STRAND       32     35       {ECO:0000244|PDB:4FAO}.
FT   STRAND       42     56       {ECO:0000244|PDB:4FAO}.
FT   STRAND       59     61       {ECO:0000244|PDB:4FAO}.
FT   STRAND       64     68       {ECO:0000244|PDB:4FAO}.
FT   HELIX        74     78       {ECO:0000244|PDB:4FAO}.
FT   STRAND       83     90       {ECO:0000244|PDB:4FAO}.
FT   TURN         93     96       {ECO:0000244|PDB:4FAO}.
FT   HELIX       198    201       {ECO:0000244|PDB:3MY0}.
FT   STRAND      203    211       {ECO:0000244|PDB:3MY0}.
FT   STRAND      214    221       {ECO:0000244|PDB:3MY0}.
FT   STRAND      224    231       {ECO:0000244|PDB:3MY0}.
FT   HELIX       233    235       {ECO:0000244|PDB:3MY0}.
FT   HELIX       236    248       {ECO:0000244|PDB:3MY0}.
FT   STRAND      259    265       {ECO:0000244|PDB:3MY0}.
FT   STRAND      267    269       {ECO:0000244|PDB:3MY0}.
FT   STRAND      272    278       {ECO:0000244|PDB:3MY0}.
FT   HELIX       285    291       {ECO:0000244|PDB:3MY0}.
FT   HELIX       296    314       {ECO:0000244|PDB:3MY0}.
FT   STRAND      325    327       {ECO:0000244|PDB:3MY0}.
FT   STRAND      335    338       {ECO:0000244|PDB:3MY0}.
FT   STRAND      344    346       {ECO:0000244|PDB:3MY0}.
FT   STRAND      353    355       {ECO:0000244|PDB:3MY0}.
FT   STRAND      357    359       {ECO:0000244|PDB:3MY0}.
FT   HELIX       373    375       {ECO:0000244|PDB:3MY0}.
FT   HELIX       378    381       {ECO:0000244|PDB:3MY0}.
FT   HELIX       390    410       {ECO:0000244|PDB:3MY0}.
FT   TURN        424    428       {ECO:0000244|PDB:3MY0}.
FT   HELIX       435    442       {ECO:0000244|PDB:3MY0}.
FT   STRAND      455    459       {ECO:0000244|PDB:3MY0}.
FT   TURN        460    462       {ECO:0000244|PDB:3MY0}.
FT   HELIX       463    469       {ECO:0000244|PDB:3MY0}.
FT   HELIX       476    478       {ECO:0000244|PDB:3MY0}.
FT   HELIX       482    491       {ECO:0000244|PDB:3MY0}.
SQ   SEQUENCE   503 AA;  56124 MW;  074522AA802325DD CRC64;
     MTLGSPRKGL LMLLMALVTQ GDPVKPSRGP LVTCTCESPH CKGPTCRGAW CTVVLVREEG
     RHPQEHRGCG NLHRELCRGR PTEFVNHYCC DSHLCNHNVS LVLEATQPPS EQPGTDGQLA
     LILGPVLALL ALVALGVLGL WHVRRRQEKQ RGLHSELGES SLILKASEQG DSMLGDLLDS
     DCTTGSGSGL PFLVQRTVAR QVALVECVGK GRYGEVWRGL WHGESVAVKI FSSRDEQSWF
     RETEIYNTVL LRHDNILGFI ASDMTSRNSS TQLWLITHYH EHGSLYDFLQ RQTLEPHLAL
     RLAVSAACGL AHLHVEIFGT QGKPAIAHRD FKSRNVLVKS NLQCCIADLG LAVMHSQGSD
     YLDIGNNPRV GTKRYMAPEV LDEQIRTDCF ESYKWTDIWA FGLVLWEIAR RTIVNGIVED
     YRPPFYDVVP NDPSFEDMKK VVCVDQQTPT IPNRLAADPV LSGLAQMMRE CWYPNPSARL
     TALRIKKTLQ KISNSPEKPK VIQ
//
ID   CO2A1_HUMAN             Reviewed;        1487 AA.
AC   P02458; A6NGA0; Q12985; Q14009; Q14044; Q14045; Q14046; Q14047;
AC   Q14056; Q14058; Q16672; Q1JQ82; Q2V4X7; Q6LBY1; Q6LBY2; Q6LBY3;
AC   Q96IT5; Q99227; Q9UE38; Q9UE39; Q9UE40; Q9UE41; Q9UE42; Q9UE43;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   17-FEB-2016, entry version 197.
DE   RecName: Full=Collagen alpha-1(II) chain;
DE   AltName: Full=Alpha-1 type II collagen;
DE   Contains:
DE     RecName: Full=Collagen alpha-1(II) chain;
DE   Contains:
DE     RecName: Full=Chondrocalcin;
DE   Flags: Precursor;
GN   Name=COL2A1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS SER-9 AND
RP   LEU-158.
RX   PubMed=2587267; DOI=10.1093/nar/17.22.9473;
RA   Su M.W., Lee B., Ramirez F., Machado M.A., Horton W.A.;
RT   "Nucleotide sequence of the full length cDNA encoding for human type
RT   II procollagen.";
RL   Nucleic Acids Res. 17:9473-9473(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 2), AND VARIANT SER-9.
RC   TISSUE=Blood;
RX   PubMed=8948452;
RA   Ala-Kokko L., Kvist A.-P., Metsaranta M., Kivirikko K.I.,
RA   de Crombrugghe B., Prockop D.J., Vuorio E.;
RT   "Conservation of the sizes of 53 introns and over 100 intronic
RT   sequences for the binding of common transcription factors in the human
RT   and mouse genes for type II procollagen (COL2A1).";
RL   Biochem. J. 308:923-929(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M.,
RA   Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Montgomery K.T., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D.,
RA   Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., Zhang Z.,
RA   Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., Draper H.,
RA   Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., Kelly S.H.,
RA   Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V.,
RA   Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., Santibanez J.,
RA   Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., Williams G.A.,
RA   Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., Bailey M.,
RA   Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., Burkett C.E.,
RA   Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M.,
RA   Dathorne S.R., David R., Davis C.M., Davy-Carroll L., Deshazo D.R.,
RA   Donlin J.E., D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J.,
RA   Escotto M., Flagg N., Forbes L.D., Gabisi A.M., Garza M., Hamilton C.,
RA   Henderson N., Hernandez O., Hines S., Hogues M.E., Huang M.,
RA   Idlebird D.G., Johnson R., Jolivet A., Jones S., Kagan R., King L.M.,
RA   Leal B., Lebow H., Lee S., LeVan J.M., Lewis L.C., London P.,
RA   Lorensuhewa L.M., Loulseged H., Lovett D.A., Lucier A., Lucier R.L.,
RA   Ma J., Madu R.C., Mapua P., Martindale A.D., Martinez E., Massey E.,
RA   Mawhiney S., Meador M.G., Mendez S., Mercado C., Mercado I.C.,
RA   Merritt C.E., Miner Z.L., Minja E., Mitchell T., Mohabbat F.,
RA   Mohabbat K., Montgomery B., Moore N., Morris S., Munidasa M.,
RA   Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., Nwokenkwo S.,
RA   Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D.,
RA   Trejos Z.Y., Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I.,
RA   Vera V.A., Villasana D.M., Wang L., Ward-Moore S., Warren J.T.,
RA   Wei X., White F., Williamson A.L., Wleczyk R., Wooden H.S.,
RA   Wooden S.H., Yen J., Yoon L., Yoon V., Zorrilla S.E., Nelson D.,
RA   Kucherlapati R., Weinstock G., Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND NUCLEOTIDE
RP   SEQUENCE [LARGE SCALE MRNA] OF 1109-1487 (ISOFORMS 1/2).
RC   TISSUE=Embryonic stem cell, and Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-1229 (ISOFORM 1), AND VARIANT SER-9.
RX   PubMed=2803268;
RA   Baldwin C.T., Reginato A.M., Smith C., Jimenez S.A., Prockop D.J.;
RT   "Structure of cDNA clones coding for human type II procollagen. The
RT   alpha 1(II) chain is more similar to the alpha 1(I) chain than two
RT   other alpha chains of fibrillar collagens.";
RL   Biochem. J. 262:521-528(1989).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-236 (ISOFORM 1), AND VARIANT
RP   SER-9.
RX   PubMed=2714801; DOI=10.1016/0888-7543(89)90353-4;
RA   Su M.W., Benson-Chanda V., Vissing H., Ramirez F.;
RT   "Organization of the exons coding for pro alpha 1(II) collagen N-
RT   propeptide confirms a distinct evolutionary history of this domain of
RT   the fibrillar collagen genes.";
RL   Genomics 4:438-441(1989).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-103 (ISOFORM 2), AND VARIANT
RP   SER-9.
RX   PubMed=2081599; DOI=10.1016/0888-7543(90)90224-I;
RA   Ryan M.C., Sieraski M., Sandell L.J.;
RT   "The human type II procollagen gene: identification of an additional
RT   protein-coding domain and location of potential regulatory sequences
RT   in the promoter and first intron.";
RL   Genomics 8:41-48(1990).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-28 (ISOFORMS 1/2).
RX   PubMed=3021582; DOI=10.1016/0378-1119(86)90037-5;
RA   Nunez A.M., Kohno K., Martin G.R., Yamada Y.;
RT   "Promoter region of the human pro-alpha 1(II)-collagen gene.";
RL   Gene 44:11-16(1986).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-28 (ISOFORMS 1/2).
RX   PubMed=1637314;
RA   Vikkula M., Metsaranta M., Syvaenen A.-C., Ala-Kokko L., Vuorio E.,
RA   Peltonen L.;
RT   "Structural analysis of the regulatory elements of the type-II
RT   procollagen gene. Conservation of promoter and first intron sequences
RT   between human and mouse.";
RL   Biochem. J. 285:287-294(1992).
RN   [11]
RP   NUCLEOTIDE SEQUENCE OF 27-103 (ISOFORM 2), AND TISSUE SPECIFICITY.
RX   PubMed=2355003;
RA   Ryan M.C., Sandell L.J.;
RT   "Differential expression of a cysteine-rich domain in the amino-
RT   terminal propeptide of type II (cartilage) procollagen by alternative
RT   splicing of mRNA.";
RL   J. Biol. Chem. 265:10334-10339(1990).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 99-341 (ISOFORMS 1/2).
RC   TISSUE=Fetal sternum;
RX   PubMed=1999183; DOI=10.1111/j.1432-1033.1991.tb15742.x;
RA   Huang M.C., Seyer J.M., Thompson J.P., Spinella D.G., Cheah K.S.,
RA   Kang A.H.;
RT   "Genomic organization of the human procollagen alpha 1(II) collagen
RT   gene.";
RL   Eur. J. Biochem. 195:593-600(1991).
RN   [13]
RP   PROTEIN SEQUENCE OF 188-195 AND 1224-1236.
RX   PubMed=8660302;
RA   Diab M., Wu J.J., Eyre D.R.;
RT   "Collagen type IX from human cartilage: a structural profile of
RT   intermolecular cross-linking sites.";
RL   Biochem. J. 314:327-332(1996).
RN   [14]
RP   PROTEIN SEQUENCE OF 243-261; 575-590 AND 756-779.
RX   PubMed=8529631; DOI=10.1111/j.1432-1033.1995.125_c.x;
RA   Franc S., Marzin E., Boutillon M.-M., Lafont R.,
RA   Lechene de la Porte P., Herbage D.;
RT   "Immunohistochemical and biochemical analyses of 20,000-25,000-year-
RT   old fossil cartilage.";
RL   Eur. J. Biochem. 234:125-131(1995).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 440-509 (ISOFORMS 1/2).
RX   PubMed=7847372;
RA   Tiller G.E., Weis M.A., Polumbo P.A., Gruber H.E., Rimoin D.L.,
RA   Cohn D.H., Eyre D.R.;
RT   "An RNA-splicing mutation (G+5IVS20) in the type II collagen gene
RT   (COL2A1) in a family with spondyloepiphyseal dysplasia congenita.";
RL   Am. J. Hum. Genet. 56:388-395(1995).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 501-1214 (ISOFORMS 1/2).
RA   Ramirez F.;
RL   Submitted (DEC-1988) to the EMBL/GenBank/DDBJ databases.
RN   [17]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 541-578; 784-803; 1056-1109 AND
RP   1200-1487 (ISOFORMS 1/2).
RX   PubMed=2987845; DOI=10.1093/nar/13.7.2207;
RA   Sangiorgi F.O., Benson-Chanda V., de Wet W.J., Sobel M.E.,
RA   Tsipouras P., Ramirez F.;
RT   "Isolation and partial characterization of the entire human pro alpha
RT   1(II) collagen gene.";
RL   Nucleic Acids Res. 13:2207-2225(1985).
RN   [18]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 630-785 (ISOFORMS 1/2).
RX   PubMed=2753125; DOI=10.1016/0014-5793(89)80713-6;
RA   Vikkula M., Peltonen L.;
RT   "Structural analyses of the polymorphic area in type II collagen
RT   gene.";
RL   FEBS Lett. 250:171-174(1989).
RN   [19]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1032-1487 (ISOFORMS 1/2).
RX   PubMed=3857598; DOI=10.1073/pnas.82.9.2555;
RA   Cheah K.S.E., Stoker N.G., Griffin J.R., Grosveld F.G., Solomon E.;
RT   "Identification and characterization of the human type II collagen
RT   gene (COL2A1).";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:2555-2559(1985).
RN   [20]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1038-1055 (ISOFORMS 1/2), AND
RP   VARIANT HYPOCHONDROGENESIS GLU-1053.
RX   PubMed=1429602;
RA   Bogaert R., Tiller G.E., Wies M.A., Gruber H.E., Rimoin D.L.,
RA   Cohn D.H., Eyre D.R.;
RT   "An amino acid substitution (Gly853-->Glu) in the collagen alpha 1(II)
RT   chain produces hypochondrogenesis.";
RL   J. Biol. Chem. 267:22522-22526(1992).
RN   [21]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1082-1288 (ISOFORMS 1/2).
RX   PubMed=1905723;
RA   Chan D., Cole W.G.;
RT   "Low basal transcription of genes for tissue-specific collagens by
RT   fibroblasts and lymphoblastoid cells. Application to the
RT   characterization of a glycine 997 to serine substitution in alpha
RT   1(II) collagen chains of a patient with spondyloepiphyseal
RT   dysplasia.";
RL   J. Biol. Chem. 266:12487-12494(1991).
RN   [22]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1146-1199 (ISOFORMS 1/2), AND
RP   VARIANT SEDC 1164-GLY--TYR-1399 DEL.
RX   PubMed=2543071; DOI=10.1126/science.2543071;
RA   Lee B., Vissing H., Ramirez F., Rogers D., Rimoin D.L.;
RT   "Identification of the molecular defect in a family with
RT   spondyloepiphyseal dysplasia.";
RL   Science 244:978-980(1989).
RN   [23]
RP   NUCLEOTIDE SEQUENCE OF 1164-1199 (ISOFORMS 1/2), AND VARIANT SEDC
RP   GLY-PRO-SER-GLY-LYS-ASP-GLY-ALA-ASN-GLY-ILE-PRO-GLY-PRO-ILE-1184 INS.
RX   PubMed=2339128; DOI=10.1073/pnas.87.10.3889;
RA   Tiller G.E., Rimoin D.L., Murray L.W., Cohn D.H.;
RT   "Tandem duplication within a type II collagen gene (COL2A1) exon in an
RT   individual with spondyloepiphyseal dysplasia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:3889-3893(1990).
RN   [24]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1175-1487 (ISOFORMS 1/2).
RX   PubMed=2825137; DOI=10.1093/nar/15.22.9499;
RA   Elima K., Vuorio T., Vuorio E.;
RT   "Determination of the single polyadenylation site of the human pro
RT   alpha 1(II) collagen gene.";
RL   Nucleic Acids Res. 15:9499-9504(1987).
RN   [25]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1189-1467 (ISOFORMS 1/2).
RX   PubMed=3840017;
RA   Elima K., Maekelae J.K., Vuorio T., Kauppinen S., Knowles J.,
RA   Vuorio E.;
RT   "Construction and identification of a cDNA clone for human type II
RT   procollagen mRNA.";
RL   Biochem. J. 229:183-188(1985).
RN   [26]
RP   PROTEIN SEQUENCE OF 1242-1265; 1295-1305 AND 1395-1408.
RX   PubMed=3800925;
RA   Van der Rest M., Rosenberg L.C., Olsen B.R., Poole A.R.;
RT   "Chondrocalcin is identical with the C-propeptide of type II
RT   procollagen.";
RL   Biochem. J. 237:923-925(1986).
RN   [27]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1245-1295 (ISOFORMS 1/2/3).
RX   PubMed=6320112; DOI=10.1093/nar/12.2.1025;
RA   Strom C.M., Upholt W.B.;
RT   "Isolation and characterization of genomic clones corresponding to the
RT   human type II procollagen gene.";
RL   Nucleic Acids Res. 12:1025-1038(1984).
RN   [28]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1296-1358 (ISOFORMS 1/2/3).
RX   PubMed=3002437; DOI=10.1021/bi00344a004;
RA   Nunez A.M., Francomano C., Young M.F., Martin G.R., Yamada Y.;
RT   "Isolation and partial characterization of genomic clones coding for a
RT   human pro-alpha 1 (II) collagen chain and demonstration of restriction
RT   fragment length polymorphism at the 3' end of the gene.";
RL   Biochemistry 24:6343-6348(1985).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 1238-1247.
RX   PubMed=9354468; DOI=10.1016/S1074-7613(00)80369-6;
RA   Dessen A., Lawrence C.M., Cupo S., Zaller D.M., Wiley D.C.;
RT   "X-ray crystal structure of HLA-DR4 (DRA*0101, DRB1*0401) complexed
RT   with a peptide from human collagen II.";
RL   Immunity 7:473-481(1997).
RN   [30]
RP   STRUCTURE BY NMR OF 25-162 (ISOFORM 2), AND DISULFIDE BONDS.
RX   PubMed=15466413; DOI=10.1074/jbc.M409225200;
RA   O'Leary J.M., Hamilton J.M., Deane C.M., Valeyev N.V., Sandell L.J.,
RA   Downing A.K.;
RT   "Solution structure and dynamics of a prototypical chordin-like
RT   cysteine-rich repeat (von Willebrand Factor type C module) from
RT   collagen IIA.";
RL   J. Biol. Chem. 279:53857-53866(2004).
RN   [31]
RP   REVIEW ON VARIANTS.
RX   PubMed=2010058;
RA   Kuivaniemi H., Tromp G., Prockop D.J.;
RT   "Mutations in collagen genes: causes of rare and some common diseases
RT   in humans.";
RL   FASEB J. 5:2052-2060(1991).
RN   [32]
RP   REVIEW ON VARIANTS.
RX   PubMed=9101290;
RX   DOI=10.1002/(SICI)1098-1004(1997)9:4<300::AID-HUMU2>3.0.CO;2-9;
RA   Kuivaniemi H., Tromp G., Prockop D.J.;
RT   "Mutations in fibrillar collagens (types I, II, III, and XI), fibril-
RT   associated collagen (type IX), and network-forming collagen (type X)
RT   cause a spectrum of diseases of bone, cartilage, and blood vessels.";
RL   Hum. Mutat. 9:300-315(1997).
RN   [33]
RP   VARIANT ACG2 SER-1143.
RX   PubMed=2572591;
RA   Vissing H., D'Alessio M., Lee B., Ramirez F., Godfrey M.,
RA   Hollister D.W.;
RT   "Glycine to serine substitution in the triple helical domain of pro-
RT   alpha 1 (II) collagen results in a lethal perinatal form of short-
RT   limbed dwarfism.";
RL   J. Biol. Chem. 264:18265-18267(1989).
RN   [34]
RP   VARIANT OSCDP CYS-719.
RX   PubMed=1975693; DOI=10.1073/pnas.87.17.6565;
RA   Ala-Kokko L., Baldwin C.T., Moskowitz R.W., Prockop D.J.;
RT   "Single base mutation in the type II procollagen gene (COL2A1) as a
RT   cause of primary osteoarthritis associated with a mild
RT   chondrodysplasia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:6565-6568(1990).
RN   [35]
RP   VARIANT OSCDP CYS-719.
RX   PubMed=1985108; DOI=10.1172/JCI114994;
RA   Eyre D.R., Weis M.A., Moskowitz R.W.;
RT   "Cartilage expression of a type II collagen mutation in an inherited
RT   form of osteoarthritis associated with a mild chondrodysplasia.";
RL   J. Clin. Invest. 87:357-361(1991).
RN   [36]
RP   VARIANT HYPOCHONDROGENESIS SER-774.
RX   PubMed=1374906; DOI=10.1073/pnas.89.10.4583;
RA   Horton W.A., Machado M.A., Ellard J., Campbell D., Bartley J.,
RA   Ramirez F., Vitale E., Lee B.;
RT   "Characterization of a type II collagen gene (COL2A1) mutation
RT   identified in cultured chondrocytes from human hypochondrogenesis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:4583-4587(1992).
RN   [37]
RP   VARIANT STL1O ASP-267.
RX   PubMed=8317498;
RA   Koerkkoe J., Ritvaniemi P., Haataja L., Kaeaeriaeinen H.,
RA   Kivirikko K.I., Prockop D.J., Ala-Kokko L.;
RT   "Mutation in type II procollagen (COL2A1) that substitutes aspartate
RT   for glycine alpha 1-67 and that causes cataracts and retinal
RT   detachment: evidence for molecular heterogeneity in the Wagner
RT   syndrome and the Stickler syndrome (arthro-ophthalmopathy).";
RL   Am. J. Hum. Genet. 53:55-61(1993).
RN   [38]
RP   VARIANTS SEMDSTWK VAL-897 AND CYS-909.
RA   Tiller G.E., Weis M.A., Lachman R.S., Cohn D.H., Rimoin D.L.,
RA   Eyre D.R.;
RT   "A dominant mutation in the type II collagen gene (COL2A1) produces
RT   spondyloepimetaphyseal dysplasia (SEMD), Strudwick type.";
RL   Am. J. Hum. Genet. 53:A209-A209(1993).
RN   [39]
RP   VARIANT OSCDP CYS-719.
RX   PubMed=8507190; DOI=10.1006/bbrc.1993.1539;
RA   Holderbaum D., Malemud C.J., Moskowitz R.W., Haqqi T.M.;
RT   "Human cartilage from late stage familial osteoarthritis transcribes
RT   type II collagen mRNA encoding a cysteine in position 519.";
RL   Biochem. Biophys. Res. Commun. 192:1169-1174(1993).
RN   [40]
RP   VARIANT SPONDYLOMETAPHYSEAL DYSPLASIA ARG-354.
RX   PubMed=8486375; DOI=10.1006/geno.1993.1179;
RA   Vikkula M., Ritvaniemi P., Vuorio A.F., Kaitila I., Ala-Kokko L.,
RA   Peltonen L.;
RT   "A mutation in the amino-terminal end of the triple helix of type II
RT   collagen causing severe osteochondrodysplasia.";
RL   Genomics 16:282-285(1993).
RN   [41]
RP   VARIANT CZECHD CYS-275.
RX   PubMed=8244341; DOI=10.1007/BF00216458;
RA   Williams C.J., Considine E.L., Knowlton R.G., Reginato A., Neumann G.,
RA   Harrison D., Buxton P., Jimenez S.A., Prockop D.J.;
RT   "Spondyloepiphyseal dysplasia and precocious osteoarthritis in a
RT   family with an Arg75-->Cys mutation in the procollagen type II gene
RT   (COL2A1).";
RL   Hum. Genet. 92:499-505(1993).
RN   [42]
RP   VARIANT SEDC CYS-989.
RX   PubMed=8325895;
RA   Chan D., Taylor T.K.F., Cole W.G.;
RT   "Characterization of an arginine 789 to cysteine substitution in alpha
RT   1 (II) collagen chains of a patient with spondyloepiphyseal
RT   dysplasia.";
RL   J. Biol. Chem. 268:15238-15245(1993).
RN   [43]
RP   VARIANT SEDC SER-1197.
RX   PubMed=8423604; DOI=10.1136/jmg.30.1.27;
RA   Cole W.G., Hall R.K., Rogers J.G.;
RT   "The clinical features of spondyloepiphyseal dysplasia congenita
RT   resulting from the substitution of glycine 997 by serine in the alpha
RT   1(II) chain of type II collagen.";
RL   J. Med. Genet. 30:27-35(1993).
RN   [44]
RP   VARIANT STL1 302-ALA--LYS-308 DEL.
RX   PubMed=7977371;
RA   Bogaert R., Wilkin D.J., Wilcox W.R., Lachman R.S., Rimoin D.L.,
RA   Cohn D.H., Eyre D.R.;
RT   "Expression, in cartilage, of a 7-amino-acid deletion in type II
RT   collagen from two unrelated individuals with Kniest dysplasia.";
RL   Am. J. Hum. Genet. 55:1128-1136(1994).
RN   [45]
RP   VARIANT KD ASP-303.
RX   PubMed=7874117; DOI=10.1093/hmg/3.11.1999;
RA   Wilkin D.J., Bogaert R., Lachman R.S., Rimoin D.L., Eyres D.R.,
RA   Cohn D.H.;
RT   "A single amino acid substitution (G103D) in the type II collagen
RT   triple helix produces Kniest dysplasia.";
RL   Hum. Mol. Genet. 3:1999-2003(1994).
RN   [46]
RP   VARIANT SEDC SER-447.
RX   PubMed=8019561; DOI=10.1002/humu.1380030314;
RA   Ritvaniemi P., Sokolov B.P., Williams C.J., Considine W., Yurgenev L.,
RA   Meerson E.M., Ala-Kokko L., Prockop D.J.;
RT   "A single base mutation in the type II procollagen gene (COL2A1) that
RT   converts glycine alpha 1-247 to serine in a family with late-onset
RT   spondyloepiphyseal dysplasia.";
RL   Hum. Mutat. 3:261-267(1994).
RN   [47]
RP   VARIANT ACG2 ARG-891.
RX   PubMed=7757081; DOI=10.1093/hmg/4.2.285;
RA   Mortier G.R., Wilkin D.J., Wilcox W.R., Rimoin D.L., Lachman R.S.,
RA   Eyre D.R., Cohn D.H.;
RT   "A radiographic, morphologic, biochemical and molecular analysis of a
RT   case of achondrogenesis type II resulting from substitution for a
RT   glycine residue (Gly691-->Arg) in the type II collagen trimer.";
RL   Hum. Mol. Genet. 4:285-288(1995).
RN   [48]
RP   VARIANT CZECHD CYS-275, VARIANT SEDC SER-1176, VARIANT OSCDP CYS-719,
RP   VARIANT HYPOCHONDROGENESIS ARG-891, AND VARIANT ACG2 ARG-1188.
RX   PubMed=7757086; DOI=10.1093/hmg/4.2.309;
RA   Williams C.J., Rock M., Considine E.L., McCarron S., Gow P., Ladda R.,
RA   McLain D., Michels V.M., Murphy W., Prockop D.J., Ganguly A.;
RT   "Three new point mutations in type II procollagen (COL2A1) and
RT   identification of a fourth family with the COL2A1 Arg519-->Cys base
RT   substitution using conformation sensitive gel electrophoresis.";
RL   Hum. Mol. Genet. 4:309-312(1995).
RN   [49]
RP   VARIANT ACG2 SER-969.
RX   PubMed=7829510; DOI=10.1074/jbc.270.44.26292;
RA   Chan D., Cole W.G., Chow C.W., Mundlos S., Bateman J.F.;
RT   "A COL2A1 mutation in achondrogenesis type II results in the
RT   replacement of type II collagen by type I and III collagens in
RT   cartilage.";
RL   J. Biol. Chem. 270:1747-1753(1995).
RN   [50]
RP   VARIANTS SEMDSTWK VAL-492; CYS-504 AND CYS-909.
RX   PubMed=7550321; DOI=10.1038/ng0995-87;
RA   Tiller G.E., Polumbo P.A., Weis M.A., Bogaert R., Lachman R.S.,
RA   Cohn D.H., Rimoin D.L., Eyre D.R.;
RT   "Dominant mutations in the type II collagen gene, COL2A1, produce
RT   spondyloepimetaphyseal dysplasia, Strudwick type.";
RL   Nat. Genet. 11:87-89(1995).
RN   [51]
RP   VARIANT HYPOCHONDROGENESIS CYS-1113.
RX   PubMed=8723098;
RX   DOI=10.1002/(SICI)1096-8628(19960503)63:1<129::AID-AJMG23>3.0.CO;2-P;
RA   Mundlos S., Chan D., McGill J., Bateman J.F.;
RT   "An alpha 1(II) Gly913 to Cys substitution prevents the matrix
RT   incorporation of type II collagen which is replaced with type I and
RT   III collagens in cartilage from a patient with hypochondrogenesis.";
RL   Am. J. Med. Genet. 63:129-136(1996).
RN   [52]
RP   VARIANT KD 1207-PRO--GLY-1212 DEL.
RX   PubMed=8863156; DOI=10.1136/jmg.33.8.649;
RA   Winterpacht A., Superti-Furga A., Schwarze U., Stoess H.,
RA   Steinmann B., Spranger J., Zabel B.;
RT   "The deletion of six amino acids at the C-terminus of the alpha 1 (II)
RT   chain causes overmodification of type II and type XI collagen: further
RT   evidence for the association between small deletions in COL2A1 and
RT   Kniest dysplasia.";
RL   J. Med. Genet. 33:649-654(1996).
RN   [53]
RP   VARIANT EDMMD CYS-904.
RX   PubMed=9800905;
RX   DOI=10.1002/(SICI)1096-8628(19981102)80:1<6::AID-AJMG2>3.0.CO;2-0;
RA   Ballo R., Beighton P.H., Ramesar R.S.;
RT   "Stickler-like syndrome due to a dominant negative mutation in the
RT   COL2A1 gene.";
RL   Am. J. Med. Genet. 80:6-11(1998).
RN   [54]
RP   VARIANT SPONDYLOEPIPHYSEAL DYSPLASIA CYS-719.
RX   PubMed=9711874;
RX   DOI=10.1002/(SICI)1098-1004(1998)12:3<172::AID-HUMU4>3.0.CO;2-J;
RA   Bleasel J.F., Holderbaum D., Brancolini V., Moskowitz R.W.,
RA   Considine E.L., Prockop D.J., Devoto M., Williams C.J.;
RT   "Five families with arginine 519-cysteine mutation in COL2A1: evidence
RT   for three distinct founders.";
RL   Hum. Mutat. 12:172-176(1998).
RN   [55]
RP   VARIANT STL1 CYS-565, AND VARIANT DRRD PHE-667.
RX   PubMed=11007540; DOI=10.1086/321189;
RA   Richards A.J., Baguley D.M., Yates J.R.W., Lane C., Nicol M.,
RA   Harper P.S., Scott J.D., Snead M.P.;
RT   "Variation in the vitreous phenotype of Stickler syndrome can be
RT   caused by different amino acid substitutions in the X position of the
RT   type II collagen Gly-X-Y triple helix.";
RL   Am. J. Hum. Genet. 67:1083-1094(2000).
RN   [56]
RP   VARIANT SEDC ARG-1173.
RX   PubMed=10678662;
RX   DOI=10.1002/(SICI)1096-8628(20000131)90:3<239::AID-AJMG10>3.3.CO;2-F;
RA   Sobetzko D., Eich G., Kalff-Suske M., Grzeschik K.-H.,
RA   Superti-Furga A.;
RT   "Boy with syndactylies, macrocephaly, and severe skeletal dysplasia:
RT   not a new syndrome, but two dominant mutations (GLI3 E543X and COL2A1
RT   G973R) in the same individual.";
RL   Am. J. Med. Genet. 90:239-242(2000).
RN   [57]
RP   VARIANTS ACG2 VAL-453; ASP-453; ASP-771; ARG-780; ARG-795; GLU-894;
RP   ASP-948; SER-981; VAL-1065 AND ARG-1119, VARIANT HYPOCHONDROGENESIS
RP   1017-GLY--VAL-1022 DEL, AND VARIANT ILE-1331.
RX   PubMed=10797431;
RX   DOI=10.1002/(SICI)1096-8628(20000515)92:2<95::AID-AJMG3>3.0.CO;2-9;
RA   Koerkkoe J., Cohn D.H., Ala-Kokko L., Krakow D., Prockop D.J.;
RT   "Widely distributed mutations in the COL2A1 gene produce
RT   achondrogenesis type II/hypochondrogenesis.";
RL   Am. J. Med. Genet. 92:95-100(2000).
RN   [58]
RP   VARIANTS ACG2 SER-513; VAL-717; ALA-771; CYS-1110 AND SER-1143, AND
RP   VARIANT PLSD-T ASN-1390.
RX   PubMed=10745044; DOI=10.1136/jmg.37.4.263;
RA   Mortier G.R., Weis M., Nuytinck L., King L.M., Wilkin D.J.,
RA   De Paepe A., Lachman R.S., Rimoin D.L., Eyre D.R., Cohn D.H.;
RT   "Report of five novel and one recurrent COL2A1 mutations with analysis
RT   of genotype-phenotype correlation in patients with a lethal type II
RT   collagen disorder.";
RL   J. Med. Genet. 37:263-271(2000).
RN   [59]
RP   VARIANT SEDC MET-1439.
RX   PubMed=11746045; DOI=10.1002/ajmg.10062;
RA   Unger S., Koerkkoe J., Krakow D., Lachman R.S., Rimoin D.L.,
RA   Cohn D.H.;
RT   "Double heterozygosity for pseudoachondroplasia and spondyloepiphyseal
RT   dysplasia congenita.";
RL   Am. J. Med. Genet. 104:140-146(2001).
RN   [60]
RP   VARIANT VITREORETINOPATHY ASP-1305.
RX   PubMed=12205109; DOI=10.1136/jmg.39.9.661;
RA   Richards A.J., Morgan J., Bearcroft P.W.P., Pickering E., Owen M.J.,
RA   Holmans P., Williams N., Tysoe C., Pope F.M., Snead M.P., Hughes H.;
RT   "Vitreoretinopathy with phalangeal epiphyseal dysplasia, a type II
RT   collagenopathy resulting from a novel mutation in the C-propeptide
RT   region of the molecule.";
RL   J. Med. Genet. 39:661-665(2002).
RN   [61]
RP   VARIANT ACGA2 ASP-516.
RX   PubMed=15054848; DOI=10.1002/ajmg.a.20597;
RA   Faivre L., Le Merrer M., Douvier S., Laurent N., Thauvin-Robinet C.,
RA   Rousseau T., Vereecke I., Sagot P., Delezoide A.-L., Coucke P.,
RA   Mortier G.;
RT   "Recurrence of achondrogenesis type II within the same family:
RT   evidence for germline mosaicism.";
RL   Am. J. Med. Genet. A 126:308-312(2004).
RN   [62]
RP   INVOLVEMENT IN SPONDYLOPERIPHERAL DYSPLASIA.
RX   PubMed=15316962; DOI=10.1002/ajmg.a.30222;
RA   Zankl A., Zabel B., Hilbert K., Wildhardt G., Cuenot S., Xavier B.,
RA   Ha-Vinh R., Bonafe L., Spranger J., Superti-Furga A.;
RT   "Spondyloperipheral dysplasia is caused by truncating mutations in the
RT   C-propeptide of COL2A1.";
RL   Am. J. Med. Genet. A 129:144-148(2004).
RN   [63]
RP   VARIANT PLSD-T CYS-1391.
RX   PubMed=14729840; DOI=10.1136/jmg.2003.013722;
RA   Nishimura G., Nakashima E., Mabuchi A., Shimamoto K., Shimamoto T.,
RA   Shimao Y., Nagai T., Yamaguchi T., Kosaki R., Ohashi H., Makita Y.,
RA   Ikegawa S.;
RT   "Identification of COL2A1 mutations in platyspondylic skeletal
RT   dysplasia, Torrance type.";
RL   J. Med. Genet. 41:75-79(2004).
RN   [64]
RP   VARIANTS PLSD-T PRO-1448; HIS-1469; VAL-1484 DEL AND GLY-1485, AND
RP   DISCUSSION OF VARIANT ASN-1390.
RX   PubMed=15643621; DOI=10.1002/ajmg.a.30531;
RA   Zankl A., Neumann L., Ignatius J., Nikkels P., Schrander-Stumpel C.,
RA   Mortier G., Omran H., Wright M., Hilbert K., Bonafe L., Spranger J.,
RA   Zabel B., Superti-Furga A.;
RT   "Dominant negative mutations in the C-propeptide of COL2A1 cause
RT   platyspondylic lethal skeletal dysplasia, torrance type, and define a
RT   novel subfamily within the type 2 collagenopathies.";
RL   Am. J. Med. Genet. A 133:61-67(2005).
RN   [65]
RP   VARIANT SEMDSTWK GLY-992.
RX   PubMed=16088915; DOI=10.1002/ajmg.a.30881;
RA   Sulko J., Czarny-Ratajczak M., Wozniak A., Latos-Bielenska A.,
RA   Kozlowski K.;
RT   "Novel amino acid substitution in the Y-position of collagen type II
RT   causes spondyloepimetaphyseal dysplasia congenita.";
RL   Am. J. Med. Genet. A 137:292-297(2005).
RN   [66]
RP   VARIANTS DRRD ARG-318 AND PHE-667.
RX   PubMed=15671297; DOI=10.1167/iovs.04-1017;
RA   Richards A.J., Meredith S., Poulson A., Bearcroft P., Crossland G.,
RA   Baguley D.M., Scott J.D., Snead M.P.;
RT   "A novel mutation of COL2A1 resulting in dominantly inherited
RT   rhegmatogenous retinal detachment.";
RL   Invest. Ophthalmol. Vis. Sci. 46:663-668(2005).
RN   [67]
RP   VARIANTS ANFH SER-717 AND SER-1170.
RX   PubMed=15930420; DOI=10.1056/NEJMoa042480;
RA   Liu Y.-F., Chen W.-M., Lin Y.-F., Yang R.-C., Lin M.-W., Li L.-H.,
RA   Chang Y.-H., Jou Y.-S., Lin P.-Y., Su J.-S., Huang S.-F., Hsiao K.-J.,
RA   Fann C.S.J., Hwang H.-W., Chen Y.-T., Tsai S.-F.;
RT   "Type II collagen gene variants and inherited osteonecrosis of the
RT   femoral head.";
RL   N. Engl. J. Med. 352:2294-2301(2005).
RN   [68]
RP   INVOLVEMENT IN STL1O.
RX   PubMed=16752401; DOI=10.1002/humu.20347;
RA   Richards A.J., Laidlaw M., Whittaker J., Treacy B., Rai H.,
RA   Bearcroft P., Baguley D.M., Poulson A., Ang A., Scott J.D.,
RA   Snead M.P.;
RT   "High efficiency of mutation detection in type 1 stickler syndrome
RT   using a two-stage approach: vitreoretinal assessment coupled with exon
RT   sequencing for screening COL2A1.";
RL   Hum. Mutat. 27:696-704(2006).
RN   [69]
RP   VARIANT ACG2 VAL-547.
RX   PubMed=17994563; DOI=10.1002/ajmg.a.32047;
RA   Forzano F., Lituania M., Viassolo A., Superti-Furga V., Wildhardt G.,
RA   Zabel B., Faravelli F.;
RT   "A familial case of achondrogenesis type II caused by a dominant
RT   COL2A1 mutation and 'patchy' expression in the mosaic father.";
RL   Am. J. Med. Genet. A 143:2815-2820(2007).
RN   [70]
RP   VARIANT LCPD SER-1170.
RX   PubMed=17394019; DOI=10.1007/s00439-007-0354-y;
RA   Miyamoto Y., Matsuda T., Kitoh H., Haga N., Ohashi H., Nishimura G.,
RA   Ikegawa S.;
RT   "A recurrent mutation in type II collagen gene causes Legg-Calve-
RT   Perthes disease in a Japanese family.";
RL   Hum. Genet. 121:625-629(2007).
RN   [71]
RP   VARIANT CZECHD CYS-275.
RX   PubMed=18553548; DOI=10.1002/ajmg.a.32389;
RA   Tzschach A., Tinschert S., Kaminsky E., Lusga E., Mundlos S.,
RA   Graul-Neumann L.M.;
RT   "Czech dysplasia: report of a large family and further delineation of
RT   the phenotype.";
RL   Am. J. Med. Genet. A 146:1859-1864(2008).
RN   [72]
RP   VARIANTS SER-9; ASP-142; ILE-638; THR-1051; ILE-1331 AND SER-1405.
RX   PubMed=18272325; DOI=10.1016/j.ygeno.2007.12.008;
RA   Chan T.F., Poon A., Basu A., Addleman N.R., Chen J., Phong A.,
RA   Byers P.H., Klein T.E., Kwok P.Y.;
RT   "Natural variation in four human collagen genes across an ethnically
RT   diverse population.";
RL   Genomics 91:307-314(2008).
RN   [73]
RP   VARIANT STL1O TYR-57.
RX   PubMed=17721977; DOI=10.1002/humu.20603;
RA   McAlinden A., Majava M., Bishop P.N., Perveen R., Black G.C.M.,
RA   Pierpont M.E., Ala-Kokko L., Maennikkoe M.;
RT   "Missense and nonsense mutations in the alternatively-spliced exon 2
RT   of COL2A1 cause the ocular variant of Stickler syndrome.";
RL   Hum. Mutat. 29:83-90(2008).
RN   [74]
RP   VARIANT CZECHD CYS-275.
RX   PubMed=19764028; DOI=10.1002/ajmg.a.33010;
RA   Matsui Y., Michigami T., Tachikawa K., Yamazaki M., Kawabata H.,
RA   Nishimura G.;
RT   "Czech dysplasia occurring in a Japanese family.";
RL   Am. J. Med. Genet. A 149:2285-2289(2009).
RN   [75]
RP   VARIANTS STL1 ASP-240; ARG-270; ASP-282; ALA-453; ARG-501; CYS-904 AND
RP   ALA-1158.
RX   PubMed=20513134; DOI=10.1002/humu.21257;
RA   Richards A.J., McNinch A., Martin H., Oakhill K., Rai H., Waller S.,
RA   Treacy B., Whittaker J., Meredith S., Poulson A., Snead M.P.;
RT   "Stickler syndrome and the vitreous phenotype: mutations in COL2A1 and
RT   COL11A1.";
RL   Hum. Mutat. 31:E1461-E1471(2010).
RN   [76]
RP   VARIANTS VAL-1176 AND ARG-1179.
RX   PubMed=21922596; DOI=10.1002/humu.21611;
RA   Jackson G.C., Mittaz-Crettol L., Taylor J.A., Mortier G.R.,
RA   Spranger J., Zabel B., Le Merrer M., Cormier-Daire V., Hall C.M.,
RA   Offiah A., Wright M.J., Savarirayan R., Nishimura G., Ramsden S.C.,
RA   Elles R., Bonafe L., Superti-Furga A., Unger S., Zankl A.,
RA   Briggs M.D.;
RT   "Pseudoachondroplasia and multiple epiphyseal dysplasia: A 7-year
RT   comprehensive analysis of the known disease genes identify novel and
RT   recurrent mutations and provides an accurate assessment of their
RT   relative contribution.";
RL   Hum. Mutat. 33:144-157(2012).
CC   -!- FUNCTION: Type II collagen is specific for cartilaginous tissues.
CC       It is essential for the normal embryonic development of the
CC       skeleton, for linear growth and for the ability of cartilage to
CC       resist compressive forces.
CC   -!- SUBUNIT: Homotrimers of alpha 1(II) chains.
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular
CC       matrix {ECO:0000255|PROSITE-ProRule:PRU00793}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=2;
CC         IsoId=P02458-2; Sequence=Displayed;
CC       Name=1;
CC         IsoId=P02458-1; Sequence=VSP_022366;
CC       Name=3;
CC         IsoId=P02458-3; Sequence=VSP_022365;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Isoform 2 is highly expressed in juvenile
CC       chondrocyte and low in fetal chondrocyte.
CC       {ECO:0000269|PubMed:2355003}.
CC   -!- DOMAIN: The C-terminal propeptide, also known as COLFI domain,
CC       have crucial roles in tissue growth and repair by controlling both
CC       the intracellular assembly of procollagen molecules and the
CC       extracellular assembly of collagen fibrils. It binds a calcium ion
CC       which is essential for its function (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: Probably 3-hydroxylated on prolines by LEPREL1 (By
CC       similarity). Proline residues at the third position of the
CC       tripeptide repeating unit (G-X-P) are hydroxylated in some or all
CC       of the chains. Proline residues at the second position of the
CC       tripeptide repeating unit (G-P-X) are hydroxylated in some of the
CC       chains. {ECO:0000250}.
CC   -!- PTM: The N-telopeptide is covalently linked to the helical COL2
CC       region of alpha 1(IX), alpha 2(IX) and alpha 3(IX) chain. The C-
CC       telopeptide is covalently linked to an another site in the helical
CC       region of alpha 3(IX) COL2.
CC   -!- DISEASE: Spondyloepiphyseal dysplasia congenital type (SEDC)
CC       [MIM:183900]: Disorder characterized by disproportionate short
CC       stature and pleiotropic involvement of the skeletal and ocular
CC       systems. {ECO:0000269|PubMed:10678662,
CC       ECO:0000269|PubMed:11746045, ECO:0000269|PubMed:2339128,
CC       ECO:0000269|PubMed:2543071, ECO:0000269|PubMed:7757086,
CC       ECO:0000269|PubMed:8019561, ECO:0000269|PubMed:8325895,
CC       ECO:0000269|PubMed:8423604}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Spondyloepimetaphyseal dysplasia, Strudwick type
CC       (SEMDSTWK) [MIM:184250]: A bone disease characterized by
CC       disproportionate short stature from birth, with a very short trunk
CC       and shortened limbs, and skeletal abnormalities including
CC       lordosis, scoliosis, flattened vertebrae, pectus carinatum, coxa
CC       vara, clubfoot, and abnormal epiphyses or metaphyses. A
CC       distinctive radiographic feature is irregular sclerotic changes,
CC       described as dappled in the metaphyses of the long bones.
CC       {ECO:0000269|PubMed:16088915, ECO:0000269|PubMed:7550321,
CC       ECO:0000269|Ref.38}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Achondrogenesis 2 (ACG2) [MIM:200610]: A disease
CC       characterized by the absence of ossification in the vertebral
CC       column, sacrum and pubic bones. {ECO:0000269|PubMed:10745044,
CC       ECO:0000269|PubMed:10797431, ECO:0000269|PubMed:17994563,
CC       ECO:0000269|PubMed:2572591, ECO:0000269|PubMed:7757081,
CC       ECO:0000269|PubMed:7757086, ECO:0000269|PubMed:7829510}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Legg-Calve-Perthes disease (LCPD) [MIM:150600]:
CC       Characterized by loss of circulation to the femoral head,
CC       resulting in avascular necrosis in a growing child. Clinical
CC       pictures of the disease vary, depending on the phase of disease
CC       progression through ischemia, revascularization, fracture and
CC       collapse, and repair and remodeling of the bone.
CC       {ECO:0000269|PubMed:17394019}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Kniest dysplasia (KD) [MIM:156550]: Moderately severe
CC       chondrodysplasia phenotype that results from mutations in the
CC       COL2A1 gene. Characteristics of the disorder include a short trunk
CC       and extremities, mid-face hypoplasia, cleft palate, myopia,
CC       retinal detachment, and hearing loss. {ECO:0000269|PubMed:7874117,
CC       ECO:0000269|PubMed:8863156}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Avascular necrosis of the femoral head, primary (ANFH)
CC       [MIM:608805]: A disease characterized by mechanical failure of the
CC       subchondral bone, and degeneration of the hip joint. It usually
CC       leads to destruction of the hip joint in the third to fifth decade
CC       of life. The clinical manifestations, such as pain on exertion, a
CC       limping gait, and a discrepancy in leg length, cause considerable
CC       disability. {ECO:0000269|PubMed:15930420}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Osteoarthritis with mild chondrodysplasia (OSCDP)
CC       [MIM:604864]: Osteoarthritis is a common disease that produces
CC       joint pain and stiffness together with radiologic evidence of
CC       progressive degeneration of joint cartilage.
CC       {ECO:0000269|PubMed:1975693, ECO:0000269|PubMed:1985108,
CC       ECO:0000269|PubMed:7757086, ECO:0000269|PubMed:8507190}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Platyspondylic lethal skeletal dysplasia Torrance type
CC       (PLSD-T) [MIM:151210]: Platyspondylic lethal skeletal dysplasias
CC       (PLSDs) are a heterogeneous group of chondrodysplasias
CC       characterized by severe platyspondyly and limb shortening. PLSD-T
CC       is characterized by varying platyspondyly, short ribs with
CC       anterior cupping, hypoplasia of the lower ilia with broad ischial
CC       and pubic bones, and shortening of the tubular bones with splayed
CC       and cupped metaphyses. Histology of the growth plate typically
CC       shows focal hypercellularity with slightly enlarged chondrocytes
CC       in the resting cartilage and relatively well-preserved columnar
CC       formation and ossification at the chondro-osseous junction. PLSD-T
CC       is generally a perinatally lethal disease, but a few long-term
CC       survivors have been reported. {ECO:0000269|PubMed:10745044,
CC       ECO:0000269|PubMed:14729840, ECO:0000269|PubMed:15643621}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Multiple epiphyseal dysplasia with myopia and conductive
CC       deafness (EDMMD) [MIM:132450]: A generalized skeletal dysplasia
CC       associated with significant morbidity. Joint pain, joint
CC       deformity, waddling gait, and short stature are the main clinical
CC       signs and symptoms. EDMMD is an autosomal dominant disorder
CC       characterized by epiphyseal dysplasia associated with progressive
CC       myopia, retinal thinning, crenated cataracts, conductive deafness.
CC       {ECO:0000269|PubMed:9800905}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Spondyloperipheral dysplasia (SPD) [MIM:271700]: SPD
CC       patients manifest short stature, midface hypoplasia, sensorineural
CC       hearing loss, spondyloepiphyseal dysplasia, platyspondyly and
CC       brachydactyly. {ECO:0000269|PubMed:15316962}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Stickler syndrome 1 (STL1) [MIM:108300]: An autosomal
CC       dominant form of Stickler syndrome, an inherited disorder that
CC       associates ocular signs with more or less complete forms of Pierre
CC       Robin sequence, bone disorders and sensorineural deafness. Ocular
CC       disorders may include juvenile cataract, myopia, strabismus,
CC       vitreoretinal or chorioretinal degeneration, retinal detachment,
CC       and chronic uveitis. Pierre Robin sequence includes an opening in
CC       the roof of the mouth (a cleft palate), a large tongue
CC       (macroglossia), and a small lower jaw (micrognathia). Bones are
CC       affected by slight platyspondylisis and large, often defective
CC       epiphyses. Juvenile joint laxity is followed by early signs of
CC       arthrosis. The degree of hearing loss varies among affected
CC       individuals and may become more severe over time. Syndrome
CC       expressivity is variable. {ECO:0000269|PubMed:11007540,
CC       ECO:0000269|PubMed:20513134, ECO:0000269|PubMed:7977371}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Stickler syndrome 1 non-syndromic ocular (STL1O)
CC       [MIM:609508]: An autosomal dominant form of Stickler syndrome
CC       characterized by the ocular signs typically seen in Stickler
CC       syndrome type 1 such as cataract, myopia, retinal detachment.
CC       Systemic features of premature osteoarthritis, cleft palate,
CC       hearing impairment, and craniofacial abnormalities are either
CC       absent or very mild. {ECO:0000269|PubMed:16752401,
CC       ECO:0000269|PubMed:17721977, ECO:0000269|PubMed:8317498}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Rhegmatogenous retinal detachment autosomal dominant
CC       (DRRD) [MIM:609508]: A eye disease that most frequently results
CC       from a break or tear in the retina that allows fluid from the
CC       vitreous humor to enter the potential space beneath the retina. It
CC       is often associated with pathologic myopia and in most cases leads
CC       to visual impairment or blindness if untreated.
CC       {ECO:0000269|PubMed:11007540, ECO:0000269|PubMed:15671297}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Czech dysplasia (CZECHD) [MIM:609162]: A skeletal
CC       dysplasia characterized by early-onset, progressive
CC       pseudorheumatoid arthritis, platyspondyly, and short third and
CC       fourth toes. {ECO:0000269|PubMed:18553548,
CC       ECO:0000269|PubMed:19764028, ECO:0000269|PubMed:7757086,
CC       ECO:0000269|PubMed:8244341}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the fibrillar collagen family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00793}.
CC   -!- SIMILARITY: Contains 1 fibrillar collagen NC1 domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00793}.
CC   -!- SIMILARITY: Contains 1 VWFC domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00220}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH07252.1; Type=Frameshift; Positions=1198; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X16468; CAA34488.1; -; mRNA.
DR   EMBL; L10347; AAC41772.1; -; Genomic_DNA.
DR   EMBL; BT007205; AAP35869.1; -; mRNA.
DR   EMBL; AC004801; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC007252; AAH07252.1; ALT_FRAME; mRNA.
DR   EMBL; BC116449; AAI16450.1; -; mRNA.
DR   EMBL; X16711; CAA34683.1; -; mRNA.
DR   EMBL; M25730; AAA58428.2; -; Genomic_DNA.
DR   EMBL; M32168; AAA58428.2; JOINED; Genomic_DNA.
DR   EMBL; M25655; AAA58428.2; JOINED; Genomic_DNA.
DR   EMBL; M25656; AAA58428.2; JOINED; Genomic_DNA.
DR   EMBL; M64345; AAA58428.2; JOINED; Genomic_DNA.
DR   EMBL; M60299; AAA73873.1; -; Genomic_DNA.
DR   EMBL; M25698; AAA52051.1; -; Genomic_DNA.
DR   EMBL; X58709; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; X57010; CAA40330.1; -; Genomic_DNA.
DR   EMBL; U15195; AAB60370.1; -; Genomic_DNA.
DR   EMBL; X13783; CAA32030.1; -; mRNA.
DR   EMBL; M25728; AAD15287.1; -; Genomic_DNA.
DR   EMBL; X02371; CAA26223.1; -; Genomic_DNA.
DR   EMBL; X02372; CAA26223.1; JOINED; Genomic_DNA.
DR   EMBL; X02373; CAA26223.1; JOINED; Genomic_DNA.
DR   EMBL; X02374; CAA26223.1; JOINED; Genomic_DNA.
DR   EMBL; X02375; CAA26224.1; -; Genomic_DNA.
DR   EMBL; X02376; CAA26225.1; -; Genomic_DNA.
DR   EMBL; X02377; CAA26226.1; -; Genomic_DNA.
DR   EMBL; X02378; CAA26227.1; -; Genomic_DNA.
DR   EMBL; X16158; CAA34278.1; -; Genomic_DNA.
DR   EMBL; X16158; CAA34279.1; -; Genomic_DNA.
DR   EMBL; X16158; CAA34280.1; -; Genomic_DNA.
DR   EMBL; X16158; CAA34281.1; -; Genomic_DNA.
DR   EMBL; X16158; CAA34282.1; -; Genomic_DNA.
DR   EMBL; X16158; CAA34283.1; -; Genomic_DNA.
DR   EMBL; X16158; CAA34284.1; -; Genomic_DNA.
DR   EMBL; J00116; AAA51997.1; -; Genomic_DNA.
DR   EMBL; L00977; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M63281; AAA52038.1; -; mRNA.
DR   EMBL; M27468; AAA52039.1; -; Genomic_DNA.
DR   EMBL; X06268; CAA29604.1; -; mRNA.
DR   EMBL; X00339; CAA25092.1; -; Genomic_DNA.
DR   EMBL; M12048; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS41778.1; -. [P02458-2]
DR   CCDS; CCDS8759.1; -. [P02458-1]
DR   PIR; A38513; CGHU6C.
DR   RefSeq; NP_001835.3; NM_001844.4. [P02458-2]
DR   RefSeq; NP_149162.2; NM_033150.2. [P02458-1]
DR   UniGene; Hs.408182; -.
DR   PDB; 1U5M; NMR; -; A=29-97.
DR   PDB; 2FSE; X-ray; 3.10 A; E/F=461-474.
DR   PDB; 2SEB; X-ray; 2.50 A; E=1238-1247.
DR   PDBsum; 1U5M; -.
DR   PDBsum; 2FSE; -.
DR   PDBsum; 2SEB; -.
DR   DisProt; DP00274; -.
DR   ProteinModelPortal; P02458; -.
DR   SMR; P02458; 27-97, 1271-1487.
DR   BioGrid; 107677; 24.
DR   IntAct; P02458; 3.
DR   MINT; MINT-6796075; -.
DR   STRING; 9606.ENSP00000369889; -.
DR   ChEMBL; CHEMBL2364188; -.
DR   DrugBank; DB00048; Collagenase clostridium histolyticum.
DR   iPTMnet; P02458; -.
DR   PhosphoSite; P02458; -.
DR   BioMuta; COL2A1; -.
DR   DMDM; 124056489; -.
DR   MaxQB; P02458; -.
DR   PaxDb; P02458; -.
DR   PRIDE; P02458; -.
DR   DNASU; 1280; -.
DR   Ensembl; ENST00000337299; ENSP00000338213; ENSG00000139219. [P02458-1]
DR   Ensembl; ENST00000380518; ENSP00000369889; ENSG00000139219. [P02458-2]
DR   GeneID; 1280; -.
DR   KEGG; hsa:1280; -.
DR   UCSC; uc001rqt.3; human. [P02458-3]
DR   UCSC; uc001rqu.3; human. [P02458-2]
DR   UCSC; uc001rqv.3; human. [P02458-1]
DR   CTD; 1280; -.
DR   GeneCards; COL2A1; -.
DR   GeneReviews; COL2A1; -.
DR   HGNC; HGNC:2200; COL2A1.
DR   HPA; CAB002214; -.
DR   HPA; HPA045939; -.
DR   MalaCards; COL2A1; -.
DR   MIM; 108300; phenotype.
DR   MIM; 120140; gene+phenotype.
DR   MIM; 132450; phenotype.
DR   MIM; 150600; phenotype.
DR   MIM; 151210; phenotype.
DR   MIM; 156550; phenotype.
DR   MIM; 183900; phenotype.
DR   MIM; 184250; phenotype.
DR   MIM; 200610; phenotype.
DR   MIM; 271700; phenotype.
DR   MIM; 604864; phenotype.
DR   MIM; 608805; phenotype.
DR   MIM; 609162; phenotype.
DR   MIM; 609508; phenotype.
DR   neXtProt; NX_P02458; -.
DR   Orphanet; 93296; Achondrogenesis type 2.
DR   Orphanet; 209867; Autosomal dominant rhegmatogenous retinal detachment.
DR   Orphanet; 137678; Czech dysplasia, metatarsal type.
DR   Orphanet; 85198; Dysspondyloenchondromatosis.
DR   Orphanet; 86820; Familial avascular necrosis of femoral head.
DR   Orphanet; 93297; Hypochondrogenesis.
DR   Orphanet; 485; Kniest dysplasia.
DR   Orphanet; 2380; Legg-Calve-Perthes disease.
DR   Orphanet; 93279; Mild spondyloepiphyseal dysplasia due to COL2A1 mutation with early-onset osteoarthritis.
DR   Orphanet; 166011; Multiple epiphyseal dysplasia, Beighton type.
DR   Orphanet; 85166; Platyspondylic dysplasia, Torrance type.
DR   Orphanet; 93346; Spondyloepimetaphyseal dysplasia congenita, Strudwick type.
DR   Orphanet; 94068; Spondyloepiphyseal dysplasia congenita.
DR   Orphanet; 93315; Spondylometaphyseal dysplasia, 'corner fracture' type.
DR   Orphanet; 93316; Spondylometaphyseal dysplasia, Schmidt type.
DR   Orphanet; 1856; Spondyloperipheral dysplasia - short ulna.
DR   Orphanet; 90653; Stickler syndrome type 1.
DR   Orphanet; 3450; Weissenbacher- Zweymuller syndrome.
DR   PharmGKB; PA26715; -.
DR   eggNOG; KOG3544; Eukaryota.
DR   eggNOG; ENOG410XNMM; LUCA.
DR   GeneTree; ENSGT00830000128243; -.
DR   HOVERGEN; HBG004933; -.
DR   InParanoid; P02458; -.
DR   KO; K19719; -.
DR   OMA; LRCQGQD; -.
DR   OrthoDB; EOG7TJ3HH; -.
DR   PhylomeDB; P02458; -.
DR   TreeFam; TF344135; -.
DR   Reactome; R-HSA-1442490; Collagen degradation.
DR   Reactome; R-HSA-1474244; Extracellular matrix organization.
DR   Reactome; R-HSA-1650814; Collagen biosynthesis and modifying enzymes.
DR   Reactome; R-HSA-186797; Signaling by PDGF.
DR   Reactome; R-HSA-198933; Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell.
DR   Reactome; R-HSA-2022090; Assembly of collagen fibrils and other multimeric structures.
DR   Reactome; R-HSA-216083; Integrin cell surface interactions.
DR   Reactome; R-HSA-3000171; Non-integrin membrane-ECM interactions.
DR   Reactome; R-HSA-3000178; ECM proteoglycans.
DR   Reactome; R-HSA-419037; NCAM1 interactions.
DR   ChiTaRS; COL2A1; human.
DR   EvolutionaryTrace; P02458; -.
DR   GeneWiki; Collagen,_type_II,_alpha_1; -.
DR   GenomeRNAi; 1280; -.
DR   NextBio; 5171; -.
DR   PMAP-CutDB; P02458; -.
DR   PRO; PR:P02458; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   Bgee; P02458; -.
DR   Genevisible; P02458; HS.
DR   GO; GO:0005604; C:basement membrane; IEA:Ensembl.
DR   GO; GO:0005585; C:collagen type II trimer; IDA:BHF-UCL.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0031012; C:extracellular matrix; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IEA:Ensembl.
DR   GO; GO:0030020; F:extracellular matrix structural constituent conferring tensile strength; IC:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; NAS:BHF-UCL.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0048407; F:platelet-derived growth factor binding; IDA:MGI.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0001502; P:cartilage condensation; IEA:Ensembl.
DR   GO; GO:0051216; P:cartilage development; TAS:BHF-UCL.
DR   GO; GO:0060351; P:cartilage development involved in endochondral bone morphogenesis; IEA:Ensembl.
DR   GO; GO:0071773; P:cellular response to BMP stimulus; IEA:Ensembl.
DR   GO; GO:0007417; P:central nervous system development; IEA:Ensembl.
DR   GO; GO:0002062; P:chondrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0030574; P:collagen catabolic process; TAS:Reactome.
DR   GO; GO:0030199; P:collagen fibril organization; IMP:BHF-UCL.
DR   GO; GO:0060272; P:embryonic skeletal joint morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0001958; P:endochondral ossification; IEA:Ensembl.
DR   GO; GO:0022617; P:extracellular matrix disassembly; TAS:Reactome.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0003007; P:heart morphogenesis; IEA:Ensembl.
DR   GO; GO:0042472; P:inner ear morphogenesis; IEA:Ensembl.
DR   GO; GO:0060174; P:limb bud formation; IEA:Ensembl.
DR   GO; GO:2001240; P:negative regulation of extrinsic apoptotic signaling pathway in absence of ligand; IEA:Ensembl.
DR   GO; GO:0030903; P:notochord development; IEA:Ensembl.
DR   GO; GO:0071599; P:otic vesicle development; IEA:Ensembl.
DR   GO; GO:0060021; P:palate development; IEA:Ensembl.
DR   GO; GO:0006029; P:proteoglycan metabolic process; IEA:Ensembl.
DR   GO; GO:0010468; P:regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0050776; P:regulation of immune response; TAS:Reactome.
DR   GO; GO:0007605; P:sensory perception of sound; IMP:BHF-UCL.
DR   GO; GO:0001501; P:skeletal system development; IMP:BHF-UCL.
DR   GO; GO:0001894; P:tissue homeostasis; IEA:Ensembl.
DR   GO; GO:0007601; P:visual perception; IMP:UniProtKB.
DR   InterPro; IPR008160; Collagen.
DR   InterPro; IPR000885; Fib_collagen_C.
DR   InterPro; IPR001007; VWF_dom.
DR   Pfam; PF01410; COLFI; 1.
DR   Pfam; PF01391; Collagen; 6.
DR   Pfam; PF00093; VWC; 1.
DR   ProDom; PD002078; Fib_collagen_C; 1.
DR   SMART; SM00038; COLFI; 1.
DR   SMART; SM00214; VWC; 1.
DR   PROSITE; PS51461; NC1_FIB; 1.
DR   PROSITE; PS01208; VWFC_1; 1.
DR   PROSITE; PS50184; VWFC_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Cataract; Collagen;
KW   Complete proteome; Deafness; Direct protein sequencing;
KW   Disease mutation; Disulfide bond; Dwarfism; Extracellular matrix;
KW   Glycoprotein; Hydroxylation; Metal-binding; Polymorphism;
KW   Reference proteome; Repeat; Secreted; Signal; Stickler syndrome.
FT   SIGNAL        1     25       {ECO:0000255}.
FT   PROPEP       26    181       N-terminal propeptide.
FT                                /FTId=PRO_0000005729.
FT   CHAIN       182   1241       Collagen alpha-1(II) chain.
FT                                /FTId=PRO_0000005730.
FT   CHAIN      1242   1487       Chondrocalcin.
FT                                /FTId=PRO_0000005731.
FT   DOMAIN       32     90       VWFC. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00220}.
FT   DOMAIN     1253   1487       Fibrillar collagen NC1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00793}.
FT   REGION      201   1214       Triple-helical region.
FT   REGION     1215   1241       Nonhelical region (C-terminal).
FT   METAL      1301   1301       Calcium. {ECO:0000250}.
FT   METAL      1303   1303       Calcium. {ECO:0000250}.
FT   METAL      1304   1304       Calcium; via carbonyl oxygen.
FT                                {ECO:0000250}.
FT   METAL      1306   1306       Calcium; via carbonyl oxygen.
FT                                {ECO:0000250}.
FT   METAL      1309   1309       Calcium. {ECO:0000250}.
FT   SITE        181    182       Cleavage; by procollagen N-endopeptidase.
FT                                {ECO:0000250}.
FT   SITE       1241   1242       Cleavage; by procollagen C-endopeptidase.
FT                                {ECO:0000250}.
FT   MOD_RES     190    190       5-hydroxylysine. {ECO:0000250}.
FT   MOD_RES     287    287       5-hydroxylysine. {ECO:0000250}.
FT   MOD_RES     299    299       5-hydroxylysine. {ECO:0000250}.
FT   MOD_RES     308    308       5-hydroxylysine. {ECO:0000250}.
FT   MOD_RES     374    374       5-hydroxylysine. {ECO:0000250}.
FT   MOD_RES     608    608       5-hydroxylysine. {ECO:0000250}.
FT   MOD_RES     620    620       5-hydroxylysine. {ECO:0000250}.
FT   MOD_RES     670    670       3-hydroxyproline. {ECO:0000250}.
FT   MOD_RES     907    907       3-hydroxyproline. {ECO:0000250}.
FT   MOD_RES    1130   1130       5-hydroxylysine. {ECO:0000250}.
FT   MOD_RES    1144   1144       3-hydroxyproline. {ECO:0000250}.
FT   MOD_RES    1186   1186       3-hydroxyproline. {ECO:0000250}.
FT   MOD_RES    1201   1201       3-hydroxyproline. {ECO:0000250}.
FT   MOD_RES    1207   1207       3-hydroxyproline. {ECO:0000250}.
FT   MOD_RES    1213   1213       3-hydroxyproline. {ECO:0000250}.
FT   CARBOHYD    190    190       O-linked (Gal...). {ECO:0000250}.
FT   CARBOHYD    287    287       O-linked (Gal...). {ECO:0000250}.
FT   CARBOHYD    299    299       O-linked (Gal...). {ECO:0000250}.
FT   CARBOHYD    308    308       O-linked (Gal...). {ECO:0000250}.
FT   CARBOHYD    374    374       O-linked (Gal...). {ECO:0000250}.
FT   CARBOHYD    608    608       O-linked (Gal...). {ECO:0000250}.
FT   CARBOHYD    620    620       O-linked (Gal...). {ECO:0000250}.
FT   CARBOHYD   1130   1130       O-linked (Gal...). {ECO:0000250}.
FT   CARBOHYD   1388   1388       N-linked (GlcNAc...).
FT   DISULFID   1283   1315       {ECO:0000255|PROSITE-ProRule:PRU00793}.
FT   DISULFID   1289   1289       Interchain (with C-1306).
FT                                {ECO:0000255|PROSITE-ProRule:PRU00793}.
FT   DISULFID   1306   1306       Interchain (with C-1289).
FT                                {ECO:0000255|PROSITE-ProRule:PRU00793}.
FT   DISULFID   1323   1485       {ECO:0000255|PROSITE-ProRule:PRU00793}.
FT   DISULFID   1393   1438       {ECO:0000255|PROSITE-ProRule:PRU00793}.
FT   VAR_SEQ       1   1219       Missing (in isoform 3).
FT                                {ECO:0000303|Ref.3}.
FT                                /FTId=VSP_022365.
FT   VAR_SEQ      29     98       QEAGSCVQDGQRYNDKDVWKPEPCRICVCDTGTVLCDDIIC
FT                                EDVKDCLSPEIPFGECCPICPTDLATASG -> R (in
FT                                isoform 1). {ECO:0000303|PubMed:2587267,
FT                                ECO:0000303|PubMed:2803268}.
FT                                /FTId=VSP_022366.
FT   VARIANT       9      9       T -> S (in dbSNP:rs3803183).
FT                                {ECO:0000269|PubMed:18272325,
FT                                ECO:0000269|PubMed:2081599,
FT                                ECO:0000269|PubMed:2587267,
FT                                ECO:0000269|PubMed:2714801,
FT                                ECO:0000269|PubMed:2803268,
FT                                ECO:0000269|PubMed:8948452}.
FT                                /FTId=VAR_017638.
FT   VARIANT      57     57       C -> Y (in STL1O).
FT                                {ECO:0000269|PubMed:17721977}.
FT                                /FTId=VAR_063891.
FT   VARIANT     142    142       E -> D (in dbSNP:rs34392760).
FT                                {ECO:0000269|PubMed:18272325}.
FT                                /FTId=VAR_033782.
FT   VARIANT     158    158       P -> L (in dbSNP:rs1050861).
FT                                {ECO:0000269|PubMed:2587267}.
FT                                /FTId=VAR_019836.
FT   VARIANT     240    240       G -> D (in STL1).
FT                                {ECO:0000269|PubMed:20513134}.
FT                                /FTId=VAR_063892.
FT   VARIANT     267    267       G -> D (in STL1O).
FT                                {ECO:0000269|PubMed:8317498}.
FT                                /FTId=VAR_001738.
FT   VARIANT     270    270       G -> R (in STL1).
FT                                {ECO:0000269|PubMed:20513134}.
FT                                /FTId=VAR_063893.
FT   VARIANT     275    275       R -> C (in CZECHD).
FT                                {ECO:0000269|PubMed:18553548,
FT                                ECO:0000269|PubMed:19764028,
FT                                ECO:0000269|PubMed:7757086,
FT                                ECO:0000269|PubMed:8244341}.
FT                                /FTId=VAR_001739.
FT   VARIANT     282    282       G -> D (in STL1).
FT                                {ECO:0000269|PubMed:20513134}.
FT                                /FTId=VAR_063894.
FT   VARIANT     302    308       Missing (in STL1).
FT                                {ECO:0000269|PubMed:7977371}.
FT                                /FTId=VAR_001740.
FT   VARIANT     303    303       G -> D (in KD; abnormal allele expressed
FT                                in the cartilage).
FT                                {ECO:0000269|PubMed:7874117}.
FT                                /FTId=VAR_001741.
FT   VARIANT     318    318       G -> R (in DRRD).
FT                                {ECO:0000269|PubMed:15671297}.
FT                                /FTId=VAR_023925.
FT   VARIANT     354    354       G -> R (in spondylometaphyseal dysplasia;
FT                                congenital type).
FT                                {ECO:0000269|PubMed:8486375}.
FT                                /FTId=VAR_001742.
FT   VARIANT     375    375       G -> R (in SEDC).
FT                                /FTId=VAR_001743.
FT   VARIANT     447    447       G -> S (in SEDC).
FT                                {ECO:0000269|PubMed:8019561}.
FT                                /FTId=VAR_001744.
FT   VARIANT     453    453       G -> A (in STL1).
FT                                {ECO:0000269|PubMed:20513134}.
FT                                /FTId=VAR_063895.
FT   VARIANT     453    453       G -> D (in ACG2).
FT                                {ECO:0000269|PubMed:10797431}.
FT                                /FTId=VAR_017639.
FT   VARIANT     453    453       G -> V (in ACG2).
FT                                {ECO:0000269|PubMed:10797431}.
FT                                /FTId=VAR_017640.
FT   VARIANT     492    492       G -> V (in SEMDSTWK).
FT                                {ECO:0000269|PubMed:7550321}.
FT                                /FTId=VAR_001745.
FT   VARIANT     501    501       G -> R (in STL1).
FT                                {ECO:0000269|PubMed:20513134}.
FT                                /FTId=VAR_063896.
FT   VARIANT     504    504       G -> C (in SEMDSTWK).
FT                                {ECO:0000269|PubMed:7550321}.
FT                                /FTId=VAR_001746.
FT   VARIANT     510    510       G -> D (in ACG2).
FT                                /FTId=VAR_001747.
FT   VARIANT     513    513       G -> S (in ACG2).
FT                                {ECO:0000269|PubMed:10745044}.
FT                                /FTId=VAR_024819.
FT   VARIANT     516    516       G -> D (in ACGA2).
FT                                {ECO:0000269|PubMed:15054848}.
FT                                /FTId=VAR_023926.
FT   VARIANT     547    547       D -> V (in ACG2).
FT                                {ECO:0000269|PubMed:17994563}.
FT                                /FTId=VAR_063897.
FT   VARIANT     565    565       R -> C (in STL1).
FT                                {ECO:0000269|PubMed:11007540}.
FT                                /FTId=VAR_023927.
FT   VARIANT     638    638       T -> I (in dbSNP:rs41263847).
FT                                {ECO:0000269|PubMed:18272325}.
FT                                /FTId=VAR_033783.
FT   VARIANT     667    667       L -> F (in DRRD).
FT                                {ECO:0000269|PubMed:11007540,
FT                                ECO:0000269|PubMed:15671297}.
FT                                /FTId=VAR_023928.
FT   VARIANT     717    717       G -> S (in ANFH).
FT                                {ECO:0000269|PubMed:15930420}.
FT                                /FTId=VAR_023929.
FT   VARIANT     717    717       G -> V (in ACG2).
FT                                {ECO:0000269|PubMed:10745044}.
FT                                /FTId=VAR_024820.
FT   VARIANT     719    719       R -> C (in OSCDP; also in mild
FT                                spondyloepiphyseal dysplasia and
FT                                precocious osteoarthritis).
FT                                {ECO:0000269|PubMed:1975693,
FT                                ECO:0000269|PubMed:1985108,
FT                                ECO:0000269|PubMed:7757086,
FT                                ECO:0000269|PubMed:8507190,
FT                                ECO:0000269|PubMed:9711874}.
FT                                /FTId=VAR_001748.
FT   VARIANT     771    771       G -> A (in ACG2).
FT                                {ECO:0000269|PubMed:10745044}.
FT                                /FTId=VAR_024821.
FT   VARIANT     771    771       G -> D (in ACG2).
FT                                {ECO:0000269|PubMed:10797431}.
FT                                /FTId=VAR_017641.
FT   VARIANT     774    774       G -> S (in SEDC and hypochondrogenesis;
FT                                lethal). {ECO:0000269|PubMed:1374906}.
FT                                /FTId=VAR_001749.
FT   VARIANT     780    780       G -> R (in ACG2).
FT                                {ECO:0000269|PubMed:10797431}.
FT                                /FTId=VAR_017642.
FT   VARIANT     795    795       G -> R (in ACG2).
FT                                {ECO:0000269|PubMed:10797431}.
FT                                /FTId=VAR_017643.
FT   VARIANT     804    804       G -> A (in hypochondrogenesis).
FT                                /FTId=VAR_001751.
FT   VARIANT     855    855       G -> S (in SEDC).
FT                                /FTId=VAR_023930.
FT   VARIANT     891    891       G -> R (in ACG2 and SEDC).
FT                                {ECO:0000269|PubMed:7757081,
FT                                ECO:0000269|PubMed:7757086}.
FT                                /FTId=VAR_001752.
FT   VARIANT     894    894       G -> E (in ACG2).
FT                                {ECO:0000269|PubMed:10797431}.
FT                                /FTId=VAR_017644.
FT   VARIANT     897    897       G -> V (in SEMDSTWK).
FT                                {ECO:0000269|Ref.38}.
FT                                /FTId=VAR_023931.
FT   VARIANT     904    904       R -> C (in EDMMD and STL1).
FT                                {ECO:0000269|PubMed:20513134,
FT                                ECO:0000269|PubMed:9800905}.
FT                                /FTId=VAR_017645.
FT   VARIANT     909    909       G -> C (in SEMDSTWK).
FT                                {ECO:0000269|PubMed:7550321,
FT                                ECO:0000269|Ref.38}.
FT                                /FTId=VAR_001753.
FT   VARIANT     948    948       G -> D (in ACG2).
FT                                {ECO:0000269|PubMed:10797431}.
FT                                /FTId=VAR_017646.
FT   VARIANT     969    969       G -> S (in ACG2).
FT                                {ECO:0000269|PubMed:7829510}.
FT                                /FTId=VAR_001754.
FT   VARIANT     981    981       G -> S (in ACG2).
FT                                {ECO:0000269|PubMed:10797431}.
FT                                /FTId=VAR_017647.
FT   VARIANT     989    989       R -> C (in SEDC).
FT                                {ECO:0000269|PubMed:8325895}.
FT                                /FTId=VAR_001755.
FT   VARIANT     992    992       R -> G (in SEMDSTWK).
FT                                {ECO:0000269|PubMed:16088915}.
FT                                /FTId=VAR_023932.
FT   VARIANT    1005   1005       G -> S (in hypochondrogenesis).
FT                                /FTId=VAR_001756.
FT   VARIANT    1017   1022       Missing (in hypochondrogenesis).
FT                                {ECO:0000269|PubMed:10797431}.
FT                                /FTId=VAR_017648.
FT   VARIANT    1017   1017       G -> V (in ACG2).
FT                                /FTId=VAR_001757.
FT   VARIANT    1051   1051       A -> T (in dbSNP:rs41272041).
FT                                {ECO:0000269|PubMed:18272325}.
FT                                /FTId=VAR_033784.
FT   VARIANT    1053   1053       G -> E (in hypochondrogenesis; lethal).
FT                                {ECO:0000269|PubMed:1429602}.
FT                                /FTId=VAR_001758.
FT   VARIANT    1065   1065       G -> V (in ACG2).
FT                                {ECO:0000269|PubMed:10797431}.
FT                                /FTId=VAR_017649.
FT   VARIANT    1110   1110       G -> C (in ACG2).
FT                                {ECO:0000269|PubMed:10745044}.
FT                                /FTId=VAR_001759.
FT   VARIANT    1113   1113       G -> C (in hypochondrogenesis).
FT                                {ECO:0000269|PubMed:8723098}.
FT                                /FTId=VAR_001760.
FT   VARIANT    1119   1119       G -> R (in ACG2).
FT                                {ECO:0000269|PubMed:10797431}.
FT                                /FTId=VAR_017650.
FT   VARIANT    1143   1143       G -> S (in ACG2).
FT                                {ECO:0000269|PubMed:10745044,
FT                                ECO:0000269|PubMed:2572591}.
FT                                /FTId=VAR_001761.
FT   VARIANT    1158   1158       G -> A (in STL1).
FT                                {ECO:0000269|PubMed:20513134}.
FT                                /FTId=VAR_063898.
FT   VARIANT    1164   1199       Missing (in SEDC).
FT                                /FTId=VAR_001762.
FT   VARIANT    1170   1170       G -> S (in ANFH and in LCPD).
FT                                {ECO:0000269|PubMed:15930420,
FT                                ECO:0000269|PubMed:17394019}.
FT                                /FTId=VAR_023933.
FT   VARIANT    1173   1173       G -> R (in SEDC).
FT                                {ECO:0000269|PubMed:10678662}.
FT                                /FTId=VAR_017651.
FT   VARIANT    1176   1176       G -> S (in SEDC).
FT                                {ECO:0000269|PubMed:7757086}.
FT                                /FTId=VAR_001763.
FT   VARIANT    1176   1176       G -> V (mutation found in a patient with
FT                                features of multiple epiphyseal
FT                                dysplasia; features overlap with SEDC).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066836.
FT   VARIANT    1179   1179       G -> R (mutation found in a patient with
FT                                features of multiple epiphyseal
FT                                dysplasia; features overlap with SEDC).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066837.
FT   VARIANT    1184   1184       I -> IGPSGKDGANGIPGPI (in SEDC).
FT                                {ECO:0000269|PubMed:2339128}.
FT                                /FTId=VAR_019837.
FT   VARIANT    1188   1188       G -> R (in ACG2).
FT                                {ECO:0000269|PubMed:7757086}.
FT                                /FTId=VAR_001764.
FT   VARIANT    1197   1197       G -> S (in SEDC).
FT                                {ECO:0000269|PubMed:8423604}.
FT                                /FTId=VAR_001765.
FT   VARIANT    1207   1212       Missing (in KD).
FT                                {ECO:0000269|PubMed:8863156}.
FT                                /FTId=VAR_001766.
FT   VARIANT    1305   1305       G -> D (in vitreoretinopathy; with
FT                                phalangeal epiphyseal dysplasia).
FT                                {ECO:0000269|PubMed:12205109}.
FT                                /FTId=VAR_023934.
FT   VARIANT    1331   1331       V -> I (in dbSNP:rs12721427).
FT                                {ECO:0000269|PubMed:10797431,
FT                                ECO:0000269|PubMed:18272325}.
FT                                /FTId=VAR_017652.
FT   VARIANT    1390   1390       T -> N (in PLSD-T; phenotype previously
FT                                considered as achondrogenesis-
FT                                hypochondrogenesis type 2).
FT                                {ECO:0000269|PubMed:10745044,
FT                                ECO:0000269|PubMed:15643621}.
FT                                /FTId=VAR_024822.
FT   VARIANT    1391   1391       Y -> C (in PLSD-T).
FT                                {ECO:0000269|PubMed:14729840}.
FT                                /FTId=VAR_023935.
FT   VARIANT    1405   1405       G -> S (in dbSNP:rs2070739).
FT                                {ECO:0000269|PubMed:18272325}.
FT                                /FTId=VAR_033785.
FT   VARIANT    1439   1439       T -> M (in SEDC).
FT                                {ECO:0000269|PubMed:11746045}.
FT                                /FTId=VAR_017105.
FT   VARIANT    1448   1448       T -> P (in PLSD-T).
FT                                {ECO:0000269|PubMed:15643621}.
FT                                /FTId=VAR_024823.
FT   VARIANT    1469   1469       D -> H (in PLSD-T).
FT                                {ECO:0000269|PubMed:15643621}.
FT                                /FTId=VAR_024824.
FT   VARIANT    1484   1484       Missing (in PLSD-T).
FT                                {ECO:0000269|PubMed:15643621}.
FT                                /FTId=VAR_024825.
FT   VARIANT    1485   1485       C -> G (in PLSD-T).
FT                                {ECO:0000269|PubMed:15643621}.
FT                                /FTId=VAR_024826.
FT   CONFLICT    441    441       G -> D (in Ref. 1; CAA34488).
FT                                {ECO:0000305}.
FT   CONFLICT    457    457       E -> K (in Ref. 1; CAA34488).
FT                                {ECO:0000305}.
FT   CONFLICT    481    481       A -> P (in Ref. 15; AAB60370).
FT                                {ECO:0000305}.
FT   CONFLICT    641    641       A -> E (in Ref. 1; CAA34488 and 16;
FT                                CAA32030). {ECO:0000305}.
FT   CONFLICT    677    677       G -> A (in Ref. 16; CAA32030).
FT                                {ECO:0000305}.
FT   CONFLICT    784    784       G -> A (in Ref. 16; CAA32030).
FT                                {ECO:0000305}.
FT   CONFLICT    832    835       PAGF -> TSGI (in Ref. 1; CAA34488).
FT                                {ECO:0000305}.
FT   CONFLICT   1006   1006       K -> Q (in Ref. 1; CAA34488 and 16;
FT                                CAA32030). {ECO:0000305}.
FT   CONFLICT   1037   1037       E -> Q (in Ref. 6; CAA34683).
FT                                {ECO:0000305}.
FT   CONFLICT   1057   1057       D -> N (in Ref. 17; AAD15287/CAA26223 and
FT                                19; AAA51997). {ECO:0000305}.
FT   CONFLICT   1069   1069       A -> T (in Ref. 6; CAA34683, 17;
FT                                AAD15287/CAA26223 and 19; AAA51997).
FT                                {ECO:0000305}.
FT   CONFLICT   1243   1243       Q -> E (in Ref. 24; CAA29604).
FT                                {ECO:0000305}.
FT   CONFLICT   1247   1247       G -> N (in Ref. 24; CAA29604).
FT                                {ECO:0000305}.
FT   CONFLICT   1271   1271       S -> T (in Ref. 21; AAA52038).
FT                                {ECO:0000305}.
FT   CONFLICT   1274   1274       G -> A (in Ref. 21; AAA52038).
FT                                {ECO:0000305}.
FT   CONFLICT   1333   1333       K -> R (in Ref. 28; M12048).
FT                                {ECO:0000305}.
FT   CONFLICT   1350   1350       G -> A (in Ref. 28; M12048).
FT                                {ECO:0000305}.
FT   CONFLICT   1372   1372       N -> D (in Ref. 17; CAA26223).
FT                                {ECO:0000305}.
FT   CONFLICT   1383   1383       T -> A (in Ref. 17; CAA26223).
FT                                {ECO:0000305}.
FT   CONFLICT   1400   1400       L -> M (in Ref. 17; CAA26223).
FT                                {ECO:0000305}.
FT   STRAND       34     38       {ECO:0000244|PDB:1U5M}.
FT   STRAND       51     58       {ECO:0000244|PDB:1U5M}.
FT   STRAND       61     66       {ECO:0000244|PDB:1U5M}.
FT   STRAND       91     94       {ECO:0000244|PDB:1U5M}.
SQ   SEQUENCE   1487 AA;  141785 MW;  A8312503825BF0BB CRC64;
     MIRLGAPQTL VLLTLLVAAV LRCQGQDVQE AGSCVQDGQR YNDKDVWKPE PCRICVCDTG
     TVLCDDIICE DVKDCLSPEI PFGECCPICP TDLATASGQP GPKGQKGEPG DIKDIVGPKG
     PPGPQGPAGE QGPRGDRGDK GEKGAPGPRG RDGEPGTPGN PGPPGPPGPP GPPGLGGNFA
     AQMAGGFDEK AGGAQLGVMQ GPMGPMGPRG PPGPAGAPGP QGFQGNPGEP GEPGVSGPMG
     PRGPPGPPGK PGDDGEAGKP GKAGERGPPG PQGARGFPGT PGLPGVKGHR GYPGLDGAKG
     EAGAPGVKGE SGSPGENGSP GPMGPRGLPG ERGRTGPAGA AGARGNDGQP GPAGPPGPVG
     PAGGPGFPGA PGAKGEAGPT GARGPEGAQG PRGEPGTPGS PGPAGASGNP GTDGIPGAKG
     SAGAPGIAGA PGFPGPRGPP GPQGATGPLG PKGQTGEPGI AGFKGEQGPK GEPGPAGPQG
     APGPAGEEGK RGARGEPGGV GPIGPPGERG APGNRGFPGQ DGLAGPKGAP GERGPSGLAG
     PKGANGDPGR PGEPGLPGAR GLTGRPGDAG PQGKVGPSGA PGEDGRPGPP GPQGARGQPG
     VMGFPGPKGA NGEPGKAGEK GLPGAPGLRG LPGKDGETGA AGPPGPAGPA GERGEQGAPG
     PSGFQGLPGP PGPPGEGGKP GDQGVPGEAG APGLVGPRGE RGFPGERGSP GAQGLQGPRG
     LPGTPGTDGP KGASGPAGPP GAQGPPGLQG MPGERGAAGI AGPKGDRGDV GEKGPEGAPG
     KDGGRGLTGP IGPPGPAGAN GEKGEVGPPG PAGSAGARGA PGERGETGPP GPAGFAGPPG
     ADGQPGAKGE QGEAGQKGDA GAPGPQGPSG APGPQGPTGV TGPKGARGAQ GPPGATGFPG
     AAGRVGPPGS NGNPGPPGPP GPSGKDGPKG ARGDSGPPGR AGEPGLQGPA GPPGEKGEPG
     DDGPSGAEGP PGPQGLAGQR GIVGLPGQRG ERGFPGLPGP SGEPGKQGAP GASGDRGPPG
     PVGPPGLTGP AGEPGREGSP GADGPPGRDG AAGVKGDRGE TGAVGAPGAP GPPGSPGPAG
     PTGKQGDRGE AGAQGPMGPS GPAGARGIQG PQGPRGDKGE AGEPGERGLK GHRGFTGLQG
     LPGPPGPSGD QGASGPAGPS GPRGPPGPVG PSGKDGANGI PGPIGPPGPR GRSGETGPAG
     PPGNPGPPGP PGPPGPGIDM SAFAGLGPRE KGPDPLQYMR ADQAAGGLRQ HDAEVDATLK
     SLNNQIESIR SPEGSRKNPA RTCRDLKLCH PEWKSGDYWI DPNQGCTLDA MKVFCNMETG
     ETCVYPNPAN VPKKNWWSSK SKEKKHIWFG ETINGGFHFS YGDDNLAPNT ANVQMTFLRL
     LSTEGSQNIT YHCKNSIAYL DEAAGNLKKA LLIQGSNDVE IRAEGNSRFT YTALKDGCTK
     HTGKWGKTVI EYRSQKTSRL PIIDIAPMDI GGPEQEFGVD IGPVCFL
//
ID   TGFB1_RAT               Reviewed;         390 AA.
AC   P17246; Q53YM8;
DT   01-AUG-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1990, sequence version 1.
DT   17-FEB-2016, entry version 146.
DE   RecName: Full=Transforming growth factor beta-1;
DE            Short=TGF-beta-1;
DE   Contains:
DE     RecName: Full=Latency-associated peptide;
DE              Short=LAP;
DE   Flags: Precursor;
GN   Name=Tgfb1;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley; TISSUE=Heart;
RX   PubMed=2349108; DOI=10.1093/nar/18.10.3059;
RA   Qian S.W., Kondaiah P., Roberts A.B., Sporn M.B.;
RT   "cDNA cloning by PCR of rat transforming growth factor beta-1.";
RL   Nucleic Acids Res. 18:3059-3059(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RA   Dai W.-J., Jiang H.-C., Fu S.-B.;
RT   "Open reading frame sequence of rat TGF beta 1.";
RL   Submitted (FEB-2004) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   SUBUNIT.
RX   PubMed=11907708; DOI=10.1007/s002230010032;
RA   Maeda S., Dean D.D., Gomez R., Schwartz Z., Boyan B.D.;
RT   "The first stage of transforming growth factor beta1 activation is
RT   release of the large latent complex from the extracellular matrix of
RT   growth plate chondrocytes by matrix vesicle stromelysin-1 (MMP-3).";
RL   Calcif. Tissue Int. 70:54-65(2002).
RN   [5]
RP   ROLE IN BONE REMODELING, AND TISSUE SPECIFICITY.
RX   PubMed=2070682;
RA   Mundy G.R.;
RT   "The effects of TGF-beta on bone.";
RL   Ciba Found. Symp. 157:137-143(1991).
CC   -!- FUNCTION: Multifunctional protein that controls proliferation,
CC       differentiation and other functions in many cell types. Many cells
CC       synthesize TGFB1 and have specific receptors for it. It positively
CC       and negatively regulates many other growth factors. It plays an
CC       important role in bone remodeling as it is a potent stimulator of
CC       osteoblastic bone formation, causing chemotaxis, proliferation and
CC       differentiation in committed osteoblasts. Can promote either T-
CC       helper 17 cells (Th17) or regulatory T-cells (Treg) lineage
CC       differentiation in a concentration-dependent manner. At high
CC       concentrations, leads to FOXP3-mediated suppression of RORC and
CC       down-regulation of IL-17 expression, favoring Treg cell
CC       development. At low concentrations in concert with IL-6 and IL-21,
CC       leads to expression of the IL-17 and IL-23 receptors, favoring
CC       differentiation to Th17 cells (By similarity).
CC       {ECO:0000250|UniProtKB:P04202, ECO:0000269|PubMed:2070682}.
CC   -!- SUBUNIT: Homodimer; disulfide-linked, or heterodimer with TGFB2
CC       (By similarity). Secreted and stored as a biologically inactive
CC       form in the extracellular matrix in a 290 kDa complex (large
CC       latent TGF-beta1 complex) containing the TGFB1 homodimer, the
CC       latency-associated peptide (LAP), and the latent TGFB1 binding
CC       protein-1 (LTBP1). The complex without LTBP1 is known as the'small
CC       latent TGF-beta1 complex'. Dissociation of the TGFB1 from LAP is
CC       required for growth factor activation and biological activity.
CC       Release of the large latent TGF-beta1 complex from the
CC       extracellular matrix is carried out by the matrix
CC       metalloproteinase MMP3. Interacts with CD109 and DPT. Interacts
CC       with ASPN. May interact with THSD4; this interaction may lead to
CC       sequestration by FBN1 microfibril assembly and attenuation of TGFB
CC       signaling. Interacts with the serine proteases, HTRA1 and HTRA3:
CC       the interaction with either inhibits TGFB1-mediated signaling. The
CC       HTRA protease activity is required for this inhibition (By
CC       similarity). Latency-associated peptide interacts with NREP; the
CC       interaction results in a decrease in TGFB1 autoinduction (By
CC       similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular
CC       matrix {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Abundant in the bone matrix.
CC       {ECO:0000269|PubMed:2070682}.
CC   -!- DOMAIN: The 'straitjacket' and 'arm' domains encircle the growth
CC       factor monomers and are fastened together by strong bonding
CC       between Lys-56 and Tyr-103/Tyr-104. Activation of TGF-beta1
CC       requires the binding of integrin alpha-V to an RGD sequence in the
CC       prodomain and exertion of force on this domain, which is held in
CC       the extracellular matrix by latent TGF-beta binding proteins. The
CC       sheer physical force unfastens the straitjacket and releases the
CC       active growth factor dimer (By similarity). {ECO:0000250}.
CC   -!- PTM: Glycosylated. {ECO:0000250}.
CC   -!- PTM: The precursor is cleaved into mature TGF-beta-1 and LAP,
CC       which remains non-covalently linked to mature TGF-beta-1 rendering
CC       it inactive. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the TGF-beta family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X52498; CAA36741.1; -; mRNA.
DR   EMBL; AY550025; AAS55640.1; -; mRNA.
DR   EMBL; BC076380; AAH76380.1; -; mRNA.
DR   PIR; S10219; S10219.
DR   RefSeq; NP_067589.1; NM_021578.2.
DR   UniGene; Rn.40136; -.
DR   ProteinModelPortal; P17246; -.
DR   SMR; P17246; 279-390.
DR   BioGrid; 248721; 1.
DR   DIP; DIP-6247N; -.
DR   STRING; 10116.ENSRNOP00000028051; -.
DR   PaxDb; P17246; -.
DR   PRIDE; P17246; -.
DR   Ensembl; ENSRNOT00000028051; ENSRNOP00000028051; ENSRNOG00000020652.
DR   GeneID; 59086; -.
DR   KEGG; rno:59086; -.
DR   UCSC; RGD:69051; rat.
DR   CTD; 7040; -.
DR   RGD; 69051; Tgfb1.
DR   eggNOG; KOG3900; Eukaryota.
DR   eggNOG; ENOG410XT8Z; LUCA.
DR   GeneTree; ENSGT00760000119112; -.
DR   HOGENOM; HOG000290198; -.
DR   HOVERGEN; HBG074115; -.
DR   InParanoid; P17246; -.
DR   KO; K13375; -.
DR   OMA; SHSIYMF; -.
DR   OrthoDB; EOG70GMFT; -.
DR   PhylomeDB; P17246; -.
DR   TreeFam; TF318514; -.
DR   Reactome; R-RNO-114608; Platelet degranulation.
DR   Reactome; R-RNO-2129379; Molecules associated with elastic fibres.
DR   Reactome; R-RNO-2173788; Downregulation of TGF-beta receptor signaling.
DR   Reactome; R-RNO-2173789; TGF-beta receptor signaling activates SMADs.
DR   Reactome; R-RNO-2173791; TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition).
DR   Reactome; R-RNO-3000170; Syndecan interactions.
DR   NextBio; 611708; -.
DR   PRO; PR:P17246; -.
DR   Proteomes; UP000002494; Chromosome 1.
DR   Genevisible; P17246; RN.
DR   GO; GO:0030424; C:axon; IDA:RGD.
DR   GO; GO:0072562; C:blood microparticle; ISS:AgBase.
DR   GO; GO:0009986; C:cell surface; IDA:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; IDA:RGD.
DR   GO; GO:0005615; C:extracellular space; IDA:RGD.
DR   GO; GO:0005902; C:microvillus; IEA:Ensembl.
DR   GO; GO:0043025; C:neuronal cell body; IDA:RGD.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0005578; C:proteinaceous extracellular matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:0030141; C:secretory granule; IDA:RGD.
DR   GO; GO:0003823; F:antigen binding; ISS:AgBase.
DR   GO; GO:0005125; F:cytokine activity; IBA:GO_Central.
DR   GO; GO:0001948; F:glycoprotein binding; ISS:AgBase.
DR   GO; GO:0046982; F:protein heterodimerization activity; IDA:RGD.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:RGD.
DR   GO; GO:0047485; F:protein N-terminus binding; IMP:RGD.
DR   GO; GO:0043539; F:protein serine/threonine kinase activator activity; IEA:Ensembl.
DR   GO; GO:0005160; F:transforming growth factor beta receptor binding; TAS:RGD.
DR   GO; GO:0034713; F:type I transforming growth factor beta receptor binding; ISS:AgBase.
DR   GO; GO:0005114; F:type II transforming growth factor beta receptor binding; ISS:UniProtKB.
DR   GO; GO:0034714; F:type III transforming growth factor beta receptor binding; ISS:AgBase.
DR   GO; GO:0002460; P:adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains; IEA:Ensembl.
DR   GO; GO:0007568; P:aging; IEP:RGD.
DR   GO; GO:0006754; P:ATP biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0060751; P:branch elongation involved in mammary gland duct branching; IEA:Ensembl.
DR   GO; GO:0007050; P:cell cycle arrest; ISS:UniProtKB.
DR   GO; GO:0016049; P:cell growth; IEA:InterPro.
DR   GO; GO:0045216; P:cell-cell junction organization; ISS:UniProtKB.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; IEA:Ensembl.
DR   GO; GO:0071549; P:cellular response to dexamethasone stimulus; IDA:UniProtKB.
DR   GO; GO:0071407; P:cellular response to organic cyclic compound; ISS:UniProtKB.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; ISS:AgBase.
DR   GO; GO:0002062; P:chondrocyte differentiation; ISS:UniProtKB.
DR   GO; GO:0007182; P:common-partner SMAD protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0009817; P:defense response to fungus, incompatible interaction; IDA:RGD.
DR   GO; GO:0048565; P:digestive tract development; IEP:RGD.
DR   GO; GO:0007492; P:endoderm development; IEA:Ensembl.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0001837; P:epithelial to mesenchymal transition; IDA:RGD.
DR   GO; GO:0019049; P:evasion or tolerance of host defenses by virus; ISS:UniProtKB.
DR   GO; GO:0085029; P:extracellular matrix assembly; ISS:UniProtKB.
DR   GO; GO:0097191; P:extrinsic apoptotic signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0060325; P:face morphogenesis; IEA:Ensembl.
DR   GO; GO:0007565; P:female pregnancy; IEP:RGD.
DR   GO; GO:0060364; P:frontal suture morphogenesis; IEP:RGD.
DR   GO; GO:0008354; P:germ cell migration; IEA:Ensembl.
DR   GO; GO:0002244; P:hematopoietic progenitor cell differentiation; ISS:UniProtKB.
DR   GO; GO:0030214; P:hyaluronan catabolic process; ISS:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; ISS:AgBase.
DR   GO; GO:0048839; P:inner ear development; IEP:RGD.
DR   GO; GO:0070306; P:lens fiber cell differentiation; IEA:Ensembl.
DR   GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; ISS:UniProtKB.
DR   GO; GO:0030324; P:lung development; TAS:RGD.
DR   GO; GO:0048535; P:lymph node development; IEA:Ensembl.
DR   GO; GO:0060744; P:mammary gland branching involved in thelarche; IEA:Ensembl.
DR   GO; GO:0000165; P:MAPK cascade; ISS:UniProtKB.
DR   GO; GO:0007093; P:mitotic cell cycle checkpoint; ISS:UniProtKB.
DR   GO; GO:0032943; P:mononuclear cell proliferation; IEA:Ensembl.
DR   GO; GO:0001763; P:morphogenesis of a branching structure; IDA:RGD.
DR   GO; GO:0042552; P:myelination; IMP:RGD.
DR   GO; GO:0043011; P:myeloid dendritic cell differentiation; IEA:Ensembl.
DR   GO; GO:0043537; P:negative regulation of blood vessel endothelial cell migration; ISS:UniProtKB.
DR   GO; GO:0045786; P:negative regulation of cell cycle; ISS:UniProtKB.
DR   GO; GO:0030308; P:negative regulation of cell growth; ISS:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; ISS:UniProtKB.
DR   GO; GO:0022408; P:negative regulation of cell-cell adhesion; ISS:UniProtKB.
DR   GO; GO:0008156; P:negative regulation of DNA replication; ISS:UniProtKB.
DR   GO; GO:0050680; P:negative regulation of epithelial cell proliferation; IDA:RGD.
DR   GO; GO:0045599; P:negative regulation of fat cell differentiation; ISS:UniProtKB.
DR   GO; GO:0010629; P:negative regulation of gene expression; ISS:BHF-UCL.
DR   GO; GO:0060965; P:negative regulation of gene silencing by miRNA; IEA:Ensembl.
DR   GO; GO:1900126; P:negative regulation of hyaluronan biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0050777; P:negative regulation of immune response; IDA:RGD.
DR   GO; GO:0032700; P:negative regulation of interleukin-17 production; IEA:Ensembl.
DR   GO; GO:0010936; P:negative regulation of macrophage cytokine production; ISS:AgBase.
DR   GO; GO:0045930; P:negative regulation of mitotic cell cycle; ISS:UniProtKB.
DR   GO; GO:0045662; P:negative regulation of myoblast differentiation; ISS:UniProtKB.
DR   GO; GO:0007406; P:negative regulation of neuroblast proliferation; IDA:RGD.
DR   GO; GO:0030279; P:negative regulation of ossification; IEA:Ensembl.
DR   GO; GO:0050765; P:negative regulation of phagocytosis; IDA:RGD.
DR   GO; GO:1903077; P:negative regulation of protein localization to plasma membrane; IEA:Ensembl.
DR   GO; GO:0001933; P:negative regulation of protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0051280; P:negative regulation of release of sequestered calcium ion into cytosol; IDA:RGD.
DR   GO; GO:0048642; P:negative regulation of skeletal muscle tissue development; ISS:UniProtKB.
DR   GO; GO:0042130; P:negative regulation of T cell proliferation; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0007219; P:Notch signaling pathway; IEA:Ensembl.
DR   GO; GO:0014003; P:oligodendrocyte development; IEA:Ensembl.
DR   GO; GO:0031100; P:organ regeneration; IMP:RGD.
DR   GO; GO:0043932; P:ossification involved in bone remodeling; ISS:AgBase.
DR   GO; GO:0060389; P:pathway-restricted SMAD protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0006796; P:phosphate-containing compound metabolic process; ISS:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:RGD.
DR   GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; ISS:UniProtKB.
DR   GO; GO:0030501; P:positive regulation of bone mineralization; ISS:AgBase.
DR   GO; GO:0090190; P:positive regulation of branching involved in ureteric bud morphogenesis; IMP:UniProtKB.
DR   GO; GO:0071158; P:positive regulation of cell cycle arrest; IEA:Ensembl.
DR   GO; GO:0030335; P:positive regulation of cell migration; ISS:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; ISS:UniProtKB.
DR   GO; GO:0032270; P:positive regulation of cellular protein metabolic process; ISS:UniProtKB.
DR   GO; GO:0050921; P:positive regulation of chemotaxis; ISS:UniProtKB.
DR   GO; GO:0032967; P:positive regulation of collagen biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IDA:RGD.
DR   GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; ISS:UniProtKB.
DR   GO; GO:0031536; P:positive regulation of exit from mitosis; IDA:RGD.
DR   GO; GO:0010763; P:positive regulation of fibroblast migration; ISS:UniProtKB.
DR   GO; GO:0048146; P:positive regulation of fibroblast proliferation; IEA:Ensembl.
DR   GO; GO:0010628; P:positive regulation of gene expression; ISS:UniProtKB.
DR   GO; GO:0035066; P:positive regulation of histone acetylation; IEA:Ensembl.
DR   GO; GO:0031065; P:positive regulation of histone deacetylation; IEA:Ensembl.
DR   GO; GO:0032740; P:positive regulation of interleukin-17 production; ISS:UniProtKB.
DR   GO; GO:0048298; P:positive regulation of isotype switching to IgA isotypes; ISS:AgBase.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; ISS:UniProtKB.
DR   GO; GO:1901666; P:positive regulation of NAD+ ADP-ribosyltransferase activity; ISS:UniProtKB.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IDA:RGD.
DR   GO; GO:0042482; P:positive regulation of odontogenesis; IEA:Ensembl.
DR   GO; GO:0010862; P:positive regulation of pathway-restricted SMAD protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; ISS:UniProtKB.
DR   GO; GO:0010800; P:positive regulation of peptidyl-threonine phosphorylation; ISS:UniProtKB.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IEA:Ensembl.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; ISS:UniProtKB.
DR   GO; GO:0031334; P:positive regulation of protein complex assembly; ISS:UniProtKB.
DR   GO; GO:0035307; P:positive regulation of protein dephosphorylation; ISS:UniProtKB.
DR   GO; GO:0042307; P:positive regulation of protein import into nucleus; ISS:AgBase.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; ISS:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0050714; P:positive regulation of protein secretion; ISS:UniProtKB.
DR   GO; GO:1903911; P:positive regulation of receptor clustering; IEA:Ensembl.
DR   GO; GO:0045591; P:positive regulation of regulatory T cell differentiation; IEA:Ensembl.
DR   GO; GO:0060391; P:positive regulation of SMAD protein import into nucleus; ISS:AgBase.
DR   GO; GO:0051152; P:positive regulation of smooth muscle cell differentiation; IDA:MGI.
DR   GO; GO:0032930; P:positive regulation of superoxide anion generation; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; ISS:AgBase.
DR   GO; GO:2000679; P:positive regulation of transcription regulatory region DNA binding; ISS:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0043117; P:positive regulation of vascular permeability; IEA:Ensembl.
DR   GO; GO:0006611; P:protein export from nucleus; ISS:UniProtKB.
DR   GO; GO:0000060; P:protein import into nucleus, translocation; ISS:UniProtKB.
DR   GO; GO:0043491; P:protein kinase B signaling; ISS:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:CACAO.
DR   GO; GO:0032801; P:receptor catabolic process; ISS:UniProtKB.
DR   GO; GO:2000249; P:regulation of actin cytoskeleton reorganization; IEA:Ensembl.
DR   GO; GO:0060762; P:regulation of branching involved in mammary gland duct morphogenesis; IEA:Ensembl.
DR   GO; GO:0061035; P:regulation of cartilage development; IEA:Ensembl.
DR   GO; GO:0001558; P:regulation of cell growth; TAS:RGD.
DR   GO; GO:0042127; P:regulation of cell proliferation; TAS:RGD.
DR   GO; GO:0032667; P:regulation of interleukin-23 production; IEA:Ensembl.
DR   GO; GO:0043408; P:regulation of MAPK cascade; IBA:GO_Central.
DR   GO; GO:0002028; P:regulation of sodium ion transport; IEA:Ensembl.
DR   GO; GO:0017015; P:regulation of transforming growth factor beta receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0045066; P:regulatory T cell differentiation; IEA:Ensembl.
DR   GO; GO:0070723; P:response to cholesterol; ISS:UniProtKB.
DR   GO; GO:0042493; P:response to drug; IEP:RGD.
DR   GO; GO:0032355; P:response to estradiol; ISS:AgBase.
DR   GO; GO:0009749; P:response to glucose; IEP:RGD.
DR   GO; GO:0001666; P:response to hypoxia; IEP:RGD.
DR   GO; GO:0034616; P:response to laminar fluid shear stress; IEP:RGD.
DR   GO; GO:0014070; P:response to organic cyclic compound; IEP:RGD.
DR   GO; GO:0010033; P:response to organic substance; IDA:RGD.
DR   GO; GO:0032570; P:response to progesterone; ISS:UniProtKB.
DR   GO; GO:0009314; P:response to radiation; IEP:RGD.
DR   GO; GO:0033280; P:response to vitamin D; IEP:RGD.
DR   GO; GO:0009611; P:response to wounding; ISS:AgBase.
DR   GO; GO:0007435; P:salivary gland morphogenesis; ISS:AgBase.
DR   GO; GO:0007183; P:SMAD protein complex assembly; ISS:UniProtKB.
DR   GO; GO:0007184; P:SMAD protein import into nucleus; IDA:RGD.
DR   GO; GO:0060395; P:SMAD protein signal transduction; IBA:GO_Central.
DR   GO; GO:0043029; P:T cell homeostasis; IEA:Ensembl.
DR   GO; GO:0002513; P:tolerance induction to self antigen; IEA:Ensembl.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0001657; P:ureteric bud development; IEA:Ensembl.
DR   GO; GO:0042060; P:wound healing; IMP:RGD.
DR   Gene3D; 2.10.90.10; -; 1.
DR   InterPro; IPR029034; Cystine-knot_cytokine.
DR   InterPro; IPR001839; TGF-b_C.
DR   InterPro; IPR001111; TGF-b_N.
DR   InterPro; IPR016319; TGF-beta.
DR   InterPro; IPR015615; TGF-beta-rel.
DR   InterPro; IPR003939; TGFb1.
DR   InterPro; IPR017948; TGFb_CS.
DR   PANTHER; PTHR11848; PTHR11848; 1.
DR   Pfam; PF00019; TGF_beta; 1.
DR   Pfam; PF00688; TGFb_propeptide; 1.
DR   PIRSF; PIRSF001787; TGF-beta; 1.
DR   PRINTS; PR01423; TGFBETA.
DR   PRINTS; PR01424; TGFBETA1.
DR   SMART; SM00204; TGFB; 1.
DR   SUPFAM; SSF57501; SSF57501; 1.
DR   PROSITE; PS00250; TGF_BETA_1; 1.
DR   PROSITE; PS51362; TGF_BETA_2; 1.
PE   1: Evidence at protein level;
KW   Cleavage on pair of basic residues; Complete proteome; Disulfide bond;
KW   Extracellular matrix; Glycoprotein; Growth factor; Mitogen;
KW   Reference proteome; Secreted; Signal.
FT   SIGNAL        1     29       {ECO:0000250}.
FT   CHAIN        30    278       Latency-associated peptide.
FT                                /FTId=PRO_0000033770.
FT   CHAIN       279    390       Transforming growth factor beta-1.
FT                                /FTId=PRO_0000033771.
FT   REGION       30     74       Straightjacket domain. {ECO:0000250}.
FT   REGION       75    271       Arm domain. {ECO:0000250}.
FT   MOTIF       244    246       Cell attachment site. {ECO:0000255}.
FT   CARBOHYD     82     82       N-linked (GlcNAc...). {ECO:0000250}.
FT   CARBOHYD    136    136       N-linked (GlcNAc...). {ECO:0000250}.
FT   CARBOHYD    176    176       N-linked (GlcNAc...). {ECO:0000250}.
FT   DISULFID     33     33       Interchain (with C-1350 or C-1375 in
FT                                LTBP1); in inactive form. {ECO:0000250}.
FT   DISULFID    223    223       Interchain (with C-225). {ECO:0000250}.
FT   DISULFID    225    225       Interchain (with C-223). {ECO:0000250}.
FT   DISULFID    285    294       {ECO:0000250}.
FT   DISULFID    293    356       {ECO:0000250}.
FT   DISULFID    322    387       {ECO:0000250}.
FT   DISULFID    326    389       {ECO:0000250}.
FT   DISULFID    355    355       Interchain. {ECO:0000250}.
SQ   SEQUENCE   390 AA;  44329 MW;  5E21108ED50D853C CRC64;
     MPPSGLRLLP LLLPLPWLLV LTPGRPAAGL STCKTIDMEL VKRKRIEAIR GQILSKLRLA
     SPPSQGEVPP GPLPEAVLAL YNSTRDRVAG ESADPEPEPE ADYYAKEVTR VLMVDRNNAI
     YDKTKDITHS IYMFFNTSDI REAVPEPPLL SRAELRLQRF KSTVEQHVEL YQKYSNNSWR
     YLGNRLLTPT DTPEWLSFDV TGVVRQWLNQ GDGIQGFRFS AHCSCDSKDN VLHVEINGIS
     PKRRGDLGTI HDMNRPFLLL MATPLERAQH LHSSRHRRAL DTNYCFSSTE KNCCVRQLYI
     DFRKDLGWKW IHEPKGYHAN FCLGPCPYIW SLDTQYSKVL ALYNQHNPGA SASPCCVPQA
     LEPLPIVYYV GRKPKVEQLS NMIVRSCKCS
//
ID   WNT3A_MOUSE             Reviewed;         352 AA.
AC   P27467;
DT   01-AUG-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1992, sequence version 1.
DT   17-FEB-2016, entry version 150.
DE   RecName: Full=Protein Wnt-3a;
DE   Flags: Precursor;
GN   Name=Wnt3a; Synonyms=Wnt-3a;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Embryo;
RX   PubMed=2001840; DOI=10.1101/gad.5.3.381;
RA   Roelink H., Nusse R.;
RT   "Expression of two members of the Wnt family during mouse development
RT   -- restricted temporal and spatial patterns in the developing neural
RT   tube.";
RL   Genes Dev. 5:381-388(1991).
RN   [2]
RP   INTERACTION WITH PORCN.
RX   PubMed=10866835; DOI=10.1046/j.1432-1033.2000.01478.x;
RA   Tanaka K., Okabayashi H., Asashima M., Perrimon N., Kadowaki T.;
RT   "The evolutionarily conserved porcupine gene family is involved in the
RT   processing of the Wnt family.";
RL   Eur. J. Biochem. 267:4300-4311(2000).
RN   [3]
RP   PRELIMINARY CYSTEINE PALMITOYLATION.
RX   PubMed=12717451; DOI=10.1038/nature01611;
RA   Willert K., Brown J.D., Danenberg E., Duncan A.W., Weissman I.L.,
RA   Reya T., Yates J.R. III, Nusse R.;
RT   "Wnt proteins are lipid-modified and can act as stem cell growth
RT   factors.";
RL   Nature 423:448-452(2003).
RN   [4]
RP   PROTEOLYTIC PROCESSING BY TIKI1 AND TIKI2, DISULFIDE BONDS, SUBUNIT,
RP   AND MUTAGENESIS OF 25-SER-LEU-26; 33-SER-SER-34 AND CYS-77.
RX   PubMed=22726442; DOI=10.1016/j.cell.2012.04.039;
RA   Zhang X., Abreu J.G., Yokota C., Macdonald B.T., Singh S.,
RA   Coburn K.L., Cheong S.M., Zhang M.M., Ye Q.Z., Hang H.C., Steen H.,
RA   He X.;
RT   "Tiki1 is required for head formation via Wnt cleavage-oxidation and
RT   inactivation.";
RL   Cell 149:1565-1577(2012).
RN   [5]
RP   PALMITOLEYLATION AT SER-209, MUTAGENESIS OF CYS-77; SER-209; SER-211;
RP   THR-216; SER-277 AND THR-292, AND GLYCOSYLATION.
RX   PubMed=17141155; DOI=10.1016/j.devcel.2006.10.003;
RA   Takada R., Satomi Y., Kurata T., Ueno N., Norioka S., Kondoh H.,
RA   Takao T., Takada S.;
RT   "Monounsaturated fatty acid modification of Wnt protein: its role in
RT   Wnt secretion.";
RL   Dev. Cell 11:791-801(2006).
RN   [6]
RP   PALMITOLEYLATION AT SER-209.
RX   PubMed=24798332; DOI=10.1074/jbc.M114.561209;
RA   Rios-Esteves J., Haugen B., Resh M.D.;
RT   "Identification of key residues and regions important for porcupine-
RT   mediated Wnt acylation.";
RL   J. Biol. Chem. 289:17009-17019(2014).
RN   [7]
RP   SUBUNIT, PALMITOLEYLATION AT SER-209, DEPALMITOLEYLATION AT SER-209,
RP   AND MUTAGENESIS OF SER-209.
RX   PubMed=25771893; DOI=10.1016/j.devcel.2015.02.014;
RA   Zhang X., Cheong S.M., Amado N.G., Reis A.H., MacDonald B.T.,
RA   Zebisch M., Jones E.Y., Abreu J.G., He X.;
RT   "Notum is required for neural and head induction via Wnt deacylation,
RT   oxidation, and inactivation.";
RL   Dev. Cell 32:719-730(2015).
CC   -!- FUNCTION: Ligand for members of the frizzled family of seven
CC       transmembrane receptors. Wnt-3 and Wnt-3a play distinct roles in
CC       cell-cell signaling during morphogenesis of the developing neural
CC       tube.
CC   -!- SUBUNIT: Homooligomer; disulfide-linked, leading to inactivation
CC       (PubMed:25771893). Interacts with APCDD1 and WLS. Component of the
CC       Wnt-Fzd-LRP5-LRP6 signaling complex that contains a WNT protein, a
CC       FZD protein and LRP5 or LRP6. Interacts directly in the complex
CC       with LRP6 (By similarity). Interacts with PORCN. {ECO:0000250,
CC       ECO:0000269|PubMed:10866835, ECO:0000269|PubMed:22726442,
CC       ECO:0000269|PubMed:25771893}.
CC   -!- INTERACTION:
CC       E9Q612:Ptpro; NbExp=2; IntAct=EBI-2899665, EBI-8183885;
CC       A6NFA1:TRABD2B (xeno); NbExp=2; IntAct=EBI-2899665, EBI-6257471;
CC       Q9Y5W5:WIF1 (xeno); NbExp=7; IntAct=EBI-2899665, EBI-3922719;
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular
CC       matrix.
CC   -!- TISSUE SPECIFICITY: Dorsal portion of the neural tube (developing
CC       roof plate), and mesenchyme tissue surrounding the umbilical
CC       veins.
CC   -!- PTM: Proteolytic processing by TIKI1 and TIKI2 promotes oxidation
CC       and formation of large disulfide-bond oligomers, leading to
CC       inactivation of WNT3A. {ECO:0000269|PubMed:22726442}.
CC   -!- PTM: Disulfide bonds have critical and distinct roles in secretion
CC       and activity. Loss of each conserved cysteine in WNT3A results in
CC       high molecular weight oxidized Wnt oligomers, which are formed
CC       through inter-Wnt disulfide bonding.
CC       {ECO:0000269|PubMed:22726442}.
CC   -!- PTM: Palmitoleylation by PORCN is required for efficient binding
CC       to frizzled receptors. Palmitoleylation is required for proper
CC       trafficking to cell surface, vacuolar acidification is critical to
CC       release palmitoleylated WNT3A from WLS in secretory vesicles
CC       (PubMed:17141155, PubMed:24798332). Depalmitoleylated by NOTUM,
CC       leading to inhibit Wnt signaling pathway, possibly by promoting
CC       disulfide bond formation and oligomerization (PubMed:25771893).
CC       {ECO:0000250|UniProtKB:P56704, ECO:0000269|PubMed:17141155,
CC       ECO:0000269|PubMed:24798332, ECO:0000269|PubMed:25771893}.
CC   -!- SIMILARITY: Belongs to the Wnt family. {ECO:0000305}.
CC   -!- CAUTION: A palmitoylation site was proposed at Cys-77, but it was
CC       later shown that this cysteine is engaged in a disulfide bond.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X56842; CAA40173.1; -; mRNA.
DR   CCDS; CCDS24766.1; -.
DR   PIR; A39532; A39532.
DR   RefSeq; NP_033548.1; NM_009522.2.
DR   UniGene; Mm.1367; -.
DR   ProteinModelPortal; P27467; -.
DR   SMR; P27467; 57-351.
DR   BioGrid; 204575; 9.
DR   DIP; DIP-55954N; -.
DR   IntAct; P27467; 5.
DR   MINT; MINT-7992042; -.
DR   STRING; 10090.ENSMUSP00000010044; -.
DR   BindingDB; P27467; -.
DR   ChEMBL; CHEMBL5617; -.
DR   PhosphoSite; P27467; -.
DR   SwissPalm; P27467; -.
DR   MaxQB; P27467; -.
DR   PaxDb; P27467; -.
DR   PRIDE; P27467; -.
DR   DNASU; 22416; -.
DR   Ensembl; ENSMUST00000010044; ENSMUSP00000010044; ENSMUSG00000009900.
DR   GeneID; 22416; -.
DR   KEGG; mmu:22416; -.
DR   UCSC; uc007jdp.2; mouse.
DR   CTD; 89780; -.
DR   MGI; MGI:98956; Wnt3a.
DR   eggNOG; KOG3913; Eukaryota.
DR   eggNOG; ENOG410XQZ1; LUCA.
DR   GeneTree; ENSGT00760000118943; -.
DR   HOGENOM; HOG000039529; -.
DR   HOVERGEN; HBG001595; -.
DR   InParanoid; P27467; -.
DR   KO; K00312; -.
DR   OMA; FLKCKCH; -.
DR   OrthoDB; EOG7C8GJ8; -.
DR   PhylomeDB; P27467; -.
DR   TreeFam; TF105310; -.
DR   Reactome; R-MMU-3238698; WNT ligand biogenesis and trafficking.
DR   Reactome; R-MMU-4641262; Disassembly of the destruction complex and recruitment of AXIN to the membrane.
DR   Reactome; R-MMU-4641263; Regulation of FZD by ubiquitination.
DR   NextBio; 302833; -.
DR   PRO; PR:P27467; -.
DR   Proteomes; UP000000589; Chromosome 11.
DR   Bgee; P27467; -.
DR   CleanEx; MM_WNT3A; -.
DR   Genevisible; P27467; MM.
DR   GO; GO:0009986; C:cell surface; IDA:BHF-UCL.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0005578; C:proteinaceous extracellular matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:1990909; C:Wnt signalosome; NAS:ParkinsonsUK-UCL.
DR   GO; GO:0005109; F:frizzled binding; IPI:MGI.
DR   GO; GO:0005110; F:frizzled-2 binding; IDA:MGI.
DR   GO; GO:0019904; F:protein domain specific binding; IPI:UniProtKB.
DR   GO; GO:0048018; F:receptor agonist activity; ISO:MGI.
DR   GO; GO:0005102; F:receptor binding; TAS:MGI.
DR   GO; GO:0003713; F:transcription coactivator activity; IDA:UniProtKB.
DR   GO; GO:0009952; P:anterior/posterior pattern specification; IDA:MGI.
DR   GO; GO:0090245; P:axis elongation involved in somitogenesis; IGI:MGI.
DR   GO; GO:0007411; P:axon guidance; IDA:MGI.
DR   GO; GO:0007409; P:axonogenesis; IDA:MGI.
DR   GO; GO:0030509; P:BMP signaling pathway; ISO:MGI.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; IDA:UniProtKB.
DR   GO; GO:0061317; P:canonical Wnt signaling pathway involved in cardiac muscle cell fate commitment; ISO:MGI.
DR   GO; GO:0060923; P:cardiac muscle cell fate commitment; IGI:MGI.
DR   GO; GO:0021846; P:cell proliferation in forebrain; IDA:BHF-UCL.
DR   GO; GO:0033278; P:cell proliferation in midbrain; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0007267; P:cell-cell signaling; TAS:MGI.
DR   GO; GO:0034613; P:cellular protein localization; IDA:MGI.
DR   GO; GO:0010387; P:COP9 signalosome assembly; IDA:BHF-UCL.
DR   GO; GO:0007368; P:determination of left/right symmetry; IMP:MGI.
DR   GO; GO:0021904; P:dorsal/ventral neural tube patterning; IMP:MGI.
DR   GO; GO:0030198; P:extracellular matrix organization; IDA:MGI.
DR   GO; GO:0001947; P:heart looping; IMP:MGI.
DR   GO; GO:0030097; P:hemopoiesis; IDA:MGI.
DR   GO; GO:0021766; P:hippocampus development; IMP:MGI.
DR   GO; GO:0001701; P:in utero embryonic development; IMP:MGI.
DR   GO; GO:0042472; P:inner ear morphogenesis; IGI:MGI.
DR   GO; GO:0030879; P:mammary gland development; IDA:MGI.
DR   GO; GO:0007498; P:mesoderm development; IMP:MGI.
DR   GO; GO:0030901; P:midbrain development; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0048843; P:negative regulation of axon extension involved in axon guidance; IDA:MGI.
DR   GO; GO:1904339; P:negative regulation of dopaminergic neuron differentiation; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0045599; P:negative regulation of fat cell differentiation; IDA:MGI.
DR   GO; GO:0003136; P:negative regulation of heart induction by canonical Wnt signaling pathway; ISO:MGI.
DR   GO; GO:0050768; P:negative regulation of neurogenesis; IDA:BHF-UCL.
DR   GO; GO:0010977; P:negative regulation of neuron projection development; IDA:UniProtKB.
DR   GO; GO:0022008; P:neurogenesis; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0009887; P:organ morphogenesis; TAS:MGI.
DR   GO; GO:0001649; P:osteoblast differentiation; IGI:MGI.
DR   GO; GO:0060021; P:palate development; ISO:MGI.
DR   GO; GO:0048343; P:paraxial mesodermal cell fate commitment; IMP:MGI.
DR   GO; GO:0030168; P:platelet activation; IDA:MGI.
DR   GO; GO:0070527; P:platelet aggregation; IDA:MGI.
DR   GO; GO:0030890; P:positive regulation of B cell proliferation; IDA:MGI.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IDA:MGI.
DR   GO; GO:2000081; P:positive regulation of canonical Wnt signaling pathway involved in controlling type B pancreatic cell proliferation; IDA:UniProtKB.
DR   GO; GO:2000727; P:positive regulation of cardiac muscle cell differentiation; ISO:MGI.
DR   GO; GO:0035413; P:positive regulation of catenin import into nucleus; IDA:MGI.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:UniProtKB.
DR   GO; GO:2000049; P:positive regulation of cell-cell adhesion mediated by cadherin; IDA:MGI.
DR   GO; GO:0048697; P:positive regulation of collateral sprouting in absence of injury; IDA:MGI.
DR   GO; GO:0043280; P:positive regulation of cysteine-type endopeptidase activity involved in apoptotic process; IDA:MGI.
DR   GO; GO:0001819; P:positive regulation of cytokine production; IDA:MGI.
DR   GO; GO:0061184; P:positive regulation of dermatome development; ISO:MGI.
DR   GO; GO:2000347; P:positive regulation of hepatocyte proliferation; IDA:MGI.
DR   GO; GO:0048337; P:positive regulation of mesodermal cell fate specification; ISO:MGI.
DR   GO; GO:2000179; P:positive regulation of neural precursor cell proliferation; IDA:MGI.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; ISO:MGI.
DR   GO; GO:0032092; P:positive regulation of protein binding; ISO:MGI.
DR   GO; GO:0045860; P:positive regulation of protein kinase activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:1903078; P:positive regulation of protein localization to plasma membrane; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0061098; P:positive regulation of protein tyrosine kinase activity; IGI:MGI.
DR   GO; GO:0002092; P:positive regulation of receptor internalization; ISO:MGI.
DR   GO; GO:0051091; P:positive regulation of sequence-specific DNA binding transcription factor activity; IDA:BHF-UCL.
DR   GO; GO:0048643; P:positive regulation of skeletal muscle tissue development; IMP:CACAO.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; NAS:BHF-UCL.
DR   GO; GO:2000679; P:positive regulation of transcription regulatory region DNA binding; IMP:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0036342; P:post-anal tail morphogenesis; IMP:MGI.
DR   GO; GO:0050770; P:regulation of axonogenesis; IGI:MGI.
DR   GO; GO:0045595; P:regulation of cell differentiation; IDA:MGI.
DR   GO; GO:0070507; P:regulation of microtubule cytoskeleton organization; IGI:MGI.
DR   GO; GO:0007165; P:signal transduction; TAS:MGI.
DR   GO; GO:0035914; P:skeletal muscle cell differentiation; IGI:MGI.
DR   GO; GO:0048103; P:somatic stem cell division; IDA:MGI.
DR   GO; GO:0001756; P:somitogenesis; IMP:MGI.
DR   GO; GO:0021527; P:spinal cord association neuron differentiation; IDA:MGI.
DR   GO; GO:0016055; P:Wnt signaling pathway; IGI:MGI.
DR   GO; GO:0021874; P:Wnt signaling pathway involved in forebrain neuroblast division; IMP:MGI.
DR   InterPro; IPR005817; Wnt.
DR   InterPro; IPR009141; Wnt3.
DR   InterPro; IPR018161; Wnt_CS.
DR   PANTHER; PTHR12027; PTHR12027; 1.
DR   Pfam; PF00110; wnt; 1.
DR   PRINTS; PR01843; WNT3PROTEIN.
DR   PRINTS; PR01349; WNTPROTEIN.
DR   SMART; SM00097; WNT1; 1.
DR   PROSITE; PS00246; WNT1; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Developmental protein; Disulfide bond;
KW   Extracellular matrix; Glycoprotein; Lipoprotein; Reference proteome;
KW   Secreted; Signal; Wnt signaling pathway.
FT   SIGNAL        1     18       {ECO:0000255}.
FT   CHAIN        19    352       Protein Wnt-3a.
FT                                /FTId=PRO_0000041419.
FT   SITE         26     27       Cleavage; by TIKI1 and TIKI2.
FT                                {ECO:0000269|PubMed:22726442}.
FT   LIPID       209    209       O-palmitoleyl serine; by PORCN.
FT                                {ECO:0000269|PubMed:17141155,
FT                                ECO:0000269|PubMed:24798332,
FT                                ECO:0000269|PubMed:25771893}.
FT   CARBOHYD     87     87       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    298    298       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     77     88       {ECO:0000250|UniProtKB:P28026}.
FT   DISULFID    128    136       {ECO:0000250|UniProtKB:P28026}.
FT   DISULFID    138    155       {ECO:0000250|UniProtKB:P28026}.
FT   DISULFID    203    217       {ECO:0000250|UniProtKB:P28026}.
FT   DISULFID    205    212       {ECO:0000250|UniProtKB:P28026}.
FT   DISULFID    297    312       {ECO:0000250|UniProtKB:P28026}.
FT   DISULFID    327    342       {ECO:0000250|UniProtKB:P28026}.
FT   DISULFID    329    339       {ECO:0000250|UniProtKB:P28026}.
FT   DISULFID    334    335       {ECO:0000250|UniProtKB:P28026}.
FT   MUTAGEN      25     26       SL->DD: Partially resistant to
FT                                proteolysis by TIKI1 and TIKI2.
FT                                Completely resistant to proteolysis by
FT                                TIKI1 and TIKI2; when associated with 33-
FT                                D-D-34. {ECO:0000269|PubMed:22726442}.
FT   MUTAGEN      33     34       SS->DD: Completely resistant to
FT                                proteolysis by TIKI1 and TIKI2; when
FT                                associated with 25-D-D-26.
FT                                {ECO:0000269|PubMed:22726442}.
FT   MUTAGEN      77     77       C->A: Forms oxidized oligomers regardless
FT                                of TIKI2. Does not affect
FT                                palmitoleylation.
FT                                {ECO:0000269|PubMed:17141155,
FT                                ECO:0000269|PubMed:22726442}.
FT   MUTAGEN     209    209       S->A: Abolishes palmitoleylation,
FT                                promoting formation of disulfide bonds
FT                                and oligomerization.
FT                                {ECO:0000269|PubMed:17141155,
FT                                ECO:0000269|PubMed:25771893}.
FT   MUTAGEN     211    211       S->A: Does not affect palmitoleylation.
FT                                {ECO:0000269|PubMed:17141155}.
FT   MUTAGEN     216    216       T->A: Does not affect palmitoleylation.
FT                                {ECO:0000269|PubMed:17141155}.
FT   MUTAGEN     277    277       S->A: Does not affect palmitoleylation.
FT                                {ECO:0000269|PubMed:17141155}.
FT   MUTAGEN     292    292       T->A: Does not affect palmitoleylation.
FT                                {ECO:0000269|PubMed:17141155}.
SQ   SEQUENCE   352 AA;  39258 MW;  7ADFC5B38A8EFF63 CRC64;
     MAPLGYLLVL CSLKQALGSY PIWWSLAVGP QYSSLSTQPI LCASIPGLVP KQLRFCRNYV
     EIMPSVAEGV KAGIQECQHQ FRGRRWNCTT VSNSLAIFGP VLDKATRESA FVHAIASAGV
     AFAVTRSCAE GSAAICGCSS RLQGSPGEGW KWGGCSEDIE FGGMVSREFA DARENRPDAR
     SAMNRHNNEA GRQAIASHMH LKCKCHGLSG SCEVKTCWWS QPDFRTIGDF LKDKYDSASE
     MVVEKHRESR GWVETLRPRY TYFKVPTERD LVYYEASPNF CEPNPETGSF GTRDRTCNVS
     SHGIDGCDLL CCGRGHNART ERRREKCHCV FHWCCYVSCQ ECTRVYDVHT CK
//
ID   DLL1_MOUSE              Reviewed;         722 AA.
AC   Q61483; Q6PFV7;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   27-JUL-2011, sequence version 2.
DT   20-JAN-2016, entry version 153.
DE   RecName: Full=Delta-like protein 1 {ECO:0000305};
DE   AltName: Full=Drosophila Delta homolog 1;
DE            Short=Delta1 {ECO:0000303|PubMed:12794186};
DE   Contains:
DE     RecName: Full=Dll1-soluble form {ECO:0000303|PubMed:12794186};
DE              Short=Dll1-EC {ECO:0000305|PubMed:12794186};
DE              Short=Shed form {ECO:0000303|PubMed:12794186};
DE   Contains:
DE     RecName: Full=Dll1-derived cell-associated form {ECO:0000303|PubMed:12794186};
DE              Short=Dll1-TMIC {ECO:0000305|PubMed:12794186};
DE              Short=Membrane-associated fragment {ECO:0000303|PubMed:12794186};
DE   Contains:
DE     RecName: Full=Dll1-intracellular form {ECO:0000303|PubMed:12794186};
DE              Short=Dll1-IC {ECO:0000305|PubMed:12794186};
DE   Flags: Precursor;
GN   Name=Dll1;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], DEVELOPMENTAL STAGE, TISSUE SPECIFICITY,
RP   AND FUNCTION.
RC   STRAIN=C57BL/6 X BALB/c; TISSUE=Embryo;
RX   PubMed=7671806;
RA   Bettenhausen B., de Angelis M.H., Simon D., Guenet J.-L., Gossler A.;
RT   "Transient and restricted expression during mouse embryogenesis of
RT   Dll1, a murine gene closely related to Drosophila Delta.";
RL   Development 121:2407-2418(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=C57BL/6J;
RX   PubMed=19468303; DOI=10.1371/journal.pbio.1000112;
RA   Church D.M., Goodstadt L., Hillier L.W., Zody M.C., Goldstein S.,
RA   She X., Bult C.J., Agarwala R., Cherry J.L., DiCuccio M., Hlavina W.,
RA   Kapustin Y., Meric P., Maglott D., Birtle Z., Marques A.C., Graves T.,
RA   Zhou S., Teague B., Potamousis K., Churas C., Place M., Herschleb J.,
RA   Runnheim R., Forrest D., Amos-Landgraf J., Schwartz D.C., Cheng Z.,
RA   Lindblad-Toh K., Eichler E.E., Ponting C.P.;
RT   "Lineage-specific biology revealed by a finished genome assembly of
RT   the mouse.";
RL   PLoS Biol. 7:E1000112-E1000112(2009).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Adams M.D., Myers E.W., Smith H.O., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J; TISSUE=Embryonic brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   PROTEIN SEQUENCE OF 527-534 AND 536-543, PROTEOLYTIC CLEAVAGE BY
RP   MMP14, INTERACTION WITH MMP14, IDENTIFICATION BY MASS SPECTROMETRY,
RP   AND FUNCTION.
RX   PubMed=21572390; DOI=10.1038/emboj.2011.136;
RA   Jin G., Zhang F., Chan K.M., Xavier Wong H.L., Liu B., Cheah K.S.,
RA   Liu X., Mauch C., Liu D., Zhou Z.;
RT   "MT1-MMP cleaves Dll1 to negatively regulate Notch signalling to
RT   maintain normal B-cell development.";
RL   EMBO J. 30:2281-2293(2011).
RN   [6]
RP   PROTEIN SEQUENCE OF 536-554, PROTEOLYTIC CLEAVAGE, HOMODIMERIZATION,
RP   INTERACTION WITH PSEN1, AND SUBCELLULAR LOCATION.
RX   PubMed=12794186; DOI=10.1073/pnas.1230693100;
RA   Six E., Ndiaye D., Laabi Y., Brou C., Gupta-Rossi N., Israel A.,
RA   Logeat F.;
RT   "The Notch ligand Delta1 is sequentially cleaved by an ADAM protease
RT   and gamma-secretase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:7638-7643(2003).
RN   [7]
RP   FUNCTION.
RX   PubMed=10958687; DOI=10.1128/MCB.20.18.6913-6922.2000;
RA   Shimizu K., Chiba S., Hosoya N., Kumano K., Saito T., Kurokawa M.,
RA   Kanda Y., Hamada Y., Hirai H.;
RT   "Binding of Delta1, Jagged1, and Jagged2 to Notch2 rapidly induces
RT   cleavage, nuclear translocation, and hyperphosphorylation of Notch2.";
RL   Mol. Cell. Biol. 20:6913-6922(2000).
RN   [8]
RP   FUNCTION.
RX   PubMed=15146182; DOI=10.1038/ni1075;
RA   Hozumi K., Negishi N., Suzuki D., Abe N., Sotomaru Y., Tamaoki N.,
RA   Mailhos C., Ish-Horowicz D., Habu S., Owen M.J.;
RT   "Delta-like 1 is necessary for the generation of marginal zone B cells
RT   but not T cells in vivo.";
RL   Nat. Immunol. 5:638-644(2004).
RN   [9]
RP   INTERACTION WITH MFAP5.
RX   PubMed=15788413; DOI=10.1074/jbc.M500273200;
RA   Nehring L.C., Miyamoto A., Hein P.W., Weinmaster G., Shipley J.M.;
RT   "The extracellular matrix protein MAGP-2 interacts with Jagged1 and
RT   induces its shedding from the cell surface.";
RL   J. Biol. Chem. 280:20349-20355(2005).
RN   [10]
RP   INTERACTION WITH MAGI1, AND SUBCELLULAR LOCATION.
RX   PubMed=15908431; DOI=10.1074/jbc.M500375200;
RA   Mizuhara E., Nakatani T., Minaki Y., Sakamoto Y., Ono Y., Takai Y.;
RT   "MAGI1 recruits Dll1 to cadherin-based adherens junctions and
RT   stabilizes it on the cell surface.";
RL   J. Biol. Chem. 280:26499-26507(2005).
RN   [11]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=16495313; DOI=10.1242/dev.02284;
RA   Brooker R., Hozumi K., Lewis J.;
RT   "Notch ligands with contrasting functions: Jagged1 and Delta1 in the
RT   mouse inner ear.";
RL   Development 133:1277-1286(2006).
RN   [12]
RP   INTERACTION WITH NEURL1B, AND UBIQUITINATION.
RX   PubMed=17003037; DOI=10.1074/jbc.M606601200;
RA   Song R., Koo B.-K., Yoon K.-J., Yoon M.-J., Yoo K.-W., Kim H.-T.,
RA   Oh H.-J., Kim Y.-Y., Han J.-K., Kim C.-H., Kong Y.-Y.;
RT   "Neuralized-2 regulates a Notch ligand in cooperation with Mind bomb-
RT   1.";
RL   J. Biol. Chem. 281:36391-36400(2006).
RN   [13]
RP   DEVELOPMENTAL STAGE, DISRUPTION PHENOTYPE, AND FUNCTION.
RX   PubMed=17194759; DOI=10.1073/pnas.0608281104;
RA   Schuster-Gossler K., Cordes R., Gossler A.;
RT   "Premature myogenic differentiation and depletion of progenitor cells
RT   cause severe muscle hypotrophy in Delta1 mutants.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:537-542(2007).
RN   [14]
RP   FUNCTION, DEVELOPMENTAL STAGE, AND DISRUPTION PHENOTYPE.
RX   PubMed=18997111; DOI=10.1242/dev.024570;
RA   Kawaguchi D., Yoshimatsu T., Hozumi K., Gotoh Y.;
RT   "Selection of differentiating cells by different levels of delta-like
RT   1 among neural precursor cells in the developing mouse
RT   telencephalon.";
RL   Development 135:3849-3858(2008).
RN   [15]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=17960184; DOI=10.1038/sj.jid.5701113;
RA   Estrach S., Cordes R., Hozumi K., Gossler A., Watt F.M.;
RT   "Role of the Notch ligand Delta1 in embryonic and adult mouse
RT   epidermis.";
RL   J. Invest. Dermatol. 128:825-832(2008).
RN   [16]
RP   UBIQUITINATION, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=18676613; DOI=10.1073/pnas.0800695105;
RA   Heuss S.F., Ndiaye-Lobry D., Six E.M., Israel A., Logeat F.;
RT   "The intracellular region of Notch ligands Dll1 and Dll3 regulates
RT   their trafficking and signaling activity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:11212-11217(2008).
RN   [17]
RP   INTERACTION WITH NEURL1 AND NEURL1B.
RX   PubMed=19723503; DOI=10.1016/j.bbrc.2009.08.147;
RA   Rullinkov G., Tamme R., Sarapuu A., Lauren J., Sepp M., Palm K.,
RA   Timmusk T.;
RT   "Neuralized-2: Expression in human and rodents and interaction with
RT   Delta-like ligands.";
RL   Biochem. Biophys. Res. Commun. 389:420-425(2009).
RN   [18]
RP   DEVELOPMENTAL STAGE, DISRUPTION PHENOTYPE, AND FUNCTION.
RX   PubMed=19144989; DOI=10.1182/blood-2008-08-174508;
RA   Soerensen I., Adams R.H., Gossler A.;
RT   "DLL1-mediated Notch activation regulates endothelial identity in
RT   mouse fetal arteries.";
RL   Blood 113:5680-5688(2009).
RN   [19]
RP   FUNCTION, AND DEVELOPMENTAL STAGE.
RX   PubMed=19389377; DOI=10.1016/j.ydbio.2009.01.011;
RA   Rocha S.F., Lopes S.S., Gossler A., Henrique D.;
RT   "Dll1 and Dll4 function sequentially in the retina and pV2 domain of
RT   the spinal cord to regulate neurogenesis and create cell diversity.";
RL   Dev. Biol. 328:54-65(2009).
RN   [20]
RP   FUNCTION.
RX   PubMed=19217325; DOI=10.1016/j.immuni.2008.12.016;
RA   Tan J.B., Xu K., Cretegny K., Visan I., Yuan J.S., Egan S.E.,
RA   Guidos C.J.;
RT   "Lunatic and manic fringe cooperatively enhance marginal zone B cell
RT   precursor competition for delta-like 1 in splenic endothelial
RT   niches.";
RL   Immunity 30:254-263(2009).
RN   [21]
RP   DISRUPTION PHENOTYPE, AND FUNCTION.
RX   PubMed=19562077; DOI=10.1371/journal.pone.0006054;
RA   Rubio-Aliaga I., Przemeck G.K., Fuchs H., Gailus-Durner V., Adler T.,
RA   Hans W., Horsch M., Rathkolb B., Rozman J., Schrewe A., Wagner S.,
RA   Hoelter S.M., Becker L., Klopstock T., Wurst W., Wolf E.,
RA   Klingenspor M., Ivandic B.T., Busch D.H., Beckers J.,
RA   Hrabe de Angelis M.;
RT   "Dll1 haploinsufficiency in adult mice leads to a complex phenotype
RT   affecting metabolic and immunological processes.";
RL   PLoS ONE 4:E6054-E6054(2009).
RN   [22]
RP   FUNCTION.
RX   PubMed=20081190; DOI=10.1242/dev.036806;
RA   Marklund U., Hansson E.M., Sundstroem E., de Angelis M.H.,
RA   Przemeck G.K., Lendahl U., Muhr J., Ericson J.;
RT   "Domain-specific control of neurogenesis achieved through patterned
RT   regulation of Notch ligand expression.";
RL   Development 137:437-445(2010).
RN   [23]
RP   MUTAGENESIS OF 613-LYS--LYS-618; LYS-613; LYS-689; LYS-699 AND
RP   LYS-713, INTERACTION WITH MIB1, SUBCELLULAR LOCATION, FUNCTION, AND
RP   UBIQUITINATION AT LYS-613.
RX   PubMed=21985982; DOI=10.1016/j.bbamcr.2011.08.019;
RA   Zhang L., Widau R.C., Herring B.P., Gallagher P.J.;
RT   "Delta-like 1-Lysine613 regulates notch signaling.";
RL   Biochim. Biophys. Acta 1813:2036-2043(2011).
RN   [24]
RP   FUNCTION.
RX   PubMed=21238454; DOI=10.1053/j.gastro.2011.01.005;
RA   Pellegrinet L., Rodilla V., Liu Z., Chen S., Koch U., Espinosa L.,
RA   Kaestner K.H., Kopan R., Lewis J., Radtke F.;
RT   "Dll1- and dll4-mediated notch signaling are required for homeostasis
RT   of intestinal stem cells.";
RL   Gastroenterology 140:1230-1240(2011).
RN   [25]
RP   FUNCTION.
RX   PubMed=21915337; DOI=10.1371/journal.pone.0024484;
RA   Stamataki D., Holder M., Hodgetts C., Jeffery R., Nye E.,
RA   Spencer-Dene B., Winton D.J., Lewis J.;
RT   "Delta1 expression, cell cycle exit, and commitment to a specific
RT   secretory fate coincide within a few hours in the mouse intestinal
RT   stem cell system.";
RL   PLoS ONE 6:E24484-E24484(2011).
RN   [26]
RP   FUNCTION.
RX   PubMed=22282195; DOI=10.1161/CIRCRESAHA.111.263319;
RA   Napp L.C., Augustynik M., Paesler F., Krishnasamy K., Woiterski J.,
RA   Limbourg A., Bauersachs J., Drexler H., Le Noble F., Limbourg F.P.;
RT   "Extrinsic Notch ligand Delta-like 1 regulates tip cell selection and
RT   vascular branching morphogenesis.";
RL   Circ. Res. 110:530-535(2012).
RN   [27]
RP   FUNCTION, AND INDUCTION.
RX   PubMed=22096075; DOI=10.1242/dev.071761;
RA   Ahnfelt-Roenne J., Joergensen M.C., Klinck R., Jensen J.N.,
RA   Fuechtbauer E.M., Deering T., MacDonald R.J., Wright C.V.,
RA   Madsen O.D., Serup P.;
RT   "Ptf1a-mediated control of Dll1 reveals an alternative to the lateral
RT   inhibition mechanism.";
RL   Development 139:33-45(2012).
RN   [28]
RP   INDUCTION.
RX   PubMed=22015720; DOI=10.1016/j.ydbio.2011.09.034;
RA   Grainger S., Lam J., Savory J.G., Mears A.J., Rijli F.M., Lohnes D.;
RT   "Cdx regulates Dll1 in multiple lineages.";
RL   Dev. Biol. 361:1-11(2012).
RN   [29]
RP   FUNCTION.
RX   PubMed=22940113; DOI=10.1016/j.devcel.2012.07.014;
RA   Broehl D., Vasyutina E., Czajkowski M.T., Griger J., Rassek C.,
RA   Rahn H.P., Purfuerst B., Wende H., Birchmeier C.;
RT   "Colonization of the satellite cell niche by skeletal muscle
RT   progenitor cells depends on Notch signals.";
RL   Dev. Cell 23:469-481(2012).
RN   [30]
RP   FUNCTION.
RX   PubMed=22529374; DOI=10.1073/pnas.1203605109;
RA   Horn S., Kobberup S., Joergensen M.C., Kalisz M., Klein T.,
RA   Kageyama R., Gegg M., Lickert H., Lindner J., Magnuson M.A.,
RA   Kong Y.Y., Serup P., Ahnfelt-Roenne J., Jensen J.N.;
RT   "Mind bomb 1 is required for pancreatic beta-cell formation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:7356-7361(2012).
RN   [31]
RP   FUNCTION.
RX   PubMed=23806616; DOI=10.1016/j.devcel.2013.05.022;
RA   Liu Z., Chen S., Boyle S., Zhu Y., Zhang A., Piwnica-Worms D.R.,
RA   Ilagan M.X., Kopan R.;
RT   "The extracellular domain of Notch2 increases its cell-surface
RT   abundance and ligand responsiveness during kidney development.";
RL   Dev. Cell 25:585-598(2013).
RN   [32]
RP   FUNCTION.
RX   PubMed=23699523; DOI=10.1523/JNEUROSCI.0791-13.2013;
RA   Nelson B.R., Hodge R.D., Bedogni F., Hevner R.F.;
RT   "Dynamic interactions between intermediate neurogenic progenitors and
RT   radial glia in embryonic mouse neocortex: potential role in Dll1-Notch
RT   signaling.";
RL   J. Neurosci. 33:9122-9139(2013).
RN   [33]
RP   DISRUPTION PHENOTYPE, AND FUNCTION.
RX   PubMed=23688253; DOI=10.1186/1756-6606-6-25;
RA   Hiraoka Y., Komine O., Nagaoka M., Bai N., Hozumi K., Tanaka K.;
RT   "Delta-like 1 regulates Bergmann glial monolayer formation during
RT   cerebellar development.";
RL   Mol. Brain 6:25-25(2013).
RN   [34]
RP   FUNCTION.
RX   PubMed=23695674; DOI=10.1038/ncomms2895;
RA   Kawaguchi D., Furutachi S., Kawai H., Hozumi K., Gotoh Y.;
RT   "Dll1 maintains quiescence of adult neural stem cells and segregates
RT   asymmetrically during mitosis.";
RL   Nat. Commun. 4:1880-1880(2013).
RN   [35]
RP   INTERACTION WITH TJP1, AND SUBCELLULAR LOCATION.
RX   PubMed=24715457; DOI=10.1242/dev.102988;
RA   Hatakeyama J., Wakamatsu Y., Nagafuchi A., Kageyama R., Shigemoto R.,
RA   Shimamura K.;
RT   "Cadherin-based adhesions in the apical endfoot are required for
RT   active Notch signaling to control neurogenesis in vertebrates.";
RL   Development 141:1671-1682(2014).
RN   [36]
RP   FUNCTION, DEVELOPMENTAL STAGE, DISRUPTION PHENOTYPE, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=25220152; DOI=10.1016/j.ydbio.2014.09.005;
RA   Czajkowski M.T., Rassek C., Lenhard D.C., Broehl D., Birchmeier C.;
RT   "Divergent and conserved roles of Dll1 signaling in development of
RT   craniofacial and trunk muscle.";
RL   Dev. Biol. 395:307-316(2014).
RN   [37]
RP   IDENTIFICATION BY MASS SPECTROMETRY, PHOSPHORYLATION AT THR-638;
RP   SER-693 AND SER-696, AND MUTAGENESIS OF THR-638; SER-693 AND SER-696.
RX   PubMed=24449764; DOI=10.1128/MCB.00965-13;
RA   Braune E.B., Schuster-Gossler K., Lyszkiewicz M., Serth K.,
RA   Preusse K., Madlung J., Macek B., Krueger A., Gossler A.;
RT   "S/T phosphorylation of DLL1 is required for full ligand activity in
RT   vitro but dispensable for DLL1 function in vivo during embryonic
RT   patterning and marginal zone B cell development.";
RL   Mol. Cell. Biol. 34:1221-1233(2014).
RN   [38]
RP   FUNCTION.
RX   PubMed=26114479; DOI=10.1371/journal.pgen.1005328;
RA   Preusse K., Tveriakhina L., Schuster-Gossler K., Gaspar C., Rosa A.I.,
RA   Henrique D., Gossler A., Stauber M.;
RT   "Context-dependent functional divergence of the Notch ligands DLL1 and
RT   DLL4 in vivo.";
RL   PLoS Genet. 11:E1005328-E1005328(2015).
CC   -!- FUNCTION: Transmembrane ligand protein of NOTCH1, NOTCH2 and
CC       NOTCH3 receptors that binds the extracellular domain (ECD) of
CC       Notch receptor in a cis and trans fashion manner (PubMed:21985982,
CC       PubMed:10958687). Following transinteraction, ligand cells produce
CC       mechanical force that depends of a clathrin-mediated endocytosis,
CC       requiring ligand ubiquitination, EPN1 interaction, and actin
CC       polymerisation; these events promote Notch receptor extracellular
CC       domain (NECD) transendocytosis and triggers Notch signaling
CC       through induction of cleavage, hyperphosphorylation, and nuclear
CC       accumulation of the intracellular domain of Notch receptors (NICD)
CC       (PubMed:10958687, PubMed:18676613). Is required for embryonic
CC       development and maintenance of adult stem cells in many different
CC       tissues and immune systeme; the DLL1-induced Notch signaling is
CC       mediated through an intercellular communication that regulates
CC       cell lineage, cell specification, cell patterning and
CC       morphogenesis through effects on differentiation and proliferation
CC       (PubMed:17194759, PubMed:19562077, PubMed:18997111,
CC       PubMed:23695674, PubMed:16495313, PubMed:21238454,
CC       PubMed:22282195, PubMed:7671806, PubMed:17960184, PubMed:22529374,
CC       PubMed:19389377, PubMed:23699523, PubMed:19144989,
CC       PubMed:23688253, PubMed:23806616, PubMed:26114479,
CC       PubMed:22940113, PubMed:25220152, PubMed:20081190,
CC       PubMed:21572390, PubMed:22096075). Plays a role in brain
CC       development at different level, namely by regulating neuronal
CC       differentiation of neural precursor cells via cell-cell
CC       interaction, most likely through the lateral inhibitory system in
CC       an endogenous level dependent-manner (PubMed:7671806,
CC       PubMed:18997111). During neocortex development, Dll1-Notch
CC       signaling transmission is mediated by dynamic interactions between
CC       intermediate neurogenic progenitors and radial glia; the cell-cell
CC       interactions are mediated via dynamic and transient elongation
CC       processes, likely to reactivate/maintain Notch activity in
CC       neighboring progenitors, and coordinate progenitor cell division
CC       and differentiation across radial and zonal boundaries
CC       (PubMed:23699523). During cerebellar development, regulates
CC       Bergmann glial monolayer formation and its morphological
CC       maturation through a Notch signaling pathway (PubMed:23688253). At
CC       the retina and spinal cord level, regulates neurogenesis by
CC       preventing the premature differentiation of neural progenitors and
CC       also by maintaining progenitors in spinal cord through Notch
CC       signaling pathway (PubMed:19389377, PubMed:26114479). Also
CC       controls neurogenesis of the neural tube in a progenitor domain-
CC       specific fashion along the dorsoventral axis (PubMed:20081190).
CC       Maintains quiescence of neural stem cells and plays a role as a
CC       fate determinant that segregates asymmetrically to one daughter
CC       cell during neural stem cells mitosis, resulting in neuronal
CC       differentiation in Dll1-inheriting cell (PubMed:23695674). Plays a
CC       role in immune systeme development, namely the development of all
CC       T cells and marginal zone (MZ) B cells (PubMed:15146182,
CC       PubMed:19217325). Blocks the differentiation of progenitor cells
CC       into the B-cell lineage while promoting the emergence of a
CC       population of cells with the characteristics of a T-cell/NK-cell
CC       precursor (By similarity). Upon MMP14 cleavage, negatively
CC       regulates Notch signaling in haematopoietic progenitor cells to
CC       specifically maintain normal B-cell development in bone marrow
CC       (PubMed:21572390). Also plays a role during muscle development.
CC       During early development, inhibits myoblasts differentiation from
CC       the medial dermomyotomal lip and later regulates progenitor cell
CC       differentiation (PubMed:17194759). Directly modulates cell
CC       adhesion and basal lamina formation in satellite cells through
CC       Notch signaling. Maintains myogenic progenitors pool by
CC       suppressing differentiation through down-regulation of MYOD1 and
CC       is required for satellite cell homing and PAX7 expression
CC       (PubMed:22940113). During craniofacial and trunk myogenesis
CC       suppresses differentiation of cranial mesoderm-derived and somite-
CC       derived muscle via MYOD1 regulation but in cranial mesoderm-
CC       derived progenitors, is neither required for satellite cell homing
CC       nor for PAX7 expression (PubMed:25220152). Also plays a role
CC       during pancreatic cell development. During type B pancreatic cell
CC       development, may be involved in the initiation of proximodistal
CC       patterning in the early pancreatic epithelium (PubMed:22529374).
CC       Stimulates multipotent pancreatic progenitor cells proliferation
CC       and pancreatic growth by maintaining HES1 expression and PTF1A
CC       protein levels (PubMed:22096075). During fetal stages of
CC       development, is required to maintain arterial identity and the
CC       responsiveness of arterial endothelial cells for VEGFA through
CC       regulation of KDR activation and NRP1 expression
CC       (PubMed:19144989). Controls sprouting angiogenesis and subsequent
CC       vertical branch formation througth regulation on tip cell
CC       differentiation (PubMed:22282195). Negatively regulates goblet
CC       cell differentiation in intestine and controls secretory fat
CC       commitment through lateral inhibition in small intestine
CC       (PubMed:21238454, PubMed:21915337). Plays a role during inner ear
CC       development; negatively regulates auditory hair cell
CC       differentiation (PubMed:16495313). Plays a role during nephron
CC       development through Notch signaling pathway (PubMed:23806616).
CC       Regulates growth, blood pressure and energy homeostasis
CC       (PubMed:19562077). {ECO:0000250|UniProtKB:O00548,
CC       ECO:0000250|UniProtKB:P97677, ECO:0000269|PubMed:10958687,
CC       ECO:0000269|PubMed:15146182, ECO:0000269|PubMed:16495313,
CC       ECO:0000269|PubMed:17194759, ECO:0000269|PubMed:17960184,
CC       ECO:0000269|PubMed:18676613, ECO:0000269|PubMed:18997111,
CC       ECO:0000269|PubMed:19144989, ECO:0000269|PubMed:19217325,
CC       ECO:0000269|PubMed:19389377, ECO:0000269|PubMed:19562077,
CC       ECO:0000269|PubMed:20081190, ECO:0000269|PubMed:21238454,
CC       ECO:0000269|PubMed:21572390, ECO:0000269|PubMed:21915337,
CC       ECO:0000269|PubMed:21985982, ECO:0000269|PubMed:22096075,
CC       ECO:0000269|PubMed:22282195, ECO:0000269|PubMed:22529374,
CC       ECO:0000269|PubMed:22940113, ECO:0000269|PubMed:23688253,
CC       ECO:0000269|PubMed:23695674, ECO:0000269|PubMed:23699523,
CC       ECO:0000269|PubMed:23806616, ECO:0000269|PubMed:25220152,
CC       ECO:0000269|PubMed:26114479, ECO:0000269|PubMed:7671806}.
CC   -!- SUBUNIT: Homodimer (PubMed:12794186). Interacts with TJP1
CC       (PubMed:24715457). Interacts with MMP14; inhibits DLL1-induced
CC       Notch signaling (PubMed:21572390). Interacts with MAGI1 (via PDZ
CC       domain); forms a complex with CTNNB1 and CDH2 and promotes
CC       recruitment to the adherens junction and stabilization on the cell
CC       surface (PubMed:15908431). Interacts with PSEN1; undergoes a
CC       presenilin-dependent gamma-secretase cleavage that releases a
CC       Dll1-intracellular form (PubMed:12794186). Interacts with MFAP5
CC       (PubMed:15788413). Interacts with MIB1 (PubMed:21985982).
CC       Interacts with NEURL1B; leads to ubiquitination (PubMed:17003037,
CC       PubMed:19723503). Interacts with NEURL1 (PubMed:19723503).
CC       Interacts with SYNJ2BP; enhances DLL1 protein stability, and
CC       promotes Notch signaling in endothelial cells (By similarity).
CC       Interacts with MAGI1, MAGI2, MAGI3 and MPDZ (By similarity).
CC       Interacts (via ubiquitin) with EPN1 (via IUM domain); binding with
CC       NOTCH1 attached to neighboring cell, promotes ligand
CC       ubiquitination and EPN1 interaction, leading to NECD
CC       transendocytosis and Notch signaling (By similarity).
CC       {ECO:0000250|UniProtKB:O00548, ECO:0000250|UniProtKB:P97677,
CC       ECO:0000269|PubMed:12794186, ECO:0000269|PubMed:15788413,
CC       ECO:0000269|PubMed:15908431, ECO:0000269|PubMed:17003037,
CC       ECO:0000269|PubMed:19723503, ECO:0000269|PubMed:21572390,
CC       ECO:0000269|PubMed:21985982, ECO:0000269|PubMed:24715457}.
CC   -!- INTERACTION:
CC       Q9WVQ1:Magi2; NbExp=2; IntAct=EBI-297125, EBI-297151;
CC   -!- SUBCELLULAR LOCATION: Apical cell membrane
CC       {ECO:0000269|PubMed:24715457}; Single-pass type I membrane protein
CC       {ECO:0000269|PubMed:24715457}. Cell junction, adherens junction
CC       {ECO:0000269|PubMed:15908431, ECO:0000269|PubMed:24715457}.
CC       Membrane raft {ECO:0000269|PubMed:18676613,
CC       ECO:0000269|PubMed:21985982}. Note=Distributed around adherens
CC       junction in the apical endfeet through interactions with MAGI1.
CC       {ECO:0000269|PubMed:15908431, ECO:0000269|PubMed:24715457}.
CC   -!- SUBCELLULAR LOCATION: Dll1-derived cell-associated form: Cell
CC       membrane {ECO:0000269|PubMed:12794186}.
CC   -!- SUBCELLULAR LOCATION: Dll1-intracellular form: Nucleus
CC       {ECO:0000269|PubMed:12794186}.
CC   -!- TISSUE SPECIFICITY: In the embryo, expressed in the paraxial
CC       mesoderm and nervous system. Expressed at high levels in adult
CC       heart and at lower levels, in adult lung. Highly expressed in
CC       satellite cells from masseter and tongue than in satellite cells
CC       from leg and extraocular muscle.? (PubMed:25220152).
CC       {ECO:0000269|PubMed:25220152, ECO:0000269|PubMed:7671806}.
CC   -!- DEVELOPMENTAL STAGE: Expressed until E15. Expression then
CC       decreases and increases again in the adult. In differentiating
CC       somites, is expressed at low levels in cells emerging from the
CC       dorsomedial lip and subsequently throughout myotomes. In the limb
CC       buds, is found in myoblasts and myocytes but not in the progenitor
CC       cells (PubMed:17194759). Highly expressed in the endothelium and
CC       in the smooth muscle layer starting at E13.5 in arterial vessels,
CC       but not in veins. At E12.5, there is no detectable expression in
CC       arteries or veins. This pattern persists until E18.5
CC       (PubMed:19144989). Strongly expressed in developing muscle of
CC       tongue, cheek, and in extraocular muscle at E11.5. Found at E18
CC       and P21 in head muscle (PubMed:25220152). Detected in a subset of
CC       cells in the ventricular zone (VZ), the intermediate zone (IZ) and
CC       the cortical plate (CP) of neocortex and in the ganglionic
CC       eminences at E13.5. At later stages, such as at E16.5, found in
CC       the VZ and IZ, but at very low levels in the CP of the neocortex
CC       (PubMed:18997111). Highly expressed in embryonic cells located in
CC       the ventricular zone (VZ) of the retinal neuroepithelium that form
CC       clusters; is first detected in cells located in the central
CC       retina. As the retina grows, expression spreads peripherally along
CC       the expanding neurogenic region, being always absent from the
CC       ciliary margin zone (CMZ) (PubMed:19389377).
CC       {ECO:0000269|PubMed:17194759, ECO:0000269|PubMed:18997111,
CC       ECO:0000269|PubMed:19144989, ECO:0000269|PubMed:19389377,
CC       ECO:0000269|PubMed:25220152, ECO:0000269|PubMed:7671806}.
CC   -!- INDUCTION: Induced by PTF1A in multipotent pancreatic progenitor
CC       cells (PubMed:22096075). Induced by CDX1 and CDX2 during
CC       somitogenesis and goblet cell differentiation (PubMed:22015720).
CC       {ECO:0000269|PubMed:22015720, ECO:0000269|PubMed:22096075}.
CC   -!- PTM: Ubiquitinated by MIB (MIB1 or MIB2), leading to its
CC       endocytosis and subsequent degradation. Ubiquitinated; promotes
CC       recycling back to the plasma membrane and confers a strong
CC       affinity for NOTCH1 (PubMed:18676613). Multi-ubiquitination of
CC       LYS-613 by MIB1 promotes both cis and trans-interaction with
CC       NOTCH1, as well as activation of Notch signaling
CC       (PubMed:21985982). Ubiquitinated by NEURL1B (PubMed:17003037).
CC       {ECO:0000250|UniProtKB:P10041, ECO:0000269|PubMed:17003037,
CC       ECO:0000269|PubMed:18676613, ECO:0000269|PubMed:21985982}.
CC   -!- PTM: Phosphorylated in a membrane association-dependent manner.
CC       Phosphorylation at Ser-696 requires the presence of Ser-693,
CC       whereas phosphorylation at Thr-638 and Ser-693 occurs
CC       independently of the other sites. Phosphorylation is required for
CC       full ligand activity in vitro and affects surface presentation,
CC       ectodomain shedding, and endocytosis.
CC       {ECO:0000269|PubMed:24449764}.
CC   -!- PTM: Cleaved by MMP14; negatively regulates DLL1-induced Notch
CC       signaling in HPCs, modulating B-lymphocyte differentiation in bone
CC       marrow (PubMed:21572390). Undergoes two consecutive processing
CC       events: a shedding event, partially by ADAM10, that generates a
CC       soluble extracellular form and an intracelular membrane-anchored
CC       form, followed by a gamma-secretase cleavage releasing an
CC       intracellular fragment (PubMed:12794186).
CC       {ECO:0000269|PubMed:12794186, ECO:0000269|PubMed:21572390}.
CC   -!- PTM: O-fucosylated. Can be elongated to a disaccharide by MFNG.
CC       {ECO:0000250|UniProtKB:P97677}.
CC   -!- DISRUPTION PHENOTYPE: Heterozygous Dll1 mice mutants are lighter
CC       and smaller, with altered fat to lean ratio and have increased
CC       blood pressure and a slight bradycardia. The animals have reduced
CC       cholesterol and triglyceride levels in blood (PubMed:19562077).
CC       Heterozygous Dll1 mice mutants and hypomorphic Dll1 mice mutants
CC       survive until birth, despite significantly reduced Notch activity
CC       (PubMed:17194759). Conditional knockout in inner ear leads to an
CC       early and excessive production of hair cells and have vestibular
CC       defects (PubMed:16495313). Conditional knockout in a small
CC       proportion of neural precursor cells reduces neurogenesis, whereas
CC       conditional knockout in a large proportion promotes premature
CC       neurogenesis (PubMed:18997111). Hypomorph Dll1 pups mutant survive
CC       until birth but are smaller. Conditional knockout Dll1 mice mutant
CC       in epidermis, survive and have no gross abnormalities
CC       (PubMed:17960184). Hypomorph Dll1 mice mutant survive until birth
CC       and have severe skeletal muscle defects (PubMed:19144989).
CC       Heterozygous Dll1 mutant embryos show disrupted muscle growth
CC       (PubMed:25220152). Conditional knockout Dll1 mice mutant show
CC       disorganization of Bergmann fibers, ectopic localization of
CC       Bergmann glia in the molecular layer and a reduction in the number
CC       of Bergmann glia (PubMed:23688253). {ECO:0000269|PubMed:16495313,
CC       ECO:0000269|PubMed:17194759, ECO:0000269|PubMed:17960184,
CC       ECO:0000269|PubMed:18997111, ECO:0000269|PubMed:19144989,
CC       ECO:0000269|PubMed:19562077, ECO:0000269|PubMed:23688253,
CC       ECO:0000269|PubMed:25220152}.
CC   -!- SIMILARITY: Contains 1 DSL domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00377}.
CC   -!- SIMILARITY: Contains 8 EGF-like domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00076}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X80903; CAA56865.1; -; mRNA.
DR   EMBL; AY497019; AAR30869.1; -; Genomic_DNA.
DR   EMBL; CH466630; EDL20466.1; -; Genomic_DNA.
DR   EMBL; BC057400; AAH57400.1; -; mRNA.
DR   EMBL; BC065063; AAH65063.1; -; mRNA.
DR   CCDS; CCDS37452.1; -.
DR   PIR; I48324; I48324.
DR   RefSeq; NP_031891.2; NM_007865.3.
DR   UniGene; Mm.4875; -.
DR   ProteinModelPortal; Q61483; -.
DR   SMR; Q61483; 22-551.
DR   BioGrid; 199232; 6.
DR   DIP; DIP-32600N; -.
DR   IntAct; Q61483; 3.
DR   MINT; MINT-8187263; -.
DR   STRING; 10090.ENSMUSP00000014917; -.
DR   iPTMnet; Q61483; -.
DR   PhosphoSite; Q61483; -.
DR   MaxQB; Q61483; -.
DR   PRIDE; Q61483; -.
DR   Ensembl; ENSMUST00000014917; ENSMUSP00000014917; ENSMUSG00000014773.
DR   GeneID; 13388; -.
DR   KEGG; mmu:13388; -.
DR   UCSC; uc008aoi.2; mouse.
DR   CTD; 28514; -.
DR   MGI; MGI:104659; Dll1.
DR   eggNOG; NOG249767; -.
DR   GeneTree; ENSGT00810000125346; -.
DR   HOGENOM; HOG000267024; -.
DR   HOVERGEN; HBG007139; -.
DR   InParanoid; Q61483; -.
DR   KO; K06051; -.
DR   OMA; CQREKDV; -.
DR   OrthoDB; EOG7GQXZ5; -.
DR   TreeFam; TF351835; -.
DR   Reactome; R-MMU-1980148; Signaling by NOTCH3.
DR   Reactome; R-MMU-1980150; Signaling by NOTCH4.
DR   NextBio; 283748; -.
DR   PMAP-CutDB; Q6PFV7; -.
DR   PRO; PR:Q61483; -.
DR   Proteomes; UP000000589; Chromosome 17.
DR   Bgee; Q61483; -.
DR   CleanEx; MM_DLL1; -.
DR   Genevisible; Q61483; MM.
DR   GO; GO:0005912; C:adherens junction; IDA:UniProtKB.
DR   GO; GO:0016324; C:apical plasma membrane; IDA:UniProtKB.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IDA:MGI.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0045121; C:membrane raft; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:MGI.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0005112; F:Notch binding; IPI:UniProtKB.
DR   GO; GO:0097110; F:scaffold protein binding; IPI:UniProtKB.
DR   GO; GO:0030957; F:Tat protein binding; ISO:MGI.
DR   GO; GO:0014002; P:astrocyte development; IMP:UniProtKB.
DR   GO; GO:0042491; P:auditory receptor cell differentiation; NAS:UniProtKB.
DR   GO; GO:0009912; P:auditory receptor cell fate commitment; NAS:UniProtKB.
DR   GO; GO:0007267; P:cell-cell signaling; IDA:MGI.
DR   GO; GO:0021688; P:cerebellar molecular layer formation; IMP:UniProtKB.
DR   GO; GO:0021693; P:cerebellar Purkinje cell layer structural organization; IMP:UniProtKB.
DR   GO; GO:0072583; P:clathrin-mediated endocytosis; ISS:UniProtKB.
DR   GO; GO:0007386; P:compartment pattern specification; IMP:MGI.
DR   GO; GO:0007368; P:determination of left/right symmetry; IMP:MGI.
DR   GO; GO:0097102; P:endothelial tip cell fate specification; IMP:UniProtKB.
DR   GO; GO:0001947; P:heart looping; IMP:BHF-UCL.
DR   GO; GO:0001701; P:in utero embryonic development; NAS:UniProtKB.
DR   GO; GO:0048839; P:inner ear development; IMP:MGI.
DR   GO; GO:0042472; P:inner ear morphogenesis; NAS:UniProtKB.
DR   GO; GO:0046331; P:lateral inhibition; IDA:UniProtKB.
DR   GO; GO:0070986; P:left/right axis specification; IMP:BHF-UCL.
DR   GO; GO:0072070; P:loop of Henle development; IEP:UniProtKB.
DR   GO; GO:0002315; P:marginal zone B cell differentiation; IMP:UniProtKB.
DR   GO; GO:0045608; P:negative regulation of auditory receptor cell differentiation; IMP:MGI.
DR   GO; GO:0045596; P:negative regulation of cell differentiation; IMP:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IMP:UniProtKB.
DR   GO; GO:0045605; P:negative regulation of epidermal cell differentiation; IMP:UniProtKB.
DR   GO; GO:0030857; P:negative regulation of epithelial cell differentiation; IMP:UniProtKB.
DR   GO; GO:0034351; P:negative regulation of glial cell apoptotic process; IMP:UniProtKB.
DR   GO; GO:0032693; P:negative regulation of interleukin-10 production; ISO:MGI.
DR   GO; GO:0045638; P:negative regulation of myeloid cell differentiation; IDA:MGI.
DR   GO; GO:0045662; P:negative regulation of myoblast differentiation; IMP:UniProtKB.
DR   GO; GO:0045665; P:negative regulation of neuron differentiation; IMP:UniProtKB.
DR   GO; GO:0072006; P:nephron development; IMP:UniProtKB.
DR   GO; GO:0007399; P:nervous system development; NAS:UniProtKB.
DR   GO; GO:0048665; P:neuron fate specification; IDA:UniProtKB.
DR   GO; GO:0097150; P:neuronal stem cell population maintenance; IMP:UniProtKB.
DR   GO; GO:0061314; P:Notch signaling involved in heart development; IC:BHF-UCL.
DR   GO; GO:0007219; P:Notch signaling pathway; IMP:UniProtKB.
DR   GO; GO:0060853; P:Notch signaling pathway involved in arterial endothelial cell fate commitment; IMP:UniProtKB.
DR   GO; GO:0042475; P:odontogenesis of dentin-containing tooth; NAS:UniProtKB.
DR   GO; GO:0035265; P:organ growth; IMP:UniProtKB.
DR   GO; GO:0009887; P:organ morphogenesis; NAS:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IMP:UniProtKB.
DR   GO; GO:0045807; P:positive regulation of endocytosis; IDA:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:MGI.
DR   GO; GO:0045747; P:positive regulation of Notch signaling pathway; IDA:UniProtKB.
DR   GO; GO:0048633; P:positive regulation of skeletal muscle tissue growth; IMP:UniProtKB.
DR   GO; GO:1903672; P:positive regulation of sprouting angiogenesis; IMP:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IMP:BHF-UCL.
DR   GO; GO:0072014; P:proximal tubule development; IEP:UniProtKB.
DR   GO; GO:0009954; P:proximal/distal pattern formation; IMP:UniProtKB.
DR   GO; GO:0008217; P:regulation of blood pressure; IMP:UniProtKB.
DR   GO; GO:0030155; P:regulation of cell adhesion; IMP:UniProtKB.
DR   GO; GO:0051302; P:regulation of cell division; IMP:UniProtKB.
DR   GO; GO:2000505; P:regulation of energy homeostasis; IMP:UniProtKB.
DR   GO; GO:0040008; P:regulation of growth; IMP:UniProtKB.
DR   GO; GO:0050767; P:regulation of neurogenesis; IMP:UniProtKB.
DR   GO; GO:0048631; P:regulation of skeletal muscle tissue growth; IMP:UniProtKB.
DR   GO; GO:0014807; P:regulation of somitogenesis; IMP:UniProtKB.
DR   GO; GO:1900746; P:regulation of vascular endothelial growth factor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0060041; P:retina development in camera-type eye; IMP:UniProtKB.
DR   GO; GO:0060042; P:retina morphogenesis in camera-type eye; IMP:UniProtKB.
DR   GO; GO:0048630; P:skeletal muscle tissue growth; IMP:UniProtKB.
DR   GO; GO:0098773; P:skin epidermis development; IMP:UniProtKB.
DR   GO; GO:0001757; P:somite specification; IMP:MGI.
DR   GO; GO:0001756; P:somitogenesis; IMP:UniProtKB.
DR   GO; GO:0021510; P:spinal cord development; IMP:UniProtKB.
DR   GO; GO:0003323; P:type B pancreatic cell development; IMP:UniProtKB.
DR   InterPro; IPR001774; DSL.
DR   InterPro; IPR001881; EGF-like_Ca-bd_dom.
DR   InterPro; IPR013032; EGF-like_CS.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR000152; EGF-type_Asp/Asn_hydroxyl_site.
DR   InterPro; IPR018097; EGF_Ca-bd_CS.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR011651; Notch_ligand_N.
DR   Pfam; PF01414; DSL; 1.
DR   Pfam; PF00008; EGF; 5.
DR   Pfam; PF07645; EGF_CA; 1.
DR   Pfam; PF07657; MNNL; 1.
DR   SMART; SM00051; DSL; 1.
DR   SMART; SM00181; EGF; 4.
DR   SMART; SM00179; EGF_CA; 4.
DR   SUPFAM; SSF57184; SSF57184; 1.
DR   PROSITE; PS00010; ASX_HYDROXYL; 3.
DR   PROSITE; PS51051; DSL; 1.
DR   PROSITE; PS00022; EGF_1; 8.
DR   PROSITE; PS01186; EGF_2; 8.
DR   PROSITE; PS50026; EGF_3; 7.
DR   PROSITE; PS01187; EGF_CA; 2.
PE   1: Evidence at protein level;
KW   Cell junction; Cell membrane; Complete proteome;
KW   Developmental protein; Differentiation; Direct protein sequencing;
KW   Disulfide bond; EGF-like domain; Glycoprotein; Isopeptide bond;
KW   Membrane; Notch signaling pathway; Nucleus; Phosphoprotein;
KW   Reference proteome; Repeat; Signal; Transmembrane;
KW   Transmembrane helix; Ubl conjugation.
FT   SIGNAL        1     17       {ECO:0000255}.
FT   CHAIN        18    722       Delta-like protein 1.
FT                                /FTId=PRO_0000007507.
FT   CHAIN        18    535       Dll1-soluble form.
FT                                {ECO:0000269|PubMed:12794186}.
FT                                /FTId=PRO_0000434830.
FT   CHAIN       536    722       Dll1-derived cell-associated form.
FT                                {ECO:0000269|PubMed:12794186}.
FT                                /FTId=PRO_0000434831.
FT   CHAIN         ?    722       Dll1-intracellular form.
FT                                {ECO:0000269|PubMed:12794186}.
FT                                /FTId=PRO_0000434832.
FT   TOPO_DOM     18    545       Extracellular. {ECO:0000255}.
FT   TRANSMEM    546    568       Helical. {ECO:0000255}.
FT   TOPO_DOM    569    722       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      176    220       DSL. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00377}.
FT   DOMAIN      225    253       EGF-like 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      256    284       EGF-like 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      291    324       EGF-like 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      331    362       EGF-like 4; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      369    401       EGF-like 5. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      408    439       EGF-like 6. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      446    477       EGF-like 7; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      484    515       EGF-like 8. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   REGION      719    722       Interaction with MAGI1.
FT                                {ECO:0000269|PubMed:15908431}.
FT   SITE        527    527       Cleavage; by MMP14.
FT                                {ECO:0000269|PubMed:21572390}.
FT   SITE        535    536       Cleavage; by ADAM protease.
FT                                {ECO:0000269|PubMed:12794186}.
FT   MOD_RES     638    638       Phosphothreonine.
FT                                {ECO:0000269|PubMed:24449764}.
FT   MOD_RES     693    693       Phosphoserine; by PKB.
FT                                {ECO:0000269|PubMed:24449764}.
FT   MOD_RES     696    696       Phosphoserine.
FT                                {ECO:0000269|PubMed:24449764}.
FT   CARBOHYD    476    476       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID    178    187       {ECO:0000250}.
FT   DISULFID    191    203       {ECO:0000250}.
FT   DISULFID    211    220       {ECO:0000250}.
FT   DISULFID    225    236       {ECO:0000250}.
FT   DISULFID    229    242       {ECO:0000250}.
FT   DISULFID    244    253       {ECO:0000250}.
FT   DISULFID    256    267       {ECO:0000250}.
FT   DISULFID    262    273       {ECO:0000250}.
FT   DISULFID    275    284       {ECO:0000250}.
FT   DISULFID    291    303       {ECO:0000250}.
FT   DISULFID    297    313       {ECO:0000250}.
FT   DISULFID    315    324       {ECO:0000250}.
FT   DISULFID    331    342       {ECO:0000250}.
FT   DISULFID    336    351       {ECO:0000250}.
FT   DISULFID    353    362       {ECO:0000250}.
FT   DISULFID    369    380       {ECO:0000250}.
FT   DISULFID    374    390       {ECO:0000250}.
FT   DISULFID    392    401       {ECO:0000250}.
FT   DISULFID    408    419       {ECO:0000250}.
FT   DISULFID    413    428       {ECO:0000250}.
FT   DISULFID    430    439       {ECO:0000250}.
FT   DISULFID    446    457       {ECO:0000250}.
FT   DISULFID    451    466       {ECO:0000250}.
FT   DISULFID    468    477       {ECO:0000250}.
FT   DISULFID    484    495       {ECO:0000250}.
FT   DISULFID    489    504       {ECO:0000250}.
FT   DISULFID    506    515       {ECO:0000250}.
FT   CROSSLNK    613    613       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:21985982}.
FT   MUTAGEN     613    618       KNTNKK->RNTNRR: Highly decreases Notch
FT                                signaling pathway. Multi-ubiquitination
FT                                pattern is reduced, although it does
FT                                appear to be mono-ubiquitinated.
FT                                Interacts with MIB1. Loss of cis
FT                                interaction with NOTCH1.
FT                                {ECO:0000269|PubMed:21985982}.
FT   MUTAGEN     613    613       K->R: Highly decreases Notch signaling
FT                                pathway. Multi-ubiquitination pattern is
FT                                reduced, although it does appear to be
FT                                mono-ubiquitinated. Interacts with MIB1.
FT                                Loss of cis and trans interaction with
FT                                NOTCH1. Increases its association with
FT                                lipid raft microdomains.
FT                                {ECO:0000269|PubMed:21985982}.
FT   MUTAGEN     638    638       T->V: Not phosphorylated; when associated
FT                                with A-693 and A-696. Not phosphorylated
FT                                and doesn't prevent phosphorylation at S-
FT                                693 and S-696. Reduces NOTCH1
FT                                transactivation; when associated with A-
FT                                693 and A-696. Reduces cell surface
FT                                levels of proteins; when associated with
FT                                A-693 and A-696. Increases ectodomain
FT                                shedding; when associated with A-693 and
FT                                A-696. {ECO:0000269|PubMed:24449764}.
FT   MUTAGEN     689    689       K->R: Decreases Notch signaling pathway.
FT                                {ECO:0000269|PubMed:21985982}.
FT   MUTAGEN     693    693       S->A: Not phosphorylated; when associated
FT                                with V-638 and A-696. Not phosphorylated
FT                                and prevents phosphorylation at S-696.
FT                                Reduces NOTCH1 transactivation; when
FT                                associated with V-638 and A-696. Reduces
FT                                cell surface levels of proteins; when
FT                                associated with V-638 and A-696.
FT                                Increases ectodomain shedding; when
FT                                associated with V-638 and A-696.
FT                                {ECO:0000269|PubMed:24449764}.
FT   MUTAGEN     696    696       S->A: Not phosphorylated; when associated
FT                                with V-638 and A-693. Not phosphorylated
FT                                and doesn't prevent phosphorylation at T-
FT                                638 and S-693, Reduces NOTCH1
FT                                transactivation; when associated with V-
FT                                638 and A-693. Reduces cell surface
FT                                levels of proteins; when associated with
FT                                V-638 and A-693. Increases ectodomain
FT                                shedding; when associated with V-638 and
FT                                A-693. {ECO:0000269|PubMed:24449764}.
FT   MUTAGEN     699    699       K->R: Decreases Notch signaling pathway.
FT                                {ECO:0000269|PubMed:21985982}.
FT   MUTAGEN     713    713       K->R: Decreases Notch signaling pathway.
FT                                {ECO:0000269|PubMed:21985982}.
FT   CONFLICT    628    628       E -> K (in Ref. 1; CAA56865).
FT                                {ECO:0000305}.
SQ   SEQUENCE   722 AA;  78449 MW;  9D570B9DC7EEC75E CRC64;
     MGRRSALALA VVSALLCQVW SSGVFELKLQ EFVNKKGLLG NRNCCRGGSG PPCACRTFFR
     VCLKHYQASV SPEPPCTYGS AVTPVLGVDS FSLPDGAGID PAFSNPIRFP FGFTWPGTFS
     LIIEALHTDS PDDLATENPE RLISRLTTQR HLTVGEEWSQ DLHSSGRTDL RYSYRFVCDE
     HYYGEGCSVF CRPRDDAFGH FTCGDRGEKM CDPGWKGQYC TDPICLPGCD DQHGYCDKPG
     ECKCRVGWQG RYCDECIRYP GCLHGTCQQP WQCNCQEGWG GLFCNQDLNY CTHHKPCRNG
     ATCTNTGQGS YTCSCRPGYT GANCELEVDE CAPSPCKNGA SCTDLEDSFS CTCPPGFYGK
     VCELSAMTCA DGPCFNGGRC SDNPDGGYTC HCPLGFSGFN CEKKMDLCGS SPCSNGAKCV
     DLGNSYLCRC QAGFSGRYCE DNVDDCASSP CANGGTCRDS VNDFSCTCPP GYTGKNCSAP
     VSRCEHAPCH NGATCHQRGQ RYMCECAQGY GGPNCQFLLP EPPPGPMVVD LSERHMESQG
     GPFPWVAVCA GVVLVLLLLL GCAAVVVCVR LKLQKHQPPP EPCGGETETM NNLANCQREK
     DVSVSIIGAT QIKNTNKKAD FHGDHGAEKS SFKVRYPTVD YNLVRDLKGD EATVRDTHSK
     RDTKCQSQSS AGEEKIAPTL RGGEIPDRKR PESVYSTSKD TKYQSVYVLS AEKDECVIAT
     EV
//
ID   FINC_HUMAN              Reviewed;        2386 AA.
AC   P02751; B7ZLF0; E9PE77; E9PG29; O95609; O95610; Q14312; Q14325;
AC   Q14326; Q17RV7; Q564H7; Q585T2; Q59EH1; Q60FE4; Q68DP8; Q68DP9;
AC   Q68DT4; Q6LDP6; Q6MZS0; Q6MZU5; Q6N025; Q6N0A6; Q7Z391; Q86T27;
AC   Q8IVI8; Q96KP7; Q96KP8; Q96KP9; Q9H1B8; Q9HAP3; Q9UMK2;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   13-JUL-2010, sequence version 4.
DT   17-FEB-2016, entry version 216.
DE   RecName: Full=Fibronectin;
DE            Short=FN;
DE   AltName: Full=Cold-insoluble globulin;
DE            Short=CIG;
DE   Contains:
DE     RecName: Full=Anastellin;
DE   Contains:
DE     RecName: Full=Ugl-Y1;
DE   Contains:
DE     RecName: Full=Ugl-Y2;
DE   Contains:
DE     RecName: Full=Ugl-Y3;
DE   Flags: Precursor;
GN   Name=FN1; Synonyms=FN;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND VARIANTS PRO-817 AND
RP   ILE-2170.
RX   PubMed=11737888; DOI=10.1186/bcr325;
RA   Schor S.L., Schor A.M.;
RT   "Phenotypic and genetic alterations in mammary stroma: implications
RT   for tumour progression.";
RL   Breast Cancer Res. 3:373-379(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 16).
RX   PubMed=16322219; DOI=10.1158/0008-5472.CAN-05-2038;
RA   Kay R.A., Ellis I.R., Jones S.J., Perrier S., Florence M.M.,
RA   Schor A.M., Schor S.L.;
RT   "The expression of migration stimulating factor, a potent oncofetal
RT   cytokine, is uniquely controlled by 3'-untranslated region-dependent
RT   nuclear sequestration of its precursor messenger RNA.";
RL   Cancer Res. 65:10742-10749(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 14), AND VARIANTS PRO-817 AND
RP   ILE-2170.
RC   TISSUE=Retinal pigment epithelium;
RX   PubMed=16106752; DOI=10.1093/dnares/12.1.53;
RA   Kato S., Ohtoko K., Ohtake H., Kimura T.;
RT   "Vector-capping: a simple method for preparing a high-quality full-
RT   length cDNA library.";
RL   DNA Res. 12:53-62(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 14), AND VARIANTS
RP   LEU-15; PRO-817 AND ILE-2170.
RC   TISSUE=Aortic endothelium;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3; 7; 8; 9; 10; 13;
RP   14; 15 AND 16), AND VARIANTS LEU-15; PRO-817 AND ILE-2170.
RC   TISSUE=Amygdala, Cervix, Endometrial tumor, and Uterine endothelium;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 10), AND VARIANTS
RP   LEU-15; PRO-817 AND ILE-2170.
RC   TISSUE=Cerebellum;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-38.
RX   PubMed=3770189; DOI=10.1016/0014-5793(86)80029-1;
RA   Gutman A., Yamada K.M., Kornblihtt A.R.;
RT   "Human fibronectin is synthesized as a pre-propolypeptide.";
RL   FEBS Lett. 207:145-148(1986).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-49, AND VARIANT LEU-15.
RX   PubMed=3031656; DOI=10.1073/pnas.84.7.1876;
RA   Dean D.C., Bowlus C.L., Bourgeois S.;
RT   "Cloning and analysis of the promotor region of the human fibronectin
RT   gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:1876-1880(1987).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 28-2386 (ISOFORM 3), AND VARIANTS
RP   PRO-817 AND ILE-2170.
RX   PubMed=2992939;
RA   Kornblihtt A.R., Umezawa K., Vibe-Pedersen K., Baralle F.E.;
RT   "Primary structure of human fibronectin: differential splicing may
RT   generate at least 10 polypeptides from a single gene.";
RL   EMBO J. 4:1755-1759(1985).
RN   [12]
RP   PROTEIN SEQUENCE OF 32-290, AND PYROGLUTAMATE FORMATION AT GLN-32.
RX   PubMed=6630202;
RA   Garcia-Pardo A., Pearlstein E., Frangione B.;
RT   "Primary structure of human plasma fibronectin. The 29,000-dalton NH2-
RT   terminal domain.";
RL   J. Biol. Chem. 258:12670-12674(1983).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 103-481 (ISOFORMS
RP   1/3/4/5/6/7/8/9/10/11/12/13/14/15), NUCLEOTIDE SEQUENCE [MRNA] OF
RP   1116-1422 (ISOFORMS 1/3/4/5/6/8/9/10/14), NUCLEOTIDE SEQUENCE [MRNA]
RP   OF 1238-2160 (ISOFORMS 9 AND 12), NUCLEOTIDE SEQUENCE [MRNA] OF
RP   1449-1825 (ISOFORMS 8/9/10/13/14), NUCLEOTIDE SEQUENCE [MRNA] OF
RP   1919-2161 (ISOFORMS 3/7/14), AND NUCLEOTIDE SEQUENCE [MRNA] OF
RP   2228-2386 (ISOFORMS 1/3/6/7/8/9/10/11/12/13/14/15).
RC   TISSUE=Peripheral blood T-cell, and Umbilical vein endothelial cell;
RA   Godfrey H.P., Ebrahim A.A.;
RL   Submitted (DEC-1995) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   PROTEIN SEQUENCE OF 309-608, AND COLLAGEN-BINDING.
RX   PubMed=3024962;
RA   Owens R.J., Baralle F.E.;
RT   "Mapping the collagen-binding site of human fibronectin by expression
RT   in Escherichia coli.";
RL   EMBO J. 5:2825-2830(1986).
RN   [15]
RP   PROTEIN SEQUENCE OF 616-705.
RX   PubMed=3900070;
RA   Calaycay J., Pande H., Lee T., Borsi L., Siri A., Shively J.E.,
RA   Zardi L.;
RT   "Primary structure of a DNA- and heparin-binding domain (Domain III)
RT   in human plasma fibronectin.";
RL   J. Biol. Chem. 260:12136-12141(1985).
RN   [16]
RP   PROTEIN SEQUENCE OF 723-911, TISSUE SPECIFICITY, DEVELOPMENTAL STAGE,
RP   GLYCOSYLATION AT ASN-877, AND VARIANT PRO-817.
RC   TISSUE=Urine;
RX   PubMed=17614963; DOI=10.1111/j.1742-4658.2007.05926.x;
RA   Iida R., Yasuda T., Kishi K.;
RT   "Identification of novel fibronectin fragments detected specifically
RT   in juvenile urine.";
RL   FEBS J. 274:3939-3947(2007).
RN   [17]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 973-2386 (ISOFORM 3), AND VARIANT
RP   ILE-2170.
RX   PubMed=6462919; DOI=10.1093/nar/12.14.5853;
RA   Kornblihtt A.R., Vibe-Pedersen K., Baralle F.E.;
RT   "Human fibronectin: cell specific alternative mRNA splicing generates
RT   polypeptide chains differing in the number of internal repeats.";
RL   Nucleic Acids Res. 12:5853-5868(1984).
RN   [18]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1232-1782 (ISOFORMS 7/15).
RX   PubMed=3375063; DOI=10.1093/nar/16.8.3545;
RA   Paolella G., Henchcliffe C., Sebastio G., Baralle F.E.;
RT   "Sequence analysis and in vivo expression show that alternative
RT   splicing of ED-B and ED-A regions of the human fibronectin gene are
RT   independent events.";
RL   Nucleic Acids Res. 16:3545-3557(1988).
RN   [19]
RP   PROTEIN SEQUENCE OF 1234-1286 (ISOFORM 7).
RX   PubMed=2822387;
RA   Zardi L., Carnemolla B., Siri A., Petersen T.E., Paolella G.,
RA   Sebastio G., Baralle F.E.;
RT   "Transformed human cells produce a new fibronectin isoform by
RT   preferential alternative splicing of a previously unobserved exon.";
RL   EMBO J. 6:2337-2342(1987).
RN   [20]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1257-1365 (ISOFORM 11).
RX   PubMed=3478690; DOI=10.1073/pnas.84.20.7179;
RA   Gutman A., Kornblihtt A.R.;
RT   "Identification of a third region of cell-specific alternative
RT   splicing in human fibronectin mRNA.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:7179-7182(1987).
RN   [21]
RP   PROTEIN SEQUENCE OF 1441-1548.
RX   PubMed=7050098;
RA   Pierschbacher M.D., Ruoslahti E., Sundelin J., Lind P., Peterson P.A.;
RT   "The cell attachment domain of fibronectin. Determination of the
RT   primary structure.";
RL   J. Biol. Chem. 257:9593-9597(1982).
RN   [22]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1448-1540.
RX   PubMed=6688418;
RA   Oldberg A., Linney E., Ruoslahti E.;
RT   "Molecular cloning and nucleotide sequence of a cDNA clone coding for
RT   the cell attachment domain in human fibronectin.";
RL   J. Biol. Chem. 258:10193-10196(1983).
RN   [23]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1448-1540.
RX   PubMed=3003095;
RA   Oldberg A., Ruoslahti E.;
RT   "Evolution of the fibronectin gene. Exon structure of cell attachment
RT   domain.";
RL   J. Biol. Chem. 261:2113-2116(1986).
RN   [24]
RP   PROTEIN SEQUENCE OF 1589-2058.
RX   PubMed=3593230;
RA   Garcia-Pardo A., Rostagno A., Frangione B.;
RT   "Primary structure of human plasma fibronectin. Characterization of a
RT   38 kDa domain containing the C-terminal heparin-binding site (Hep III
RT   site) and a region of molecular heterogeneity.";
RL   Biochem. J. 241:923-928(1987).
RN   [25]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1594-2386 (ISOFORMS 1/11/15), AND
RP   VARIANT ILE-2170.
RX   PubMed=2992573; DOI=10.1021/bi00332a016;
RA   Bernard M.P., Kolbe M., Weil D., Chu M.-L.;
RT   "Human cellular fibronectin: comparison of the carboxyl-terminal
RT   portion with rat identifies primary structural domains separated by
RT   hypervariable regions.";
RL   Biochemistry 24:2698-2704(1985).
RN   [26]
RP   PROTEIN SEQUENCE OF 1614-1623; 1730-1748; 1756-1759; 1803-1811;
RP   1860-1923; 1930-1945; 1949-1972; 1982-1989; 1991-2003; 2020-2038;
RP   2060-2131; 2150-2180; 2185-2205 AND 2231-2242, GLYCOSYLATION AT
RP   THR-2064 AND THR-2065, LACK OF GLYCOSYLATION AT ASN-2108, VARIANT
RP   ILE-2170, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=2012601;
RA   Tressel T., McCarthy J.B., Calaycay J., Lee T.D., Legesse K.,
RA   Shively J.E., Pande H.;
RT   "Human plasma fibronectin. Demonstration of structural differences
RT   between the A- and B-chains in the III CS region.";
RL   Biochem. J. 274:731-738(1991).
RN   [27]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1624-1727 (ISOFORMS 8/9/10/12/13/14).
RX   PubMed=6200322;
RA   Kornblihtt A.R., Vibe-Pedersen K., Baralle F.E.;
RT   "Human fibronectin: molecular cloning evidence for two mRNA species
RT   differing by an internal segment coding for a structural domain.";
RL   EMBO J. 3:221-226(1984).
RN   [28]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1712-1739 (ISOFORMS 1/3/4/5/6/7/11/15).
RX   PubMed=3021206; DOI=10.1021/bi00365a032;
RA   Sekiguchi K., Klos A.M., Kurachi K., Yoshitake S., Hakomori S.;
RT   "Human liver fibronectin complementary DNAs: identification of two
RT   different messenger RNAs possibly encoding the alpha and beta subunits
RT   of plasma fibronectin.";
RL   Biochemistry 25:4936-4941(1986).
RN   [29]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1788-2386 (ISOFORMS 4; 5 AND 6), AND
RP   VARIANT ILE-2170.
RC   TISSUE=Cartilage;
RX   PubMed=12127832; DOI=10.1053/joca.2002.0792;
RA   Parker A.E., Boutell J., Carr A., Maciewicz R.A.;
RT   "Novel cartilage-specific splice variants of fibronectin.";
RL   Osteoarthritis Cartilage 10:528-534(2002).
RN   [30]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1948-2067 (ISOFORMS 1/8/10/11/15).
RX   PubMed=2989004; DOI=10.1016/0014-5793(85)81333-8;
RA   Umezawa K., Kornblihtt A.R., Baralle F.E.;
RT   "Isolation and characterization of cDNA clones for human liver
RT   fibronectin.";
RL   FEBS Lett. 186:31-34(1985).
RN   [31]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1992-2147.
RX   PubMed=3770201; DOI=10.1016/0014-5793(86)81506-X;
RA   Vibe-Pedersen K., Magnusson S., Baralle F.E.;
RT   "Donor and acceptor splice signals within an exon of the human
RT   fibronectin gene: a new type of differential splicing.";
RL   FEBS Lett. 207:287-291(1986).
RN   [32]
RP   PROTEIN SEQUENCE OF 2071-2356 (ISOFORM 3), AND VARIANT ILE-2170.
RX   PubMed=4019516;
RA   Garcia-Pardo A., Pearlstein E., Frangione B.;
RT   "Primary structure of human plasma fibronectin. Characterization of a
RT   31,000-dalton fragment from the COOH-terminal region containing a free
RT   sulfhydryl group and a fibrin-binding site.";
RL   J. Biol. Chem. 260:10320-10325(1985).
RN   [33]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 2291-2386.
RX   PubMed=6304699; DOI=10.1073/pnas.80.11.3218;
RA   Kornblihtt A.R., Vibe-Pedersen K., Baralle F.E.;
RT   "Isolation and characterization of cDNA clones for human and bovine
RT   fibronectins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 80:3218-3222(1983).
RN   [34]
RP   SULFATION.
RX   PubMed=2414772; DOI=10.1073/pnas.82.21.7160;
RA   Liu M.C., Yu S., Sy J., Redman C.M., Lipmann F.;
RT   "Tyrosine sulfation of proteins from the human hepatoma cell line
RT   HepG2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:7160-7164(1985).
RN   [35]
RP   IDENTIFICATION OF UGL-Y1, TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, AND
RP   GLYCOSYLATION.
RX   PubMed=3584091;
RA   Iida R., Yasuda T., Kishi K.;
RT   "Purification of a young age-related glycoprotein (Ugl-Y) from normal
RT   human urine.";
RL   J. Biochem. 101:357-363(1987).
RN   [36]
RP   INTERACTION WITH FBLN1.
RX   PubMed=1400330;
RA   Balbona K., Tran H., Godyna S., Ingham K.C., Strickland D.K.,
RA   Argraves W.S.;
RT   "Fibulin binds to itself and to the carboxyl-terminal heparin-binding
RT   region of fibronectin.";
RL   J. Biol. Chem. 267:20120-20125(1992).
RN   [37]
RP   CHARACTERIZATION OF FIBRIN-BINDING SITE 1.
RX   PubMed=7989369;
RA   Rostagno A., Williams M.J., Baron M., Campbell I.D., Gold L.I.;
RT   "Further characterization of the NH2-terminal fibrin-binding site on
RT   fibronectin.";
RL   J. Biol. Chem. 269:31938-31945(1994).
RN   [38]
RP   SUBUNIT, AND FUNCTION OF ANASTELLIN.
RX   PubMed=8114919; DOI=10.1038/367193a0;
RA   Morla A., Zhang Z., Ruoslahti E.;
RT   "Superfibronectin is a functionally distinct form of fibronectin.";
RL   Nature 367:193-196(1994).
RN   [39]
RP   INTERACTION WITH LGALS3BP.
RX   PubMed=9501082; DOI=10.1093/emboj/17.6.1606;
RA   Sasaki T., Brakebusch C., Engel J., Timpl R.;
RT   "Mac-2 binding protein is a cell-adhesive protein of the extracellular
RT   matrix which self-assembles into ring-like structures and binds beta1
RT   integrins, collagens and fibronectin.";
RL   EMBO J. 17:1606-1613(1998).
RN   [40]
RP   FUNCTION OF ANASTELLIN.
RX   PubMed=11209058; DOI=10.1073/pnas.98.2.620;
RA   Yi M., Ruoslahti E.;
RT   "A fibronectin fragment inhibits tumor growth, angiogenesis, and
RT   metastasis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:620-624(2001).
RN   [41]
RP   INTERACTION WITH COL13A1.
RX   PubMed=11956183; DOI=10.1074/jbc.M107583200;
RA   Tu H., Sasaki T., Snellman A., Gohring W., Pirila P., Timpl R.,
RA   Pihlajaniemi T.;
RT   "The type XIII collagen ectodomain is a 150-nm rod and capable of
RT   binding to fibronectin, nidogen-2, perlecan, and heparin.";
RL   J. Biol. Chem. 277:23092-23099(2002).
RN   [42]
RP   INTERACTION WITH COMP.
RX   PubMed=12225811; DOI=10.1016/S0945-053X(02)00015-X;
RA   Di Cesare P.E., Chen F.S., Moergelin M., Carlson C.S., Leslie M.P.,
RA   Perris R., Fang C.;
RT   "Matrix-matrix interaction of cartilage oligomeric matrix protein and
RT   fibronectin.";
RL   Matrix Biol. 21:461-470(2002).
RN   [43]
RP   INTERACTION WITH MYOC.
RX   PubMed=11773026;
RA   Filla M.S., Liu X., Nguyen T.D., Polansky J.R., Brandt C.R.,
RA   Kaufman P.L., Peters D.M.;
RT   "In vitro localization of TIGR/MYOC in trabecular meshwork
RT   extracellular matrix and binding to fibronectin.";
RL   Invest. Ophthalmol. Vis. Sci. 43:151-161(2002).
RN   [44]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-528.
RC   TISSUE=Plasma;
RX   PubMed=14760718; DOI=10.1002/pmic.200300556;
RA   Bunkenborg J., Pilch B.J., Podtelejnikov A.V., Wisniewski J.R.;
RT   "Screening for N-glycosylated proteins by liquid chromatography mass
RT   spectrometry.";
RL   Proteomics 4:454-465(2004).
RN   [45]
RP   FUNCTION OF ANASTELLIN.
RX   PubMed=15665290;
RA   Ambesi A., Klein R.M., Pumiglia K.M., McKeown-Longo P.J.;
RT   "Anastellin, a fragment of the first type III repeat of fibronectin,
RT   inhibits extracellular signal-regulated kinase and causes G(1) arrest
RT   in human microvessel endothelial cells.";
RL   Cancer Res. 65:148-156(2005).
RN   [46]
RP   GLYCOSYLATION AT THR-279; ASN-430; ASN-528; ASN-542; ASN-877;
RP   ASN-1007; ASN-1244 AND ASN-2108.
RX   PubMed=16037490; DOI=10.1093/glycob/cwj019;
RA   Tajiri M., Yoshida S., Wada Y.;
RT   "Differential analysis of site-specific glycans on plasma and cellular
RT   fibronectins: application of a hydrophilic affinity method for
RT   glycopeptide enrichment.";
RL   Glycobiology 15:1332-1340(2005).
RN   [47]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-430; ASN-528; ASN-542;
RP   ASN-1007 AND ASN-1244.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [48]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2384, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [49]
RP   INTERACTION WITH FST3.
RX   PubMed=16336961; DOI=10.1016/j.yexcr.2005.11.006;
RA   Maguer-Satta V., Forissier S., Bartholin L., Martel S., Jeanpierre S.,
RA   Bachelard E., Rimokh R.;
RT   "A novel role for fibronectin type I domain in the regulation of human
RT   hematopoietic cell adhesiveness through binding to follistatin domains
RT   of FLRG and follistatin.";
RL   Exp. Cell Res. 312:434-442(2006).
RN   [50]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2384, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=18318008; DOI=10.1002/pmic.200700884;
RA   Han G., Ye M., Zhou H., Jiang X., Feng S., Jiang X., Tian R., Wan D.,
RA   Zou H., Gu J.;
RT   "Large-scale phosphoproteome analysis of human liver tissue by
RT   enrichment and fractionation of phosphopeptides with strong anion
RT   exchange chromatography.";
RL   Proteomics 8:1346-1361(2008).
RN   [51]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-528 AND ASN-1007.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [52]
RP   GLYCOSYLATION AT ASN-528; ASN-542 AND ASN-1007.
RX   PubMed=19139490; DOI=10.1074/mcp.M800504-MCP200;
RA   Jia W., Lu Z., Fu Y., Wang H.P., Wang L.H., Chi H., Yuan Z.F.,
RA   Zheng Z.B., Song L.N., Han H.H., Liang Y.M., Wang J.L., Cai Y.,
RA   Zhang Y.K., Deng Y.L., Ying W.T., He S.M., Qian X.H.;
RT   "A strategy for precise and large scale identification of core
RT   fucosylated glycoproteins.";
RL   Mol. Cell. Proteomics 8:913-923(2009).
RN   [53]
RP   FUNCTION OF ANASTELLIN, AND MUTAGENESIS OF LEU-663 AND TYR-666.
RX   PubMed=19379667; DOI=10.1016/j.matbio.2009.01.003;
RA   You R., Klein R.M., Zheng M., McKeown-Longo P.J.;
RT   "Regulation of p38 MAP kinase by anastellin is independent of
RT   anastellin's effect on matrix fibronectin.";
RL   Matrix Biol. 28:101-109(2009).
RN   [54]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22905912; DOI=10.1021/pr300539b;
RA   Rosenow A., Noben J.P., Jocken J., Kallendrusch S.,
RA   Fischer-Posovszky P., Mariman E.C., Renes J.;
RT   "Resveratrol-induced changes of the human adipocyte secretion
RT   profile.";
RL   J. Proteome Res. 11:4733-4743(2012).
RN   [55]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-2363 AND SER-2384, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [56]
RP   PHOSPHORYLATION AT SER-2384.
RX   PubMed=26091039; DOI=10.1016/j.cell.2015.05.028;
RA   Tagliabracci V.S., Wiley S.E., Guo X., Kinch L.N., Durrant E., Wen J.,
RA   Xiao J., Cui J., Nguyen K.B., Engel J.L., Coon J.J., Grishin N.,
RA   Pinna L.A., Pagliarini D.J., Dixon J.E.;
RT   "A single kinase generates the majority of the secreted
RT   phosphoproteome.";
RL   Cell 161:1619-1632(2015).
RN   [57]
RP   STRUCTURE BY NMR OF 1447-1540.
RX   PubMed=1311202; DOI=10.1021/bi00122a025;
RA   Baron M., Main A.L., Driscoll P.C., Mardon H.J., Boyd J.,
RA   Campbell I.D.;
RT   "1H NMR assignment and secondary structure of the cell adhesion type
RT   III module of fibronectin.";
RL   Biochemistry 31:2068-2073(1992).
RN   [58]
RP   STRUCTURE BY NMR OF 1447-1540.
RX   PubMed=1423622; DOI=10.1016/0092-8674(92)90600-H;
RA   Main A.L., Harvey T.S., Baron M., Boyd J., Campbell I.D.;
RT   "The three-dimensional structure of the tenth type III module of
RT   fibronectin: an insight into RGD-mediated interactions.";
RL   Cell 71:671-678(1992).
RN   [59]
RP   STRUCTURE BY NMR OF 183-275, AND DISULFIDE BONDS.
RX   PubMed=8308892; DOI=10.1006/jmbi.1994.1083;
RA   Williams M.J., Phan I., Harvey T.S., Rostagno A., Gold L.I.,
RA   Campbell I.D.;
RT   "Solution structure of a pair of fibronectin type 1 modules with
RT   fibrin binding activity.";
RL   J. Mol. Biol. 235:1302-1311(1994).
RN   [60]
RP   STRUCTURE BY NMR OF 32-92.
RX   PubMed=7583666; DOI=10.1038/nsb1195-946;
RA   Potts J.R., Phan I., Williams M.J., Campbell I.D.;
RT   "High-resolution structural studies of the factor XIIIa crosslinking
RT   site and the first type 1 module of fibronectin.";
RL   Nat. Struct. Biol. 2:946-950(1995).
RN   [61]
RP   STRUCTURE BY NMR OF 406-464.
RX   PubMed=9514732; DOI=10.1006/jmbi.1997.1528;
RA   Sticht H., Pickford A.R., Potts J.R., Campbell I.D.;
RT   "Solution structure of the glycosylated second type 2 module of
RT   fibronectin.";
RL   J. Mol. Biol. 276:177-187(1998).
RN   [62]
RP   STRUCTURE BY NMR OF EXTRA ED-B DOMAIN FROM ISOFORM 7.
RX   PubMed=10196121; DOI=10.1016/S0969-2126(99)80051-3;
RA   Fattorusso R., Pellecchia M., Viti F., Neri P., Neri D., Wuethrich K.;
RT   "NMR structure of the human oncofoetal fibronectin ED-B domain, a
RT   specific marker for angiogenesis.";
RL   Structure 7:381-390(1999).
RN   [63]
RP   STRUCTURE BY NMR OF 305-405.
RX   PubMed=10647176; DOI=10.1016/S0969-2126(00)88336-7;
RA   Bocquier A.A., Potts J.R., Pickford A.R., Campbell I.D.;
RT   "Solution structure of a pair of modules from the gelatin-binding
RT   domain of fibronectin.";
RL   Structure 7:1451-1460(1999).
RN   [64]
RP   STRUCTURE BY NMR OF 305-464, AND GLYCOSYLATION AT ASN-430.
RX   PubMed=11285216; DOI=10.1093/emboj/20.7.1519;
RA   Pickford A.R., Smith S.P., Staunton D., Boyd J., Campbell I.D.;
RT   "The hairpin structure of the (6)F1(1)F2(2)F2 fragment from human
RT   fibronectin enhances gelatin binding.";
RL   EMBO J. 20:1519-1529(2001).
RN   [65]
RP   STRUCTURE BY NMR OF 1631-1724.
RX   PubMed=11775745; DOI=10.1023/A:1012947209393;
RA   Niimi T., Osawa M., Yamaji N., Yasunaga K., Sakashita H., Mase T.,
RA   Tanaka A., Fujita S.;
RT   "NMR structure of human fibronectin EDA.";
RL   J. Biomol. NMR 21:281-284(2001).
RN   [66]
RP   STRUCTURE BY NMR OF 631-705, AND MUTAGENESIS OF TYR-641; ILE-642;
RP   LEU-663; TYR-666; LEU-681; ILE-682; SER-683; ILE-684; GLU-691;
RP   VAL-692; ARG-694; PHE-695; ASP-696 AND PHE-697.
RX   PubMed=12946358; DOI=10.1016/S0022-2836(03)00890-8;
RA   Briknarova K., Aakerman M.E., Hoyt D.W., Ruoslahti E., Ely K.R.;
RT   "Anastellin, an FN3 fragment with fibronectin polymerization activity,
RT   resembles amyloid fibril precursors.";
RL   J. Mol. Biol. 332:205-215(2003).
RN   [67]
RP   STRUCTURE BY NMR OF 48-140 IN COMPLEX WITH A BACTERIAL
RP   FIBRONECTIN-BINDING PROTEIN.
RX   PubMed=12736686; DOI=10.1038/nature01589;
RA   Schwarz-Linek U., Werner J.M., Pickford A.R., Gurusiddappa S.,
RA   Kim J.H., Pilka E.S., Briggs J.A., Gough T.S., Hoeoek M.,
RA   Campbell I.D., Potts J.R.;
RT   "Pathogenic bacteria attach to human fibronectin through a tandem
RT   beta-zipper.";
RL   Nature 423:177-181(2003).
RN   [68]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 1447-1535.
RX   PubMed=8120888; DOI=10.1016/0022-2836(94)90013-2;
RA   Dickinson C.D., Veerapandian B., Dai X.-P., Hamlin R.C., Xuong N.-H.,
RA   Ruoslahti E., Ely K.R.;
RT   "Crystal structure of the tenth type III cell adhesion module of human
RT   fibronectin.";
RL   J. Mol. Biol. 236:1079-1092(1994).
RN   [69]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 1173-1540.
RX   PubMed=8548820; DOI=10.1016/S0092-8674(00)81002-8;
RA   Leahy D.J., Aukhil I., Erickson H.P.;
RT   "2.0 A crystal structure of a four-domain segment of human fibronectin
RT   encompassing the RGD loop and synergy region.";
RL   Cell 84:155-164(1996).
RN   [70]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 1721-1991.
RX   PubMed=10075919; DOI=10.1093/emboj/18.6.1468;
RA   Sharma A., Askari J.A., Humphries M.J., Jones E.Y., Stuart D.I.;
RT   "Crystal structure of a heparin- and integrin-binding segment of human
RT   fibronectin.";
RL   EMBO J. 18:1468-1479(1999).
RN   [71]
RP   STRUCTURE BY NMR OF 608-701.
RX   PubMed=14657397; DOI=10.1073/pnas.2334390100;
RA   Gao M., Craig D., Lequin O., Campbell I.D., Vogel V., Schulten K.;
RT   "Structure and functional significance of mechanically unfolded
RT   fibronectin type III1 intermediates.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:14784-14789(2003).
RN   [72]
RP   STRUCTURE BY NMR OF 609-809.
RX   PubMed=17464288; DOI=10.1038/sj.emboj.7601694;
RA   Vakonakis I., Staunton D., Rooney L.M., Campbell I.D.;
RT   "Interdomain association in fibronectin: insight into cryptic sites
RT   and fibrillogenesis.";
RL   EMBO J. 26:2575-2583(2007).
RN   [73]
RP   STRUCTURE BY NMR OF 93-182, X-RAY CRYSTALLOGRAPHY (1.2 ANGSTROMS) OF
RP   93-182, AND DISULFIDE BONDS.
RX   PubMed=17368672; DOI=10.1016/j.jmb.2007.02.061;
RA   Rudino-Pinera E., Ravelli R.B., Sheldrick G.M., Nanao M.H.,
RA   Korostelev V.V., Werner J.M., Schwarz-Linek U., Potts J.R.,
RA   Garman E.F.;
RT   "The solution and crystal structures of a module pair from the
RT   Staphylococcus aureus-binding site of human fibronectin -- a tale with
RT   a twist.";
RL   J. Mol. Biol. 368:833-844(2007).
RN   [74]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 93-275 IN COMPLEX WITH
RP   STAPHYLOCOCCUS AUREUS FNBA.
RX   PubMed=18713862; DOI=10.1073/pnas.0803556105;
RA   Bingham R.J., Rudino-Pinera E., Meenan N.A.G., Schwarz-Linek U.,
RA   Turkenburg J.P., Hoeoek M., Garman E.F., Potts J.R.;
RT   "Crystal structures of fibronectin-binding sites from Staphylococcus
RT   aureus FnBPA in complex with fibronectin domains.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:12254-12258(2008).
RN   [75]
RP   STRUCTURE BY NMR OF 2239-2299.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the 11th FN1 domain from human fibronectin 1.";
RL   Submitted (MAR-2008) to the PDB data bank.
RN   [76]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 516-608 IN COMPLEX WITH TYPE
RP   I COLLAGEN.
RX   PubMed=19251642; DOI=10.1073/pnas.0812516106;
RA   Erat M.C., Slatter D.A., Lowe E.D., Millard C.J., Farndale R.W.,
RA   Campbell I.D., Vakonakis I.;
RT   "Identification and structural analysis of type I collagen sites in
RT   complex with fibronectin fragments.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:4195-4200(2009).
RN   [77]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASN-940; PRO-1120 AND ASN-2380.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [78]
RP   VARIANTS GFND2 CYS-973; ARG-1834 AND ARG-1883, VARIANTS LEU-15 AND
RP   VAL-1960, AND CHARACTERIZATION OF VARIANTS GFND2 ARG-1834 AND
RP   ARG-1883.
RX   PubMed=18268355; DOI=10.1073/pnas.0707730105;
RA   Castelletti F., Donadelli R., Banterla F., Hildebrandt F.,
RA   Zipfel P.F., Bresin E., Otto E., Skerka C., Renieri A., Todeschini M.,
RA   Caprioli J., Caruso R.M., Artuso R., Remuzzi G., Noris M.;
RT   "Mutations in FN1 cause glomerulopathy with fibronectin deposits.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:2538-2543(2008).
RN   [79]
RP   VARIANT [LARGE SCALE ANALYSIS] ILE-2170, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
CC   -!- FUNCTION: Fibronectins bind cell surfaces and various compounds
CC       including collagen, fibrin, heparin, DNA, and actin. Fibronectins
CC       are involved in cell adhesion, cell motility, opsonization, wound
CC       healing, and maintenance of cell shape. Involved in osteoblast
CC       compaction through the fibronectin fibrillogenesis cell-mediated
CC       matrix assembly process, essential for osteoblast mineralization.
CC       Participates in the regulation of type I collagen deposition by
CC       osteoblasts.
CC   -!- FUNCTION: Anastellin binds fibronectin and induces fibril
CC       formation. This fibronectin polymer, named superfibronectin,
CC       exhibits enhanced adhesive properties. Both anastellin and
CC       superfibronectin inhibit tumor growth, angiogenesis and
CC       metastasis. Anastellin activates p38 MAPK and inhibits
CC       lysophospholipid signaling.
CC   -!- SUBUNIT: Mostly heterodimers or multimers of alternatively spliced
CC       variants, connected by 2 disulfide bonds near the carboxyl ends;
CC       to a lesser extent homodimers. Interacts with FBLN1, AMBP, TNR,
CC       LGALS3BP and COL13A1. Interacts with FBLN7 (By similarity).
CC       Interacts with COMP. Interacts with S.aureus fnbA. Interacts with
CC       TNR; the interaction inhibits cell adhesion and neurite outgrowth
CC       (By similarity). Interacts with FST3 and MYOC. {ECO:0000250,
CC       ECO:0000269|PubMed:11773026, ECO:0000269|PubMed:11956183,
CC       ECO:0000269|PubMed:12225811, ECO:0000269|PubMed:12736686,
CC       ECO:0000269|PubMed:1400330, ECO:0000269|PubMed:16336961,
CC       ECO:0000269|PubMed:18713862, ECO:0000269|PubMed:19251642,
CC       ECO:0000269|PubMed:8114919, ECO:0000269|PubMed:9501082}.
CC   -!- INTERACTION:
CC       Q99IB8:- (xeno); NbExp=3; IntAct=EBI-1220319, EBI-6927928;
CC       P29279:CTGF; NbExp=5; IntAct=EBI-1220319, EBI-2835375;
CC       P35555:FBN1; NbExp=2; IntAct=EBI-1220319, EBI-2505934;
CC       P35556:FBN2; NbExp=2; IntAct=EBI-1220319, EBI-6164392;
CC       P14738:fnbA (xeno); NbExp=18; IntAct=EBI-1220319, EBI-8398157;
CC       Q53682:fnbB (xeno); NbExp=19; IntAct=EBI-1220319, EBI-8398005;
CC       Q93ED6:fne (xeno); NbExp=8; IntAct=EBI-1220319, EBI-9826140;
CC       P06241:FYN; NbExp=2; IntAct=EBI-7133890, EBI-515315;
CC       P08519:LPA; NbExp=2; IntAct=EBI-1220319, EBI-9232288;
CC       P11684:SCGB1A1; NbExp=3; IntAct=EBI-1220319, EBI-7797649;
CC       P21980:TGM2; NbExp=3; IntAct=EBI-1220319, EBI-727668;
CC       Q9UMX0:UBQLN1; NbExp=3; IntAct=EBI-1220319, EBI-741480;
CC       P40337:VHL; NbExp=2; IntAct=EBI-1220319, EBI-301246;
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular
CC       matrix.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=17;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=1;
CC         IsoId=P02751-1; Sequence=Displayed;
CC       Name=2; Synonyms=MSF-FN70, Migration stimulation factor FN70;
CC         IsoId=P02751-2; Sequence=VSP_003255, VSP_003256, VSP_003257;
CC       Name=3; Synonyms=V89;
CC         IsoId=P02751-3; Sequence=VSP_008110;
CC       Name=4; Synonyms=Fibronectin III-15X;
CC         IsoId=P02751-4; Sequence=VSP_008107, VSP_008111, VSP_008112;
CC       Name=5; Synonyms=Fibronectin (V+I-10)-;
CC         IsoId=P02751-5; Sequence=VSP_008107, VSP_008113;
CC       Name=6; Synonyms=Fibronectin (V+III-15)-;
CC         IsoId=P02751-6; Sequence=VSP_008109;
CC       Name=7; Synonyms=Fibronectin containing extra ED-B domain;
CC         IsoId=P02751-7; Sequence=VSP_008104, VSP_008110;
CC       Name=8; Synonyms=Fibronectin not containing EIIIA domain;
CC         IsoId=P02751-8; Sequence=VSP_008106;
CC       Name=9; Synonyms=Fibronectin not containing EIIIA and EIIIB and
CC       uses V64 variant of IIICS region;
CC         IsoId=P02751-9; Sequence=VSP_008106, VSP_008108, VSP_008110;
CC       Name=10;
CC         IsoId=P02751-10; Sequence=VSP_008106, VSP_008107;
CC       Name=11; Synonyms=Fibronectin containing extra type III repeat
CC       (EDII), exon x+2;
CC         IsoId=P02751-11; Sequence=VSP_008105;
CC       Name=12;
CC         IsoId=P02751-12; Sequence=VSP_013681, VSP_008106, VSP_008108,
CC                                   VSP_008110;
CC       Name=13;
CC         IsoId=P02751-13; Sequence=VSP_008104, VSP_008106, VSP_008107;
CC         Note=No experimental confirmation available.;
CC       Name=14;
CC         IsoId=P02751-14; Sequence=VSP_008106, VSP_008110;
CC       Name=15;
CC         IsoId=P02751-15; Sequence=VSP_008104;
CC         Note=No experimental confirmation available.;
CC       Name=16; Synonyms=Migration stimulation factor, MSF;
CC         IsoId=P02751-16; Sequence=VSP_003256, VSP_003257;
CC         Note=Expressed by fetal and tumor-associated cells.;
CC       Name=17;
CC         IsoId=P02751-17; Sequence=VSP_047310, VSP_047311;
CC         Note=Gene prediction based on EST data.;
CC   -!- TISSUE SPECIFICITY: Plasma FN (soluble dimeric form) is secreted
CC       by hepatocytes. Cellular FN (dimeric or cross-linked multimeric
CC       forms), made by fibroblasts, epithelial and other cell types, is
CC       deposited as fibrils in the extracellular matrix. Ugl-Y1, Ugl-Y2
CC       and Ugl-Y3 are found in urine. {ECO:0000269|PubMed:17614963,
CC       ECO:0000269|PubMed:3584091}.
CC   -!- DEVELOPMENTAL STAGE: Ugl-Y1, Ugl-Y2 and Ugl-Y3 are present in the
CC       urine from 0 to 17 years of age. {ECO:0000269|PubMed:17614963,
CC       ECO:0000269|PubMed:3584091}.
CC   -!- PTM: Sulfated. {ECO:0000269|PubMed:2414772}.
CC   -!- PTM: It is not known whether both or only one of Thr-2064 and Thr-
CC       2065 are/is glycosylated. {ECO:0000269|PubMed:11285216,
CC       ECO:0000269|PubMed:14760718, ECO:0000269|PubMed:16037490,
CC       ECO:0000269|PubMed:16335952, ECO:0000269|PubMed:17614963,
CC       ECO:0000269|PubMed:19139490, ECO:0000269|PubMed:19159218,
CC       ECO:0000269|PubMed:2012601, ECO:0000269|PubMed:3584091}.
CC   -!- PTM: Forms covalent cross-links mediated by a transglutaminase,
CC       such as F13A or TGM2, between a glutamine and the epsilon-amino
CC       group of a lysine residue, forming homopolymers and heteropolymers
CC       (e.g. fibrinogen-fibronectin, collagen-fibronectin
CC       heteropolymers).
CC   -!- PTM: Phosphorylated by FAM20C in the extracellular medium.
CC       {ECO:0000269|PubMed:26091039}.
CC   -!- PTM: Proteolytic processing produces the C-terminal NC1 peptide,
CC       anastellin.
CC   -!- DISEASE: Glomerulopathy with fibronectin deposits 2 (GFND2)
CC       [MIM:601894]: Genetically heterogeneous autosomal dominant
CC       disorder characterized clinically by proteinuria, microscopic
CC       hematuria, and hypertension that leads to end-stage renal failure
CC       in the second to fifth decade of life.
CC       {ECO:0000269|PubMed:18268355}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Contains 12 fibronectin type-I domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00478}.
CC   -!- SIMILARITY: Contains 2 fibronectin type-II domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00479}.
CC   -!- SIMILARITY: Contains 16 fibronectin type-III domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00316}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAX76513.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=BAD93077.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC       Sequence=CAD91166.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC       Sequence=CAD97964.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC       Sequence=CAD97965.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC       Sequence=CAD97984.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC       Sequence=CAH18136.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Fibronectin entry;
CC       URL="https://en.wikipedia.org/wiki/Fibronectin";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AJ276395; CAC20427.1; -; mRNA.
DR   EMBL; AJ535086; CAD59389.1; -; mRNA.
DR   EMBL; AJ849445; CAH60958.1; -; mRNA.
DR   EMBL; AB191261; BAD52437.1; -; mRNA.
DR   EMBL; AB209840; BAD93077.1; ALT_INIT; mRNA.
DR   EMBL; AL832202; CAD91166.1; ALT_INIT; mRNA.
DR   EMBL; BX537590; CAD97791.1; -; mRNA.
DR   EMBL; BX538017; CAD97964.1; ALT_INIT; mRNA.
DR   EMBL; BX538018; CAD97965.1; ALT_INIT; mRNA.
DR   EMBL; BX538045; CAD97984.1; ALT_INIT; mRNA.
DR   EMBL; BX640608; CAE45714.1; -; mRNA.
DR   EMBL; BX640731; CAE45847.1; -; mRNA.
DR   EMBL; BX640875; CAE45932.1; -; mRNA.
DR   EMBL; BX640920; CAE45958.1; -; mRNA.
DR   EMBL; CR749281; CAH18136.1; ALT_INIT; mRNA.
DR   EMBL; CR749316; CAH18171.1; -; mRNA.
DR   EMBL; CR749317; CAH18172.1; -; mRNA.
DR   EMBL; AC012462; AAX76513.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AC073284; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471063; EAW70536.1; -; Genomic_DNA.
DR   EMBL; BC117176; AAI17177.1; -; mRNA.
DR   EMBL; BC143763; AAI43764.1; -; mRNA.
DR   EMBL; M15801; AAA53376.1; -; Genomic_DNA.
DR   EMBL; AF312399; AAG30571.1; -; mRNA.
DR   EMBL; X02761; CAA26536.1; -; mRNA.
DR   EMBL; U41850; AAD00014.1; -; mRNA.
DR   EMBL; U42404; AAD00015.1; -; mRNA.
DR   EMBL; U42592; AAD00017.1; -; mRNA.
DR   EMBL; U42593; AAD00018.1; -; mRNA.
DR   EMBL; U42594; AAD00019.1; -; mRNA.
DR   EMBL; U42455; AAD09448.1; -; mRNA.
DR   EMBL; U42456; AAD09449.1; -; mRNA.
DR   EMBL; U42458; AAD09450.1; -; mRNA.
DR   EMBL; U42457; AAD04751.1; -; mRNA.
DR   EMBL; X07718; CAB52436.1; ALT_TERM; Genomic_DNA.
DR   EMBL; X07717; CAB52437.1; -; Genomic_DNA.
DR   EMBL; M18179; AAA52461.1; -; Genomic_DNA.
DR   EMBL; M18177; AAA52461.1; JOINED; Genomic_DNA.
DR   EMBL; M18178; AAA52461.1; JOINED; Genomic_DNA.
DR   EMBL; M12549; AAA58483.1; -; Genomic_DNA.
DR   EMBL; M10905; AAA52462.1; -; mRNA.
DR   EMBL; M14059; AAA52463.1; -; mRNA.
DR   EMBL; AJ320525; CAC86914.1; -; mRNA.
DR   EMBL; AJ320526; CAC86915.1; -; mRNA.
DR   EMBL; AJ320527; CAC86916.1; -; mRNA.
DR   EMBL; M27589; AAA52465.1; -; mRNA.
DR   EMBL; X04530; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS2399.1; -. [P02751-3]
DR   CCDS; CCDS2400.1; -. [P02751-10]
DR   CCDS; CCDS42813.1; -. [P02751-8]
DR   CCDS; CCDS42814.1; -. [P02751-15]
DR   CCDS; CCDS46510.1; -. [P02751-17]
DR   CCDS; CCDS46512.1; -. [P02751-16]
DR   CCDS; CCDS77522.1; -. [P02751-9]
DR   CCDS; CCDS77523.1; -. [P02751-14]
DR   CCDS; CCDS77525.1; -. [P02751-13]
DR   CCDS; CCDS77526.1; -. [P02751-7]
DR   PIR; A26460; FNHU.
DR   PIR; I52394; I52394.
DR   PIR; S00848; S00848.
DR   RefSeq; NP_001293058.1; NM_001306129.1.
DR   RefSeq; NP_001293059.1; NM_001306130.1.
DR   RefSeq; NP_001293060.1; NM_001306131.1.
DR   RefSeq; NP_001293061.1; NM_001306132.1.
DR   RefSeq; NP_002017.1; NM_002026.2.
DR   RefSeq; NP_473375.2; NM_054034.2. [P02751-16]
DR   RefSeq; NP_997639.1; NM_212474.1.
DR   RefSeq; NP_997641.1; NM_212476.1.
DR   RefSeq; NP_997643.1; NM_212478.1.
DR   RefSeq; NP_997647.1; NM_212482.1.
DR   RefSeq; XP_005246463.1; XM_005246406.1. [P02751-1]
DR   UniGene; Hs.203717; -.
DR   PDB; 1E88; NMR; -; A=305-464.
DR   PDB; 1E8B; NMR; -; A=305-464.
DR   PDB; 1FBR; NMR; -; A=183-275.
DR   PDB; 1FNA; X-ray; 1.80 A; A=1452-1542.
DR   PDB; 1FNF; X-ray; 2.00 A; A=1173-1540.
DR   PDB; 1FNH; X-ray; 2.80 A; A=1721-1991.
DR   PDB; 1J8K; NMR; -; A=1631-1724.
DR   PDB; 1O9A; NMR; -; A=48-140.
DR   PDB; 1OWW; NMR; -; A=608-701.
DR   PDB; 1Q38; NMR; -; A=631-705.
DR   PDB; 1QGB; NMR; -; A=48-140.
DR   PDB; 1QO6; NMR; -; A=305-405.
DR   PDB; 1TTF; NMR; -; A=1447-1540.
DR   PDB; 1TTG; NMR; -; A=1447-1540.
DR   PDB; 2CG6; X-ray; 1.55 A; A=93-182.
DR   PDB; 2CG7; X-ray; 1.20 A; A=93-182.
DR   PDB; 2CK2; X-ray; 2.00 A; A/B=1447-1542.
DR   PDB; 2CKU; NMR; -; A=93-182.
DR   PDB; 2EC3; NMR; -; A=2239-2299.
DR   PDB; 2FN2; NMR; -; A=406-464.
DR   PDB; 2FNB; NMR; -; A=1265-1355.
DR   PDB; 2GEE; X-ray; 2.01 A; A=1205-1356.
DR   PDB; 2H41; NMR; -; A=721-809.
DR   PDB; 2H45; NMR; -; A=721-809.
DR   PDB; 2HA1; NMR; -; A=609-809.
DR   PDB; 2N1K; NMR; -; A=808-905.
DR   PDB; 2OCF; X-ray; 2.95 A; D=1447-1540.
DR   PDB; 2RKY; X-ray; 1.80 A; A/C=183-275.
DR   PDB; 2RKZ; X-ray; 2.00 A; A/B/C/D/E/F=93-182.
DR   PDB; 2RL0; X-ray; 2.00 A; A/B/D/F/I/K=184-272.
DR   PDB; 3CAL; X-ray; 1.70 A; A/C=93-182.
DR   PDB; 3EJH; X-ray; 2.10 A; A/B=516-608.
DR   PDB; 3GXE; X-ray; 2.60 A; A/B=516-608.
DR   PDB; 3M7P; X-ray; 2.50 A; A=297-604.
DR   PDB; 3MQL; X-ray; 3.00 A; A=308-515.
DR   PDB; 3R8Q; X-ray; 2.40 A; A=1721-1991.
DR   PDB; 3T1W; X-ray; 2.40 A; A=1173-1448.
DR   PDB; 3ZRZ; X-ray; 1.70 A; A/B=93-182.
DR   PDB; 4GH7; X-ray; 2.60 A; B/D=1173-1427.
DR   PDB; 4JE4; X-ray; 2.31 A; B=1450-1540.
DR   PDB; 4JEG; X-ray; 2.30 A; B=1450-1540.
DR   PDB; 4LXO; X-ray; 1.42 A; A/B=1357-1540.
DR   PDB; 4MMX; X-ray; 3.32 A; C=1448-1540.
DR   PDB; 4MMY; X-ray; 3.18 A; C=1448-1540.
DR   PDB; 4MMZ; X-ray; 3.10 A; C=1448-1540.
DR   PDB; 4PZ5; X-ray; 1.96 A; A=93-182.
DR   PDBsum; 1E88; -.
DR   PDBsum; 1E8B; -.
DR   PDBsum; 1FBR; -.
DR   PDBsum; 1FNA; -.
DR   PDBsum; 1FNF; -.
DR   PDBsum; 1FNH; -.
DR   PDBsum; 1J8K; -.
DR   PDBsum; 1O9A; -.
DR   PDBsum; 1OWW; -.
DR   PDBsum; 1Q38; -.
DR   PDBsum; 1QGB; -.
DR   PDBsum; 1QO6; -.
DR   PDBsum; 1TTF; -.
DR   PDBsum; 1TTG; -.
DR   PDBsum; 2CG6; -.
DR   PDBsum; 2CG7; -.
DR   PDBsum; 2CK2; -.
DR   PDBsum; 2CKU; -.
DR   PDBsum; 2EC3; -.
DR   PDBsum; 2FN2; -.
DR   PDBsum; 2FNB; -.
DR   PDBsum; 2GEE; -.
DR   PDBsum; 2H41; -.
DR   PDBsum; 2H45; -.
DR   PDBsum; 2HA1; -.
DR   PDBsum; 2N1K; -.
DR   PDBsum; 2OCF; -.
DR   PDBsum; 2RKY; -.
DR   PDBsum; 2RKZ; -.
DR   PDBsum; 2RL0; -.
DR   PDBsum; 3CAL; -.
DR   PDBsum; 3EJH; -.
DR   PDBsum; 3GXE; -.
DR   PDBsum; 3M7P; -.
DR   PDBsum; 3MQL; -.
DR   PDBsum; 3R8Q; -.
DR   PDBsum; 3T1W; -.
DR   PDBsum; 3ZRZ; -.
DR   PDBsum; 4GH7; -.
DR   PDBsum; 4JE4; -.
DR   PDBsum; 4JEG; -.
DR   PDBsum; 4LXO; -.
DR   PDBsum; 4MMX; -.
DR   PDBsum; 4MMY; -.
DR   PDBsum; 4MMZ; -.
DR   PDBsum; 4PZ5; -.
DR   ProteinModelPortal; P02751; -.
DR   SMR; P02751; 48-274, 297-606, 609-809, 1173-1540, 1631-1991, 2242-2299.
DR   BioGrid; 108621; 731.
DR   DIP; DIP-29547N; -.
DR   IntAct; P02751; 460.
DR   MINT; MINT-1779779; -.
DR   BindingDB; P02751; -.
DR   ChEMBL; CHEMBL3810; -.
DR   DrugBank; DB08888; Ocriplasmin.
DR   iPTMnet; P02751; -.
DR   PhosphoSite; P02751; -.
DR   UniCarbKB; P02751; -.
DR   BioMuta; FN1; -.
DR   DMDM; 300669710; -.
DR   DOSAC-COBS-2DPAGE; P02751; -.
DR   MaxQB; P02751; -.
DR   PRIDE; P02751; -.
DR   DNASU; 2335; -.
DR   Ensembl; ENST00000323926; ENSP00000323534; ENSG00000115414. [P02751-7]
DR   Ensembl; ENST00000336916; ENSP00000338200; ENSG00000115414. [P02751-3]
DR   Ensembl; ENST00000354785; ENSP00000346839; ENSG00000115414. [P02751-15]
DR   Ensembl; ENST00000356005; ENSP00000348285; ENSG00000115414. [P02751-8]
DR   Ensembl; ENST00000357867; ENSP00000350534; ENSG00000115414. [P02751-10]
DR   Ensembl; ENST00000359671; ENSP00000352696; ENSG00000115414. [P02751-1]
DR   Ensembl; ENST00000421182; ENSP00000394423; ENSG00000115414. [P02751-9]
DR   Ensembl; ENST00000426059; ENSP00000398907; ENSG00000115414. [P02751-16]
DR   Ensembl; ENST00000432072; ENSP00000399538; ENSG00000115414. [P02751-13]
DR   Ensembl; ENST00000443816; ENSP00000415018; ENSG00000115414. [P02751-14]
DR   Ensembl; ENST00000446046; ENSP00000410422; ENSG00000115414. [P02751-17]
DR   GeneID; 2335; -.
DR   KEGG; hsa:2335; -.
DR   UCSC; uc002vfa.3; human. [P02751-15]
DR   UCSC; uc002vfb.3; human. [P02751-14]
DR   UCSC; uc002vfc.3; human. [P02751-9]
DR   UCSC; uc002vfe.3; human. [P02751-3]
DR   UCSC; uc002vfg.3; human. [P02751-8]
DR   UCSC; uc002vfh.3; human.
DR   UCSC; uc002vfi.3; human. [P02751-7]
DR   UCSC; uc002vfj.3; human. [P02751-13]
DR   CTD; 2335; -.
DR   GeneCards; FN1; -.
DR   HGNC; HGNC:3778; FN1.
DR   HPA; CAB000126; -.
DR   HPA; HPA027066; -.
DR   MalaCards; FN1; -.
DR   MIM; 135600; gene.
DR   MIM; 601894; phenotype.
DR   neXtProt; NX_P02751; -.
DR   Orphanet; 84090; Fibronectin glomerulopathy.
DR   PharmGKB; PA28194; -.
DR   GeneTree; ENSGT00830000128240; -.
DR   HOGENOM; HOG000234344; -.
DR   HOVERGEN; HBG005731; -.
DR   InParanoid; P02751; -.
DR   KO; K05717; -.
DR   OMA; VTLPHPN; -.
DR   OrthoDB; EOG7X9G60; -.
DR   PhylomeDB; P02751; -.
DR   TreeFam; TF329915; -.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   Reactome; R-HSA-1474228; Degradation of the extracellular matrix.
DR   Reactome; R-HSA-1474244; Extracellular matrix organization.
DR   Reactome; R-HSA-1566977; Fibronectin matrix formation.
DR   Reactome; R-HSA-202733; Cell surface interactions at the vascular wall.
DR   Reactome; R-HSA-2129379; Molecules associated with elastic fibres.
DR   Reactome; R-HSA-216083; Integrin cell surface interactions.
DR   Reactome; R-HSA-3000170; Syndecan interactions.
DR   Reactome; R-HSA-3000171; Non-integrin membrane-ECM interactions.
DR   Reactome; R-HSA-3000178; ECM proteoglycans.
DR   Reactome; R-HSA-354192; Integrin alphaIIb beta3 signaling.
DR   Reactome; R-HSA-354194; GRB2:SOS provides linkage to MAPK signaling for Integrins.
DR   Reactome; R-HSA-372708; p130Cas linkage to MAPK signaling for integrins.
DR   Reactome; R-HSA-5674135; MAP2K and MAPK activation.
DR   ChiTaRS; FN1; human.
DR   EvolutionaryTrace; P02751; -.
DR   GeneWiki; Fibronectin; -.
DR   GenomeRNAi; 2335; -.
DR   NextBio; 35481280; -.
DR   PRO; PR:P02751; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; P02751; -.
DR   ExpressionAtlas; P02751; baseline and differential.
DR   Genevisible; P02751; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:Ensembl.
DR   GO; GO:0005605; C:basal lamina; IEA:Ensembl.
DR   GO; GO:0072562; C:blood microparticle; IDA:UniProtKB.
DR   GO; GO:0005793; C:endoplasmic reticulum-Golgi intermediate compartment; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0031012; C:extracellular matrix; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; NAS:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0005577; C:fibrinogen complex; IDA:BHF-UCL.
DR   GO; GO:0031093; C:platelet alpha granule lumen; TAS:Reactome.
DR   GO; GO:0005518; F:collagen binding; NAS:UniProtKB.
DR   GO; GO:0008201; F:heparin binding; NAS:UniProtKB.
DR   GO; GO:0005178; F:integrin binding; IDA:UniProtKB.
DR   GO; GO:0045340; F:mercury ion binding; IEA:Ensembl.
DR   GO; GO:0016504; F:peptidase activator activity; IEA:Ensembl.
DR   GO; GO:0002020; F:protease binding; IPI:BHF-UCL.
DR   GO; GO:0006953; P:acute-phase response; IEA:UniProtKB-KW.
DR   GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0007161; P:calcium-independent cell-matrix adhesion; IEA:Ensembl.
DR   GO; GO:0007155; P:cell adhesion; NAS:UniProtKB.
DR   GO; GO:0007044; P:cell-substrate junction assembly; IEA:Ensembl.
DR   GO; GO:0071773; P:cellular response to BMP stimulus; IEA:Ensembl.
DR   GO; GO:0071333; P:cellular response to glucose stimulus; IEA:Ensembl.
DR   GO; GO:0071347; P:cellular response to interleukin-1; IEA:Ensembl.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0071288; P:cellular response to mercury ion; IEA:Ensembl.
DR   GO; GO:0036120; P:cellular response to platelet-derived growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0071380; P:cellular response to prostaglandin E stimulus; IEA:Ensembl.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IEA:Ensembl.
DR   GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0035987; P:endodermal cell differentiation; IDA:UniProtKB.
DR   GO; GO:0022617; P:extracellular matrix disassembly; TAS:Reactome.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0008347; P:glial cell migration; IEA:Ensembl.
DR   GO; GO:0033622; P:integrin activation; IMP:UniProtKB.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:2001202; P:negative regulation of transforming growth factor-beta secretion; IDA:UniProtKB.
DR   GO; GO:0018149; P:peptide cross-linking; IDA:BHF-UCL.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0002576; P:platelet degranulation; TAS:Reactome.
DR   GO; GO:0045773; P:positive regulation of axon extension; IEA:Ensembl.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:UniProtKB.
DR   GO; GO:0050921; P:positive regulation of chemotaxis; IEA:Ensembl.
DR   GO; GO:0048146; P:positive regulation of fibroblast proliferation; IDA:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; IDA:UniProtKB.
DR   GO; GO:1904237; P:positive regulation of substrate-dependent cell migration, cell attachment to substrate; IDA:UniProtKB.
DR   GO; GO:0008360; P:regulation of cell shape; IEA:UniProtKB-KW.
DR   GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0001932; P:regulation of protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0051384; P:response to glucocorticoid; IEA:Ensembl.
DR   GO; GO:0002931; P:response to ischemia; IEA:Ensembl.
DR   GO; GO:0010193; P:response to ozone; IEA:Ensembl.
DR   GO; GO:0009611; P:response to wounding; NAS:UniProtKB.
DR   GO; GO:0034446; P:substrate adhesion-dependent cell spreading; IMP:UniProtKB.
DR   Gene3D; 2.10.10.10; -; 2.
DR   Gene3D; 2.60.40.10; -; 16.
DR   InterPro; IPR000083; Fibronectin_type1.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR000562; FN_type2_col-bd.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013806; Kringle-like.
DR   Pfam; PF00039; fn1; 12.
DR   Pfam; PF00040; fn2; 2.
DR   Pfam; PF00041; fn3; 16.
DR   SMART; SM00058; FN1; 12.
DR   SMART; SM00059; FN2; 2.
DR   SMART; SM00060; FN3; 16.
DR   SUPFAM; SSF49265; SSF49265; 10.
DR   SUPFAM; SSF57440; SSF57440; 2.
DR   PROSITE; PS00022; EGF_1; 2.
DR   PROSITE; PS01253; FN1_1; 12.
DR   PROSITE; PS51091; FN1_2; 12.
DR   PROSITE; PS00023; FN2_1; 2.
DR   PROSITE; PS51092; FN2_2; 2.
DR   PROSITE; PS50853; FN3; 16.
PE   1: Evidence at protein level;
KW   3D-structure; Acute phase; Alternative splicing; Angiogenesis;
KW   Cell adhesion; Cell shape; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Disulfide bond;
KW   Extracellular matrix; Glycoprotein; Heparin-binding; Isopeptide bond;
KW   Phosphoprotein; Polymorphism; Pyrrolidone carboxylic acid;
KW   Reference proteome; Repeat; Secreted; Signal; Sulfation.
FT   SIGNAL        1     31       {ECO:0000269|PubMed:6630202}.
FT   CHAIN        32   2386       Fibronectin.
FT                                /FTId=PRO_0000019235.
FT   CHAIN       627    702       Anastellin.
FT                                /FTId=PRO_0000390479.
FT   CHAIN       723    911       Ugl-Y1.
FT                                /FTId=PRO_0000300249.
FT   CHAIN       723    903       Ugl-Y2.
FT                                /FTId=PRO_0000300250.
FT   CHAIN       723      ?       Ugl-Y3.
FT                                /FTId=PRO_0000300251.
FT   DOMAIN       50     90       Fibronectin type-I 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00478}.
FT   DOMAIN       95    138       Fibronectin type-I 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00478}.
FT   DOMAIN      139    182       Fibronectin type-I 3.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00478}.
FT   DOMAIN      184    228       Fibronectin type-I 4.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00478}.
FT   DOMAIN      229    273       Fibronectin type-I 5.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00478}.
FT   DOMAIN      306    345       Fibronectin type-I 6.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00478}.
FT   DOMAIN      355    403       Fibronectin type-II 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00478,
FT                                ECO:0000255|PROSITE-ProRule:PRU00479}.
FT   DOMAIN      415    463       Fibronectin type-II 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00478,
FT                                ECO:0000255|PROSITE-ProRule:PRU00479}.
FT   DOMAIN      468    511       Fibronectin type-I 7.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00478}.
FT   DOMAIN      516    558       Fibronectin type-I 8.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00478}.
FT   DOMAIN      559    602       Fibronectin type-I 9.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00478}.
FT   DOMAIN      610    702       Fibronectin type-III 1.
FT   DOMAIN      722    812       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316,
FT                                ECO:0000255|PROSITE-ProRule:PRU00478,
FT                                ECO:0000255|PROSITE-ProRule:PRU00479}.
FT   DOMAIN      813    904       Fibronectin type-III 3.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316,
FT                                ECO:0000255|PROSITE-ProRule:PRU00478,
FT                                ECO:0000255|PROSITE-ProRule:PRU00479}.
FT   DOMAIN      909    998       Fibronectin type-III 4.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316,
FT                                ECO:0000255|PROSITE-ProRule:PRU00478,
FT                                ECO:0000255|PROSITE-ProRule:PRU00479}.
FT   DOMAIN      999   1088       Fibronectin type-III 5.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316,
FT                                ECO:0000255|PROSITE-ProRule:PRU00478,
FT                                ECO:0000255|PROSITE-ProRule:PRU00479}.
FT   DOMAIN     1089   1175       Fibronectin type-III 6.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316,
FT                                ECO:0000255|PROSITE-ProRule:PRU00478,
FT                                ECO:0000255|PROSITE-ProRule:PRU00479}.
FT   DOMAIN     1176   1266       Fibronectin type-III 7.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316,
FT                                ECO:0000255|PROSITE-ProRule:PRU00478,
FT                                ECO:0000255|PROSITE-ProRule:PRU00479}.
FT   DOMAIN     1269   1361       Fibronectin type-III 8.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316,
FT                                ECO:0000255|PROSITE-ProRule:PRU00478,
FT                                ECO:0000255|PROSITE-ProRule:PRU00479}.
FT   DOMAIN     1362   1449       Fibronectin type-III 9.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316,
FT                                ECO:0000255|PROSITE-ProRule:PRU00478,
FT                                ECO:0000255|PROSITE-ProRule:PRU00479}.
FT   DOMAIN     1450   1543       Fibronectin type-III 10.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     1544   1635       Fibronectin type-III 11.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     1636   1723       Fibronectin type-III 12; extra domain.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316,
FT                                ECO:0000255|PROSITE-ProRule:PRU00478,
FT                                ECO:0000255|PROSITE-ProRule:PRU00479}.
FT   DOMAIN     1724   1817       Fibronectin type-III 13.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     1818   1904       Fibronectin type-III 14.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     1905   1995       Fibronectin type-III 15.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     2103   2197       Fibronectin type-III 16.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     2204   2248       Fibronectin type-I 10.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00478}.
FT   DOMAIN     2249   2291       Fibronectin type-I 11.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00478}.
FT   DOMAIN     2293   2336       Fibronectin type-I 12.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00478}.
FT   DNA_BIND    907   1172
FT   REGION       52    272       Fibrin- and heparin-binding 1.
FT   REGION      308    608       Collagen-binding.
FT   REGION      464    477       Critical for collagen binding.
FT   REGION     1267   1540       Cell-attachment.
FT   REGION     1721   1991       Heparin-binding 2.
FT   REGION     1813   1991       Binds to FBLN1.
FT   REGION     1992   2102       Connecting strand 3 (CS-3) (V region).
FT   REGION     2206   2337       Fibrin-binding 2.
FT   MOTIF      1524   1526       Cell attachment site.
FT   SITE        663    663       Important for superfibronectin formation.
FT   SITE        666    666       Important for superfibronectin formation.
FT   SITE       2108   2108       Not glycosylated.
FT   MOD_RES      32     32       Pyrrolidone carboxylic acid.
FT                                {ECO:0000269|PubMed:6630202}.
FT   MOD_RES     876    876       Sulfotyrosine. {ECO:0000255}.
FT   MOD_RES     881    881       Sulfotyrosine. {ECO:0000255}.
FT   MOD_RES    2363   2363       Phosphothreonine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES    2384   2384       Phosphoserine; by FAM20C.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:18318008,
FT                                ECO:0000244|PubMed:24275569,
FT                                ECO:0000269|PubMed:26091039}.
FT   CARBOHYD    279    279       O-linked (GalNAc...).
FT                                {ECO:0000269|PubMed:16037490}.
FT   CARBOHYD    430    430       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:11285216,
FT                                ECO:0000269|PubMed:16037490,
FT                                ECO:0000269|PubMed:16335952}.
FT   CARBOHYD    528    528       N-linked (GlcNAc...) (complex).
FT                                {ECO:0000269|PubMed:14760718,
FT                                ECO:0000269|PubMed:16037490,
FT                                ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19139490,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    542    542       N-linked (GlcNAc...) (complex).
FT                                {ECO:0000269|PubMed:16037490,
FT                                ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19139490}.
FT   CARBOHYD    877    877       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16037490,
FT                                ECO:0000269|PubMed:17614963}.
FT   CARBOHYD   1007   1007       N-linked (GlcNAc...) (complex).
FT                                {ECO:0000269|PubMed:16037490,
FT                                ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19139490,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   1244   1244       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16037490,
FT                                ECO:0000269|PubMed:16335952}.
FT   CARBOHYD   2064   2064       O-linked (GalNAc...).
FT                                {ECO:0000269|PubMed:2012601}.
FT   CARBOHYD   2065   2065       O-linked (GalNAc...).
FT                                {ECO:0000269|PubMed:2012601}.
FT   CARBOHYD   2108   2108       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16037490}.
FT   DISULFID     52     78
FT   DISULFID     76     87
FT   DISULFID     97    125
FT   DISULFID    123    135
FT   DISULFID    141    169
FT   DISULFID    167    179
FT   DISULFID    186    215
FT   DISULFID    213    225
FT   DISULFID    231    260
FT   DISULFID    258    270
FT   DISULFID    308    335
FT   DISULFID    333    342
FT   DISULFID    360    386
FT   DISULFID    374    401
FT   DISULFID    420    446
FT   DISULFID    434    461
FT   DISULFID    470    498       {ECO:0000250}.
FT   DISULFID    496    508       {ECO:0000250}.
FT   DISULFID    518    545       {ECO:0000250}.
FT   DISULFID    543    555       {ECO:0000250}.
FT   DISULFID    561    589       {ECO:0000250}.
FT   DISULFID    587    599       {ECO:0000250}.
FT   DISULFID   2206   2235       {ECO:0000250}.
FT   DISULFID   2233   2245       {ECO:0000250}.
FT   DISULFID   2251   2278       {ECO:0000250}.
FT   DISULFID   2276   2288       {ECO:0000250}.
FT   DISULFID   2295   2319       {ECO:0000250}.
FT   DISULFID   2317   2333       {ECO:0000250}.
FT   DISULFID   2367   2367       Interchain (with C-2371).
FT   DISULFID   2371   2371       Interchain (with C-2367).
FT   CROSSLNK     34     34       Isoglutamyl lysine isopeptide (Gln-Lys)
FT                                (interchain with K-?). {ECO:0000250}.
FT   CROSSLNK     35     35       Isoglutamyl lysine isopeptide (Gln-Lys)
FT                                (interchain with K-?). {ECO:0000250}.
FT   CROSSLNK     47     47       Isoglutamyl lysine isopeptide (Gln-Lys)
FT                                (interchain with K-?). {ECO:0000250}.
FT   VAR_SEQ     368    388       GRTFYSCTTEGRQDGHLWCST -> DRTDST (in
FT                                isoform 2).
FT                                {ECO:0000303|PubMed:11737888}.
FT                                /FTId=VSP_003255.
FT   VAR_SEQ     648    657       KNSVGRWKEA -> VSIPPRNLGY (in isoform 2
FT                                and isoform 16).
FT                                {ECO:0000303|PubMed:11737888,
FT                                ECO:0000303|PubMed:16322219,
FT                                ECO:0000303|PubMed:17974005}.
FT                                /FTId=VSP_003256.
FT   VAR_SEQ     658   2386       Missing (in isoform 2 and isoform 16).
FT                                {ECO:0000303|PubMed:11737888,
FT                                ECO:0000303|PubMed:16322219,
FT                                ECO:0000303|PubMed:17974005}.
FT                                /FTId=VSP_003257.
FT   VAR_SEQ    1256   1487       Missing (in isoform 12).
FT                                {ECO:0000303|Ref.13}.
FT                                /FTId=VSP_013681.
FT   VAR_SEQ    1265   1265       P -> PEVPQLTDLSFVDITDSSIGLRWTPLNSSTIIGYRI
FT                                TVVAAGEGIPIFEDFVDSSVGYYTVTGLEPGIDYDISVITL
FT                                INGGESAPTTLTQQT (in isoform 7, isoform 13
FT                                and isoform 15).
FT                                {ECO:0000303|PubMed:17974005}.
FT                                /FTId=VSP_008104.
FT   VAR_SEQ    1266   1365       AVPPPTDLRFTNIGPDTMRVTWAPPPSIDLTNFLVRYSPVK
FT                                NEEDVAELSISPSDNAVVLTNLLPGTEYVVSVSSVYEQHES
FT                                TPLRGRQKTGLDSPTGID -> EVPQLTDLSFVDITDSSIG
FT                                LRWTPLNSSTIIGYRITVVAAGEGIPIFEDFVDSSVGYYTV
FT                                TGLEPGIDYDISVITLINGGESAPTTLTQQTAVPPPTDLR
FT                                (in isoform 11). {ECO:0000305}.
FT                                /FTId=VSP_008105.
FT   VAR_SEQ    1631   1721       NIDRPKGLAFTDVDVDSIKIAWESPQGQVSRYRVTYSSPED
FT                                GIHELFPAPDGEEDTAELQGLRPGSEYTVSVVALHDDMESQ
FT                                PLIGTQSTA -> T (in isoform 8, isoform 9,
FT                                isoform 10, isoform 12, isoform 13 and
FT                                isoform 14).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:16106752,
FT                                ECO:0000303|PubMed:17974005,
FT                                ECO:0000303|Ref.13, ECO:0000303|Ref.4}.
FT                                /FTId=VSP_008106.
FT   VAR_SEQ    1991   2110       Missing (in isoform 4, isoform 5, isoform
FT                                10 and isoform 13).
FT                                {ECO:0000303|PubMed:12127832,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:17974005}.
FT                                /FTId=VSP_008107.
FT   VAR_SEQ    1991   2015       Missing (in isoform 9 and isoform 12).
FT                                {ECO:0000303|PubMed:17974005,
FT                                ECO:0000303|Ref.13}.
FT                                /FTId=VSP_008108.
FT   VAR_SEQ    1992   2193       Missing (in isoform 6).
FT                                {ECO:0000303|PubMed:12127832}.
FT                                /FTId=VSP_008109.
FT   VAR_SEQ    1992   2016       Missing (in isoform 17). {ECO:0000305}.
FT                                /FTId=VSP_047310.
FT   VAR_SEQ    2081   2111       Missing (in isoform 3, isoform 7, isoform
FT                                9, isoform 12 and isoform 14).
FT                                {ECO:0000303|PubMed:16106752,
FT                                ECO:0000303|PubMed:17974005,
FT                                ECO:0000303|PubMed:2992939,
FT                                ECO:0000303|PubMed:6462919,
FT                                ECO:0000303|Ref.13, ECO:0000303|Ref.4}.
FT                                /FTId=VSP_008110.
FT   VAR_SEQ    2082   2112       Missing (in isoform 17). {ECO:0000305}.
FT                                /FTId=VSP_047311.
FT   VAR_SEQ    2148   2151       FRVP -> STKA (in isoform 4).
FT                                {ECO:0000303|PubMed:12127832}.
FT                                /FTId=VSP_008111.
FT   VAR_SEQ    2152   2386       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:12127832}.
FT                                /FTId=VSP_008112.
FT   VAR_SEQ    2193   2247       Missing (in isoform 5).
FT                                {ECO:0000303|PubMed:12127832}.
FT                                /FTId=VSP_008113.
FT   VARIANT      15     15       Q -> L (in dbSNP:rs1250259).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:17974005,
FT                                ECO:0000269|PubMed:18268355,
FT                                ECO:0000269|PubMed:3031656,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_043917.
FT   VARIANT     817    817       T -> P (in dbSNP:rs2577301).
FT                                {ECO:0000269|PubMed:11737888,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:16106752,
FT                                ECO:0000269|PubMed:17614963,
FT                                ECO:0000269|PubMed:17974005,
FT                                ECO:0000269|PubMed:2992939,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_059529.
FT   VARIANT     940    940       D -> N (in a breast cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036018.
FT   VARIANT     973    973       Y -> C (in GFND2).
FT                                {ECO:0000269|PubMed:18268355}.
FT                                /FTId=VAR_043918.
FT   VARIANT    1120   1120       R -> P (in a breast cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036019.
FT   VARIANT    1467   1467       S -> R (in dbSNP:rs11687611).
FT                                /FTId=VAR_056576.
FT   VARIANT    1834   1834       W -> R (in GFND2; reduced binding to
FT                                heparin, endothelial cells and podocytes;
FT                                impaired capability to induce stress-
FT                                fiber formation).
FT                                {ECO:0000269|PubMed:18268355}.
FT                                /FTId=VAR_043919.
FT   VARIANT    1883   1883       L -> R (in GFND2; reduced binding to
FT                                heparin, endothelial cells and podocytes;
FT                                impaired capability to induce stress-
FT                                fiber formation).
FT                                {ECO:0000269|PubMed:18268355}.
FT                                /FTId=VAR_043920.
FT   VARIANT    1960   1960       I -> V (in dbSNP:rs1250209).
FT                                {ECO:0000269|PubMed:18268355}.
FT                                /FTId=VAR_043921.
FT   VARIANT    2121   2121       I -> V (in dbSNP:rs17449032).
FT                                /FTId=VAR_056577.
FT   VARIANT    2170   2170       V -> I (in dbSNP:rs1250209).
FT                                {ECO:0000244|PubMed:21269460,
FT                                ECO:0000269|PubMed:11737888,
FT                                ECO:0000269|PubMed:12127832,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:16106752,
FT                                ECO:0000269|PubMed:17974005,
FT                                ECO:0000269|PubMed:2012601,
FT                                ECO:0000269|PubMed:2992573,
FT                                ECO:0000269|PubMed:2992939,
FT                                ECO:0000269|PubMed:4019516,
FT                                ECO:0000269|PubMed:6462919,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_061486.
FT   VARIANT    2380   2380       D -> N (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036020.
FT   MUTAGEN     641    641       Y->A: Severely compromised ability to
FT                                form fibronectin aggregates; when
FT                                associated with A-681 and A-683.
FT                                {ECO:0000269|PubMed:12946358}.
FT   MUTAGEN     642    642       I->A: Little effect on ability to form
FT                                fibronectin aggregates; when associated
FT                                with A-682; A-684 and A-692.
FT                                {ECO:0000269|PubMed:12946358}.
FT   MUTAGEN     663    663       L->A: No effect on secondary structure
FT                                nor on fibronectin binding nor on
FT                                activation of p38 K but abolishes
FT                                polymerization activity; when associated
FT                                with A-666. {ECO:0000269|PubMed:12946358,
FT                                ECO:0000269|PubMed:19379667}.
FT   MUTAGEN     666    666       Y->A: No effect on secondary structure
FT                                nor on fibronectin binding nor on
FT                                activation of p38 kinase but abolishes
FT                                polymerization activity; when associated
FT                                with A-663. {ECO:0000269|PubMed:12946358,
FT                                ECO:0000269|PubMed:19379667}.
FT   MUTAGEN     681    681       L->A: Severely compromised ability to
FT                                form fibronectin aggregates; when
FT                                associated with A-641 and A-683.
FT                                {ECO:0000269|PubMed:12946358}.
FT   MUTAGEN     682    682       I->A: Little effect on ability to form
FT                                fibronectin aggregates; when associated
FT                                with A-642; A-684 and A-692.
FT                                {ECO:0000269|PubMed:12946358}.
FT   MUTAGEN     683    683       S->A: Severely compromised ability to
FT                                form fibronectin aggregates; when
FT                                associated with A-641 and A-681.
FT                                {ECO:0000269|PubMed:12946358}.
FT   MUTAGEN     684    684       I->A: Little effect on ability to form
FT                                fibronectin aggregates; when associated
FT                                with A-642; A-682 and A-692.
FT                                {ECO:0000269|PubMed:12946358}.
FT   MUTAGEN     691    691       E->A: Slightly enhanced ability to form
FT                                fibronectin aggregates; when associated
FT                                with A-694 and A-696.
FT                                {ECO:0000269|PubMed:12946358}.
FT   MUTAGEN     692    692       V->A: Little effect on ability to form
FT                                fibronectin aggregates; when associated
FT                                with A-642; A-682 and A-684.
FT                                {ECO:0000269|PubMed:12946358}.
FT   MUTAGEN     694    694       R->A: Slightly enhanced ability to form
FT                                fibronectin aggregates; when associated
FT                                with A-691 and A-696.
FT                                {ECO:0000269|PubMed:12946358}.
FT   MUTAGEN     695    695       F->A: Loss of ability to form fibronectin
FT                                aggregates; when associated with A-697.
FT                                {ECO:0000269|PubMed:12946358}.
FT   MUTAGEN     696    696       D->A: Slightly enhanced ability to form
FT                                fibronectin aggregates; when associated
FT                                with A-691 and A-694.
FT                                {ECO:0000269|PubMed:12946358}.
FT   MUTAGEN     697    697       F->A: Loss of ability to form fibronectin
FT                                aggregates; when associated with A-695.
FT                                {ECO:0000269|PubMed:12946358}.
FT   CONFLICT     32     32       Q -> R (in Ref. 5; CAH18171).
FT                                {ECO:0000305}.
FT   CONFLICT     69     69       Y -> N (in Ref. 5; CAH18172).
FT                                {ECO:0000305}.
FT   CONFLICT     73     73       A -> V (in Ref. 11; CAA26536).
FT                                {ECO:0000305}.
FT   CONFLICT    126    126       I -> V (in Ref. 5; CAH18136).
FT                                {ECO:0000305}.
FT   CONFLICT    199    199       E -> G (in Ref. 5; CAD91166).
FT                                {ECO:0000305}.
FT   CONFLICT    247    247       S -> R (in Ref. 1; CAD59389 and 2;
FT                                CAH60958). {ECO:0000305}.
FT   CONFLICT    260    260       C -> R (in Ref. 5; CAH18172).
FT                                {ECO:0000305}.
FT   CONFLICT    289    289       V -> A (in Ref. 5; CAE45847).
FT                                {ECO:0000305}.
FT   CONFLICT    355    355       S -> L (in Ref. 13; AAD00015).
FT                                {ECO:0000305}.
FT   CONFLICT    357    357       G -> E (in Ref. 5; CAD97984).
FT                                {ECO:0000305}.
FT   CONFLICT    375    375       T -> A (in Ref. 5; CAH18136).
FT                                {ECO:0000305}.
FT   CONFLICT    411    411       R -> Q (in Ref. 13; AAD00015).
FT                                {ECO:0000305}.
FT   CONFLICT    518    518       C -> R (in Ref. 5; CAD97791).
FT                                {ECO:0000305}.
FT   CONFLICT    552    552       R -> K (in Ref. 5; CAD97965/CAD97964).
FT                                {ECO:0000305}.
FT   CONFLICT    580    580       V -> A (in Ref. 5; CAH18172).
FT                                {ECO:0000305}.
FT   CONFLICT    678    678       E -> Q (in Ref. 15; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    704    705       TP -> PT (in Ref. 15; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    980    980       V -> L (in Ref. 5; CAD97791).
FT                                {ECO:0000305}.
FT   CONFLICT   1030   1030       T -> A (in Ref. 5; CAH18136).
FT                                {ECO:0000305}.
FT   CONFLICT   1048   1048       V -> D (in Ref. 5; CAD97965/CAD97964).
FT                                {ECO:0000305}.
FT   CONFLICT   1134   1134       D -> G (in Ref. 5; CAH18136).
FT                                {ECO:0000305}.
FT   CONFLICT   1137   1137       S -> N (in Ref. 5; CAD97965/CAD97964).
FT                                {ECO:0000305}.
FT   CONFLICT   1152   1152       T -> I (in Ref. 5; CAH18136).
FT                                {ECO:0000305}.
FT   CONFLICT   1222   1222       E -> G (in Ref. 5; CAD97791).
FT                                {ECO:0000305}.
FT   CONFLICT   1226   1226       H -> Q (in Ref. 5; CAE45932).
FT                                {ECO:0000305}.
FT   CONFLICT   1555   1555       D -> G (in Ref. 5; CAE45714).
FT                                {ECO:0000305}.
FT   CONFLICT   1601   1601       G -> S (in Ref. 5; CAD97965/CAD97964).
FT                                {ECO:0000305}.
FT   CONFLICT   1622   1622       Q -> E (in Ref. 26; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT   1715   1721       IGTQSTA -> VQTAVTT (in Ref. 28;
FT                                AAA52463). {ECO:0000305}.
FT   CONFLICT   1726   1726       T -> A (in Ref. 5; CAE45847).
FT                                {ECO:0000305}.
FT   CONFLICT   1755   1755       R -> W (in Ref. 5; CAH18136).
FT                                {ECO:0000305}.
FT   CONFLICT   1768   1768       I -> V (in Ref. 18; CAB52436).
FT                                {ECO:0000305}.
FT   CONFLICT   1783   1783       M -> T (in Ref. 5; CAE45932).
FT                                {ECO:0000305}.
FT   CONFLICT   1927   1927       R -> C (in Ref. 13; AAD00014).
FT                                {ECO:0000305}.
FT   CONFLICT   1934   1934       I -> V (in Ref. 5; CAH18172).
FT                                {ECO:0000305}.
FT   CONFLICT   1992   1992       D -> G (in Ref. 5; CAD97965/CAD97964).
FT                                {ECO:0000305}.
FT   CONFLICT   2023   2023       V -> A (in Ref. 5; CAD97965/CAD97964).
FT                                {ECO:0000305}.
FT   CONFLICT   2027   2027       G -> R (in Ref. 5; CAD97965/CAD97964).
FT                                {ECO:0000305}.
FT   CONFLICT   2251   2251       C -> R (in Ref. 5; CAH18172).
FT                                {ECO:0000305}.
FT   CONFLICT   2312   2312       Y -> N (in Ref. 5; CAD97965/CAD97964).
FT                                {ECO:0000305}.
FT   CONFLICT   2341   2341       S -> T (in Ref. 5; CAE45714/CAH18171/
FT                                CAH18172/CAE45958). {ECO:0000305}.
FT   CONFLICT   2367   2367       C -> Y (in Ref. 5; CAE45932).
FT                                {ECO:0000305}.
FT   STRAND       52     54       {ECO:0000244|PDB:1QGB}.
FT   STRAND       57     59       {ECO:0000244|PDB:1QGB}.
FT   STRAND       64     69       {ECO:0000244|PDB:1O9A}.
FT   STRAND       72     78       {ECO:0000244|PDB:1O9A}.
FT   TURN         81     83       {ECO:0000244|PDB:1QGB}.
FT   STRAND       85     89       {ECO:0000244|PDB:1O9A}.
FT   STRAND       96     98       {ECO:0000244|PDB:2CG7}.
FT   TURN        100    102       {ECO:0000244|PDB:2CG7}.
FT   STRAND      105    107       {ECO:0000244|PDB:2CG7}.
FT   STRAND      111    116       {ECO:0000244|PDB:2CG7}.
FT   STRAND      119    127       {ECO:0000244|PDB:2CG7}.
FT   TURN        128    131       {ECO:0000244|PDB:2CG7}.
FT   STRAND      132    136       {ECO:0000244|PDB:2CG7}.
FT   STRAND      140    143       {ECO:0000244|PDB:2CG7}.
FT   STRAND      146    149       {ECO:0000244|PDB:2CG7}.
FT   STRAND      153    157       {ECO:0000244|PDB:2CG7}.
FT   STRAND      161    171       {ECO:0000244|PDB:2CG7}.
FT   TURN        172    175       {ECO:0000244|PDB:2CG7}.
FT   STRAND      176    181       {ECO:0000244|PDB:2CG7}.
FT   STRAND      185    188       {ECO:0000244|PDB:2RKY}.
FT   TURN        189    192       {ECO:0000244|PDB:2RKY}.
FT   STRAND      193    196       {ECO:0000244|PDB:2RKY}.
FT   STRAND      200    205       {ECO:0000244|PDB:2RKY}.
FT   TURN        206    208       {ECO:0000244|PDB:2RKY}.
FT   STRAND      209    217       {ECO:0000244|PDB:2RKY}.
FT   TURN        218    221       {ECO:0000244|PDB:2RKY}.
FT   STRAND      222    226       {ECO:0000244|PDB:2RKY}.
FT   STRAND      230    233       {ECO:0000244|PDB:2RKY}.
FT   TURN        234    237       {ECO:0000244|PDB:2RKY}.
FT   STRAND      238    241       {ECO:0000244|PDB:2RKY}.
FT   STRAND      245    249       {ECO:0000244|PDB:2RKY}.
FT   STRAND      251    253       {ECO:0000244|PDB:2RKY}.
FT   STRAND      255    262       {ECO:0000244|PDB:2RKY}.
FT   TURN        263    266       {ECO:0000244|PDB:2RKY}.
FT   STRAND      267    271       {ECO:0000244|PDB:2RKY}.
FT   STRAND      302    304       {ECO:0000244|PDB:3M7P}.
FT   STRAND      307    309       {ECO:0000244|PDB:3M7P}.
FT   TURN        311    313       {ECO:0000244|PDB:1E88}.
FT   STRAND      315    317       {ECO:0000244|PDB:3M7P}.
FT   STRAND      321    326       {ECO:0000244|PDB:3M7P}.
FT   STRAND      329    336       {ECO:0000244|PDB:3M7P}.
FT   STRAND      339    344       {ECO:0000244|PDB:3M7P}.
FT   TURN        353    356       {ECO:0000244|PDB:3M7P}.
FT   STRAND      360    366       {ECO:0000244|PDB:3M7P}.
FT   STRAND      369    373       {ECO:0000244|PDB:3M7P}.
FT   STRAND      381    383       {ECO:0000244|PDB:1E88}.
FT   STRAND      385    391       {ECO:0000244|PDB:3M7P}.
FT   HELIX       392    395       {ECO:0000244|PDB:3M7P}.
FT   STRAND      398    401       {ECO:0000244|PDB:3M7P}.
FT   HELIX       403    405       {ECO:0000244|PDB:1E8B}.
FT   TURN        413    417       {ECO:0000244|PDB:3M7P}.
FT   STRAND      422    426       {ECO:0000244|PDB:3M7P}.
FT   STRAND      429    433       {ECO:0000244|PDB:3M7P}.
FT   STRAND      440    442       {ECO:0000244|PDB:2FN2}.
FT   STRAND      445    451       {ECO:0000244|PDB:3M7P}.
FT   HELIX       452    455       {ECO:0000244|PDB:3M7P}.
FT   STRAND      458    460       {ECO:0000244|PDB:3M7P}.
FT   HELIX       465    467       {ECO:0000244|PDB:3MQL}.
FT   STRAND      469    471       {ECO:0000244|PDB:3M7P}.
FT   STRAND      477    479       {ECO:0000244|PDB:3M7P}.
FT   STRAND      483    485       {ECO:0000244|PDB:3M7P}.
FT   STRAND      490    492       {ECO:0000244|PDB:3M7P}.
FT   STRAND      495    500       {ECO:0000244|PDB:3M7P}.
FT   TURN        501    504       {ECO:0000244|PDB:3M7P}.
FT   STRAND      505    513       {ECO:0000244|PDB:3M7P}.
FT   STRAND      517    520       {ECO:0000244|PDB:3EJH}.
FT   STRAND      523    526       {ECO:0000244|PDB:3EJH}.
FT   STRAND      529    534       {ECO:0000244|PDB:3EJH}.
FT   STRAND      540    547       {ECO:0000244|PDB:3EJH}.
FT   TURN        548    551       {ECO:0000244|PDB:3EJH}.
FT   STRAND      552    557       {ECO:0000244|PDB:3EJH}.
FT   STRAND      559    562       {ECO:0000244|PDB:3EJH}.
FT   TURN        564    566       {ECO:0000244|PDB:3EJH}.
FT   STRAND      569    571       {ECO:0000244|PDB:3EJH}.
FT   STRAND      575    578       {ECO:0000244|PDB:3EJH}.
FT   STRAND      585    591       {ECO:0000244|PDB:3EJH}.
FT   TURN        592    595       {ECO:0000244|PDB:3EJH}.
FT   STRAND      596    601       {ECO:0000244|PDB:3EJH}.
FT   STRAND      613    615       {ECO:0000244|PDB:1OWW}.
FT   STRAND      626    631       {ECO:0000244|PDB:1OWW}.
FT   STRAND      634    636       {ECO:0000244|PDB:1OWW}.
FT   STRAND      638    647       {ECO:0000244|PDB:1OWW}.
FT   TURN        648    651       {ECO:0000244|PDB:1Q38}.
FT   STRAND      655    659       {ECO:0000244|PDB:1OWW}.
FT   STRAND      661    664       {ECO:0000244|PDB:1Q38}.
FT   STRAND      665    668       {ECO:0000244|PDB:1OWW}.
FT   STRAND      673    688       {ECO:0000244|PDB:1OWW}.
FT   STRAND      690    699       {ECO:0000244|PDB:1OWW}.
FT   HELIX       732    734       {ECO:0000244|PDB:2H41}.
FT   STRAND      736    739       {ECO:0000244|PDB:2H41}.
FT   STRAND      747    756       {ECO:0000244|PDB:2H41}.
FT   TURN        757    759       {ECO:0000244|PDB:2H41}.
FT   STRAND      764    769       {ECO:0000244|PDB:2H41}.
FT   STRAND      774    777       {ECO:0000244|PDB:2H41}.
FT   STRAND      785    794       {ECO:0000244|PDB:2H41}.
FT   STRAND      799    808       {ECO:0000244|PDB:2H41}.
FT   STRAND      818    822       {ECO:0000244|PDB:2N1K}.
FT   STRAND      824    830       {ECO:0000244|PDB:2N1K}.
FT   STRAND      839    847       {ECO:0000244|PDB:2N1K}.
FT   STRAND      854    859       {ECO:0000244|PDB:2N1K}.
FT   STRAND      864    869       {ECO:0000244|PDB:2N1K}.
FT   STRAND      875    883       {ECO:0000244|PDB:2N1K}.
FT   STRAND      892    897       {ECO:0000244|PDB:2N1K}.
FT   STRAND     1178   1184       {ECO:0000244|PDB:1FNF}.
FT   STRAND     1186   1189       {ECO:0000244|PDB:1FNF}.
FT   STRAND     1191   1196       {ECO:0000244|PDB:1FNF}.
FT   STRAND     1205   1212       {ECO:0000244|PDB:1FNF}.
FT   TURN       1213   1215       {ECO:0000244|PDB:1FNF}.
FT   STRAND     1221   1225       {ECO:0000244|PDB:1FNF}.
FT   STRAND     1231   1233       {ECO:0000244|PDB:1FNF}.
FT   STRAND     1243   1251       {ECO:0000244|PDB:1FNF}.
FT   STRAND     1259   1263       {ECO:0000244|PDB:1FNF}.
FT   STRAND     1271   1277       {ECO:0000244|PDB:1FNF}.
FT   STRAND     1283   1288       {ECO:0000244|PDB:1FNF}.
FT   STRAND     1296   1304       {ECO:0000244|PDB:1FNF}.
FT   HELIX      1308   1310       {ECO:0000244|PDB:2GEE}.
FT   STRAND     1312   1316       {ECO:0000244|PDB:1FNF}.
FT   STRAND     1322   1325       {ECO:0000244|PDB:1FNF}.
FT   STRAND     1333   1342       {ECO:0000244|PDB:1FNF}.
FT   STRAND     1350   1355       {ECO:0000244|PDB:1FNF}.
FT   STRAND     1362   1368       {ECO:0000244|PDB:4LXO}.
FT   STRAND     1374   1379       {ECO:0000244|PDB:4LXO}.
FT   STRAND     1386   1394       {ECO:0000244|PDB:4LXO}.
FT   STRAND     1402   1406       {ECO:0000244|PDB:4LXO}.
FT   STRAND     1412   1415       {ECO:0000244|PDB:4LXO}.
FT   STRAND     1423   1432       {ECO:0000244|PDB:4LXO}.
FT   STRAND     1440   1445       {ECO:0000244|PDB:4LXO}.
FT   STRAND     1452   1460       {ECO:0000244|PDB:4LXO}.
FT   STRAND     1463   1469       {ECO:0000244|PDB:4LXO}.
FT   STRAND     1476   1484       {ECO:0000244|PDB:4LXO}.
FT   TURN       1485   1490       {ECO:0000244|PDB:4JE4}.
FT   STRAND     1492   1497       {ECO:0000244|PDB:4LXO}.
FT   STRAND     1502   1505       {ECO:0000244|PDB:4LXO}.
FT   STRAND     1513   1522       {ECO:0000244|PDB:4LXO}.
FT   STRAND     1525   1527       {ECO:0000244|PDB:4LXO}.
FT   STRAND     1534   1539       {ECO:0000244|PDB:4LXO}.
FT   STRAND     1639   1644       {ECO:0000244|PDB:1J8K}.
FT   STRAND     1647   1651       {ECO:0000244|PDB:1J8K}.
FT   STRAND     1662   1668       {ECO:0000244|PDB:1J8K}.
FT   TURN       1669   1671       {ECO:0000244|PDB:1J8K}.
FT   STRAND     1672   1676       {ECO:0000244|PDB:1J8K}.
FT   STRAND     1686   1689       {ECO:0000244|PDB:1J8K}.
FT   STRAND     1696   1704       {ECO:0000244|PDB:1J8K}.
FT   STRAND     1706   1708       {ECO:0000244|PDB:1J8K}.
FT   STRAND     1714   1719       {ECO:0000244|PDB:1J8K}.
FT   STRAND     1726   1733       {ECO:0000244|PDB:3R8Q}.
FT   STRAND     1738   1743       {ECO:0000244|PDB:3R8Q}.
FT   STRAND     1751   1763       {ECO:0000244|PDB:3R8Q}.
FT   STRAND     1766   1770       {ECO:0000244|PDB:3R8Q}.
FT   STRAND     1776   1779       {ECO:0000244|PDB:3R8Q}.
FT   STRAND     1787   1796       {ECO:0000244|PDB:3R8Q}.
FT   STRAND     1804   1809       {ECO:0000244|PDB:3R8Q}.
FT   STRAND     1818   1825       {ECO:0000244|PDB:3R8Q}.
FT   STRAND     1830   1835       {ECO:0000244|PDB:3R8Q}.
FT   STRAND     1843   1853       {ECO:0000244|PDB:3R8Q}.
FT   STRAND     1857   1861       {ECO:0000244|PDB:3R8Q}.
FT   STRAND     1866   1870       {ECO:0000244|PDB:3R8Q}.
FT   STRAND     1878   1887       {ECO:0000244|PDB:3R8Q}.
FT   STRAND     1895   1900       {ECO:0000244|PDB:3R8Q}.
FT   STRAND     1907   1915       {ECO:0000244|PDB:3R8Q}.
FT   STRAND     1918   1924       {ECO:0000244|PDB:3R8Q}.
FT   STRAND     1932   1938       {ECO:0000244|PDB:3R8Q}.
FT   STRAND     1957   1960       {ECO:0000244|PDB:3R8Q}.
FT   STRAND     1968   1977       {ECO:0000244|PDB:3R8Q}.
FT   STRAND     1985   1990       {ECO:0000244|PDB:3R8Q}.
FT   STRAND     2253   2255       {ECO:0000244|PDB:2EC3}.
FT   STRAND     2263   2267       {ECO:0000244|PDB:2EC3}.
FT   STRAND     2269   2280       {ECO:0000244|PDB:2EC3}.
FT   TURN       2281   2284       {ECO:0000244|PDB:2EC3}.
FT   STRAND     2285   2290       {ECO:0000244|PDB:2EC3}.
SQ   SEQUENCE   2386 AA;  262625 MW;  5F7EDB9700335098 CRC64;
     MLRGPGPGLL LLAVQCLGTA VPSTGASKSK RQAQQMVQPQ SPVAVSQSKP GCYDNGKHYQ
     INQQWERTYL GNALVCTCYG GSRGFNCESK PEAEETCFDK YTGNTYRVGD TYERPKDSMI
     WDCTCIGAGR GRISCTIANR CHEGGQSYKI GDTWRRPHET GGYMLECVCL GNGKGEWTCK
     PIAEKCFDHA AGTSYVVGET WEKPYQGWMM VDCTCLGEGS GRITCTSRNR CNDQDTRTSY
     RIGDTWSKKD NRGNLLQCIC TGNGRGEWKC ERHTSVQTTS SGSGPFTDVR AAVYQPQPHP
     QPPPYGHCVT DSGVVYSVGM QWLKTQGNKQ MLCTCLGNGV SCQETAVTQT YGGNSNGEPC
     VLPFTYNGRT FYSCTTEGRQ DGHLWCSTTS NYEQDQKYSF CTDHTVLVQT RGGNSNGALC
     HFPFLYNNHN YTDCTSEGRR DNMKWCGTTQ NYDADQKFGF CPMAAHEEIC TTNEGVMYRI
     GDQWDKQHDM GHMMRCTCVG NGRGEWTCIA YSQLRDQCIV DDITYNVNDT FHKRHEEGHM
     LNCTCFGQGR GRWKCDPVDQ CQDSETGTFY QIGDSWEKYV HGVRYQCYCY GRGIGEWHCQ
     PLQTYPSSSG PVEVFITETP SQPNSHPIQW NAPQPSHISK YILRWRPKNS VGRWKEATIP
     GHLNSYTIKG LKPGVVYEGQ LISIQQYGHQ EVTRFDFTTT STSTPVTSNT VTGETTPFSP
     LVATSESVTE ITASSFVVSW VSASDTVSGF RVEYELSEEG DEPQYLDLPS TATSVNIPDL
     LPGRKYIVNV YQISEDGEQS LILSTSQTTA PDAPPDTTVD QVDDTSIVVR WSRPQAPITG
     YRIVYSPSVE GSSTELNLPE TANSVTLSDL QPGVQYNITI YAVEENQEST PVVIQQETTG
     TPRSDTVPSP RDLQFVEVTD VKVTIMWTPP ESAVTGYRVD VIPVNLPGEH GQRLPISRNT
     FAEVTGLSPG VTYYFKVFAV SHGRESKPLT AQQTTKLDAP TNLQFVNETD STVLVRWTPP
     RAQITGYRLT VGLTRRGQPR QYNVGPSVSK YPLRNLQPAS EYTVSLVAIK GNQESPKATG
     VFTTLQPGSS IPPYNTEVTE TTIVITWTPA PRIGFKLGVR PSQGGEAPRE VTSDSGSIVV
     SGLTPGVEYV YTIQVLRDGQ ERDAPIVNKV VTPLSPPTNL HLEANPDTGV LTVSWERSTT
     PDITGYRITT TPTNGQQGNS LEEVVHADQS SCTFDNLSPG LEYNVSVYTV KDDKESVPIS
     DTIIPAVPPP TDLRFTNIGP DTMRVTWAPP PSIDLTNFLV RYSPVKNEED VAELSISPSD
     NAVVLTNLLP GTEYVVSVSS VYEQHESTPL RGRQKTGLDS PTGIDFSDIT ANSFTVHWIA
     PRATITGYRI RHHPEHFSGR PREDRVPHSR NSITLTNLTP GTEYVVSIVA LNGREESPLL
     IGQQSTVSDV PRDLEVVAAT PTSLLISWDA PAVTVRYYRI TYGETGGNSP VQEFTVPGSK
     STATISGLKP GVDYTITVYA VTGRGDSPAS SKPISINYRT EIDKPSQMQV TDVQDNSISV
     KWLPSSSPVT GYRVTTTPKN GPGPTKTKTA GPDQTEMTIE GLQPTVEYVV SVYAQNPSGE
     SQPLVQTAVT NIDRPKGLAF TDVDVDSIKI AWESPQGQVS RYRVTYSSPE DGIHELFPAP
     DGEEDTAELQ GLRPGSEYTV SVVALHDDME SQPLIGTQST AIPAPTDLKF TQVTPTSLSA
     QWTPPNVQLT GYRVRVTPKE KTGPMKEINL APDSSSVVVS GLMVATKYEV SVYALKDTLT
     SRPAQGVVTT LENVSPPRRA RVTDATETTI TISWRTKTET ITGFQVDAVP ANGQTPIQRT
     IKPDVRSYTI TGLQPGTDYK IYLYTLNDNA RSSPVVIDAS TAIDAPSNLR FLATTPNSLL
     VSWQPPRARI TGYIIKYEKP GSPPREVVPR PRPGVTEATI TGLEPGTEYT IYVIALKNNQ
     KSEPLIGRKK TDELPQLVTL PHPNLHGPEI LDVPSTVQKT PFVTHPGYDT GNGIQLPGTS
     GQQPSVGQQM IFEEHGFRRT TPPTTATPIR HRPRPYPPNV GEEIQIGHIP REDVDYHLYP
     HGPGLNPNAS TGQEALSQTT ISWAPFQDTS EYIISCHPVG TDEEPLQFRV PGTSTSATLT
     GLTRGATYNV IVEALKDQQR HKVREEVVTV GNSVNEGLNQ PTDDSCFDPY TVSHYAVGDE
     WERMSESGFK LLCQCLGFGS GHFRCDSSRW CHDNGVNYKI GEKWDRQGEN GQMMSCTCLG
     NGKGEFKCDP HEATCYDDGK TYHVGEQWQK EYLGAICSCT CFGGQRGWRC DNCRRPGGEP
     SPEGTTGQSY NQYSQRYHQR TNTNVNCPIE CFMPLDVQAD REDSRE
//
ID   PDGFB_HUMAN             Reviewed;         241 AA.
AC   P01127; G3XAG8; P78431; Q15354; Q6FHE7; Q9UF23;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   21-JUL-1986, sequence version 1.
DT   20-JAN-2016, entry version 194.
DE   RecName: Full=Platelet-derived growth factor subunit B;
DE            Short=PDGF subunit B;
DE   AltName: Full=PDGF-2;
DE   AltName: Full=Platelet-derived growth factor B chain;
DE   AltName: Full=Platelet-derived growth factor beta polypeptide;
DE   AltName: Full=Proto-oncogene c-Sis;
DE   AltName: INN=Becaplermin;
DE   Flags: Precursor;
GN   Name=PDGFB; Synonyms=PDGF2, SIS;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=6740330; DOI=10.1126/science.6740330;
RA   Josephs S.F., Ratner L., Clarke M.F., Westin E.H., Reitz M.S.,
RA   Wong-Staal F.;
RT   "Transforming potential of human c-sis nucleotide sequences encoding
RT   platelet-derived growth factor.";
RL   Science 225:636-639(1984).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=4033772; DOI=10.1038/316748a0;
RA   Collins T., Ginsburg D., Boss J.M., Orkin S.H., Pober J.S.;
RT   "Cultured human endothelial cells express platelet-derived growth
RT   factor B chain: cDNA cloning and structural analysis.";
RL   Nature 316:748-750(1985).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2991848; DOI=10.1093/nar/13.14.5007;
RA   Ratner L., Josephs S.F., Jarrett R., Reitz M.S., Wong-Staal F.;
RT   "Nucleotide sequence of transforming human c-sis cDNA clones with
RT   homology to platelet-derived growth factor.";
RL   Nucleic Acids Res. 13:5007-5018(1985).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=3472769;
RA   Rao C.D., Igarashi H., Pech M.W., Robbins K.C., Aaronson S.A.;
RT   "Oncogenic potential of the human platelet-derived growth factor
RT   transcriptional unit.";
RL   Cold Spring Harb. Symp. Quant. Biol. 51:959-966(1986).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=3517869; DOI=10.1073/pnas.83.8.2392;
RA   Rao C.D., Igarashi H., Chiu I.-M., Robbins K.C., Aaronson S.A.;
RT   "Structure and sequence of the human c-sis/platelet-derived growth
RT   factor 2 (SIS/PDGF2) transcriptional unit.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:2392-2396(1986).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84;
RA   Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A.,
RA   Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J.,
RA   Beare D.M., Dunham I.;
RT   "A genome annotation-driven approach to cloning the human ORFeome.";
RL   Genome Biol. 5:R84.1-R84.11(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M.,
RA   Clamp M., Smink L.J., Ainscough R., Almeida J.P., Babbage A.K.,
RA   Bagguley C., Bailey J., Barlow K.F., Bates K.N., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Buck D., Burgess J.,
RA   Burrill W.D., Burton J., Carder C., Carter N.P., Chen Y., Clark G.,
RA   Clegg S.M., Cobley V.E., Cole C.G., Collier R.E., Connor R.,
RA   Conroy D., Corby N.R., Coville G.J., Cox A.V., Davis J., Dawson E.,
RA   Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., Ellington A.G.,
RA   Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S.,
RA   Hunt S.E., Jones M.C., Kershaw J., Kimberley A.M., King A.,
RA   Laird G.K., Langford C.F., Leversha M.A., Lloyd C., Lloyd D.M.,
RA   Martyn I.D., Mashreghi-Mohammadi M., Matthews L.H., Mccann O.T.,
RA   Mcclay J., Mclaren S., McMurray A.A., Milne S.A., Mortimore B.J.,
RA   Odell C.N., Pavitt R., Pearce A.V., Pearson D., Phillimore B.J.C.T.,
RA   Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., Rogers L., Ross M.T.,
RA   Scott C.E., Sehra H.K., Skuce C.D., Smalley S., Smith M.L.,
RA   Soderlund C., Spragon L., Steward C.A., Sulston J.E., Swann R.M.,
RA   Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J.,
RA   Shintani A., Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S.,
RA   Roe B.A., Chen F., Chu L., Crabtree J., Deschamps S., Do A., Do T.,
RA   Dorman A., Fang F., Fu Y., Hu P., Hua A., Kenton S., Lai H., Lao H.I.,
RA   Lewis J., Lewis S., Lin S.-P., Loh P., Malaj E., Nguyen T., Pan H.,
RA   Phan S., Qi S., Qian Y., Ray L., Ren Q., Shaull S., Sloan D., Song L.,
RA   Wang Q., Wang Y., Wang Z., White J., Willingham D., Wu H., Yao Z.,
RA   Zhan M., Zhang G., Chissoe S., Murray J., Miller N., Minx P.,
RA   Fulton R., Johnson D., Bemis G., Bentley D., Bradshaw H., Bourne S.,
RA   Cordes M., Du Z., Fulton L., Goela D., Graves T., Hawkins J.,
RA   Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., Rohlfing T.,
RA   Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., Nelson J.,
RA   Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S.,
RA   Budarf M.L., McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E.,
RA   Edelmann L., Kim U.J., Shizuya H., Simon M.I., Dumanski J.P.,
RA   Peyrard M., Kedra D., Seroussi E., Fransson I., Tapia I., Bruder C.E.,
RA   O'Brien K.P., Wilkinson P., Bodenteich A., Hartman K., Hu X.,
RA   Khan A.S., Lane L., Tilahun Y., Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain, Lung, Pancreas, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-185 (ISOFORM 2).
RC   TISSUE=Choriocarcinoma;
RX   PubMed=7659502; DOI=10.1093/nar/23.15.2815;
RA   Dirks R.P.H., Onnekink C., Jansen H.J., de Jong A., Bloemers H.P.J.;
RT   "A novel human c-sis mRNA species is transcribed from a promoter in c-
RT   sis intron 1 and contains the code for an alternative PDGF B-like
RT   protein.";
RL   Nucleic Acids Res. 23:2815-2822(1995).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-53, AND CHROMOSOMAL
RP   TRANSLOCATION WITH COL1A1.
RX   PubMed=8988177; DOI=10.1038/ng0197-95;
RA   Simon M.-P., Pedeutour F., Sirvent N., Grosgeorge J., Minoletti F.,
RA   Coindre J.-M., Terrier-Lacombe M.-J., Mandahl N., Craver R.D.,
RA   Blin N., Sozzi G., Turc-Carel C., O'Brien K.P., Kedra D., Fransson I.,
RA   Guilbaud C., Dumanski J.P.;
RT   "Deregulation of the platelet-derived growth factor B-chain gene via
RT   fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans
RT   and giant-cell fibroblastoma.";
RL   Nat. Genet. 15:95-98(1997).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 22-241.
RX   PubMed=6327048; DOI=10.1016/0092-8674(84)90307-6;
RA   Chiu I.-M., Reddy E.P., Givol D., Robbins K.C., Tronick S.R.,
RA   Aaronson S.A.;
RT   "Nucleotide sequence analysis identifies the human c-sis proto-
RT   oncogene as a structural gene for platelet-derived growth factor.";
RL   Cell 37:123-129(1984).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 26-241 (ISOFORM 1).
RX   PubMed=3456904; DOI=10.1016/0014-5793(86)80433-1;
RA   Weich H.A., Sebald W., Schairer H.U., Hoppe J.;
RT   "The human osteosarcoma cell line U-2 OS expresses a 3.8 kilobase mRNA
RT   which codes for the sequence of the PDGF-B chain.";
RL   FEBS Lett. 198:344-348(1986).
RN   [15]
RP   PROTEIN SEQUENCE OF 82-112.
RX   PubMed=6306471; DOI=10.1038/304035a0;
RA   Waterfield M.D., Scrace G.T., Whittle N., Stroobant P., Johnsson A.,
RA   Wasteson A., Westermark B., Heldin C.H., Huang J.S., Deuel T.F.;
RT   "Platelet-derived growth factor is structurally related to the
RT   putative transforming protein p28sis of simian sarcoma virus.";
RL   Nature 304:35-39(1983).
RN   [16]
RP   PROTEIN SEQUENCE OF 82-110.
RX   PubMed=6844921; DOI=10.1126/science.6844921;
RA   Antoniades H.N., Hunkapiller M.W.;
RT   "Human platelet-derived growth factor (PDGF): amino-terminal amino
RT   acid sequence.";
RL   Science 220:963-965(1983).
RN   [17]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 153-200, AND PARTIAL PROTEIN
RP   SEQUENCE.
RX   PubMed=6329745;
RA   Johnsson A., Heldin C.H., Wasteson A., Westermark B., Deuel T.F.,
RA   Huang J.S., Seeburg P.H., Gray A., Ullrich A., Scrace G.,
RA   Stroobant P., Waterfield M.D.;
RT   "The c-sis gene encodes a precursor of the B chain of platelet-derived
RT   growth factor.";
RL   EMBO J. 3:921-928(1984).
RN   [18]
RP   MUTAGENESIS, AND IMPORTANCE OF ARG-108 AND ILE-111 FOR RECEPTOR
RP   BINDING.
RX   PubMed=1661670;
RA   Clements J.M., Bawden L.J., Bloxidge R.E., Catlin G., Cook A.L.,
RA   Craig S., Drummond A.H., Edwards R.M., Fallon A., Green D.R.,
RA   Hellewell P.G., Kirwin P.M., Nayee P.D., Richardson S.J., Brown D.,
RA   Chahwala S.B., Snarey M., Winslow D.;
RT   "Two PDGF-B chain residues, arginine 27 and isoleucine 30, mediate
RT   receptor binding and activation.";
RL   EMBO J. 10:4113-4120(1991).
RN   [19]
RP   INTERCHAIN DISULFIDE BONDS.
RX   PubMed=1317862;
RA   Andersson M., Oestman A., Baeckstroem G., Hellman U.,
RA   George-Nascimento C., Westermark B., Heldin C.-H.;
RT   "Assignment of interchain disulfide bonds in platelet-derived growth
RT   factor (PDGF) and evidence for agonist activity of monomeric PDGF.";
RL   J. Biol. Chem. 267:11260-11266(1992).
RN   [20]
RP   TISSUE SPECIFICITY.
RX   PubMed=11331882; DOI=10.1038/35074593;
RA   LaRochelle W.J., Jeffers M., McDonald W.F., Chillakuru R.A.,
RA   Giese N.A., Lokker N.A., Sullivan C., Boldog F.L., Yang M., Vernet C.,
RA   Burgess C.E., Fernandez E., Deegler L.L., Rittman B., Shimkets J.,
RA   Shimkets R.A., Rothberg J.M., Lichenstein H.S.;
RT   "PDGF D, a novel protease-activated growth factor.";
RL   Nat. Cell Biol. 3:517-521(2001).
RN   [21]
RP   DISEASE, AND CHROMOSOMAL TRANSLOCATION WITH COL1A1.
RX   PubMed=12660034; DOI=10.1016/S0165-4608(02)00844-0;
RA   Sandberg A.A., Anderson W.D., Fredenberg C., Hashimoto H.;
RT   "Dermatofibrosarcoma protuberans of breast.";
RL   Cancer Genet. Cytogenet. 142:56-59(2003).
RN   [22]
RP   REVIEW ON FUNCTION IN DEVELOPMENT AND DISEASE.
RX   PubMed=18483217; DOI=10.1101/gad.1653708;
RA   Andrae J., Gallini R., Betsholtz C.;
RT   "Role of platelet-derived growth factors in physiology and medicine.";
RL   Genes Dev. 22:1276-1312(2008).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS).
RX   PubMed=1396586;
RA   Oefner C., D'Arcy A., Winkler F.K., Eggimann B., Hosang M.;
RT   "Crystal structure of human platelet-derived growth factor BB.";
RL   EMBO J. 11:3921-3926(1992).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 21-185 IN COMPLEX WITH
RP   PDGFRB, SUBUNIT, AND DISULFIDE BONDS.
RX   PubMed=20534510; DOI=10.1073/pnas.1000806107;
RA   Shim A.H., Liu H., Focia P.J., Chen X., Lin P.C., He X.;
RT   "Structures of a platelet-derived growth factor/propeptide complex and
RT   a platelet-derived growth factor/receptor complex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:11307-11312(2010).
RN   [25]
RP   VARIANTS IBGC5 ARG-9 AND PRO-119.
RX   PubMed=23913003; DOI=10.1038/ng.2723;
RA   Keller A., Westenberger A., Sobrido M.J., Garcia-Murias M.,
RA   Domingo A., Sears R.L., Lemos R.R., Ordonez-Ugalde A., Nicolas G.,
RA   da Cunha J.E., Rushing E.J., Hugelshofer M., Wurnig M.C., Kaech A.,
RA   Reimann R., Lohmann K., Dobricic V., Carracedo A., Petrovic I.,
RA   Miyasaki J.M., Abakumova I., Mae M.A., Raschperger E., Zatz M.,
RA   Zschiedrich K., Klepper J., Spiteri E., Prieto J.M., Navas I.,
RA   Preuss M., Dering C., Jankovic M., Paucar M., Svenningsson P.,
RA   Saliminejad K., Khorshid H.R., Novakovic I., Aguzzi A., Boss A.,
RA   Le Ber I., Defer G., Hannequin D., Kostic V.S., Campion D.,
RA   Geschwind D.H., Coppola G., Betsholtz C., Klein C., Oliveira J.R.;
RT   "Mutations in the gene encoding PDGF-B cause brain calcifications in
RT   humans and mice.";
RL   Nat. Genet. 45:1077-1082(2013).
CC   -!- FUNCTION: Growth factor that plays an essential role in the
CC       regulation of embryonic development, cell proliferation, cell
CC       migration, survival and chemotaxis. Potent mitogen for cells of
CC       mesenchymal origin. Required for normal proliferation and
CC       recruitment of pericytes and vascular smooth muscle cells in the
CC       central nervous system, skin, lung, heart and placenta. Required
CC       for normal blood vessel development, and for normal development of
CC       kidney glomeruli. Plays an important role in wound healing.
CC       Signaling is modulated by the formation of heterodimers with PDGFA
CC       (By similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Homodimer; antiparallel disulfide-linked dimer.
CC       Heterodimer with PDGFA; antiparallel disulfide-linked dimer. The
CC       PDGFB homodimer interacts with PDGFRA and PDGFRB homodimers, and
CC       with heterodimers formed by PDGFRA and PDGFRB. The heterodimer
CC       composed of PDGFA and PDGFB interacts with PDGFRB homodimers, and
CC       with heterodimers formed by PDGFRA and PDGFRB. Interacts with
CC       XLKD1 (By similarity). {ECO:0000250}.
CC   -!- INTERACTION:
CC       Self; NbExp=2; IntAct=EBI-1554925, EBI-1554925;
CC       P16234:PDGFRA; NbExp=11; IntAct=EBI-1554925, EBI-2861522;
CC       P09619:PDGFRB; NbExp=13; IntAct=EBI-1554925, EBI-641237;
CC   -!- SUBCELLULAR LOCATION: Secreted. Note=Released by platelets upon
CC       wounding.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage; Named isoforms=2;
CC       Name=1;
CC         IsoId=P01127-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P01127-2; Sequence=VSP_044913;
CC   -!- TISSUE SPECIFICITY: Expressed at high levels in the heart, brain
CC       (sustantia nigra), placenta and fetal kidney. Expressed at
CC       moderate levels in the brain (hippocampus), skeletal muscle,
CC       kidney and lung. {ECO:0000269|PubMed:11331882}.
CC   -!- DISEASE: Basal ganglia calcification, idiopathic, 5 (IBGC5)
CC       [MIM:615483]: A form of basal ganglia calcification, an autosomal
CC       dominant condition characterized by symmetric calcification in the
CC       basal ganglia and other brain regions. Affected individuals can
CC       either be asymptomatic or show a wide spectrum of neuropsychiatric
CC       symptoms, including parkinsonism, dystonia, tremor, ataxia,
CC       dementia, psychosis, seizures, and chronic headache. Serum levels
CC       of calcium, phosphate, alkaline phosphatase and parathyroid
CC       hormone are normal. The neuropathological hallmark of the disease
CC       is vascular and pericapillary calcification, mainly of calcium
CC       phosphate, in the affected brain areas.
CC       {ECO:0000269|PubMed:23913003}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Note=A chromosomal aberration involving PDGFB is found in
CC       dermatofibrosarcoma protuberans. Translocation t(17;22)(q22;q13)
CC       with PDGFB. {ECO:0000269|PubMed:12660034}.
CC   -!- PHARMACEUTICAL: Available under the name Regranex (Ortho-McNeil).
CC       Used to promote healing in diabetic neuropathic foot ulcers.
CC   -!- SIMILARITY: Belongs to the PDGF/VEGF growth factor family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=R&D Systems' cytokine source book: PDGF;
CC       URL="http://www.rndsystems.com/molecule_detail.aspx?m=1967";
CC   -!- WEB RESOURCE: Name=Regranex; Note=Clinical information on
CC       Regranex;
CC       URL="http://www.regranex.com/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PDGFBID155.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; K01401; AAA60552.1; -; Genomic_DNA.
DR   EMBL; K01918; AAA60552.1; JOINED; Genomic_DNA.
DR   EMBL; J00121; AAA60552.1; JOINED; Genomic_DNA.
DR   EMBL; K01398; AAA60552.1; JOINED; Genomic_DNA.
DR   EMBL; K01399; AAA60552.1; JOINED; Genomic_DNA.
DR   EMBL; K01400; AAA60552.1; JOINED; Genomic_DNA.
DR   EMBL; X02811; CAA26579.1; -; mRNA.
DR   EMBL; X02744; CAA26524.1; -; mRNA.
DR   EMBL; M12783; AAA60553.1; -; mRNA.
DR   EMBL; CR456538; CAG30424.1; -; mRNA.
DR   EMBL; Z81010; CAB02635.1; -; Genomic_DNA.
DR   EMBL; Z81010; CAP58849.1; -; Genomic_DNA.
DR   EMBL; CR541807; CAG46606.1; -; mRNA.
DR   EMBL; CH471095; EAW60306.1; -; Genomic_DNA.
DR   EMBL; CH471095; EAW60307.1; -; Genomic_DNA.
DR   EMBL; BC029822; AAH29822.1; -; mRNA.
DR   EMBL; BC077725; AAH77725.1; -; mRNA.
DR   EMBL; X83705; CAA58679.1; -; mRNA.
DR   EMBL; X98706; CAA67262.1; -; Genomic_DNA.
DR   EMBL; K01917; AAA98793.1; -; Genomic_DNA.
DR   EMBL; K01913; AAA98793.1; JOINED; Genomic_DNA.
DR   EMBL; K01914; AAA98793.1; JOINED; Genomic_DNA.
DR   EMBL; K01915; AAA98793.1; JOINED; Genomic_DNA.
DR   EMBL; K01916; AAA98793.1; JOINED; Genomic_DNA.
DR   EMBL; X03702; CAA27333.1; -; mRNA.
DR   EMBL; X00561; CAA25228.1; -; Genomic_DNA.
DR   EMBL; X00561; CAA25229.1; -; Genomic_DNA.
DR   CCDS; CCDS13987.1; -. [P01127-1]
DR   CCDS; CCDS33650.1; -. [P01127-2]
DR   PIR; A94276; PFHUG2.
DR   RefSeq; NP_002599.1; NM_002608.3. [P01127-1]
DR   RefSeq; NP_148937.1; NM_033016.3. [P01127-2]
DR   UniGene; Hs.1976; -.
DR   PDB; 1PDG; X-ray; 3.00 A; A/B/C=82-190.
DR   PDB; 3MJG; X-ray; 2.30 A; A/B=21-185.
DR   PDB; 4HQU; X-ray; 2.20 A; A=82-190.
DR   PDB; 4HQX; X-ray; 2.30 A; A=82-183.
DR   PDB; 4QCI; X-ray; 2.30 A; C/D=82-190.
DR   PDBsum; 1PDG; -.
DR   PDBsum; 3MJG; -.
DR   PDBsum; 4HQU; -.
DR   PDBsum; 4HQX; -.
DR   PDBsum; 4QCI; -.
DR   ProteinModelPortal; P01127; -.
DR   SMR; P01127; 25-182.
DR   BioGrid; 111181; 77.
DR   DIP; DIP-5737N; -.
DR   IntAct; P01127; 6.
DR   STRING; 9606.ENSP00000330382; -.
DR   BindingDB; P01127; -.
DR   ChEMBL; CHEMBL3108633; -.
DR   iPTMnet; P01127; -.
DR   PhosphoSite; P01127; -.
DR   UniCarbKB; P01127; -.
DR   BioMuta; PDGFB; -.
DR   DMDM; 129724; -.
DR   PaxDb; P01127; -.
DR   PRIDE; P01127; -.
DR   DNASU; 5155; -.
DR   Ensembl; ENST00000331163; ENSP00000330382; ENSG00000100311. [P01127-1]
DR   Ensembl; ENST00000381551; ENSP00000370963; ENSG00000100311. [P01127-2]
DR   GeneID; 5155; -.
DR   KEGG; hsa:5155; -.
DR   UCSC; uc003axe.3; human.
DR   UCSC; uc003axf.3; human. [P01127-1]
DR   CTD; 5155; -.
DR   GeneCards; PDGFB; -.
DR   HGNC; HGNC:8800; PDGFB.
DR   HPA; CAB011604; -.
DR   HPA; CAB018341; -.
DR   HPA; HPA011972; -.
DR   MalaCards; PDGFB; -.
DR   MIM; 190040; gene.
DR   MIM; 607907; phenotype.
DR   MIM; 615483; phenotype.
DR   neXtProt; NX_P01127; -.
DR   Orphanet; 1980; Bilateral striopallidodentate calcinosis.
DR   Orphanet; 31112; Dermatofibrosarcoma protuberans.
DR   Orphanet; 263662; Familial multiple meningioma.
DR   PharmGKB; PA33145; -.
DR   eggNOG; ENOG410IJ45; Eukaryota.
DR   eggNOG; ENOG410XWTB; LUCA.
DR   GeneTree; ENSGT00510000046755; -.
DR   HOGENOM; HOG000286027; -.
DR   HOVERGEN; HBG053546; -.
DR   InParanoid; P01127; -.
DR   KO; K17386; -.
DR   OMA; HGDSVDE; -.
DR   OrthoDB; EOG78H3VV; -.
DR   PhylomeDB; P01127; -.
DR   TreeFam; TF319554; -.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-186763; Downstream signal transduction.
DR   Reactome; R-HSA-186797; Signaling by PDGF.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-3000171; Non-integrin membrane-ECM interactions.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   SignaLink; P01127; -.
DR   ChiTaRS; PDGFB; human.
DR   EvolutionaryTrace; P01127; -.
DR   GeneWiki; PDGFB; -.
DR   GenomeRNAi; 5155; -.
DR   NextBio; 19940; -.
DR   PMAP-CutDB; P01127; -.
DR   PRO; PR:P01127; -.
DR   Proteomes; UP000005640; Chromosome 22.
DR   Bgee; P01127; -.
DR   CleanEx; HS_PDGFB; -.
DR   ExpressionAtlas; P01127; baseline and differential.
DR   Genevisible; P01127; HS.
DR   GO; GO:0016323; C:basolateral plasma membrane; ISS:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IDA:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0005576; C:extracellular region; NAS:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IBA:GO_Central.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0031093; C:platelet alpha granule lumen; TAS:Reactome.
DR   GO; GO:0042056; F:chemoattractant activity; IDA:BHF-UCL.
DR   GO; GO:0005518; F:collagen binding; IDA:MGI.
DR   GO; GO:0008083; F:growth factor activity; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0048407; F:platelet-derived growth factor binding; IPI:BHF-UCL.
DR   GO; GO:0005161; F:platelet-derived growth factor receptor binding; NAS:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:BHF-UCL.
DR   GO; GO:0016176; F:superoxide-generating NADPH oxidase activator activity; IDA:UniProtKB.
DR   GO; GO:0000186; P:activation of MAPKK activity; TAS:Reactome.
DR   GO; GO:0032147; P:activation of protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0032148; P:activation of protein kinase B activity; IDA:UniProtKB.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0060326; P:cell chemotaxis; IDA:UniProtKB.
DR   GO; GO:0016049; P:cell growth; IEA:Ensembl.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IDA:BHF-UCL.
DR   GO; GO:0071506; P:cellular response to mycophenolic acid; ISS:UniProtKB.
DR   GO; GO:0006260; P:DNA replication; IEA:Ensembl.
DR   GO; GO:0001892; P:embryonic placenta development; ISS:UniProtKB.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007507; P:heart development; ISS:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; TAS:Reactome.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0072255; P:metanephric glomerular mesangial cell development; ISS:UniProtKB.
DR   GO; GO:0002548; P:monocyte chemotaxis; IDA:BHF-UCL.
DR   GO; GO:0010512; P:negative regulation of phosphatidylinositol biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0010544; P:negative regulation of platelet activation; IDA:BHF-UCL.
DR   GO; GO:0032091; P:negative regulation of protein binding; IDA:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0038001; P:paracrine signaling; ISS:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; TAS:Reactome.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0002576; P:platelet degranulation; TAS:Reactome.
DR   GO; GO:0048008; P:platelet-derived growth factor receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0050918; P:positive chemotaxis; IDA:GOC.
DR   GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; IDA:BHF-UCL.
DR   GO; GO:0090280; P:positive regulation of calcium ion import; IDA:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0050921; P:positive regulation of chemotaxis; IDA:UniProtKB.
DR   GO; GO:0045737; P:positive regulation of cyclin-dependent protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:2000573; P:positive regulation of DNA biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0045740; P:positive regulation of DNA replication; IDA:BHF-UCL.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0048146; P:positive regulation of fibroblast proliferation; IDA:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; IDA:UniProtKB.
DR   GO; GO:0003104; P:positive regulation of glomerular filtration; ISS:UniProtKB.
DR   GO; GO:0072126; P:positive regulation of glomerular mesangial cell proliferation; IDA:UniProtKB.
DR   GO; GO:1900127; P:positive regulation of hyaluronan biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IDA:UniProtKB.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IMP:UniProtKB.
DR   GO; GO:2000591; P:positive regulation of metanephric mesenchymal cell migration; IDA:UniProtKB.
DR   GO; GO:0035793; P:positive regulation of metanephric mesenchymal cell migration by platelet-derived growth factor receptor-beta signaling pathway; IDA:UniProtKB.
DR   GO; GO:0045840; P:positive regulation of mitotic nuclear division; IDA:UniProtKB.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; IDA:UniProtKB.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; IDA:UniProtKB.
DR   GO; GO:0031954; P:positive regulation of protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0061098; P:positive regulation of protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IDA:UniProtKB.
DR   GO; GO:0014911; P:positive regulation of smooth muscle cell migration; IDA:UniProtKB.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IDA:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0070528; P:protein kinase C signaling; IMP:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0007265; P:Ras protein signal transduction; TAS:Reactome.
DR   GO; GO:0072593; P:reactive oxygen species metabolic process; IMP:UniProtKB.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0032355; P:response to estradiol; IEA:Ensembl.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0009611; P:response to wounding; NAS:UniProtKB.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; TAS:Reactome.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   Gene3D; 2.10.90.10; -; 1.
DR   InterPro; IPR029034; Cystine-knot_cytokine.
DR   InterPro; IPR023581; PD_growth_factor_CS.
DR   InterPro; IPR000072; PDGF/VEGF_dom.
DR   InterPro; IPR006782; PDGF_N.
DR   Pfam; PF00341; PDGF; 1.
DR   Pfam; PF04692; PDGF_N; 1.
DR   SMART; SM00141; PDGF; 1.
DR   SUPFAM; SSF57501; SSF57501; 1.
DR   PROSITE; PS00249; PDGF_1; 1.
DR   PROSITE; PS50278; PDGF_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative promoter usage; Chromosomal rearrangement;
KW   Cleavage on pair of basic residues; Complete proteome;
KW   Developmental protein; Direct protein sequencing; Disease mutation;
KW   Disulfide bond; Glycoprotein; Growth factor; Mitogen; Pharmaceutical;
KW   Polymorphism; Proto-oncogene; Reference proteome; Secreted; Signal.
FT   SIGNAL        1     20
FT   PROPEP       21     81       Removed in mature form.
FT                                /FTId=PRO_0000023371.
FT   CHAIN        82    190       Platelet-derived growth factor subunit B.
FT                                /FTId=PRO_0000023372.
FT   PROPEP      191    241       Removed in mature form.
FT                                /FTId=PRO_0000023373.
FT   SITE        108    108       Involved in receptor binding.
FT   SITE        111    111       Involved in receptor binding.
FT   CARBOHYD     63     63       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     97    141       {ECO:0000269|PubMed:20534510}.
FT   DISULFID    124    124       Interchain.
FT                                {ECO:0000269|PubMed:20534510}.
FT   DISULFID    130    178       {ECO:0000269|PubMed:20534510}.
FT   DISULFID    133    133       Interchain.
FT                                {ECO:0000269|PubMed:20534510}.
FT   DISULFID    134    180       {ECO:0000269|PubMed:20534510}.
FT   VAR_SEQ       1     21       MNRCWALFLSLCCYLRLVSAE -> MFIMGL (in
FT                                isoform 2). {ECO:0000303|PubMed:7659502}.
FT                                /FTId=VSP_044913.
FT   VARIANT       9      9       L -> R (in IBGC5).
FT                                {ECO:0000269|PubMed:23913003}.
FT                                /FTId=VAR_070870.
FT   VARIANT      88     88       I -> V (in dbSNP:rs17565).
FT                                /FTId=VAR_014578.
FT   VARIANT     119    119       L -> P (in IBGC5).
FT                                {ECO:0000269|PubMed:23913003}.
FT                                /FTId=VAR_070871.
FT   CONFLICT    101    101       T -> E (in Ref. 16; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    105    105       E -> C (in Ref. 16; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    107    107       S -> C (in Ref. 16; AA sequence).
FT                                {ECO:0000305}.
FT   STRAND       97    105       {ECO:0000244|PDB:4HQU}.
FT   HELIX       108    111       {ECO:0000244|PDB:4HQU}.
FT   STRAND      118    121       {ECO:0000244|PDB:4HQU}.
FT   STRAND      123    131       {ECO:0000244|PDB:4HQU}.
FT   STRAND      140    159       {ECO:0000244|PDB:4HQU}.
FT   STRAND      162    181       {ECO:0000244|PDB:4HQU}.
SQ   SEQUENCE   241 AA;  27283 MW;  9F9A3474CE203C0B CRC64;
     MNRCWALFLS LCCYLRLVSA EGDPIPEELY EMLSDHSIRS FDDLQRLLHG DPGEEDGAEL
     DLNMTRSHSG GELESLARGR RSLGSLTIAE PAMIAECKTR TEVFEISRRL IDRTNANFLV
     WPPCVEVQRC SGCCNNRNVQ CRPTQVQLRP VQVRKIEIVR KKPIFKKATV TLEDHLACKC
     ETVAAARPVT RSPGGSQEQR AKTPQTRVTI RTVRVRRPPK GKHRKFKHTH DKTALKETLG
     A
//
ID   CO1A2_HUMAN             Reviewed;        1366 AA.
AC   P08123; P02464; Q13897; Q13997; Q13998; Q14038; Q14057; Q15177;
AC   Q15947; Q16480; Q16511; Q7Z5S6; Q9UEB6; Q9UEF9; Q9UM83; Q9UMI1;
AC   Q9UML5; Q9UMM6; Q9UPH0;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   18-MAY-2010, sequence version 7.
DT   17-FEB-2016, entry version 189.
DE   RecName: Full=Collagen alpha-2(I) chain;
DE   AltName: Full=Alpha-2 type I collagen;
DE   Flags: Precursor;
GN   Name=COL1A2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS ASN-249; THR-276; VAL-483;
RP   ALA-549; HIS-678; GLY-743; PHE-1022; GLU-1189; PRO-1198 AND HIS-1354.
RX   PubMed=2824475;
RA   de Wet W.J., Bernard M.P., Benson-Chanda V., Chu M.-L., Dickson L.A.,
RA   Weil D., Ramirez F.;
RT   "Organization of the human pro-alpha 2(I) collagen gene.";
RL   J. Biol. Chem. 262:16032-16036(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], REVIEW ON OI VARIANTS, AND VARIANTS
RP   ALA-549; HIS-678 AND HIS-1354.
RX   PubMed=9016532; DOI=10.1093/nar/25.1.181;
RA   Dalgleish R.;
RT   "The human type I collagen mutation database.";
RL   Nucleic Acids Res. 25:181-187(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ILE-270; VAL-483;
RP   HIS-678; GLY-743; PHE-1022; GLU-1189; PRO-1198 AND HIS-1354.
RX   PubMed=9443882; DOI=10.1086/301689;
RA   Korkko J.M., Ala-Kokko L., De Paepe A., Nuytinck L., Earley J.J.,
RA   Prockop D.J.;
RT   "Analysis of the COL1A1 and COL1A2 genes by PCR amplification and
RT   scanning by conformation-sensitive gel electrophoresis identifies only
RT   COL1A1 mutations in 15 patients with osteogenesis imperfecta type I:
RT   identification of common sequences of null-allele mutations.";
RL   Am. J. Hum. Genet. 62:98-110(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ALA-549.
RC   TISSUE=Skin, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-765, AND VARIANTS HIS-678 AND GLY-743.
RC   TISSUE=Placenta;
RX   PubMed=3421913;
RA   Kuivaniemi H., Tromp G., Chu M.-L., Prockop D.J.;
RT   "Structure of a full-length cDNA clone for the prepro alpha 2(I) chain
RT   of human type I procollagen. Comparison with the chicken gene confirms
RT   unusual patterns of gene conservation.";
RL   Biochem. J. 252:633-640(1988).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-93, AND VARIANT PRO-59.
RX   PubMed=4011429; DOI=10.1093/nar/13.10.3427;
RA   Dickson L.A., de Wet W., Di Liberto M., Weil D., Ramirez F.;
RT   "Analysis of the promoter region and the N-propeptide domain of the
RT   human pro alpha 2(I) collagen gene.";
RL   Nucleic Acids Res. 13:3427-3438(1985).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-32.
RA   Akai J., Kimura A., Arai K., Uehara K., Hata R.;
RT   "Fine structural analysis of the unique 5' region of the human COL1A2
RT   gene containing two regions of dinucleotide repeats adjacent to the
RT   transcriptional start site.";
RL   Connect. Tissue Res. 30:1-6(1998).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 76-93, AND VARIANT EDS7B
RP   76-ASN--MET-93 DEL.
RX   PubMed=2394758;
RA   Weil D., D'Alessio M., Ramirez F., Eyre D.R.;
RT   "Structural and functional characterization of a splicing mutation in
RT   the pro-alpha 2(I) collagen gene of an Ehlers-Danlos type VII
RT   patient.";
RL   J. Biol. Chem. 265:16007-16011(1990).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 76-93, AND VARIANT EDS7B
RP   76-ASN--MET-93 DEL.
RX   PubMed=1577745;
RA   Watson R.B., Wallis G.A., Holmes D.F., Viljoen D., Byers P.H.,
RA   Kadler K.E.;
RT   "Ehlers Danlos syndrome type VIIB. Incomplete cleavage of abnormal
RT   type I procollagen by N-proteinase in vitro results in the formation
RT   of copolymers of collagen and partially cleaved pNcollagen that are
RT   near circular in cross-section.";
RL   J. Biol. Chem. 267:9093-9100(1992).
RN   [10]
RP   PROTEIN SEQUENCE OF 80-96.
RC   TISSUE=Skin;
RX   PubMed=5529814; DOI=10.1021/bi00826a012;
RA   Click E.M., Bornstein P.;
RT   "Isolation and characterization of the cyanogen bromide peptides from
RT   the alpha 1 and alpha 2 chains of human skin collagen.";
RL   Biochemistry 9:4699-4706(1970).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 145-198.
RX   PubMed=3403536;
RA   Kuivaniemi H., Sabol C., Tromp G., Sippola-Thiele M., Prockop D.J.;
RT   "A 19-base pair deletion in the pro-alpha 2(I) gene of type I
RT   procollagen that causes in-frame RNA splicing from exon 10 to exon 12
RT   in a proband with atypical osteogenesis imperfecta and in his
RT   asymptomatic mother.";
RL   J. Biol. Chem. 263:11407-11413(1988).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 163-213, AND VARIANT OI4
RP   181-GLY--LYS-198 DEL.
RX   PubMed=1642148; DOI=10.1002/jbmr.5650070709;
RA   Chipman S.D., Shapiro J.R., McKinstry M.B., Stover M.L., Branson P.,
RA   Rowe D.W.;
RT   "Expression of mutant alpha (I)-procollagen in osteoblast and
RT   fibroblast cultures from a proband with osteogenesis imperfecta type
RT   IV.";
RL   J. Bone Miner. Res. 7:793-805(1992).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 181-1366.
RA   Kalicki J., Wamsley P., Gibson A.;
RL   Submitted (SEP-1997) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   PROTEIN SEQUENCE OF 417-447, AND HYDROXYLATION AT PRO-420; PRO-441 AND
RP   PRO-444.
RC   TISSUE=Skin;
RX   PubMed=4412529; DOI=10.1111/j.1432-1033.1974.tb03689.x;
RA   Fietzek P.P., Furthmayr H., Kuehn K.;
RT   "Comparative sequence studies on alpha2-CB2 from calf, human, rabbit
RT   and pig-skin collagen.";
RL   Eur. J. Biochem. 47:257-261(1974).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 520-573, AND VARIANT ALA-549.
RX   PubMed=2839839; DOI=10.1073/pnas.85.14.5254;
RA   Tromp G., Prockop D.J.;
RT   "Single base mutation in the pro alpha 2(I) collagen gene that causes
RT   efficient splicing of RNA from exon 27 to exon 29 and synthesis of a
RT   shortened but in-frame pro alpha 2(I) chain.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:5254-5258(1988).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 622-657.
RX   PubMed=6321602; DOI=10.1111/1523-1747.ep12260213;
RA   Tajima S., Ting J.P., Pinnell S.R., Kaufman R.E.;
RT   "Isolation and characterization of a human pro alpha 2(I) collagen
RT   gene segment.";
RL   J. Invest. Dermatol. 82:265-269(1984).
RN   [17]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 623-1366, AND VARIANTS HIS-678;
RP   PHE-1022; GLU-1189; PRO-1198 AND HIS-1354.
RX   PubMed=6687691; DOI=10.1021/bi00274a023;
RA   Bernard M.P., Myers J.C., Chu M.-L., Ramirez F., Eikenberry E.F.,
RA   Prockop D.J.;
RT   "Structure of a cDNA for the pro alpha 2 chain of human type I
RT   procollagen. Comparison with chick cDNA for pro alpha 2(I) identifies
RT   structurally conserved features of the protein and the gene.";
RL   Biochemistry 22:1139-1145(1983).
RN   [18]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 631-864, AND VARIANT OI2
RP   676-GLY--ALA-855 DEL.
RX   PubMed=1339453;
RA   Chessler S.D., Byers P.H.;
RT   "Defective folding and stable association with protein disulfide
RT   isomerase/prolyl hydroxylase of type I procollagen with a deletion in
RT   the pro alpha 2(I) chain that preserves the Gly-X-Y repeat pattern.";
RL   J. Biol. Chem. 267:7751-7757(1992).
RN   [19]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 663-746, AND VARIANT OI3 VAL-676.
RX   PubMed=7881420; DOI=10.1093/hmg/3.12.2201;
RA   Forlino A., Zolezzi F., Valli M., Pignatti P.F., Cetta G.,
RA   Brunelli P.C., Mottes M.;
RT   "Severe (type III) osteogenesis imperfecta due to glycine
RT   substitutions in the central domain of the collagen triple helix.";
RL   Hum. Mol. Genet. 3:2201-2206(1994).
RN   [20]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 960-1356, AND VARIANT HIS-1354.
RC   TISSUE=Skin;
RX   PubMed=2364107;
RA   Maekelae J.K., Vuorio T., Vuorio E.;
RT   "Growth-dependent modulation of type I collagen production and mRNA
RT   levels in cultured human skin fibroblasts.";
RL   Biochim. Biophys. Acta 1049:171-176(1990).
RN   [21]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 964-1019.
RX   PubMed=6267597; DOI=10.1073/pnas.78.6.3516;
RA   Myers J.C., Chu M.-L., Faro S.H., Clark W.J., Prockop D.J.,
RA   Ramirez F.;
RT   "Cloning a cDNA for the pro-alpha 2 chain of human type I collagen.";
RL   Proc. Natl. Acad. Sci. U.S.A. 78:3516-3520(1981).
RN   [22]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 1090-1107, AND VARIANT OI4
RP   ARG-1102.
RX   PubMed=2897363;
RA   Wenstrup R.J., Cohn D.H., Cohen T., Byers P.H.;
RT   "Arginine for glycine substitution in the triple-helical domain of the
RT   products of one alpha 2(I) collagen allele (COL1A2) produces the
RT   osteogenesis imperfecta type IV phenotype.";
RL   J. Biol. Chem. 263:7734-7740(1988).
RN   [23]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1319-1366, AND VARIANT HIS-1354.
RX   PubMed=6309769;
RA   Myers J.C., Dickson L.A., de Wet W.J., Bernard M.P., Chu M.-L.,
RA   Di Liberto M., Pepe G., Sangiorgi F.O., Ramirez F.;
RT   "Analysis of the 3' end of the human pro-alpha 2(I) collagen gene.
RT   Utilization of multiple polyadenylation sites in cultured
RT   fibroblasts.";
RL   J. Biol. Chem. 258:10128-10135(1983).
RN   [24]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1319-1366, AND VARIANT HIS-1354.
RC   TISSUE=Skin;
RX   PubMed=6092353;
RA   Pihlajaniemi T., Dickson L.A., Pope F.M., Korhonen V.R., Nicholls A.,
RA   Prockop D.J., Myers J.C.;
RT   "Osteogenesis imperfecta: cloning of a pro-alpha 2(I) collagen gene
RT   with a frameshift mutation.";
RL   J. Biol. Chem. 259:12941-12944(1984).
RN   [25]
RP   REVIEW ON VARIANTS.
RX   PubMed=2010058;
RA   Kuivaniemi H., Tromp G., Prockop D.J.;
RT   "Mutations in collagen genes: causes of rare and some common diseases
RT   in humans.";
RL   FASEB J. 5:2052-2060(1991).
RN   [26]
RP   REVIEW ON VARIANTS.
RX   PubMed=9101290;
RX   DOI=10.1002/(SICI)1098-1004(1997)9:4<300::AID-HUMU2>3.0.CO;2-9;
RA   Kuivaniemi H., Tromp G., Prockop D.J.;
RT   "Mutations in fibrillar collagens (types I, II, III, and XI), fibril-
RT   associated collagen (type IX), and network-forming collagen (type X)
RT   cause a spectrum of diseases of bone, cartilage, and blood vessels.";
RL   Hum. Mutat. 9:300-315(1997).
RN   [27]
RP   REVIEW ON OI VARIANTS.
RX   PubMed=1895312; DOI=10.1136/jmg.28.7.433;
RA   Byers P.H., Wallis G.A., Willing M.C.;
RT   "Osteogenesis imperfecta: translation of mutation to phenotype.";
RL   J. Med. Genet. 28:433-442(1991).
RN   [28]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22905912; DOI=10.1021/pr300539b;
RA   Rosenow A., Noben J.P., Jocken J., Kallendrusch S.,
RA   Fischer-Posovszky P., Mariman E.C., Renes J.;
RT   "Resveratrol-induced changes of the human adipocyte secretion
RT   profile.";
RL   J. Proteome Res. 11:4733-4743(2012).
RN   [29]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [30]
RP   VARIANT EDS7B 76-ASN--MET-93 DEL.
RX   PubMed=3680255;
RA   Wirtz M.K., Glanville R.W., Steinmann B., Rao V.H., Hollister D.W.;
RT   "Ehlers-Danlos syndrome type VIIB. Deletion of 18 amino acids
RT   comprising the N-telopeptide region of a pro-alpha 2(I) chain.";
RL   J. Biol. Chem. 262:16376-16385(1987).
RN   [31]
RP   VARIANT OI2 ASP-997.
RX   PubMed=2914942;
RA   Baldwin C.T., Constantinou C., Dumars K.W., Prockop D.J.;
RT   "A single base mutation that converts glycine 907 of the alpha 2(I)
RT   chain of type I procollagen to aspartate in a lethal variant of
RT   osteogenesis imperfecta. The single amino acid substitution near the
RT   carboxyl terminus destabilizes the whole triple helix.";
RL   J. Biol. Chem. 264:3002-3006(1989).
RN   [32]
RP   VARIANT OI2 SER-955.
RX   PubMed=2777764;
RA   Lamande S.R., Dahl H.-H.M., Cole W.G., Bateman J.F.;
RT   "Characterization of point mutations in the collagen COL1A1 and COL1A2
RT   genes causing lethal perinatal osteogenesis imperfecta.";
RL   J. Biol. Chem. 264:15809-15812(1989).
RN   [33]
RP   VARIANT OI2 CYS-877.
RA   Fertala A., Westerhausen A., Morris G.M., Rooney J.E., Prockop D.J.;
RT   "Two cysteine substitutions in the type I procollagen genes (COL1A1
RT   and COL1A2) that cause lethal osteogenesis imperfecta. The location of
RT   glycine substitutions does not in any simple way predict their effects
RT   on protein function or phenotype.";
RL   Am. J. Hum. Genet. 47:A216-A216(1990).
RN   [34]
RP   VARIANT OI4 VAL-676.
RX   PubMed=2064612;
RA   Bateman J.F., Hannagan M., Chan D., Cole W.G.;
RT   "Characterization of a type I collagen alpha 2(I) glycine-586 to
RT   valine substitution in osteogenesis imperfecta type IV. Detection of
RT   the mutation and prenatal diagnosis by a chemical cleavage method.";
RL   Biochem. J. 276:765-770(1991).
RN   [35]
RP   VARIANT OI3 CYS-349, AND VARIANT OI1 CYS-736.
RX   PubMed=1990009;
RA   Wenstrup R.J., Shrago-Howe A.W., Lever L.W., Phillips C.L.,
RA   Byers P.H., Cohn D.H.;
RT   "The effects of different cysteine for glycine substitutions within
RT   alpha 2(I) chains. Evidence of distinct structural domains within the
RT   type I collagen triple helix.";
RL   J. Biol. Chem. 266:2590-2594(1991).
RN   [36]
RP   VARIANT OI2 ARG-784.
RX   PubMed=1874719;
RA   Tsuneyoshi T., Westerhausen A., Constantinou C.D., Prockop D.J.;
RT   "Substitutions for glycine alpha 1-637 and glycine alpha 2-694 of type
RT   I procollagen in lethal osteogenesis imperfecta. The conformational
RT   strain on the triple helix introduced by a glycine substitution can be
RT   transmitted along the helix.";
RL   J. Biol. Chem. 266:15608-15613(1991).
RN   [37]
RP   VARIANT OI4 SER-751.
RX   PubMed=2052622; DOI=10.1073/pnas.88.12.5423;
RA   Spotila L.D., Constantinou C.D., Sereda L., Ganguly A., Riggs B.L.,
RA   Prockop D.J.;
RT   "Mutation in a gene for type I procollagen (COL1A2) in a woman with
RT   postmenopausal osteoporosis: evidence for phenotypic and genotypic
RT   overlap with mild osteogenesis imperfecta.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:5423-5427(1991).
RN   [38]
RP   VARIANT OI2 ARG-547.
RX   PubMed=1284475; DOI=10.1002/humu.1380010109;
RA   Bateman J.F., Moeller I., Hannagan M., Chan D., Cole W.G.;
RT   "Lethal perinatal osteogenesis imperfecta due to a type I collagen
RT   alpha 2(I) Gly to Arg substitution detected by chemical cleavage of an
RT   mRNA:cDNA sequence mismatch.";
RL   Hum. Mutat. 1:55-62(1992).
RN   [39]
RP   VARIANT OI2 ASP-670.
RX   PubMed=1385413;
RA   Niyibizi C., Bonadio J., Byers P.H., Eyre D.R.;
RT   "Incorporation of type I collagen molecules that contain a mutant
RT   alpha 2(I) chain (Gly580-->Asp) into bone matrix in a lethal case of
RT   osteogenesis imperfecta.";
RL   J. Biol. Chem. 267:23108-23112(1992).
RN   [40]
RP   VARIANT OI3 CYS-349, AND VARIANT OI1 CYS-736.
RX   PubMed=8456807; DOI=10.1002/ajmg.1320450215;
RA   Wenstrup R.J., Lever L.W., Phillips C.L., Quarles L.D.;
RT   "Mutations in the COL1A2 gene of type I collagen that result in
RT   nonlethal forms of osteogenesis imperfecta.";
RL   Am. J. Med. Genet. 45:228-232(1993).
RN   [41]
RP   VARIANT ALA-549.
RX   PubMed=8456808; DOI=10.1002/ajmg.1320450216;
RA   Bateman J.F., Lamande S.R., Hannagan M., Moeller I., Dahl H.-H.M.,
RA   Cole W.G.;
RT   "Chemical cleavage method for the detection of RNA base changes:
RT   experience in the application to collagen mutations in osteogenesis
RT   imperfecta.";
RL   Am. J. Med. Genet. 45:233-240(1993).
RN   [42]
RP   VARIANT OI3 VAL-345 DEL.
RX   PubMed=8444468; DOI=10.1007/BF00202479;
RA   Molyneux K., Starman B.J., Byers P.H., Dalgleish R.;
RT   "A single amino acid deletion in the alpha 2(I) chain of type I
RT   collagen produces osteogenesis imperfecta type III.";
RL   Hum. Genet. 90:621-628(1993).
RN   [43]
RP   VARIANT OI4 VAL-634.
RX   PubMed=8401517; DOI=10.1093/hmg/2.8.1319;
RA   Sztrolovics R., Glorieux F.H., van der Rest M., Roughley P.J.;
RT   "Identification of type I collagen gene (COL1A2) mutations in
RT   nonlethal osteogenesis imperfecta.";
RL   Hum. Mol. Genet. 2:1319-1321(1993).
RN   [44]
RP   VARIANT OI2 GLU-433.
RX   PubMed=7906591; DOI=10.1093/hmg/2.12.2175;
RA   Rose N.J., Mackay K., Byers P.H., Dalgleish R.;
RT   "A novel glycine to glutamic acid substitution at position 343 in the
RT   alpha 2 chain of type I collagen in an individual with lethal
RT   osteogenesis imperfecta.";
RL   Hum. Mol. Genet. 2:2175-2177(1993).
RN   [45]
RP   VARIANT OI4 SER-1012.
RX   PubMed=8094076;
RA   Marini J.C., Lewis M.B., Wang Q., Chen K.J., Orrison B.M.;
RT   "Serine for glycine substitutions in type I collagen in two cases of
RT   type IV osteogenesis imperfecta (OI). Additional evidence for a
RT   regional model of OI pathophysiology.";
RL   J. Biol. Chem. 268:2667-2673(1993).
RN   [46]
RP   VARIANT OI4 VAL-766, AND VARIANT OI2 SER-796.
RX   PubMed=7693712;
RA   Wang Q., Orrison B.M., Marini J.C.;
RT   "Two additional cases of osteogenesis imperfecta with substitutions
RT   for glycine in the alpha 2(I) collagen chain. A regional model
RT   relating mutation location with phenotype.";
RL   J. Biol. Chem. 268:25162-25167(1993).
RN   [47]
RP   VARIANT OI3 ARG-517.
RX   PubMed=7520724; DOI=10.1016/8756-3282(94)90295-X;
RA   Sztrolovics R., Glorieux F.H., Travers R., van der Rest M.,
RA   Roughley P.J.;
RT   "Osteogenesis imperfecta: comparison of molecular defects with bone
RT   histological changes.";
RL   Bone 15:321-328(1994).
RN   [48]
RP   VARIANT OI2 SER-592.
RX   PubMed=7959683; DOI=10.1007/BF00211014;
RA   Rose N.J., Mackay K., de Paepe A., Steinmann B., Punnett H.H.,
RA   Dalgleish R.;
RT   "Three unrelated individuals with perinatally lethal osteogenesis
RT   imperfecta resulting from identical Gly502Ser substitutions in the
RT   alpha 2-chain of type I collagen.";
RL   Hum. Genet. 94:497-503(1994).
RN   [49]
RP   VARIANT OI3 SER-949.
RX   PubMed=8081394; DOI=10.1002/humu.1380030411;
RA   Rose N.J., Mackay K., Byers P.H., Dalgleish R.;
RT   "A Gly859Ser substitution in the triple helical domain of the alpha 2
RT   chain of type I collagen resulting in osteogenesis imperfecta type III
RT   in two unrelated individuals.";
RL   Hum. Mutat. 3:391-394(1994).
RN   [50]
RP   VARIANT OI2 ASP-790.
RX   PubMed=8182080;
RA   Cohen-Solal L., Zylberberg L., Sangalli A., Gomez Lira M., Mottes M.;
RT   "Substitution of an aspartic acid for glycine 700 in the alpha 2(I)
RT   chain of type I collagen in a recurrent lethal type II osteogenesis
RT   imperfecta dramatically affects the mineralization of bone.";
RL   J. Biol. Chem. 269:14751-14758(1994).
RN   [51]
RP   VARIANT OI2 CYS-730.
RX   PubMed=7891382; DOI=10.1136/jmg.31.12.965;
RA   Gomez Lira M., Sangalli A., Pignatti P.F., Digilio M.C., Giannotti A.,
RA   Carnevale E., Mottes M.;
RT   "Determination of a new collagen type I alpha 2 gene point mutation
RT   which causes a Gly640 Cys substitution in osteogenesis imperfecta and
RT   prenatal diagnosis by DNA hybridisation.";
RL   J. Med. Genet. 31:965-968(1994).
RN   [52]
RP   VARIANT OI3 SER-778.
RX   PubMed=7720740; DOI=10.1007/BF01991915;
RA   Raghunath M., Mackay K., Dalgleish R., Steinmann B.;
RT   "Genetic counselling on brittle grounds: recurring osteogenesis
RT   imperfecta due to parental mosaicism for a dominant mutation.";
RL   Eur. J. Pediatr. 154:123-129(1995).
RN   [53]
RP   VARIANT OI3 SER-328.
RX   PubMed=7860070; DOI=10.1007/BF00209405;
RA   Rose N.J., Mackay K., Byers P.H., Dalgleish R.;
RT   "A Gly238Ser substitution in the alpha 2 chain of type I collagen
RT   results in osteogenesis imperfecta type III.";
RL   Hum. Genet. 95:215-218(1995).
RN   [54]
RP   VARIANT OI3 ALA-1096.
RX   PubMed=7749416; DOI=10.1002/humu.1380050212;
RA   Lu J., Costa T., Cole W.G.;
RT   "A novel G1006A substitution in the alpha 2(I) chain of type I
RT   collagen produces osteogenesis imperfecta type III.";
RL   Hum. Mutat. 5:175-178(1995).
RN   [55]
RP   VARIANT OI3 ASP-892, AND VARIANT OI4 ASP-892.
RX   PubMed=8800927;
RA   Lund A.M., Schwartz M., Raghunath M., Steinmann B., Skovby F.;
RT   "Gly802Asp substitution in the pro alpha 2(I) collagen chain in a
RT   family with recurrent osteogenesis imperfecta due to paternal
RT   mosaicism.";
RL   Eur. J. Hum. Genet. 4:39-45(1996).
RN   [56]
RP   VARIANTS OI1 ASP-211 AND SER-835, VARIANTS OI3 SER-337 AND SER-460,
RP   AND VARIANT HIS-822.
RX   PubMed=8829649;
RX   DOI=10.1002/(SICI)1098-1004(1996)7:2<89::AID-HUMU1>3.0.CO;2-K;
RA   Zhuang J., Tromp G., Kuivaniemi H., Castells S., Bugge M.,
RA   Prockop D.J.;
RT   "Direct sequencing of PCR products derived from cDNAs for the pro
RT   alpha 1 and pro alpha 2 chains of type I procollagen as a screening
RT   method to detect mutations in patients with osteogenesis imperfecta.";
RL   Hum. Mutat. 7:89-99(1996).
RN   [57]
RP   VARIANT OI3 PRO-1148.
RX   PubMed=8723681;
RX   DOI=10.1002/(SICI)1098-1004(1996)7:4<318::AID-HUMU5>3.0.CO;2-4;
RA   Oliver J.E., Thompson E.M., Pope F.M., Nicholls A.C.;
RT   "Mutation in the carboxy-terminal propeptide of the Pro alpha 1(I)
RT   chain of type I collagen in a child with severe osteogenesis
RT   imperfecta (OI type III): possible implications for protein folding.";
RL   Hum. Mutat. 7:318-326(1996).
RN   [58]
RP   VARIANTS OI2 VAL-409 AND CYS-787.
RX   PubMed=10627137;
RX   DOI=10.1002/(SICI)1098-1004(1998)12:1<71::AID-HUMU16>3.0.CO;2-4;
RA   Mottes M., Gomez Lira M., Zolezzi F., Valli M., Lisi V., Freising P.;
RT   "Four new cases of lethal osteogenesis imperfecta due to glycine
RT   substitutions in COL1A1 and genes.";
RL   Hum. Mutat. 12:71-72(1998).
RN   [59]
RP   VARIANTS OI3 ASP-331; CYS-337 AND VAL-973.
RX   PubMed=10408781;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:6<503::AID-HUMU11>3.0.CO;2-L;
RA   Lund A.M., Astroem E., Soederhaell S., Schwartz M., Skovby F.;
RT   "Osteogenesis imperfecta: mosaicism and refinement of the genotype-
RT   phenotype map in OI type III.";
RL   Hum. Mutat. 13:503-503(1999).
RN   [60]
RP   CHROMOSOMAL REARRANGEMENT WITH PLAG1.
RX   PubMed=10987300;
RA   Hibbard M.K., Kozakewich H.P., Dal Cin P., Sciot R., Tan X., Xiao S.,
RA   Fletcher J.A.;
RT   "PLAG1 fusion oncogenes in lipoblastoma.";
RL   Cancer Res. 60:4869-4872(2000).
RN   [61]
RP   INVOLVEMENT IN CARDIAC VALVULAR EDS.
RX   PubMed=15077201; DOI=10.1086/420794;
RA   Schwarze U., Hata R., McKusick V.A., Shinkai H., Hoyme H.E.,
RA   Pyeritz R.E., Byers P.H.;
RT   "Rare autosomal recessive cardiac valvular form of Ehlers-Danlos
RT   syndrome results from mutations in the COL1A2 gene that activate the
RT   nonsense-mediated RNA decay pathway.";
RL   Am. J. Hum. Genet. 74:917-930(2004).
RN   [62]
RP   INVOLVEMENT IN EDSCV.
RX   PubMed=16816023; DOI=10.1136/jmg.2005.038224;
RA   Malfait F., Symoens S., Coucke P., Nunes L., De Almeida S.,
RA   De Paepe A.;
RT   "Total absence of the alpha2(I) chain of collagen type I causes a rare
RT   form of Ehlers-Danlos syndrome with hypermobility and propensity to
RT   cardiac valvular problems.";
RL   J. Med. Genet. 43:E36-E36(2006).
RN   [63]
RP   VARIANTS OI4 SER-193 AND CYS-754, VARIANT OI2 ASP-625, AND VARIANTS
RP   OI3 CYS-835 AND VAL-991.
RX   PubMed=16879195; DOI=10.1111/j.1399-0004.2006.00646.x;
RA   Venturi G., Tedeschi E., Mottes M., Valli M., Camilot M., Viglio S.,
RA   Antoniazzi F., Tato L.;
RT   "Osteogenesis imperfecta: clinical, biochemical and molecular
RT   findings.";
RL   Clin. Genet. 70:131-139(2006).
RN   [64]
RP   VARIANTS OI1/OI3/OI4 GLU-325; SER-328; SER-358; SER-601; ASP-676;
RP   SER-820; ARG-856; SER-1012; PRO-PRO-GLY-811 INS; VAL-GLY-PRO-989 INS
RP   AND 1094-PRO--GLY-1096 DEL.
RX   PubMed=16705691; DOI=10.1002/humu.9423;
RA   Lee K.S., Song H.R., Cho T.J., Kim H.J., Lee T.M., Jin H.S.,
RA   Park H.Y., Kang S., Jung S.C., Koo S.K.;
RT   "Mutational spectrum of type I collagen genes in Korean patients with
RT   osteogenesis imperfecta.";
RL   Hum. Mutat. 27:599-599(2006).
RN   [65]
RP   VARIANTS OI4 ARG-202 AND VAL-256, VARIANTS OI1 ARG-247; ARG-319;
RP   CYS-733 AND TYR-1195, VARIANTS OI2 ASP-253; ASP-982 AND ASP-1003, AND
RP   VARIANT OI3 ASP-1087.
RX   PubMed=16786509; DOI=10.1002/humu.9430;
RA   Pollitt R., McMahon R., Nunn J., Bamford R., Afifi A., Bishop N.,
RA   Dalton A.;
RT   "Mutation analysis of COL1A1 and COL1A2 in patients diagnosed with
RT   osteogenesis imperfecta type I-IV.";
RL   Hum. Mutat. 27:716-716(2006).
RN   [66]
RP   VARIANTS SER-528; ALA-549 AND THR-564.
RX   PubMed=18272325; DOI=10.1016/j.ygeno.2007.12.008;
RA   Chan T.F., Poon A., Basu A., Addleman N.R., Chen J., Phong A.,
RA   Byers P.H., Klein T.E., Kwok P.Y.;
RT   "Natural variation in four human collagen genes across an ethnically
RT   diverse population.";
RL   Genomics 91:307-314(2008).
RN   [67]
RP   VARIANTS OI2 CYS-234; ARG-283; GLU-397; CYS-454; LEU-457;
RP   461-PRO--GLY-466 DEL; GLU-526; VAL-562; 705-ALA--PRO-707 DEL; ARG-739;
RP   VAL-748; ASP-790; PRO-798 INS; 806-PRO--GLY-811 DEL; VAL-856; SER-949;
RP   ASP-955; GLU-1027 AND 1058-PRO--ALA-1062 DEL, AND VARIANT ALA-549.
RX   PubMed=18996919; DOI=10.1093/hmg/ddn374;
RA   Bodian D.L., Chan T.F., Poon A., Schwarze U., Yang K., Byers P.H.,
RA   Kwok P.Y., Klein T.E.;
RT   "Mutation and polymorphism spectrum in osteogenesis imperfecta type
RT   II: implications for genotype-phenotype relationships.";
RL   Hum. Mol. Genet. 18:463-471(2009).
RN   [68]
RP   VARIANT THR-1119, AND CHARACTERIZATION OF VARIANT THR-1119.
RX   PubMed=21344539; DOI=10.1002/humu.21475;
RA   Lindahl K., Barnes A.M., Fratzl-Zelman N., Whyte M.P., Hefferan T.E.,
RA   Makareeva E., Brusel M., Yaszemski M.J., Rubin C.J., Kindmark A.,
RA   Roschger P., Klaushofer K., McAlister W.H., Mumm S., Leikin S.,
RA   Kessler E., Boskey A.L., Ljunggren O., Marini J.C.;
RT   "COL1 C-propeptide cleavage site mutations cause high bone mass
RT   osteogenesis imperfecta.";
RL   Hum. Mutat. 32:598-609(2011).
RN   [69]
RP   VARIANT HIS-1067.
RX   PubMed=23656646; DOI=10.1056/NEJMoa1215458;
RA   Laine C.M., Joeng K.S., Campeau P.M., Kiviranta R., Tarkkonen K.,
RA   Grover M., Lu J.T., Pekkinen M., Wessman M., Heino T.J.,
RA   Nieminen-Pihala V., Aronen M., Laine T., Kroeger H., Cole W.G.,
RA   Lehesjoki A.E., Nevarez L., Krakow D., Curry C.J., Cohn D.H.,
RA   Gibbs R.A., Lee B.H., Maekitie O.;
RT   "WNT1 mutations in early-onset osteoporosis and osteogenesis
RT   imperfecta.";
RL   N. Engl. J. Med. 368:1809-1816(2013).
CC   -!- FUNCTION: Type I collagen is a member of group I collagen
CC       (fibrillar forming collagen).
CC   -!- SUBUNIT: Trimers of one alpha 2(I) and two alpha 1(I) chains.
CC   -!- INTERACTION:
CC       O43765:SGTA; NbExp=3; IntAct=EBI-983038, EBI-347996;
CC       Q9UMX0:UBQLN1; NbExp=3; IntAct=EBI-983038, EBI-741480;
CC       Q9UMX0-2:UBQLN1; NbExp=3; IntAct=EBI-983038, EBI-10173939;
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular
CC       matrix {ECO:0000255|PROSITE-ProRule:PRU00793}.
CC   -!- TISSUE SPECIFICITY: Forms the fibrils of tendon, ligaments and
CC       bones. In bones the fibrils are mineralized with calcium
CC       hydroxyapatite.
CC   -!- DOMAIN: The C-terminal propeptide, also known as COLFI domain,
CC       have crucial roles in tissue growth and repair by controlling both
CC       the intracellular assembly of procollagen molecules and the
CC       extracellular assembly of collagen fibrils. It binds a calcium ion
CC       which is essential for its function (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: Prolines at the third position of the tripeptide repeating
CC       unit (G-X-Y) are hydroxylated in some or all of the chains.
CC       {ECO:0000269|PubMed:4412529}.
CC   -!- DISEASE: Ehlers-Danlos syndrome 7B (EDS7B) [MIM:130060]: A
CC       connective tissue disorder characterized by hyperextensible skin,
CC       atrophic cutaneous scars due to tissue fragility and joint
CC       hyperlaxity. Marked by bilateral congenital hip dislocation,
CC       hyperlaxity of the joints, and recurrent partial dislocations.
CC       {ECO:0000269|PubMed:1577745, ECO:0000269|PubMed:2394758,
CC       ECO:0000269|PubMed:3680255}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Osteogenesis imperfecta 1 (OI1) [MIM:166200]: An
CC       autosomal dominant form of osteogenesis imperfecta, a connective
CC       tissue disorder characterized by low bone mass, bone fragility and
CC       susceptibility to fractures after minimal trauma. Disease severity
CC       ranges from very mild forms without fractures to intrauterine
CC       fractures and perinatal lethality. Extraskeletal manifestations,
CC       which affect a variable number of patients, are dentinogenesis
CC       imperfecta, hearing loss, and blue sclerae. OI1 is a non-deforming
CC       form with normal height or mild short stature, and no
CC       dentinogenesis imperfecta. {ECO:0000269|PubMed:16705691,
CC       ECO:0000269|PubMed:16786509, ECO:0000269|PubMed:1990009,
CC       ECO:0000269|PubMed:8456807, ECO:0000269|PubMed:8829649}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Osteogenesis imperfecta 2 (OI2) [MIM:166210]: An
CC       autosomal dominant form of osteogenesis imperfecta, a connective
CC       tissue disorder characterized by low bone mass, bone fragility and
CC       susceptibility to fractures after minimal trauma. Disease severity
CC       ranges from very mild forms without fractures to intrauterine
CC       fractures and perinatal lethality. Extraskeletal manifestations,
CC       which affect a variable number of patients, are dentinogenesis
CC       imperfecta, hearing loss, and blue sclerae. OI2 is characterized
CC       by bone fragility, with many perinatal fractures, severe bowing of
CC       long bones, undermineralization, and death in the perinatal period
CC       due to respiratory insufficiency. {ECO:0000269|PubMed:10627137,
CC       ECO:0000269|PubMed:1284475, ECO:0000269|PubMed:1339453,
CC       ECO:0000269|PubMed:1385413, ECO:0000269|PubMed:16786509,
CC       ECO:0000269|PubMed:16879195, ECO:0000269|PubMed:1874719,
CC       ECO:0000269|PubMed:18996919, ECO:0000269|PubMed:2777764,
CC       ECO:0000269|PubMed:2914942, ECO:0000269|PubMed:7693712,
CC       ECO:0000269|PubMed:7891382, ECO:0000269|PubMed:7906591,
CC       ECO:0000269|PubMed:7959683, ECO:0000269|PubMed:8182080,
CC       ECO:0000269|Ref.33}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Ehlers-Danlos syndrome, autosomal recessive, cardiac
CC       valvular form (EDSCV) [MIM:225320]: A connective tissue disorder
CC       characterized by hyperextensible skin, atrophic cutaneous scars
CC       due to tissue fragility and joint hyperlaxity. In addition to
CC       joint laxity, skin hyperextensibility and friability, and abnormal
CC       scar formation, patients have mitral valve prolapse and
CC       insufficiency, mitral regurgitation, and aortic insufficiency.
CC       {ECO:0000269|PubMed:16816023}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Osteogenesis imperfecta 3 (OI3) [MIM:259420]: An
CC       autosomal dominant form of osteogenesis imperfecta, a connective
CC       tissue disorder characterized by low bone mass, bone fragility and
CC       susceptibility to fractures after minimal trauma. Disease severity
CC       ranges from very mild forms without fractures to intrauterine
CC       fractures and perinatal lethality. Extraskeletal manifestations,
CC       which affect a variable number of patients, are dentinogenesis
CC       imperfecta, hearing loss, and blue sclerae. OI3 is characterized
CC       by progressively deforming bones, very short stature, a triangular
CC       face, severe scoliosis, grayish sclera and dentinogenesis
CC       imperfecta. {ECO:0000269|PubMed:10408781,
CC       ECO:0000269|PubMed:16786509, ECO:0000269|PubMed:16879195,
CC       ECO:0000269|PubMed:1990009, ECO:0000269|PubMed:7520724,
CC       ECO:0000269|PubMed:7720740, ECO:0000269|PubMed:7749416,
CC       ECO:0000269|PubMed:7860070, ECO:0000269|PubMed:7881420,
CC       ECO:0000269|PubMed:8081394, ECO:0000269|PubMed:8444468,
CC       ECO:0000269|PubMed:8456807, ECO:0000269|PubMed:8723681,
CC       ECO:0000269|PubMed:8800927, ECO:0000269|PubMed:8829649}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Osteogenesis imperfecta 4 (OI4) [MIM:166220]: An
CC       autosomal dominant form of osteogenesis imperfecta, a connective
CC       tissue disorder characterized by low bone mass, bone fragility and
CC       susceptibility to fractures after minimal trauma. Disease severity
CC       ranges from very mild forms without fractures to intrauterine
CC       fractures and perinatal lethality. Extraskeletal manifestations,
CC       which affect a variable number of patients, are dentinogenesis
CC       imperfecta, hearing loss, and blue sclerae. OI4 is characterized
CC       by moderately short stature, mild to moderate scoliosis, grayish
CC       or white sclera and dentinogenesis imperfecta.
CC       {ECO:0000269|PubMed:1642148, ECO:0000269|PubMed:16786509,
CC       ECO:0000269|PubMed:16879195, ECO:0000269|PubMed:2052622,
CC       ECO:0000269|PubMed:2064612, ECO:0000269|PubMed:2897363,
CC       ECO:0000269|PubMed:7693712, ECO:0000269|PubMed:8094076,
CC       ECO:0000269|PubMed:8401517, ECO:0000269|PubMed:8800927}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Note=A chromosomal aberration involving COL1A2 may be a
CC       cause of lipoblastomas, which are benign tumors resulting from
CC       transformation of adipocytes, usually diagnosed in children.
CC       Translocation t(7;8)(p22;q13) with PLAG1.
CC   -!- SIMILARITY: Belongs to the fibrillar collagen family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00793}.
CC   -!- SIMILARITY: Contains 1 fibrillar collagen NC1 domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00793}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/COL1A2ID411ch7q22.html";
CC   -!- WEB RESOURCE: Name=Osteogenesis imperfecta variant database;
CC       Note=Collagen type I alpha 2 (COL1A2);
CC       URL="http://oi.gene.le.ac.uk/home.php?select_db=COL1A2";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J03464; AAB59374.1; -; mRNA.
DR   EMBL; Z74616; CAA98969.1; -; mRNA.
DR   EMBL; AF004877; AAB93981.1; -; Genomic_DNA.
DR   EMBL; BC042586; AAH42586.1; -; mRNA.
DR   EMBL; BC054498; AAH54498.1; -; mRNA.
DR   EMBL; Y00724; CAA68709.1; -; mRNA.
DR   EMBL; X02488; CAA26320.1; -; mRNA.
DR   EMBL; AB004317; BAA25383.1; -; Genomic_DNA.
DR   EMBL; M35391; AAA60041.1; -; Genomic_DNA.
DR   EMBL; S98904; AAB22126.1; -; Genomic_DNA.
DR   EMBL; M21671; AAA59994.1; -; Genomic_DNA.
DR   EMBL; S41099; AAB22761.1; -; mRNA.
DR   EMBL; AC002528; AAB69977.1; -; Genomic_DNA.
DR   EMBL; M21353; AAA52053.1; -; Genomic_DNA.
DR   EMBL; M28985; AAA60356.1; -; Genomic_DNA.
DR   EMBL; V00503; CAA23761.1; -; mRNA.
DR   EMBL; S96821; AAB22020.2; -; mRNA.
DR   EMBL; L47668; AAB59577.1; -; mRNA.
DR   EMBL; X55525; CAA39142.1; -; mRNA.
DR   EMBL; J00114; AAA51996.1; -; mRNA.
DR   EMBL; M22816; AAA51844.1; -; mRNA.
DR   EMBL; M22817; AAA51846.1; -; Genomic_DNA.
DR   EMBL; K01078; AAA51887.1; -; Genomic_DNA.
DR   EMBL; K02568; AAA51850.1; -; Genomic_DNA.
DR   CCDS; CCDS34682.1; -.
DR   PIR; A28500; CGHU2S.
DR   RefSeq; NP_000080.2; NM_000089.3.
DR   UniGene; Hs.489142; -.
DR   ProteinModelPortal; P08123; -.
DR   SMR; P08123; 1151-1365.
DR   BioGrid; 107675; 13.
DR   DIP; DIP-36079N; -.
DR   IntAct; P08123; 15.
DR   MINT; MINT-4791958; -.
DR   STRING; 9606.ENSP00000297268; -.
DR   ChEMBL; CHEMBL2364188; -.
DR   DrugBank; DB00048; Collagenase clostridium histolyticum.
DR   iPTMnet; P08123; -.
DR   PhosphoSite; P08123; -.
DR   BioMuta; COL1A2; -.
DR   DMDM; 296439507; -.
DR   MaxQB; P08123; -.
DR   PaxDb; P08123; -.
DR   PRIDE; P08123; -.
DR   Ensembl; ENST00000297268; ENSP00000297268; ENSG00000164692.
DR   GeneID; 1278; -.
DR   KEGG; hsa:1278; -.
DR   UCSC; uc003ung.1; human.
DR   CTD; 1278; -.
DR   GeneCards; COL1A2; -.
DR   GeneReviews; COL1A2; -.
DR   H-InvDB; HIX0006854; -.
DR   HGNC; HGNC:2198; COL1A2.
DR   HPA; CAB032650; -.
DR   MalaCards; COL1A2; -.
DR   MIM; 120160; gene.
DR   MIM; 130060; phenotype.
DR   MIM; 166200; phenotype.
DR   MIM; 166210; phenotype.
DR   MIM; 166220; phenotype.
DR   MIM; 225320; phenotype.
DR   MIM; 259420; phenotype.
DR   neXtProt; NX_P08123; -.
DR   Orphanet; 99876; Ehlers-Danlos syndrome type 7B.
DR   Orphanet; 230851; Ehlers-Danlos syndrome, cardiac valvular type.
DR   Orphanet; 230857; Ehlers-Danlos/osteogenesis imperfecta syndrome.
DR   Orphanet; 314029; High bone mass osteogenesis imperfecta.
DR   Orphanet; 216796; Osteogenesis imperfecta type 1.
DR   Orphanet; 216804; Osteogenesis imperfecta type 2.
DR   Orphanet; 216812; Osteogenesis imperfecta type 3.
DR   Orphanet; 216820; Osteogenesis imperfecta type 4.
DR   PharmGKB; PA35042; -.
DR   eggNOG; KOG3544; Eukaryota.
DR   eggNOG; ENOG410XNMM; LUCA.
DR   GeneTree; ENSGT00830000128243; -.
DR   HOVERGEN; HBG004933; -.
DR   InParanoid; P08123; -.
DR   KO; K06236; -.
DR   OMA; PTGKHGN; -.
DR   OrthoDB; EOG7TJ3HH; -.
DR   PhylomeDB; P08123; -.
DR   TreeFam; TF344135; -.
DR   Reactome; R-HSA-114604; GPVI-mediated activation cascade.
DR   Reactome; R-HSA-1442490; Collagen degradation.
DR   Reactome; R-HSA-1474244; Extracellular matrix organization.
DR   Reactome; R-HSA-1650814; Collagen biosynthesis and modifying enzymes.
DR   Reactome; R-HSA-198933; Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell.
DR   Reactome; R-HSA-2022090; Assembly of collagen fibrils and other multimeric structures.
DR   Reactome; R-HSA-202733; Cell surface interactions at the vascular wall.
DR   Reactome; R-HSA-216083; Integrin cell surface interactions.
DR   Reactome; R-HSA-2214320; Anchoring fibril formation.
DR   Reactome; R-HSA-2243919; Crosslinking of collagen fibrils.
DR   Reactome; R-HSA-3000170; Syndecan interactions.
DR   Reactome; R-HSA-3000171; Non-integrin membrane-ECM interactions.
DR   Reactome; R-HSA-3000178; ECM proteoglycans.
DR   Reactome; R-HSA-3000480; Scavenging by Class A Receptors.
DR   Reactome; R-HSA-75892; Platelet Adhesion to exposed collagen.
DR   ChiTaRS; COL1A2; human.
DR   GeneWiki; COL1A2; -.
DR   GenomeRNAi; 1278; -.
DR   NextBio; 5165; -.
DR   PRO; PR:P08123; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   Bgee; P08123; -.
DR   ExpressionAtlas; P08123; baseline and differential.
DR   Genevisible; P08123; HS.
DR   GO; GO:0005584; C:collagen type I trimer; IDA:UniProtKB.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0031012; C:extracellular matrix; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005201; F:extracellular matrix structural constituent; NAS:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0048407; F:platelet-derived growth factor binding; IDA:MGI.
DR   GO; GO:0030674; F:protein binding, bridging; IMP:UniProtKB.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0001568; P:blood vessel development; IMP:UniProtKB.
DR   GO; GO:0071230; P:cellular response to amino acid stimulus; IEA:Ensembl.
DR   GO; GO:0030574; P:collagen catabolic process; TAS:Reactome.
DR   GO; GO:0030199; P:collagen fibril organization; IMP:UniProtKB.
DR   GO; GO:0022617; P:extracellular matrix disassembly; TAS:Reactome.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0042476; P:odontogenesis; NAS:UniProtKB.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0070208; P:protein heterotrimerization; IEA:Ensembl.
DR   GO; GO:0006898; P:receptor-mediated endocytosis; TAS:Reactome.
DR   GO; GO:0008217; P:regulation of blood pressure; IMP:UniProtKB.
DR   GO; GO:0050776; P:regulation of immune response; TAS:Reactome.
DR   GO; GO:0007266; P:Rho protein signal transduction; IDA:UniProtKB.
DR   GO; GO:0001501; P:skeletal system development; IMP:UniProtKB.
DR   GO; GO:0043589; P:skin morphogenesis; IMP:UniProtKB.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IDA:UniProtKB.
DR   InterPro; IPR008160; Collagen.
DR   InterPro; IPR000885; Fib_collagen_C.
DR   Pfam; PF01410; COLFI; 1.
DR   Pfam; PF01391; Collagen; 6.
DR   ProDom; PD002078; Fib_collagen_C; 1.
DR   SMART; SM00038; COLFI; 1.
DR   PROSITE; PS51461; NC1_FIB; 1.
PE   1: Evidence at protein level;
KW   Calcium; Chromosomal rearrangement; Collagen; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Disulfide bond; Dwarfism;
KW   Ehlers-Danlos syndrome; Extracellular matrix; Glycoprotein;
KW   Hydroxylation; Metal-binding; Osteogenesis imperfecta; Polymorphism;
KW   Pyrrolidone carboxylic acid; Reference proteome; Repeat; Secreted;
KW   Signal.
FT   SIGNAL        1     24       {ECO:0000255}.
FT   PROPEP       25     79       N-terminal propeptide.
FT                                {ECO:0000269|PubMed:5529814}.
FT                                /FTId=PRO_0000005804.
FT   CHAIN        80   1102       Collagen alpha-2(I) chain.
FT                                /FTId=PRO_0000005805.
FT   PROPEP     1103   1366       C-terminal propeptide.
FT                                /FTId=PRO_0000005806.
FT   DOMAIN     1133   1366       Fibrillar collagen NC1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00793}.
FT   METAL      1181   1181       Calcium. {ECO:0000250}.
FT   METAL      1183   1183       Calcium. {ECO:0000250}.
FT   METAL      1184   1184       Calcium; via carbonyl oxygen.
FT                                {ECO:0000250}.
FT   METAL      1186   1186       Calcium; via carbonyl oxygen.
FT                                {ECO:0000250}.
FT   METAL      1189   1189       Calcium. {ECO:0000250}.
FT   MOD_RES      80     80       Pyrrolidone carboxylic acid.
FT                                {ECO:0000250|UniProtKB:P02465}.
FT   MOD_RES      84     84       Allysine.
FT   MOD_RES     420    420       Hydroxyproline.
FT                                {ECO:0000269|PubMed:4412529}.
FT   MOD_RES     441    441       Hydroxyproline.
FT                                {ECO:0000269|PubMed:4412529}.
FT   MOD_RES     444    444       Hydroxyproline.
FT                                {ECO:0000269|PubMed:4412529}.
FT   CARBOHYD   1267   1267       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID   1163   1195       {ECO:0000255|PROSITE-ProRule:PRU00793}.
FT   DISULFID   1203   1364       {ECO:0000255|PROSITE-ProRule:PRU00793}.
FT   DISULFID   1272   1317       {ECO:0000255|PROSITE-ProRule:PRU00793}.
FT   VARIANT      59     59       T -> P (in dbSNP:rs1800221).
FT                                {ECO:0000269|PubMed:4011429}.
FT                                /FTId=VAR_030116.
FT   VARIANT      76     93       Missing (in EDS7B).
FT                                {ECO:0000269|PubMed:1577745,
FT                                ECO:0000269|PubMed:2394758,
FT                                ECO:0000269|PubMed:3680255}.
FT                                /FTId=VAR_001851.
FT   VARIANT     181    198       Missing (in OI4).
FT                                {ECO:0000269|PubMed:1642148}.
FT                                /FTId=VAR_030117.
FT   VARIANT     193    193       G -> S (in OI4).
FT                                {ECO:0000269|PubMed:16879195}.
FT                                /FTId=VAR_063343.
FT   VARIANT     202    202       G -> R (in OI4).
FT                                {ECO:0000269|PubMed:16786509}.
FT                                /FTId=VAR_063344.
FT   VARIANT     211    211       G -> D (in OI1).
FT                                {ECO:0000269|PubMed:8829649}.
FT                                /FTId=VAR_001852.
FT   VARIANT     234    234       R -> C (in OI2).
FT                                {ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_063345.
FT   VARIANT     247    247       G -> R (in OI1).
FT                                {ECO:0000269|PubMed:16786509}.
FT                                /FTId=VAR_063346.
FT   VARIANT     249    249       I -> N (in dbSNP:rs1800228).
FT                                {ECO:0000269|PubMed:2824475}.
FT                                /FTId=VAR_001853.
FT   VARIANT     253    253       G -> D (in OI2).
FT                                {ECO:0000269|PubMed:16786509}.
FT                                /FTId=VAR_063347.
FT   VARIANT     256    256       G -> V (in OI4).
FT                                {ECO:0000269|PubMed:16786509}.
FT                                /FTId=VAR_063348.
FT   VARIANT     270    270       V -> I (in dbSNP:rs368468).
FT                                {ECO:0000269|PubMed:9443882}.
FT                                /FTId=VAR_030118.
FT   VARIANT     276    276       A -> T (in dbSNP:rs1800231).
FT                                {ECO:0000269|PubMed:2824475}.
FT                                /FTId=VAR_001854.
FT   VARIANT     283    283       G -> R (in OI2).
FT                                {ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_063349.
FT   VARIANT     319    319       G -> R (in OI1).
FT                                {ECO:0000269|PubMed:16786509}.
FT                                /FTId=VAR_063350.
FT   VARIANT     325    325       G -> E (in OI4).
FT                                {ECO:0000269|PubMed:16705691}.
FT                                /FTId=VAR_063351.
FT   VARIANT     328    328       G -> S (in OI1, OI3 AND OI4).
FT                                {ECO:0000269|PubMed:16705691,
FT                                ECO:0000269|PubMed:7860070}.
FT                                /FTId=VAR_001855.
FT   VARIANT     331    331       G -> D (in OI3).
FT                                {ECO:0000269|PubMed:10408781}.
FT                                /FTId=VAR_008119.
FT   VARIANT     334    334       G -> C (in OI2).
FT                                /FTId=VAR_001856.
FT   VARIANT     337    337       G -> C (in OI3).
FT                                {ECO:0000269|PubMed:10408781}.
FT                                /FTId=VAR_001857.
FT   VARIANT     337    337       G -> S (in OI3).
FT                                {ECO:0000269|PubMed:8829649}.
FT                                /FTId=VAR_001858.
FT   VARIANT     344    344       L -> V (in dbSNP:rs16868573).
FT                                /FTId=VAR_055677.
FT   VARIANT     345    345       Missing (in OI3).
FT                                {ECO:0000269|PubMed:8444468}.
FT                                /FTId=VAR_001859.
FT   VARIANT     349    349       G -> C (in OI3).
FT                                {ECO:0000269|PubMed:1990009,
FT                                ECO:0000269|PubMed:8456807}.
FT                                /FTId=VAR_001860.
FT   VARIANT     358    358       G -> S (in OI3).
FT                                {ECO:0000269|PubMed:16705691}.
FT                                /FTId=VAR_063352.
FT   VARIANT     397    397       G -> E (in OI2).
FT                                {ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_063353.
FT   VARIANT     409    409       G -> V (in OI2).
FT                                {ECO:0000269|PubMed:10627137}.
FT                                /FTId=VAR_001861.
FT   VARIANT     433    433       G -> E (in OI2).
FT                                {ECO:0000269|PubMed:7906591}.
FT                                /FTId=VAR_001862.
FT   VARIANT     454    454       G -> C (in OI2).
FT                                {ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_063354.
FT   VARIANT     457    457       G -> L (in OI2; requires 2 nucleotide
FT                                substitutions).
FT                                {ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_063355.
FT   VARIANT     460    460       G -> S (in OI3).
FT                                {ECO:0000269|PubMed:8829649}.
FT                                /FTId=VAR_001863.
FT   VARIANT     461    466       Missing (in OI2).
FT                                {ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_063356.
FT   VARIANT     483    483       A -> V (in dbSNP:rs414408).
FT                                {ECO:0000269|PubMed:2824475,
FT                                ECO:0000269|PubMed:9443882}.
FT                                /FTId=VAR_030119.
FT   VARIANT     511    511       G -> D (in OI2).
FT                                /FTId=VAR_001864.
FT   VARIANT     517    517       G -> R (in OI3).
FT                                {ECO:0000269|PubMed:7520724}.
FT                                /FTId=VAR_001865.
FT   VARIANT     526    526       G -> E (in OI2).
FT                                {ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_063357.
FT   VARIANT     528    528       N -> S (in dbSNP:rs41317144).
FT                                {ECO:0000269|PubMed:18272325}.
FT                                /FTId=VAR_033040.
FT   VARIANT     547    547       G -> R (in OI2).
FT                                {ECO:0000269|PubMed:1284475}.
FT                                /FTId=VAR_001866.
FT   VARIANT     549    549       P -> A (in dbSNP:rs42524).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:18272325,
FT                                ECO:0000269|PubMed:18996919,
FT                                ECO:0000269|PubMed:2824475,
FT                                ECO:0000269|PubMed:2839839,
FT                                ECO:0000269|PubMed:8456808,
FT                                ECO:0000269|PubMed:9016532}.
FT                                /FTId=VAR_001867.
FT   VARIANT     562    562       G -> C (in OI2).
FT                                /FTId=VAR_001868.
FT   VARIANT     562    562       G -> V (in OI2).
FT                                {ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_063358.
FT   VARIANT     564    564       A -> T (in dbSNP:rs41317153).
FT                                {ECO:0000269|PubMed:18272325}.
FT                                /FTId=VAR_033041.
FT   VARIANT     586    586       G -> R (in OI2).
FT                                /FTId=VAR_001869.
FT   VARIANT     592    592       G -> S (in OI2).
FT                                {ECO:0000269|PubMed:7959683}.
FT                                /FTId=VAR_001870.
FT   VARIANT     601    601       G -> S (in OI).
FT                                {ECO:0000269|PubMed:16705691}.
FT                                /FTId=VAR_063359.
FT   VARIANT     625    625       G -> D (in OI2).
FT                                {ECO:0000269|PubMed:16879195}.
FT                                /FTId=VAR_063360.
FT   VARIANT     634    634       G -> V (in OI4).
FT                                {ECO:0000269|PubMed:8401517}.
FT                                /FTId=VAR_001871.
FT   VARIANT     637    637       G -> D (in OI2).
FT                                /FTId=VAR_001872.
FT   VARIANT     640    640       G -> S (in OI2).
FT                                /FTId=VAR_001873.
FT   VARIANT     670    670       G -> D (in OI2).
FT                                {ECO:0000269|PubMed:1385413}.
FT                                /FTId=VAR_001874.
FT   VARIANT     676    855       Missing (in OI2).
FT                                {ECO:0000269|PubMed:1339453}.
FT                                /FTId=VAR_030120.
FT   VARIANT     676    676       G -> D (in OI3).
FT                                {ECO:0000269|PubMed:16705691}.
FT                                /FTId=VAR_063361.
FT   VARIANT     676    676       G -> V (in OI3 and OI4).
FT                                {ECO:0000269|PubMed:2064612,
FT                                ECO:0000269|PubMed:7881420}.
FT                                /FTId=VAR_001875.
FT   VARIANT     678    678       P -> H (in dbSNP:rs409108).
FT                                {ECO:0000269|PubMed:2824475,
FT                                ECO:0000269|PubMed:3421913,
FT                                ECO:0000269|PubMed:6687691,
FT                                ECO:0000269|PubMed:9016532,
FT                                ECO:0000269|PubMed:9443882}.
FT                                /FTId=VAR_030121.
FT   VARIANT     705    707       Missing (in OI2).
FT                                {ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_063362.
FT   VARIANT     708    708       R -> Q (in Marfan syndrome).
FT                                /FTId=VAR_001876.
FT   VARIANT     715    715       G -> D (in OI2).
FT                                /FTId=VAR_001877.
FT   VARIANT     730    730       G -> C (in OI2).
FT                                {ECO:0000269|PubMed:7891382}.
FT                                /FTId=VAR_001878.
FT   VARIANT     733    733       G -> C (in OI1).
FT                                {ECO:0000269|PubMed:16786509}.
FT                                /FTId=VAR_063363.
FT   VARIANT     736    736       G -> C (in OI1; mild).
FT                                {ECO:0000269|PubMed:1990009,
FT                                ECO:0000269|PubMed:8456807}.
FT                                /FTId=VAR_001879.
FT   VARIANT     739    739       G -> R (in OI2).
FT                                {ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_063364.
FT   VARIANT     743    743       A -> G (in dbSNP:rs408535).
FT                                {ECO:0000269|PubMed:2824475,
FT                                ECO:0000269|PubMed:3421913,
FT                                ECO:0000269|PubMed:9443882}.
FT                                /FTId=VAR_001880.
FT   VARIANT     748    748       G -> V (in OI2).
FT                                {ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_063365.
FT   VARIANT     751    751       G -> S (in OI4).
FT                                {ECO:0000269|PubMed:2052622}.
FT                                /FTId=VAR_001881.
FT   VARIANT     754    754       G -> C (in OI4).
FT                                {ECO:0000269|PubMed:16879195}.
FT                                /FTId=VAR_063366.
FT   VARIANT     754    754       G -> R (in OI2).
FT                                /FTId=VAR_001882.
FT   VARIANT     766    766       G -> V (in OI4).
FT                                {ECO:0000269|PubMed:7693712}.
FT                                /FTId=VAR_001883.
FT   VARIANT     778    778       G -> S (in OI3).
FT                                {ECO:0000269|PubMed:7720740}.
FT                                /FTId=VAR_001884.
FT   VARIANT     784    784       G -> R (in OI2).
FT                                {ECO:0000269|PubMed:1874719}.
FT                                /FTId=VAR_001885.
FT   VARIANT     787    787       G -> C (in OI2).
FT                                {ECO:0000269|PubMed:10627137}.
FT                                /FTId=VAR_001886.
FT   VARIANT     790    790       G -> D (in OI2).
FT                                {ECO:0000269|PubMed:18996919,
FT                                ECO:0000269|PubMed:8182080}.
FT                                /FTId=VAR_001887.
FT   VARIANT     796    796       G -> S (in OI2).
FT                                {ECO:0000269|PubMed:7693712}.
FT                                /FTId=VAR_001888.
FT   VARIANT     798    798       P -> PP (in OI2).
FT                                {ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_063367.
FT   VARIANT     806    811       Missing (in OI2).
FT                                {ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_063368.
FT   VARIANT     811    811       G -> GPPG (in OI4).
FT                                /FTId=VAR_063369.
FT   VARIANT     820    820       G -> S (in OI3).
FT                                {ECO:0000269|PubMed:16705691}.
FT                                /FTId=VAR_063370.
FT   VARIANT     822    822       R -> H (in dbSNP:rs1800240).
FT                                {ECO:0000269|PubMed:8829649}.
FT                                /FTId=VAR_001889.
FT   VARIANT     835    835       G -> C (in OI3).
FT                                {ECO:0000269|PubMed:16879195}.
FT                                /FTId=VAR_063371.
FT   VARIANT     835    835       G -> S (in OI1).
FT                                {ECO:0000269|PubMed:8829649}.
FT                                /FTId=VAR_001890.
FT   VARIANT     856    856       G -> R (in OI3).
FT                                {ECO:0000269|PubMed:16705691}.
FT                                /FTId=VAR_063372.
FT   VARIANT     856    856       G -> V (in OI2).
FT                                {ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_063373.
FT   VARIANT     877    877       G -> C (in OI2). {ECO:0000269|Ref.33}.
FT                                /FTId=VAR_001891.
FT   VARIANT     892    892       G -> D (in OI3 and OI4).
FT                                {ECO:0000269|PubMed:8800927}.
FT                                /FTId=VAR_001892.
FT   VARIANT     895    895       G -> D (in OI2).
FT                                /FTId=VAR_001893.
FT   VARIANT     949    949       G -> S (in OI3; moderate).
FT                                {ECO:0000269|PubMed:18996919,
FT                                ECO:0000269|PubMed:8081394}.
FT                                /FTId=VAR_001894.
FT   VARIANT     955    955       G -> D (in OI2).
FT                                {ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_063374.
FT   VARIANT     955    955       G -> S (in OI2).
FT                                {ECO:0000269|PubMed:2777764}.
FT                                /FTId=VAR_001895.
FT   VARIANT     973    973       G -> V (in OI3).
FT                                {ECO:0000269|PubMed:10408781}.
FT                                /FTId=VAR_008120.
FT   VARIANT     982    982       G -> D (in OI2).
FT                                {ECO:0000269|PubMed:16786509}.
FT                                /FTId=VAR_063375.
FT   VARIANT     989    989       P -> PVGP (in OI4).
FT                                /FTId=VAR_063376.
FT   VARIANT     991    991       G -> V (in OI3).
FT                                {ECO:0000269|PubMed:16879195}.
FT                                /FTId=VAR_063377.
FT   VARIANT     997    997       G -> D (in OI2).
FT                                {ECO:0000269|PubMed:2914942}.
FT                                /FTId=VAR_001896.
FT   VARIANT    1003   1003       G -> D (in OI2).
FT                                {ECO:0000269|PubMed:16786509}.
FT                                /FTId=VAR_063378.
FT   VARIANT    1012   1012       G -> S (in OI3 and OI4; moderate).
FT                                {ECO:0000269|PubMed:16705691,
FT                                ECO:0000269|PubMed:8094076}.
FT                                /FTId=VAR_001897.
FT   VARIANT    1022   1022       L -> F (in dbSNP:rs392609).
FT                                {ECO:0000269|PubMed:2824475,
FT                                ECO:0000269|PubMed:6687691,
FT                                ECO:0000269|PubMed:9443882}.
FT                                /FTId=VAR_001898.
FT   VARIANT    1027   1027       G -> E (in OI2).
FT                                {ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_063379.
FT   VARIANT    1058   1062       Missing (in OI2).
FT                                {ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_063380.
FT   VARIANT    1066   1066       G -> D (in OI2).
FT                                /FTId=VAR_001899.
FT   VARIANT    1067   1067       R -> H. {ECO:0000269|PubMed:23656646}.
FT                                /FTId=VAR_069633.
FT   VARIANT    1078   1078       G -> C (in OI2).
FT                                /FTId=VAR_001900.
FT   VARIANT    1087   1087       G -> D (in OI3).
FT                                {ECO:0000269|PubMed:16786509}.
FT                                /FTId=VAR_063381.
FT   VARIANT    1094   1096       Missing (in OI4).
FT                                {ECO:0000269|PubMed:16705691}.
FT                                /FTId=VAR_063382.
FT   VARIANT    1096   1096       G -> A (in OI3).
FT                                {ECO:0000269|PubMed:7749416}.
FT                                /FTId=VAR_001901.
FT   VARIANT    1101   1101       P -> L.
FT                                /FTId=VAR_001903.
FT   VARIANT    1102   1102       G -> R (in OI4).
FT                                {ECO:0000269|PubMed:2897363}.
FT                                /FTId=VAR_001902.
FT   VARIANT    1119   1119       A -> T (found in a patient with mild
FT                                osteogenesis imperfecta associated with
FT                                increased bone mineral density; results
FT                                in defective type I procollagen
FT                                processing; incorporation of the immature
FT                                procollagen into the matrix leads to
FT                                increased bone matrix mineralization and
FT                                altered collagen fibril structure).
FT                                {ECO:0000269|PubMed:21344539}.
FT                                /FTId=VAR_066386.
FT   VARIANT    1148   1148       T -> P (in OI3; dbSNP:rs1800250).
FT                                {ECO:0000269|PubMed:8723681}.
FT                                /FTId=VAR_001904.
FT   VARIANT    1189   1189       D -> E (in dbSNP:rs422361).
FT                                {ECO:0000269|PubMed:2824475,
FT                                ECO:0000269|PubMed:6687691,
FT                                ECO:0000269|PubMed:9443882}.
FT                                /FTId=VAR_001905.
FT   VARIANT    1195   1195       C -> Y (in OI1).
FT                                {ECO:0000269|PubMed:16786509}.
FT                                /FTId=VAR_063383.
FT   VARIANT    1198   1198       S -> P (in dbSNP:rs384487).
FT                                {ECO:0000269|PubMed:2824475,
FT                                ECO:0000269|PubMed:6687691,
FT                                ECO:0000269|PubMed:9443882}.
FT                                /FTId=VAR_001906.
FT   VARIANT    1354   1354       Q -> H (in dbSNP:rs418570).
FT                                {ECO:0000269|PubMed:2364107,
FT                                ECO:0000269|PubMed:2824475,
FT                                ECO:0000269|PubMed:6092353,
FT                                ECO:0000269|PubMed:6309769,
FT                                ECO:0000269|PubMed:6687691,
FT                                ECO:0000269|PubMed:9016532,
FT                                ECO:0000269|PubMed:9443882}.
FT                                /FTId=VAR_030122.
FT   CONFLICT     55     55       E -> G (in Ref. 6; CAA26320).
FT                                {ECO:0000305}.
FT   CONFLICT    333    333       V -> P (in Ref. 1; AAB59374).
FT                                {ECO:0000305}.
FT   CONFLICT    338    338       A -> T (in Ref. 1; AAB59374).
FT                                {ECO:0000305}.
FT   CONFLICT    549    549       P -> D (in Ref. 5; CAA68709).
FT                                {ECO:0000305}.
FT   CONFLICT    828    828       V -> A (in Ref. 17; CAA23761).
FT                                {ECO:0000305}.
FT   CONFLICT    831    831       T -> P (in Ref. 17; CAA23761).
FT                                {ECO:0000305}.
FT   CONFLICT    837    837       V -> P (in Ref. 17; CAA23761).
FT                                {ECO:0000305}.
FT   CONFLICT    980    980       E -> V (in Ref. 21; AAA51996).
FT                                {ECO:0000305}.
FT   CONFLICT   1098   1098       P -> L (in Ref. 17; CAA23761).
FT                                {ECO:0000305}.
FT   CONFLICT   1122   1125       Missing (in Ref. 17; CAA23761).
FT                                {ECO:0000305}.
FT   CONFLICT   1338   1338       R -> A (in Ref. 23; AAA51887).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1366 AA;  129314 MW;  1E68A5970FB4210A CRC64;
     MLSFVDTRTL LLLAVTLCLA TCQSLQEETV RKGPAGDRGP RGERGPPGPP GRDGEDGPTG
     PPGPPGPPGP PGLGGNFAAQ YDGKGVGLGP GPMGLMGPRG PPGAAGAPGP QGFQGPAGEP
     GEPGQTGPAG ARGPAGPPGK AGEDGHPGKP GRPGERGVVG PQGARGFPGT PGLPGFKGIR
     GHNGLDGLKG QPGAPGVKGE PGAPGENGTP GQTGARGLPG ERGRVGAPGP AGARGSDGSV
     GPVGPAGPIG SAGPPGFPGA PGPKGEIGAV GNAGPAGPAG PRGEVGLPGL SGPVGPPGNP
     GANGLTGAKG AAGLPGVAGA PGLPGPRGIP GPVGAAGATG ARGLVGEPGP AGSKGESGNK
     GEPGSAGPQG PPGPSGEEGK RGPNGEAGSA GPPGPPGLRG SPGSRGLPGA DGRAGVMGPP
     GSRGASGPAG VRGPNGDAGR PGEPGLMGPR GLPGSPGNIG PAGKEGPVGL PGIDGRPGPI
     GPAGARGEPG NIGFPGPKGP TGDPGKNGDK GHAGLAGARG APGPDGNNGA QGPPGPQGVQ
     GGKGEQGPPG PPGFQGLPGP SGPAGEVGKP GERGLHGEFG LPGPAGPRGE RGPPGESGAA
     GPTGPIGSRG PSGPPGPDGN KGEPGVVGAV GTAGPSGPSG LPGERGAAGI PGGKGEKGEP
     GLRGEIGNPG RDGARGAPGA VGAPGPAGAT GDRGEAGAAG PAGPAGPRGS PGERGEVGPA
     GPNGFAGPAG AAGQPGAKGE RGAKGPKGEN GVVGPTGPVG AAGPAGPNGP PGPAGSRGDG
     GPPGMTGFPG AAGRTGPPGP SGISGPPGPP GPAGKEGLRG PRGDQGPVGR TGEVGAVGPP
     GFAGEKGPSG EAGTAGPPGT PGPQGLLGAP GILGLPGSRG ERGLPGVAGA VGEPGPLGIA
     GPPGARGPPG AVGSPGVNGA PGEAGRDGNP GNDGPPGRDG QPGHKGERGY PGNIGPVGAA
     GAPGPHGPVG PAGKHGNRGE TGPSGPVGPA GAVGPRGPSG PQGIRGDKGE PGEKGPRGLP
     GLKGHNGLQG LPGIAGHHGD QGAPGSVGPA GPRGPAGPSG PAGKDGRTGH PGTVGPAGIR
     GPQGHQGPAG PPGPPGPPGP PGVSGGGYDF GYDGDFYRAD QPRSAPSLRP KDYEVDATLK
     SLNNQIETLL TPEGSRKNPA RTCRDLRLSH PEWSSGYYWI DPNQGCTMDA IKVYCDFSTG
     ETCIRAQPEN IPAKNWYRSS KDKKHVWLGE TINAGSQFEY NVEGVTSKEM ATQLAFMRLL
     ANYASQNITY HCKNSIAYMD EETGNLKKAV ILQGSNDVEL VAEGNSRFTY TVLVDGCSKK
     TNEWGKTIIE YKTNKPSRLP FLDIAPLDIG GADQEFFVDI GPVCFK
//
ID   KIT_MOUSE               Reviewed;         979 AA.
AC   P05532; Q61415; Q61416; Q61417; Q6LEE9; Q6QJB7; Q6QJB8; Q7TS86;
AC   Q8C8K9;
DT   01-NOV-1988, integrated into UniProtKB/Swiss-Prot.
DT   19-OCT-2011, sequence version 3.
DT   20-JAN-2016, entry version 179.
DE   RecName: Full=Mast/stem cell growth factor receptor Kit;
DE            Short=SCFR;
DE            EC=2.7.10.1;
DE   AltName: Full=Proto-oncogene c-Kit;
DE   AltName: Full=Tyrosine-protein kinase Kit;
DE   AltName: CD_antigen=CD117;
DE   Flags: Precursor;
GN   Name=Kit; Synonyms=Sl;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND VARIANT GLU-207.
RC   STRAIN=BALB/cJ; TISSUE=Brain;
RX   PubMed=2456920;
RA   Qiu F., Ray P., Brown K., Barker P.E., Jhanwar S., Ruddle F.H.,
RA   Besmer P.;
RT   "Primary structure of c-kit: relationship with the CSF-1/PDGF receptor
RT   kinase family -- oncogenic activation of v-kit involves deletion of
RT   extracellular domain and C-terminus.";
RL   EMBO J. 7:1003-1011(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   STRAIN=C57BL/6J; TISSUE=Medulla oblongata;
RX   PubMed=1709486; DOI=10.1093/nar/19.6.1267;
RA   Hayashi S., Kunisada T., Ogawa M., Yamaguchi K., Nishikawa S.;
RT   "Exon skipping by mutation of an authentic splice site of c-kit gene
RT   in W/W mouse.";
RL   Nucleic Acids Res. 19:1267-1271(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 3), AND TISSUE
RP   SPECIFICITY.
RC   STRAIN=ICR;
RX   PubMed=1378413; DOI=10.1016/0012-1606(92)90172-D;
RA   Rossi P., Marziali G., Albanesi C., Charlesworth A., Geremia R.,
RA   Sorrentino V.;
RT   "A novel c-kit transcript, potentially encoding a truncated receptor,
RT   originates within a kit gene intron in mouse spermatids.";
RL   Dev. Biol. 152:203-207(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND MUTAGENESIS OF PHE-860.
RC   STRAIN=C57BL/6J;
RX   PubMed=15731517; DOI=10.1534/genetics.104.027177;
RA   Ruan H.B., Zhang N., Gao X.;
RT   "Identification of a novel point mutation of mouse proto-oncogene c-
RT   kit through N-ethyl-N-nitrosourea mutagenesis.";
RL   Genetics 169:819-831(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=C57BL/6J;
RX   PubMed=19468303; DOI=10.1371/journal.pbio.1000112;
RA   Church D.M., Goodstadt L., Hillier L.W., Zody M.C., Goldstein S.,
RA   She X., Bult C.J., Agarwala R., Cherry J.L., DiCuccio M., Hlavina W.,
RA   Kapustin Y., Meric P., Maglott D., Birtle Z., Marques A.C., Graves T.,
RA   Zhou S., Teague B., Potamousis K., Churas C., Place M., Herschleb J.,
RA   Runnheim R., Forrest D., Amos-Landgraf J., Schwartz D.C., Cheng Z.,
RA   Lindblad-Toh K., Eichler E.E., Ponting C.P.;
RT   "Lineage-specific biology revealed by a finished genome assembly of
RT   the mouse.";
RL   PLoS Biol. 7:E1000112-E1000112(2009).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   STRAIN=C57BL/6J, and FVB/N; TISSUE=Brain, and Mammary tumor;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-22.
RC   STRAIN=BALB/cJ;
RX   PubMed=7682073; DOI=10.1006/bbrc.1993.1301;
RA   Yasuda H., Galli S.J., Geissler E.N.;
RT   "Cloning and functional analysis of the mouse c-kit promoter.";
RL   Biochem. Biophys. Res. Commun. 191:893-901(1993).
RN   [8]
RP   FUNCTION, AND SUBUNIT.
RX   PubMed=1698611;
RA   Tan J.C., Buck J., Levi E., Besmer P.;
RT   "Candidate ligand for the c-kit transmembrane kinase receptor: KL, a
RT   fibroblast derived growth factor stimulates mast cells and erythroid
RT   progenitors.";
RL   EMBO J. 9:3287-3294(1990).
RN   [9]
RP   FUNCTION IN ACTIVATION OF PLCG1, INTERACTION WITH PLCG1, ALTERNATIVE
RP   SPLICING, PHOSPHORYLATION, GLYCOSYLATION, AND CHARACTERIZATION OF
RP   VARIANTS W37 LYS-586 AND W41 MET-835.
RX   PubMed=1714377;
RA   Reith A.D., Ellis C., Lyman S.D., Anderson D.M., Williams D.E.,
RA   Bernstein A., Pawson T.;
RT   "Signal transduction by normal isoforms and W mutant variants of the
RT   Kit receptor tyrosine kinase.";
RL   EMBO J. 10:2451-2459(1991).
RN   [10]
RP   INTERACTION WITH PIK3R1, AND FUNCTION IN PHOSPHORYLATION OF PIK3R1.
RX   PubMed=7509796;
RA   Serve H., Hsu Y.C., Besmer P.;
RT   "Tyrosine residue 719 of the c-kit receptor is essential for binding
RT   of the P85 subunit of phosphatidylinositol (PI) 3-kinase and for c-
RT   kit-associated PI 3-kinase activity in COS-1 cells.";
RL   J. Biol. Chem. 269:6026-6030(1994).
RN   [11]
RP   UBIQUITINATION, SUBCELLULAR LOCATION, CATALYTIC ACTIVITY,
RP   PHOSPHORYLATION AT TYR-825, INTERACTION WITH PIK3R1, CHARACTERIZATION
RP   OF VARIANT W42 ASN-794, MUTAGENESIS OF TYR-723, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=7527401;
RA   Yee N.S., Hsiau C.W., Serve H., Vosseller K., Besmer P.;
RT   "Mechanism of down-regulation of c-kit receptor. Roles of receptor
RT   tyrosine kinase, phosphatidylinositol 3'-kinase, and protein kinase
RT   C.";
RL   J. Biol. Chem. 269:31991-31998(1994).
RN   [12]
RP   ALTERNATIVE SPLICING, AND FUNCTION IN ACTIVATION OF PLCG1.
RX   PubMed=9722617; DOI=10.1083/jcb.142.4.1063;
RA   Sette C., Bevilacqua A., Geremia R., Rossi P.;
RT   "Involvement of phospholipase Cgamma1 in mouse egg activation induced
RT   by a truncated form of the C-kit tyrosine kinase present in
RT   spermatozoa.";
RL   J. Cell Biol. 142:1063-1074(1998).
RN   [13]
RP   INTERACTION WITH PTPN6/SHP-1 AND PTPN11/SHP-2, FUNCTION IN
RP   PHOSPHORYLATION OF PTPN6/SHP-1, AND MUTAGENESIS OF TYR-571 AND
RP   TYR-573.
RX   PubMed=9528781;
RA   Kozlowski M., Larose L., Lee F., Le D.M., Rottapel R.,
RA   Siminovitch K.A.;
RT   "SHP-1 binds and negatively modulates the c-Kit receptor by
RT   interaction with tyrosine 569 in the c-Kit juxtamembrane domain.";
RL   Mol. Cell. Biol. 18:2089-2099(1998).
RN   [14]
RP   REVIEW ON ROLE IN SPERMATOGENESIS AND FERTILITY.
RX   PubMed=12558531; DOI=10.1046/j.1439-0272.2003.00539.x;
RA   Rossi P., Dolci S., Sette C., Geremia R.;
RT   "Molecular mechanisms utilized by alternative c-kit gene products in
RT   the control of spermatogonial proliferation and sperm-mediated egg
RT   activation.";
RL   Andrologia 35:71-78(2003).
RN   [15]
RP   INTERACTION WITH FES/FPS.
RX   PubMed=17595334; DOI=10.1182/blood-2007-02-076471;
RA   Voisset E., Lopez S., Dubreuil P., De Sepulveda P.;
RT   "The tyrosine kinase FES is an essential effector of KITD816V
RT   proliferation signal.";
RL   Blood 110:2593-2599(2007).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-571; TYR-573; TYR-706
RP   AND TYR-938, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Mast cell;
RX   PubMed=17947660; DOI=10.4049/jimmunol.179.9.5864;
RA   Cao L., Yu K., Banh C., Nguyen V., Ritz A., Raphael B.J., Kawakami Y.,
RA   Kawakami T., Salomon A.R.;
RT   "Quantitative time-resolved phosphoproteomic analysis of mast cell
RT   signaling.";
RL   J. Immunol. 179:5864-5876(2007).
RN   [17]
RP   FUNCTION IN MAST CELL MIGRATION, AND IN SIGNALING VIA FYN.
RX   PubMed=18725415; DOI=10.1074/jbc.M804077200;
RA   Samayawardhena L.A., Pallen C.J.;
RT   "Protein-tyrosine phosphatase alpha regulates stem cell factor-
RT   dependent c-Kit activation and migration of mast cells.";
RL   J. Biol. Chem. 283:29175-29185(2008).
RN   [18]
RP   ALTERNATIVE SPLICING, AND TISSUE SPECIFICITY.
RX   PubMed=18447649; DOI=10.1089/scd.2007.0101;
RA   Zayas J., Spassov D.S., Nachtman R.G., Jurecic R.;
RT   "Murine hematopoietic stem cells and multipotent progenitors express
RT   truncated intracellular form of c-kit receptor.";
RL   Stem Cells Dev. 17:343-353(2008).
RN   [19]
RP   FUNCTION IN MAST CELL DEGRANULATION.
RX   PubMed=21037083; DOI=10.2353/ajpath.2010.100369;
RA   Chen S., Burgin S., McDaniel A., Li X., Yuan J., Chen M., Khalaf W.,
RA   Clapp D.W., Yang F.C.;
RT   "Nf1-/- Schwann cell-conditioned medium modulates mast cell
RT   degranulation by c-Kit-mediated hyperactivation of
RT   phosphatidylinositol 3-kinase.";
RL   Am. J. Pathol. 177:3125-3132(2010).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-720, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brain, Lung, Spleen, and Testis;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and
RT   expression.";
RL   Cell 143:1174-1189(2010).
RN   [21]
RP   VARIANT GLU-207.
RA   Jawad-Alam J.;
RL   Unpublished observations (APR-2010).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 25-314 IN COMPLEX WITH
RP   KITLG/SCF, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-296 AND ASN-303.
RX   PubMed=17255936; DOI=10.1038/sj.emboj.7601545;
RA   Liu H., Chen X., Focia P.J., He X.;
RT   "Structural basis for stem cell factor-KIT signaling and activation of
RT   class III receptor tyrosine kinases.";
RL   EMBO J. 26:891-901(2007).
RN   [23]
RP   VARIANT W42 ASN-794.
RX   PubMed=1688471; DOI=10.1126/science.1688471;
RA   Tan J.C., Nocka K., Ray P., Traktman P., Besmer P.;
RT   "The dominant W42 spotting phenotype results from a missense mutation
RT   in the c-kit receptor kinase.";
RL   Science 247:209-212(1990).
RN   [24]
RP   VARIANTS W37 LYS-586; WV MET-664 AND W41 MET-835.
RX   PubMed=1693331;
RA   Nocka K., Tan J.C., Chiu E., Chu T.Y., Ray P., Traktman P., Besmer P.;
RT   "Molecular bases of dominant negative and loss of function mutations
RT   at the murine c-kit/white spotting locus: W37, Wv, W41 and W.";
RL   EMBO J. 9:1805-1813(1990).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts as cell-surface
CC       receptor for the cytokine KITLG/SCF and plays an essential role in
CC       the regulation of cell survival and proliferation, hematopoiesis,
CC       stem cell maintenance, gametogenesis, mast cell development,
CC       migration and function, and in melanogenesis. In response to
CC       KITLG/SCF binding, KIT can activate several signaling pathways.
CC       Phosphorylates PIK3R1, PLCG1, SH2B2/APS and CBL. Activates the
CC       AKT1 signaling pathway by phosphorylation of PIK3R1, the
CC       regulatory subunit of phosphatidylinositol 3-kinase. Activated KIT
CC       also transmits signals via GRB2 and activation of RAS, RAF1 and
CC       the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. Promotes activation
CC       of STAT family members STAT1, STAT3, STAT5A and STAT5B. Activation
CC       of PLCG1 leads to the production of the cellular signaling
CC       molecules diacylglycerol and inositol 1,4,5-trisphosphate. KIT
CC       signaling is modulated by protein phosphatases, and by rapid
CC       internalization and degradation of the receptor. Activated KIT
CC       promotes phosphorylation of the protein phosphatases PTPN6/SHP-1
CC       and PTPRU, and of the transcription factors STAT1, STAT3, STAT5A
CC       and STAT5B. Promotes phosphorylation of PIK3R1, CBL, CRK (isoform
CC       Crk-II), LYN, MAPK1/ERK2 and/or MAPK3/ERK1, PLCG1, SRC and SHC1.
CC       {ECO:0000269|PubMed:1698611, ECO:0000269|PubMed:1714377,
CC       ECO:0000269|PubMed:18725415, ECO:0000269|PubMed:21037083,
CC       ECO:0000269|PubMed:7509796, ECO:0000269|PubMed:9528781,
CC       ECO:0000269|PubMed:9722617}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:7527401}.
CC   -!- ENZYME REGULATION: Present in an inactive conformation in the
CC       absence of bound ligand. KITLG/SCF binding leads to dimerization
CC       and activation by autophosphorylation.
CC   -!- SUBUNIT: Monomer in the absence of bound KITLG/SCF. Homodimer in
CC       the presence of bound KITLG/SCF, forming a heterotetramer with two
CC       KITLG/SCF molecules. Interacts (via phosphorylated tyrosine
CC       residues) with the adapter proteins GRB2 and GRB7 (via SH2
CC       domain), and SH2B2/APS. Interacts (via C-terminus) with MPDZ (via
CC       the tenth PDZ domain). Interacts (via phosphorylated tyrosine
CC       residues) with the protein phosphatases PTPN6/SHP-1 (via SH2
CC       domain), PTPN11/SHP-2 (via SH2 domain) and PTPRU. Interacts with
CC       DOK1 and TEC (By similarity). Interacts with the protein kinase
CC       FES/FPS. Interacts with PLCG1. Interacts (via phosphorylated
CC       tyrosine residues) with PIK3R1 and PIK3 catalytic subunit.
CC       {ECO:0000250, ECO:0000269|PubMed:1698611,
CC       ECO:0000269|PubMed:1714377, ECO:0000269|PubMed:17255936,
CC       ECO:0000269|PubMed:17595334, ECO:0000269|PubMed:7509796,
CC       ECO:0000269|PubMed:7527401, ECO:0000269|PubMed:9528781}.
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Cell membrane; Single-pass type I
CC       membrane protein.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Cell membrane; Single-pass type I
CC       membrane protein.
CC   -!- SUBCELLULAR LOCATION: Isoform 3: Cytoplasm. Note=Detected in the
CC       cytoplasm of spermatozoa, especially in the equatorial and
CC       subacrosomal region of the sperm head. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=GNNK(+), Kit(+);
CC         IsoId=P05532-1; Sequence=Displayed;
CC       Name=2; Synonyms=GNNK(-), KitA(+);
CC         IsoId=P05532-2; Sequence=VSP_041870;
CC       Name=3; Synonyms=Tr-kit, Truncated;
CC         IsoId=P05532-3; Sequence=VSP_041868, VSP_041869;
CC   -!- TISSUE SPECIFICITY: Isoform 1 and isoform 2 are detected in bone
CC       marrow cells, spermatogonia and spermatocytes, but not in round
CC       spermatids, elongating spermatids and spermatozoa. Isoform 3 is
CC       detected in round spermatids, elongating spermatids and
CC       spermatozoa, but not in spermatogonia and spermatocytes (at
CC       protein level). Isoform 1 is widely expressed and detected in
CC       fetal liver and bone marrow. Isoform 3 is detected in bone marrow
CC       cells enriched in hematopoietic stem cells.
CC       {ECO:0000269|PubMed:1378413, ECO:0000269|PubMed:18447649,
CC       ECO:0000269|PubMed:7527401}.
CC   -!- PTM: Ubiquitinated by SOCS6. KIT is rapidly ubiquitinated after
CC       autophosphorylation induced by KITLG/SCF binding, leading to
CC       internalization and degradation (By similarity). {ECO:0000250}.
CC   -!- PTM: Autophosphorylated on tyrosine residues. KITLG/SCF binding
CC       promotes autophosphorylation of isoform 1 and isoform 2. Isoform 1
CC       shows low levels of tyrosine phosphorylation in the absence of
CC       added KITLG/SCF, while isoform 2 requires stimulation by KITLG/SCF
CC       for phosphorylation (in vitro). Phosphorylation of Tyr-573 is
CC       required for interaction with PTPN6/SHP-1. Phosphorylation of Tyr-
CC       571 is required for interaction with PTPN11/SHP-2. Phosphorylated
CC       tyrosine residues are important for interaction with specific
CC       binding partners. {ECO:0000269|PubMed:1714377,
CC       ECO:0000269|PubMed:7527401}.
CC   -!- DISEASE: Note=Defects in Kit are the cause of the white-spotting
CC       phenotype (W). White-spotting variants induces severe effects on
CC       pigmentation, gametogenesis and hematopoiesis. Mice homozygous for
CC       W42 die perinatally of macrocytic anemia.
CC   -!- MISCELLANEOUS: Numerous proteins are phosphorylated in response to
CC       KIT signaling, but it is not evident to determine which are
CC       directly phosphorylated by KIT under in vivo conditions.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. CSF-1/PDGF receptor subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 5 Ig-like C2-type (immunoglobulin-like)
CC       domains. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y00864; CAA68772.1; -; mRNA.
DR   EMBL; AK046795; BAC32872.1; -; mRNA.
DR   EMBL; X65997; CAA46798.1; -; mRNA.
DR   EMBL; X65998; CAA46799.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; X65998; CAA46800.1; -; Genomic_DNA.
DR   EMBL; AY536430; AAS45606.1; -; mRNA.
DR   EMBL; AY536431; AAS45607.1; -; mRNA.
DR   EMBL; AC013622; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC115853; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC052457; AAH52457.1; -; mRNA.
DR   EMBL; BC075716; AAH75716.1; -; mRNA.
DR   EMBL; L11358; AAA37420.1; -; Genomic_DNA.
DR   CCDS; CCDS51525.1; -. [P05532-1]
DR   CCDS; CCDS80302.1; -. [P05532-2]
DR   PIR; A44876; A44876.
DR   PIR; S00474; TVMSKT.
DR   PIR; S24667; S24667.
DR   PIR; S34435; S34435.
DR   RefSeq; NP_001116205.1; NM_001122733.1. [P05532-1]
DR   RefSeq; NP_066922.2; NM_021099.3. [P05532-2]
DR   UniGene; Mm.247073; -.
DR   PDB; 2O26; X-ray; 2.50 A; U/W/X/Y=25-314.
DR   PDBsum; 2O26; -.
DR   ProteinModelPortal; P05532; -.
DR   SMR; P05532; 33-511, 550-934.
DR   BioGrid; 200957; 18.
DR   DIP; DIP-59622N; -.
DR   IntAct; P05532; 3.
DR   STRING; 10090.ENSMUSP00000005815; -.
DR   BindingDB; P05532; -.
DR   ChEMBL; CHEMBL2034798; -.
DR   iPTMnet; P05532; -.
DR   PhosphoSite; P05532; -.
DR   MaxQB; P05532; -.
DR   PaxDb; P05532; -.
DR   PRIDE; P05532; -.
DR   Ensembl; ENSMUST00000005815; ENSMUSP00000005815; ENSMUSG00000005672. [P05532-1]
DR   Ensembl; ENSMUST00000144270; ENSMUSP00000116465; ENSMUSG00000005672. [P05532-2]
DR   GeneID; 16590; -.
DR   KEGG; mmu:16590; -.
DR   UCSC; uc008xug.2; mouse. [P05532-1]
DR   UCSC; uc012dxj.1; mouse. [P05532-2]
DR   CTD; 3815; -.
DR   MGI; MGI:96677; Kit.
DR   eggNOG; KOG0200; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118923; -.
DR   HOGENOM; HOG000112008; -.
DR   HOVERGEN; HBG004335; -.
DR   InParanoid; P05532; -.
DR   KO; K05091; -.
DR   TreeFam; TF325768; -.
DR   BRENDA; 2.7.10.1; 3474.
DR   Reactome; R-MMU-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-MMU-1433557; Signaling by SCF-KIT.
DR   Reactome; R-MMU-1433559; Regulation of KIT signaling.
DR   Reactome; R-MMU-5673001; RAF/MAP kinase cascade.
DR   ChiTaRS; Kit; mouse.
DR   EvolutionaryTrace; P05532; -.
DR   NextBio; 290137; -.
DR   PRO; PR:P05532; -.
DR   Proteomes; UP000000589; Chromosome 5.
DR   Bgee; P05532; -.
DR   CleanEx; MM_KIT; -.
DR   ExpressionAtlas; P05532; baseline and differential.
DR   Genevisible; P05532; MM.
DR   GO; GO:0001669; C:acrosomal vesicle; IEA:Ensembl.
DR   GO; GO:0009986; C:cell surface; IDA:MGI.
DR   GO; GO:0005911; C:cell-cell junction; IDA:MGI.
DR   GO; GO:0009898; C:cytoplasmic side of plasma membrane; IEA:Ensembl.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:MGI.
DR   GO; GO:0005615; C:extracellular space; ISO:MGI.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0042629; C:mast cell granule; ISO:MGI.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019955; F:cytokine binding; ISS:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0002020; F:protease binding; IPI:BHF-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; ISO:MGI.
DR   GO; GO:0004716; F:receptor signaling protein tyrosine kinase activity; IEA:InterPro.
DR   GO; GO:0005020; F:stem cell factor receptor activity; IDA:MGI.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; ISS:UniProtKB.
DR   GO; GO:0031532; P:actin cytoskeleton reorganization; ISS:UniProtKB.
DR   GO; GO:0000187; P:activation of MAPK activity; ISO:MGI.
DR   GO; GO:0060326; P:cell chemotaxis; ISS:UniProtKB.
DR   GO; GO:0030154; P:cell differentiation; TAS:MGI.
DR   GO; GO:0097067; P:cellular response to thyroid hormone stimulus; IDA:UniProtKB.
DR   GO; GO:0006935; P:chemotaxis; TAS:MGI.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; IDA:MGI.
DR   GO; GO:0002371; P:dendritic cell cytokine production; IMP:UniProtKB.
DR   GO; GO:0050910; P:detection of mechanical stimulus involved in sensory perception of sound; IMP:UniProtKB.
DR   GO; GO:0048066; P:developmental pigmentation; IMP:MGI.
DR   GO; GO:0048565; P:digestive tract development; IMP:UniProtKB.
DR   GO; GO:0035234; P:ectopic germ cell programmed cell death; IGI:MGI.
DR   GO; GO:0035162; P:embryonic hemopoiesis; IMP:UniProtKB.
DR   GO; GO:0050673; P:epithelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0030218; P:erythrocyte differentiation; IMP:UniProtKB.
DR   GO; GO:0038162; P:erythropoietin-mediated signaling pathway; IMP:UniProtKB.
DR   GO; GO:0038093; P:Fc receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0007281; P:germ cell development; TAS:MGI.
DR   GO; GO:0008354; P:germ cell migration; IEA:Ensembl.
DR   GO; GO:0006687; P:glycosphingolipid metabolic process; IMP:MGI.
DR   GO; GO:0035701; P:hematopoietic stem cell migration; IMP:MGI.
DR   GO; GO:0030097; P:hemopoiesis; IMP:MGI.
DR   GO; GO:0002327; P:immature B cell differentiation; IMP:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; IMP:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:MGI.
DR   GO; GO:0038109; P:Kit signaling pathway; ISO:MGI.
DR   GO; GO:0030032; P:lamellipodium assembly; IDA:UniProtKB.
DR   GO; GO:0002320; P:lymphoid progenitor cell differentiation; IGI:MGI.
DR   GO; GO:0008584; P:male gonad development; IEA:Ensembl.
DR   GO; GO:0002551; P:mast cell chemotaxis; ISO:MGI.
DR   GO; GO:0032762; P:mast cell cytokine production; ISS:UniProtKB.
DR   GO; GO:0043303; P:mast cell degranulation; ISS:UniProtKB.
DR   GO; GO:0060374; P:mast cell differentiation; IMP:UniProtKB.
DR   GO; GO:0035855; P:megakaryocyte development; IMP:UniProtKB.
DR   GO; GO:0097326; P:melanocyte adhesion; IDA:UniProtKB.
DR   GO; GO:0030318; P:melanocyte differentiation; IMP:UniProtKB.
DR   GO; GO:0097324; P:melanocyte migration; IMP:UniProtKB.
DR   GO; GO:0002573; P:myeloid leukocyte differentiation; IMP:MGI.
DR   GO; GO:0002318; P:myeloid progenitor cell differentiation; IGI:MGI.
DR   GO; GO:0043069; P:negative regulation of programmed cell death; IMP:MGI.
DR   GO; GO:0001541; P:ovarian follicle development; IMP:UniProtKB.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:MGI.
DR   GO; GO:0043473; P:pigmentation; IMP:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; IEA:Ensembl.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IGI:MGI.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:MGI.
DR   GO; GO:0046427; P:positive regulation of JAK-STAT cascade; ISO:MGI.
DR   GO; GO:0048170; P:positive regulation of long-term neuronal synaptic plasticity; IEA:Ensembl.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IGI:MGI.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; ISO:MGI.
DR   GO; GO:0045747; P:positive regulation of Notch signaling pathway; IEA:Ensembl.
DR   GO; GO:0031274; P:positive regulation of pseudopodium assembly; IEA:Ensembl.
DR   GO; GO:0051091; P:positive regulation of sequence-specific DNA binding transcription factor activity; ISO:MGI.
DR   GO; GO:0042511; P:positive regulation of tyrosine phosphorylation of Stat1 protein; ISO:MGI.
DR   GO; GO:0042517; P:positive regulation of tyrosine phosphorylation of Stat3 protein; ISO:MGI.
DR   GO; GO:0042523; P:positive regulation of tyrosine phosphorylation of Stat5 protein; ISO:MGI.
DR   GO; GO:0046777; P:protein autophosphorylation; ISO:MGI.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:MGI.
DR   GO; GO:0008360; P:regulation of cell shape; IDA:UniProtKB.
DR   GO; GO:0048070; P:regulation of developmental pigmentation; IMP:MGI.
DR   GO; GO:0009314; P:response to radiation; IMP:MGI.
DR   GO; GO:0048103; P:somatic stem cell division; IEA:Ensembl.
DR   GO; GO:0035019; P:somatic stem cell population maintenance; IEA:Ensembl.
DR   GO; GO:0007286; P:spermatid development; IMP:MGI.
DR   GO; GO:0007283; P:spermatogenesis; IMP:UniProtKB.
DR   GO; GO:0048863; P:stem cell differentiation; IMP:UniProtKB.
DR   GO; GO:0030217; P:T cell differentiation; IMP:UniProtKB.
DR   GO; GO:0008542; P:visual learning; IEA:Ensembl.
DR   Gene3D; 2.60.40.10; -; 5.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR013151; Immunoglobulin.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR027263; SCGF_receptor.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016243; Tyr_kinase_CSF1/PDGF_rcpt.
DR   InterPro; IPR001824; Tyr_kinase_rcpt_3_CS.
DR   Pfam; PF00047; ig; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PIRSF; PIRSF500951; SCGF_recepter; 1.
DR   PIRSF; PIRSF000615; TyrPK_CSF1-R; 1.
DR   SMART; SM00409; IG; 2.
DR   SMART; SM00408; IGc2; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 4.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00240; RECEPTOR_TYR_KIN_III; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Complete proteome; Cytoplasm; Disease mutation; Disulfide bond;
KW   Glycoprotein; Immunoglobulin domain; Kinase; Magnesium; Membrane;
KW   Metal-binding; Nucleotide-binding; Phosphoprotein; Proto-oncogene;
KW   Receptor; Reference proteome; Repeat; Signal; Transferase;
KW   Transmembrane; Transmembrane helix; Tyrosine-protein kinase;
KW   Ubl conjugation.
FT   SIGNAL        1     24       {ECO:0000255}.
FT   CHAIN        25    979       Mast/stem cell growth factor receptor
FT                                Kit.
FT                                /FTId=PRO_0000016755.
FT   TOPO_DOM     25    527       Extracellular. {ECO:0000255}.
FT   TRANSMEM    528    548       Helical. {ECO:0000255}.
FT   TOPO_DOM    549    979       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       31    117       Ig-like C2-type 1.
FT   DOMAIN      126    210       Ig-like C2-type 2.
FT   DOMAIN      217    315       Ig-like C2-type 3.
FT   DOMAIN      324    417       Ig-like C2-type 4.
FT   DOMAIN      420    514       Ig-like C2-type 5.
FT   DOMAIN      592    939       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     599    606       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     674    680       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      571    573       Important for interaction with
FT                                phosphotyrosine-binding proteins.
FT                                {ECO:0000250}.
FT   ACT_SITE    794    794       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   METAL       571    571       Magnesium. {ECO:0000250}.
FT   METAL       799    799       Magnesium. {ECO:0000250}.
FT   METAL       812    812       Magnesium. {ECO:0000250}.
FT   BINDING     626    626       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   BINDING     798    798       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   SITE        938    938       Important for interaction with
FT                                phosphotyrosine-binding proteins.
FT                                {ECO:0000250}.
FT   MOD_RES     550    550       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     556    556       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     571    571       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:17947660}.
FT   MOD_RES     573    573       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:17947660}.
FT   MOD_RES     706    706       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:17947660}.
FT   MOD_RES     720    720       Phosphoserine.
FT                                {ECO:0000244|PubMed:21183079}.
FT   MOD_RES     723    723       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     732    732       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     743    743       Phosphoserine; by PKC/PRKCA.
FT                                {ECO:0000250}.
FT   MOD_RES     748    748       Phosphoserine; by PKC/PRKCA.
FT                                {ECO:0000250}.
FT   MOD_RES     823    823       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P10721}.
FT   MOD_RES     825    825       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:7527401}.
FT   MOD_RES     893    893       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P10721}.
FT   MOD_RES     902    902       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     938    938       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:17947660}.
FT   MOD_RES     962    962       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P10721}.
FT   CARBOHYD    146    146       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    296    296       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:17255936}.
FT   CARBOHYD    303    303       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:17255936}.
FT   CARBOHYD    323    323       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    355    355       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    370    370       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    466    466       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    489    489       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     58     98       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:17255936}.
FT   DISULFID    137    187       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:17255936}.
FT   DISULFID    152    184       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:17255936}.
FT   DISULFID    234    293       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:17255936}.
FT   DISULFID    431    494       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   VAR_SEQ       1     12       MRGARGAWDLLC -> MAVAVFPFLPQQ (in isoform
FT                                3). {ECO:0000303|PubMed:1378413}.
FT                                /FTId=VSP_041868.
FT   VAR_SEQ      13    789       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:1378413}.
FT                                /FTId=VSP_041869.
FT   VAR_SEQ     512    515       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:15731517,
FT                                ECO:0000303|PubMed:2456920}.
FT                                /FTId=VSP_041870.
FT   VARIANT     207    207       A -> E (loss-of-function mutation
FT                                abolishing ligand binding).
FT                                {ECO:0000269|PubMed:2456920,
FT                                ECO:0000269|Ref.21}.
FT   VARIANT     586    586       E -> K (in W37 spotting; impaired protein
FT                                stability and loss of kinase activity).
FT                                {ECO:0000269|PubMed:1693331,
FT                                ECO:0000269|PubMed:1714377}.
FT   VARIANT     664    664       T -> M (in Wv spotting).
FT                                {ECO:0000269|PubMed:1693331}.
FT   VARIANT     794    794       D -> N (in W42 spotting; loss of kinase
FT                                activity and impaired internalization
FT                                after exposure to KITLG/SCF).
FT                                {ECO:0000269|PubMed:1688471,
FT                                ECO:0000269|PubMed:7527401}.
FT   VARIANT     835    835       V -> M (in W41 spotting; decreased kinase
FT                                activity). {ECO:0000269|PubMed:1693331,
FT                                ECO:0000269|PubMed:1714377}.
FT   MUTAGEN     571    571       Y->F: Abolishes interaction with
FT                                PTPN11/SHP-2.
FT                                {ECO:0000269|PubMed:9528781}.
FT   MUTAGEN     573    573       Y->F: Abolishes interaction with
FT                                PTPN6/SHP-1.
FT                                {ECO:0000269|PubMed:9528781}.
FT   MUTAGEN     573    573       Missing: Abolishes interaction with
FT                                PTPN6/SHP-1.
FT                                {ECO:0000269|PubMed:9528781}.
FT   MUTAGEN     723    723       Y->F: Abolishes interaction with PIK3R1.
FT                                {ECO:0000269|PubMed:7527401}.
FT   MUTAGEN     860    860       F->S: Mice display white fur, hearing
FT                                loss, anemia and mast cell deficiency,
FT                                plus sterility in both males and females.
FT                                {ECO:0000269|PubMed:15731517}.
FT   CONFLICT    551    551       L -> F (in Ref. 6; AAH52457).
FT                                {ECO:0000305}.
FT   CONFLICT    781    781       G -> A (in Ref. 1; CAA68772 and 2;
FT                                CAA46799). {ECO:0000305}.
FT   CONFLICT    860    860       F -> S (in Ref. 4; AAS45607).
FT                                {ECO:0000305}.
FT   STRAND       38     41       {ECO:0000244|PDB:2O26}.
FT   STRAND       43     49       {ECO:0000244|PDB:2O26}.
FT   STRAND       54     59       {ECO:0000244|PDB:2O26}.
FT   STRAND       63     69       {ECO:0000244|PDB:2O26}.
FT   STRAND       71     73       {ECO:0000244|PDB:2O26}.
FT   STRAND       75     78       {ECO:0000244|PDB:2O26}.
FT   STRAND       80     85       {ECO:0000244|PDB:2O26}.
FT   HELIX        90     92       {ECO:0000244|PDB:2O26}.
FT   STRAND       94    103       {ECO:0000244|PDB:2O26}.
FT   STRAND      105    113       {ECO:0000244|PDB:2O26}.
FT   STRAND      125    128       {ECO:0000244|PDB:2O26}.
FT   STRAND      133    135       {ECO:0000244|PDB:2O26}.
FT   STRAND      145    151       {ECO:0000244|PDB:2O26}.
FT   STRAND      162    166       {ECO:0000244|PDB:2O26}.
FT   TURN        167    169       {ECO:0000244|PDB:2O26}.
FT   STRAND      170    175       {ECO:0000244|PDB:2O26}.
FT   HELIX       178    180       {ECO:0000244|PDB:2O26}.
FT   STRAND      184    191       {ECO:0000244|PDB:2O26}.
FT   STRAND      194    197       {ECO:0000244|PDB:2O26}.
FT   STRAND      201    206       {ECO:0000244|PDB:2O26}.
FT   STRAND      214    216       {ECO:0000244|PDB:2O26}.
FT   STRAND      230    240       {ECO:0000244|PDB:2O26}.
FT   STRAND      244    256       {ECO:0000244|PDB:2O26}.
FT   STRAND      264    268       {ECO:0000244|PDB:2O26}.
FT   STRAND      271    282       {ECO:0000244|PDB:2O26}.
FT   STRAND      285    287       {ECO:0000244|PDB:2O26}.
FT   STRAND      289    296       {ECO:0000244|PDB:2O26}.
FT   STRAND      301    308       {ECO:0000244|PDB:2O26}.
SQ   SEQUENCE   979 AA;  109343 MW;  03FB4D672248585E CRC64;
     MRGARGAWDL LCVLLVLLRG QTATSQPSAS PGEPSPPSIH PAQSELIVEA GDTLSLTCID
     PDFVRWTFKT YFNEMVENKK NEWIQEKAEA TRTGTYTCSN SNGLTSSIYV FVRDPAKLFL
     VGLPLFGKED SDALVRCPLT DPQVSNYSLI ECDGKSLPTD LTFVPNPKAG ITIKNVKRAY
     HRLCVRCAAQ RDGTWLHSDK FTLKVRAAIK AIPVVSVPET SHLLKKGDTF TVVCTIKDVS
     TSVNSMWLKM NPQPQHIAQV KHNSWHRGDF NYERQETLTI SSARVDDSGV FMCYANNTFG
     SANVTTTLKV VEKGFINISP VKNTTVFVTD GENVDLVVEY EAYPKPEHQQ WIYMNRTSAN
     KGKDYVKSDN KSNIRYVNQL RLTRLKGTEG GTYTFLVSNS DASASVTFNV YVNTKPEILT
     YDRLINGMLQ CVAEGFPEPT IDWYFCTGAE QRCTTPVSPV DVQVQNVSVS PFGKLVVQSS
     IDSSVFRHNG TVECKASNDV GKSSAFFNFA FKGNNKEQIQ AHTLFTPLLI GFVVAAGAMG
     IIVMVLTYKY LQKPMYEVQW KVVEEINGNN YVYIDPTQLP YDHKWEFPRN RLSFGKTLGA
     GAFGKVVEAT AYGLIKSDAA MTVAVKMLKP SAHLTEREAL MSELKVLSYL GNHMNIVNLL
     GACTVGGPTL VITEYCCYGD LLNFLRRKRD SFIFSKQEEQ AEAALYKNLL HSTEPSCDSS
     NEYMDMKPGV SYVVPTKTDK RRSARIDSYI ERDVTPAIME DDELALDLDD LLSFSYQVAK
     GMAFLASKNC IHRDLAARNI LLTHGRITKI CDFGLARDIR NDSNYVVKGN ARLPVKWMAP
     ESIFSCVYTF ESDVWSYGIF LWELFSLGSS PYPGMPVDSK FYKMIKEGFR MVSPEHAPAE
     MYDVMKTCWD ADPLKRPTFK QVVQLIEKQI SDSTKHIYSN LANCNPNPEN PVVVDHSVRV
     NSVGSSASST QPLLVHEDA
//
ID   FA7_HUMAN               Reviewed;         466 AA.
AC   P08709; B0YJC8; Q14339; Q5JVF1; Q5JVF2; Q9UD52; Q9UD53; Q9UD54;
DT   01-JAN-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1988, sequence version 1.
DT   17-FEB-2016, entry version 223.
DE   RecName: Full=Coagulation factor VII;
DE            EC=3.4.21.21;
DE   AltName: Full=Proconvertin;
DE   AltName: Full=Serum prothrombin conversion accelerator;
DE            Short=SPCA;
DE   AltName: INN=Eptacog alfa;
DE   Contains:
DE     RecName: Full=Factor VII light chain;
DE   Contains:
DE     RecName: Full=Factor VII heavy chain;
DE   Flags: Precursor;
GN   Name=F7;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS A AND B).
RC   TISSUE=Liver;
RX   PubMed=3486420; DOI=10.1073/pnas.83.8.2412;
RA   Hagen F.S., Gray C.L., O'Hara P.J., Grant F.J., Saari G.C.,
RA   Woodbury R.G., Hart C.E., Insley M.Y., Kisiel W., Kurachi K.,
RA   Davie E.W.;
RT   "Characterization of a cDNA coding for human factor VII.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:2412-2416(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=3037537; DOI=10.1073/pnas.84.15.5158;
RA   O'Hara P.J., Grant F.J., Haldeman B.A., Gray C.L., Insley M.Y.,
RA   Hagen F.S., Murray M.J.;
RT   "Nucleotide sequence of the gene coding for human factor VII, a
RT   vitamin K-dependent protein participating in blood coagulation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:5158-5162(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS VAL-354 AND GLN-413.
RX   PubMed=16292673; DOI=10.1007/s00439-005-0045-5;
RA   Sabater-Lleal M., Soria J.M., Bertranpetit J., Almasy L., Blangero J.,
RA   Fontcuberta J., Calafell F.;
RT   "Human F7 sequence is split into three deep clades that are related to
RT   FVII plasma levels.";
RL   Hum. Genet. 118:741-751(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Soria J.M., Almasy L., Souto J.C., Sabater M., Fontcuberta J.,
RA   Blangero J.;
RT   "Complete dissection of a human quantitative trait locus: allelic
RT   architecture of F7 and factor VII levels.";
RL   Submitted (DEC-2002) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A).
RA   Masroori N., Habibi Roudkenar M., Halabian R.;
RL   Submitted (MAR-2008) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS THR-352; GLN-413 AND
RP   LYS-445.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JAN-2002) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (FEB-2007) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057823; DOI=10.1038/nature02379;
RA   Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L.,
RA   Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E.,
RA   Griffiths-Jones S., Jones M.C., Keenan S.J., Oliver K., Scott C.E.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Andrews D.T.,
RA   Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., Bannerjee R.,
RA   Barlow K.F., Bates K., Beasley H., Bird C.P., Bray-Allen S.,
RA   Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M.,
RA   Clegg S.C., Cobley V., Collins J.E., Corby N., Coville G.J.,
RA   Deloukas P., Dhami P., Dunham I., Dunn M., Earthrowl M.E.,
RA   Ellington A.G., Faulkner L., Frankish A.G., Frankland J., French L.,
RA   Garner P., Garnett J., Gilbert J.G.R., Gilson C.J., Ghori J.,
RA   Grafham D.V., Gribble S.M., Griffiths C., Hall R.E., Hammond S.,
RA   Harley J.L., Hart E.A., Heath P.D., Howden P.J., Huckle E.J.,
RA   Hunt P.J., Hunt A.R., Johnson C., Johnson D., Kay M., Kimberley A.M.,
RA   King A., Laird G.K., Langford C.J., Lawlor S., Leongamornlert D.A.,
RA   Lloyd D.M., Lloyd C., Loveland J.E., Lovell J., Martin S.,
RA   Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S.,
RA   Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K.M., Rice C.M., Searle S.,
RA   Sehra H.K., Shownkeen R., Skuce C.D., Smith M., Steward C.A.,
RA   Sycamore N., Tester J., Thomas D.W., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., Whitehead S.L., Willey D.L.,
RA   Wilming L., Wray P.W., Wright M.W., Young L., Coulson A., Durbin R.M.,
RA   Hubbard T., Sulston J.E., Beck S., Bentley D.R., Rogers J., Ross M.T.;
RT   "The DNA sequence and analysis of human chromosome 13.";
RL   Nature 428:522-528(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM B).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   PROTEIN SEQUENCE OF 61-466, GAMMA-CARBOXYGLUTAMATION AT GLU-66;
RP   GLU-67; GLU-74; GLU-76; GLU-79; GLU-80; GLU-85; GLU-86; GLU-89 AND
RP   GLU-95, HYDROXYLATION AT ASP-123, AND GLYCOSYLATION AT ASN-205 AND
RP   ASN-382.
RX   PubMed=3264725; DOI=10.1021/bi00420a030;
RA   Thim L., Bjoern S., Christensen M., Nicolaisen E.M., Lund-Hansen T.,
RA   Pedersen A.H., Hedner U.;
RT   "Amino acid sequence and posttranslational modifications of human
RT   factor VIIa from plasma and transfected baby hamster kidney cells.";
RL   Biochemistry 27:7785-7793(1988).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 354-412, VARIANTS FA7D ILE-358;
RP   GLN-364; PHE-370 AND ARG-402, AND VARIANT GLN-413.
RX   PubMed=8043443; DOI=10.1111/j.1365-2141.1994.tb04793.x;
RA   Bernardi F., Liney D.L., Patracchini P., Gemmati D., Legnani C.,
RA   Arcieri P., Pinotti M., Redaelli R., Ballerini G., Pemberton S.,
RA   Wacey A.I., Mariani G., Tuddenham E.G.D., Marchetti G.;
RT   "Molecular defects in CRM+ factor VII deficiencies: modelling of
RT   missense mutations in the catalytic domain of FVII.";
RL   Br. J. Haematol. 86:610-618(1994).
RN   [12]
RP   STRUCTURE OF CARBOHYDRATE ON SER-112.
RX   PubMed=2511201;
RA   Nishimura H., Kawabata S., Kisiel W., Hase S., Ikenaka T., Takao T.,
RA   Shimonishi Y., Iwanaga S.;
RT   "Identification of a disaccharide (Xyl-Glc) and a trisaccharide (Xyl2-
RT   Glc) O-glycosidically linked to a serine residue in the first
RT   epidermal growth factor-like domain of human factors VII and IX and
RT   protein Z and bovine protein Z.";
RL   J. Biol. Chem. 264:20320-20325(1989).
RN   [13]
RP   STRUCTURE OF CARBOHYDRATE ON SER-112.
RX   PubMed=2129367;
RA   Iwanaga S., Nishimura H., Kawabata S., Kisiel W., Hase S., Ikenaka T.;
RT   "A new trisaccharide sugar chain linked to a serine residue in the
RT   first EGF-like domain of clotting factors VII and IX and protein Z.";
RL   Adv. Exp. Med. Biol. 281:121-131(1990).
RN   [14]
RP   GLYCOSYLATION AT SER-112 AND SER-120.
RX   PubMed=1904059;
RA   Bjoern S., Foster D.C., Thim L., Wiberg F.C., Christensen M.,
RA   Komiyama Y., Pedersen A.H., Kisiel W.;
RT   "Human plasma and recombinant factor VII. Characterization of O-
RT   glycosylations at serine residues 52 and 60 and effects of site-
RT   directed mutagenesis of serine 52 to alanine.";
RL   J. Biol. Chem. 266:11051-11057(1991).
RN   [15]
RP   GLYCOSYLATION AT SER-120, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=9023546; DOI=10.1093/glycob/6.8.837;
RA   Wang Y., Lee G.F., Kelley R.F., Spellman M.W.;
RT   "Identification of a GDP-L-fucose:polypeptide fucosyltransferase and
RT   enzymatic addition of O-linked fucose to EGF domains.";
RL   Glycobiology 6:837-842(1996).
RN   [16]
RP   GLYCOSYLATION AT ASN-205 AND ASN-382.
RX   PubMed=19167329; DOI=10.1016/j.cell.2008.11.047;
RA   Ruiz-Canada C., Kelleher D.J., Gilmore R.;
RT   "Cotranslational and posttranslational N-glycosylation of polypeptides
RT   by distinct mammalian OST isoforms.";
RL   Cell 136:272-283(2009).
RN   [17]
RP   GLYCOSYLATION AT SER-112, AND MUTAGENESIS OF SER-112 AND SER-113.
RX   PubMed=21949356; DOI=10.1073/pnas.1109696108;
RA   Takeuchi H., Fernandez-Valdivia R.C., Caswell D.S., Nita-Lazar A.,
RA   Rana N.A., Garner T.P., Weldeghiorghis T.K., Macnaughtan M.A.,
RA   Jafar-Nejad H., Haltiwanger R.S.;
RT   "Rumi functions as both a protein O-glucosyltransferase and a protein
RT   O-xylosyltransferase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:16600-16605(2011).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF FVIIA IN COMPLEX WITH TF.
RX   PubMed=8598903; DOI=10.1038/380041a0;
RA   Banner D.W., D'Arcy A., Chene C., Winkler F.K., Guha A.,
RA   Konigsberg W.H., Nemreson Y., Kirchhofer D.;
RT   "The crystal structure of the complex of blood coagulation factor VIIa
RT   with soluble tissue factor.";
RL   Nature 380:41-46(1996).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF FVIIA IN COMPLEX WITH TF.
RX   PubMed=9925787; DOI=10.1006/jmbi.1998.2452;
RA   Zhang E., St Charles R., Tulinsky A.;
RT   "Structure of extracellular tissue factor complexed with factor VIIa
RT   inhibited with a BPTI mutant.";
RL   J. Mol. Biol. 285:2089-2104(1999).
RN   [20]
RP   STRUCTURE BY NMR OF 105-145.
RX   PubMed=9692950; DOI=10.1021/bi980522f;
RA   Muranyi A., Finn B.E., Gippert G.P., Forsen S., Stenflo J.,
RA   Drakenberg T.;
RT   "Solution structure of the N-terminal EGF-like domain from human
RT   factor VII.";
RL   Biochemistry 37:10605-10615(1998).
RN   [21]
RP   VARIANT FA7D GLN-364.
RX   PubMed=2070047;
RA   O'Brien D.P., Gale K.M., Anderson J.S., McVey J.H., Miller G.J.,
RA   Meade T.W., Tuddenham E.G.D.;
RT   "Purification and characterization of factor VII 304-Gln: a variant
RT   molecule with reduced activity isolated from a clinically unaffected
RT   male.";
RL   Blood 78:132-140(1991).
RN   [22]
RP   VARIANTS FA7D GLN-364 AND PHE-370.
RX   PubMed=1634227; DOI=10.1007/BF00219173;
RA   Marchetti G., Patracchini P., Gemmati D., Derosa V., Pinotti M.,
RA   Rodorigo G., Casonato A., Girolami A., Bernardi F.;
RT   "Detection of two missense mutations and characterization of a repeat
RT   polymorphism in the factor VII gene (F7).";
RL   Hum. Genet. 89:497-502(1992).
RN   [23]
RP   VARIANT FA7D TYR-238.
RX   PubMed=8364544; DOI=10.1093/hmg/2.7.1055;
RA   Marchetti G., Ferrati M., Patracchini P., Redaelli R., Bernardi F.;
RT   "A missense mutation (178Cys-->Tyr) and two neutral dimorphisms
RT   (115His and 333Ser) in the human coagulation factor VII gene.";
RL   Hum. Mol. Genet. 2:1055-1056(1993).
RN   [24]
RP   VARIANTS.
RX   PubMed=8242057; DOI=10.1093/hmg/2.9.1355;
RA   Takamiya O., Kemball-Cook G., Martin D.M.A., Cooper D.N.,
RA   von Felten A., Meili E., Hahn I., Prangnell D.R., Lumley H.,
RA   Tuddenham E.G.D., McVey J.H.;
RT   "Detection of missense mutations by single-strand conformational
RT   polymorphism (SSCP) analysis in five dysfunctional variants of
RT   coagulation factor VII.";
RL   Hum. Mol. Genet. 2:1355-1359(1993).
RN   [25]
RP   VARIANTS FA7D GLN-139 AND GLN-212.
RX   PubMed=8204879;
RA   Chaing S., Clarke B., Sridhara S., Chu K., Friedman P., Vandusen W.,
RA   Roberts H.R., Blajchman M., Monroe D.M., High K.A.;
RT   "Severe factor VII deficiency caused by mutations abolishing the
RT   cleavage site for activation and altering binding to tissue factor.";
RL   Blood 83:3524-3535(1994).
RN   [26]
RP   VARIANT SER-367.
RX   PubMed=7860081;
RA   Dewald G., Noethen M.M., Ruther K.;
RT   "A common Ser/Thr polymorphism in the perforin-homologous region of
RT   human complement component C7.";
RL   Hum. Hered. 44:301-304(1994).
RN   [27]
RP   VARIANT FA7D VAL-354.
RX   PubMed=7981691; DOI=10.1093/hmg/3.7.1175;
RA   Bernardi F., Castaman G., Redaelli R., Pinotti M., Lunghi B.,
RA   Rodeghiero F., Marchetti G.;
RT   "Topologically equivalent mutations causing dysfunctional coagulation
RT   factors VII (294Ala-->Val) and X (334Ser-->Pro).";
RL   Hum. Mol. Genet. 3:1175-1177(1994).
RN   [28]
RP   VARIANT FA7D HIS-307.
RX   PubMed=7974346;
RA   Ohiwa M., Hayashi T., Wada H., Minamikawa K., Shirakawa S., Suzuki K.;
RT   "Factor VII Mie: homozygous asymptomatic type I deficiency caused by
RT   an amino acid substitution of His (CAC) for Arg(247) (CGC) in the
RT   catalytic domain.";
RL   Thromb. Haemost. 71:773-777(1994).
RN   [29]
RP   VARIANT FA7D MET-419.
RX   PubMed=8652821;
RA   Arbini A.A., Mannucci P.M., Bauer K.A.;
RT   "A Thr359Met mutation in factor VII of a patient with a hereditary
RT   deficiency causes defective secretion of the molecule.";
RL   Blood 87:5085-5094(1996).
RN   [30]
RP   VARIANTS FA7D TRP-283; LYS-325; VAL-358; GLN-364 AND GLU-402, AND
RP   VARIANT GLN-413.
RX   PubMed=8844208;
RX   DOI=10.1002/(SICI)1098-1004(1996)8:2<108::AID-HUMU2>3.0.CO;2-7;
RA   Bernardi F., Castaman G., Pinotti M., Ferraresi P., di Iasio M.G.,
RA   Lunghi B., Rodeghiero F., Marchetti G.;
RT   "Mutation pattern in clinically asymptomatic coagulation factor VII
RT   deficiency.";
RL   Hum. Mutat. 8:108-115(1996).
RN   [31]
RP   VARIANT FA7D SER-388, AND CHARACTERIZATION OF VARIANT FA7D SER-388.
RX   PubMed=8940045; DOI=10.1074/jbc.271.48.30685;
RA   Bharadwaj D., Iino M., Kontoyianni M., Smith K.J., Foster D.C.,
RA   Kisiel W.;
RT   "Factor VII central. A novel mutation in the catalytic domain that
RT   reduces tissue factor binding, impairs activation by factor Xa, and
RT   abolishes amidolytic and coagulant activity.";
RL   J. Biol. Chem. 271:30685-30691(1996).
RN   [32]
RP   VARIANT FA7D VAL-304.
RX   PubMed=8883260;
RA   Tamary H., Fromovich Y., Shalmon L., Reich Z., Dym O., Lanir N.,
RA   Brenner B., Paz M., Luder A.S., Blau O., Korostishevsky M., Zaizov R.,
RA   Seligsohn U.;
RT   "Ala244Val is a common, probably ancient mutation causing factor VII
RT   deficiency in Moroccan and Iranian Jews.";
RL   Thromb. Haemost. 76:283-291(1996).
RN   [33]
RP   VARIANT FA7D ASP-117, AND CHARACTERIZATION OF VARIANT FA7D ASP-117.
RX   PubMed=9414278;
RA   Leonard B.J., Chen Q., Blajchman M.A., Ofosu F.A., Sridhara S.,
RA   Yang D., Clarke B.J.;
RT   "Factor VII deficiency caused by a structural variant N57D of the
RT   first epidermal growth factor domain.";
RL   Blood 91:142-148(1998).
RN   [34]
RP   VARIANT FA7D PRO-13.
RX   PubMed=9576180; DOI=10.1046/j.1365-2141.1998.00666.x;
RA   Ozawa T., Takikawa Y., Niiya K., Ejiri N., Suzuki K., Sato S.,
RA   Sakuragawa N.;
RT   "Factor VII Morioka (FVII L-26P): a homozygous missense mutation in
RT   the signal sequence identified in a patient with factor VII
RT   deficiency.";
RL   Br. J. Haematol. 101:47-49(1998).
RN   [35]
RP   VARIANTS FA7D THR-194 AND VAL-304.
RX   PubMed=9452082;
RA   Alshinawi C., Scerri C., Galdies R., Aquilina A., Felice A.E.;
RT   "Two new missense mutations (P134T and A244V) in the coagulation
RT   factor VII gene.";
RL   Hum. Mutat. Suppl. 1:S189-S191(1998).
RN   [36]
RP   VARIANTS ASP-295 AND GLN-413.
RX   PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions
RT   of human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [37]
RP   ERRATUM.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
RN   [38]
RP   VARIANT FA7D GLY-389.
RX   PubMed=11091194; DOI=10.1046/j.1365-2141.2000.02332.x;
RA   Au W.Y., Lam C.C.K., Chan E.C., Kwong Y.L.;
RT   "Two novel factor VII gene mutations in a Chinese family with factor
RT   VII deficiency.";
RL   Br. J. Haematol. 111:143-145(2000).
RN   [39]
RP   VARIANTS FA7D GLN-73; GLN-79; PHE-121; PRO-125; CYS-128; TRP-139;
RP   SER-151; VAL-157; ARG-160; ARG-195; ASN-241; HIS-302; ASN-302;
RP   THR-304; VAL-304; CYS-307; MET-332; VAL-354; ILE-358; PHE-370;
RP   GLY-389; SER-391 AND GLU-435.
RX   PubMed=11129332; DOI=10.1007/s004390000373;
RA   Millar D.S., Kemball-Cook G., McVey J.H., Tuddenham E.G.D.,
RA   Mumford A.D., Attock G.B., Reverter J.C., Lanir N., Parapia L.A.,
RA   Reynaud J., Meili E., von Felton A., Martinowitz U., Prangnell D.R.,
RA   Krawczak M., Cooper D.N.;
RT   "Molecular analysis of the genotype-phenotype relationship in factor
RT   VII deficiency.";
RL   Hum. Genet. 107:327-342(2000).
RN   [40]
RP   VARIANTS FA7D LEU-64; PRO-120; CYS-128; LYS-154; SER-157; ARG-160;
RP   ARG-195; GLN-212; ASP-216; TYR-254; THR-266; HIS-302; VAL-304;
RP   CYS-307; MET-312; LYS-325; PHE-341; VAL-354; ILE-358; ARG-363;
RP   PHE-370; HIS-403 AND MET-419.
RX   PubMed=10862079;
RX   DOI=10.1002/1098-1004(200006)15:6<489::AID-HUMU1>3.3.CO;2-A;
RA   Wulff K., Herrmann F.H.;
RT   "Twenty two novel mutations of the factor VII gene in factor VII
RT   deficiency.";
RL   Hum. Mutat. 15:489-496(2000).
RN   [41]
RP   VARIANT GLN-413.
RX   PubMed=10984565; DOI=10.1056/NEJM200009143431104;
RA   Girelli D., Russo C., Ferraresi P., Olivieri O., Pinotti M., Friso S.,
RA   Manzato F., Mazzucco A., Bernardi F., Corrocher R.;
RT   "Polymorphisms in the factor VII gene and the risk of myocardial
RT   infarction in patients with coronary artery disease.";
RL   N. Engl. J. Med. 343:774-780(2000).
RN   [42]
RP   VARIANTS FA7D LYS-85 AND GLN-408.
RX   PubMed=12472587; DOI=10.1046/j.1365-2141.2002.03933.x;
RA   Nagaizumi K., Inaba H., Suzuki T., Hatta Y., Hagiwara T., Amano K.,
RA   Arai M., Fukutake K.;
RT   "Two double heterozygous mutations in the F7 gene show different
RT   manifestations.";
RL   Br. J. Haematol. 119:1052-1058(2002).
RN   [43]
RP   VARIANT FA7D CYS-414, AND CHARACTERIZATION OF VARIANT FA7D CYS-414.
RX   PubMed=14717781; DOI=10.1046/j.1365-2141.2003.04778.x;
RA   Takamiya O., Hino K.;
RT   "A patient homozygous for a Gly354Cys mutation in factor VII that
RT   results in severely impaired secretion of the molecule, but not
RT   complete deficiency.";
RL   Br. J. Haematol. 124:336-342(2004).
RN   [44]
RP   VARIANTS FA7D ARG-82; ARG-177; THR-198; GLN-212; PRO-251; ARG-323;
RP   ARG-344; PHE-370; MET-384; GLU-398 AND ARG-408.
RX   PubMed=19751712; DOI=10.1016/j.cca.2009.09.007;
RA   Mota L., Shetty S., Idicula-Thomas S., Ghosh K.;
RT   "Phenotypic and genotypic characterization of Factor VII deficiency
RT   patients from Western India.";
RL   Clin. Chim. Acta 409:106-111(2009).
RN   [45]
RP   VARIANTS FA7D LEU-64; GLN-73; PHE-82; PHE-84 DEL; GLY-88; PRO-88;
RP   PRO-120; CYS-128; ASP-138; GLN-139; LYS-154; SER-156; SER-157;
RP   ARG-160; PHE-171; PRO-181; ASN-183; PHE-186; SER-189; LEU-194;
RP   THR-194; ARG-195; GLN-212; ASP-216; ASN-241; THR-251; ARG-254;
RP   TYR-254; PRO-264; THR-266; ASN-272; ASN-277; TRP-283; ILE-298;
RP   GLN-301; ASN-302; HIS-302; THR-304; VAL-304; CYS-307; HIS-307;
RP   MET-312; PHE-321; LYS-325; GLN-326; CYS-337; PHE-341; SER-343;
RP   SER-345; CYS-350; VAL-354; ILE-358; PRO-360; ARG-363; HIS-363;
RP   GLN-364; TRP-364; PHE-370; TRP-375; MET-384; THR-387; VAL-387;
RP   SER-388; CYS-391; SER-391; GLU-401; HIS-403; ASN-404; GLY-413;
RP   MET-419; PHE-422; ALA-425; CYS-425; THR-429; ASP-432; GLU-435 AND
RP   PHE-437.
RX   PubMed=18976247; DOI=10.1111/j.1365-2516.2008.01910.x;
RA   Herrmann F.H., Wulff K., Auerswald G., Schulman S., Astermark J.,
RA   Batorova A., Kreuz W., Pollmann H., Ruiz-Saez A., De Bosch N.,
RA   Salazar-Sanchez L.;
RT   "Factor VII deficiency: clinical manifestation of 717 subjects from
RT   Europe and Latin America with mutations in the factor 7 gene.";
RL   Haemophilia 15:267-280(2009).
RN   [46]
RP   VARIANT FA7D ARG-240.
RX   PubMed=19432927; DOI=10.1111/j.1365-2516.2009.02004.x;
RA   Landau D., Rosenberg N., Zivelin A., Staretz-Chacham O.,
RA   Kapelushnik J.;
RT   "Familial factor VII deficiency with foetal and neonatal fatal
RT   cerebral haemorrhage associated with homozygosis to Gly180Arg
RT   mutation.";
RL   Haemophilia 15:774-778(2009).
RN   [47]
RP   VARIANTS FA7D ARG-59 INS; VAL-314; SER-343 AND GLY-389.
RX   PubMed=21206266; DOI=10.1097/MBC.0b013e328343641a;
RA   Kwon M.J., Yoo K.Y., Lee K.O., Kim S.H., Kim H.J.;
RT   "Recurrent mutations and genotype-phenotype correlations in hereditary
RT   factor VII deficiency in Korea.";
RL   Blood Coagul. Fibrinolysis 22:102-105(2011).
RN   [48]
RP   VARIANT FA7D PHE-250.
RX   PubMed=21372693; DOI=10.1097/MBC.0b013e3283447388;
RA   Jiang M., Wang Z., Yu Z., Bai X., Su J., Cao L., Zhang W., Ruan C.;
RT   "A novel missense mutation close to the charge-stabilizing system in a
RT   patient with congenital factor VII deficiency.";
RL   Blood Coagul. Fibrinolysis 22:264-270(2011).
CC   -!- FUNCTION: Initiates the extrinsic pathway of blood coagulation.
CC       Serine protease that circulates in the blood in a zymogen form.
CC       Factor VII is converted to factor VIIa by factor Xa, factor XIIa,
CC       factor IXa, or thrombin by minor proteolysis. In the presence of
CC       tissue factor and calcium ions, factor VIIa then converts factor X
CC       to factor Xa by limited proteolysis. Factor VIIa will also convert
CC       factor IX to factor IXa in the presence of tissue factor and
CC       calcium.
CC   -!- CATALYTIC ACTIVITY: Selective cleavage of Arg-|-Ile bond in factor
CC       X to form factor Xa.
CC   -!- SUBUNIT: Heterodimer of a light chain and a heavy chain linked by
CC       a disulfide bond. {ECO:0000269|PubMed:8598903,
CC       ECO:0000269|PubMed:9925787}.
CC   -!- INTERACTION:
CC       P13726:F3; NbExp=6; IntAct=EBI-355972, EBI-1040727;
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=A;
CC         IsoId=P08709-1; Sequence=Displayed;
CC       Name=B;
CC         IsoId=P08709-2; Sequence=VSP_005387;
CC   -!- TISSUE SPECIFICITY: Plasma.
CC   -!- PTM: The vitamin K-dependent, enzymatic carboxylation of some
CC       glutamate residues allows the modified protein to bind calcium.
CC   -!- PTM: The iron and 2-oxoglutarate dependent 3-hydroxylation of
CC       aspartate and asparagine is (R) stereospecific within EGF domains.
CC       {ECO:0000269|PubMed:3264725}.
CC   -!- PTM: O- and N-glycosylated. N-glycosylation at Asn-205 occurs
CC       cotranslationally and is mediated by STT3A-containing complexes,
CC       while glycosylation at Asn-382 is post-translational and is
CC       mediated STT3B-containing complexes before folding. O-fucosylated
CC       by POFUT1 on a conserved serine or threonine residue found in the
CC       consensus sequence C2-X(4,5)-[S/T]-C3 of EGF domains, where C2 and
CC       C3 are the second and third conserved cysteines.
CC       {ECO:0000269|PubMed:1904059, ECO:0000269|PubMed:19167329,
CC       ECO:0000269|PubMed:21949356, ECO:0000269|PubMed:3264725,
CC       ECO:0000269|PubMed:9023546}.
CC   -!- PTM: Can be either O-glucosylated or O-xylosylated at Ser-112 by
CC       POGLUT1 in vitro.
CC   -!- DISEASE: Factor VII deficiency (FA7D) [MIM:227500]: A hemorrhagic
CC       disease with variable presentation. The clinical picture can be
CC       very severe, with the early occurrence of intracerebral
CC       hemorrhages or repeated hemarthroses, or, in contrast, moderate
CC       with cutaneous-mucosal hemorrhages (epistaxis, menorrhagia) or
CC       hemorrhages provoked by a surgical intervention. Finally, numerous
CC       subjects are completely asymptomatic despite very low factor VII
CC       levels. {ECO:0000269|PubMed:10862079, ECO:0000269|PubMed:11091194,
CC       ECO:0000269|PubMed:11129332, ECO:0000269|PubMed:12472587,
CC       ECO:0000269|PubMed:14717781, ECO:0000269|PubMed:1634227,
CC       ECO:0000269|PubMed:18976247, ECO:0000269|PubMed:19432927,
CC       ECO:0000269|PubMed:19751712, ECO:0000269|PubMed:2070047,
CC       ECO:0000269|PubMed:21206266, ECO:0000269|PubMed:21372693,
CC       ECO:0000269|PubMed:7974346, ECO:0000269|PubMed:7981691,
CC       ECO:0000269|PubMed:8043443, ECO:0000269|PubMed:8204879,
CC       ECO:0000269|PubMed:8364544, ECO:0000269|PubMed:8652821,
CC       ECO:0000269|PubMed:8844208, ECO:0000269|PubMed:8883260,
CC       ECO:0000269|PubMed:8940045, ECO:0000269|PubMed:9414278,
CC       ECO:0000269|PubMed:9452082, ECO:0000269|PubMed:9576180}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- PHARMACEUTICAL: Available under the names Niastase or Novoseven
CC       (Novo Nordisk). Used for the treatment of bleeding episodes in
CC       hemophilia A or B patients with antibodies to coagulation factors
CC       VIII or IX.
CC   -!- SIMILARITY: Belongs to the peptidase S1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00274}.
CC   -!- SIMILARITY: Contains 2 EGF-like domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00076}.
CC   -!- SIMILARITY: Contains 1 Gla (gamma-carboxy-glutamate) domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00463}.
CC   -!- SIMILARITY: Contains 1 peptidase S1 domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00274}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Factor VII entry;
CC       URL="https://en.wikipedia.org/wiki/Factor_VII";
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/f7/";
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=F7";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M13232; AAA88040.1; -; mRNA.
DR   EMBL; M13232; AAA88041.1; -; mRNA.
DR   EMBL; J02933; AAA51983.1; -; Genomic_DNA.
DR   EMBL; DQ142911; ABD17891.1; -; Genomic_DNA.
DR   EMBL; AY212252; AAP33841.1; -; Genomic_DNA.
DR   EMBL; EU557239; ACB87203.1; -; mRNA.
DR   EMBL; AF466933; AAL66184.1; -; Genomic_DNA.
DR   EMBL; EF445049; ACA06107.1; -; Genomic_DNA.
DR   EMBL; EF445049; ACA06108.1; -; Genomic_DNA.
DR   EMBL; AL137002; CAI41381.1; -; Genomic_DNA.
DR   EMBL; AL137002; CAI41382.1; -; Genomic_DNA.
DR   EMBL; BC130468; AAI30469.1; -; mRNA.
DR   CCDS; CCDS9528.1; -. [P08709-1]
DR   CCDS; CCDS9529.1; -. [P08709-2]
DR   PIR; A28322; KFHU7.
DR   RefSeq; NP_000122.1; NM_000131.4. [P08709-1]
DR   RefSeq; NP_062562.1; NM_019616.3. [P08709-2]
DR   UniGene; Hs.36989; -.
DR   PDB; 1BF9; NMR; -; A=105-145.
DR   PDB; 1CVW; X-ray; 2.28 A; H=213-466, L=150-204.
DR   PDB; 1DAN; X-ray; 2.00 A; H=213-466, L=61-212.
DR   PDB; 1DVA; X-ray; 3.00 A; H/I=213-466, L/M=102-202.
DR   PDB; 1F7E; NMR; -; A=105-147.
DR   PDB; 1F7M; NMR; -; A=105-147.
DR   PDB; 1FAK; X-ray; 2.10 A; H=213-466, L=61-212.
DR   PDB; 1FF7; NMR; -; A=105-147.
DR   PDB; 1FFM; NMR; -; A=105-147.
DR   PDB; 1J9C; X-ray; 2.90 A; H=213-466, L=108-202.
DR   PDB; 1JBU; X-ray; 2.00 A; H=213-466, L=150-212.
DR   PDB; 1KLI; X-ray; 1.69 A; H=213-466, L=144-212.
DR   PDB; 1KLJ; X-ray; 2.44 A; H=213-466, L=144-212.
DR   PDB; 1NL8; Model; -; H=213-466, M=61-202.
DR   PDB; 1O5D; X-ray; 2.05 A; H=213-466, L=61-212.
DR   PDB; 1QFK; X-ray; 2.80 A; H=213-466, L=109-212.
DR   PDB; 1W0Y; X-ray; 2.50 A; H=213-466, L=61-202.
DR   PDB; 1W2K; X-ray; 3.00 A; H=213-466, L=61-202.
DR   PDB; 1W7X; X-ray; 1.80 A; H=213-466, L=150-204.
DR   PDB; 1W8B; X-ray; 3.00 A; H=213-466, L=148-204.
DR   PDB; 1WQV; X-ray; 2.50 A; H=213-466, L=61-212.
DR   PDB; 1WSS; X-ray; 2.60 A; H=213-466, L=61-212.
DR   PDB; 1WTG; X-ray; 2.20 A; H=213-466, L=61-212.
DR   PDB; 1WUN; X-ray; 2.40 A; H=213-466, L=61-212.
DR   PDB; 1WV7; X-ray; 2.70 A; H=213-466, L=61-212.
DR   PDB; 1YGC; X-ray; 2.00 A; H=213-466, L=150-212.
DR   PDB; 1Z6J; X-ray; 2.00 A; H=213-466, L=61-202.
DR   PDB; 2A2Q; X-ray; 1.80 A; H=213-466, L=61-212.
DR   PDB; 2AEI; X-ray; 2.52 A; H=213-466, L=61-212.
DR   PDB; 2AER; X-ray; 1.87 A; H=213-466, L=61-202.
DR   PDB; 2B7D; X-ray; 2.24 A; H=213-466, L=61-212.
DR   PDB; 2B8O; X-ray; 2.80 A; H=213-466, L=61-202.
DR   PDB; 2BZ6; X-ray; 1.60 A; H=213-466, L=150-202.
DR   PDB; 2C4F; X-ray; 1.72 A; H=213-466, L=61-202.
DR   PDB; 2EC9; X-ray; 2.00 A; H=213-466, L=61-202.
DR   PDB; 2F9B; X-ray; 2.54 A; H=213-466, L=61-212.
DR   PDB; 2FIR; X-ray; 2.00 A; H=213-466, L=61-202.
DR   PDB; 2FLB; X-ray; 1.95 A; H=213-466, L=61-212.
DR   PDB; 2FLR; X-ray; 2.35 A; H=213-466, L=61-212.
DR   PDB; 2PUQ; X-ray; 2.05 A; H=213-466, L=109-202.
DR   PDB; 2ZP0; X-ray; 2.70 A; H=213-466, L=61-212.
DR   PDB; 2ZWL; X-ray; 2.20 A; H=213-466, L=61-212.
DR   PDB; 2ZZU; X-ray; 2.50 A; H=213-466, L=61-212.
DR   PDB; 3ELA; X-ray; 2.20 A; H=213-466, L=61-212.
DR   PDB; 3TH2; X-ray; 1.72 A; H=213-466, L=61-202.
DR   PDB; 3TH3; X-ray; 2.70 A; H=213-466, L=61-202.
DR   PDB; 3TH4; X-ray; 1.80 A; H=213-466, L=61-202.
DR   PDB; 4IBL; X-ray; 1.80 A; H=213-466, L=61-212.
DR   PDB; 4ISH; X-ray; 1.82 A; H=213-466, L=150-204.
DR   PDB; 4ISI; X-ray; 1.94 A; H=213-466, L=150-204.
DR   PDB; 4JYU; X-ray; 1.80 A; H=213-466, L=150-204.
DR   PDB; 4JYV; X-ray; 2.19 A; H=213-466, L=150-204.
DR   PDB; 4JZD; X-ray; 2.20 A; H=213-466, L=150-204.
DR   PDB; 4JZE; X-ray; 1.52 A; H=213-466, L=150-204.
DR   PDB; 4JZF; X-ray; 1.84 A; H=213-466, L=150-204.
DR   PDB; 4NA9; X-ray; 2.24 A; H=213-466, L=150-204.
DR   PDB; 4NG9; X-ray; 2.20 A; H=213-466, L=150-204.
DR   PDB; 4NGA; X-ray; 2.15 A; H=213-466, L=150-204.
DR   PDB; 4X8S; X-ray; 2.10 A; H=213-466, L=150-204.
DR   PDB; 4X8T; X-ray; 2.20 A; H=213-466, L=150-204.
DR   PDB; 4X8U; X-ray; 2.10 A; H=213-466, L=150-204.
DR   PDB; 4X8V; X-ray; 2.50 A; H=213-466, L=150-204.
DR   PDB; 4YLQ; X-ray; 1.40 A; H=213-466, L=61-212.
DR   PDB; 4YT6; X-ray; 2.07 A; H=213-466, L=148-204.
DR   PDB; 4YT7; X-ray; 2.30 A; H=213-466, L=148-204.
DR   PDB; 4Z6A; X-ray; 2.25 A; H=213-466, L=108-203.
DR   PDB; 4ZMA; X-ray; 2.30 A; H=213-466, L=61-212.
DR   PDB; 4ZXX; X-ray; 2.60 A; H=213-466, L=150-204.
DR   PDB; 4ZXY; X-ray; 2.06 A; H=213-466, L=150-204.
DR   PDBsum; 1BF9; -.
DR   PDBsum; 1CVW; -.
DR   PDBsum; 1DAN; -.
DR   PDBsum; 1DVA; -.
DR   PDBsum; 1F7E; -.
DR   PDBsum; 1F7M; -.
DR   PDBsum; 1FAK; -.
DR   PDBsum; 1FF7; -.
DR   PDBsum; 1FFM; -.
DR   PDBsum; 1J9C; -.
DR   PDBsum; 1JBU; -.
DR   PDBsum; 1KLI; -.
DR   PDBsum; 1KLJ; -.
DR   PDBsum; 1NL8; -.
DR   PDBsum; 1O5D; -.
DR   PDBsum; 1QFK; -.
DR   PDBsum; 1W0Y; -.
DR   PDBsum; 1W2K; -.
DR   PDBsum; 1W7X; -.
DR   PDBsum; 1W8B; -.
DR   PDBsum; 1WQV; -.
DR   PDBsum; 1WSS; -.
DR   PDBsum; 1WTG; -.
DR   PDBsum; 1WUN; -.
DR   PDBsum; 1WV7; -.
DR   PDBsum; 1YGC; -.
DR   PDBsum; 1Z6J; -.
DR   PDBsum; 2A2Q; -.
DR   PDBsum; 2AEI; -.
DR   PDBsum; 2AER; -.
DR   PDBsum; 2B7D; -.
DR   PDBsum; 2B8O; -.
DR   PDBsum; 2BZ6; -.
DR   PDBsum; 2C4F; -.
DR   PDBsum; 2EC9; -.
DR   PDBsum; 2F9B; -.
DR   PDBsum; 2FIR; -.
DR   PDBsum; 2FLB; -.
DR   PDBsum; 2FLR; -.
DR   PDBsum; 2PUQ; -.
DR   PDBsum; 2ZP0; -.
DR   PDBsum; 2ZWL; -.
DR   PDBsum; 2ZZU; -.
DR   PDBsum; 3ELA; -.
DR   PDBsum; 3TH2; -.
DR   PDBsum; 3TH3; -.
DR   PDBsum; 3TH4; -.
DR   PDBsum; 4IBL; -.
DR   PDBsum; 4ISH; -.
DR   PDBsum; 4ISI; -.
DR   PDBsum; 4JYU; -.
DR   PDBsum; 4JYV; -.
DR   PDBsum; 4JZD; -.
DR   PDBsum; 4JZE; -.
DR   PDBsum; 4JZF; -.
DR   PDBsum; 4NA9; -.
DR   PDBsum; 4NG9; -.
DR   PDBsum; 4NGA; -.
DR   PDBsum; 4X8S; -.
DR   PDBsum; 4X8T; -.
DR   PDBsum; 4X8U; -.
DR   PDBsum; 4X8V; -.
DR   PDBsum; 4YLQ; -.
DR   PDBsum; 4YT6; -.
DR   PDBsum; 4YT7; -.
DR   PDBsum; 4Z6A; -.
DR   PDBsum; 4ZMA; -.
DR   PDBsum; 4ZXX; -.
DR   PDBsum; 4ZXY; -.
DR   ProteinModelPortal; P08709; -.
DR   SMR; P08709; 68-466.
DR   BioGrid; 108453; 15.
DR   DIP; DIP-6135N; -.
DR   IntAct; P08709; 10.
DR   MINT; MINT-1155299; -.
DR   STRING; 9606.ENSP00000364731; -.
DR   BindingDB; P08709; -.
DR   ChEMBL; CHEMBL2111412; -.
DR   DrugBank; DB00100; Coagulation Factor IX.
DR   DrugBank; DB00036; Coagulation factor VIIa.
DR   DrugBank; DB00170; Menadione.
DR   GuidetoPHARMACOLOGY; 2363; -.
DR   MEROPS; S01.215; -.
DR   UniCarbKB; P08709; -.
DR   BioMuta; F7; -.
DR   DMDM; 119766; -.
DR   MaxQB; P08709; -.
DR   PaxDb; P08709; -.
DR   PRIDE; P08709; -.
DR   Ensembl; ENST00000346342; ENSP00000329546; ENSG00000057593. [P08709-2]
DR   Ensembl; ENST00000375581; ENSP00000364731; ENSG00000057593. [P08709-1]
DR   GeneID; 2155; -.
DR   KEGG; hsa:2155; -.
DR   UCSC; uc001vsv.4; human. [P08709-1]
DR   UCSC; uc001vsw.4; human. [P08709-2]
DR   CTD; 2155; -.
DR   GeneCards; F7; -.
DR   HGNC; HGNC:3544; F7.
DR   HPA; HPA004826; -.
DR   MalaCards; F7; -.
DR   MIM; 227500; phenotype.
DR   MIM; 613878; gene.
DR   neXtProt; NX_P08709; -.
DR   Orphanet; 327; Congenital factor VII deficiency.
DR   PharmGKB; PA160; -.
DR   eggNOG; ENOG410IIMB; Eukaryota.
DR   eggNOG; COG5640; LUCA.
DR   GeneTree; ENSGT00760000118890; -.
DR   HOVERGEN; HBG013304; -.
DR   InParanoid; P08709; -.
DR   KO; K01320; -.
DR   OMA; GCEQYCS; -.
DR   OrthoDB; EOG75B84T; -.
DR   PhylomeDB; P08709; -.
DR   TreeFam; TF327329; -.
DR   BRENDA; 3.4.21.21; 2681.
DR   Reactome; R-HSA-1368108; BMAL1:CLOCK,NPAS2 activates circadian gene expression.
DR   Reactome; R-HSA-140834; Extrinsic Pathway of Fibrin Clot Formation.
DR   Reactome; R-HSA-159740; Gamma-carboxylation of protein precursors.
DR   Reactome; R-HSA-159763; Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus.
DR   Reactome; R-HSA-159782; Removal of aminoterminal propeptides from gamma-carboxylated proteins.
DR   SABIO-RK; P08709; -.
DR   EvolutionaryTrace; P08709; -.
DR   GeneWiki; Factor_VII; -.
DR   GenomeRNAi; 2155; -.
DR   NextBio; 8705; -.
DR   PMAP-CutDB; P08709; -.
DR   PRO; PR:P08709; -.
DR   Proteomes; UP000005640; Chromosome 13.
DR   Bgee; P08709; -.
DR   CleanEx; HS_F7; -.
DR   ExpressionAtlas; P08709; baseline and differential.
DR   Genevisible; P08709; HS.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IEA:Ensembl.
DR   GO; GO:0005796; C:Golgi lumen; TAS:Reactome.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0031982; C:vesicle; IEA:Ensembl.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0001948; F:glycoprotein binding; IPI:BHF-UCL.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; TAS:ProtInc.
DR   GO; GO:0008236; F:serine-type peptidase activity; TAS:ProtInc.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0007598; P:blood coagulation, extrinsic pathway; TAS:Reactome.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0007623; P:circadian rhythm; TAS:Reactome.
DR   GO; GO:0031100; P:organ regeneration; IEA:Ensembl.
DR   GO; GO:0017187; P:peptidyl-glutamic acid carboxylation; TAS:Reactome.
DR   GO; GO:0030194; P:positive regulation of blood coagulation; IEA:Ensembl.
DR   GO; GO:0030335; P:positive regulation of cell migration; TAS:BHF-UCL.
DR   GO; GO:0002690; P:positive regulation of leukocyte chemotaxis; IDA:BHF-UCL.
DR   GO; GO:0010641; P:positive regulation of platelet-derived growth factor receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0050927; P:positive regulation of positive chemotaxis; IDA:BHF-UCL.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IDA:BHF-UCL.
DR   GO; GO:0043687; P:post-translational protein modification; TAS:Reactome.
DR   GO; GO:0006508; P:proteolysis; TAS:Reactome.
DR   GO; GO:0043627; P:response to estrogen; IEA:Ensembl.
DR   GO; GO:0060416; P:response to growth hormone; IEA:Ensembl.
DR   GO; GO:0032571; P:response to vitamin K; IEA:Ensembl.
DR   Gene3D; 4.10.740.10; -; 1.
DR   InterPro; IPR017857; Coagulation_fac_subgr_Gla_dom.
DR   InterPro; IPR001881; EGF-like_Ca-bd_dom.
DR   InterPro; IPR013032; EGF-like_CS.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR000152; EGF-type_Asp/Asn_hydroxyl_site.
DR   InterPro; IPR018097; EGF_Ca-bd_CS.
DR   InterPro; IPR000294; GLA_domain.
DR   InterPro; IPR012224; Pept_S1A_FX.
DR   InterPro; IPR018114; Peptidase_S1_AS.
DR   InterPro; IPR009003; Peptidase_S1_PA.
DR   InterPro; IPR001314; Peptidase_S1A.
DR   InterPro; IPR001254; Trypsin_dom.
DR   Pfam; PF00008; EGF; 1.
DR   Pfam; PF00594; Gla; 1.
DR   Pfam; PF00089; Trypsin; 1.
DR   PIRSF; PIRSF001143; Factor_X; 1.
DR   PRINTS; PR00722; CHYMOTRYPSIN.
DR   PRINTS; PR00001; GLABLOOD.
DR   SMART; SM00181; EGF; 1.
DR   SMART; SM00179; EGF_CA; 1.
DR   SMART; SM00069; GLA; 1.
DR   SMART; SM00020; Tryp_SPc; 1.
DR   SUPFAM; SSF50494; SSF50494; 1.
DR   SUPFAM; SSF57630; SSF57630; 1.
DR   PROSITE; PS00010; ASX_HYDROXYL; 1.
DR   PROSITE; PS00022; EGF_1; 1.
DR   PROSITE; PS01186; EGF_2; 1.
DR   PROSITE; PS50026; EGF_3; 1.
DR   PROSITE; PS01187; EGF_CA; 1.
DR   PROSITE; PS00011; GLA_1; 1.
DR   PROSITE; PS50998; GLA_2; 1.
DR   PROSITE; PS50240; TRYPSIN_DOM; 1.
DR   PROSITE; PS00134; TRYPSIN_HIS; 1.
DR   PROSITE; PS00135; TRYPSIN_SER; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Blood coagulation; Calcium;
KW   Cleavage on pair of basic residues; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Disulfide bond;
KW   EGF-like domain; Gamma-carboxyglutamic acid; Glycoprotein; Hemostasis;
KW   Hydrolase; Hydroxylation; Pharmaceutical; Polymorphism; Protease;
KW   Reference proteome; Repeat; Secreted; Serine protease; Signal;
KW   Zymogen.
FT   SIGNAL        1     20       {ECO:0000255}.
FT   PROPEP       21     60       {ECO:0000269|PubMed:3264725}.
FT                                /FTId=PRO_0000027729.
FT   CHAIN        61    212       Factor VII light chain.
FT                                /FTId=PRO_0000027730.
FT   CHAIN       213    466       Factor VII heavy chain.
FT                                /FTId=PRO_0000027731.
FT   DOMAIN       61    105       Gla. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463}.
FT   DOMAIN      106    142       EGF-like 1; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      147    188       EGF-like 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      213    452       Peptidase S1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00274}.
FT   ACT_SITE    253    253       Charge relay system. {ECO:0000250}.
FT   ACT_SITE    302    302       Charge relay system. {ECO:0000250}.
FT   ACT_SITE    404    404       Charge relay system. {ECO:0000250}.
FT   BINDING     398    398       Substrate. {ECO:0000250}.
FT   SITE        113    113       Important for S-112 for O-xylosylation.
FT   SITE        212    213       Cleavage; by factor Xa, factor XIIa,
FT                                factor IXa, or thrombin.
FT   MOD_RES      66     66       4-carboxyglutamate. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463,
FT                                ECO:0000269|PubMed:3264725,
FT                                ECO:0000269|PubMed:3486420}.
FT   MOD_RES      67     67       4-carboxyglutamate. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463,
FT                                ECO:0000269|PubMed:3264725,
FT                                ECO:0000269|PubMed:3486420}.
FT   MOD_RES      74     74       4-carboxyglutamate. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463,
FT                                ECO:0000269|PubMed:3264725,
FT                                ECO:0000269|PubMed:3486420}.
FT   MOD_RES      76     76       4-carboxyglutamate. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463,
FT                                ECO:0000269|PubMed:3264725,
FT                                ECO:0000269|PubMed:3486420}.
FT   MOD_RES      79     79       4-carboxyglutamate. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463,
FT                                ECO:0000269|PubMed:3264725}.
FT   MOD_RES      80     80       4-carboxyglutamate. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463,
FT                                ECO:0000269|PubMed:3264725,
FT                                ECO:0000269|PubMed:3486420}.
FT   MOD_RES      85     85       4-carboxyglutamate. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463,
FT                                ECO:0000269|PubMed:3264725,
FT                                ECO:0000269|PubMed:3486420}.
FT   MOD_RES      86     86       4-carboxyglutamate. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463,
FT                                ECO:0000269|PubMed:3264725,
FT                                ECO:0000269|PubMed:3486420}.
FT   MOD_RES      89     89       4-carboxyglutamate. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463,
FT                                ECO:0000269|PubMed:3264725,
FT                                ECO:0000269|PubMed:3486420}.
FT   MOD_RES      95     95       4-carboxyglutamate. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463,
FT                                ECO:0000269|PubMed:3264725,
FT                                ECO:0000269|PubMed:3486420}.
FT   MOD_RES     123    123       (3R)-3-hydroxyaspartate.
FT                                {ECO:0000269|PubMed:3264725}.
FT   CARBOHYD    112    112       O-linked (Glc...).
FT                                {ECO:0000269|PubMed:1904059,
FT                                ECO:0000269|PubMed:21949356}.
FT                                /FTId=CAR_000007.
FT   CARBOHYD    112    112       O-linked (Glc...); alternate.
FT                                {ECO:0000269|PubMed:1904059,
FT                                ECO:0000269|PubMed:21949356}.
FT   CARBOHYD    112    112       O-linked (Xyl...); alternate.
FT                                {ECO:0000269|PubMed:1904059,
FT                                ECO:0000269|PubMed:21949356}.
FT   CARBOHYD    120    120       O-linked (Fuc).
FT                                {ECO:0000269|PubMed:1904059,
FT                                ECO:0000269|PubMed:9023546}.
FT                                /FTId=CAR_000180.
FT   CARBOHYD    205    205       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19167329,
FT                                ECO:0000269|PubMed:3264725}.
FT   CARBOHYD    382    382       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19167329,
FT                                ECO:0000269|PubMed:3264725}.
FT   DISULFID     77     82
FT   DISULFID    110    121
FT   DISULFID    115    130
FT   DISULFID    132    141
FT   DISULFID    151    162
FT   DISULFID    158    172
FT   DISULFID    174    187
FT   DISULFID    195    322
FT   DISULFID    219    224
FT   DISULFID    238    254
FT   DISULFID    370    389
FT   DISULFID    400    428
FT   VAR_SEQ      22     43       Missing (in isoform B).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:3486420}.
FT                                /FTId=VSP_005387.
FT   VARIANT      13     13       L -> P (in FA7D; Morioka).
FT                                {ECO:0000269|PubMed:9576180}.
FT                                /FTId=VAR_014391.
FT   VARIANT      59     59       R -> RR (in FA7D).
FT                                {ECO:0000269|PubMed:21206266}.
FT                                /FTId=VAR_065369.
FT   VARIANT      64     64       F -> L (in FA7D).
FT                                {ECO:0000269|PubMed:10862079,
FT                                ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_015135.
FT   VARIANT      73     73       L -> Q (in FA7D; dbSNP:rs45572939).
FT                                {ECO:0000269|PubMed:11129332,
FT                                ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_014405.
FT   VARIANT      79     79       E -> Q (in FA7D).
FT                                {ECO:0000269|PubMed:11129332}.
FT                                /FTId=VAR_014406.
FT   VARIANT      82     82       C -> F (in FA7D).
FT                                {ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_065370.
FT   VARIANT      82     82       C -> R (in FA7D).
FT                                {ECO:0000269|PubMed:19751712}.
FT                                /FTId=VAR_065371.
FT   VARIANT      84     84       Missing (in FA7D).
FT                                {ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_065372.
FT   VARIANT      85     85       E -> K (in FA7D).
FT                                {ECO:0000269|PubMed:12472587}.
FT                                /FTId=VAR_065373.
FT   VARIANT      88     88       R -> G (in FA7D).
FT                                {ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_065374.
FT   VARIANT      88     88       R -> P (in FA7D).
FT                                {ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_065375.
FT   VARIANT     117    117       N -> D (in FA7D; exhibits no procoagulant
FT                                activity and is unable to bind tissue
FT                                factor). {ECO:0000269|PubMed:9414278}.
FT                                /FTId=VAR_065376.
FT   VARIANT     120    120       S -> P (in FA7D).
FT                                {ECO:0000269|PubMed:10862079,
FT                                ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_015136.
FT   VARIANT     121    121       C -> F (in FA7D).
FT                                {ECO:0000269|PubMed:11129332}.
FT                                /FTId=VAR_014407.
FT   VARIANT     125    125       L -> P (in FA7D).
FT                                {ECO:0000269|PubMed:11129332}.
FT                                /FTId=VAR_014408.
FT   VARIANT     128    128       Y -> C (in FA7D).
FT                                {ECO:0000269|PubMed:10862079,
FT                                ECO:0000269|PubMed:11129332,
FT                                ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_014409.
FT   VARIANT     138    138       G -> D (in FA7D).
FT                                {ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_065377.
FT   VARIANT     139    139       R -> K (in FA7D).
FT                                /FTId=VAR_006497.
FT   VARIANT     139    139       R -> Q (in FA7D; Charlotte;
FT                                dbSNP:rs150525536).
FT                                {ECO:0000269|PubMed:18976247,
FT                                ECO:0000269|PubMed:8204879}.
FT                                /FTId=VAR_006498.
FT   VARIANT     139    139       R -> W (in FA7D).
FT                                {ECO:0000269|PubMed:11129332}.
FT                                /FTId=VAR_006499.
FT   VARIANT     151    151       C -> S (in FA7D).
FT                                {ECO:0000269|PubMed:11129332}.
FT                                /FTId=VAR_014410.
FT   VARIANT     154    154       E -> K (in FA7D; dbSNP:rs146795869).
FT                                {ECO:0000269|PubMed:10862079,
FT                                ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_015137.
FT   VARIANT     156    156       G -> S (in FA7D).
FT                                {ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_065378.
FT   VARIANT     157    157       G -> C (in FA7D).
FT                                /FTId=VAR_006501.
FT   VARIANT     157    157       G -> S (in FA7D).
FT                                {ECO:0000269|PubMed:10862079,
FT                                ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_006500.
FT   VARIANT     157    157       G -> V (in FA7D).
FT                                {ECO:0000269|PubMed:11129332}.
FT                                /FTId=VAR_014411.
FT   VARIANT     160    160       Q -> R (in FA7D).
FT                                {ECO:0000269|PubMed:10862079,
FT                                ECO:0000269|PubMed:11129332,
FT                                ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_006502.
FT   VARIANT     171    171       S -> F (in FA7D).
FT                                {ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_065379.
FT   VARIANT     177    177       G -> R (in FA7D).
FT                                {ECO:0000269|PubMed:19751712}.
FT                                /FTId=VAR_065380.
FT   VARIANT     181    181       L -> P (in FA7D).
FT                                {ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_065381.
FT   VARIANT     183    183       D -> N (in FA7D).
FT                                {ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_065382.
FT   VARIANT     186    186       S -> F (in FA7D).
FT                                {ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_065383.
FT   VARIANT     189    189       P -> S (in FA7D).
FT                                {ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_065384.
FT   VARIANT     194    194       P -> L (in FA7D).
FT                                {ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_065385.
FT   VARIANT     194    194       P -> T (in FA7D; Malta-I).
FT                                {ECO:0000269|PubMed:18976247,
FT                                ECO:0000269|PubMed:9452082}.
FT                                /FTId=VAR_006503.
FT   VARIANT     195    195       C -> R (in FA7D).
FT                                {ECO:0000269|PubMed:10862079,
FT                                ECO:0000269|PubMed:11129332,
FT                                ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_014412.
FT   VARIANT     197    197       K -> E (in FA7D).
FT                                /FTId=VAR_006504.
FT   VARIANT     198    198       I -> T (in FA7D).
FT                                {ECO:0000269|PubMed:19751712}.
FT                                /FTId=VAR_065386.
FT   VARIANT     212    212       R -> Q (in FA7D; Charlotte).
FT                                {ECO:0000269|PubMed:10862079,
FT                                ECO:0000269|PubMed:18976247,
FT                                ECO:0000269|PubMed:19751712,
FT                                ECO:0000269|PubMed:8204879}.
FT                                /FTId=VAR_006505.
FT   VARIANT     216    216       G -> D (in FA7D).
FT                                {ECO:0000269|PubMed:10862079,
FT                                ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_015138.
FT   VARIANT     238    238       C -> Y (in FA7D).
FT                                {ECO:0000269|PubMed:8364544}.
FT                                /FTId=VAR_006506.
FT   VARIANT     240    240       G -> R (in FA7D).
FT                                {ECO:0000269|PubMed:19432927}.
FT                                /FTId=VAR_065387.
FT   VARIANT     241    241       T -> N (in FA7D).
FT                                {ECO:0000269|PubMed:11129332,
FT                                ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_014413.
FT   VARIANT     250    250       S -> F (in FA7D).
FT                                {ECO:0000269|PubMed:21372693}.
FT                                /FTId=VAR_065388.
FT   VARIANT     251    251       A -> P (in FA7D).
FT                                {ECO:0000269|PubMed:19751712}.
FT                                /FTId=VAR_065389.
FT   VARIANT     251    251       A -> T (in FA7D).
FT                                {ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_065390.
FT   VARIANT     254    254       C -> R (in FA7D).
FT                                {ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_065391.
FT   VARIANT     254    254       C -> Y (in FA7D).
FT                                {ECO:0000269|PubMed:10862079,
FT                                ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_015139.
FT   VARIANT     264    264       L -> P (in FA7D).
FT                                {ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_065392.
FT   VARIANT     266    266       A -> T (in FA7D).
FT                                {ECO:0000269|PubMed:10862079,
FT                                ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_015140.
FT   VARIANT     272    272       D -> N (in FA7D).
FT                                {ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_065393.
FT   VARIANT     277    277       D -> N (in FA7D).
FT                                {ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_065394.
FT   VARIANT     283    283       R -> W (in FA7D).
FT                                {ECO:0000269|PubMed:18976247,
FT                                ECO:0000269|PubMed:8844208}.
FT                                /FTId=VAR_006507.
FT   VARIANT     295    295       V -> D (in dbSNP:rs6045).
FT                                {ECO:0000269|PubMed:10391209}.
FT                                /FTId=VAR_013936.
FT   VARIANT     298    298       T -> I (in FA7D).
FT                                {ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_065395.
FT   VARIANT     301    301       H -> Q (in FA7D).
FT                                {ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_065396.
FT   VARIANT     302    302       D -> H (in FA7D).
FT                                {ECO:0000269|PubMed:10862079,
FT                                ECO:0000269|PubMed:11129332,
FT                                ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_014414.
FT   VARIANT     302    302       D -> N (in FA7D).
FT                                {ECO:0000269|PubMed:11129332,
FT                                ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_014415.
FT   VARIANT     304    304       A -> T (in FA7D).
FT                                {ECO:0000269|PubMed:11129332,
FT                                ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_014416.
FT   VARIANT     304    304       A -> V (in FA7D; Malta-II).
FT                                {ECO:0000269|PubMed:10862079,
FT                                ECO:0000269|PubMed:11129332,
FT                                ECO:0000269|PubMed:18976247,
FT                                ECO:0000269|PubMed:8883260,
FT                                ECO:0000269|PubMed:9452082}.
FT                                /FTId=VAR_006508.
FT   VARIANT     307    307       R -> C (in FA7D).
FT                                {ECO:0000269|PubMed:10862079,
FT                                ECO:0000269|PubMed:11129332,
FT                                ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_014417.
FT   VARIANT     307    307       R -> H (in FA7D; Mie).
FT                                {ECO:0000269|PubMed:18976247,
FT                                ECO:0000269|PubMed:7974346}.
FT                                /FTId=VAR_006509.
FT   VARIANT     312    312       V -> M (in FA7D).
FT                                {ECO:0000269|PubMed:10862079,
FT                                ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_015141.
FT   VARIANT     314    314       L -> V (in FA7D).
FT                                {ECO:0000269|PubMed:21206266}.
FT                                /FTId=VAR_065397.
FT   VARIANT     321    321       L -> F (in FA7D).
FT                                {ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_065398.
FT   VARIANT     323    323       L -> R (in FA7D).
FT                                {ECO:0000269|PubMed:19751712}.
FT                                /FTId=VAR_065399.
FT   VARIANT     325    325       E -> K (in FA7D).
FT                                {ECO:0000269|PubMed:10862079,
FT                                ECO:0000269|PubMed:18976247,
FT                                ECO:0000269|PubMed:8844208}.
FT                                /FTId=VAR_006510.
FT   VARIANT     326    326       R -> Q (in FA7D).
FT                                {ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_065400.
FT   VARIANT     332    332       T -> M (in FA7D).
FT                                {ECO:0000269|PubMed:11129332}.
FT                                /FTId=VAR_014418.
FT   VARIANT     337    337       R -> C (in FA7D).
FT                                {ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_065401.
FT   VARIANT     341    341       V -> F (in FA7D).
FT                                {ECO:0000269|PubMed:10862079,
FT                                ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_015142.
FT   VARIANT     343    343       G -> S (in FA7D).
FT                                {ECO:0000269|PubMed:18976247,
FT                                ECO:0000269|PubMed:21206266}.
FT                                /FTId=VAR_065402.
FT   VARIANT     344    344       W -> R (in FA7D).
FT                                {ECO:0000269|PubMed:19751712}.
FT                                /FTId=VAR_065403.
FT   VARIANT     345    345       G -> S (in FA7D).
FT                                {ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_065404.
FT   VARIANT     350    350       R -> C (in FA7D).
FT                                {ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_065405.
FT   VARIANT     352    352       A -> T (in dbSNP:rs3093267).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_013122.
FT   VARIANT     354    354       A -> V (in FA7D; dbSNP:rs36209567).
FT                                {ECO:0000269|PubMed:10862079,
FT                                ECO:0000269|PubMed:11129332,
FT                                ECO:0000269|PubMed:16292673,
FT                                ECO:0000269|PubMed:18976247,
FT                                ECO:0000269|PubMed:7981691}.
FT                                /FTId=VAR_006511.
FT   VARIANT     358    358       M -> I (in FA7D).
FT                                {ECO:0000269|PubMed:10862079,
FT                                ECO:0000269|PubMed:11129332,
FT                                ECO:0000269|PubMed:18976247,
FT                                ECO:0000269|PubMed:8043443}.
FT                                /FTId=VAR_006512.
FT   VARIANT     358    358       M -> V (in FA7D).
FT                                {ECO:0000269|PubMed:8844208}.
FT                                /FTId=VAR_006513.
FT   VARIANT     360    360       L -> P (in FA7D).
FT                                {ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_065406.
FT   VARIANT     363    363       P -> H (in FA7D).
FT                                {ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_065407.
FT   VARIANT     363    363       P -> R (in FA7D).
FT                                {ECO:0000269|PubMed:10862079,
FT                                ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_015143.
FT   VARIANT     364    364       R -> Q (in FA7D; Harrow/Padua;
FT                                dbSNP:rs121964926).
FT                                {ECO:0000269|PubMed:1634227,
FT                                ECO:0000269|PubMed:18976247,
FT                                ECO:0000269|PubMed:2070047,
FT                                ECO:0000269|PubMed:8043443,
FT                                ECO:0000269|PubMed:8844208}.
FT                                /FTId=VAR_006514.
FT   VARIANT     364    364       R -> W (in FA7D).
FT                                {ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_065408.
FT   VARIANT     367    367       T -> S. {ECO:0000269|PubMed:7860081}.
FT                                /FTId=VAR_018671.
FT   VARIANT     370    370       C -> F (in FA7D).
FT                                {ECO:0000269|PubMed:10862079,
FT                                ECO:0000269|PubMed:11129332,
FT                                ECO:0000269|PubMed:1634227,
FT                                ECO:0000269|PubMed:18976247,
FT                                ECO:0000269|PubMed:19751712,
FT                                ECO:0000269|PubMed:8043443}.
FT                                /FTId=VAR_006515.
FT   VARIANT     375    375       R -> W (in FA7D; dbSNP:rs137919286).
FT                                {ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_065409.
FT   VARIANT     384    384       T -> M (in FA7D).
FT                                {ECO:0000269|PubMed:18976247,
FT                                ECO:0000269|PubMed:19751712}.
FT                                /FTId=VAR_065410.
FT   VARIANT     387    387       M -> T (in FA7D).
FT                                {ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_065411.
FT   VARIANT     387    387       M -> V (in FA7D).
FT                                {ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_065412.
FT   VARIANT     388    388       F -> S (in FA7D; reduces tissue factor
FT                                binding; impairs activation by factor Xa;
FT                                abolishes amidolytic and coagulant
FT                                activities).
FT                                {ECO:0000269|PubMed:18976247,
FT                                ECO:0000269|PubMed:8940045}.
FT                                /FTId=VAR_065413.
FT   VARIANT     389    389       C -> G (in FA7D).
FT                                {ECO:0000269|PubMed:11091194,
FT                                ECO:0000269|PubMed:11129332,
FT                                ECO:0000269|PubMed:21206266}.
FT                                /FTId=VAR_014392.
FT   VARIANT     391    391       G -> C (in FA7D).
FT                                {ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_065414.
FT   VARIANT     391    391       G -> S (in FA7D; dbSNP:rs190485816).
FT                                {ECO:0000269|PubMed:11129332,
FT                                ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_014419.
FT   VARIANT     398    398       D -> E (in FA7D).
FT                                {ECO:0000269|PubMed:19751712}.
FT                                /FTId=VAR_065415.
FT   VARIANT     401    401       K -> E (in FA7D).
FT                                {ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_065416.
FT   VARIANT     402    402       G -> E (in FA7D).
FT                                {ECO:0000269|PubMed:8844208}.
FT                                /FTId=VAR_006517.
FT   VARIANT     402    402       G -> R (in FA7D).
FT                                {ECO:0000269|PubMed:8043443}.
FT                                /FTId=VAR_006516.
FT   VARIANT     403    403       D -> H (in FA7D).
FT                                {ECO:0000269|PubMed:10862079,
FT                                ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_015144.
FT   VARIANT     404    404       S -> N (in FA7D).
FT                                {ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_065417.
FT   VARIANT     408    408       H -> Q (in FA7D; dbSNP:rs121964936).
FT                                {ECO:0000269|PubMed:12472587}.
FT                                /FTId=VAR_065418.
FT   VARIANT     408    408       H -> R (in FA7D).
FT                                {ECO:0000269|PubMed:19751712}.
FT                                /FTId=VAR_065419.
FT   VARIANT     413    413       R -> G (in FA7D).
FT                                {ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_065420.
FT   VARIANT     413    413       R -> Q (may be associated with decreased
FT                                susceptibility to myocardial infarction;
FT                                dbSNP:rs6046).
FT                                {ECO:0000269|PubMed:10391209,
FT                                ECO:0000269|PubMed:10984565,
FT                                ECO:0000269|PubMed:16292673,
FT                                ECO:0000269|PubMed:8043443,
FT                                ECO:0000269|PubMed:8844208,
FT                                ECO:0000269|Ref.6}.
FT                                /FTId=VAR_006518.
FT   VARIANT     414    414       G -> C (in FA7D; results in severely
FT                                impaired protein secretion).
FT                                {ECO:0000269|PubMed:14717781}.
FT                                /FTId=VAR_065421.
FT   VARIANT     419    419       T -> M (in FA7D).
FT                                {ECO:0000269|PubMed:10862079,
FT                                ECO:0000269|PubMed:18976247,
FT                                ECO:0000269|PubMed:8652821}.
FT                                /FTId=VAR_006519.
FT   VARIANT     422    422       V -> F (in FA7D).
FT                                {ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_065422.
FT   VARIANT     425    425       G -> A (in FA7D).
FT                                {ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_065423.
FT   VARIANT     425    425       G -> C (in FA7D).
FT                                {ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_065424.
FT   VARIANT     429    429       A -> T (in FA7D).
FT                                {ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_065425.
FT   VARIANT     432    432       G -> D (in FA7D).
FT                                {ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_065426.
FT   VARIANT     435    435       G -> E (in FA7D).
FT                                {ECO:0000269|PubMed:11129332,
FT                                ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_014420.
FT   VARIANT     437    437       Y -> F (in FA7D).
FT                                {ECO:0000269|PubMed:18976247}.
FT                                /FTId=VAR_065427.
FT   VARIANT     445    445       E -> K (in dbSNP:rs3093248).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_013123.
FT   MUTAGEN     112    112       S->A: Complete loss of O-glycosylation
FT                                and O-xylosylation by POGLUT1.
FT                                {ECO:0000269|PubMed:21949356}.
FT   MUTAGEN     113    113       S->A: No effect on O-glycosylation by
FT                                POGLUT1. Drastic decrease in O-
FT                                xylosylation.
FT                                {ECO:0000269|PubMed:21949356}.
FT   HELIX        65     68       {ECO:0000244|PDB:2C4F}.
FT   HELIX        73     76       {ECO:0000244|PDB:2C4F}.
FT   TURN         77     79       {ECO:0000244|PDB:2C4F}.
FT   HELIX        84     91       {ECO:0000244|PDB:2C4F}.
FT   HELIX        94    104       {ECO:0000244|PDB:2C4F}.
FT   HELIX       109    112       {ECO:0000244|PDB:2C4F}.
FT   TURN        116    118       {ECO:0000244|PDB:1QFK}.
FT   STRAND      120    124       {ECO:0000244|PDB:2C4F}.
FT   STRAND      127    131       {ECO:0000244|PDB:2C4F}.
FT   STRAND      136    138       {ECO:0000244|PDB:2C4F}.
FT   HELIX       145    147       {ECO:0000244|PDB:2C4F}.
FT   STRAND      148    150       {ECO:0000244|PDB:1QFK}.
FT   TURN        151    153       {ECO:0000244|PDB:4JZE}.
FT   HELIX       154    157       {ECO:0000244|PDB:4JZE}.
FT   STRAND      159    164       {ECO:0000244|PDB:4JZE}.
FT   STRAND      166    168       {ECO:0000244|PDB:4JZE}.
FT   STRAND      170    173       {ECO:0000244|PDB:4JZE}.
FT   STRAND      178    180       {ECO:0000244|PDB:4JZE}.
FT   STRAND      187    189       {ECO:0000244|PDB:4JZE}.
FT   STRAND      191    193       {ECO:0000244|PDB:4JZE}.
FT   HELIX       199    202       {ECO:0000244|PDB:4JZE}.
FT   HELIX       220    222       {ECO:0000244|PDB:1JBU}.
FT   STRAND      227    232       {ECO:0000244|PDB:4JZE}.
FT   STRAND      235    242       {ECO:0000244|PDB:4JZE}.
FT   STRAND      244    250       {ECO:0000244|PDB:4JZE}.
FT   HELIX       252    255       {ECO:0000244|PDB:4JZE}.
FT   HELIX       261    263       {ECO:0000244|PDB:4JZE}.
FT   STRAND      264    269       {ECO:0000244|PDB:4JZE}.
FT   STRAND      272    274       {ECO:0000244|PDB:2FLB}.
FT   STRAND      281    291       {ECO:0000244|PDB:4JZE}.
FT   STRAND      298    301       {ECO:0000244|PDB:1JBU}.
FT   STRAND      304    310       {ECO:0000244|PDB:4JZE}.
FT   HELIX       326    331       {ECO:0000244|PDB:4JZE}.
FT   HELIX       333    335       {ECO:0000244|PDB:4JZE}.
FT   STRAND      338    344       {ECO:0000244|PDB:4JZE}.
FT   STRAND      346    348       {ECO:0000244|PDB:4JZE}.
FT   TURN        352    355       {ECO:0000244|PDB:1DVA}.
FT   STRAND      358    365       {ECO:0000244|PDB:4JZE}.
FT   HELIX       367    372       {ECO:0000244|PDB:4JZE}.
FT   STRAND      378    380       {ECO:0000244|PDB:1KLI}.
FT   HELIX       383    386       {ECO:0000244|PDB:1JBU}.
FT   STRAND      387    391       {ECO:0000244|PDB:4JZE}.
FT   STRAND      393    396       {ECO:0000244|PDB:4JZE}.
FT   HELIX       401    403       {ECO:0000244|PDB:2BZ6}.
FT   STRAND      407    412       {ECO:0000244|PDB:4JZE}.
FT   STRAND      415    424       {ECO:0000244|PDB:4JZE}.
FT   TURN        427    429       {ECO:0000244|PDB:2BZ6}.
FT   STRAND      435    439       {ECO:0000244|PDB:4JZE}.
FT   HELIX       440    443       {ECO:0000244|PDB:4JZE}.
FT   HELIX       444    451       {ECO:0000244|PDB:4JZE}.
FT   STRAND      457    463       {ECO:0000244|PDB:4JZE}.
SQ   SEQUENCE   466 AA;  51594 MW;  9B5D501669D67B06 CRC64;
     MVSQALRLLC LLLGLQGCLA AGGVAKASGG ETRDMPWKPG PHRVFVTQEE AHGVLHRRRR
     ANAFLEELRP GSLERECKEE QCSFEEAREI FKDAERTKLF WISYSDGDQC ASSPCQNGGS
     CKDQLQSYIC FCLPAFEGRN CETHKDDQLI CVNENGGCEQ YCSDHTGTKR SCRCHEGYSL
     LADGVSCTPT VEYPCGKIPI LEKRNASKPQ GRIVGGKVCP KGECPWQVLL LVNGAQLCGG
     TLINTIWVVS AAHCFDKIKN WRNLIAVLGE HDLSEHDGDE QSRRVAQVII PSTYVPGTTN
     HDIALLRLHQ PVVLTDHVVP LCLPERTFSE RTLAFVRFSL VSGWGQLLDR GATALELMVL
     NVPRLMTQDC LQQSRKVGDS PNITEYMFCA GYSDGSKDSC KGDSGGPHAT HYRGTWYLTG
     IVSWGQGCAT VGHFGVYTRV SQYIEWLQKL MRSEPRPGVL LRAPFP
//
ID   PCSK9_HUMAN             Reviewed;         692 AA.
AC   Q8NBP7; A8T640; C0JYY9; Q5PSM5; Q5SZQ2;
DT   07-NOV-2003, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2011, sequence version 3.
DT   17-FEB-2016, entry version 150.
DE   RecName: Full=Proprotein convertase subtilisin/kexin type 9;
DE            EC=3.4.21.-;
DE   AltName: Full=Neural apoptosis-regulated convertase 1;
DE            Short=NARC-1;
DE   AltName: Full=Proprotein convertase 9;
DE            Short=PC9;
DE   AltName: Full=Subtilisin/kexin-like protease PC9;
DE   Flags: Precursor;
GN   Name=PCSK9; Synonyms=NARC1; ORFNames=PSEC0052;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS ILE-474 AND
RP   GLU-670.
RA   Chiang L.W.;
RT   "Nucleic acid molecules derived from rat brain and programmed cell
RT   death models.";
RL   Patent number WO0131007, 03-MAY-2001.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS ILE-474 AND
RP   GLU-670.
RX   PubMed=17971861; DOI=10.1371/journal.pone.0001098;
RA   Ding K., McDonough S.J., Kullo I.J.;
RT   "Evidence for positive selection in the C-terminal domain of the
RT   cholesterol metabolism gene PCSK9 based on phylogenetic analysis in 14
RT   primate species.";
RL   PLoS ONE 2:E1098-E1098(2007).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   ILE-474.
RC   TISSUE=Cerebellum, and Teratocarcinoma;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS LEU-23 INS; LEU-46;
RP   VAL-53; SER-425; THR-443; ILE-474; ARG-553; PRO-619 AND GLU-670.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (NOV-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS LEU-23 INS; ILE-474
RP   AND GLU-670.
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (DEC-2008) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANTS ILE-474
RP   AND GLU-670.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   PROTEIN SEQUENCE OF N-TERMINUS, CHARACTERIZATION, AND MUTAGENESIS OF
RP   CYS-67; HIS-226 AND ASN-533.
RX   PubMed=12552133; DOI=10.1073/pnas.0335507100;
RA   Seidah N.G., Benjannet S., Wickham L., Marcinkiewicz J., Jasmin S.B.,
RA   Stifani S., Basak A., Prat A., Chretien M.;
RT   "The secretory proprotein convertase neural apoptosis-regulated
RT   convertase 1 (NARC-1): liver regeneration and neuronal
RT   differentiation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:928-933(2003).
RN   [9]
RP   AUTOCATALYTIC CLEAVAGE SITE.
RX   PubMed=14622975; DOI=10.1016/j.abb.2003.09.011;
RA   Naureckiene S., Ma L., Sreekumar K., Purandare U., Lo C.F., Huang Y.,
RA   Chiang L.W., Grenier J.M., Ozenberger B.A., Jacobsen J.S.,
RA   Kennedy J.D., DiStefano P.S., Wood A., Bingham B.;
RT   "Functional characterization of Narc 1, a novel proteinase related to
RT   proteinase K.";
RL   Arch. Biochem. Biophys. 420:55-67(2003).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-688, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [11]
RP   GLYCOSYLATION AT ASN-533, SULFATION AT TYR-38, AND CLEAVAGE AT ARG-218
RP   BY FURIN AND PCSK5.
RX   PubMed=16912035; DOI=10.1074/jbc.M606495200;
RA   Benjannet S., Rhainds D., Hamelin J., Nassoury N., Seidah N.G.;
RT   "The proprotein convertase (PC) PCSK9 is inactivated by furin and/or
RT   PC5/6A: functional consequences of natural mutations and post-
RT   translational modifications.";
RL   J. Biol. Chem. 281:30561-30572(2006).
RN   [12]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH LDLR.
RX   PubMed=17461796; DOI=10.1111/j.1600-0854.2007.00562.x;
RA   Nassoury N., Blasiole D.A., Tebon Oler A., Benjannet S., Hamelin J.,
RA   Poupon V., McPherson P.S., Attie A.D., Prat A., Seidah N.G.;
RT   "The cellular trafficking of the secretory proprotein convertase PCSK9
RT   and its dependence on the LDLR.";
RL   Traffic 8:718-732(2007).
RN   [13]
RP   FUNCTION, AND SUBUNIT.
RX   PubMed=18197702; DOI=10.1021/bi7016359;
RA   Fan D., Yancey P.G., Qiu S., Ding L., Weeber E.J., Linton M.F.,
RA   Fazio S.;
RT   "Self-association of human PCSK9 correlates with its LDLR-degrading
RT   activity.";
RL   Biochemistry 47:1631-1639(2008).
RN   [14]
RP   FUNCTION, AND INTERACTION WITH BACE1.
RX   PubMed=18660751; DOI=10.1038/embor.2008.132;
RA   Jonas M.C., Costantini C., Puglielli L.;
RT   "PCSK9 is required for the disposal of non-acetylated intermediates of
RT   the nascent membrane protein BACE1.";
RL   EMBO Rep. 9:916-922(2008).
RN   [15]
RP   PHOSPHORYLATION AT SER-47 AND SER-688, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=18498363; DOI=10.1111/j.1742-4658.2008.06495.x;
RA   Dewpura T., Raymond A., Hamelin J., Seidah N.G., Mbikay M.,
RA   Chretien M., Mayne J.;
RT   "PCSK9 is phosphorylated by a Golgi casein kinase-like kinase ex vivo
RT   and circulates as a phosphoprotein in humans.";
RL   FEBS J. 275:3480-3493(2008).
RN   [16]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH VLDLR AND
RP   LRP8/APOER2.
RX   PubMed=18039658; DOI=10.1074/jbc.M708098200;
RA   Poirier S., Mayer G., Benjannet S., Bergeron E., Marcinkiewicz J.,
RA   Nassoury N., Mayer H., Nimpf J., Prat A., Seidah N.G.;
RT   "The proprotein convertase PCSK9 induces the degradation of low
RT   density lipoprotein receptor (LDLR) and its closest family members
RT   VLDLR and ApoER2.";
RL   J. Biol. Chem. 283:2363-2372(2008).
RN   [17]
RP   FUNCTION, INTERACTION WITH ANXA2, VARIANT HCHOLA3 TYR-374,
RP   CHARACTERIZATION OF VARIANT HCHOLA3 TYR-374, VARIANT GLU-554, AND
RP   CHARACTERIZATION OF VARIANT GLU-554.
RX   PubMed=18799458; DOI=10.1074/jbc.M805971200;
RA   Mayer G., Poirier S., Seidah N.G.;
RT   "Annexin A2 is a C-terminal PCSK9-binding protein that regulates
RT   endogenous low density lipoprotein receptor levels.";
RL   J. Biol. Chem. 283:31791-31801(2008).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-688, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [20]
RP   FUNCTION.
RX   PubMed=22074827; DOI=10.1016/j.bbrc.2011.10.110;
RA   Chen Y., Wang H., Yu L., Yu X., Qian Y.W., Cao G., Wang J.;
RT   "Role of ubiquitination in PCSK9-mediated low-density lipoprotein
RT   receptor degradation.";
RL   Biochem. Biophys. Res. Commun. 415:515-518(2011).
RN   [21]
RP   INTERACTION WITH LDLR.
RX   PubMed=21149300; DOI=10.1074/jbc.M110.199042;
RA   Yamamoto T., Lu C., Ryan R.O.;
RT   "A two-step binding model of PCSK9 interaction with the low density
RT   lipoprotein receptor.";
RL   J. Biol. Chem. 286:5464-5470(2011).
RN   [22]
RP   DOMAIN C-TERMINAL.
RX   PubMed=22027821; DOI=10.1074/jbc.M111.273474;
RA   Du F., Hui Y., Zhang M., Linton M.F., Fazio S., Fan D.;
RT   "Novel domain interaction regulates secretion of proprotein convertase
RT   subtilisin/kexin type 9 (PCSK9) protein.";
RL   J. Biol. Chem. 286:43054-43061(2011).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-688, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [24]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH APOB.
RX   PubMed=22580899; DOI=10.1161/ATVBAHA.112.250043;
RA   Sun H., Samarghandi A., Zhang N., Yao Z., Xiong M., Teng B.B.;
RT   "Proprotein convertase subtilisin/kexin type 9 interacts with
RT   apolipoprotein B and prevents its intracellular degradation,
RT   irrespective of the low-density lipoprotein receptor.";
RL   Arterioscler. Thromb. Vasc. Biol. 32:1585-1595(2012).
RN   [25]
RP   PHOSPHORYLATION AT SER-47 AND SER-688.
RX   PubMed=26091039; DOI=10.1016/j.cell.2015.05.028;
RA   Tagliabracci V.S., Wiley S.E., Guo X., Kinch L.N., Durrant E., Wen J.,
RA   Xiao J., Cui J., Nguyen K.B., Engel J.L., Coon J.J., Grishin N.,
RA   Pinna L.A., Pagliarini D.J., Dixon J.E.;
RT   "A single kinase generates the majority of the secreted
RT   phosphoproteome.";
RL   Cell 161:1619-1632(2015).
RN   [26]
RP   REVIEW.
RX   PubMed=18280815; DOI=10.1016/j.bbalip.2008.01.003;
RA   Lopez D.;
RT   "PCSK9: an enigmatic protease.";
RL   Biochim. Biophys. Acta 1781:184-191(2008).
RN   [27]
RP   REVIEW.
RX   PubMed=18649882; DOI=10.1016/j.atherosclerosis.2008.06.010;
RA   Lambert G., Charlton F., Rye K.A., Piper D.E.;
RT   "Molecular basis of PCSK9 function.";
RL   Atherosclerosis 203:1-7(2009).
RN   [28]
RP   REVIEW.
RX   PubMed=19930098; DOI=10.1111/j.1365-2796.2009.02167.x;
RA   Mousavi S.A., Berge K.E., Leren T.P.;
RT   "The unique role of proprotein convertase subtilisin/kexin 9 in
RT   cholesterol homeostasis.";
RL   J. Intern. Med. 266:507-519(2009).
RN   [29]
RP   REVIEW.
RX   PubMed=19020338; DOI=10.1194/jlr.R800091-JLR200;
RA   Horton J.D., Cohen J.C., Hobbs H.H.;
RT   "PCSK9: a convertase that coordinates LDL catabolism.";
RL   J. Lipid Res. 50:S172-S177(2009).
RN   [30]
RP   REVIEW.
RX   PubMed=21943799; DOI=10.1016/j.numecd.2011.06.002;
RA   Tibolla G., Norata G.D., Artali R., Meneghetti F., Catapano A.L.;
RT   "Proprotein convertase subtilisin/kexin type 9 (PCSK9): from
RT   structure-function relation to therapeutic inhibition.";
RL   Nutr. Metab. Cardiovasc. Dis. 21:835-843(2011).
RN   [31]
RP   REVIEW ON VARIANTS.
RX   PubMed=19191301; DOI=10.1002/humu.20882;
RA   Abifadel M., Rabes J.P., Devillers M., Munnich A., Erlich D.,
RA   Junien C., Varret M., Boileau C.;
RT   "Mutations and polymorphisms in the proprotein convertase subtilisin
RT   kexin 9 (PCSK9) gene in cholesterol metabolism and disease.";
RL   Hum. Mutat. 30:520-529(2009).
RN   [32]
RP   POLYMORPHISM, AND VARIANT SER-174.
RX   PubMed=22417841; DOI=10.1016/j.atherosclerosis.2012.02.018;
RA   Slimani A., Jelassi A., Jguirim I., Najah M., Rebhi L., Omezzine A.,
RA   Maatouk F., Hamda K.B., Kacem M., Rabes J.P., Abifadel M., Boileau C.,
RA   Rouis M., Slimane M.N., Varret M.;
RT   "Effect of mutations in LDLR and PCSK9 genes on phenotypic variability
RT   in Tunisian familial hypercholesterolemia patients.";
RL   Atherosclerosis 222:158-166(2012).
RN   [33]
RP   FUNCTION, AND INTERACTION WITH SCNN1A; SCNN1B AND SCNN1G.
RX   PubMed=22493497; DOI=10.1074/jbc.M112.363382;
RA   Sharotri V., Collier D.M., Olson D.R., Zhou R., Snyder P.M.;
RT   "Regulation of epithelial sodium channel trafficking by proprotein
RT   convertase subtilisin/kexin type 9 (PCSK9).";
RL   J. Biol. Chem. 287:19266-19274(2012).
RN   [34]
RP   FUNCTION, INTERACTION WITH ANXA2, VARIANT GLN-482, CHARACTERIZATION OF
RP   VARIANT GLN-482, VARIANTS HCHOLA3 SER-218 AND TYR-374,
RP   CHARACTERIZATION OF VARIANTS HCHOLA3 SER-218 AND TYR-374, SULFATION,
RP   PHOSPHORYLATION, GLYCOSYLATION, AND SUBUNIT.
RX   PubMed=24808179; DOI=10.1074/jbc.M113.541094;
RA   Ly K., Saavedra Y.G., Canuel M., Routhier S., Desjardins R.,
RA   Hamelin J., Mayne J., Lazure C., Seidah N.G., Day R.;
RT   "Annexin A2 reduces PCSK9 protein levels via a translational mechanism
RT   and interacts with the M1 and M2 domains of PCSK9.";
RL   J. Biol. Chem. 289:17732-17746(2014).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 31-692.
RX   PubMed=17502100; DOI=10.1016/j.str.2007.04.004;
RA   Piper D.E., Jackson S., Liu Q., Romanow W.G., Shetterly S.,
RA   Thibault S.T., Shan B., Walker N.P.;
RT   "The crystal structure of PCSK9: a regulator of plasma LDL-
RT   cholesterol.";
RL   Structure 15:545-552(2007).
RN   [36]
RP   VARIANTS HCHOLA3 ARG-127 AND LEU-216, AND VARIANTS LEU-46; VAL-53 AND
RP   GLU-670.
RX   PubMed=12730697; DOI=10.1038/ng1161;
RA   Abifadel M., Varret M., Rabes J.-P., Allard D., Ouguerram K.,
RA   Devillers M., Cruaud C., Benjannet S., Wickham L., Erlich D.,
RA   Derre A., Villeger L., Farnier M., Beucler I., Bruckert E.,
RA   Chambaz J., Chanu B., Lecerf J.-M., Luc G., Moulin P., Weissenbach J.,
RA   Prat A., Krempf M., Junien C., Seidah N.G., Boileau C.;
RT   "Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.";
RL   Nat. Genet. 34:154-156(2003).
RN   [37]
RP   VARIANTS LEU-46; VAL-53; LYS-57; TRP-237; PHE-253; ASN-391; GLN-417;
RP   SER-425; THR-443; TRP-469; ILE-474; GLY-482; LEU-515; ARG-553;
RP   GLU-554; PRO-619 AND GLU-670.
RX   PubMed=16465619; DOI=10.1086/500615;
RA   Kotowski I.K., Pertsemlidis A., Luke A., Cooper R.S., Vega G.L.,
RA   Cohen J.C., Hobbs H.H.;
RT   "A spectrum of PCSK9 alleles contributes to plasma levels of low-
RT   density lipoprotein cholesterol.";
RL   Am. J. Hum. Genet. 78:410-422(2006).
RN   [38]
RP   POLYMORPHISM, VARIANT LEU-23 INS, AND IMPACT ON FAMILIAL
RP   HYPERCHOLESTEROLEMIA.
RX   PubMed=19319977; DOI=10.1002/humu.21002;
RA   Abifadel M., Rabes J.-P., Jambart S., Halaby G., Gannage-Yared M.-H.,
RA   Sarkis A., Beaino G., Varret M., Salem N., Corbani S., Aydenian H.,
RA   Junien C., Munnich A., Boileau C.;
RT   "The molecular basis of familial hypercholesterolemia in Lebanon:
RT   spectrum of LDLR mutations and role of PCSK9 as a modifier gene.";
RL   Hum. Mutat. 30:E682-E691(2009).
RN   [39]
RP   POLYMORPHISM, AND VARIANTS LEU-23 INS; LEU-46; VAL-53; SER-394;
RP   ILE-474 AND GLU-670.
RX   PubMed=22095935; DOI=10.1002/humu.21660;
RA   Huijgen R., Sjouke B., Vis K., de Randamie J.S., Defesche J.C.,
RA   Kastelein J.J., Hovingh G.K., Fouchier S.W.;
RT   "Genetic variation in APOB, PCSK9, and ANGPTL3 in carriers of
RT   pathogenic autosomal dominant hypercholesterolemic mutations with
RT   unexpected low LDL-Cl Levels.";
RL   Hum. Mutat. 33:448-455(2012).
CC   -!- FUNCTION: Crucial player in the regulation of plasma cholesterol
CC       homeostasis. Binds to low-density lipid receptor family members:
CC       low density lipoprotein receptor (LDLR), very low density
CC       lipoprotein receptor (VLDLR), apolipoprotein E receptor
CC       (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and
CC       promotes their degradation in intracellular acidic compartments
CC       (PubMed:18039658). Acts via a non-proteolytic mechanism to enhance
CC       the degradation of the hepatic LDLR through a clathrin
CC       LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR
CC       from endosomes to the cell surface or direct it to lysosomes for
CC       degradation. Can induce ubiquitination of LDLR leading to its
CC       subsequent degradation (PubMed:18799458, PubMed:17461796,
CC       PubMed:18197702, PubMed:22074827). Inhibits intracellular
CC       degradation of APOB via the autophagosome/lysosome pathway in a
CC       LDLR-independent manner. Involved in the disposal of non-
CC       acetylated intermediates of BACE1 in the early secretory pathway
CC       (PubMed:18660751). Inhibits epithelial Na(+) channel (ENaC)-
CC       mediated Na(+) absorption by reducing ENaC surface expression
CC       primarily by increasing its proteasomal degradation. Regulates
CC       neuronal apoptosis via modulation of LRP8/APOER2 levels and
CC       related anti-apoptotic signaling pathways.
CC       {ECO:0000269|PubMed:17461796, ECO:0000269|PubMed:18039658,
CC       ECO:0000269|PubMed:18197702, ECO:0000269|PubMed:18660751,
CC       ECO:0000269|PubMed:18799458, ECO:0000269|PubMed:22074827,
CC       ECO:0000269|PubMed:22493497, ECO:0000269|PubMed:22580899}.
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108; Evidence={ECO:0000305};
CC   -!- ENZYME REGULATION: Its proteolytic activity is autoinhibited by
CC       the non-covalent binding of the propeptide to the catalytic
CC       domain. Inhibited by EGTA.
CC   -!- SUBUNIT: Monomer. Can self-associate to form dimers and higher
CC       multimers which may have increased LDLR degrading activity. The
CC       precursor protein but not the mature protein may form multimers.
CC       Interacts with APOB, VLDLR, LRP8/APOER2 and BACE1. The full length
CC       immature form (pro-PCSK9) interacts with SCNN1A, SCNN1B and
CC       SCNN1G. The pro-PCSK9 form (via C-terminal domain) interacts with
CC       LDLR. Interacts (via the C-terminal domain) with ANXA2 (via repeat
CC       Annexin 1); the interaction inhibits the degradation of LDLR
CC       (PubMed:18799458). {ECO:0000269|PubMed:17461796,
CC       ECO:0000269|PubMed:18039658, ECO:0000269|PubMed:18197702,
CC       ECO:0000269|PubMed:18660751, ECO:0000269|PubMed:18799458,
CC       ECO:0000269|PubMed:21149300, ECO:0000269|PubMed:22493497,
CC       ECO:0000269|PubMed:22580899, ECO:0000269|PubMed:24808179}.
CC   -!- INTERACTION:
CC       P07355:ANXA2; NbExp=7; IntAct=EBI-7539251, EBI-352622;
CC       P01130:LDLR; NbExp=10; IntAct=EBI-7539251, EBI-988319;
CC       P08253:MMP2; NbExp=4; IntAct=EBI-7539251, EBI-1033518;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Secreted. Endosome. Lysosome.
CC       Cell surface. Endoplasmic reticulum. Golgi apparatus.
CC       Note=Autocatalytic cleavage is required to transport it from the
CC       endoplasmic reticulum to the Golgi apparatus and for the secretion
CC       of the mature protein. Localizes to the endoplasmic reticulum in
CC       the absence of LDLR and colocalizes to the cell surface and to the
CC       endosomes/lysosomes in the presence of LDLR. The sorting to the
CC       cell surface and endosomes is required in order to fully promote
CC       LDLR degradation.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q8NBP7-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8NBP7-2; Sequence=VSP_008844, VSP_008845, VSP_008846;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed in neuro-epithelioma, colon
CC       carcinoma, hepatic and pancreatic cell lines, and in Schwann
CC       cells.
CC   -!- DOMAIN: The C-terminal domain (CRD) is essential for the LDLR-
CC       binding and degrading activities. {ECO:0000269|PubMed:22027821}.
CC   -!- DOMAIN: The catalytic domain is responsible for mediating its
CC       self-association. {ECO:0000269|PubMed:22027821}.
CC   -!- PTM: Cleavage by furin and PCSK5 generates a truncated inactive
CC       protein that is unable to induce LDLR degradation.
CC   -!- PTM: Undergoes autocatalytic cleavage in the endoplasmic reticulum
CC       to release the propeptide from the N-terminus and the cleavage of
CC       the propeptide is strictly required for its maturation and
CC       activation. The cleaved propeptide however remains associated with
CC       the catalytic domain through non-covalent interactions, preventing
CC       potential substrates from accessing its active site. As a result,
CC       it is secreted from cells as a propeptide-containing,
CC       enzymatically inactive protein. {ECO:0000269|PubMed:16912035}.
CC   -!- PTM: Phosphorylation protects the propeptide against proteolysis.
CC       {ECO:0000269|PubMed:18498363}.
CC   -!- POLYMORPHISM: Variant Leu-23 ins polymorphism in PCSK9 might have
CC       a modifier effect on LDLR mutation and familial
CC       hypercholesterolemia.
CC   -!- POLYMORPHISM: Genetic variations in PCSK9 define the low density
CC       lipoprotein cholesterol level quantitative trait locus 1 (LDLCQ1)
CC       [MIM:603776]. {ECO:0000269|PubMed:19319977,
CC       ECO:0000269|PubMed:22095935, ECO:0000269|PubMed:22417841}.
CC   -!- DISEASE: Hypercholesterolemia, autosomal dominant, 3 (HCHOLA3)
CC       [MIM:603776]: A familial condition characterized by elevated
CC       circulating cholesterol contained in either low-density
CC       lipoproteins alone or also in very-low-density lipoproteins.
CC       {ECO:0000269|PubMed:12730697, ECO:0000269|PubMed:18799458,
CC       ECO:0000269|PubMed:24808179}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the peptidase S8 family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 peptidase S8 domain. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAC11572.1; Type=Frameshift; Positions=494; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/pcsk9/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AX127530; CAC38896.1; -; mRNA.
DR   EMBL; EF692496; ABV59216.1; -; mRNA.
DR   EMBL; AK075365; BAC11572.1; ALT_FRAME; mRNA.
DR   EMBL; AK124635; BAC85910.1; -; mRNA.
DR   EMBL; AY829011; AAV67948.1; -; Genomic_DNA.
DR   EMBL; FJ525880; ACN81318.1; -; Genomic_DNA.
DR   EMBL; AL589790; CAI17845.1; -; Genomic_DNA.
DR   EMBL; AC091609; CAI17845.1; JOINED; Genomic_DNA.
DR   EMBL; CH471059; EAX06660.1; -; Genomic_DNA.
DR   CCDS; CCDS603.1; -. [Q8NBP7-1]
DR   RefSeq; NP_777596.2; NM_174936.3. [Q8NBP7-1]
DR   UniGene; Hs.18844; -.
DR   PDB; 2P4E; X-ray; 1.98 A; A/P=1-692.
DR   PDB; 2PMW; X-ray; 2.30 A; A=31-152, B=153-692.
DR   PDB; 2QTW; X-ray; 1.90 A; A=29-152, B=153-692.
DR   PDB; 2W2M; X-ray; 2.40 A; A=153-451, P=53-152.
DR   PDB; 2W2N; X-ray; 2.30 A; A=153-451, P=53-152.
DR   PDB; 2W2O; X-ray; 2.62 A; A=153-451, P=53-152.
DR   PDB; 2W2P; X-ray; 2.62 A; A=153-451, P=53-152.
DR   PDB; 2W2Q; X-ray; 2.33 A; A=153-451, P=53-152.
DR   PDB; 2XTJ; X-ray; 2.70 A; A=153-451, P=53-152.
DR   PDB; 3BPS; X-ray; 2.41 A; A=153-692, P=53-152.
DR   PDB; 3GCW; X-ray; 2.70 A; A=153-692, P=53-152.
DR   PDB; 3GCX; X-ray; 2.70 A; A=153-692, P=53-152.
DR   PDB; 3H42; X-ray; 2.30 A; A=31-152, B=153-692.
DR   PDB; 3M0C; X-ray; 7.01 A; A=29-152, B=153-692.
DR   PDB; 3P5B; X-ray; 3.30 A; A=153-692, P=61-152.
DR   PDB; 3P5C; X-ray; 4.20 A; A=153-692, P=61-152.
DR   PDB; 3SQO; X-ray; 2.70 A; A=153-692, P=31-152.
DR   PDB; 4K8R; X-ray; 3.22 A; A=61-152, B=153-692.
DR   PDB; 4NE9; X-ray; 2.60 A; A/B=153-692, C/P=1-152.
DR   PDB; 4NMX; X-ray; 1.85 A; A=31-152, B=153-452.
DR   PDB; 4OV6; X-ray; 2.69 A; A/D=60-152, B/E=153-446.
DR   PDBsum; 2P4E; -.
DR   PDBsum; 2PMW; -.
DR   PDBsum; 2QTW; -.
DR   PDBsum; 2W2M; -.
DR   PDBsum; 2W2N; -.
DR   PDBsum; 2W2O; -.
DR   PDBsum; 2W2P; -.
DR   PDBsum; 2W2Q; -.
DR   PDBsum; 2XTJ; -.
DR   PDBsum; 3BPS; -.
DR   PDBsum; 3GCW; -.
DR   PDBsum; 3GCX; -.
DR   PDBsum; 3H42; -.
DR   PDBsum; 3M0C; -.
DR   PDBsum; 3P5B; -.
DR   PDBsum; 3P5C; -.
DR   PDBsum; 3SQO; -.
DR   PDBsum; 4K8R; -.
DR   PDBsum; 4NE9; -.
DR   PDBsum; 4NMX; -.
DR   PDBsum; 4OV6; -.
DR   ProteinModelPortal; Q8NBP7; -.
DR   SMR; Q8NBP7; 61-682.
DR   BioGrid; 129116; 25.
DR   DIP; DIP-29694N; -.
DR   IntAct; Q8NBP7; 4.
DR   MINT; MINT-3041747; -.
DR   STRING; 9606.ENSP00000303208; -.
DR   BindingDB; Q8NBP7; -.
DR   ChEMBL; CHEMBL2929; -.
DR   DrugBank; DB09302; Alirocumab.
DR   DrugBank; DB09303; Evolocumab.
DR   GuidetoPHARMACOLOGY; 2388; -.
DR   MEROPS; S08.039; -.
DR   iPTMnet; Q8NBP7; -.
DR   PhosphoSite; Q8NBP7; -.
DR   BioMuta; PCSK9; -.
DR   DMDM; 317373487; -.
DR   MaxQB; Q8NBP7; -.
DR   PaxDb; Q8NBP7; -.
DR   PRIDE; Q8NBP7; -.
DR   DNASU; 255738; -.
DR   Ensembl; ENST00000302118; ENSP00000303208; ENSG00000169174. [Q8NBP7-1]
DR   GeneID; 255738; -.
DR   KEGG; hsa:255738; -.
DR   UCSC; uc001cyf.2; human. [Q8NBP7-1]
DR   CTD; 255738; -.
DR   GeneCards; PCSK9; -.
DR   GeneReviews; PCSK9; -.
DR   H-InvDB; HIX0023558; -.
DR   HGNC; HGNC:20001; PCSK9.
DR   HPA; CAB025575; -.
DR   MalaCards; PCSK9; -.
DR   MIM; 603776; phenotype.
DR   MIM; 607786; gene.
DR   neXtProt; NX_Q8NBP7; -.
DR   Orphanet; 426; Familial hypobetalipoproteinemia.
DR   Orphanet; 406; Heterozygous familial hypercholesterolemia.
DR   Orphanet; 391665; Homozygous familial hypercholesterolemia.
DR   PharmGKB; PA38617; -.
DR   eggNOG; KOG1153; Eukaryota.
DR   eggNOG; COG1404; LUCA.
DR   GeneTree; ENSGT00490000043472; -.
DR   HOGENOM; HOG000049267; -.
DR   HOVERGEN; HBG053530; -.
DR   InParanoid; Q8NBP7; -.
DR   KO; K13050; -.
DR   OMA; CHAPGLE; -.
DR   OrthoDB; EOG79PJNT; -.
DR   PhylomeDB; Q8NBP7; -.
DR   TreeFam; TF106271; -.
DR   BRENDA; 3.4.21.61; 2681.
DR   SignaLink; Q8NBP7; -.
DR   EvolutionaryTrace; Q8NBP7; -.
DR   GeneWiki; PCSK9; -.
DR   GenomeRNAi; 255738; -.
DR   NextBio; 92626; -.
DR   PRO; PR:Q8NBP7; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; Q8NBP7; -.
DR   CleanEx; HS_PCSK9; -.
DR   Genevisible; Q8NBP7; HS.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005769; C:early endosome; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0030134; C:ER to Golgi transport vesicle; IEA:Ensembl.
DR   GO; GO:0005615; C:extracellular space; IDA:HGNC.
DR   GO; GO:0031232; C:extrinsic component of external side of plasma membrane; IC:BHF-UCL.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0005770; C:late endosome; IDA:UniProtKB.
DR   GO; GO:0005764; C:lysosome; IDA:UniProtKB.
DR   GO; GO:1990667; C:PCSK9-AnxA2 complex; IDA:BHF-UCL.
DR   GO; GO:1990666; C:PCSK9-LDLR complex; IDA:BHF-UCL.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005791; C:rough endoplasmic reticulum; IEA:Ensembl.
DR   GO; GO:0034185; F:apolipoprotein binding; ISS:UniProtKB.
DR   GO; GO:0034190; F:apolipoprotein receptor binding; IDA:BHF-UCL.
DR   GO; GO:0030169; F:low-density lipoprotein particle binding; ISS:UniProtKB.
DR   GO; GO:0050750; F:low-density lipoprotein particle receptor binding; IDA:HGNC.
DR   GO; GO:0044822; F:poly(A) RNA binding; IDA:UniProtKB.
DR   GO; GO:0043621; F:protein self-association; IDA:UniProtKB.
DR   GO; GO:0030547; F:receptor inhibitor activity; IDA:BHF-UCL.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IDA:HGNC.
DR   GO; GO:0019871; F:sodium channel inhibitor activity; IDA:UniProtKB.
DR   GO; GO:0034189; F:very-low-density lipoprotein particle binding; ISS:UniProtKB.
DR   GO; GO:0070326; F:very-low-density lipoprotein particle receptor binding; IDA:BHF-UCL.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; ISS:HGNC.
DR   GO; GO:0009267; P:cellular response to starvation; ISS:HGNC.
DR   GO; GO:0042632; P:cholesterol homeostasis; IMP:HGNC.
DR   GO; GO:0008203; P:cholesterol metabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0001822; P:kidney development; ISS:HGNC.
DR   GO; GO:0042157; P:lipoprotein metabolic process; IEA:Ensembl.
DR   GO; GO:0001889; P:liver development; ISS:HGNC.
DR   GO; GO:0032802; P:low-density lipoprotein particle receptor catabolic process; IDA:UniProtKB.
DR   GO; GO:0007041; P:lysosomal transport; IDA:BHF-UCL.
DR   GO; GO:0010989; P:negative regulation of low-density lipoprotein particle clearance; IDA:BHF-UCL.
DR   GO; GO:2000272; P:negative regulation of receptor activity; IDA:BHF-UCL.
DR   GO; GO:0001920; P:negative regulation of receptor recycling; IDA:BHF-UCL.
DR   GO; GO:2000650; P:negative regulation of sodium ion transmembrane transporter activity; IDA:BHF-UCL.
DR   GO; GO:0022008; P:neurogenesis; ISS:HGNC.
DR   GO; GO:0030182; P:neuron differentiation; ISS:HGNC.
DR   GO; GO:0006644; P:phospholipid metabolic process; IEA:Ensembl.
DR   GO; GO:0032805; P:positive regulation of low-density lipoprotein particle receptor catabolic process; IDA:BHF-UCL.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IMP:HGNC.
DR   GO; GO:0002092; P:positive regulation of receptor internalization; IDA:BHF-UCL.
DR   GO; GO:0016540; P:protein autoprocessing; IDA:HGNC.
DR   GO; GO:0043523; P:regulation of neuron apoptotic process; ISS:UniProtKB.
DR   GO; GO:0010469; P:regulation of receptor activity; IDA:BHF-UCL.
DR   GO; GO:0006641; P:triglyceride metabolic process; IEA:Ensembl.
DR   Gene3D; 3.30.70.80; -; 1.
DR   Gene3D; 3.40.50.200; -; 1.
DR   InterPro; IPR000209; Peptidase_S8/S53_dom.
DR   InterPro; IPR015500; Peptidase_S8_subtilisin-rel.
DR   InterPro; IPR009020; Prot_inh_propept.
DR   InterPro; IPR010259; S8pro/Inhibitor_I9.
DR   PANTHER; PTHR10795; PTHR10795; 1.
DR   Pfam; PF05922; Inhibitor_I9; 1.
DR   Pfam; PF00082; Peptidase_S8; 1.
DR   PRINTS; PR00723; SUBTILISIN.
DR   SUPFAM; SSF52743; SSF52743; 1.
DR   SUPFAM; SSF54897; SSF54897; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Apoptosis; Autocatalytic cleavage;
KW   Calcium; Cholesterol metabolism; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Disease mutation; Disulfide bond;
KW   Endoplasmic reticulum; Endosome; Glycoprotein; Golgi apparatus;
KW   Hydrolase; Lipid metabolism; Lysosome; Phosphoprotein; Polymorphism;
KW   Protease; Reference proteome; Secreted; Serine protease; Signal;
KW   Steroid metabolism; Sterol metabolism; Sulfation; Zymogen.
FT   SIGNAL        1     30       {ECO:0000269|PubMed:12552133}.
FT   PROPEP       31    152       {ECO:0000269|PubMed:12552133}.
FT                                /FTId=PRO_0000027120.
FT   CHAIN       153    692       Proprotein convertase subtilisin/kexin
FT                                type 9.
FT                                /FTId=PRO_0000027121.
FT   DOMAIN      182    424       Peptidase S8.
FT   REGION      450    692       C-terminal domain.
FT   ACT_SITE    186    186       Charge relay system. {ECO:0000250}.
FT   ACT_SITE    226    226       Charge relay system. {ECO:0000250}.
FT   ACT_SITE    386    386       Charge relay system. {ECO:0000250}.
FT   SITE        152    153       Cleavage; by autolysis.
FT   SITE        218    219       Cleavage; by furin and PCSK5.
FT   MOD_RES      38     38       Sulfotyrosine.
FT                                {ECO:0000269|PubMed:16912035}.
FT   MOD_RES      47     47       Phosphoserine; by FAM20C.
FT                                {ECO:0000269|PubMed:18498363,
FT                                ECO:0000269|PubMed:26091039}.
FT   MOD_RES     688    688       Phosphoserine; by FAM20C.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000269|PubMed:18498363,
FT                                ECO:0000269|PubMed:26091039}.
FT   CARBOHYD    533    533       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16912035}.
FT   DISULFID    223    255       {ECO:0000255}.
FT   DISULFID    323    358       {ECO:0000255}.
FT   DISULFID    457    527       {ECO:0000255}.
FT   DISULFID    477    526       {ECO:0000255}.
FT   DISULFID    486    509       {ECO:0000255}.
FT   DISULFID    534    601       {ECO:0000255}.
FT   DISULFID    552    600       {ECO:0000255}.
FT   DISULFID    562    588       {ECO:0000255}.
FT   DISULFID    608    679       {ECO:0000255}.
FT   DISULFID    626    678       {ECO:0000255}.
FT   DISULFID    635    654       {ECO:0000255}.
FT   VAR_SEQ       1    174       MGTVSSRRSWWPLPLLLLLLLLLGPAGARAQEDEDGDYEEL
FT                                VLALRSEEDGLAEAPEHGTTATFHRCAKDPWRLPGTYVVVL
FT                                KEETHLSQSERTARRLQAQAARRGYLTKILHVFHGLLPGFL
FT                                VKMSGDLLELALKLPHVDYIEEDSSVFAQSIPWNLERITPP
FT                                RYRADEYQPP -> MSPWK (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_008844.
FT   VAR_SEQ     333    365       VITVGATNAQDQPVTLGTLGTNFGRCVDLFAPG -> GRTS
FT                                LVPPATAAPALCHRVGHHRLLPTWLALQP (in isoform
FT                                2). {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_008845.
FT   VAR_SEQ     366    692       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_008846.
FT   VARIANT      23     23       L -> LL (this polymoprhism seems to have
FT                                a modifier effect on LDLR mutation and
FT                                familial hypercholesterolemia).
FT                                {ECO:0000269|PubMed:19319977,
FT                                ECO:0000269|PubMed:22095935,
FT                                ECO:0000269|Ref.4, ECO:0000269|Ref.5}.
FT                                /FTId=VAR_021336.
FT   VARIANT      46     46       R -> L (polymorphism; associated with
FT                                lower plasma levels of low-density
FT                                lipoprotein cholesterol and reduced
FT                                phosphorylation at Ser-47;
FT                                dbSNP:rs11591147).
FT                                {ECO:0000269|PubMed:12730697,
FT                                ECO:0000269|PubMed:16465619,
FT                                ECO:0000269|PubMed:22095935,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_017197.
FT   VARIANT      53     53       A -> V (polymorphism; associated with
FT                                reduced phosphorylation at Ser-47;
FT                                dbSNP:rs11583680).
FT                                {ECO:0000269|PubMed:12730697,
FT                                ECO:0000269|PubMed:16465619,
FT                                ECO:0000269|PubMed:22095935,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_017198.
FT   VARIANT      57     57       E -> K. {ECO:0000269|PubMed:16465619}.
FT                                /FTId=VAR_025451.
FT   VARIANT      77     77       T -> I.
FT                                /FTId=VAR_058520.
FT   VARIANT      93     93       R -> C (in dbSNP:rs151193009).
FT                                /FTId=VAR_058521.
FT   VARIANT     106    106       G -> R.
FT                                /FTId=VAR_058522.
FT   VARIANT     114    114       V -> A.
FT                                /FTId=VAR_058523.
FT   VARIANT     127    127       S -> R (in HCHOLA3; dbSNP:rs28942111).
FT                                {ECO:0000269|PubMed:12730697}.
FT                                /FTId=VAR_017199.
FT   VARIANT     129    129       D -> G (in HCHOLA3).
FT                                /FTId=VAR_058524.
FT   VARIANT     157    157       N -> K.
FT                                /FTId=VAR_058525.
FT   VARIANT     174    174       P -> S (found in patients with familial
FT                                hypercholesterolemia carrying a
FT                                homozygous LDLR mutation; acts as a
FT                                disease modifier resulting in a mild
FT                                phenotype).
FT                                {ECO:0000269|PubMed:22417841}.
FT                                /FTId=VAR_067351.
FT   VARIANT     215    215       R -> H (in HCHOLA3).
FT                                /FTId=VAR_058526.
FT   VARIANT     216    216       F -> L (in HCHOLA3; partial loss of
FT                                cleavage by furin and PCSK5;
FT                                dbSNP:rs28942112).
FT                                {ECO:0000269|PubMed:12730697}.
FT                                /FTId=VAR_017200.
FT   VARIANT     218    218       R -> S (in HCHOLA3; complete loss of
FT                                cleavage by furin and PCSK5; reduces
FT                                glycosylation levels; no effect on
FT                                protein sulfation and phosphorylation; no
FT                                effect on protein sulfation but inhibits
FT                                phosphorylation when associated with Y-
FT                                374; highly reduces LDL uptake when
FT                                associated with Y-374).
FT                                {ECO:0000269|PubMed:18799458,
FT                                ECO:0000269|PubMed:24808179}.
FT                                /FTId=VAR_058527.
FT   VARIANT     219    219       Q -> E.
FT                                /FTId=VAR_058528.
FT   VARIANT     237    237       R -> W. {ECO:0000269|PubMed:16465619}.
FT                                /FTId=VAR_025452.
FT   VARIANT     239    239       A -> D.
FT                                /FTId=VAR_058529.
FT   VARIANT     253    253       L -> F (polymorphism; associated with
FT                                lower plasma levels of low-density
FT                                lipoprotein cholesterol;
FT                                dbSNP:rs28362270).
FT                                {ECO:0000269|PubMed:16465619}.
FT                                /FTId=VAR_025453.
FT   VARIANT     357    357       R -> H (in HCHOLA3).
FT                                /FTId=VAR_058530.
FT   VARIANT     374    374       D -> H (in HCHOLA3).
FT                                /FTId=VAR_058531.
FT   VARIANT     374    374       D -> Y (in HCHOLA3; partial loss of
FT                                cleavage by furin and PCSK5; no effect on
FT                                protein sulfation but inhibits
FT                                phosphorylation when associated with S-
FT                                218; highly increases LDL uptake when
FT                                associated with S-218).
FT                                {ECO:0000269|PubMed:18799458,
FT                                ECO:0000269|PubMed:24808179}.
FT                                /FTId=VAR_058532.
FT   VARIANT     391    391       H -> N. {ECO:0000269|PubMed:16465619}.
FT                                /FTId=VAR_025454.
FT   VARIANT     394    394       G -> S (found in a patient associated
FT                                with autosomal dominant
FT                                hypercholesterolemia; unknown
FT                                pathological significance).
FT                                {ECO:0000269|PubMed:22095935}.
FT                                /FTId=VAR_067282.
FT   VARIANT     417    417       H -> Q (in dbSNP:rs143275858).
FT                                {ECO:0000269|PubMed:16465619}.
FT                                /FTId=VAR_025455.
FT   VARIANT     425    425       N -> S (in dbSNP:rs28362261).
FT                                {ECO:0000269|PubMed:16465619,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_021337.
FT   VARIANT     443    443       A -> T (polymorphism; associated with
FT                                lower plasma levels of low-density
FT                                lipoprotein cholesterol; more extensive
FT                                cleavage by furin and PCSK5;
FT                                dbSNP:rs28362263).
FT                                {ECO:0000269|PubMed:16465619,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_021338.
FT   VARIANT     452    452       G -> D.
FT                                /FTId=VAR_058533.
FT   VARIANT     469    469       R -> W (in dbSNP:rs141502002).
FT                                {ECO:0000269|PubMed:16465619}.
FT                                /FTId=VAR_025456.
FT   VARIANT     474    474       V -> I (in dbSNP:rs562556).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:16465619,
FT                                ECO:0000269|PubMed:17971861,
FT                                ECO:0000269|PubMed:22095935,
FT                                ECO:0000269|Ref.1, ECO:0000269|Ref.4,
FT                                ECO:0000269|Ref.5, ECO:0000269|Ref.7}.
FT                                /FTId=VAR_021339.
FT   VARIANT     482    482       E -> G. {ECO:0000269|PubMed:16465619}.
FT                                /FTId=VAR_025457.
FT   VARIANT     482    482       E -> Q (no effect on interaction with
FT                                ANXA2). {ECO:0000269|PubMed:24808179}.
FT                                /FTId=VAR_073657.
FT   VARIANT     496    496       R -> W (in HCHOLA3).
FT                                /FTId=VAR_058534.
FT   VARIANT     515    515       F -> L. {ECO:0000269|PubMed:16465619}.
FT                                /FTId=VAR_025458.
FT   VARIANT     522    522       A -> T.
FT                                /FTId=VAR_058535.
FT   VARIANT     553    553       H -> R (in dbSNP:rs28362270).
FT                                {ECO:0000269|PubMed:16465619,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_021340.
FT   VARIANT     554    554       Q -> E (increases interaction with ANXA2;
FT                                dbSNP:rs149311926).
FT                                {ECO:0000269|PubMed:16465619,
FT                                ECO:0000269|PubMed:18799458}.
FT                                /FTId=VAR_025459.
FT   VARIANT     616    616       P -> L.
FT                                /FTId=VAR_058536.
FT   VARIANT     619    619       Q -> P (in dbSNP:rs28362277).
FT                                {ECO:0000269|PubMed:16465619,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_021341.
FT   VARIANT     668    668       S -> R.
FT                                /FTId=VAR_058537.
FT   VARIANT     670    670       G -> E (in dbSNP:rs505151).
FT                                {ECO:0000269|PubMed:12730697,
FT                                ECO:0000269|PubMed:16465619,
FT                                ECO:0000269|PubMed:17971861,
FT                                ECO:0000269|PubMed:22095935,
FT                                ECO:0000269|Ref.1, ECO:0000269|Ref.4,
FT                                ECO:0000269|Ref.5, ECO:0000269|Ref.7}.
FT                                /FTId=VAR_017201.
FT   MUTAGEN      67     67       C->A: Does not affect multimerization or
FT                                zymogen processing.
FT                                {ECO:0000269|PubMed:12552133}.
FT   MUTAGEN     226    226       H->A: Remains in the endoplasmic
FT                                reticulum and is not secreted.
FT                                {ECO:0000269|PubMed:12552133}.
FT   MUTAGEN     533    533       N->A: 1.5 kDa decrease of the apparent
FT                                molecular mass of pro-PCSK9 and PCSK9 and
FT                                no effect on processing and secretion.
FT                                {ECO:0000269|PubMed:12552133}.
FT   CONFLICT    423    423       V -> A (in Ref. 3; BAC11572).
FT                                {ECO:0000305}.
FT   STRAND       63     65       {ECO:0000244|PDB:4NMX}.
FT   HELIX        70     72       {ECO:0000244|PDB:4NMX}.
FT   STRAND       73     82       {ECO:0000244|PDB:4NMX}.
FT   STRAND       84     86       {ECO:0000244|PDB:4OV6}.
FT   HELIX        88    104       {ECO:0000244|PDB:4NMX}.
FT   STRAND      110    115       {ECO:0000244|PDB:4NMX}.
FT   STRAND      117    119       {ECO:0000244|PDB:4NMX}.
FT   STRAND      121    125       {ECO:0000244|PDB:4NMX}.
FT   HELIX       128    130       {ECO:0000244|PDB:4NMX}.
FT   HELIX       131    135       {ECO:0000244|PDB:4NMX}.
FT   STRAND      140    151       {ECO:0000244|PDB:4NMX}.
FT   HELIX       156    160       {ECO:0000244|PDB:4NMX}.
FT   HELIX       168    170       {ECO:0000244|PDB:3BPS}.
FT   STRAND      181    187       {ECO:0000244|PDB:4NMX}.
FT   TURN        194    199       {ECO:0000244|PDB:4NMX}.
FT   STRAND      200    206       {ECO:0000244|PDB:4NMX}.
FT   STRAND      212    214       {ECO:0000244|PDB:4NMX}.
FT   TURN        218    220       {ECO:0000244|PDB:3H42}.
FT   TURN        221    224       {ECO:0000244|PDB:2QTW}.
FT   HELIX       225    235       {ECO:0000244|PDB:4NMX}.
FT   TURN        237    239       {ECO:0000244|PDB:4NMX}.
FT   STRAND      241    244       {ECO:0000244|PDB:2P4E}.
FT   STRAND      246    251       {ECO:0000244|PDB:4NMX}.
FT   STRAND      257    260       {ECO:0000244|PDB:4NMX}.
FT   HELIX       261    277       {ECO:0000244|PDB:4NMX}.
FT   STRAND      283    287       {ECO:0000244|PDB:4NMX}.
FT   STRAND      289    292       {ECO:0000244|PDB:4NMX}.
FT   HELIX       295    306       {ECO:0000244|PDB:4NMX}.
FT   STRAND      310    314       {ECO:0000244|PDB:4NMX}.
FT   STRAND      317    321       {ECO:0000244|PDB:4NMX}.
FT   HELIX       322    324       {ECO:0000244|PDB:4NMX}.
FT   TURN        327    329       {ECO:0000244|PDB:4NMX}.
FT   STRAND      333    339       {ECO:0000244|PDB:4NMX}.
FT   STRAND      343    345       {ECO:0000244|PDB:2PMW}.
FT   STRAND      349    352       {ECO:0000244|PDB:2W2Q}.
FT   STRAND      355    358       {ECO:0000244|PDB:3P5B}.
FT   STRAND      361    364       {ECO:0000244|PDB:4NMX}.
FT   STRAND      366    372       {ECO:0000244|PDB:4NMX}.
FT   STRAND      373    375       {ECO:0000244|PDB:2XTJ}.
FT   STRAND      378    382       {ECO:0000244|PDB:4NMX}.
FT   HELIX       385    402       {ECO:0000244|PDB:4NMX}.
FT   HELIX       408    417       {ECO:0000244|PDB:4NMX}.
FT   STRAND      419    422       {ECO:0000244|PDB:4NMX}.
FT   HELIX       426    428       {ECO:0000244|PDB:4NMX}.
FT   HELIX       431    433       {ECO:0000244|PDB:4NMX}.
FT   TURN        434    436       {ECO:0000244|PDB:4NMX}.
FT   STRAND      440    442       {ECO:0000244|PDB:3P5B}.
FT   STRAND      456    461       {ECO:0000244|PDB:2QTW}.
FT   STRAND      467    470       {ECO:0000244|PDB:3SQO}.
FT   STRAND      472    475       {ECO:0000244|PDB:2QTW}.
FT   STRAND      482    489       {ECO:0000244|PDB:2QTW}.
FT   STRAND      491    493       {ECO:0000244|PDB:3GCX}.
FT   STRAND      495    503       {ECO:0000244|PDB:2QTW}.
FT   STRAND      506    513       {ECO:0000244|PDB:2QTW}.
FT   STRAND      521    528       {ECO:0000244|PDB:2QTW}.
FT   STRAND      533    539       {ECO:0000244|PDB:2QTW}.
FT   STRAND      544    546       {ECO:0000244|PDB:2QTW}.
FT   STRAND      548    551       {ECO:0000244|PDB:2QTW}.
FT   STRAND      558    565       {ECO:0000244|PDB:2QTW}.
FT   STRAND      568    570       {ECO:0000244|PDB:2P4E}.
FT   STRAND      587    590       {ECO:0000244|PDB:2QTW}.
FT   STRAND      594    602       {ECO:0000244|PDB:2QTW}.
FT   STRAND      606    615       {ECO:0000244|PDB:2QTW}.
FT   STRAND      621    625       {ECO:0000244|PDB:2QTW}.
FT   STRAND      631    637       {ECO:0000244|PDB:2QTW}.
FT   STRAND      644    650       {ECO:0000244|PDB:2QTW}.
FT   STRAND      653    658       {ECO:0000244|PDB:2QTW}.
FT   STRAND      672    681       {ECO:0000244|PDB:2QTW}.
SQ   SEQUENCE   692 AA;  74286 MW;  9BCB9418B90AEE23 CRC64;
     MGTVSSRRSW WPLPLLLLLL LLLGPAGARA QEDEDGDYEE LVLALRSEED GLAEAPEHGT
     TATFHRCAKD PWRLPGTYVV VLKEETHLSQ SERTARRLQA QAARRGYLTK ILHVFHGLLP
     GFLVKMSGDL LELALKLPHV DYIEEDSSVF AQSIPWNLER ITPPRYRADE YQPPDGGSLV
     EVYLLDTSIQ SDHREIEGRV MVTDFENVPE EDGTRFHRQA SKCDSHGTHL AGVVSGRDAG
     VAKGASMRSL RVLNCQGKGT VSGTLIGLEF IRKSQLVQPV GPLVVLLPLA GGYSRVLNAA
     CQRLARAGVV LVTAAGNFRD DACLYSPASA PEVITVGATN AQDQPVTLGT LGTNFGRCVD
     LFAPGEDIIG ASSDCSTCFV SQSGTSQAAA HVAGIAAMML SAEPELTLAE LRQRLIHFSA
     KDVINEAWFP EDQRVLTPNL VAALPPSTHG AGWQLFCRTV WSAHSGPTRM ATAVARCAPD
     EELLSCSSFS RSGKRRGERM EAQGGKLVCR AHNAFGGEGV YAIARCCLLP QANCSVHTAP
     PAEASMGTRV HCHQQGHVLT GCSSHWEVED LGTHKPPVLR PRGQPNQCVG HREASIHASC
     CHAPGLECKV KEHGIPAPQE QVTVACEEGW TLTGCSALPG TSHVLGAYAV DNTCVVRSRD
     VSTTGSTSEG AVTAVAICCR SRHLAQASQE LQ
//
ID   ADIPO_HUMAN             Reviewed;         244 AA.
AC   Q15848; Q58EX9;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   09-DEC-2015, entry version 164.
DE   RecName: Full=Adiponectin;
DE   AltName: Full=30 kDa adipocyte complement-related protein;
DE   AltName: Full=Adipocyte complement-related 30 kDa protein;
DE            Short=ACRP30;
DE   AltName: Full=Adipocyte, C1q and collagen domain-containing protein;
DE   AltName: Full=Adipose most abundant gene transcript 1 protein;
DE            Short=apM-1;
DE   AltName: Full=Gelatin-binding protein;
DE   Flags: Precursor;
GN   Name=ADIPOQ; Synonyms=ACDC, ACRP30, APM1, GBP28;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Adipose tissue;
RX   PubMed=8619847; DOI=10.1006/bbrc.1996.0587;
RA   Maeda K., Okubo K., Shimomura I., Funahashi T., Matsuzawa Y.,
RA   Matsubara K.;
RT   "cDNA cloning and expression of a novel adipose specific collagen-like
RT   factor, apM1 (AdiPose Most abundant Gene transcript 1).";
RL   Biochem. Biophys. Res. Commun. 221:286-289(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=10095105; DOI=10.1016/S0378-1119(99)00041-4;
RA   Saito K., Tobe T., Minoshima S., Asakawa S., Sumiya J., Yoda M.,
RA   Nakano Y., Shimizu N., Tomita M.;
RT   "Organization of the gene for gelatin-binding protein (GBP28).";
RL   Gene 229:67-73(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=10403784; DOI=10.1006/bbrc.1999.0865;
RA   Schaeffler A., Orso E., Palitzsch K.D., Buechler C., Drobnik W.,
RA   Fuerst A., Schoelmerich J., Schmitz G.;
RT   "The human apM-1, an adipocyte-specific gene linked to the family of
RT   TNF's and to genes expressed in activated T cells, is mapped to
RT   chromosome 1q21.3-q23, a susceptibility locus identified for familial
RT   combined hyperlipidemia (FCH).";
RL   Biochem. Biophys. Res. Commun. 260:416-425(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   PROTEIN SEQUENCE OF 19-33.
RX   PubMed=15340161; DOI=10.1110/ps.04682504;
RA   Zhang Z., Henzel W.J.;
RT   "Signal peptide prediction based on analysis of experimentally
RT   verified cleavage sites.";
RL   Protein Sci. 13:2819-2824(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF N-TERMINUS, AND PARTIAL PROTEIN SEQUENCE.
RX   PubMed=8947845; DOI=10.1093/oxfordjournals.jbchem.a021483;
RA   Nakano Y., Tobe T., Choi-Miura N.H., Mazda T., Tomita M.;
RT   "Isolation and characterization of GBP28, a novel gelatin-binding
RT   protein purified from human plasma.";
RL   J. Biochem. 120:803-812(1996).
RN   [7]
RP   CHARACTERIZATION.
RX   PubMed=10961870;
RA   Yokota T., Oritani K., Takahashi I., Ishikawa J., Matsuyama A.,
RA   Ouchi N., Kihara S., Funahashi T., Tenner A.J., Tomiyama Y.,
RA   Matsuzawa Y.;
RT   "Adiponectin, a new member of the family of soluble defense collagens,
RT   negatively regulates the growth of myelomonocytic progenitors and the
RT   functions of macrophages.";
RL   Blood 96:1723-1732(2000).
RN   [8]
RP   CHARACTERIZATION.
RX   PubMed=10982546; DOI=10.1161/01.CIR.102.11.1296;
RA   Ouchi N., Kihara S., Arita Y., Okamoto Y., Maeda K., Kuriyama H.,
RA   Hotta K., Nishida M., Takahashi M., Muraguchi M., Ohmoto Y.,
RA   Nakamura T., Yamashita S., Funahashi T., Matsuzawa Y.;
RT   "Adiponectin, an adipocyte-derived plasma protein, inhibits
RT   endothelial NF-kappaB signaling through a cAMP-dependent pathway.";
RL   Circulation 102:1296-1301(2000).
RN   [9]
RP   FUNCTION.
RX   PubMed=11479627; DOI=10.1038/90984;
RA   Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K.,
RA   Mori Y., Ide T., Murakami K., Tsuboyama-Kasaoka N., Ezaki O.,
RA   Akanuma Y., Gavrilova O., Vinson C., Reitman M.L., Kagechika H.,
RA   Shudo K., Yoda M., Nakano Y., Tobe K., Nagai R., Kimura S., Tomita M.,
RA   Froguel P., Kadowaki T.;
RT   "The fat-derived hormone adiponectin reverses insulin resistance
RT   associated with both lipoatrophy and obesity.";
RL   Nat. Med. 7:941-946(2001).
RN   [10]
RP   SUBUNIT, DISULFIDE BOND, MUTAGENESIS OF CYS-36, AND CHARACTERIZATION
RP   OF VARIANTS ARG-84; SER-90; CYS-112 AND THR-164.
RX   PubMed=12878598; DOI=10.1074/jbc.M300365200;
RA   Waki H., Yamauchi T., Kamon J., Ito Y., Uchida S., Kita S., Hara K.,
RA   Hada Y., Vasseur F., Froguel P., Kimura S., Nagai R., Kadowaki T.;
RT   "Impaired multimerization of human adiponectin mutants associated with
RT   diabetes. Molecular structure and multimer formation of adiponectin.";
RL   J. Biol. Chem. 278:40352-40363(2003).
RN   [11]
RP   SUBUNIT, HYDROXYLATION AT PRO-44; PRO-47; PRO-53; LYS-65; LYS-68;
RP   PRO-71; PRO-76; LYS-77; PRO-91; PRO-95 AND LYS-101, GLYCOSYLATION AT
RP   LYS-65; LYS-68; LYS-77 AND LYS-101, DISULFIDE BOND, LACK OF
RP   HYDROXYLATION AT PRO-62; PRO-86 AND PRO-104, LACK OF GLYCOSYLATION AT
RP   ASN-230, MUTAGENESIS OF LYS-33; CYS-36; LYS-65; LYS-68; LYS-77 AND
RP   LYS-101, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=16497731; DOI=10.1210/me.2005-0390;
RA   Richards A.A., Stephens T., Charlton H.K., Jones A., Macdonald G.A.,
RA   Prins J.B., Whitehead J.P.;
RT   "Adiponectin multimerization is dependent on conserved lysines in the
RT   collagenous domain: evidence for regulation of multimerization by
RT   alterations in posttranslational modifications.";
RL   Mol. Endocrinol. 20:1673-1687(2006).
RN   [12]
RP   GLYCOSYLATION AT THR-21 AND THR-22, SUBUNIT, IDENTIFICATION BY MASS
RP   SPECTROMETRY, AND MUTAGENESIS OF THR-20; THR-21 AND THR-22.
RX   PubMed=19855092; DOI=10.1210/me.2009-0133;
RA   Richards A.A., Colgrave M.L., Zhang J., Webster J., Simpson F.,
RA   Preston E., Wilks D., Hoehn K.L., Stephenson M., Macdonald G.A.,
RA   Prins J.B., Cooney G.J., Xu A., Whitehead J.P.;
RT   "Sialic acid modification of adiponectin is not required for
RT   multimerization or secretion but determines half-life in
RT   circulation.";
RL   Mol. Endocrinol. 24:229-239(2010).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22905912; DOI=10.1021/pr300539b;
RA   Rosenow A., Noben J.P., Jocken J., Kallendrusch S.,
RA   Fischer-Posovszky P., Mariman E.C., Renes J.;
RT   "Resveratrol-induced changes of the human adipocyte secretion
RT   profile.";
RL   J. Proteome Res. 11:4733-4743(2012).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 104-244, AND SUBUNIT.
RX   PubMed=22449980; DOI=10.1016/j.febslet.2012.02.024;
RA   Min X., Lemon B., Tang J., Liu Q., Zhang R., Walker N., Li Y.,
RA   Wang Z.;
RT   "Crystal structure of a single-chain trimer of human adiponectin
RT   globular domain.";
RL   FEBS Lett. 586:912-917(2012).
RN   [15]
RP   VARIANT ADPND CYS-112.
RX   PubMed=10918532; DOI=10.1038/sj.ijo.0801244;
RA   Takahashi M., Arita Y., Yamagata K., Matsukawa Y., Okutomi K.,
RA   Horie M., Shimomura I., Hotta K., Kuriyama H., Kihara S., Nakamura T.,
RA   Yamashita S., Funahashi T., Matsuzawa Y.;
RT   "Genomic structure and mutations in adipose-specific gene,
RT   adiponectin.";
RL   Int. J. Obes. Relat. Metab. Disord. 24:861-868(2000).
RN   [16]
RP   VARIANTS ARG-84; MET-117; THR-164; SER-221 AND PRO-241.
RX   PubMed=11812766; DOI=10.2337/diabetes.51.2.536;
RA   Hara K., Boutin P., Mori Y., Tobe K., Dina C., Yasuda K., Yamauchi T.,
RA   Otabe S., Okada T., Eto K., Kadowaki H., Hagura R., Akanuma Y.,
RA   Yazaki Y., Nagai R., Taniyama M., Matsubara K., Yoda M., Nakano Y.,
RA   Kimura S., Tomita M., Kimura S., Ito C., Froguel P., Kadowaki T.;
RT   "Genetic variation in the gene encoding adiponectin is associated with
RT   an increased risk of type 2 diabetes in the Japanese population.";
RL   Diabetes 51:536-540(2002).
RN   [17]
RP   ERRATUM.
RA   Hara K., Boutin P., Mori Y., Tobe K., Dina C., Yasuda K., Yamauchi T.,
RA   Otabe S., Okada T., Eto K., Kadowaki H., Hagura R., Akanuma Y.,
RA   Yazaki Y., Nagai R., Taniyama M., Matsubara K., Yoda M., Nakano Y.,
RA   Kimura S., Tomita M., Kimura S., Ito C., Froguel P., Kadowaki T.;
RL   Diabetes 51:1294-1294(2002).
RN   [18]
RP   VARIANTS CYS-112; THR-164; SER-221 AND PRO-241, AND ASSOCIATION WITH
RP   LOW PLASMA ADIPONECTIN CONCENTRATION AND DIABETES MELLITUS TYPE 2.
RX   PubMed=12086969; DOI=10.2337/diabetes.51.7.2325;
RA   Kondo H., Shimomura I., Matsukawa Y., Kumada M., Takahashi M.,
RA   Matsuda M., Ouchi N., Kihara S., Kawamoto T., Sumitsuji S.,
RA   Funahashi T., Matsuzawa Y.;
RT   "Association of adiponectin mutation with type 2 diabetes: a candidate
RT   gene for the insulin resistance syndrome.";
RL   Diabetes 51:2325-2328(2002).
RN   [19]
RP   VARIANTS ARG-84; SER-90 AND HIS-111.
RX   PubMed=12354786; DOI=10.1093/hmg/11.21.2607;
RA   Vasseur F., Helbecque N., Dina C., Lobbens S., Delannoy V., Gaget S.,
RA   Boutin P., Vaxillaire M., Lepretre F., Dupont S., Hara K., Clement K.,
RA   Bihain B., Kadowaki T., Froguel P.;
RT   "Single-nucleotide polymorphism haplotypes in the both proximal
RT   promoter and exon 3 of the APM1 gene modulate adipocyte-secreted
RT   adiponectin hormone levels and contribute to the genetic risk for type
RT   2 diabetes in French Caucasians.";
RL   Hum. Mol. Genet. 11:2607-2614(2002).
CC   -!- FUNCTION: Important adipokine involved in the control of fat
CC       metabolism and insulin sensitivity, with direct anti-diabetic,
CC       anti-atherogenic and anti-inflammatory activities. Stimulates AMPK
CC       phosphorylation and activation in the liver and the skeletal
CC       muscle, enhancing glucose utilization and fatty-acid combustion.
CC       Antagonizes TNF-alpha by negatively regulating its expression in
CC       various tissues such as liver and macrophages, and also by
CC       counteracting its effects. Inhibits endothelial NF-kappa-B
CC       signaling through a cAMP-dependent pathway. May play a role in
CC       cell growth, angiogenesis and tissue remodeling by binding and
CC       sequestering various growth factors with distinct binding
CC       affinities, depending on the type of complex, LMW, MMW or HMW.
CC       {ECO:0000269|PubMed:11479627}.
CC   -!- SUBUNIT: Homomultimer. Forms trimers, hexamers and 12- to 18-mers.
CC       The trimers (low molecular weight complexes / LMW) are assembled
CC       via non-covalent interactions of the collagen-like domains in a
CC       triple helix and hydrophobic interactions within the globular C1q
CC       domain. Several trimers can associate to form disulfide-linked
CC       hexamers (middle molecular weight complexes / MMW) and larger
CC       complexes (higher molecular weight / HMW). The HMW-complex
CC       assembly may rely additionally on lysine hydroxylation and
CC       glycosylation. LMW, MMW and HMW complexes bind to HBEGF, MMW and
CC       HMW complexes bind to PDGFB, and HMW complex binds to FGF2.
CC       Interacts with CTRP9A via the C1q domain (heterotrimeric complex)
CC       (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- TISSUE SPECIFICITY: Synthesized exclusively by adipocytes and
CC       secreted into plasma.
CC   -!- DOMAIN: The C1q domain is commonly called the globular domain.
CC   -!- PTM: Hydroxylated Lys-33 was not identified in PubMed:16497731,
CC       probably due to poor representation of the N-terminal peptide in
CC       mass fingerprinting. {ECO:0000269|PubMed:16497731}.
CC   -!- PTM: HMW complexes are more extensively glycosylated than smaller
CC       oligomers. Hydroxylation and glycosylation of the lysine residues
CC       within the collagene-like domain of adiponectin seem to be
CC       critically involved in regulating the formation and/or secretion
CC       of HMW complexes and consequently contribute to the insulin-
CC       sensitizing activity of adiponectin in hepatocytes (By
CC       similarity). {ECO:0000250}.
CC   -!- PTM: O-glycosylated. Not N-glycosylated. O-linked glycans on
CC       hydroxylysines consist of Glc-Gal disaccharides bound to the
CC       oxygen atom of post-translationally added hydroxyl groups.
CC       Sialylated to varying degrees depending on tissue. Thr-22 appears
CC       to be the major site of sialylation. Higher sialylation found in
CC       SGBS adipocytes than in HEK fibroblasts. Sialylation is not
CC       required neither for heterodimerization nor for secretion. Not
CC       sialylated on the glycosylated hydroxylysines. Desialylated forms
CC       are rapidly cleared from the circulation.
CC       {ECO:0000269|PubMed:16497731, ECO:0000269|PubMed:19855092}.
CC   -!- POLYMORPHISM: Genetic variations in ADIPOQ influence the variance
CC       in adiponectin serum levels and define the adiponectin serum
CC       levels quantitative trait locus 1 (ADIPQTL1) [MIM:612556].
CC   -!- DISEASE: Adiponectin deficiency (ADPND) [MIM:612556]: A condition
CC       that results in very low concentrations of plasma adiponectin.
CC       {ECO:0000269|PubMed:10918532}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Diabetes mellitus, non-insulin-dependent (NIDDM)
CC       [MIM:125853]: A multifactorial disorder of glucose homeostasis
CC       caused by a lack of sensitivity to the body's own insulin.
CC       Affected individuals usually have an obese body habitus and
CC       manifestations of a metabolic syndrome characterized by diabetes,
CC       insulin resistance, hypertension and hypertriglyceridemia. The
CC       disease results in long-term complications that affect the eyes,
CC       kidneys, nerves, and blood vessels. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- PHARMACEUTICAL: Adiponectin might be used in the treatment of
CC       diabetes type 2 and insulin resistance.
CC   -!- MISCELLANEOUS: Variants Arg-84 and Ser-90 show impaired formation
CC       of HMW complexes whereas variants Cys-112 and Thr-164 show
CC       impaired secretion of adiponectin in any form.
CC   -!- MISCELLANEOUS: HMW-complex blood contents are higher in females
CC       than in males, are increased in males by castration and decreased
CC       again upon subsequent testosterone treatment, which blocks HMW-
CC       complex secretion (By similarity). In type 2 diabetic patients,
CC       both the ratios of HMW to total adiponectin and the degree of
CC       adiponectin glycosylation are significantly decreased as compared
CC       with healthy controls. {ECO:0000250}.
CC   -!- SIMILARITY: Contains 1 C1q domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00368}.
CC   -!- SIMILARITY: Contains 1 collagen-like domain. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Adiponectin entry;
CC       URL="https://en.wikipedia.org/wiki/Adiponectin";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D45371; BAA08227.1; -; mRNA.
DR   EMBL; AB012165; BAA86716.1; -; Genomic_DNA.
DR   EMBL; AJ131460; CAB52413.1; -; Genomic_DNA.
DR   EMBL; AJ131461; CAB52413.1; JOINED; Genomic_DNA.
DR   EMBL; BC054496; AAH54496.1; -; mRNA.
DR   EMBL; BC096308; AAH96308.1; -; mRNA.
DR   EMBL; BC096309; AAH96309.1; -; mRNA.
DR   EMBL; BC096310; AAH96310.1; -; mRNA.
DR   EMBL; BC096311; AAH96311.1; -; mRNA.
DR   CCDS; CCDS3284.1; -.
DR   PIR; JC4708; JC4708.
DR   RefSeq; NP_001171271.1; NM_001177800.1.
DR   RefSeq; NP_004788.1; NM_004797.3.
DR   RefSeq; XP_011511626.1; XM_011513324.1.
DR   UniGene; Hs.80485; -.
DR   PDB; 4DOU; X-ray; 2.00 A; A=104-244.
DR   PDBsum; 4DOU; -.
DR   ProteinModelPortal; Q15848; -.
DR   SMR; Q15848; 109-243.
DR   BioGrid; 114771; 5.
DR   IntAct; Q15848; 2.
DR   STRING; 9606.ENSP00000320709; -.
DR   BioMuta; ADIPOQ; -.
DR   DMDM; 2493789; -.
DR   PaxDb; Q15848; -.
DR   PeptideAtlas; Q15848; -.
DR   PRIDE; Q15848; -.
DR   Ensembl; ENST00000320741; ENSP00000320709; ENSG00000181092.
DR   Ensembl; ENST00000444204; ENSP00000389814; ENSG00000181092.
DR   GeneID; 9370; -.
DR   KEGG; hsa:9370; -.
DR   UCSC; uc003fra.3; human.
DR   CTD; 9370; -.
DR   GeneCards; ADIPOQ; -.
DR   HGNC; HGNC:13633; ADIPOQ.
DR   HPA; CAB046467; -.
DR   HPA; HPA051767; -.
DR   MalaCards; ADIPOQ; -.
DR   MIM; 125853; phenotype.
DR   MIM; 605441; gene.
DR   MIM; 612556; phenotype.
DR   neXtProt; NX_Q15848; -.
DR   PharmGKB; PA134933118; -.
DR   eggNOG; ENOG410IHSJ; Eukaryota.
DR   eggNOG; ENOG4111F5K; LUCA.
DR   GeneTree; ENSGT00760000118830; -.
DR   HOGENOM; HOG000085653; -.
DR   HOVERGEN; HBG108220; -.
DR   InParanoid; Q15848; -.
DR   KO; K07296; -.
DR   OMA; KAMLFTY; -.
DR   OrthoDB; EOG70ZZPW; -.
DR   PhylomeDB; Q15848; -.
DR   TreeFam; TF329591; -.
DR   Reactome; R-HSA-381340; Transcriptional regulation of white adipocyte differentiation.
DR   ChiTaRS; ADIPOQ; human.
DR   GeneWiki; Adiponectin; -.
DR   GenomeRNAi; 9370; -.
DR   NextBio; 35094; -.
DR   PRO; PR:Q15848; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; Q15848; -.
DR   CleanEx; HS_ADIPOQ; -.
DR   ExpressionAtlas; Q15848; baseline and differential.
DR   Genevisible; Q15848; HS.
DR   GO; GO:0009986; C:cell surface; IDA:BHF-UCL.
DR   GO; GO:0005581; C:collagen trimer; IEA:UniProtKB-KW.
DR   GO; GO:0005783; C:endoplasmic reticulum; ISS:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005125; F:cytokine activity; NAS:BHF-UCL.
DR   GO; GO:0005179; F:hormone activity; IDA:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; TAS:BHF-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0005102; F:receptor binding; ISS:UniProtKB.
DR   GO; GO:0033691; F:sialic acid binding; IDA:UniProtKB.
DR   GO; GO:0033211; P:adiponectin-activated signaling pathway; IEA:Ensembl.
DR   GO; GO:0050873; P:brown fat cell differentiation; ISS:UniProtKB.
DR   GO; GO:0071320; P:cellular response to cAMP; IEA:Ensembl.
DR   GO; GO:0035690; P:cellular response to drug; ISS:UniProtKB.
DR   GO; GO:0071872; P:cellular response to epinephrine stimulus; IEA:Ensembl.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; ISS:UniProtKB.
DR   GO; GO:0007623; P:circadian rhythm; IEA:Ensembl.
DR   GO; GO:0070994; P:detection of oxidative stress; ISS:UniProtKB.
DR   GO; GO:0006635; P:fatty acid beta-oxidation; ISS:UniProtKB.
DR   GO; GO:0019395; P:fatty acid oxidation; ISS:UniProtKB.
DR   GO; GO:0006091; P:generation of precursor metabolites and energy; TAS:ProtInc.
DR   GO; GO:0042593; P:glucose homeostasis; ISS:UniProtKB.
DR   GO; GO:0006006; P:glucose metabolic process; ISS:UniProtKB.
DR   GO; GO:0034383; P:low-density lipoprotein particle clearance; IDA:BHF-UCL.
DR   GO; GO:0051899; P:membrane depolarization; IEA:Ensembl.
DR   GO; GO:0060081; P:membrane hyperpolarization; IEA:Ensembl.
DR   GO; GO:0045776; P:negative regulation of blood pressure; IDA:UniProtKB.
DR   GO; GO:0030336; P:negative regulation of cell migration; ISS:UniProtKB.
DR   GO; GO:2000279; P:negative regulation of DNA biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0070373; P:negative regulation of ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0045599; P:negative regulation of fat cell differentiation; IDA:BHF-UCL.
DR   GO; GO:0045721; P:negative regulation of gluconeogenesis; ISS:BHF-UCL.
DR   GO; GO:0030853; P:negative regulation of granulocyte differentiation; IDA:BHF-UCL.
DR   GO; GO:0034115; P:negative regulation of heterotypic cell-cell adhesion; IDA:BHF-UCL.
DR   GO; GO:0046888; P:negative regulation of hormone secretion; IEA:Ensembl.
DR   GO; GO:0043124; P:negative regulation of I-kappaB kinase/NF-kappaB signaling; IDA:BHF-UCL.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; ISS:UniProtKB.
DR   GO; GO:0090317; P:negative regulation of intracellular protein transport; IDA:UniProtKB.
DR   GO; GO:0045715; P:negative regulation of low-density lipoprotein particle receptor biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0010745; P:negative regulation of macrophage derived foam cell differentiation; IDA:BHF-UCL.
DR   GO; GO:0045650; P:negative regulation of macrophage differentiation; IDA:BHF-UCL.
DR   GO; GO:0043407; P:negative regulation of MAP kinase activity; ISS:UniProtKB.
DR   GO; GO:2000590; P:negative regulation of metanephric mesenchymal cell migration; ISS:UniProtKB.
DR   GO; GO:0050765; P:negative regulation of phagocytosis; IDA:BHF-UCL.
DR   GO; GO:0010642; P:negative regulation of platelet-derived growth factor receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:2000584; P:negative regulation of platelet-derived growth factor receptor-alpha signaling pathway; ISS:UniProtKB.
DR   GO; GO:0031953; P:negative regulation of protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:1900121; P:negative regulation of receptor binding; IDA:UniProtKB.
DR   GO; GO:0014912; P:negative regulation of smooth muscle cell migration; IDA:UniProtKB.
DR   GO; GO:0048662; P:negative regulation of smooth muscle cell proliferation; IDA:UniProtKB.
DR   GO; GO:0050805; P:negative regulation of synaptic transmission; IDA:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0032720; P:negative regulation of tumor necrosis factor production; IDA:BHF-UCL.
DR   GO; GO:0010804; P:negative regulation of tumor necrosis factor-mediated signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0045777; P:positive regulation of blood pressure; IEA:Ensembl.
DR   GO; GO:2000481; P:positive regulation of cAMP-dependent protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0032270; P:positive regulation of cellular protein metabolic process; IDA:BHF-UCL.
DR   GO; GO:0010875; P:positive regulation of cholesterol efflux; IDA:BHF-UCL.
DR   GO; GO:0045923; P:positive regulation of fatty acid metabolic process; ISS:BHF-UCL.
DR   GO; GO:0046326; P:positive regulation of glucose import; ISS:BHF-UCL.
DR   GO; GO:2000467; P:positive regulation of glycogen (starch) synthase activity; ISS:UniProtKB.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; ISS:UniProtKB.
DR   GO; GO:0032757; P:positive regulation of interleukin-8 production; IDA:UniProtKB.
DR   GO; GO:2000478; P:positive regulation of metanephric glomerular visceral epithelial cell development; ISS:UniProtKB.
DR   GO; GO:0071639; P:positive regulation of monocyte chemotactic protein-1 production; IDA:UniProtKB.
DR   GO; GO:0033034; P:positive regulation of myeloid cell apoptotic process; IDA:BHF-UCL.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IEA:Ensembl.
DR   GO; GO:0010739; P:positive regulation of protein kinase A signaling; IDA:BHF-UCL.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:2000534; P:positive regulation of renal albumin absorption; IDA:UniProtKB.
DR   GO; GO:0009967; P:positive regulation of signal transduction; ISS:BHF-UCL.
DR   GO; GO:0070208; P:protein heterotrimerization; IEA:Ensembl.
DR   GO; GO:0051260; P:protein homooligomerization; ISS:UniProtKB.
DR   GO; GO:0072659; P:protein localization to plasma membrane; IDA:UniProtKB.
DR   GO; GO:0010906; P:regulation of glucose metabolic process; IDA:UniProtKB.
DR   GO; GO:0014823; P:response to activity; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0051384; P:response to glucocorticoid; IEA:Ensembl.
DR   GO; GO:0009749; P:response to glucose; ISS:BHF-UCL.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0070543; P:response to linoleic acid; IEA:Ensembl.
DR   GO; GO:0007584; P:response to nutrient; IEA:Ensembl.
DR   GO; GO:0009744; P:response to sucrose; IEA:Ensembl.
DR   GO; GO:0034612; P:response to tumor necrosis factor; IDA:BHF-UCL.
DR   Gene3D; 2.60.120.40; -; 1.
DR   InterPro; IPR001073; C1q_dom.
DR   InterPro; IPR008160; Collagen.
DR   InterPro; IPR008983; Tumour_necrosis_fac-like_dom.
DR   Pfam; PF00386; C1q; 1.
DR   Pfam; PF01391; Collagen; 1.
DR   PRINTS; PR00007; COMPLEMNTC1Q.
DR   SMART; SM00110; C1Q; 1.
DR   SUPFAM; SSF49842; SSF49842; 1.
DR   PROSITE; PS50871; C1Q; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Collagen; Complete proteome; Diabetes mellitus;
KW   Direct protein sequencing; Disease mutation; Disulfide bond;
KW   Glycoprotein; Hormone; Hydroxylation; Obesity; Pharmaceutical;
KW   Polymorphism; Reference proteome; Repeat; Secreted; Signal.
FT   SIGNAL        1     18       {ECO:0000269|PubMed:15340161,
FT                                ECO:0000269|PubMed:8947845}.
FT   CHAIN        19    244       Adiponectin.
FT                                /FTId=PRO_0000003543.
FT   DOMAIN       42    107       Collagen-like.
FT   DOMAIN      108    244       C1q. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00368}.
FT   SITE         62     62       Not hydroxylated.
FT   SITE         86     86       Not hydroxylated.
FT   SITE        104    104       Not hydroxylated.
FT   SITE        230    230       Not glycosylated.
FT   MOD_RES      33     33       5-hydroxylysine. {ECO:0000305}.
FT   MOD_RES      44     44       4-hydroxyproline.
FT                                {ECO:0000269|PubMed:16497731}.
FT   MOD_RES      47     47       4-hydroxyproline.
FT                                {ECO:0000269|PubMed:16497731}.
FT   MOD_RES      53     53       4-hydroxyproline.
FT                                {ECO:0000269|PubMed:16497731}.
FT   MOD_RES      65     65       5-hydroxylysine.
FT                                {ECO:0000269|PubMed:16497731}.
FT   MOD_RES      68     68       5-hydroxylysine.
FT                                {ECO:0000269|PubMed:16497731}.
FT   MOD_RES      71     71       4-hydroxyproline; partial.
FT                                {ECO:0000269|PubMed:16497731}.
FT   MOD_RES      76     76       4-hydroxyproline; partial.
FT                                {ECO:0000269|PubMed:16497731}.
FT   MOD_RES      77     77       5-hydroxylysine.
FT                                {ECO:0000269|PubMed:16497731}.
FT   MOD_RES      91     91       4-hydroxyproline.
FT                                {ECO:0000269|PubMed:16497731}.
FT   MOD_RES      95     95       4-hydroxyproline; partial.
FT                                {ECO:0000269|PubMed:16497731}.
FT   MOD_RES     101    101       5-hydroxylysine.
FT                                {ECO:0000269|PubMed:16497731}.
FT   CARBOHYD     21     21       O-linked (GalNAc...).
FT                                {ECO:0000269|PubMed:19855092}.
FT   CARBOHYD     22     22       O-linked (GalNAc...).
FT                                {ECO:0000269|PubMed:19855092}.
FT   CARBOHYD     65     65       O-linked (Gal...); partial.
FT                                {ECO:0000269|PubMed:16497731}.
FT   CARBOHYD     68     68       O-linked (Gal...); partial.
FT                                {ECO:0000269|PubMed:16497731}.
FT   CARBOHYD     77     77       O-linked (Gal...); partial.
FT                                {ECO:0000269|PubMed:16497731}.
FT   CARBOHYD    101    101       O-linked (Gal...); partial.
FT                                {ECO:0000269|PubMed:16497731}.
FT   DISULFID     36     36       Interchain; in form MMW and form HMW.
FT                                {ECO:0000269|PubMed:12878598,
FT                                ECO:0000269|PubMed:16497731}.
FT   VARIANT      84     84       G -> R (does not form high molecular
FT                                weight multimers).
FT                                {ECO:0000269|PubMed:11812766,
FT                                ECO:0000269|PubMed:12354786,
FT                                ECO:0000269|PubMed:12878598}.
FT                                /FTId=VAR_013273.
FT   VARIANT      90     90       G -> S (does not form high molecular
FT                                weight multimers; dbSNP:rs62625753).
FT                                {ECO:0000269|PubMed:12354786,
FT                                ECO:0000269|PubMed:12878598}.
FT                                /FTId=VAR_027395.
FT   VARIANT     111    111       Y -> H (in dbSNP:rs17366743).
FT                                {ECO:0000269|PubMed:12354786}.
FT                                /FTId=VAR_027396.
FT   VARIANT     112    112       R -> C (in ADPND; does not assemble into
FT                                trimers resulting in impaired secretion
FT                                from the cell).
FT                                {ECO:0000269|PubMed:10918532,
FT                                ECO:0000269|PubMed:12086969,
FT                                ECO:0000269|PubMed:12878598}.
FT                                /FTId=VAR_013274.
FT   VARIANT     117    117       V -> M. {ECO:0000269|PubMed:11812766}.
FT                                /FTId=VAR_013275.
FT   VARIANT     164    164       I -> T (associated with low plasma
FT                                adiponectin concentration and diabetes
FT                                mellitus type 2; does not assemble into
FT                                trimers resulting in impaired secretion
FT                                from the cell; dbSNP:rs185847354).
FT                                {ECO:0000269|PubMed:11812766,
FT                                ECO:0000269|PubMed:12086969,
FT                                ECO:0000269|PubMed:12878598}.
FT                                /FTId=VAR_013276.
FT   VARIANT     221    221       R -> S (in dbSNP:rs138773406).
FT                                {ECO:0000269|PubMed:11812766,
FT                                ECO:0000269|PubMed:12086969}.
FT                                /FTId=VAR_013277.
FT   VARIANT     241    241       H -> P (in dbSNP:rs141205818).
FT                                {ECO:0000269|PubMed:11812766,
FT                                ECO:0000269|PubMed:12086969}.
FT                                /FTId=VAR_013278.
FT   MUTAGEN      20     20       T->A: No change in sialylated isoforms.
FT                                {ECO:0000269|PubMed:19855092}.
FT   MUTAGEN      21     21       T->A: Some loss of sialylated isoforms.
FT                                {ECO:0000269|PubMed:19855092}.
FT   MUTAGEN      22     22       T->A: Abolishes sialylated isoforms.
FT                                {ECO:0000269|PubMed:19855092}.
FT   MUTAGEN      33     33       K->R: No effect on formation of HMW
FT                                multimers. {ECO:0000269|PubMed:16497731}.
FT   MUTAGEN      36     36       C->S: Impaired formation of MMW and HMW
FT                                multimers. {ECO:0000269|PubMed:12878598,
FT                                ECO:0000269|PubMed:16497731}.
FT   MUTAGEN      65     65       K->R: Impaired formation of HMW
FT                                multimers; when associated with R-68.
FT                                {ECO:0000269|PubMed:16497731}.
FT   MUTAGEN      68     68       K->R: Impaired formation of HMW
FT                                multimers; when associated with R-65.
FT                                {ECO:0000269|PubMed:16497731}.
FT   MUTAGEN      77     77       K->R: Impaired formation of HMW
FT                                multimers; when associated with R-101.
FT                                {ECO:0000269|PubMed:16497731}.
FT   MUTAGEN     101    101       K->R: Impaired formation of HMW
FT                                multimers; when associated with R-77.
FT                                {ECO:0000269|PubMed:16497731}.
FT   STRAND      114    118       {ECO:0000244|PDB:4DOU}.
FT   STRAND      134    137       {ECO:0000244|PDB:4DOU}.
FT   TURN        145    147       {ECO:0000244|PDB:4DOU}.
FT   STRAND      156    177       {ECO:0000244|PDB:4DOU}.
FT   STRAND      180    187       {ECO:0000244|PDB:4DOU}.
FT   STRAND      195    205       {ECO:0000244|PDB:4DOU}.
FT   STRAND      210    215       {ECO:0000244|PDB:4DOU}.
FT   STRAND      222    225       {ECO:0000244|PDB:4DOU}.
FT   STRAND      233    241       {ECO:0000244|PDB:4DOU}.
SQ   SEQUENCE   244 AA;  26414 MW;  64D8C6C1204B1018 CRC64;
     MLLLGAVLLL LALPGHDQET TTQGPGVLLP LPKGACTGWM AGIPGHPGHN GAPGRDGRDG
     TPGEKGEKGD PGLIGPKGDI GETGVPGAEG PRGFPGIQGR KGEPGEGAYV YRSAFSVGLE
     TYVTIPNMPI RFTKIFYNQQ NHYDGSTGKF HCNIPGLYYF AYHITVYMKD VKVSLFKKDK
     AMLFTYDQYQ ENNVDQASGS VLLHLEVGDQ VWLQVYGEGE RNGLYADNDN DSTFTGFLLY
     HDTN
//
ID   SFRP1_HUMAN             Reviewed;         314 AA.
AC   Q8N474; O00546; O14779;
DT   15-MAR-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2002, sequence version 1.
DT   17-FEB-2016, entry version 135.
DE   RecName: Full=Secreted frizzled-related protein 1;
DE            Short=FRP-1;
DE            Short=sFRP-1;
DE   AltName: Full=Secreted apoptosis-related protein 2;
DE            Short=SARP-2;
DE   Flags: Precursor;
GN   Name=SFRP1; Synonyms=FRP, FRP1, SARP2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 39-78.
RC   TISSUE=Embryonic lung fibroblast;
RX   PubMed=9192640; DOI=10.1073/pnas.94.13.6770;
RA   Finch P.W., He X., Kelley M.J., Uren A., Schaudies R.P., Popescu N.C.,
RA   Rudikoff S., Aaronson S.A., Varmus H.E., Rubin J.S.;
RT   "Purification and molecular cloning of a secreted, Frizzled-related
RT   antagonist of Wnt action.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:6770-6775(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Heart;
RX   PubMed=9391078; DOI=10.1073/pnas.94.25.13636;
RA   Melkonyan H.S., Chang W.C., Shapiro J.P., Mahadevappa M.,
RA   Fitzpatrick P.A., Kiefer M.C., Tomei L.D., Umansky S.R.;
RT   "SARPs: a family of secreted apoptosis-related proteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:13636-13641(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND INDUCTION.
RX   PubMed=9724099;
RX   DOI=10.1002/(SICI)1097-0215(19980925)78:1<95::AID-IJC15>3.0.CO;2-4;
RA   Zhou Z., Wang J., Han X., Zhou J., Linder S.;
RT   "Up-regulation of human secreted frizzled homolog in apoptosis and its
RT   down-regulation in breast tumors.";
RL   Int. J. Cancer 78:95-99(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   PROTEIN SEQUENCE OF 32-314, DISULFIDE BONDS, MASS SPECTROMETRY,
RP   GLYCOSYLATION AT ASN-173, AND MUTAGENESIS OF ASN-173 AND ASN-263.
RX   PubMed=11741940; DOI=10.1074/jbc.M108533200;
RA   Chong J.M., Ueren A., Rubin J.S., Speicher D.W.;
RT   "Disulfide bond assignments of secreted Frizzled-related protein-1
RT   provide insights about Frizzled homology and netrin modules.";
RL   J. Biol. Chem. 277:5134-5144(2002).
RN   [6]
RP   INTERACTION WITH WNT1; WNT2 AND FRZD6.
RX   PubMed=10347172; DOI=10.1074/jbc.274.23.16180;
RA   Bafico A., Gazit A., Pramila T., Finch P.W., Yaniv A., Aaronson S.A.;
RT   "Interaction of frizzled related protein (FRP) with Wnt ligands and
RT   the frizzled receptor suggests alternative mechanisms for FRP
RT   inhibition of Wnt signaling.";
RL   J. Biol. Chem. 274:16180-16187(1999).
RN   [7]
RP   INDUCTION.
RX   PubMed=11932307; DOI=10.1210/jc.87.4.1729;
RA   Fukuhara K., Kariya M., Kita M., Shime H., Kanamori T., Kosaka C.,
RA   Orii A., Fujita J., Fujii S.;
RT   "Secreted frizzled related protein 1 is overexpressed in uterine
RT   leiomyomas, associated with a high estrogenic environment and
RT   unrelated to proliferative activity.";
RL   J. Clin. Endocrinol. Metab. 87:1729-1736(2002).
CC   -!- FUNCTION: Soluble frizzled-related proteins (sFRPS) function as
CC       modulators of Wnt signaling through direct interaction with Wnts.
CC       They have a role in regulating cell growth and differentiation in
CC       specific cell types. SFRP1 decreases intracellular beta-catenin
CC       levels (By similarity). Has antiproliferative effects on vascular
CC       cells, in vitro and in vivo, and can induce, in vivo, an
CC       angiogenic response. In vascular cell cycle, delays the G1 phase
CC       and entry into the S phase (By similarity). In kidney development,
CC       inhibits tubule formation and bud growth in metanephroi (By
CC       similarity). Inhibits WNT1/WNT4-mediated TCF-dependent
CC       transcription. {ECO:0000250}.
CC   -!- SUBUNIT: Interacts with WNT1, WNT2 and FRZD6. Interacts with WNT4,
CC       WNT8 and MYOC (By similarity). {ECO:0000250}.
CC   -!- INTERACTION:
CC       O60353:FZD6; NbExp=3; IntAct=EBI-3940687, EBI-8754490;
CC   -!- SUBCELLULAR LOCATION: Secreted. Note=Cell membrane or
CC       extracellular matrix-associated. Released by heparin-binding.
CC   -!- TISSUE SPECIFICITY: Widely expressed. Absent from lung, liver and
CC       peripheral blood leukocytes. Highest levels in heart and fetal
CC       kidney. Also expressed in testis, ovary, fetal brain and lung,
CC       leiomyomal cells, myometrial cells and vascular smooth muscle
CC       cells. Expressed in foreskin fibroblasts and in keratinocytes.
CC       {ECO:0000269|PubMed:9391078}.
CC   -!- INDUCTION: Down-regulated in colorectal and breast tumors. Up-
CC       regulated in uterine leiomyomas under high estrogenic conditions.
CC       Expression, in leiomyomal cells, also increased both under hypoxic
CC       and serum deprivation conditions. {ECO:0000269|PubMed:11932307,
CC       ECO:0000269|PubMed:9724099}.
CC   -!- DOMAIN: The FZ domain is involved in binding with Wnt ligands.
CC       {ECO:0000250}.
CC   -!- MASS SPECTROMETRY: Mass=7266.4; Method=MALDI; Range=169-210;
CC       Note=Isoform N-glycosylated on Asn-173.;
CC       Evidence={ECO:0000269|PubMed:11741940};
CC   -!- MISCELLANEOUS: May have therapeutic use in cardiac surgery.
CC   -!- SIMILARITY: Belongs to the secreted frizzled-related protein
CC       (sFRP) family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 FZ (frizzled) domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00090}.
CC   -!- SIMILARITY: Contains 1 NTR domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00295}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF001900; AAB61576.1; -; mRNA.
DR   EMBL; AF017987; AAB70793.1; -; mRNA.
DR   EMBL; AF056087; AAC12877.1; -; mRNA.
DR   EMBL; BC036503; AAH36503.1; -; mRNA.
DR   CCDS; CCDS34886.1; -.
DR   RefSeq; NP_003003.3; NM_003012.4.
DR   UniGene; Hs.213424; -.
DR   ProteinModelPortal; Q8N474; -.
DR   SMR; Q8N474; 62-161.
DR   BioGrid; 112320; 7.
DR   IntAct; Q8N474; 3.
DR   STRING; 9606.ENSP00000220772; -.
DR   BindingDB; Q8N474; -.
DR   ChEMBL; CHEMBL5517; -.
DR   MEROPS; I93.002; -.
DR   iPTMnet; Q8N474; -.
DR   PhosphoSite; Q8N474; -.
DR   BioMuta; SFRP1; -.
DR   DMDM; 61216811; -.
DR   MaxQB; Q8N474; -.
DR   PaxDb; Q8N474; -.
DR   PRIDE; Q8N474; -.
DR   DNASU; 6422; -.
DR   Ensembl; ENST00000220772; ENSP00000220772; ENSG00000104332.
DR   GeneID; 6422; -.
DR   KEGG; hsa:6422; -.
DR   UCSC; uc003xnt.3; human.
DR   CTD; 6422; -.
DR   GeneCards; SFRP1; -.
DR   HGNC; HGNC:10776; SFRP1.
DR   HPA; CAB008116; -.
DR   MIM; 604156; gene.
DR   neXtProt; NX_Q8N474; -.
DR   PharmGKB; PA35692; -.
DR   eggNOG; KOG3577; Eukaryota.
DR   eggNOG; ENOG410XRC8; LUCA.
DR   GeneTree; ENSGT00760000118864; -.
DR   HOGENOM; HOG000231058; -.
DR   HOVERGEN; HBG052928; -.
DR   InParanoid; Q8N474; -.
DR   KO; K02166; -.
DR   OMA; DDVCIAM; -.
DR   OrthoDB; EOG789CBZ; -.
DR   PhylomeDB; Q8N474; -.
DR   TreeFam; TF350133; -.
DR   Reactome; R-HSA-3772470; Negative regulation of TCF-dependent signaling by WNT ligand antagonists.
DR   SignaLink; Q8N474; -.
DR   ChiTaRS; SFRP1; human.
DR   GeneWiki; Secreted_frizzled-related_protein_1; -.
DR   GenomeRNAi; 6422; -.
DR   NextBio; 24939; -.
DR   PRO; PR:Q8N474; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   Bgee; Q8N474; -.
DR   CleanEx; HS_SFRP1; -.
DR   ExpressionAtlas; Q8N474; baseline and differential.
DR   Genevisible; Q8N474; HS.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0031012; C:extracellular matrix; IDA:BHF-UCL.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; IBA:GO_Central.
DR   GO; GO:0005622; C:intracellular; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; ISS:UniProtKB.
DR   GO; GO:0005578; C:proteinaceous extracellular matrix; IDA:BHF-UCL.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IMP:UniProtKB.
DR   GO; GO:0008144; F:drug binding; IDA:UniProtKB.
DR   GO; GO:0005109; F:frizzled binding; IPI:UniProtKB.
DR   GO; GO:0004930; F:G-protein coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0008201; F:heparin binding; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:BHF-UCL.
DR   GO; GO:0042813; F:Wnt-activated receptor activity; IBA:GO_Central.
DR   GO; GO:0017147; F:Wnt-protein binding; IPI:UniProtKB.
DR   GO; GO:0060346; P:bone trabecula formation; IEA:Ensembl.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0071773; P:cellular response to BMP stimulus; IEP:UniProtKB.
DR   GO; GO:0071392; P:cellular response to estradiol stimulus; IEP:UniProtKB.
DR   GO; GO:0071391; P:cellular response to estrogen stimulus; IDA:UniProtKB.
DR   GO; GO:0044344; P:cellular response to fibroblast growth factor stimulus; IDA:UniProtKB.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IDA:UniProtKB.
DR   GO; GO:0071504; P:cellular response to heparin; IDA:UniProtKB.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEP:UniProtKB.
DR   GO; GO:0071347; P:cellular response to interleukin-1; IEP:UniProtKB.
DR   GO; GO:0071380; P:cellular response to prostaglandin E stimulus; IEP:UniProtKB.
DR   GO; GO:0009267; P:cellular response to starvation; IEP:UniProtKB.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IEP:UniProtKB.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IDA:UniProtKB.
DR   GO; GO:0071305; P:cellular response to vitamin D; IEP:UniProtKB.
DR   GO; GO:0071481; P:cellular response to X-ray; IEA:Ensembl.
DR   GO; GO:0090246; P:convergent extension involved in somitogenesis; IEA:Ensembl.
DR   GO; GO:0048546; P:digestive tract morphogenesis; IEA:Ensembl.
DR   GO; GO:0009950; P:dorsal/ventral axis specification; IDA:UniProtKB.
DR   GO; GO:0008585; P:female gonad development; IEA:Ensembl.
DR   GO; GO:0007186; P:G-protein coupled receptor signaling pathway; IBA:GOC.
DR   GO; GO:0002244; P:hematopoietic progenitor cell differentiation; IDA:UniProtKB.
DR   GO; GO:0060218; P:hematopoietic stem cell differentiation; IDA:UniProtKB.
DR   GO; GO:0008584; P:male gonad development; IEA:Ensembl.
DR   GO; GO:0022601; P:menstrual cycle phase; IEP:UniProtKB.
DR   GO; GO:0060766; P:negative regulation of androgen receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0045578; P:negative regulation of B cell differentiation; IMP:UniProtKB.
DR   GO; GO:0030514; P:negative regulation of BMP signaling pathway; IEA:Ensembl.
DR   GO; GO:0046851; P:negative regulation of bone remodeling; IMP:UniProtKB.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IDA:UniProtKB.
DR   GO; GO:2000080; P:negative regulation of canonical Wnt signaling pathway involved in controlling type B pancreatic cell proliferation; IDA:UniProtKB.
DR   GO; GO:0030308; P:negative regulation of cell growth; IDA:UniProtKB.
DR   GO; GO:0030336; P:negative regulation of cell migration; IDA:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IDA:UniProtKB.
DR   GO; GO:0050680; P:negative regulation of epithelial cell proliferation; IDA:UniProtKB.
DR   GO; GO:0010719; P:negative regulation of epithelial to mesenchymal transition; IDA:UniProtKB.
DR   GO; GO:2000270; P:negative regulation of fibroblast apoptotic process; IDA:UniProtKB.
DR   GO; GO:0048147; P:negative regulation of fibroblast proliferation; IDA:BHF-UCL.
DR   GO; GO:0010629; P:negative regulation of gene expression; IDA:UniProtKB.
DR   GO; GO:0046676; P:negative regulation of insulin secretion; IDA:UniProtKB.
DR   GO; GO:0043508; P:negative regulation of JUN kinase activity; IEA:Ensembl.
DR   GO; GO:0030279; P:negative regulation of ossification; IDA:UniProtKB.
DR   GO; GO:0045668; P:negative regulation of osteoblast differentiation; IEA:Ensembl.
DR   GO; GO:0033689; P:negative regulation of osteoblast proliferation; IMP:UniProtKB.
DR   GO; GO:0045671; P:negative regulation of osteoclast differentiation; IEA:Ensembl.
DR   GO; GO:0050732; P:negative regulation of peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:2000041; P:negative regulation of planar cell polarity pathway involved in axis elongation; IEA:Ensembl.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0030178; P:negative regulation of Wnt signaling pathway; IDA:UniProtKB.
DR   GO; GO:2000054; P:negative regulation of Wnt signaling pathway involved in dorsal/ventral axis specification; IDA:UniProtKB.
DR   GO; GO:0014034; P:neural crest cell fate commitment; IEA:Ensembl.
DR   GO; GO:0035567; P:non-canonical Wnt signaling pathway; IBA:GO_Central.
DR   GO; GO:0001649; P:osteoblast differentiation; IEP:UniProtKB.
DR   GO; GO:0090179; P:planar cell polarity pathway involved in neural tube closure; IEA:Ensembl.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IDA:UniProtKB.
DR   GO; GO:0030307; P:positive regulation of cell growth; IDA:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:UniProtKB.
DR   GO; GO:0001954; P:positive regulation of cell-matrix adhesion; ISS:BHF-UCL.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IMP:UniProtKB.
DR   GO; GO:1902043; P:positive regulation of extrinsic apoptotic signaling pathway via death domain receptors; IDA:BHF-UCL.
DR   GO; GO:0045600; P:positive regulation of fat cell differentiation; IDA:UniProtKB.
DR   GO; GO:2000271; P:positive regulation of fibroblast apoptotic process; IDA:UniProtKB.
DR   GO; GO:0051894; P:positive regulation of focal adhesion assembly; ISS:BHF-UCL.
DR   GO; GO:0043547; P:positive regulation of GTPase activity; ISS:BHF-UCL.
DR   GO; GO:2000052; P:positive regulation of non-canonical Wnt signaling pathway; IDA:UniProtKB.
DR   GO; GO:0045880; P:positive regulation of smoothened signaling pathway; IMP:UniProtKB.
DR   GO; GO:0051496; P:positive regulation of stress fiber assembly; ISS:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0030177; P:positive regulation of Wnt signaling pathway; IDA:UniProtKB.
DR   GO; GO:0060527; P:prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis; IEA:Ensembl.
DR   GO; GO:0006508; P:proteolysis; IMP:GOC.
DR   GO; GO:0045765; P:regulation of angiogenesis; ISS:BHF-UCL.
DR   GO; GO:0060687; P:regulation of branching involved in prostate gland morphogenesis; IEA:Ensembl.
DR   GO; GO:0010564; P:regulation of cell cycle process; IMP:UniProtKB.
DR   GO; GO:0042493; P:response to drug; IDA:UniProtKB.
DR   GO; GO:0014070; P:response to organic cyclic compound; IDA:UniProtKB.
DR   GO; GO:0035019; P:somatic stem cell population maintenance; IEA:Ensembl.
DR   GO; GO:0044345; P:stromal-epithelial cell signaling involved in prostate gland development; IEA:Ensembl.
DR   GO; GO:0001657; P:ureteric bud development; IEA:Ensembl.
DR   GO; GO:0090244; P:Wnt signaling pathway involved in somitogenesis; IEA:Ensembl.
DR   Gene3D; 1.10.2000.10; -; 1.
DR   InterPro; IPR015526; Frizzled/SFRP.
DR   InterPro; IPR020067; Frizzled_dom.
DR   InterPro; IPR001134; Netrin_domain.
DR   InterPro; IPR018933; Netrin_module_non-TIMP.
DR   InterPro; IPR026559; SFRP1.
DR   InterPro; IPR008993; TIMP-like_OB-fold.
DR   PANTHER; PTHR11309; PTHR11309; 1.
DR   PANTHER; PTHR11309:SF87; PTHR11309:SF87; 1.
DR   Pfam; PF01392; Fz; 1.
DR   Pfam; PF01759; NTR; 1.
DR   SMART; SM00643; C345C; 1.
DR   SMART; SM00063; FRI; 1.
DR   SUPFAM; SSF50242; SSF50242; 1.
DR   SUPFAM; SSF63501; SSF63501; 1.
DR   PROSITE; PS50038; FZ; 1.
DR   PROSITE; PS50189; NTR; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Developmental protein; Differentiation;
KW   Direct protein sequencing; Disulfide bond; Glycoprotein;
KW   Reference proteome; Secreted; Signal; Wnt signaling pathway.
FT   SIGNAL        1     31       {ECO:0000269|PubMed:11741940}.
FT   CHAIN        32    314       Secreted frizzled-related protein 1.
FT                                /FTId=PRO_0000032538.
FT   DOMAIN       53    169       FZ. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00090}.
FT   DOMAIN      186    306       NTR. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00295}.
FT   CARBOHYD    173    173       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:11741940}.
FT   DISULFID     58    121       {ECO:0000269|PubMed:11741940}.
FT   DISULFID     68    114       {ECO:0000269|PubMed:11741940}.
FT   DISULFID    105    140       {ECO:0000269|PubMed:11741940}.
FT   DISULFID    129    166       {ECO:0000269|PubMed:11741940}.
FT   DISULFID    133    157       {ECO:0000269|PubMed:11741940}.
FT   DISULFID    186    256       {ECO:0000269|PubMed:11741940}.
FT   DISULFID    189    258       {ECO:0000269|PubMed:11741940}.
FT   DISULFID    203    306       {ECO:0000269|PubMed:11741940}.
FT   MUTAGEN     173    173       N->Q: Reduced molecular weight.
FT                                {ECO:0000269|PubMed:11741940}.
FT   MUTAGEN     263    263       N->Q: No effect on molecular weight.
FT                                {ECO:0000269|PubMed:11741940}.
FT   CONFLICT     14     14       Missing (in Ref. 1 and 3). {ECO:0000305}.
FT   CONFLICT    174    174       A -> P (in Ref. 2; AAB70793).
FT                                {ECO:0000305}.
SQ   SEQUENCE   314 AA;  35386 MW;  29DD948706EB7143 CRC64;
     MGIGRSEGGR RGAALGVLLA LGAALLAVGS ASEYDYVSFQ SDIGPYQSGR FYTKPPQCVD
     IPADLRLCHN VGYKKMVLPN LLEHETMAEV KQQASSWVPL LNKNCHAGTQ VFLCSLFAPV
     CLDRPIYPCR WLCEAVRDSC EPVMQFFGFY WPEMLKCDKF PEGDVCIAMT PPNATEASKP
     QGTTVCPPCD NELKSEAIIE HLCASEFALR MKIKEVKKEN GDKKIVPKKK KPLKLGPIKK
     KDLKKLVLYL KNGADCPCHQ LDNLSHHFLI MGRKVKSQYL LTAIHKWDKK NKEFKNFMKK
     MKNHECPTFQ SVFK
//
ID   TRFL_HUMAN              Reviewed;         710 AA.
AC   P02788; A8K9U8; B2MV13; B7Z4X2; E7EQH5; O00756; Q16780; Q16785;
AC   Q16786; Q16789; Q5DSM0; Q8IU92; Q8IZH6; Q8TCD2; Q96KZ4; Q96KZ5;
AC   Q9H1Z3; Q9UCY5;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   24-JAN-2006, sequence version 6.
DT   17-FEB-2016, entry version 200.
DE   RecName: Full=Lactotransferrin;
DE            Short=Lactoferrin;
DE            EC=3.4.21.-;
DE   AltName: Full=Growth-inhibiting protein 12;
DE   AltName: Full=Talalactoferrin;
DE   Contains:
DE     RecName: Full=Lactoferricin-H;
DE              Short=Lfcin-H;
DE   Contains:
DE     RecName: Full=Kaliocin-1;
DE   Contains:
DE     RecName: Full=Lactoferroxin-A;
DE   Contains:
DE     RecName: Full=Lactoferroxin-B;
DE   Contains:
DE     RecName: Full=Lactoferroxin-C;
DE   Flags: Precursor;
GN   Name=LTF; Synonyms=GIG12, LF;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS ARG-22 INS;
RP   THR-148 AND CYS-422.
RC   TISSUE=Mammary gland;
RX   PubMed=2402455; DOI=10.1093/nar/18.17.5288;
RA   Rey M.W., Woloshuk S.L., de Boer H.A., Pieper F.R.;
RT   "Complete nucleotide sequence of human mammary gland lactoferrin.";
RL   Nucleic Acids Res. 18:5288-5288(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ARG-22 INS.
RC   TISSUE=Mammary gland;
RA   Cho Y.Y.;
RT   "Cloning of human lactoferrin gene and its polymorphism in normal and
RT   cancer cells.";
RL   Thesis (1994), Genetic Engineering Research Institute, South Korea.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND DELTALF), ALTERNATIVE
RP   SPLICING, AND TISSUE SPECIFICITY.
RC   TISSUE=Lung;
RX   PubMed=9122171; DOI=10.1073/pnas.94.6.2198;
RA   Siebert P.D., Huang B.C.;
RT   "Identification of an alternative form of human lactoferrin mRNA that
RT   is expressed differentially in normal tissues and tumor-derived cell
RT   lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:2198-2203(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS ARG-22 INS;
RP   THR-29; ARG-47 AND ASP-579.
RC   TISSUE=Mammary gland;
RX   PubMed=11702692;
RA   Cheng H., Chen X.Z., Huan L.D.;
RT   "cDNA cloning and sequence analysis of human lactoferrin.";
RL   Sheng Wu Gong Cheng Xue Bao 17:385-387(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), X-RAY CRYSTALLOGRAPHY (3.40
RP   ANGSTROMS) OF 22-710 IN COMPLEX WITH IRON AND CARBONATE, AND VARIANTS
RP   ARG-22 INS; THR-29; ARG-47 AND ASP-579.
RC   TISSUE=Seminal vesicle;
RX   PubMed=22900286;
RA   Kumar J., Weber W., Munchau S., Yadav S., Singh S.B., Saravanan K.,
RA   Paramasivam M., Sharma S., Kaur P., Bhushan A., Srinivasan A.,
RA   Betzel C., Singh T.P.;
RT   "Crystal structure of human seminal diferric lactoferrin at 3.4
RT   Angstrom resolution.";
RL   Indian J. Biochem. Biophys. 40:14-21(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 20-30,
RP   FUNCTION, AND VARIANTS ARG-22 INS; THR-29 AND ARG-47.
RC   TISSUE=Blood;
RX   PubMed=14573629; DOI=10.1128/IAI.71.11.6141-6147.2003;
RA   Velliyagounder K., Kaplan J.B., Furgang D., Legarda D., Diamond G.,
RA   Parkin R.E., Fine D.H.;
RT   "One of two human lactoferrin variants exhibits increased
RT   antibacterial and transcriptional activation activities and is
RT   associated with localized juvenile periodontitis.";
RL   Infect. Immun. 71:6141-6147(2003).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Bone marrow;
RA   Wei X., Han J., Rado T.A.;
RT   "Human neutrophil lactoferrin coding and 5' flanking region DNA
RT   sequences.";
RL   Submitted (FEB-1992) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS ARG-22 INS;
RP   THR-29 AND ARG-47.
RC   TISSUE=Prostate;
RA   Conneely O.M.;
RL   Submitted (MAY-1992) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS ARG-22 INS;
RP   THR-29; ARG-47 AND ASP-579.
RC   TISSUE=Mammary gland;
RA   Shi Y.-Q., Zhang Y., Zheng Y.-M.;
RL   Submitted (OCT-2002) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS ARG-22 INS AND
RP   CYS-422.
RA   Kim J.W.;
RT   "Identification of a growth inhibition gene.";
RL   Submitted (DEC-2003) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ARG-22 INS; THR-29 AND
RP   ARG-47.
RA   Allayous C., Marianne-Pepin T.;
RT   "Mutations in ELA2 and LTF genes.";
RL   Submitted (APR-2008) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND DELTALF), AND
RP   VARIANT ARG-22 INS.
RC   TISSUE=Lung, and Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R.,
RA   Buhay C.J., Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R.,
RA   Gunaratne P., Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V.,
RA   Hume J., Jackson A., Khan Z.M., Kovar-Smith C., Lewis L.R.,
RA   Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D., Wei S.,
RA   Wheeler D.A., Wright M.W., Worley K.C., Yuan Y., Zhang Z., Adams C.Q.,
RA   Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clendenning J., Clerc-Blankenburg K.P., Chen R., Chen Z., Davis C.,
RA   Delgado O., Dinh H.H., Dong W., Draper H., Ernst S., Fu G.,
RA   Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., Hao B.,
RA   Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., Jackson L.R.,
RA   Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., Liu J.,
RA   Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., Palmeiri A.,
RA   Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J.,
RA   Zhang X., Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H.,
RA   Reinhardt R., Naylor S.L., Yang H., Olson M., Weinstock G.,
RA   Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ARG-22
RP   INS.
RC   TISSUE=Prostate;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-15.
RX   PubMed=1480183; DOI=10.1210/me.6.11.1969;
RA   Teng C.T., Liu Y., Yang N., Walmer D., Panella T.;
RT   "Differential molecular mechanism of the estrogen action that
RT   regulates lactoferrin gene in human and mouse.";
RL   Mol. Endocrinol. 6:1969-1981(1992).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 3-710 (ISOFORM 1), AND VARIANT ARG-22
RP   INS.
RC   TISSUE=Mammary gland;
RX   PubMed=2374734; DOI=10.1093/nar/18.13.4013;
RA   Powell M.J., Ogden J.E.;
RT   "Nucleotide sequence of human lactoferrin cDNA.";
RL   Nucleic Acids Res. 18:4013-4013(1990).
RN   [17]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 6-710 (ISOFORM 1), AND VARIANT ARG-22
RP   INS.
RC   TISSUE=Mammary gland;
RA   Liang Q., Jimenez-Flores R., Richardson T.;
RT   "Molecular cloning and sequence analysis of human lactoferrin.";
RL   Submitted (DEC-1991) to the EMBL/GenBank/DDBJ databases.
RN   [18]
RP   PROTEIN SEQUENCE OF 20-710 (ISOFORM 1), AND DISULFIDE BONDS.
RX   PubMed=6510420; DOI=10.1111/j.1432-1033.1984.tb08607.x;
RA   Metz-Boutigue M.-H., Jolles J., Mazurier J., Schoentgen F.,
RA   Legrand D., Spik G., Montreuil J., Jolles P.;
RT   "Human lactotransferrin: amino acid sequence and structural
RT   comparisons with other transferrins.";
RL   Eur. J. Biochem. 145:659-676(1984).
RN   [19]
RP   PRELIMINARY PROTEIN SEQUENCE OF 20-72; 133-170; 256-277; 359-528 AND
RP   608-663 (ISOFORM 1).
RX   PubMed=6794640; DOI=10.1016/0005-2795(81)90016-7;
RA   Metz-Boutigue M.-H., Mazurier J., Jolles J., Spik G., Montreuil J.,
RA   Jolles P.;
RT   "The present state of the human lactotransferrin sequence. Study and
RT   alignment of the cyanogen bromide fragments and characterization of N-
RT   and C-terminal domains.";
RL   Biochim. Biophys. Acta 670:243-254(1981).
RN   [20]
RP   PROTEIN SEQUENCE OF 20-65 (ISOFORM 1), IDENTIFICATION OF LACTOFERRICIN
RP   PEPTIDE, FUNCTION, AND SYNTHESIS OF 36-58.
RC   TISSUE=Milk;
RX   PubMed=1599934; DOI=10.1016/0167-4838(92)90346-F;
RA   Bellamy W., Takase M., Yamauchi K., Wakabayashi H., Kawase K.,
RA   Tomita M.;
RT   "Identification of the bactericidal domain of lactoferrin.";
RL   Biochim. Biophys. Acta 1121:130-136(1992).
RN   [21]
RP   PROTEIN SEQUENCE OF 20-40 (ISOFORM 1), FUNCTION, GLYCOSAMINOGLYCAN
RP   BINDING, AND SYNTHESIS OF 20-51; 20-45 AND 25-51.
RC   TISSUE=Milk;
RX   PubMed=8089135;
RA   Mann D.M., Romm E., Migliorini M.;
RT   "Delineation of the glycosaminoglycan-binding site in the human
RT   inflammatory response protein lactoferrin.";
RL   J. Biol. Chem. 269:23661-23667(1994).
RN   [22]
RP   PROTEIN SEQUENCE OF 20-56 (ISOFORM 1).
RC   TISSUE=Seminal plasma;
RX   PubMed=8551695;
RA   Sato I.;
RT   "Characterization of the 84-kDa protein with ABH activity in human
RT   seminal plasma.";
RL   Nihon Hoigaku Zasshi 49:281-293(1995).
RN   [23]
RP   PROTEIN SEQUENCE OF 24-32; 38-43; 50-57 AND 59-67 (ISOFORM 1),
RP   STRUCTURE BY NMR OF 20-67 (LACTOFERRICIN), MASS SPECTROMETRY, AND
RP   DISULFIDE BONDS.
RC   TISSUE=Milk;
RX   PubMed=16048952; DOI=10.1128/AAC.49.8.3387-3395.2005;
RA   Hunter H.N., Demcoe A.R., Jenssen H., Gutteberg T.J., Vogel H.J.;
RT   "Human lactoferricin is partially folded in aqueous solution and is
RT   better stabilized in a membrane mimetic solvent.";
RL   Antimicrob. Agents Chemother. 49:3387-3395(2005).
RN   [24]
RP   PROTEIN SEQUENCE OF 38-57; 235-261; 509-525 AND 651-710, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Tear;
RX   PubMed=25946035; DOI=10.1021/acs.jproteome.5b00179;
RA   Azkargorta M., Soria J., Ojeda C., Guzman F., Acera A., Iloro I.,
RA   Suarez T., Elortza F.;
RT   "Human basal tear peptidome characterization by CID, HCD, and ETD
RT   followed by in silico and in vitro analyses for antimicrobial peptide
RT   identification.";
RL   J. Proteome Res. 14:2649-2658(2015).
RN   [25]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 236-710, AND VARIANT ASP-579.
RA   McCombie W.R., Wilson R., Chen E., Gibbs R., Zuo L., Johnson D.,
RA   Nhan M., Parnell L., Dedhia N., Ansari A., Mardis E., Schutz K.,
RA   Gnoj L., la Bastide M., Kaplan N., Greco T., Touchman J., Muzny D.,
RA   Chen C.N., Evans C., Fitzgerald M., See L.H., Tang M., Porcel B.M.,
RA   Dragan Y., Giacalone J., Pae A., Powell E., Solinsky K.A., Desilva U.,
RA   Diaz-Perez S., Zhou X., Yu Y., Watanabe M., Doggett N., Garcia D.,
RA   Sagripanti J.L.;
RL   Submitted (MAR-1997) to the EMBL/GenBank/DDBJ databases.
RN   [26]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 435-710.
RC   TISSUE=Myeloid;
RX   PubMed=3477300;
RA   Rado T.A., Wei X., Benz E.J. Jr.;
RT   "Isolation of lactoferrin cDNA from a human myeloid library and
RT   expression of mRNA during normal and leukemic myelopoiesis.";
RL   Blood 70:989-993(1987).
RN   [27]
RP   PROTEIN SEQUENCE OF 608-710.
RX   PubMed=7049727; DOI=10.1016/0014-5793(82)80229-9;
RA   Metz-Boutigue M.-H., Jolles J., Mazurier J., Spik G., Montreuil J.,
RA   Jolles P.;
RT   "An 88 amino acid long C-terminal sequence of human
RT   lactotransferrin.";
RL   FEBS Lett. 142:107-110(1982).
RN   [28]
RP   FUNCTION.
RX   PubMed=6802759;
RA   Arnold R.R., Russell J.E., Champion W.J., Brewer M., Gauthier J.J.;
RT   "Bactericidal activity of human lactoferrin: differentiation from the
RT   stasis of iron deprivation.";
RL   Infect. Immun. 35:792-799(1982).
RN   [29]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=2981589;
RA   Cramer E., Pryzwansky K.B., Villeval J.L., Testa U., Breton-Gorius J.;
RT   "Ultrastructural localization of lactoferrin and myeloperoxidase in
RT   human neutrophils by immunogold.";
RL   Blood 65:423-432(1985).
RN   [30]
RP   FUNCTION.
RX   PubMed=3169987;
RA   Ellison R.T. III, Giehl T.J., LaForce F.M.;
RT   "Damage of the outer membrane of enteric gram-negative bacteria by
RT   lactoferrin and transferrin.";
RL   Infect. Immun. 56:2774-2781(1988).
RN   [31]
RP   CHARACTERIZATION OF LACTOFERROXINS.
RX   PubMed=1369293;
RA   Tani F., Iio K., Chiba H., Yoshikawa M.;
RT   "Isolation and characterization of opioid antagonist peptides derived
RT   from human lactoferrin.";
RL   Agric. Biol. Chem. 54:1803-1810(1990).
RN   [32]
RP   FUNCTION, AND MUTAGENESIS OF 20-G--R-23.
RX   PubMed=9359845;
RA   van Berkel P.H., Geerts M.E., van Veen H.A., Mericskay M.,
RA   de Boer H.A., Nuijens J.H.;
RT   "N-terminal stretch Arg2, Arg3, Arg4 and Arg5 of human lactoferrin is
RT   essential for binding to heparin, bacterial lipopolysaccharide, human
RT   lysozyme and DNA.";
RL   Biochem. J. 328:145-151(1997).
RN   [33]
RP   FUNCTION.
RX   PubMed=11083624; DOI=10.1128/AAC.44.12.3257-3263.2000;
RA   Lupetti A., Paulusma-Annema A., Welling M.M., Senesi S.,
RA   van Dissel J.T., Nibbering P.H.;
RT   "Candidacidal activities of human lactoferrin peptides derived from
RT   the N terminus.";
RL   Antimicrob. Agents Chemother. 44:3257-3263(2000).
RN   [34]
RP   TISSUE SPECIFICITY.
RX   PubMed=10792619; DOI=10.1046/j.1523-1755.2000.00050.x;
RA   Abrink M., Larsson E., Gobl A., Hellman L.;
RT   "Expression of lactoferrin in the kidney: implications for innate
RT   immunity and iron metabolism.";
RL   Kidney Int. 57:2004-2010(2000).
RN   [35]
RP   FUNCTION, SYNTHESIS OF 20-29 AND 39-49, AND MUTAGENESIS OF
RP   20-GLY--ARG-22.
RX   PubMed=11179314; DOI=10.1128/IAI.69.3.1469-1476.2001;
RA   Nibbering P.H., Ravensbergen E., Welling M.M., van Berkel L.A.,
RA   van Berkel P.H., Pauwels E.K., Nuijens J.H.;
RT   "Human lactoferrin and peptides derived from its N terminus are highly
RT   effective against infections with antibiotic-resistant bacteria.";
RL   Infect. Immun. 69:1469-1476(2001).
RN   [36]
RP   FUNCTION.
RX   PubMed=12037568; DOI=10.1038/417552a;
RA   Singh P.K., Parsek M.R., Greenberg E.P., Welsh M.J.;
RT   "A component of innate immunity prevents bacterial biofilm
RT   development.";
RL   Nature 417:552-555(2002).
RN   [37]
RP   SUBCELLULAR LOCATION, AND ALTERNATIVE PROMOTER USAGE.
RX   PubMed=12565886; DOI=10.1016/S0006-291X(02)03077-2;
RA   Liu D., Wang X., Zhang Z., Teng C.T.;
RT   "An intronic alternative promoter of the human lactoferrin gene is
RT   activated by Ets.";
RL   Biochem. Biophys. Res. Commun. 301:472-479(2003).
RN   [38]
RP   FUNCTION, AND SYNTHESIS OF 36-58 AND 171-201 (KALIOCIN-1).
RX   PubMed=12693969; DOI=10.1023/A:1022657630698;
RA   Viejo-Diaz M., Andres M.T., Perez-Gil J., Sanchez M., Fierro J.F.;
RT   "Potassium efflux induced by a new lactoferrin-derived peptide
RT   mimicking the effect of native human lactoferrin on the bacterial
RT   cytoplasmic membrane.";
RL   Biochemistry (Mosc.) 68:217-227(2003).
RN   [39]
RP   FUNCTION AS A PROTEASE, AND MUTAGENESIS OF LYS-92; PRO-270 AND
RP   SER-278.
RX   PubMed=12535064; DOI=10.1046/j.1365-2958.2003.03327.x;
RA   Hendrixson D.R., Qiu J., Shewry S.C., Fink D.L., Petty S., Baker E.N.,
RA   Plaut A.G., St Geme J.W. III;
RT   "Human milk lactoferrin is a serine protease that cleaves Haemophilus
RT   surface proteins at arginine-rich sites.";
RL   Mol. Microbiol. 47:607-617(2003).
RN   [40]
RP   FUNCTION, AND SUBCELLULAR LOCATION (DELTALF).
RX   PubMed=15222485; DOI=10.1023/B:BIOM.0000027712.81056.13;
RA   Breton M., Mariller C., Benaissa M., Caillaux K., Browaeys E.,
RA   Masson M., Vilain J.P., Mazurier J., Pierce A.;
RT   "Expression of delta-lactoferrin induces cell cycle arrest.";
RL   BioMetals 17:325-329(2004).
RN   [41]
RP   FUNCTION.
RX   PubMed=15166119; DOI=10.1210/en.2003-1307;
RA   Cornish J., Callon K.E., Naot D., Palmano K.P., Banovic T., Bava U.,
RA   Watson M., Lin J.M., Tong P.C., Chen Q., Chan V.A., Reid H.E.,
RA   Fazzalari N., Baker H.M., Baker E.N., Haggarty N.W., Grey A.B.,
RA   Reid I.R.;
RT   "Lactoferrin is a potent regulator of bone cell activity and increases
RT   bone formation in vivo.";
RL   Endocrinology 145:4366-4374(2004).
RN   [42]
RP   FUNCTION.
RX   PubMed=16842782; DOI=10.1016/j.febslet.2006.06.091;
RA   Kim C.W., Son K.N., Choi S.Y., Kim J.;
RT   "Human lactoferrin upregulates expression of KDR/Flk-1 and stimulates
RT   VEGF-A-mediated endothelial cell proliferation and migration.";
RL   FEBS Lett. 580:4332-4336(2006).
RN   [43]
RP   FUNCTION.
RX   PubMed=17481742; DOI=10.1016/j.antiviral.2007.03.012;
RA   Mistry N., Drobni P., Naslund J., Sunkari V.G., Jenssen H.,
RA   Evander M.;
RT   "The anti-papillomavirus activity of human and bovine lactoferricin.";
RL   Antiviral Res. 75:258-265(2007).
RN   [44]
RP   IDENTIFICATION IN A COMPLEX WITH CLU; SEMG1 AND EPPIN.
RX   PubMed=17567961; DOI=10.1095/biolreprod.107.060194;
RA   Wang Z., Widgren E.E., Richardson R.T., O'Rand M.G.;
RT   "Characterization of an eppin protein complex from human semen and
RT   spermatozoa.";
RL   Biol. Reprod. 77:476-484(2007).
RN   [45]
RP   FUNCTION.
RX   PubMed=17079302; DOI=10.1128/JVI.01995-06;
RA   Johansson C., Jonsson M., Marttila M., Persson D., Fan X.L., Skog J.,
RA   Frangsmyr L., Wadell G., Arnberg N.;
RT   "Adenoviruses use lactoferrin as a bridge for CAR-independent binding
RT   to and infection of epithelial cells.";
RL   J. Virol. 81:954-963(2007).
RN   [46]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-156; ASN-497 AND ASN-642.
RC   TISSUE=Milk;
RX   PubMed=18780401; DOI=10.1002/pmic.200701057;
RA   Picariello G., Ferranti P., Mamone G., Roepstorff P., Addeo F.;
RT   "Identification of N-linked glycoproteins in human milk by hydrophilic
RT   interaction liquid chromatography and mass spectrometry.";
RL   Proteomics 8:3833-3847(2008).
RN   [47]
RP   FUNCTION.
RX   PubMed=19033648; DOI=10.1172/JCI36226;
RA   Bournazou I., Pound J.D., Duffin R., Bournazos S., Melville L.A.,
RA   Brown S.B., Rossi A.G., Gregory C.D.;
RT   "Apoptotic human cells inhibit migration of granulocytes via release
RT   of lactoferrin.";
RL   J. Clin. Invest. 119:20-32(2009).
RN   [48]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-497.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [49]
RP   FUNCTION, AND PTM.
RX   PubMed=20345905; DOI=10.1111/j.1742-4658.2010.07620.x;
RA   Ando K., Hasegawa K., Shindo K., Furusawa T., Fujino T., Kikugawa K.,
RA   Nakano H., Takeuchi O., Akira S., Akiyama T., Gohda J., Inoue J.,
RA   Hayakawa M.;
RT   "Human lactoferrin activates NF-kappaB through the Toll-like receptor
RT   4 pathway while it interferes with the lipopolysaccharide-stimulated
RT   TLR4 signaling.";
RL   FEBS J. 277:2051-2066(2010).
RN   [50]
RP   GLYCOSYLATION, PHOSPHORYLATION AT SER-10 (ISOFORM DELTALF), AND
RP   UBIQUITINATION (ISOFORM DELTALF).
RX   PubMed=20404350; DOI=10.1074/jbc.M109.080572;
RA   Hardiville S., Hoedt E., Mariller C., Benaissa M., Pierce A.;
RT   "O-GlcNAcylation/phosphorylation cycling at Ser10 controls both
RT   transcriptional activity and stability of delta-lactoferrin.";
RL   J. Biol. Chem. 285:19205-19218(2010).
RN   [51]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [52]
RP   FUNCTION AS A TRANSCRIPTION FACTOR (ISOFORM DELTALF), AND DNA-BINDING
RP   (ISOFORM DELTALF).
RX   PubMed=22320386; DOI=10.1139/o11-070;
RA   Mariller C., Hardiville S., Hoedt E., Huvent I., Pina-Canseco S.,
RA   Pierce A.;
RT   "Delta-lactoferrin, an intracellular lactoferrin isoform that acts as
RT   a transcription factor.";
RL   Biochem. Cell Biol. 90:307-319(2012).
RN   [53]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [54]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS), AND SEQUENCE REVISION.
RX   PubMed=2585506; DOI=10.1016/0022-2836(89)90602-5;
RA   Anderson B.F., Baker H.M., Norris G.E., Rice D.W., Baker E.N.;
RT   "Structure of human lactoferrin: crystallographic structure analysis
RT   and refinement at 2.8-A resolution.";
RL   J. Mol. Biol. 209:711-734(1989).
RN   [55]
RP   X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) OF 20-710.
RX   PubMed=1772635; DOI=10.1107/S0108768191008418;
RA   Norris G.E., Anderson B.F., Baker E.N.;
RT   "Molecular replacement solution of the structure of apolactoferrin, a
RT   protein displaying large-scale conformational change.";
RL   Acta Crystallogr. B 47:998-1004(1991).
RN   [56]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 20-710 IN COMPLEX WITH
RP   COPPER AND CARBONATE, AND GLYCOSYLATION AT ASN-156 AND ASN-497.
RX   PubMed=1581307; DOI=10.1021/bi00133a020;
RA   Smith C.A., Anderson B.F., Baker H.M., Baker E.N.;
RT   "Metal substitution in transferrins: the crystal structure of human
RT   copper-lactoferrin at 2.1-A resolution.";
RL   Biochemistry 31:4527-4533(1992).
RN   [57]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 21-352 IN COMPLEX WITH IRON
RP   AND CARBONATE, AND DISULFIDE BONDS.
RX   PubMed=8371268; DOI=10.1006/jmbi.1993.1462;
RA   Day C.L., Anderson B.F., Tweedie J.W., Baker E.N.;
RT   "Structure of the recombinant N-terminal lobe of human lactoferrin at
RT   2.0 A resolution.";
RL   J. Mol. Biol. 232:1084-1100(1993).
RN   [58]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 20-710 IN COMPLEX WITH
RP   COPPER AND OXALATE, AND GLYCOSYLATION AT ASN-156.
RX   PubMed=15299444; DOI=10.1107/S0907444994000491;
RA   Smith C.A., Anderson B.F., Baker H.M., Baker E.N.;
RT   "Structure of copper- and oxalate-substituted human lactoferrin at 2.0
RT   A resolution.";
RL   Acta Crystallogr. D 50:302-316(1994).
RN   [59]
RP   X-RAY CRYSTALLOGRAPHY (3.30 ANGSTROMS) OF 110-268, AND GLYCOSYLATION
RP   AT ASN-156.
RX   PubMed=8069634; DOI=10.1016/S0969-2126(00)00022-8;
RA   Bourne Y., Mazurier J., Legrand D., Rouge P., Montreuil J., Spik G.,
RA   Cambillau C.;
RT   "Structures of a legume lectin complexed with the human
RT   lactotransferrin N2 fragment, and with an isolated biantennary
RT   glycopeptide: role of the fucose moiety.";
RL   Structure 2:209-219(1994).
RN   [60]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 20-710 IN COMPLEX WITH IRON
RP   AND CARBONATE, AND GLYCOSYLATION AT ASN-156 AND ASN-497.
RX   PubMed=15299793; DOI=10.1107/S0907444994013521;
RA   Haridas M., Anderson B.F., Baker E.N.;
RT   "Structure of human diferric lactoferrin refined at 2.2-A
RT   resolution.";
RL   Acta Crystallogr. D 51:629-646(1995).
RN   [61]
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 20-710 IN COMPLEX WITH IRON
RP   AND OXALATE.
RX   PubMed=8703903; DOI=10.1021/bi960288y;
RA   Baker H.M., Anderson B.F., Brodie A.M., Shongwe M.S., Smith C.A.,
RA   Baker E.N.;
RT   "Anion binding by transferrins: importance of second-shell effects
RT   revealed by the crystal structure of oxalate-substituted diferric
RT   lactoferrin.";
RL   Biochemistry 35:9007-9013(1996).
RN   [62]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 22-352 OF MUTANTS GLU-140
RP   AND SER-140 IN COMPLEX WITH IRON AND CARBONATE, AND MUTAGENESIS OF
RP   ARG-140.
RX   PubMed=8931543; DOI=10.1021/bi961729g;
RA   Faber H.R., Baker C.J., Day C.L., Tweedie J.W., Baker E.N.;
RT   "Mutation of arginine 121 in lactoferrin destabilizes iron binding by
RT   disruption of anion binding: crystal structures of R121S and R121E
RT   mutants.";
RL   Biochemistry 35:14473-14479(1996).
RN   [63]
RP   X-RAY CRYSTALLOGRAPHY (2.05 ANGSTROMS) OF 21-352 OF MUTANT SER-79 IN
RP   COMPLEX WITH IRON AND CARBONATE, AND MUTAGENESIS OF ASP-79.
RX   PubMed=8594202; DOI=10.1006/jmbi.1996.0091;
RA   Faber H.R., Bland T., Day C.L., Norris G.E., Tweedie J.W., Baker E.N.;
RT   "Altered domain closure and iron binding in transferrins: the crystal
RT   structure of the Asp60Ser mutant of the amino-terminal half-molecule
RT   of human lactoferrin.";
RL   J. Mol. Biol. 256:352-363(1996).
RN   [64]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 21-353 OF MUTANT MET-272 IN
RP   COMPLEX WITH IRON AND CARBONATE, AND MUTAGENESIS OF HIS-272.
RX   PubMed=9003186; DOI=10.1021/bi961908y;
RA   Nicholson H., Anderson B.F., Bland T., Shewry S.C., Tweedie J.W.,
RA   Baker E.N.;
RT   "Mutagenesis of the histidine ligand in human lactoferrin: iron
RT   binding properties and crystal structure of the histidine-
RT   253-->methionine mutant.";
RL   Biochemistry 36:341-346(1997).
RN   [65]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 20-710.
RX   PubMed=10089508; DOI=10.1107/S0907444998004417;
RA   Jameson G.B., Anderson B.F., Norris G.E., Thomas D.H., Baker E.N.;
RT   "Structure of human apolactoferrin at 2.0 A resolution. Refinement and
RT   analysis of ligand-induced conformational change.";
RL   Acta Crystallogr. D 54:1319-1335(1998).
RN   [66]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) 20-710 IN COMPLEX WITH IRON AND
RP   CARBONATE.
RX   PubMed=10089347; DOI=10.1107/S0907444998011226;
RA   Sun X.L., Baker H.M., Shewry S.C., Jameson G.B., Baker E.N.;
RT   "Structure of recombinant human lactoferrin expressed in Aspergillus
RT   awamori.";
RL   Acta Crystallogr. D 55:403-407(1999).
RN   [67]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 21-348 OF MUTANT LYS-229 IN
RP   COMPLEX WITH IRON AND CARBONATE, AND MUTAGENESIS OF ARG-229.
RX   PubMed=10828980; DOI=10.1021/bi0001224;
RA   Peterson N.A., Anderson B.F., Jameson G.B., Tweedie J.W., Baker E.N.;
RT   "Crystal structure and iron-binding properties of the R210K mutant of
RT   the N-lobe of human lactoferrin: implications for iron release from
RT   transferrins.";
RL   Biochemistry 39:6625-6633(2000).
RN   [68]
RP   X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 21-710 IN COMPLEX WITH
RP   CERIUM AND CARBONATE.
RX   PubMed=11128996; DOI=10.1007/s007750000157;
RA   Baker H.M., Baker C.J., Smith C.A., Baker E.N.;
RT   "Metal substitution in transferrins: specific binding of cerium(IV)
RT   revealed by the crystal structure of cerium-substituted human
RT   lactoferrin.";
RL   J. Biol. Inorg. Chem. 5:692-698(2000).
RN   [69]
RP   X-RAY CRYSTALLOGRAPHY (3.00 ANGSTROMS) OF 21-351 OF MUTANT ASP-140,
RP   AND MUTAGENESIS OF ARG-140.
RX   PubMed=12037297; DOI=10.1107/S0907444902005127;
RA   Jameson G.B., Anderson B.F., Breyer W.A., Day C.L., Tweedie J.W.,
RA   Baker E.N.;
RT   "Structure of a domain-opened mutant (R121D) of the human lactoferrin
RT   N-lobe refined from a merohedrally twinned crystal form.";
RL   Acta Crystallogr. D 58:955-962(2002).
RN   [70]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 21-352 OF MUTANTS GLY-229;
RP   GLU-229 AND LEU-229 IN COMPLEX WITH IRON AND CARBONATE, AND
RP   MUTAGENESIS OF ARG-229.
RX   PubMed=12450380; DOI=10.1021/bi020443a;
RA   Peterson N.A., Arcus V.L., Anderson B.F., Tweedie J.W., Jameson G.B.,
RA   Baker E.N.;
RT   "'Dilysine trigger' in transferrins probed by mutagenesis of
RT   lactoferrin: crystal structures of the R210G, R210E, and R210L mutants
RT   of human lactoferrin.";
RL   Biochemistry 41:14167-14175(2002).
RN   [71]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 20-710 IN COMPLEX WITH IRON
RP   AND CARBONATE, AND GLYCOSYLATION AT ASN-156 AND ASN-497.
RA   Vikram P., Prem Kumar R., Singh N., Kumar J., Ethayathulla A.S.,
RA   Sharma S., Kaur P., Singh T.P.;
RT   "Structure of human diferric lactoferrin at 2.5A resolution using
RT   crystals grown at pH 6.5.";
RL   Submitted (MAR-2004) to the PDB data bank.
RN   [72]
RP   STRUCTURE BY NMR OF 39-49 IN COMPLEX WITH LIPOPOLYSACCHARIDE, AND
RP   SYNTHESIS OF 39-49.
RX   PubMed=15687491; DOI=10.1074/jbc.M500266200;
RA   Japelj B., Pristovsek P., Majerle A., Jerala R.;
RT   "Structural origin of endotoxin neutralization and antimicrobial
RT   activity of a lactoferrin-based peptide.";
RL   J. Biol. Chem. 280:16955-16961(2005).
RN   [73]
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 20-710 IN COMPLEX WITH IRON
RP   AND CARBONATE, GLYCOSYLATION AT ASN-156 AND ASN-497, AND VARIANT
RP   ASP-579.
RX   PubMed=16201406; DOI=10.1007/s11248-005-3233-0;
RA   Thomassen E.A., van Veen H.A., van Berkel P.H., Nuijens J.H.,
RA   Abrahams J.P.;
RT   "The protein structure of recombinant human lactoferrin produced in
RT   the milk of transgenic cows closely matches the structure of human
RT   milk-derived lactoferrin.";
RL   Transgenic Res. 14:397-405(2005).
RN   [74]
RP   X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 528-535 IN COMPLEX WITH
RP   PROTEINASE K.
RA   Singh A.K., Singh N., Sharma S., Bhushan A., Singh T.P.;
RT   "Crystal structure of the complex formed between proteinase K and a
RT   human lactoferrin fragment at 2.9 A resolution.";
RL   Submitted (MAY-2006) to the PDB data bank.
RN   [75]
RP   X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) OF 528-535 IN COMPLEX WITH
RP   PROTEINASE K.
RA   Prem Kumar R., Singh A.K., Singh N., Kaur P., Sharma S., Singh T.P.;
RT   "Crystal structure of proteinase K inhibited by a lactoferrin
RT   octapeptide Gly-Asp-Glu-Gln-Gly-Glu-Asn-Lys at 2.15 A resolution.";
RL   Submitted (JUN-2006) to the PDB data bank.
RN   [76]
RP   STRUCTURE BY NMR OF 39-49.
RX   PubMed=17263370; DOI=10.1021/ja067419v;
RA   Japelj B., Zorko M., Majerle A., Pristovsek P., Sanchez-Gomez S.,
RA   Martinez de Tejada G., Moriyon I., Blondelle S.E., Brandenburg K.,
RA   Andra J., Lohner K., Jerala R.;
RT   "The acyl group as the central element of the structural organization
RT   of antimicrobial lipopeptide.";
RL   J. Am. Chem. Soc. 129:1022-1023(2007).
RN   [77]
RP   X-RAY CRYSTALLOGRAPHY (2.91 ANGSTROMS) OF 21-362 IN COMPLEX WITH
RP   PNEUMOCOCCAL SURFACE PROTEIN A FRAGMENT; IRON AND CARBONATE.
RX   PubMed=17543335; DOI=10.1016/j.jmb.2007.04.075;
RA   Senkovich O., Cook W.J., Mirza S., Hollingshead S.K.,
RA   Protasevich I.I., Briles D.E., Chattopadhyay D.;
RT   "Structure of a complex of human lactoferrin N-lobe with pneumococcal
RT   surface protein a provides insight into microbial defense mechanism.";
RL   J. Mol. Biol. 370:701-713(2007).
RN   [78]
RP   VARIANTS THR-29 AND ARG-47.
RX   PubMed=9873069;
RA   Klintworth G.K., Sommer J.R., Obrian G., Han L., Ahmed M.N.,
RA   Qumsiyeh M.B., Lin P.-Y., Basti S., Reddy M.K., Kanai A., Hotta Y.,
RA   Sugar J., Kumaramanickavel G., Munier F., Schorderet D.F.,
RA   El Matri L., Iwata F., Kaiser-Kupfer M., Nagata M., Nakayasu K.,
RA   Hejtmancik J.F., Teng C.T.;
RT   "Familial subepithelial corneal amyloidosis (gelatinous drop-like
RT   corneal dystrophy): exclusion of linkage to lactoferrin gene.";
RL   Mol. Vis. 4:31-32(1998).
RN   [79]
RP   VARIANTS ARG-22 INS AND ARG-47.
RX   PubMed=22406253; DOI=10.1016/j.humimm.2012.02.014;
RA   Videm V., Dahl H., Walberg L.E., Wiseth R.;
RT   "Functional polymorphisms in the LTF gene and risk of coronary artery
RT   stenosis.";
RL   Hum. Immunol. 73:554-559(2012).
CC   -!- FUNCTION: Transferrins are iron binding transport proteins which
CC       can bind two Fe(3+) ions in association with the binding of an
CC       anion, usually bicarbonate.
CC   -!- FUNCTION: Lactotransferrin is a major iron-binding and
CC       multifunctional protein found in exocrine fluids such as breast
CC       milk and mucosal secretions. Has antimicrobial activity, which
CC       depends on the extracellular cation concentration. Antimicrobial
CC       properties include bacteriostasis, which is related to its ability
CC       to sequester free iron and thus inhibit microbial growth, as well
CC       as direct bactericidal properties leading to the release of
CC       lipopolysaccharides from the bacterial outer membrane. Can also
CC       prevent bacterial biofilm development in P.aeruginosa infection.
CC       Has weak antifungal activity against C.albicans. Has anabolic,
CC       differentiating and anti-apoptotic effects on osteoblasts and can
CC       also inhibit osteoclastogenesis, possibly playing a role in the
CC       regulation of bone growth. Promotes binding of species C
CC       adenoviruses to epithelial cells, promoting adenovirus infection.
CC       Can inhibit papillomavirus infections. Stimulates the TLR4
CC       signaling pathway leading to NF-kappa-B activation and subsequent
CC       pro-inflammatory cytokine production while also interfering with
CC       the lipopolysaccharide (LPS)-stimulated TLR4 signaling. Inhibits
CC       neutrophil granulocyte migration to sites of apoptosis, when
CC       secreted by apoptotic cells. Stimulates VEGFA-mediated endothelial
CC       cell migration and proliferation. Binds heparin, chondroitin
CC       sulfate and possibly other glycosaminoglycans (GAGs). Also binds
CC       specifically to pneumococcal surface protein A (pspA), the lipid A
CC       portion of bacterial lipopolysaccharide (LPS), lysozyme and DNA.
CC   -!- FUNCTION: Lactoferricin binds to the bacterial surface and is
CC       crucial for the bactericidal functions. Has some antiviral
CC       activity against papillomavirus infection. N-terminal region shows
CC       strong antifungal activity against C.albicans. Contains two BBXB
CC       heparin-binding consensus sequences that appear to form the
CC       predominate functional GAG-binding site.
CC   -!- FUNCTION: Kaliocin-1 has antimicrobial activity and is able to
CC       permeabilize different ions through liposomal membranes.
CC   -!- FUNCTION: Lactoferroxins A, B and C have opioid antagonist
CC       activity. Lactoferroxin A shows preference for mu-receptors, while
CC       lactoferroxin B and C have somewhat higher degrees of preference
CC       for kappa-receptors than for mu-receptors.
CC   -!- FUNCTION: The lactotransferrin transferrin-like domain 1 functions
CC       as a serine protease of the peptidase S60 family that cuts
CC       arginine rich regions. This function contributes to the
CC       antimicrobial activity.
CC   -!- FUNCTION: Isoform DeltaLf: transcription factor with
CC       antiproliferative properties and ability to induce cell cycle
CC       arrest. Binds to the DeltaLf response element found in the SKP1,
CC       BAX, DCPS, and SELH promoters.
CC   -!- CATALYTIC ACTIVITY: Preferential at -Arg-Ser-Arg-Arg-|- and -Arg-
CC       Arg-Ser-Arg-|-, and of Z-Phe-Arg-|-aminomethylcoumarin.
CC   -!- SUBUNIT: Monomer. Found in a complex with LTF, CLU, EPPIN and
CC       SEMG1. {ECO:0000269|PubMed:10089347, ECO:0000269|PubMed:10828980,
CC       ECO:0000269|PubMed:11128996, ECO:0000269|PubMed:12450380,
CC       ECO:0000269|PubMed:15299444, ECO:0000269|PubMed:15299793,
CC       ECO:0000269|PubMed:15687491, ECO:0000269|PubMed:1581307,
CC       ECO:0000269|PubMed:16201406, ECO:0000269|PubMed:17543335,
CC       ECO:0000269|PubMed:17567961, ECO:0000269|PubMed:22900286,
CC       ECO:0000269|PubMed:8371268, ECO:0000269|PubMed:8594202,
CC       ECO:0000269|PubMed:8703903, ECO:0000269|PubMed:8931543,
CC       ECO:0000269|PubMed:9003186, ECO:0000269|Ref.71,
CC       ECO:0000269|Ref.74, ECO:0000269|Ref.75}.
CC   -!- INTERACTION:
CC       P27958:- (xeno); NbExp=3; IntAct=EBI-1058602, EBI-6904259;
CC       P62157:CALM (xeno); NbExp=2; IntAct=EBI-1058602, EBI-397403;
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Secreted. Cytoplasmic granule.
CC       Note=Secreted into most exocrine fluids by various endothelial
CC       cells. Stored in the secondary granules of neutrophils.
CC   -!- SUBCELLULAR LOCATION: Isoform DeltaLf: Cytoplasm. Nucleus.
CC       Note=Mainly localized in the cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage; Named isoforms=2;
CC       Name=1;
CC         IsoId=P02788-1; Sequence=Displayed;
CC       Name=DeltaLf; Synonyms=Delta-lactoferrin;
CC         IsoId=P02788-2; Sequence=VSP_044308;
CC         Note=Contains a phosphoserine at position 10. Glycosylated at
CC         Ser-10. O-GlcNAcylation at Ser-10 inhibits DNA binding and
CC         negatively regulates DeltaLf transcriptional activity, whereas
CC         phosphorylation activates it. Phosphorylation at Ser-10 also
CC         promotes proteasomal degradation.;
CC   -!- TISSUE SPECIFICITY: High levels are found in saliva and tears,
CC       intermediate levels in serum and plasma, and low levels in urine.
CC       In kidney, detected in the distal collecting tubules in the
CC       medulla but not in the cortical region or in blood vessels.
CC       Detected in peripheral blood neutrophils (at protein level).
CC       Isoform 1 and isoform DeltaLf are expressed in breast, prostate,
CC       spleen, pancreas, kidney, small intestine, lung, skeletal muscle,
CC       uterus, thymus and fetal liver. Isoform 1 is expressed in brain,
CC       testis and peripheral blood leukocytes; isoform DeltaLf is barely
CC       detectable in these tissues. Isoform DeltaLf is expressed in
CC       placenta, liver and ovary; isoform 1 is barely detectable in these
CC       tissues. In kidney, isoform 1 is expressed at high levels in the
CC       collecting tubules of the medulla but at very low levels in the
CC       cortex. {ECO:0000269|PubMed:10792619, ECO:0000269|PubMed:2981589,
CC       ECO:0000269|PubMed:9122171}.
CC   -!- PTM: Isoform DeltaLf: Ubiquitinated at Lys-379 and Lys-391.
CC   -!- PTM: Poly-N-acetyllactosaminic carbohydrate moiety seems to be
CC       needed for TLR4 activation.
CC   -!- MASS SPECTROMETRY: Mass=5737.8; Method=Electrospray; Range=20-67;
CC       Evidence={ECO:0000269|PubMed:16048952};
CC   -!- POLYMORPHISM: The sequence shown corresponds to the reference
CC       genome sequence and is likely to represent the minor allele,
CC       whereas most publications refer to the longer sequence containing
CC       variant Arg-22 ins. Insertion of the additional arginine in
CC       variant Arg-22 ins creates an N-terminal basic cluster of four
CC       arginines, all of which appear to be important for the full
CC       functionality of the protein, including bactericidal and
CC       antifungal activities as well as binding to glycosaminoglycans,
CC       pspA, LPS, lysozyme and DNA.
CC   -!- SIMILARITY: Belongs to the transferrin family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00741}.
CC   -!- SIMILARITY: Contains 2 transferrin-like domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00741}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Lactotransferrin entry;
CC       URL="https://en.wikipedia.org/wiki/Lactotransferrin";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X53961; CAA37914.1; -; mRNA.
DR   EMBL; U07643; AAB60324.1; -; mRNA.
DR   EMBL; AF332168; AAG48753.1; -; mRNA.
DR   EMBL; AY178998; AAN75578.2; -; mRNA.
DR   EMBL; AY137470; AAN11304.1; -; mRNA.
DR   EMBL; M73700; AAA59479.1; -; Genomic_DNA.
DR   EMBL; M93150; AAA36159.1; -; mRNA.
DR   EMBL; AY165046; AAN63998.1; -; mRNA.
DR   EMBL; AY493417; AAS72878.1; -; mRNA.
DR   EMBL; EU622050; ACC95966.1; -; Genomic_DNA.
DR   EMBL; AK292813; BAF85502.1; -; mRNA.
DR   EMBL; AK298035; BAH12708.1; -; mRNA.
DR   EMBL; AC098613; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC015822; AAH15822.1; -; mRNA.
DR   EMBL; BC015823; AAH15823.1; -; mRNA.
DR   EMBL; BC022347; AAH22347.1; -; mRNA.
DR   EMBL; S52659; AAB24877.1; -; Genomic_DNA.
DR   EMBL; X52941; CAA37116.1; -; mRNA.
DR   EMBL; M83202; AAA59511.1; -; mRNA.
DR   EMBL; M83205; AAA58656.1; -; mRNA.
DR   EMBL; U95626; AAB57795.1; -; Genomic_DNA.
DR   EMBL; M18642; AAA86665.1; -; mRNA.
DR   CCDS; CCDS33747.1; -. [P02788-1]
DR   CCDS; CCDS56251.1; -. [P02788-2]
DR   PIR; G01394; TFHUL.
DR   RefSeq; NP_001186078.1; NM_001199149.1. [P02788-2]
DR   RefSeq; NP_002334.2; NM_002343.4. [P02788-1]
DR   UniGene; Hs.529517; -.
DR   PDB; 1B0L; X-ray; 2.20 A; A=20-710.
DR   PDB; 1BKA; X-ray; 2.40 A; A=20-710.
DR   PDB; 1CB6; X-ray; 2.00 A; A=20-710.
DR   PDB; 1DSN; X-ray; 2.05 A; A=21-352.
DR   PDB; 1EH3; X-ray; 2.00 A; A=21-352.
DR   PDB; 1FCK; X-ray; 2.20 A; A=21-710.
DR   PDB; 1H43; X-ray; 2.20 A; A=21-352.
DR   PDB; 1H44; X-ray; 2.00 A; A=21-352.
DR   PDB; 1H45; X-ray; 1.95 A; A=21-352.
DR   PDB; 1HSE; X-ray; 2.20 A; A=21-353.
DR   PDB; 1L5T; X-ray; 3.00 A; A/B=21-351.
DR   PDB; 1LCF; X-ray; 2.00 A; A=20-710.
DR   PDB; 1LCT; X-ray; 2.00 A; A=21-352.
DR   PDB; 1LFG; X-ray; 2.20 A; A=20-710.
DR   PDB; 1LFH; X-ray; 2.80 A; A=20-710.
DR   PDB; 1LFI; X-ray; 2.10 A; A=20-710.
DR   PDB; 1LGB; X-ray; 3.30 A; C=110-268.
DR   PDB; 1N76; X-ray; 3.40 A; A=21-710.
DR   PDB; 1SQY; X-ray; 2.50 A; A=20-710.
DR   PDB; 1U62; NMR; -; A=39-44.
DR   PDB; 1VFD; X-ray; 2.50 A; A=20-349.
DR   PDB; 1VFE; X-ray; 2.30 A; A=20-352.
DR   PDB; 1XV4; NMR; -; A=39-44.
DR   PDB; 1XV7; NMR; -; A=39-44.
DR   PDB; 1Z6V; NMR; -; A=21-67.
DR   PDB; 1Z6W; NMR; -; A=21-67.
DR   PDB; 2BJJ; X-ray; 2.40 A; X=21-710.
DR   PDB; 2DP4; X-ray; 2.90 A; I=528-535.
DR   PDB; 2GMC; NMR; -; A=39-44.
DR   PDB; 2GMD; NMR; -; A=39-44.
DR   PDB; 2HD4; X-ray; 2.15 A; B=528-535.
DR   PDB; 2PMS; X-ray; 2.91 A; A/B=21-362.
DR   PDBsum; 1B0L; -.
DR   PDBsum; 1BKA; -.
DR   PDBsum; 1CB6; -.
DR   PDBsum; 1DSN; -.
DR   PDBsum; 1EH3; -.
DR   PDBsum; 1FCK; -.
DR   PDBsum; 1H43; -.
DR   PDBsum; 1H44; -.
DR   PDBsum; 1H45; -.
DR   PDBsum; 1HSE; -.
DR   PDBsum; 1L5T; -.
DR   PDBsum; 1LCF; -.
DR   PDBsum; 1LCT; -.
DR   PDBsum; 1LFG; -.
DR   PDBsum; 1LFH; -.
DR   PDBsum; 1LFI; -.
DR   PDBsum; 1LGB; -.
DR   PDBsum; 1N76; -.
DR   PDBsum; 1SQY; -.
DR   PDBsum; 1U62; -.
DR   PDBsum; 1VFD; -.
DR   PDBsum; 1VFE; -.
DR   PDBsum; 1XV4; -.
DR   PDBsum; 1XV7; -.
DR   PDBsum; 1Z6V; -.
DR   PDBsum; 1Z6W; -.
DR   PDBsum; 2BJJ; -.
DR   PDBsum; 2DP4; -.
DR   PDBsum; 2GMC; -.
DR   PDBsum; 2GMD; -.
DR   PDBsum; 2HD4; -.
DR   PDBsum; 2PMS; -.
DR   DisProt; DP00616; -.
DR   ProteinModelPortal; P02788; -.
DR   SMR; P02788; 20-710.
DR   BioGrid; 110235; 31.
DR   DIP; DIP-41354N; -.
DR   IntAct; P02788; 9.
DR   MINT; MINT-1511753; -.
DR   STRING; 9606.ENSP00000231751; -.
DR   DrugBank; DB04743; Nimesulide.
DR   DrugBank; DB08439; Parecoxib.
DR   Allergome; 1384; Hom s LF.
DR   MEROPS; S60.001; -.
DR   iPTMnet; P02788; -.
DR   PhosphoSite; P02788; -.
DR   UniCarbKB; P02788; -.
DR   BioMuta; LTF; -.
DR   DMDM; 85700158; -.
DR   PaxDb; P02788; -.
DR   PRIDE; P02788; -.
DR   DNASU; 4057; -.
DR   Ensembl; ENST00000231751; ENSP00000231751; ENSG00000012223. [P02788-1]
DR   Ensembl; ENST00000426532; ENSP00000405719; ENSG00000012223. [P02788-2]
DR   GeneID; 4057; -.
DR   KEGG; hsa:4057; -.
DR   UCSC; uc003cpq.3; human. [P02788-1]
DR   CTD; 4057; -.
DR   GeneCards; LTF; -.
DR   HGNC; HGNC:6720; LTF.
DR   HPA; CAB008646; -.
DR   HPA; CAB016201; -.
DR   HPA; HPA057177; -.
DR   HPA; HPA059976; -.
DR   MIM; 150210; gene.
DR   MIM; 245480; phenotype.
DR   neXtProt; NX_P02788; -.
DR   PharmGKB; PA30482; -.
DR   eggNOG; ENOG410IEAI; Eukaryota.
DR   eggNOG; ENOG410XQ36; LUCA.
DR   GeneTree; ENSGT00390000001619; -.
DR   HOVERGEN; HBG000055; -.
DR   InParanoid; P02788; -.
DR   KO; K17283; -.
DR   OMA; RPVEGYL; -.
DR   OrthoDB; EOG7D59N7; -.
DR   PhylomeDB; P02788; -.
DR   TreeFam; TF324013; -.
DR   Reactome; R-HSA-1222449; Mtb iron assimilation by chelation.
DR   Reactome; R-HSA-1222556; ROS, RNS production in response to bacteria.
DR   Reactome; R-HSA-977225; Amyloid fiber formation.
DR   ChiTaRS; LTF; human.
DR   EvolutionaryTrace; P02788; -.
DR   GeneWiki; Lactoferrin; -.
DR   GenomeRNAi; 4057; -.
DR   NextBio; 15896; -.
DR   PRO; PR:P02788; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; P02788; -.
DR   ExpressionAtlas; P02788; baseline and differential.
DR   Genevisible; P02788; HS.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IMP:AgBase.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0097013; C:phagocytic vesicle lumen; TAS:Reactome.
DR   GO; GO:0043234; C:protein complex; IDA:UniProtKB.
DR   GO; GO:0030141; C:secretory granule; IDA:MGI.
DR   GO; GO:0042581; C:specific granule; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0008201; F:heparin binding; IDA:MGI.
DR   GO; GO:0005506; F:iron ion binding; IDA:UniProtKB.
DR   GO; GO:0043539; F:protein serine/threonine kinase activator activity; IDA:UniProtKB.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; TAS:ProtInc.
DR   GO; GO:0019731; P:antibacterial humoral response; IDA:UniProtKB.
DR   GO; GO:0019732; P:antifungal humoral response; IDA:UniProtKB.
DR   GO; GO:0060349; P:bone morphogenesis; IDA:UniProtKB.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0006959; P:humoral immune response; TAS:ProtInc.
DR   GO; GO:0002227; P:innate immune response in mucosa; IDA:UniProtKB.
DR   GO; GO:0051701; P:interaction with host; TAS:Reactome.
DR   GO; GO:0006811; P:ion transport; IEA:UniProtKB-KW.
DR   GO; GO:0033214; P:iron assimilation by chelation and transport; TAS:Reactome.
DR   GO; GO:0044793; P:negative regulation by host of viral process; IMP:AgBase.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; ISS:UniProtKB.
DR   GO; GO:0032780; P:negative regulation of ATPase activity; IMP:AgBase.
DR   GO; GO:0031665; P:negative regulation of lipopolysaccharide-mediated signaling pathway; IDA:UniProtKB.
DR   GO; GO:2001205; P:negative regulation of osteoclast development; ISS:UniProtKB.
DR   GO; GO:1900229; P:negative regulation of single-species biofilm formation in or on host organism; IDA:UniProtKB.
DR   GO; GO:2000308; P:negative regulation of tumor necrosis factor (ligand) superfamily member 11 production; ISS:UniProtKB.
DR   GO; GO:0045071; P:negative regulation of viral genome replication; IMP:AgBase.
DR   GO; GO:0048525; P:negative regulation of viral process; IMP:AgBase.
DR   GO; GO:0001503; P:ossification; IEA:UniProtKB-KW.
DR   GO; GO:0090382; P:phagosome maturation; TAS:Reactome.
DR   GO; GO:1900159; P:positive regulation of bone mineralization involved in bone maturation; ISS:UniProtKB.
DR   GO; GO:1902732; P:positive regulation of chondrocyte proliferation; IDA:UniProtKB.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IDA:UniProtKB.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; IDA:UniProtKB.
DR   GO; GO:0033690; P:positive regulation of osteoblast proliferation; IDA:UniProtKB.
DR   GO; GO:0071902; P:positive regulation of protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0034145; P:positive regulation of toll-like receptor 4 signaling pathway; IMP:UniProtKB.
DR   GO; GO:0001817; P:regulation of cytokine production; IDA:UniProtKB.
DR   GO; GO:0032680; P:regulation of tumor necrosis factor production; IDA:UniProtKB.
DR   GO; GO:0052572; P:response to host immune response; TAS:Reactome.
DR   GO; GO:0001895; P:retina homeostasis; IEP:UniProtKB.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   InterPro; IPR030684; Lactotransferrin.
DR   InterPro; IPR016357; Transferrin.
DR   InterPro; IPR001156; Transferrin-like_dom.
DR   InterPro; IPR018195; Transferrin_Fe_BS.
DR   Pfam; PF00405; Transferrin; 2.
DR   PIRSF; PIRSF500683; Lactotransferrin; 1.
DR   PIRSF; PIRSF002549; Transferrin; 1.
DR   PRINTS; PR00422; TRANSFERRIN.
DR   SMART; SM00094; TR_FER; 2.
DR   PROSITE; PS00205; TRANSFERRIN_LIKE_1; 2.
DR   PROSITE; PS00206; TRANSFERRIN_LIKE_2; 2.
DR   PROSITE; PS00207; TRANSFERRIN_LIKE_3; 2.
DR   PROSITE; PS51408; TRANSFERRIN_LIKE_4; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative promoter usage; Antibiotic; Antimicrobial;
KW   Complete proteome; Cytoplasm; Direct protein sequencing;
KW   Disulfide bond; DNA-binding; Glycoprotein; Heparin-binding; Hydrolase;
KW   Immunity; Ion transport; Iron; Iron transport; Metal-binding; Nucleus;
KW   Osteogenesis; Phosphoprotein; Polymorphism; Protease;
KW   Reference proteome; Repeat; Secreted; Serine protease; Signal;
KW   Transcription; Transcription regulation; Transport; Ubl conjugation.
FT   SIGNAL        1     19       {ECO:0000269|PubMed:14573629}.
FT   CHAIN        20    710       Lactotransferrin.
FT                                /FTId=PRO_0000035732.
FT   PEPTIDE      20     67       Lactoferricin-H.
FT                                /FTId=PRO_0000422770.
FT   PEPTIDE     171    201       Kaliocin-1.
FT                                /FTId=PRO_0000035733.
FT   PEPTIDE     338    343       Lactoferroxin-A.
FT                                /FTId=PRO_0000035734.
FT   PEPTIDE     543    547       Lactoferroxin-B.
FT                                /FTId=PRO_0000035735.
FT   PEPTIDE     680    686       Lactoferroxin-C.
FT                                /FTId=PRO_0000035736.
FT   DOMAIN       25    352       Transferrin-like 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00741}.
FT   DOMAIN      364    695       Transferrin-like 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00741}.
FT   REGION       20     29       Bactericidal and antifungal activity.
FT   REGION       20     24       Critical for glycosaminoglycan, lipid A,
FT                                lysozyme and DNA binding.
FT   REGION       21     22       Important for full bactericidal and
FT                                antifungal activities.
FT   REGION       39     49       Bactericidal and antifungal activity.
FT   REGION       39     49       Interaction with lipopolysaccharide.
FT   REGION       39     46       Interaction with pspA.
FT   REGION       46     51       Involved in glycosaminoglycan binding.
FT   REGION       57     58       Interaction with pspA.
FT   ACT_SITE     92     92       {ECO:0000305}.
FT   ACT_SITE    278    278       Nucleophile. {ECO:0000305}.
FT   METAL        79     79       Iron or copper 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00741,
FT                                ECO:0000269|PubMed:10089347,
FT                                ECO:0000269|PubMed:10828980,
FT                                ECO:0000269|PubMed:12450380,
FT                                ECO:0000269|PubMed:15299793,
FT                                ECO:0000269|PubMed:16201406,
FT                                ECO:0000269|PubMed:17543335,
FT                                ECO:0000269|PubMed:22900286,
FT                                ECO:0000269|PubMed:8371268,
FT                                ECO:0000269|PubMed:8594202,
FT                                ECO:0000269|PubMed:8703903,
FT                                ECO:0000269|PubMed:8931543,
FT                                ECO:0000269|PubMed:9003186,
FT                                ECO:0000269|Ref.71}.
FT   METAL       111    111       Iron or copper 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00741,
FT                                ECO:0000269|PubMed:10089347,
FT                                ECO:0000269|PubMed:10828980,
FT                                ECO:0000269|PubMed:12450380,
FT                                ECO:0000269|PubMed:15299793,
FT                                ECO:0000269|PubMed:16201406,
FT                                ECO:0000269|PubMed:17543335,
FT                                ECO:0000269|PubMed:22900286,
FT                                ECO:0000269|PubMed:8371268,
FT                                ECO:0000269|PubMed:8594202,
FT                                ECO:0000269|PubMed:8703903,
FT                                ECO:0000269|PubMed:8931543,
FT                                ECO:0000269|PubMed:9003186,
FT                                ECO:0000269|Ref.71}.
FT   METAL       211    211       Iron or copper 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00741,
FT                                ECO:0000269|PubMed:10089347,
FT                                ECO:0000269|PubMed:10828980,
FT                                ECO:0000269|PubMed:12450380,
FT                                ECO:0000269|PubMed:15299793,
FT                                ECO:0000269|PubMed:16201406,
FT                                ECO:0000269|PubMed:17543335,
FT                                ECO:0000269|PubMed:22900286,
FT                                ECO:0000269|PubMed:8371268,
FT                                ECO:0000269|PubMed:8594202,
FT                                ECO:0000269|PubMed:8703903,
FT                                ECO:0000269|PubMed:8931543,
FT                                ECO:0000269|PubMed:9003186,
FT                                ECO:0000269|Ref.71}.
FT   METAL       272    272       Iron or copper 1; via tele nitrogen.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00741,
FT                                ECO:0000269|PubMed:10089347,
FT                                ECO:0000269|PubMed:10828980,
FT                                ECO:0000269|PubMed:12450380,
FT                                ECO:0000269|PubMed:15299793,
FT                                ECO:0000269|PubMed:16201406,
FT                                ECO:0000269|PubMed:17543335,
FT                                ECO:0000269|PubMed:22900286,
FT                                ECO:0000269|PubMed:8371268,
FT                                ECO:0000269|PubMed:8594202,
FT                                ECO:0000269|PubMed:8703903,
FT                                ECO:0000269|PubMed:8931543,
FT                                ECO:0000269|PubMed:9003186,
FT                                ECO:0000269|Ref.71}.
FT   METAL       414    414       Iron or copper 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00741,
FT                                ECO:0000269|PubMed:10089347,
FT                                ECO:0000269|PubMed:10828980,
FT                                ECO:0000269|PubMed:12450380,
FT                                ECO:0000269|PubMed:15299793,
FT                                ECO:0000269|PubMed:16201406,
FT                                ECO:0000269|PubMed:17543335,
FT                                ECO:0000269|PubMed:22900286,
FT                                ECO:0000269|PubMed:8371268,
FT                                ECO:0000269|PubMed:8594202,
FT                                ECO:0000269|PubMed:8703903,
FT                                ECO:0000269|PubMed:8931543,
FT                                ECO:0000269|PubMed:9003186,
FT                                ECO:0000269|Ref.71}.
FT   METAL       454    454       Iron or copper 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00741,
FT                                ECO:0000269|PubMed:10089347,
FT                                ECO:0000269|PubMed:10828980,
FT                                ECO:0000269|PubMed:12450380,
FT                                ECO:0000269|PubMed:15299793,
FT                                ECO:0000269|PubMed:16201406,
FT                                ECO:0000269|PubMed:17543335,
FT                                ECO:0000269|PubMed:22900286,
FT                                ECO:0000269|PubMed:8371268,
FT                                ECO:0000269|PubMed:8594202,
FT                                ECO:0000269|PubMed:8703903,
FT                                ECO:0000269|PubMed:8931543,
FT                                ECO:0000269|PubMed:9003186,
FT                                ECO:0000269|Ref.71}.
FT   METAL       547    547       Iron or copper 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00741,
FT                                ECO:0000269|PubMed:10089347,
FT                                ECO:0000269|PubMed:10828980,
FT                                ECO:0000269|PubMed:12450380,
FT                                ECO:0000269|PubMed:15299793,
FT                                ECO:0000269|PubMed:16201406,
FT                                ECO:0000269|PubMed:17543335,
FT                                ECO:0000269|PubMed:22900286,
FT                                ECO:0000269|PubMed:8371268,
FT                                ECO:0000269|PubMed:8594202,
FT                                ECO:0000269|PubMed:8703903,
FT                                ECO:0000269|PubMed:8931543,
FT                                ECO:0000269|PubMed:9003186,
FT                                ECO:0000269|Ref.71}.
FT   METAL       616    616       Iron or copper 2; via tele nitrogen.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00741,
FT                                ECO:0000269|PubMed:10089347,
FT                                ECO:0000269|PubMed:10828980,
FT                                ECO:0000269|PubMed:12450380,
FT                                ECO:0000269|PubMed:15299793,
FT                                ECO:0000269|PubMed:16201406,
FT                                ECO:0000269|PubMed:17543335,
FT                                ECO:0000269|PubMed:22900286,
FT                                ECO:0000269|PubMed:8371268,
FT                                ECO:0000269|PubMed:8594202,
FT                                ECO:0000269|PubMed:8703903,
FT                                ECO:0000269|PubMed:8931543,
FT                                ECO:0000269|PubMed:9003186,
FT                                ECO:0000269|Ref.71}.
FT   BINDING      23     23       PspA.
FT   BINDING      32     32       PspA.
FT   BINDING     136    136       Carbonate or oxalate 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00741,
FT                                ECO:0000269|PubMed:10089347,
FT                                ECO:0000269|PubMed:10828980,
FT                                ECO:0000269|PubMed:11128996,
FT                                ECO:0000269|PubMed:12450380,
FT                                ECO:0000269|PubMed:15299793,
FT                                ECO:0000269|PubMed:1581307,
FT                                ECO:0000269|PubMed:16201406,
FT                                ECO:0000269|PubMed:17543335,
FT                                ECO:0000269|PubMed:22900286,
FT                                ECO:0000269|PubMed:8371268,
FT                                ECO:0000269|PubMed:8594202,
FT                                ECO:0000269|PubMed:8931543,
FT                                ECO:0000269|PubMed:9003186,
FT                                ECO:0000269|Ref.71}.
FT   BINDING     140    140       Carbonate or oxalate 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00741,
FT                                ECO:0000269|PubMed:10089347,
FT                                ECO:0000269|PubMed:10828980,
FT                                ECO:0000269|PubMed:11128996,
FT                                ECO:0000269|PubMed:12450380,
FT                                ECO:0000269|PubMed:15299793,
FT                                ECO:0000269|PubMed:1581307,
FT                                ECO:0000269|PubMed:16201406,
FT                                ECO:0000269|PubMed:17543335,
FT                                ECO:0000269|PubMed:22900286,
FT                                ECO:0000269|PubMed:8371268,
FT                                ECO:0000269|PubMed:8594202,
FT                                ECO:0000269|PubMed:8931543,
FT                                ECO:0000269|PubMed:9003186,
FT                                ECO:0000269|Ref.71}.
FT   BINDING     142    142       Carbonate or oxalate 1; via amide
FT                                nitrogen. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00741,
FT                                ECO:0000269|PubMed:10089347,
FT                                ECO:0000269|PubMed:10828980,
FT                                ECO:0000269|PubMed:11128996,
FT                                ECO:0000269|PubMed:12450380,
FT                                ECO:0000269|PubMed:15299793,
FT                                ECO:0000269|PubMed:1581307,
FT                                ECO:0000269|PubMed:16201406,
FT                                ECO:0000269|PubMed:17543335,
FT                                ECO:0000269|PubMed:22900286,
FT                                ECO:0000269|PubMed:8371268,
FT                                ECO:0000269|PubMed:8594202,
FT                                ECO:0000269|PubMed:8931543,
FT                                ECO:0000269|PubMed:9003186,
FT                                ECO:0000269|Ref.71}.
FT   BINDING     143    143       Carbonate or oxalate 1; via amide
FT                                nitrogen. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00741,
FT                                ECO:0000269|PubMed:10089347,
FT                                ECO:0000269|PubMed:10828980,
FT                                ECO:0000269|PubMed:11128996,
FT                                ECO:0000269|PubMed:12450380,
FT                                ECO:0000269|PubMed:15299793,
FT                                ECO:0000269|PubMed:1581307,
FT                                ECO:0000269|PubMed:16201406,
FT                                ECO:0000269|PubMed:17543335,
FT                                ECO:0000269|PubMed:22900286,
FT                                ECO:0000269|PubMed:8371268,
FT                                ECO:0000269|PubMed:8594202,
FT                                ECO:0000269|PubMed:8931543,
FT                                ECO:0000269|PubMed:9003186,
FT                                ECO:0000269|Ref.71}.
FT   BINDING     480    480       Carbonate or oxalate 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00741,
FT                                ECO:0000269|PubMed:10089347,
FT                                ECO:0000269|PubMed:10828980,
FT                                ECO:0000269|PubMed:11128996,
FT                                ECO:0000269|PubMed:12450380,
FT                                ECO:0000269|PubMed:15299793,
FT                                ECO:0000269|PubMed:1581307,
FT                                ECO:0000269|PubMed:16201406,
FT                                ECO:0000269|PubMed:17543335,
FT                                ECO:0000269|PubMed:22900286,
FT                                ECO:0000269|PubMed:8371268,
FT                                ECO:0000269|PubMed:8594202,
FT                                ECO:0000269|PubMed:8931543,
FT                                ECO:0000269|PubMed:9003186,
FT                                ECO:0000269|Ref.71}.
FT   BINDING     484    484       Carbonate or oxalate 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00741,
FT                                ECO:0000269|PubMed:10089347,
FT                                ECO:0000269|PubMed:10828980,
FT                                ECO:0000269|PubMed:11128996,
FT                                ECO:0000269|PubMed:12450380,
FT                                ECO:0000269|PubMed:15299793,
FT                                ECO:0000269|PubMed:1581307,
FT                                ECO:0000269|PubMed:16201406,
FT                                ECO:0000269|PubMed:17543335,
FT                                ECO:0000269|PubMed:22900286,
FT                                ECO:0000269|PubMed:8371268,
FT                                ECO:0000269|PubMed:8594202,
FT                                ECO:0000269|PubMed:8931543,
FT                                ECO:0000269|PubMed:9003186,
FT                                ECO:0000269|Ref.71}.
FT   BINDING     486    486       Carbonate or oxalate 2; via amide
FT                                nitrogen. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00741,
FT                                ECO:0000269|PubMed:10089347,
FT                                ECO:0000269|PubMed:10828980,
FT                                ECO:0000269|PubMed:11128996,
FT                                ECO:0000269|PubMed:12450380,
FT                                ECO:0000269|PubMed:15299793,
FT                                ECO:0000269|PubMed:1581307,
FT                                ECO:0000269|PubMed:16201406,
FT                                ECO:0000269|PubMed:17543335,
FT                                ECO:0000269|PubMed:22900286,
FT                                ECO:0000269|PubMed:8371268,
FT                                ECO:0000269|PubMed:8594202,
FT                                ECO:0000269|PubMed:8931543,
FT                                ECO:0000269|PubMed:9003186,
FT                                ECO:0000269|Ref.71}.
FT   BINDING     487    487       Carbonate or oxalate 2; via amide
FT                                nitrogen. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00741,
FT                                ECO:0000269|PubMed:10089347,
FT                                ECO:0000269|PubMed:10828980,
FT                                ECO:0000269|PubMed:11128996,
FT                                ECO:0000269|PubMed:12450380,
FT                                ECO:0000269|PubMed:15299793,
FT                                ECO:0000269|PubMed:1581307,
FT                                ECO:0000269|PubMed:16201406,
FT                                ECO:0000269|PubMed:17543335,
FT                                ECO:0000269|PubMed:22900286,
FT                                ECO:0000269|PubMed:8371268,
FT                                ECO:0000269|PubMed:8594202,
FT                                ECO:0000269|PubMed:8931543,
FT                                ECO:0000269|PubMed:9003186,
FT                                ECO:0000269|Ref.71}.
FT   SITE        229    229       Important for iron binding.
FT   CARBOHYD    156    156       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:15299444,
FT                                ECO:0000269|PubMed:15299793,
FT                                ECO:0000269|PubMed:1581307,
FT                                ECO:0000269|PubMed:16201406,
FT                                ECO:0000269|PubMed:18780401,
FT                                ECO:0000269|PubMed:8069634,
FT                                ECO:0000269|Ref.71}.
FT   CARBOHYD    497    497       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:15299793,
FT                                ECO:0000269|PubMed:1581307,
FT                                ECO:0000269|PubMed:16201406,
FT                                ECO:0000269|PubMed:18780401,
FT                                ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|Ref.71}.
FT   CARBOHYD    642    642       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:18780401}.
FT   DISULFID     28     64
FT   DISULFID     38     55
FT   DISULFID    134    217
FT   DISULFID    176    192
FT   DISULFID    189    200
FT   DISULFID    250    264
FT   DISULFID    367    399
FT   DISULFID    377    390
FT   DISULFID    424    705
FT   DISULFID    446    668
FT   DISULFID    478    553
FT   DISULFID    502    696
FT   DISULFID    512    526
FT   DISULFID    523    536
FT   DISULFID    594    608
FT   DISULFID    646    651
FT   VAR_SEQ       1     44       Missing (in isoform DeltaLf).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:9122171}.
FT                                /FTId=VSP_044308.
FT   VARIANT      22     22       R -> RR (associated with lower plasma
FT                                lactoferrin concentrations;
FT                                dbSNP:rs10662431).
FT                                {ECO:0000269|PubMed:11702692,
FT                                ECO:0000269|PubMed:14573629,
FT                                ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:22406253,
FT                                ECO:0000269|PubMed:22900286,
FT                                ECO:0000269|PubMed:2374734,
FT                                ECO:0000269|PubMed:2402455,
FT                                ECO:0000269|Ref.10, ECO:0000269|Ref.11,
FT                                ECO:0000269|Ref.17, ECO:0000269|Ref.2,
FT                                ECO:0000269|Ref.8, ECO:0000269|Ref.9}.
FT                                /FTId=VAR_069298.
FT   VARIANT      29     29       A -> T (in dbSNP:rs1126477).
FT                                {ECO:0000269|PubMed:11702692,
FT                                ECO:0000269|PubMed:14573629,
FT                                ECO:0000269|PubMed:22900286,
FT                                ECO:0000269|PubMed:9873069,
FT                                ECO:0000269|Ref.11, ECO:0000269|Ref.8,
FT                                ECO:0000269|Ref.9}.
FT                                /FTId=VAR_013504.
FT   VARIANT      47     47       K -> R (decreased antibacterial activity
FT                                against Gram-positive bacteria; seems to
FT                                reduce susceptibility to localized
FT                                juvenile periodontitis; associated with
FT                                increased plasma lactoferrin
FT                                concentrations and possibly with
FT                                susceptibility to coronary artery
FT                                stenosis; dbSNP:rs1126478).
FT                                {ECO:0000269|PubMed:11702692,
FT                                ECO:0000269|PubMed:14573629,
FT                                ECO:0000269|PubMed:22406253,
FT                                ECO:0000269|PubMed:22900286,
FT                                ECO:0000269|PubMed:9873069,
FT                                ECO:0000269|Ref.11, ECO:0000269|Ref.8,
FT                                ECO:0000269|Ref.9}.
FT                                /FTId=VAR_013505.
FT   VARIANT     148    148       I -> T (in dbSNP:rs1126479).
FT                                {ECO:0000269|PubMed:2402455}.
FT                                /FTId=VAR_013506.
FT   VARIANT     422    422       G -> C (in dbSNP:rs1042055).
FT                                {ECO:0000269|PubMed:2402455,
FT                                ECO:0000269|Ref.10}.
FT                                /FTId=VAR_013507.
FT   VARIANT     579    579       E -> D (in dbSNP:rs2073495).
FT                                {ECO:0000269|PubMed:11702692,
FT                                ECO:0000269|PubMed:16201406,
FT                                ECO:0000269|PubMed:22900286,
FT                                ECO:0000269|PubMed:25946035,
FT                                ECO:0000269|Ref.25, ECO:0000269|Ref.9}.
FT                                /FTId=VAR_013508.
FT   MUTAGEN      20     23       Missing: Abolishes binding to heparin,
FT                                lipid A, lysozyme and DNA.
FT                                {ECO:0000269|PubMed:9359845}.
FT   MUTAGEN      20     22       Missing: Greatly impairs binding to
FT                                heparin, lipid A, lysozyme and DNA.
FT                                Impairs antibacterial activity.
FT                                {ECO:0000269|PubMed:11179314}.
FT   MUTAGEN      20     21       Missing: Impairs binding to heparin,
FT                                lipid A, lysozyme and DNA.
FT   MUTAGEN      79     79       D->S: Impairs iron binding and changes
FT                                domain closure.
FT                                {ECO:0000269|PubMed:8594202}.
FT   MUTAGEN      92     92       K->A: Almost no protease activity.
FT                                {ECO:0000269|PubMed:12535064}.
FT   MUTAGEN     140    140       R->D,E,S: Disrupts anion binding site and
FT                                destabilizes iron binding.
FT                                {ECO:0000269|PubMed:12037297,
FT                                ECO:0000269|PubMed:8931543}.
FT   MUTAGEN     229    229       R->G,E: Destabilizes iron binding
FT                                slightly. {ECO:0000269|PubMed:10828980,
FT                                ECO:0000269|PubMed:12450380}.
FT   MUTAGEN     229    229       R->K,L: Destabilizes iron binding
FT                                significantly.
FT                                {ECO:0000269|PubMed:10828980,
FT                                ECO:0000269|PubMed:12450380}.
FT   MUTAGEN     270    270       P->V: No effect.
FT                                {ECO:0000269|PubMed:12535064}.
FT   MUTAGEN     272    272       H->A,C,G,E,F,L,M,P,Q,T,Y: Destabilizes
FT                                iron binding.
FT                                {ECO:0000269|PubMed:9003186}.
FT   MUTAGEN     278    278       S->A: No protease activity.
FT                                {ECO:0000269|PubMed:12535064}.
FT   CONFLICT     14     14       L -> P (in Ref. 17; AAA58656).
FT                                {ECO:0000305}.
FT   CONFLICT     21     21       R -> S (in Ref. 14; AAH15822/AAH15823).
FT                                {ECO:0000305}.
FT   CONFLICT     36     36       T -> D (in Ref. 22; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT     49     49       R -> C (in Ref. 14; AAH22347).
FT                                {ECO:0000305}.
FT   CONFLICT    130    130       G -> C (in Ref. 14; AAH15823).
FT                                {ECO:0000305}.
FT   CONFLICT    138    138       L -> R (in Ref. 14; AAH22347).
FT                                {ECO:0000305}.
FT   CONFLICT    140    140       Missing (in Ref. 18; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    169    169       Missing (in Ref. 18; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    409    410       DA -> NASVLMDSEGGFLAR (in Ref. 18; AA
FT                                sequence). {ECO:0000305}.
FT   CONFLICT    415    415       G -> E (in Ref. 17; AAA59511).
FT                                {ECO:0000305}.
FT   CONFLICT    431    431       A -> G (in Ref. 17; AAA58656).
FT                                {ECO:0000305}.
FT   CONFLICT    456    456       A -> T (in Ref. 14; AAH15822/AAH15823).
FT                                {ECO:0000305}.
FT   CONFLICT    487    487       G -> A (in Ref. 26; AAA86665).
FT                                {ECO:0000305}.
FT   CONFLICT    531    531       Q -> E (in Ref. 18; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    537    537       V -> E (in Ref. 14; AAH15822).
FT                                {ECO:0000305}.
FT   CONFLICT    694    694       K -> R (in Ref. 18; AA sequence and 27;
FT                                AA sequence). {ECO:0000305}.
FT   STRAND       24     31       {ECO:0000244|PDB:1H45}.
FT   HELIX        32     47       {ECO:0000244|PDB:1H45}.
FT   STRAND       50     52       {ECO:0000244|PDB:1Z6W}.
FT   STRAND       53     57       {ECO:0000244|PDB:1H45}.
FT   HELIX        61     69       {ECO:0000244|PDB:1H45}.
FT   STRAND       75     78       {ECO:0000244|PDB:1H45}.
FT   HELIX        80     87       {ECO:0000244|PDB:1H45}.
FT   TURN         89     91       {ECO:0000244|PDB:1H45}.
FT   STRAND       93    102       {ECO:0000244|PDB:1H45}.
FT   STRAND      104    118       {ECO:0000244|PDB:1H45}.
FT   STRAND      119    121       {ECO:0000244|PDB:1LGB}.
FT   HELIX       125    127       {ECO:0000244|PDB:1H45}.
FT   STRAND      132    136       {ECO:0000244|PDB:1H45}.
FT   TURN        141    144       {ECO:0000244|PDB:1H45}.
FT   HELIX       145    151       {ECO:0000244|PDB:1H45}.
FT   HELIX       152    154       {ECO:0000244|PDB:1H45}.
FT   TURN        159    161       {ECO:0000244|PDB:1LCT}.
FT   HELIX       164    171       {ECO:0000244|PDB:1H45}.
FT   STRAND      172    176       {ECO:0000244|PDB:1H45}.
FT   TURN        182    184       {ECO:0000244|PDB:1H45}.
FT   HELIX       186    188       {ECO:0000244|PDB:1H45}.
FT   TURN        189    191       {ECO:0000244|PDB:1H45}.
FT   HELIX       196    198       {ECO:0000244|PDB:1H45}.
FT   STRAND      206    208       {ECO:0000244|PDB:1N76}.
FT   HELIX       210    219       {ECO:0000244|PDB:1H45}.
FT   STRAND      224    229       {ECO:0000244|PDB:1H45}.
FT   HELIX       232    236       {ECO:0000244|PDB:1H45}.
FT   HELIX       240    243       {ECO:0000244|PDB:1H45}.
FT   STRAND      246    250       {ECO:0000244|PDB:1H45}.
FT   TURN        251    253       {ECO:0000244|PDB:1H45}.
FT   STRAND      254    257       {ECO:0000244|PDB:1H45}.
FT   HELIX       258    263       {ECO:0000244|PDB:1H45}.
FT   STRAND      266    270       {ECO:0000244|PDB:1H45}.
FT   STRAND      273    280       {ECO:0000244|PDB:1H45}.
FT   HELIX       283    297       {ECO:0000244|PDB:1H45}.
FT   TURN        299    301       {ECO:0000244|PDB:1H45}.
FT   STRAND      317    319       {ECO:0000244|PDB:1H45}.
FT   STRAND      325    328       {ECO:0000244|PDB:1H45}.
FT   HELIX       335    339       {ECO:0000244|PDB:1H45}.
FT   HELIX       341    348       {ECO:0000244|PDB:1LFI}.
FT   HELIX       349    351       {ECO:0000244|PDB:1LFI}.
FT   HELIX       354    362       {ECO:0000244|PDB:1CB6}.
FT   STRAND      363    370       {ECO:0000244|PDB:1CB6}.
FT   HELIX       371    383       {ECO:0000244|PDB:1CB6}.
FT   TURN        384    386       {ECO:0000244|PDB:1CB6}.
FT   STRAND      387    395       {ECO:0000244|PDB:1CB6}.
FT   HELIX       396    404       {ECO:0000244|PDB:1CB6}.
FT   STRAND      410    413       {ECO:0000244|PDB:1CB6}.
FT   HELIX       415    423       {ECO:0000244|PDB:1CB6}.
FT   STRAND      427    434       {ECO:0000244|PDB:1CB6}.
FT   STRAND      436    439       {ECO:0000244|PDB:1CB6}.
FT   STRAND      440    442       {ECO:0000244|PDB:1B0L}.
FT   HELIX       446    448       {ECO:0000244|PDB:1CB6}.
FT   STRAND      454    463       {ECO:0000244|PDB:1CB6}.
FT   HELIX       469    471       {ECO:0000244|PDB:1CB6}.
FT   STRAND      475    480       {ECO:0000244|PDB:1CB6}.
FT   TURN        485    488       {ECO:0000244|PDB:1CB6}.
FT   HELIX       489    499       {ECO:0000244|PDB:1CB6}.
FT   HELIX       504    506       {ECO:0000244|PDB:1CB6}.
FT   STRAND      508    512       {ECO:0000244|PDB:1CB6}.
FT   STRAND      514    516       {ECO:0000244|PDB:1LFI}.
FT   HELIX       521    523       {ECO:0000244|PDB:1CB6}.
FT   TURN        533    536       {ECO:0000244|PDB:1LFH}.
FT   HELIX       546    555       {ECO:0000244|PDB:1CB6}.
FT   STRAND      560    565       {ECO:0000244|PDB:1CB6}.
FT   HELIX       566    570       {ECO:0000244|PDB:1CB6}.
FT   STRAND      573    576       {ECO:0000244|PDB:1LFI}.
FT   HELIX       580    583       {ECO:0000244|PDB:1CB6}.
FT   HELIX       587    589       {ECO:0000244|PDB:1CB6}.
FT   STRAND      590    593       {ECO:0000244|PDB:1CB6}.
FT   STRAND      599    601       {ECO:0000244|PDB:1CB6}.
FT   HELIX       602    607       {ECO:0000244|PDB:1CB6}.
FT   STRAND      610    613       {ECO:0000244|PDB:1CB6}.
FT   STRAND      617    620       {ECO:0000244|PDB:1CB6}.
FT   HELIX       622    624       {ECO:0000244|PDB:1CB6}.
FT   HELIX       625    639       {ECO:0000244|PDB:1CB6}.
FT   STRAND      640    642       {ECO:0000244|PDB:1N76}.
FT   TURN        646    649       {ECO:0000244|PDB:1CB6}.
FT   STRAND      655    657       {ECO:0000244|PDB:1CB6}.
FT   STRAND      666    670       {ECO:0000244|PDB:1CB6}.
FT   HELIX       678    682       {ECO:0000244|PDB:1CB6}.
FT   HELIX       684    696       {ECO:0000244|PDB:1CB6}.
FT   HELIX       700    709       {ECO:0000244|PDB:1CB6}.
SQ   SEQUENCE   710 AA;  78182 MW;  0489CABA6D13C098 CRC64;
     MKLVFLVLLF LGALGLCLAG RRRSVQWCAV SQPEATKCFQ WQRNMRKVRG PPVSCIKRDS
     PIQCIQAIAE NRADAVTLDG GFIYEAGLAP YKLRPVAAEV YGTERQPRTH YYAVAVVKKG
     GSFQLNELQG LKSCHTGLRR TAGWNVPIGT LRPFLNWTGP PEPIEAAVAR FFSASCVPGA
     DKGQFPNLCR LCAGTGENKC AFSSQEPYFS YSGAFKCLRD GAGDVAFIRE STVFEDLSDE
     AERDEYELLC PDNTRKPVDK FKDCHLARVP SHAVVARSVN GKEDAIWNLL RQAQEKFGKD
     KSPKFQLFGS PSGQKDLLFK DSAIGFSRVP PRIDSGLYLG SGYFTAIQNL RKSEEEVAAR
     RARVVWCAVG EQELRKCNQW SGLSEGSVTC SSASTTEDCI ALVLKGEADA MSLDGGYVYT
     AGKCGLVPVL AENYKSQQSS DPDPNCVDRP VEGYLAVAVV RRSDTSLTWN SVKGKKSCHT
     AVDRTAGWNI PMGLLFNQTG SCKFDEYFSQ SCAPGSDPRS NLCALCIGDE QGENKCVPNS
     NERYYGYTGA FRCLAENAGD VAFVKDVTVL QNTDGNNNEA WAKDLKLADF ALLCLDGKRK
     PVTEARSCHL AMAPNHAVVS RMDKVERLKQ VLLHQQAKFG RNGSDCPDKF CLFQSETKNL
     LFNDNTECLA RLHGKTTYEK YLGPQYVAGI TNLKKCSTSP LLEACEFLRK
//
ID   TLR4_HUMAN              Reviewed;         839 AA.
AC   O00206; A8K1Y8; A9XLP9; A9XLQ0; A9XLQ1; B4E194; D1CS52; D1CS53;
AC   Q5VZI8; Q5VZI9; Q9UK78; Q9UM57;
DT   11-FEB-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 2.
DT   17-FEB-2016, entry version 169.
DE   RecName: Full=Toll-like receptor 4;
DE   AltName: Full=hToll;
DE   AltName: CD_antigen=CD284;
DE   Flags: Precursor;
GN   Name=TLR4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, SUBCELLULAR
RP   LOCATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Spleen;
RX   PubMed=9237759; DOI=10.1038/41131;
RA   Medzhitov R., Preston-Hurlburt P., Janeway C.A. Jr.;
RT   "A human homologue of the Drosophila Toll protein signals activation
RT   of adaptive immunity.";
RL   Nature 388:394-397(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND TISSUE SPECIFICITY.
RC   TISSUE=Fetal liver, Lung, and Placenta;
RX   PubMed=9435236; DOI=10.1073/pnas.95.2.588;
RA   Rock F.L., Hardiman G., Timans J.C., Kastelein R.A., Bazan J.F.;
RT   "A family of human receptors structurally related to Drosophila
RT   Toll.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:588-593(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, VARIANTS GLY-299 AND
RP   ILE-399, CHARACTERIZATION OF VARIANTS GLY-299 AND ILE-399, AND
RP   POLYMORPHISM.
RX   PubMed=11104518; DOI=10.1186/gb-2000-1-1-research002;
RA   Smirnova I., Poltorak A., Chan E.K.L., McBride C., Beutler B.;
RT   "Phylogenetic variation and polymorphism at the Toll-like receptor 4
RT   locus (TLR4).";
RL   Genome Biol. 1:RESEARCH002.1-RESEARCH002.10(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS GLY-299 AND ILE-399.
RX   PubMed=10835634; DOI=10.1038/76048;
RA   Arbour N.C., Lorenz E., Schutte B.C., Zabner J., Kline J.N., Jones M.,
RA   Frees K., Watt J.L., Schwartz D.A.;
RT   "TLR4 mutations are associated with endotoxin hyporesponsiveness in
RT   humans.";
RL   Nat. Genet. 25:187-191(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=18810425; DOI=10.1007/s00251-008-0332-0;
RA   Nakajima T., Ohtani H., Satta Y., Uno Y., Akari H., Ishida T.,
RA   Kimura A.;
RT   "Natural selection in the TLR-related genes in the course of primate
RT   evolution.";
RL   Immunogenetics 60:727-735(2008).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS GLY-299 AND ILE-399.
RX   PubMed=19924287; DOI=10.1371/journal.pone.0007803;
RA   Georgel P., Macquin C., Bahram S.;
RT   "The heterogeneous allelic repertoire of human Toll-Like receptor
RT   (TLR) genes.";
RL   PLoS ONE 4:E7803-E7803(2009).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3).
RC   TISSUE=Hippocampus, Kidney, and Uterus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Cerebellum;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-86.
RA   Liu Z., Li N., Wang J., Xiao W.;
RL   Submitted (MAR-2007) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   PROTEIN SEQUENCE OF 24-38.
RX   PubMed=15340161; DOI=10.1110/ps.04682504;
RA   Zhang Z., Henzel W.J.;
RT   "Signal peptide prediction based on analysis of experimentally
RT   verified cleavage sites.";
RL   Protein Sci. 13:2819-2824(2004).
RN   [13]
RP   MUTAGENESIS OF GLU-697; ARG-710; ASP-711 AND PRO-714.
RX   PubMed=11081518; DOI=10.1038/35040600;
RA   Xu Y., Tao X., Shen B., Horng T., Medzhitov R., Manley J.L., Tong L.;
RT   "Structural basis for signal transduction by the Toll/interleukin-1
RT   receptor domains.";
RL   Nature 408:111-115(2000).
RN   [14]
RP   SUBUNIT, AND SUBCELLULAR LOCATION.
RX   PubMed=11274165; DOI=10.1074/jbc.M009164200;
RA   da Silva Correia J., Soldau K., Christen U., Tobias P.S.,
RA   Ulevitch R.J.;
RT   "Lipopolysaccharide is in close proximity to each of the proteins in
RT   its membrane receptor complex. transfer from CD14 to TLR4 and MD-2.";
RL   J. Biol. Chem. 276:21129-21135(2001).
RN   [15]
RP   GLYCOSYLATION AT ASN-35; ASN-173; ASN-205; ASN-282; ASN-309; ASN-497;
RP   ASN-526; ASN-575 AND ASN-624, AND MUTAGENESIS OF ASN-526 AND ASN-575.
RX   PubMed=11706042; DOI=10.1074/jbc.M109910200;
RA   da Silva Correia J., Ulevitch R.J.;
RT   "MD-2 and TLR4 N-linked glycosylations are important for a functional
RT   lipopolysaccharide receptor.";
RL   J. Biol. Chem. 277:1845-1854(2002).
RN   [16]
RP   INTERACTION WITH TICAM2.
RX   PubMed=14519765; DOI=10.1074/jbc.M305820200;
RA   Oshiumi H., Sasai M., Shida K., Fujita T., Matsumoto M., Seya T.;
RT   "TIR-containing adapter molecule (TICAM)-2, a bridging adapter
RT   recruiting to toll-like receptor 4 TICAM-1 that induces interferon-
RT   beta.";
RL   J. Biol. Chem. 278:49751-49762(2003).
RN   [17]
RP   INTERACTION WITH NOX4.
RX   PubMed=15356101; DOI=10.4049/jimmunol.173.6.3589;
RA   Park H.S., Jung H.Y., Park E.Y., Kim J., Lee W.J., Bae Y.S.;
RT   "Direct interaction of TLR4 with NAD(P)H oxidase 4 isozyme is
RT   essential for lipopolysaccharide-induced production of reactive oxygen
RT   species and activation of NF-kappa B.";
RL   J. Immunol. 173:3589-3593(2004).
RN   [18]
RP   FUNCTION.
RX   PubMed=17478729; DOI=10.1161/CIRCRESAHA.106.142851;
RA   Kim F., Pham M., Luttrell I., Bannerman D.D., Tupper J., Thaler J.,
RA   Hawn T.R., Raines E.W., Schwartz M.W.;
RT   "Toll-like receptor-4 mediates vascular inflammation and insulin
RT   resistance in diet-induced obesity.";
RL   Circ. Res. 100:1589-1596(2007).
RN   [19]
RP   INTERACTION WITH HSP90B1.
RX   PubMed=20865800; DOI=10.1038/ncomms1070;
RA   Liu B., Yang Y., Qiu Z., Staron M., Hong F., Li Y., Wu S., Li Y.,
RA   Hao B., Bona R., Han D., Li Z.;
RT   "Folding of Toll-like receptors by the HSP90 paralogue gp96 requires a
RT   substrate-specific cochaperone.";
RL   Nat. Commun. 1:79-79(2010).
RN   [20]
RP   ERRATUM.
RA   Liu B., Yang Y., Qiu Z., Staron M., Hong F., Li Y., Wu S., Li Y.,
RA   Hao B., Bona R., Han D., Li Z.;
RL   Nat. Commun. 3:653-653(2012).
RN   [21]
RP   FUNCTION, INTERACTION WITH CD36 AND TLR6, AND SUBCELLULAR LOCATION.
RX   PubMed=20037584; DOI=10.1038/ni.1836;
RA   Stewart C.R., Stuart L.M., Wilkinson K., van Gils J.M., Deng J.,
RA   Halle A., Rayner K.J., Boyer L., Zhong R., Frazier W.A.,
RA   Lacy-Hulbert A., El Khoury J., Golenbock D.T., Moore K.J.;
RT   "CD36 ligands promote sterile inflammation through assembly of a Toll-
RT   like receptor 4 and 6 heterodimer.";
RL   Nat. Immunol. 11:155-161(2010).
RN   [22]
RP   FUNCTION, MUTAGENESIS OF HIS-431; HIS-456 AND HIS-458, AND INVOLVEMENT
RP   IN CONTACT ALLERGY TO NICKEL.
RX   PubMed=20711192; DOI=10.1038/ni.1919;
RA   Schmidt M., Raghavan B., Mueller V., Vogl T., Fejer G., Tchaptchet S.,
RA   Keck S., Kalis C., Nielsen P.J., Galanos C., Roth J., Skerra A.,
RA   Martin S.F., Freudenberg M.A., Goebeler M.;
RT   "Crucial role for human Toll-like receptor 4 in the development of
RT   contact allergy to nickel.";
RL   Nat. Immunol. 11:814-819(2010).
RN   [23]
RP   INTERACTION WITH MLK4.
RX   PubMed=21602844; DOI=10.1038/cmi.2011.15;
RA   Seit-Nebi A., Cheng W., Xu H., Han J.;
RT   "MLK4 has negative effect on TLR4 signaling.";
RL   Cell. Mol. Immunol. 9:27-33(2012).
RN   [24]
RP   FUNCTION.
RX   PubMed=23880187; DOI=10.1016/j.atherosclerosis.2013.05.011;
RA   Estruch M., Bancells C., Beloki L., Sanchez-Quesada J.L.,
RA   Ordonez-Llanos J., Benitez S.;
RT   "CD14 and TLR4 mediate cytokine release promoted by electronegative
RT   LDL in monocytes.";
RL   Atherosclerosis 229:356-362(2013).
RN   [25]
RP   INTERACTION WITH TICAM1 AND TICAM2.
RX   PubMed=25736436; DOI=10.15252/embr.201439637;
RA   Hu Y.H., Zhang Y., Jiang L.Q., Wang S., Lei C.Q., Sun M.S., Shu H.B.,
RA   Liu Y.;
RT   "WDFY1 mediates TLR3/4 signaling by recruiting TRIF.";
RL   EMBO Rep. 16:447-455(2015).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 27-228 IN COMPLEX WITH LY96,
RP   SUBUNIT, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-35; ASN-173 AND
RP   ASN-205.
RX   PubMed=17803912; DOI=10.1016/j.cell.2007.08.002;
RA   Kim H.M., Park B.S., Kim J.-I., Kim S.E., Lee J., Oh S.C.,
RA   Enkhbayar P., Matsushima N., Lee H., Yoo O.J., Lee J.-O.;
RT   "Crystal structure of the TLR4-MD-2 complex with bound endotoxin
RT   antagonist Eritoran.";
RL   Cell 130:906-917(2007).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF 27-631 IN COMPLEX WITH LY96
RP   AND LIPOPOLYSACCHARIDE, SUBUNIT, DISULFIDE BONDS, AND GLYCOSYLATION AT
RP   ASN-173; ASN-205; ASN-497 AND ASN-526 AND ASN-575.
RX   PubMed=19252480; DOI=10.1038/nature07830;
RA   Park B.S., Song D.H., Kim H.M., Choi B.-S., Lee H., Lee J.-O.;
RT   "The structural basis of lipopolysaccharide recognition by the TLR4-
RT   MD-2 complex.";
RL   Nature 458:1191-1195(2009).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.37 ANGSTROMS) OF 28-228, GLYCOSYLATION AT
RP   ASN-35 AND ASN-173, AND DISULFIDE BONDS.
RX   PubMed=22363519; DOI=10.1371/journal.pone.0030929;
RA   Han J., Kim H.J., Lee S.C., Hong S., Park K., Jeon Y.H., Kim D.,
RA   Cheong H.K., Kim H.S.;
RT   "Structure-based rational design of a Toll-like receptor 4 (TLR4)
RT   decoy receptor with high binding affinity for a target protein.";
RL   PLoS ONE 7:E30929-E30929(2012).
RN   [29]
RP   VARIANTS ARG-188; SER-246; GLY-299; SER-329; ILE-399; LEU-443;
RP   LYS-474; HIS-510; ARG-694; HIS-763 AND HIS-834.
RX   PubMed=11514453;
RA   Smirnova I., Hamblin M.T., McBride C., Beutler B., Di Rienzo A.;
RT   "Excess of rare amino acid polymorphisms in the Toll-like receptor 4
RT   in humans.";
RL   Genetics 158:1657-1664(2001).
RN   [30]
RP   VARIANT GLY-299, AND ASSOCIATION WITH ARMD SUSCEPTIBILITY.
RX   PubMed=15829498; DOI=10.1093/hmg/ddi154;
RA   Zareparsi S., Buraczynska M., Branham K.E.H., Shah S., Eng D., Li M.,
RA   Pawar H., Yashar B.M., Moroi S.E., Lichter P.R., Petty H.R.,
RA   Richards J.E., Abecasis G.R., Elner V.M., Swaroop A.;
RT   "Toll-like receptor 4 variant D299G is associated with susceptibility
RT   to age-related macular degeneration.";
RL   Hum. Mol. Genet. 14:1449-1455(2005).
RN   [31]
RP   VARIANT ASP-287.
RX   PubMed=25787250; DOI=10.1073/pnas.1503696112;
RA   Cromer M.K., Choi M., Nelson-Williams C., Fonseca A.L., Kunstman J.W.,
RA   Korah R.M., Overton J.D., Mane S., Kenney B., Malchoff C.D.,
RA   Stalberg P., Akerstroem G., Westin G., Hellman P., Carling T.,
RA   Bjoerklund P., Lifton R.P.;
RT   "Neomorphic effects of recurrent somatic mutations in Yin Yang 1 in
RT   insulin-producing adenomas.";
RL   Proc. Natl. Acad. Sci. U.S.A. 112:4062-4067(2015).
CC   -!- FUNCTION: Cooperates with LY96 and CD14 to mediate the innate
CC       immune response to bacterial lipopolysaccharide (LPS). Acts via
CC       MYD88, TIRAP and TRAF6, leading to NF-kappa-B activation, cytokine
CC       secretion and the inflammatory response (PubMed:9237759,
CC       PubMed:10835634). Also involved in LPS-independent inflammatory
CC       responses triggered by free fatty acids, such as palmitate, and
CC       Ni(2+). Responses triggered by Ni(2+) require non-conserved
CC       histidines and are, therefore, species-specific (PubMed:20711192).
CC       In complex with TLR6, promotes sterile inflammation in
CC       monocytes/macrophages in response to oxidized low-density
CC       lipoprotein (oxLDL) or amyloid-beta 42. In this context, the
CC       initial signal is provided by oxLDL- or amyloid-beta 42-binding to
CC       CD36. This event induces the formation of a heterodimer of TLR4
CC       and TLR6, which is rapidly internalized and triggers inflammatory
CC       response, leading to the NF-kappa-B-dependent production of CXCL1,
CC       CXCL2 and CCL9 cytokines, via MYD88 signaling pathway, and CCL5
CC       cytokine, via TICAM1 signaling pathway, as well as IL1B secretion.
CC       Binds electronegative LDL (LDL(-)) and mediates the cytokine
CC       release induced by LDL(-) (PubMed:23880187).
CC       {ECO:0000269|PubMed:10835634, ECO:0000269|PubMed:17478729,
CC       ECO:0000269|PubMed:20037584, ECO:0000269|PubMed:20711192,
CC       ECO:0000269|PubMed:23880187, ECO:0000269|PubMed:9237759}.
CC   -!- SUBUNIT: Belongs to the lipopolysaccharide (LPS) receptor, a
CC       multi-protein complex containing at least CD14, LY96 and TLR4
CC       (PubMed:11274165). Binding to bacterial LPS leads to
CC       homodimerization. Interacts with LY96 via the extracellular domain
CC       (PubMed:17803912, PubMed:19252480). Interacts with MYD88 and TIRAP
CC       via their respective TIR domains (By similarity). Interacts with
CC       TICAM2 (PubMed:14519765, PubMed:25736436). Interacts with NOX4
CC       (PubMed:15356101). Interacts with CNPY3 (By similarity). Interacts
CC       with HSP90B1. The interaction with both CNPY3 and HSP90B1 is
CC       required for proper folding in the endoplasmic reticulum.
CC       Interacts with MLK4; this interaction leads to negative regulation
CC       of TLR4 signaling (PubMed:21602844). Interacts with CD36,
CC       following CD36 stimulation by oxLDL or amyloid-beta 42, and forms
CC       a heterodimer with TLR6 (PubMed:20037584). The trimeric complex is
CC       internalized and triggers inflammatory response. LYN kinase
CC       activity facilitates TLR4-TLR6 heterodimerization and signal
CC       initiation. Interacts with TICAM1 in response to LPS in a WDFY1-
CC       dependent manner (PubMed:25736436). Interacts with WDFY1 in
CC       response to LPS (By similarity). {ECO:0000250|UniProtKB:Q9QUK6,
CC       ECO:0000269|PubMed:11274165, ECO:0000269|PubMed:14519765,
CC       ECO:0000269|PubMed:15356101, ECO:0000269|PubMed:17803912,
CC       ECO:0000269|PubMed:19252480, ECO:0000269|PubMed:20037584,
CC       ECO:0000269|PubMed:20865800, ECO:0000269|PubMed:21602844,
CC       ECO:0000269|PubMed:25736436}.
CC   -!- INTERACTION:
CC       O76552:- (xeno); NbExp=3; IntAct=EBI-528701, EBI-3870694;
CC       Q9Y6Y9:LY96; NbExp=5; IntAct=EBI-528701, EBI-1539247;
CC       Q9NPH5:NOX4; NbExp=4; IntAct=EBI-528701, EBI-11301574;
CC       P58753:TIRAP; NbExp=2; IntAct=EBI-528701, EBI-528644;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:11274165,
CC       ECO:0000269|PubMed:20037584, ECO:0000269|PubMed:9237759}; Single-
CC       pass type I membrane protein {ECO:0000269|PubMed:11274165}.
CC       Note=Upon complex formation with CD36 and TLR6, internalized
CC       through dynamin-dependent endocytosis.
CC       {ECO:0000269|PubMed:20037584}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=O00206-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O00206-2; Sequence=VSP_035794;
CC       Name=3;
CC         IsoId=O00206-3; Sequence=VSP_035793;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Highly expressed in placenta, spleen and
CC       peripheral blood leukocytes. Detected in monocytes, macrophages,
CC       dendritic cells and several types of T-cells.
CC       {ECO:0000269|PubMed:9237759, ECO:0000269|PubMed:9435236}.
CC   -!- DOMAIN: The TIR domain mediates interaction with NOX4.
CC       {ECO:0000269|PubMed:15356101}.
CC   -!- PTM: N-glycosylated. Glycosylation of Asn-526 and Asn-575 seems to
CC       be necessary for the expression of TLR4 on the cell surface and
CC       the LPS-response. Likewise, mutants lacking two or more of the
CC       other N-glycosylation sites were deficient in interaction with
CC       LPS. {ECO:0000269|PubMed:11706042, ECO:0000269|PubMed:17803912,
CC       ECO:0000269|PubMed:19252480, ECO:0000269|PubMed:22363519}.
CC   -!- POLYMORPHISM: Allele TLR4*B (Gly-299, Ile-399) is associated with
CC       a blunted response to inhaled LPS. {ECO:0000269|PubMed:10835634}.
CC   -!- DISEASE: Macular degeneration, age-related, 10 (ARMD10)
CC       [MIM:611488]: A form of age-related macular degeneration, a
CC       multifactorial eye disease and the most common cause of
CC       irreversible vision loss in the developed world. In most patients,
CC       the disease is manifest as ophthalmoscopically visible yellowish
CC       accumulations of protein and lipid that lie beneath the retinal
CC       pigment epithelium and within an elastin-containing structure
CC       known as Bruch membrane. Note=Disease susceptibility is associated
CC       with variations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: His-456 and His-458 are found in TLR4 of human and
CC       several other primate species and may be responsible for
CC       inflammatory responses triggered by nickel (Ni(2+)). Ni(2+) may
CC       cross-link the two receptor monomers through specific histidines,
CC       triggering the formation of a dimer that structurally resembles
CC       that induced by LPS. This process may be the basis for the
CC       development of contact allergy to Ni(2+). A mouse model of contact
CC       allergy to Ni(2+) in which TLR4-deficient mice expresses human
CC       TLR4 has been proposed. {ECO:0000305|PubMed:20711192}.
CC   -!- SIMILARITY: Belongs to the Toll-like receptor family.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Contains 18 LRR (leucine-rich) repeats. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 LRRCT domain. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 TIR domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00204}.
CC   -!- WEB RESOURCE: Name=Protein Spotlight; Note=Zips, necklaces and
CC       mobile telephones - Issue 134 of December 2011;
CC       URL="http://web.expasy.org/spotlight/back_issues/134";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U93091; AAC80227.1; -; mRNA.
DR   EMBL; AB445638; BAG55035.1; -; mRNA.
DR   EMBL; DQ018107; AAY82267.1; -; Genomic_DNA.
DR   EMBL; DQ018108; AAY82268.1; -; Genomic_DNA.
DR   EMBL; DQ018109; AAY82269.1; -; Genomic_DNA.
DR   EMBL; AK290053; BAF82742.1; -; mRNA.
DR   EMBL; AK293068; BAF85757.1; -; mRNA.
DR   EMBL; AK303730; BAG64706.1; -; mRNA.
DR   EMBL; AL160272; CAH72618.1; -; Genomic_DNA.
DR   EMBL; AL160272; CAH72619.1; -; Genomic_DNA.
DR   EMBL; CH471090; EAW87448.1; -; Genomic_DNA.
DR   EMBL; CH471090; EAW87451.1; -; Genomic_DNA.
DR   EMBL; BC117422; AAI17423.1; -; mRNA.
DR   EMBL; EF535831; ABU41662.1; -; Genomic_DNA.
DR   EMBL; EF535832; ABU41663.1; -; Genomic_DNA.
DR   EMBL; EF535833; ABU41664.1; -; Genomic_DNA.
DR   EMBL; AF177765; AAF05316.1; -; Genomic_DNA.
DR   EMBL; AF177766; AAF07823.1; -; Genomic_DNA.
DR   EMBL; AF172171; AAF89753.1; -; Genomic_DNA.
DR   EMBL; AF172169; AAF89753.1; JOINED; Genomic_DNA.
DR   EMBL; AF172170; AAF89753.1; JOINED; Genomic_DNA.
DR   EMBL; U88880; AAC34135.1; -; mRNA.
DR   CCDS; CCDS6818.1; -. [O00206-1]
DR   RefSeq; NP_003257.1; NM_003266.3. [O00206-2]
DR   RefSeq; NP_612564.1; NM_138554.4. [O00206-1]
DR   RefSeq; NP_612567.1; NM_138557.2. [O00206-3]
DR   UniGene; Hs.174312; -.
DR   PDB; 2Z62; X-ray; 1.70 A; A=27-228.
DR   PDB; 2Z63; X-ray; 2.00 A; A=27-527.
DR   PDB; 2Z65; X-ray; 2.70 A; A/B=27-228.
DR   PDB; 2Z66; X-ray; 1.90 A; A/B/C/D=381-627.
DR   PDB; 3FXI; X-ray; 3.10 A; A/B=27-631.
DR   PDB; 3UL7; X-ray; 2.37 A; A=28-226.
DR   PDB; 3UL8; X-ray; 2.50 A; A=27-228.
DR   PDB; 3UL9; X-ray; 2.45 A; A=28-228.
DR   PDB; 3ULA; X-ray; 3.60 A; A/C=27-228.
DR   PDB; 4G8A; X-ray; 2.40 A; A/B=23-629.
DR   PDBsum; 2Z62; -.
DR   PDBsum; 2Z63; -.
DR   PDBsum; 2Z65; -.
DR   PDBsum; 2Z66; -.
DR   PDBsum; 3FXI; -.
DR   PDBsum; 3UL7; -.
DR   PDBsum; 3UL8; -.
DR   PDBsum; 3UL9; -.
DR   PDBsum; 3ULA; -.
DR   PDBsum; 4G8A; -.
DR   ProteinModelPortal; O00206; -.
DR   SMR; O00206; 23-816.
DR   BioGrid; 112954; 30.
DR   DIP; DIP-34769N; -.
DR   IntAct; O00206; 16.
DR   MINT; MINT-3981856; -.
DR   STRING; 9606.ENSP00000363089; -.
DR   BindingDB; O00206; -.
DR   ChEMBL; CHEMBL3038512; -.
DR   DrugBank; DB01183; Naloxone.
DR   iPTMnet; O00206; -.
DR   PhosphoSite; O00206; -.
DR   BioMuta; TLR4; -.
DR   PaxDb; O00206; -.
DR   PRIDE; O00206; -.
DR   Ensembl; ENST00000355622; ENSP00000363089; ENSG00000136869. [O00206-1]
DR   Ensembl; ENST00000394487; ENSP00000377997; ENSG00000136869. [O00206-2]
DR   GeneID; 7099; -.
DR   KEGG; hsa:7099; -.
DR   UCSC; uc004bjz.4; human. [O00206-1]
DR   CTD; 7099; -.
DR   GeneCards; TLR4; -.
DR   HGNC; HGNC:11850; TLR4.
DR   HPA; CAB004025; -.
DR   HPA; HPA049174; -.
DR   MalaCards; TLR4; -.
DR   MIM; 603030; gene+phenotype.
DR   MIM; 611488; phenotype.
DR   neXtProt; NX_O00206; -.
DR   Orphanet; 117; Behcet disease.
DR   PharmGKB; PA36552; -.
DR   eggNOG; KOG4641; Eukaryota.
DR   eggNOG; COG4886; LUCA.
DR   GeneTree; ENSGT00760000119006; -.
DR   HOVERGEN; HBG018823; -.
DR   InParanoid; O00206; -.
DR   KO; K10160; -.
DR   OMA; IYCKDLQ; -.
DR   OrthoDB; EOG7ZKS9G; -.
DR   PhylomeDB; O00206; -.
DR   TreeFam; TF351113; -.
DR   Reactome; R-HSA-140534; Ligand-dependent caspase activation.
DR   Reactome; R-HSA-166016; Toll Like Receptor 4 (TLR4) Cascade.
DR   Reactome; R-HSA-166058; MyD88:Mal cascade initiated on plasma membrane.
DR   Reactome; R-HSA-166166; MyD88-independent TLR3/TLR4 cascade.
DR   Reactome; R-HSA-2562578; TRIF-mediated programmed cell death.
DR   Reactome; R-HSA-5602498; MyD88 deficiency (TLR2/4).
DR   Reactome; R-HSA-5603041; IRAK4 deficiency (TLR2/4).
DR   Reactome; R-HSA-936964; Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon.
DR   Reactome; R-HSA-937041; IKK complex recruitment mediated by RIP1.
DR   Reactome; R-HSA-937072; TRAF6 mediated induction of TAK1 complex.
DR   SignaLink; O00206; -.
DR   EvolutionaryTrace; O00206; -.
DR   GeneWiki; TLR_4; -.
DR   GenomeRNAi; 7099; -.
DR   NextBio; 27773; -.
DR   PRO; PR:O00206; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; O00206; -.
DR   Genevisible; O00206; HS.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0010008; C:endosome membrane; TAS:Reactome.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0031226; C:intrinsic component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0046696; C:lipopolysaccharide receptor complex; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0001530; F:lipopolysaccharide binding; NAS:UniProtKB.
DR   GO; GO:0001875; F:lipopolysaccharide receptor activity; IDA:UniProtKB.
DR   GO; GO:0004872; F:receptor activity; TAS:ProtInc.
DR   GO; GO:0004888; F:transmembrane signaling receptor activity; NAS:UniProtKB.
DR   GO; GO:0097296; P:activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway; TAS:Reactome.
DR   GO; GO:0000187; P:activation of MAPK activity; ISS:BHF-UCL.
DR   GO; GO:0006915; P:apoptotic process; TAS:Reactome.
DR   GO; GO:0014002; P:astrocyte development; IEA:Ensembl.
DR   GO; GO:0002322; P:B cell proliferation involved in immune response; IEA:Ensembl.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; ISS:BHF-UCL.
DR   GO; GO:0071223; P:cellular response to lipoteichoic acid; IEA:Ensembl.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEP:UniProtKB.
DR   GO; GO:0042742; P:defense response to bacterium; TAS:UniProtKB.
DR   GO; GO:0050829; P:defense response to Gram-negative bacterium; IC:BHF-UCL.
DR   GO; GO:0016046; P:detection of fungus; NAS:UniProtKB.
DR   GO; GO:0032497; P:detection of lipopolysaccharide; IDA:UniProtKB.
DR   GO; GO:0097191; P:extrinsic apoptotic signaling pathway; TAS:Reactome.
DR   GO; GO:0007249; P:I-kappaB kinase/NF-kappaB signaling; TAS:Reactome.
DR   GO; GO:0007252; P:I-kappaB phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0006955; P:immune response; TAS:ProtInc.
DR   GO; GO:0045087; P:innate immune response; TAS:BHF-UCL.
DR   GO; GO:0032609; P:interferon-gamma production; IEA:Ensembl.
DR   GO; GO:0050702; P:interleukin-1 beta secretion; ISS:UniProtKB.
DR   GO; GO:0060729; P:intestinal epithelial structure maintenance; ISS:BHF-UCL.
DR   GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; IGI:MGI.
DR   GO; GO:0042116; P:macrophage activation; IMP:UniProtKB.
DR   GO; GO:0002755; P:MyD88-dependent toll-like receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0002756; P:MyD88-independent toll-like receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0070373; P:negative regulation of ERK1 and ERK2 cascade; ISS:BHF-UCL.
DR   GO; GO:0032689; P:negative regulation of interferon-gamma production; ISS:BHF-UCL.
DR   GO; GO:0032700; P:negative regulation of interleukin-17 production; ISS:BHF-UCL.
DR   GO; GO:0032707; P:negative regulation of interleukin-23 production; ISS:BHF-UCL.
DR   GO; GO:0032715; P:negative regulation of interleukin-6 production; ISS:BHF-UCL.
DR   GO; GO:0045671; P:negative regulation of osteoclast differentiation; NAS:UniProtKB.
DR   GO; GO:0032720; P:negative regulation of tumor necrosis factor production; ISS:BHF-UCL.
DR   GO; GO:0002537; P:nitric oxide production involved in inflammatory response; IEA:Ensembl.
DR   GO; GO:0030890; P:positive regulation of B cell proliferation; IEA:Ensembl.
DR   GO; GO:0032722; P:positive regulation of chemokine production; IDA:BHF-UCL.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IEA:Ensembl.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; IC:BHF-UCL.
DR   GO; GO:0032727; P:positive regulation of interferon-alpha production; ISS:BHF-UCL.
DR   GO; GO:0045359; P:positive regulation of interferon-beta biosynthetic process; IEA:Ensembl.
DR   GO; GO:0032728; P:positive regulation of interferon-beta production; ISS:BHF-UCL.
DR   GO; GO:0032729; P:positive regulation of interferon-gamma production; ISS:BHF-UCL.
DR   GO; GO:0032732; P:positive regulation of interleukin-1 production; ISS:BHF-UCL.
DR   GO; GO:0032733; P:positive regulation of interleukin-10 production; ISS:BHF-UCL.
DR   GO; GO:0045084; P:positive regulation of interleukin-12 biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0032735; P:positive regulation of interleukin-12 production; ISS:BHF-UCL.
DR   GO; GO:0032755; P:positive regulation of interleukin-6 production; IDA:BHF-UCL.
DR   GO; GO:0045416; P:positive regulation of interleukin-8 biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0032757; P:positive regulation of interleukin-8 production; IDA:BHF-UCL.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; IEA:Ensembl.
DR   GO; GO:0060907; P:positive regulation of macrophage cytokine production; IEA:Ensembl.
DR   GO; GO:0045348; P:positive regulation of MHC class II biosynthetic process; IEA:Ensembl.
DR   GO; GO:0042346; P:positive regulation of NF-kappaB import into nucleus; IDA:BHF-UCL.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IDA:MGI.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IEA:Ensembl.
DR   GO; GO:0051770; P:positive regulation of nitric-oxide synthase biosynthetic process; ISS:BHF-UCL.
DR   GO; GO:1900227; P:positive regulation of NLRP3 inflammasome complex assembly; ISS:UniProtKB.
DR   GO; GO:0070430; P:positive regulation of nucleotide-binding oligomerization domain containing 1 signaling pathway; IEA:Ensembl.
DR   GO; GO:0070434; P:positive regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway; IEA:Ensembl.
DR   GO; GO:0010572; P:positive regulation of platelet activation; ISS:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; ISS:BHF-UCL.
DR   GO; GO:0042535; P:positive regulation of tumor necrosis factor biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; ISS:BHF-UCL.
DR   GO; GO:0012501; P:programmed cell death; TAS:Reactome.
DR   GO; GO:0050707; P:regulation of cytokine secretion; IEA:InterPro.
DR   GO; GO:0002730; P:regulation of dendritic cell cytokine production; IEA:Ensembl.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IC:BHF-UCL.
DR   GO; GO:0042088; P:T-helper 1 type immune response; NAS:UniProtKB.
DR   GO; GO:0034134; P:toll-like receptor 2 signaling pathway; TAS:Reactome.
DR   GO; GO:0034138; P:toll-like receptor 3 signaling pathway; TAS:Reactome.
DR   GO; GO:0034142; P:toll-like receptor 4 signaling pathway; TAS:Reactome.
DR   GO; GO:0002224; P:toll-like receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0038123; P:toll-like receptor TLR1:TLR2 signaling pathway; TAS:Reactome.
DR   GO; GO:0038124; P:toll-like receptor TLR6:TLR2 signaling pathway; TAS:Reactome.
DR   GO; GO:0035666; P:TRIF-dependent toll-like receptor signaling pathway; TAS:Reactome.
DR   Gene3D; 3.40.50.10140; -; 1.
DR   Gene3D; 3.80.10.10; -; 4.
DR   InterPro; IPR000483; Cys-rich_flank_reg_C.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR003591; Leu-rich_rpt_typical-subtyp.
DR   InterPro; IPR000157; TIR_dom.
DR   InterPro; IPR027168; TLR4.
DR   PANTHER; PTHR24365:SF230; PTHR24365:SF230; 2.
DR   Pfam; PF13855; LRR_8; 3.
DR   Pfam; PF01582; TIR; 1.
DR   SMART; SM00369; LRR_TYP; 2.
DR   SMART; SM00082; LRRCT; 1.
DR   SMART; SM00255; TIR; 1.
DR   SUPFAM; SSF52200; SSF52200; 1.
DR   PROSITE; PS51450; LRR; 11.
DR   PROSITE; PS50104; TIR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Age-related macular degeneration; Alternative splicing;
KW   Cell membrane; Complete proteome; Direct protein sequencing;
KW   Disulfide bond; Glycoprotein; Immunity; Inflammatory response;
KW   Innate immunity; Leucine-rich repeat; Membrane; Polymorphism;
KW   Receptor; Reference proteome; Repeat; Signal; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL        1     23       {ECO:0000269|PubMed:15340161}.
FT   CHAIN        24    839       Toll-like receptor 4.
FT                                /FTId=PRO_0000034722.
FT   TOPO_DOM     24    631       Extracellular. {ECO:0000255}.
FT   TRANSMEM    632    652       Helical. {ECO:0000255}.
FT   TOPO_DOM    653    839       Cytoplasmic. {ECO:0000255}.
FT   REPEAT       55     76       LRR 1.
FT   REPEAT       79    100       LRR 2.
FT   REPEAT      103    124       LRR 3.
FT   REPEAT      127    148       LRR 4.
FT   REPEAT      151    172       LRR 5.
FT   REPEAT      176    199       LRR 6.
FT   REPEAT      205    225       LRR 7.
FT   REPEAT      227    247       LRR 8.
FT   REPEAT      331    351       LRR 9.
FT   REPEAT      352    373       LRR 10.
FT   REPEAT      374    394       LRR 11.
FT   REPEAT      400    422       LRR 12.
FT   REPEAT      423    444       LRR 13.
FT   REPEAT      448    456       LRR 14.
FT   REPEAT      472    495       LRR 15.
FT   REPEAT      497    518       LRR 16.
FT   REPEAT      521    542       LRR 17.
FT   REPEAT      545    565       LRR 18.
FT   DOMAIN      579    629       LRRCT.
FT   DOMAIN      672    818       TIR. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00204}.
FT   CARBOHYD     35     35       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:11706042,
FT                                ECO:0000269|PubMed:17803912,
FT                                ECO:0000269|PubMed:22363519}.
FT   CARBOHYD    173    173       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:11706042,
FT                                ECO:0000269|PubMed:17803912,
FT                                ECO:0000269|PubMed:19252480,
FT                                ECO:0000269|PubMed:22363519}.
FT   CARBOHYD    205    205       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:11706042,
FT                                ECO:0000269|PubMed:17803912,
FT                                ECO:0000269|PubMed:19252480}.
FT   CARBOHYD    282    282       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:11706042}.
FT   CARBOHYD    309    309       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:11706042}.
FT   CARBOHYD    497    497       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:11706042,
FT                                ECO:0000269|PubMed:19252480}.
FT   CARBOHYD    526    526       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:11706042,
FT                                ECO:0000269|PubMed:19252480}.
FT   CARBOHYD    575    575       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:11706042,
FT                                ECO:0000269|PubMed:19252480}.
FT   CARBOHYD    624    624       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:11706042}.
FT   CARBOHYD    630    630       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     29     40       {ECO:0000269|PubMed:17803912,
FT                                ECO:0000269|PubMed:19252480}.
FT   DISULFID    281    306       {ECO:0000269|PubMed:19252480}.
FT   DISULFID    390    391       {ECO:0000269|PubMed:19252480}.
FT   DISULFID    583    609       {ECO:0000269|PubMed:19252480}.
FT   DISULFID    585    627       {ECO:0000269|PubMed:19252480}.
FT   VAR_SEQ       1    200       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_035793.
FT   VAR_SEQ       1     40       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:9435236}.
FT                                /FTId=VSP_035794.
FT   VARIANT     175    175       T -> A (in dbSNP:rs16906079).
FT                                /FTId=VAR_021977.
FT   VARIANT     188    188       Q -> R (in dbSNP:rs5030713).
FT                                {ECO:0000269|PubMed:11514453}.
FT                                /FTId=VAR_018729.
FT   VARIANT     246    246       C -> S (in dbSNP:rs5030714).
FT                                {ECO:0000269|PubMed:11514453}.
FT                                /FTId=VAR_018730.
FT   VARIANT     287    287       E -> D. {ECO:0000269|PubMed:25787250}.
FT                                /FTId=VAR_074187.
FT   VARIANT     299    299       D -> G (in allele TLR4*B; reduced LPS-
FT                                response; associated with an increased
FT                                risk for ARMD10 in Caucasian patients
FT                                carriers; dbSNP:rs4986790).
FT                                {ECO:0000269|PubMed:10835634,
FT                                ECO:0000269|PubMed:11104518,
FT                                ECO:0000269|PubMed:11514453,
FT                                ECO:0000269|PubMed:15829498,
FT                                ECO:0000269|PubMed:19924287}.
FT                                /FTId=VAR_012739.
FT   VARIANT     306    306       C -> W (in dbSNP:rs2770145).
FT                                /FTId=VAR_047563.
FT   VARIANT     310    310       V -> G (in dbSNP:rs2770144).
FT                                /FTId=VAR_047564.
FT   VARIANT     329    329       N -> S (in dbSNP:rs5030715).
FT                                {ECO:0000269|PubMed:11514453}.
FT                                /FTId=VAR_018731.
FT   VARIANT     342    342       F -> Y (in dbSNP:rs5031050).
FT                                /FTId=VAR_020334.
FT   VARIANT     385    385       L -> F (in dbSNP:rs11536884).
FT                                /FTId=VAR_037668.
FT   VARIANT     399    399       T -> I (in allele TLR4*B; reduced LPS-
FT                                response; dbSNP:rs4986791).
FT                                {ECO:0000269|PubMed:10835634,
FT                                ECO:0000269|PubMed:11104518,
FT                                ECO:0000269|PubMed:11514453,
FT                                ECO:0000269|PubMed:19924287}.
FT                                /FTId=VAR_012740.
FT   VARIANT     400    400       S -> N (in dbSNP:rs4987233).
FT                                /FTId=VAR_020335.
FT   VARIANT     443    443       F -> L (in dbSNP:rs5030716).
FT                                {ECO:0000269|PubMed:11514453}.
FT                                /FTId=VAR_018732.
FT   VARIANT     474    474       E -> K (in dbSNP:rs5030718).
FT                                {ECO:0000269|PubMed:11514453}.
FT                                /FTId=VAR_018733.
FT   VARIANT     510    510       Q -> H (in dbSNP:rs5030719).
FT                                {ECO:0000269|PubMed:11514453}.
FT                                /FTId=VAR_018734.
FT   VARIANT     694    694       K -> R (in dbSNP:rs5030722).
FT                                {ECO:0000269|PubMed:11514453}.
FT                                /FTId=VAR_018735.
FT   VARIANT     763    763       R -> H (in dbSNP:rs5030723).
FT                                {ECO:0000269|PubMed:11514453}.
FT                                /FTId=VAR_018736.
FT   VARIANT     834    834       Q -> H. {ECO:0000269|PubMed:11514453}.
FT                                /FTId=VAR_018737.
FT   MUTAGEN     431    431       H->A: Partially diminishes NF-kappa-B
FT                                activation induced by Ni(2+). Strongly
FT                                reduces NF-kappa-B activation induced by
FT                                Ni(2+); when associated with A-456 or A-
FT                                458. {ECO:0000269|PubMed:20711192}.
FT   MUTAGEN     456    456       H->A: Partially diminishes NF-kappa-B
FT                                activation induced by Ni(2+). Strongly
FT                                reduces NF-kappa-B activation induced by
FT                                Ni(2+); when associated with A-431.
FT                                Suppresses NF-kappa-B activation induced
FT                                by Ni(2+); when associated with A-458.
FT                                {ECO:0000269|PubMed:20711192}.
FT   MUTAGEN     458    458       H->A: Partially diminishes NF-kappa-B
FT                                activation induced by Ni(2+). Strongly
FT                                reduces NF-kappa-B activation induced by
FT                                Ni(2+); when associated with A-431.
FT                                Suppresses NF-kappa-B activation induced
FT                                by Ni(2+); when associated with A-456.
FT                                {ECO:0000269|PubMed:20711192}.
FT   MUTAGEN     526    526       N->A: Abolishes LPS-response and prevents
FT                                the cell surface expression.
FT                                {ECO:0000269|PubMed:11706042}.
FT   MUTAGEN     575    575       N->A: Abolishes LPS-response and prevents
FT                                the cell surface expression.
FT                                {ECO:0000269|PubMed:11706042}.
FT   MUTAGEN     697    697       E->R: Abolishes LPS-response.
FT                                {ECO:0000269|PubMed:11081518}.
FT   MUTAGEN     710    710       R->E: Abolishes LPS-response.
FT                                {ECO:0000269|PubMed:11081518}.
FT   MUTAGEN     711    711       D->K: Abolishes LPS-response.
FT                                {ECO:0000269|PubMed:11081518}.
FT   MUTAGEN     714    714       P->H,R,E: Abolishes MYD88-binding and
FT                                LPS-response.
FT                                {ECO:0000269|PubMed:11081518}.
FT   CONFLICT     73     73       S -> R (in Ref. 11; ABU41664).
FT                                {ECO:0000305}.
FT   CONFLICT    400    400       S -> C (in Ref. 7; BAF82742).
FT                                {ECO:0000305}.
FT   CONFLICT    581    581       F -> S (in Ref. 7; BAG64706).
FT                                {ECO:0000305}.
FT   STRAND       29     33       {ECO:0000244|PDB:2Z62}.
FT   TURN         34     36       {ECO:0000244|PDB:2Z62}.
FT   STRAND       37     39       {ECO:0000244|PDB:2Z62}.
FT   STRAND       50     52       {ECO:0000244|PDB:2Z62}.
FT   STRAND       58     60       {ECO:0000244|PDB:2Z62}.
FT   TURN         71     76       {ECO:0000244|PDB:2Z62}.
FT   STRAND       81     84       {ECO:0000244|PDB:2Z62}.
FT   TURN         95    100       {ECO:0000244|PDB:2Z62}.
FT   STRAND      106    108       {ECO:0000244|PDB:2Z62}.
FT   STRAND      115    117       {ECO:0000244|PDB:3UL9}.
FT   TURN        119    124       {ECO:0000244|PDB:2Z62}.
FT   STRAND      130    132       {ECO:0000244|PDB:2Z62}.
FT   HELIX       141    143       {ECO:0000244|PDB:3UL8}.
FT   TURN        145    148       {ECO:0000244|PDB:3FXI}.
FT   STRAND      154    156       {ECO:0000244|PDB:2Z62}.
FT   HELIX       169    173       {ECO:0000244|PDB:2Z62}.
FT   STRAND      179    181       {ECO:0000244|PDB:2Z62}.
FT   HELIX       192    195       {ECO:0000244|PDB:2Z62}.
FT   HELIX       196    199       {ECO:0000244|PDB:2Z62}.
FT   STRAND      206    209       {ECO:0000244|PDB:2Z62}.
FT   TURN        220    225       {ECO:0000244|PDB:2Z63}.
FT   STRAND      227    235       {ECO:0000244|PDB:2Z63}.
FT   HELIX       242    248       {ECO:0000244|PDB:2Z63}.
FT   TURN        249    252       {ECO:0000244|PDB:2Z63}.
FT   STRAND      254    262       {ECO:0000244|PDB:2Z63}.
FT   TURN        274    277       {ECO:0000244|PDB:2Z63}.
FT   HELIX       278    282       {ECO:0000244|PDB:2Z63}.
FT   STRAND      283    292       {ECO:0000244|PDB:2Z63}.
FT   STRAND      295    298       {ECO:0000244|PDB:2Z63}.
FT   TURN        301    304       {ECO:0000244|PDB:2Z63}.
FT   HELIX       305    307       {ECO:0000244|PDB:2Z63}.
FT   STRAND      311    317       {ECO:0000244|PDB:2Z63}.
FT   STRAND      319    322       {ECO:0000244|PDB:4G8A}.
FT   HELIX       324    327       {ECO:0000244|PDB:4G8A}.
FT   STRAND      333    339       {ECO:0000244|PDB:2Z63}.
FT   STRAND      341    344       {ECO:0000244|PDB:4G8A}.
FT   STRAND      355    360       {ECO:0000244|PDB:2Z63}.
FT   STRAND      377    379       {ECO:0000244|PDB:2Z63}.
FT   STRAND      387    392       {ECO:0000244|PDB:2Z66}.
FT   HELIX       393    396       {ECO:0000244|PDB:2Z66}.
FT   STRAND      403    405       {ECO:0000244|PDB:2Z66}.
FT   STRAND      410    419       {ECO:0000244|PDB:2Z66}.
FT   STRAND      426    428       {ECO:0000244|PDB:2Z66}.
FT   STRAND      432    437       {ECO:0000244|PDB:2Z66}.
FT   TURN        438    445       {ECO:0000244|PDB:2Z66}.
FT   STRAND      451    453       {ECO:0000244|PDB:2Z66}.
FT   TURN        464    469       {ECO:0000244|PDB:2Z66}.
FT   STRAND      475    477       {ECO:0000244|PDB:2Z66}.
FT   HELIX       484    486       {ECO:0000244|PDB:2Z66}.
FT   STRAND      500    502       {ECO:0000244|PDB:2Z66}.
FT   TURN        513    518       {ECO:0000244|PDB:2Z66}.
FT   STRAND      524    526       {ECO:0000244|PDB:2Z66}.
FT   HELIX       538    540       {ECO:0000244|PDB:2Z66}.
FT   STRAND      548    550       {ECO:0000244|PDB:2Z66}.
FT   STRAND      560    563       {ECO:0000244|PDB:2Z66}.
FT   STRAND      573    575       {ECO:0000244|PDB:2Z66}.
FT   HELIX       585    587       {ECO:0000244|PDB:2Z66}.
FT   HELIX       588    596       {ECO:0000244|PDB:2Z66}.
FT   HELIX       597    600       {ECO:0000244|PDB:2Z66}.
FT   HELIX       604    606       {ECO:0000244|PDB:2Z66}.
FT   STRAND      608    612       {ECO:0000244|PDB:2Z66}.
FT   HELIX       613    615       {ECO:0000244|PDB:2Z66}.
FT   STRAND      617    619       {ECO:0000244|PDB:3FXI}.
FT   HELIX       620    622       {ECO:0000244|PDB:2Z66}.
SQ   SEQUENCE   839 AA;  95680 MW;  92C48F55821133E8 CRC64;
     MMSASRLAGT LIPAMAFLSC VRPESWEPCV EVVPNITYQC MELNFYKIPD NLPFSTKNLD
     LSFNPLRHLG SYSFFSFPEL QVLDLSRCEI QTIEDGAYQS LSHLSTLILT GNPIQSLALG
     AFSGLSSLQK LVAVETNLAS LENFPIGHLK TLKELNVAHN LIQSFKLPEY FSNLTNLEHL
     DLSSNKIQSI YCTDLRVLHQ MPLLNLSLDL SLNPMNFIQP GAFKEIRLHK LTLRNNFDSL
     NVMKTCIQGL AGLEVHRLVL GEFRNEGNLE KFDKSALEGL CNLTIEEFRL AYLDYYLDDI
     IDLFNCLTNV SSFSLVSVTI ERVKDFSYNF GWQHLELVNC KFGQFPTLKL KSLKRLTFTS
     NKGGNAFSEV DLPSLEFLDL SRNGLSFKGC CSQSDFGTTS LKYLDLSFNG VITMSSNFLG
     LEQLEHLDFQ HSNLKQMSEF SVFLSLRNLI YLDISHTHTR VAFNGIFNGL SSLEVLKMAG
     NSFQENFLPD IFTELRNLTF LDLSQCQLEQ LSPTAFNSLS SLQVLNMSHN NFFSLDTFPY
     KCLNSLQVLD YSLNHIMTSK KQELQHFPSS LAFLNLTQND FACTCEHQSF LQWIKDQRQL
     LVEVERMECA TPSDKQGMPV LSLNITCQMN KTIIGVSVLS VLVVSVVAVL VYKFYFHLML
     LAGCIKYGRG ENIYDAFVIY SSQDEDWVRN ELVKNLEEGV PPFQLCLHYR DFIPGVAIAA
     NIIHEGFHKS RKVIVVVSQH FIQSRWCIFE YEIAQTWQFL SSRAGIIFIV LQKVEKTLLR
     QQVELYRLLS RNTYLEWEDS VLGRHIFWRR LRKALLDGKS WNPEGTVGTG CNWQEATSI
//
ID   INS_HUMAN               Reviewed;         110 AA.
AC   P01308; Q5EEX2;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   21-JUL-1986, sequence version 1.
DT   17-FEB-2016, entry version 211.
DE   RecName: Full=Insulin;
DE   Contains:
DE     RecName: Full=Insulin B chain;
DE   Contains:
DE     RecName: Full=Insulin A chain;
DE   Flags: Precursor;
GN   Name=INS;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=6243748; DOI=10.1038/284026a0;
RA   Bell G.I., Pictet R.L., Rutter W.J., Cordell B., Tischer E.,
RA   Goodman H.M.;
RT   "Sequence of the human insulin gene.";
RL   Nature 284:26-32(1980).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=6248962; DOI=10.1126/science.6248962;
RA   Ullrich A., Dull T.J., Gray A., Brosius J., Sures I.;
RT   "Genetic variation in the human insulin gene.";
RL   Science 209:612-615(1980).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=503234; DOI=10.1038/282525a0;
RA   Bell G.I., Swain W.F., Pictet R.L., Cordell B., Goodman H.M.,
RA   Rutter W.J.;
RT   "Nucleotide sequence of a cDNA clone encoding human preproinsulin.";
RL   Nature 282:525-527(1979).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=6927840; DOI=10.1126/science.6927840;
RA   Sures I., Goeddel D.V., Gray A., Ullrich A.;
RT   "Nucleotide sequence of human preproinsulin complementary DNA.";
RL   Science 208:57-59(1980).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8358440; DOI=10.1038/ng0793-305;
RA   Lucassen A.M., Julier C., Beressi J.-P., Boitard C., Froguel P.,
RA   Lathrop M., Bell J.I.;
RT   "Susceptibility to insulin dependent diabetes mellitus maps to a 4.1
RT   kb segment of DNA spanning the insulin gene and associated VNTR.";
RL   Nat. Genet. 4:305-310(1993).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=15070567; DOI=10.1016/S0140-6736(04)15438-X;
RA   Minn A.H., Kayton M., Lorang D., Hoffmann S.C., Harlan D.M.,
RA   Libutti S.K., Shalev A.;
RT   "Insulinomas and expression of an insulin splice variant.";
RL   Lancet 363:363-367(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=12952878; DOI=10.1101/gr.948003;
RA   Stead J.D.H., Hurles M.E., Jeffreys A.J.;
RT   "Global haplotype diversity in the human insulin gene region.";
RL   Genome Res. 13:2101-2111(2003).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-59.
RC   TISSUE=Blood;
RA   Fajardy I.I., Weill J.J., Stuckens C.C., Danze P.M.P.;
RT   "Description of a novel RFLP diallelic polymorphism (-127 BsgI C/G)
RT   within the 5' region of insulin gene.";
RL   Submitted (JUL-1998) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   PROTEIN SEQUENCE OF 25-54 AND 90-110.
RX   PubMed=14426955; DOI=10.1038/187483a0;
RA   Nicol D.S.H.W., Smith L.F.;
RT   "Amino-acid sequence of human insulin.";
RL   Nature 187:483-485(1960).
RN   [13]
RP   PROTEIN SEQUENCE OF 57-87.
RX   PubMed=5101771;
RA   Oyer P.E., Cho S., Peterson J.D., Steiner D.F.;
RT   "Studies on human proinsulin. Isolation and amino acid sequence of the
RT   human pancreatic C-peptide.";
RL   J. Biol. Chem. 246:1375-1386(1971).
RN   [14]
RP   PROTEIN SEQUENCE OF 57-87.
RX   PubMed=5560404; DOI=10.1111/j.1432-1033.1971.tb01378.x;
RA   Ko A., Smyth D.G., Markussen J., Sundby F.;
RT   "The amino acid sequence of the C-peptide of human proinsulin.";
RL   Eur. J. Biochem. 20:190-199(1971).
RN   [15]
RP   SYNTHESIS.
RX   PubMed=4443293; DOI=10.1002/hlca.19740570839;
RA   Sieber P., Kamber B., Hartmann A., Joehl A., Riniker B., Rittel W.;
RT   "Total synthesis of human insulin under directed formation of the
RT   disulfide bonds.";
RL   Helv. Chim. Acta 57:2617-2621(1974).
RN   [16]
RP   SYNTHESIS OF 57-87.
RX   PubMed=4803504;
RA   Naithani V.K.;
RT   "Studies on polypeptides, IV. The synthesis of C-peptide of human
RT   proinsulin.";
RL   Hoppe-Seyler's Z. Physiol. Chem. 354:659-672(1973).
RN   [17]
RP   SYNTHESIS OF 65-69 AND 70-73.
RX   PubMed=4698555; DOI=10.1002/cber.19731060124;
RA   Geiger R., Volk A.;
RT   "Synthesis of peptides with the properties of human proinsulin C
RT   peptides (hC peptide). 3. Synthesis of the sequences 14-17 and 9-13 of
RT   human proinsulin C peptides.";
RL   Chem. Ber. 106:199-205(1973).
RN   [18]
RP   SYNTHESIS OF 84-87.
RX   PubMed=4698553; DOI=10.1002/cber.19731060122;
RA   Geiger R., Jaeger G., Keonig W., Treuth G.;
RT   "Synthesis of peptides with the properties of human proinsulin C
RT   peptides (hC peptide). I. Scheme for the synthesis and preparation of
RT   the sequence 28-31 of human proinsulin C peptide.";
RL   Chem. Ber. 106:188-192(1973).
RN   [19]
RP   VARIANT LOS ANGELES SER-48.
RX   PubMed=6312455; DOI=10.1073/pnas.80.20.6366;
RA   Haneda M., Chan S.J., Kwok S.C.M., Rubenstein A.H., Steiner D.F.;
RT   "Studies on mutant human insulin genes: identification and sequence
RT   analysis of a gene encoding [SerB24]insulin.";
RL   Proc. Natl. Acad. Sci. U.S.A. 80:6366-6370(1983).
RN   [20]
RP   VARIANTS LOS ANGELES SER-48 AND CHICAGO LEU-49.
RX   PubMed=6424111; DOI=10.1073/pnas.80.24.7390;
RA   Shoelson S., Fickova M., Haneda M., Nahum A., Musso G., Kaiser E.T.,
RA   Rubenstein A.H., Tager H.;
RT   "Identification of a mutant human insulin predicted to contain a
RT   serine-for-phenylalanine substitution.";
RL   Proc. Natl. Acad. Sci. U.S.A. 80:7390-7394(1983).
RN   [21]
RP   VARIANT HPRI ASP-34.
RX   PubMed=3470784; DOI=10.1073/pnas.84.8.2194;
RA   Chan S.J., Seino S., Gruppuso P.A., Schwartz R., Steiner D.F.;
RT   "A mutation in the B chain coding region is associated with impaired
RT   proinsulin conversion in a family with hyperproinsulinemia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:2194-2197(1987).
RN   [22]
RP   VARIANT WAKAYAMA LEU-92.
RX   PubMed=3537011; DOI=10.1172/JCI112760;
RA   Sakura H., Iwamoto Y., Sakamoto Y., Kuzuya T., Hirata H.;
RT   "Structurally abnormal insulin in a diabetic patient. Characterization
RT   of the mutant insulin A3 (Val-->Leu) isolated from the pancreas.";
RL   J. Clin. Invest. 78:1666-1672(1986).
RN   [23]
RP   VARIANT HPRI HIS-89.
RX   PubMed=2196279; DOI=10.1210/jcem-71-1-164;
RA   Barbetti F., Raben N., Kadowaki T., Cama A., Accili D., Gabbay K.H.,
RA   Merenich J.A., Taylor S.I., Roth J.;
RT   "Two unrelated patients with familial hyperproinsulinemia due to a
RT   mutation substituting histidine for arginine at position 65 in the
RT   proinsulin molecule: identification of the mutation by direct
RT   sequencing of genomic deoxyribonucleic acid amplified by polymerase
RT   chain reaction.";
RL   J. Clin. Endocrinol. Metab. 71:164-169(1990).
RN   [24]
RP   VARIANT HPRI HIS-89.
RX   PubMed=4019786; DOI=10.1172/JCI111973;
RA   Shibasaki Y., Kawakami T., Kanazawa Y., Akanuma Y., Takaku F.;
RT   "Posttranslational cleavage of proinsulin is blocked by a point
RT   mutation in familial hyperproinsulinemia.";
RL   J. Clin. Invest. 76:378-380(1985).
RN   [25]
RP   VARIANT HPRI LEU-89.
RX   PubMed=1601997; DOI=10.1172/JCI115795;
RA   Yano H., Kitano N., Morimoto M., Polonsky K.S., Imura H., Seino Y.;
RT   "A novel point mutation in the human insulin gene giving rise to
RT   hyperproinsulinemia (proinsulin Kyoto).";
RL   J. Clin. Invest. 89:1902-1907(1992).
RN   [26]
RP   STRUCTURE BY NMR.
RX   PubMed=2271664; DOI=10.1021/bi00498a018;
RA   Hua Q.-X., Weiss M.A.;
RT   "Toward the solution structure of human insulin: sequential 2D 1H NMR
RT   assignment of a des-pentapeptide analogue and comparison with crystal
RT   structure.";
RL   Biochemistry 29:10545-10555(1990).
RN   [27]
RP   STRUCTURE BY NMR.
RX   PubMed=2036420; DOI=10.1021/bi00236a025;
RA   Hua Q.-X., Weiss M.A.;
RT   "Comparative 2D NMR studies of human insulin and des-pentapeptide
RT   insulin: sequential resonance assignment and implications for protein
RT   dynamics and receptor recognition.";
RL   Biochemistry 30:5505-5515(1991).
RN   [28]
RP   STRUCTURE BY NMR.
RX   PubMed=1646635; DOI=10.1016/0167-4838(91)90098-K;
RA   Hua Q.-X., Weiss M.A.;
RT   "Two-dimensional NMR studies of Des-(B26-B30)-insulin: sequence-
RT   specific resonance assignments and effects of solvent composition.";
RL   Biochim. Biophys. Acta 1078:101-110(1991).
RN   [29]
RP   STRUCTURE BY NMR.
RX   PubMed=1433291; DOI=10.1016/0022-2836(92)90527-Q;
RA   Joergensen A.M.M., Kristensen S.M., Led J.J., Balschmidt P.;
RT   "Three-dimensional solution structure of an insulin dimer. A study of
RT   the B9(Asp) mutant of human insulin using nuclear magnetic resonance,
RT   distance geometry and restrained molecular dynamics.";
RL   J. Mol. Biol. 227:1146-1163(1992).
RN   [30]
RP   STRUCTURE BY NMR OF VARIANT LOS-ANGELES SER-48.
RX   PubMed=8421693; DOI=10.1073/pnas.90.2.582;
RA   Hua Q.-X., Shoelson S.E., Inouye K., Weiss M.A.;
RT   "Paradoxical structure and function in a mutant human insulin
RT   associated with diabetes mellitus.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:582-586(1993).
RN   [31]
RP   STRUCTURE BY NMR.
RX   PubMed=9235985; DOI=10.1021/bi9631069;
RA   Chang X., Joergensen A.M., Bardrum P., Led J.J.;
RT   "Solution structures of the R6 human insulin hexamer.";
RL   Biochemistry 36:9409-9422(1997).
RN   [32]
RP   VARIANTS PNDM ASP-24; ARG-32; SER-32; GLY-43; VAL-47; CYS-48; CYS-89;
RP   CYS-90; TYR-96 AND CYS-108.
RX   PubMed=17855560; DOI=10.1073/pnas.0707291104;
RA   Stoy J., Edghill E.L., Flanagan S.E., Ye H., Paz V.P., Pluzhnikov A.,
RA   Below J.E., Hayes M.G., Cox N.J., Lipkind G.M., Lipton R.B.,
RA   Greeley S.A., Patch A.M., Ellard S., Steiner D.F., Hattersley A.T.,
RA   Philipson L.H., Bell G.I.;
RT   "Insulin gene mutations as a cause of permanent neonatal diabetes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:15040-15044(2007).
RN   [33]
RP   VARIANTS PNDM ASP-24; ASP-29; ARG-32; SER-32; PRO-35; GLY-43; VAL-47;
RP   CYS-48; ARG-84; CYS-89; CYS-90; SER-96; TYR-96; CYS-101; CYS-103 AND
RP   CYS-108, VARIANT MODY10 CYS-6, AND VARIANT MET-68.
RX   PubMed=18162506; DOI=10.2337/db07-1405;
RA   Edghill E.L., Flanagan S.E., Patch A.M., Boustred C., Parrish A.,
RA   Shields B., Shepherd M.H., Hussain K., Kapoor R.R., Malecki M.,
RA   MacDonald M.J., Stoy J., Steiner D.F., Philipson L.H., Bell G.I.,
RA   Hattersley A.T., Ellard S.;
RT   "Insulin mutation screening in 1,044 patients with diabetes: mutations
RT   in the INS gene are a common cause of neonatal diabetes but a rare
RT   cause of diabetes diagnosed in childhood or adulthood.";
RL   Diabetes 57:1034-1042(2008).
RN   [34]
RP   VARIANT MODY10 GLN-46, AND VARIANT IDDM2 CYS-55.
RX   PubMed=18192540; DOI=10.2337/db07-1467;
RA   Molven A., Ringdal M., Nordbo A.M., Raeder H., Stoy J., Lipkind G.M.,
RA   Steiner D.F., Philipson L.H., Bergmann I., Aarskog D., Undlien D.E.,
RA   Joner G., Sovik O., Bell G.I., Njolstad P.R.;
RT   "Mutations in the insulin gene can cause MODY and autoantibody-
RT   negative type 1 diabetes.";
RL   Diabetes 57:1131-1135(2008).
RN   [35]
RP   VARIANTS MODY10 HIS-6 AND GLN-46.
RX   PubMed=20226046; DOI=10.1186/1471-2350-11-42;
RA   Boesgaard T.W., Pruhova S., Andersson E.A., Cinek O., Obermannova B.,
RA   Lauenborg J., Damm P., Bergholdt R., Pociot F., Pisinger C.,
RA   Barbetti F., Lebl J., Pedersen O., Hansen T.;
RT   "Further evidence that mutations in INS can be a rare cause of
RT   Maturity-Onset Diabetes of the Young (MODY).";
RL   BMC Med. Genet. 11:42-42(2010).
CC   -!- FUNCTION: Insulin decreases blood glucose concentration. It
CC       increases cell permeability to monosaccharides, amino acids and
CC       fatty acids. It accelerates glycolysis, the pentose phosphate
CC       cycle, and glycogen synthesis in liver.
CC   -!- SUBUNIT: Heterodimer of a B chain and an A chain linked by two
CC       disulfide bonds.
CC   -!- INTERACTION:
CC       Self; NbExp=16; IntAct=EBI-7090529, EBI-7090529;
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P01308-1; Sequence=Displayed;
CC       Name=2; Synonyms=INS-IGF2;
CC         IsoId=F8WCM5-1; Sequence=External;
CC         Note=Based on a readthrough transcript which may produce an
CC         INS-IGF2 fusion protein.;
CC   -!- DISEASE: Hyperproinsulinemia (HPRI) [MIM:616214]: An autosomal
CC       dominant condition characterized by elevated levels of serum
CC       proinsulin-like material. {ECO:0000269|PubMed:1601997,
CC       ECO:0000269|PubMed:2196279, ECO:0000269|PubMed:3470784,
CC       ECO:0000269|PubMed:4019786}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Diabetes mellitus, insulin-dependent, 2 (IDDM2)
CC       [MIM:125852]: A multifactorial disorder of glucose homeostasis
CC       that is characterized by susceptibility to ketoacidosis in the
CC       absence of insulin therapy. Clinical features are polydipsia,
CC       polyphagia and polyuria which result from hyperglycemia-induced
CC       osmotic diuresis and secondary thirst. These derangements result
CC       in long-term complications that affect the eyes, kidneys, nerves,
CC       and blood vessels. {ECO:0000269|PubMed:18192540}. Note=The disease
CC       is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Diabetes mellitus, permanent neonatal (PNDM)
CC       [MIM:606176]: A rare form of diabetes distinct from childhood-
CC       onset autoimmune diabetes mellitus type 1. It is characterized by
CC       insulin-requiring hyperglycemia that is diagnosed within the first
CC       months of life. Permanent neonatal diabetes requires lifelong
CC       therapy. {ECO:0000269|PubMed:17855560,
CC       ECO:0000269|PubMed:18162506}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Maturity-onset diabetes of the young 10 (MODY10)
CC       [MIM:613370]: A form of diabetes that is characterized by an
CC       autosomal dominant mode of inheritance, onset in childhood or
CC       early adulthood (usually before 25 years of age), a primary defect
CC       in insulin secretion and frequent insulin-independence at the
CC       beginning of the disease. {ECO:0000269|PubMed:18162506,
CC       ECO:0000269|PubMed:18192540, ECO:0000269|PubMed:20226046}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- PHARMACEUTICAL: Available under the names Humulin or Humalog (Eli
CC       Lilly) and Novolin (Novo Nordisk). Used in the treatment of
CC       diabetes. Humalog is an insulin analog with 52-Lys-Pro-53 instead
CC       of 52-Pro-Lys-53.
CC   -!- SIMILARITY: Belongs to the insulin family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA59179.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Insulin at Eli Lilly; Note=Clinical information
CC       on Eli Lilly insulin products;
CC       URL="http://www.lillyDiabetes.com/Products/PatientInfo.cfm";
CC   -!- WEB RESOURCE: Name=Protein Spotlight; Note=Protein of the 20th
CC       century - Issue 9 of April 2001;
CC       URL="http://web.expasy.org/spotlight/back_issues/009";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Insulin entry;
CC       URL="https://en.wikipedia.org/wiki/Insulin";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; V00565; CAA23828.1; -; Genomic_DNA.
DR   EMBL; M10039; AAA59173.1; -; Genomic_DNA.
DR   EMBL; J00265; AAA59172.1; -; Genomic_DNA.
DR   EMBL; X70508; CAA49913.1; -; mRNA.
DR   EMBL; L15440; AAA59179.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AY899304; AAW83741.1; -; mRNA.
DR   EMBL; AY138590; AAN39451.1; -; Genomic_DNA.
DR   EMBL; BT006808; AAP35454.1; -; mRNA.
DR   EMBL; CH471158; EAX02488.1; -; Genomic_DNA.
DR   EMBL; BC005255; AAH05255.1; -; mRNA.
DR   EMBL; AJ009655; CAA08766.1; -; Genomic_DNA.
DR   CCDS; CCDS7729.1; -. [P01308-1]
DR   PIR; A93222; IPHU.
DR   RefSeq; NP_000198.1; NM_000207.2. [P01308-1]
DR   RefSeq; NP_001172026.1; NM_001185097.1. [P01308-1]
DR   RefSeq; NP_001172027.1; NM_001185098.1. [P01308-1]
DR   RefSeq; NP_001278826.1; NM_001291897.1. [P01308-1]
DR   UniGene; Hs.272259; -.
DR   PDB; 1A7F; NMR; -; A=90-110, B=25-53.
DR   PDB; 1AI0; NMR; -; A/C/E/G/I/K=90-110, B/D/F/H/J/L=25-54.
DR   PDB; 1AIY; NMR; -; A/C/E/G/I/K=90-110, B/D/F/H/J/L=25-54.
DR   PDB; 1B9E; X-ray; 2.50 A; A/C=90-110, B/D=25-54.
DR   PDB; 1BEN; X-ray; 1.40 A; A/C=90-110, B/D=25-54.
DR   PDB; 1EFE; NMR; -; A=25-54, A=90-110.
DR   PDB; 1EV3; X-ray; 1.78 A; A/C=90-110, B/D=25-54.
DR   PDB; 1EV6; X-ray; 1.90 A; A/C/E/G/I/K=90-110, B/D/F/H/J/L=25-54.
DR   PDB; 1EVR; X-ray; 1.90 A; A/C/E/G/I/K=90-110, B/D/F/H/J/L=25-54.
DR   PDB; 1FU2; X-ray; 3.24 A; A/C/E/G=90-110, B/D/F/H=25-54.
DR   PDB; 1FUB; X-ray; 3.09 A; A/C=90-110, B/D=25-54.
DR   PDB; 1G7A; X-ray; 1.20 A; A/C/E/G=90-110, B/D/F/H=25-54.
DR   PDB; 1G7B; X-ray; 1.30 A; A/C/E/G=90-110, B/D/F/H=25-54.
DR   PDB; 1GUJ; X-ray; 1.62 A; A/C=90-110, B/D=25-54.
DR   PDB; 1HIQ; NMR; -; A=90-110, B=25-54.
DR   PDB; 1HIS; NMR; -; A=90-110, B=25-49.
DR   PDB; 1HIT; NMR; -; A=90-110, B=25-54.
DR   PDB; 1HLS; NMR; -; A=90-110, B=25-54.
DR   PDB; 1HTV; X-ray; 1.90 A; A/C/E/G/I/K=90-110, B/D/F/H/J/L=25-51.
DR   PDB; 1HUI; NMR; -; A=90-110, B=26-53.
DR   PDB; 1IOG; NMR; -; A=90-110, B=25-53.
DR   PDB; 1IOH; NMR; -; A=90-110, B=25-53.
DR   PDB; 1J73; X-ray; 2.00 A; A/C=90-110, B/D=25-54.
DR   PDB; 1JCA; X-ray; 2.50 A; A/C=90-110, B/D=25-54.
DR   PDB; 1JCO; NMR; -; A=90-110, B=25-54.
DR   PDB; 1JK8; X-ray; 2.40 A; C=35-47.
DR   PDB; 1K3M; NMR; -; A=90-110, B=25-54.
DR   PDB; 1KMF; NMR; -; A=90-110, B=25-54.
DR   PDB; 1LKQ; NMR; -; A=90-110, B=25-54.
DR   PDB; 1LPH; X-ray; 2.30 A; A/C=90-110, B/D=25-54.
DR   PDB; 1MHI; NMR; -; A=90-110, B=25-54.
DR   PDB; 1MHJ; NMR; -; A=90-110, B=25-54.
DR   PDB; 1MSO; X-ray; 1.00 A; A/C=90-110, B/D=25-54.
DR   PDB; 1OS3; X-ray; 1.95 A; A/C=90-110, B/D=25-54.
DR   PDB; 1OS4; X-ray; 2.25 A; A/C/E/G/I/K=90-110, B/D/F/H/J/L=25-54.
DR   PDB; 1Q4V; X-ray; 2.00 A; A/C=90-110, B/D=25-54.
DR   PDB; 1QIY; X-ray; 2.30 A; A/C/E/G/I/K=90-110, B/D/F/H/J/L=25-54.
DR   PDB; 1QIZ; X-ray; 2.00 A; A/C/E/G/I/K=90-110, B/D/F/H/J/L=25-54.
DR   PDB; 1QJ0; X-ray; 2.40 A; A/C=90-110, B/D=25-54.
DR   PDB; 1RWE; X-ray; 1.80 A; A/C=90-110, B/D=25-54.
DR   PDB; 1SF1; NMR; -; A=90-110, B=25-54.
DR   PDB; 1SJT; NMR; -; A=90-110, B=25-51.
DR   PDB; 1SJU; NMR; -; A=25-110.
DR   PDB; 1T0C; NMR; -; A=57-87.
DR   PDB; 1T1K; NMR; -; A=90-110, B=25-54.
DR   PDB; 1T1P; NMR; -; A=90-110, B=25-54.
DR   PDB; 1T1Q; NMR; -; A=90-110, B=25-54.
DR   PDB; 1TRZ; X-ray; 1.60 A; A/C=90-110, B/D=25-54.
DR   PDB; 1TYL; X-ray; 1.90 A; A/C=90-110, B/D=25-54.
DR   PDB; 1TYM; X-ray; 1.90 A; A/C=90-110, B/D=25-54.
DR   PDB; 1UZ9; X-ray; 1.60 A; A=90-110, B=25-53.
DR   PDB; 1VKT; NMR; -; A=90-110, B=25-54.
DR   PDB; 1W8P; X-ray; 2.08 A; A/C/E/G/I/K=90-110, B/D/F/H/J/L=25-54.
DR   PDB; 1XDA; X-ray; 1.80 A; A/C/E/G=90-110, B/D/F/H=25-53.
DR   PDB; 1XGL; NMR; -; A=90-110, B=25-54.
DR   PDB; 1XW7; X-ray; 2.30 A; A/C=90-110, B/D=25-54.
DR   PDB; 1ZEG; X-ray; 1.60 A; A/C=90-110, B/D=25-54.
DR   PDB; 1ZEH; X-ray; 1.50 A; A/C=90-110, B/D=25-54.
DR   PDB; 1ZNJ; X-ray; 2.00 A; A/C/E/G/I/K=90-110, B/D/F/H/J/L=25-54.
DR   PDB; 2AIY; NMR; -; A/C/E/G/I/K=90-110, B/D/F/H/J/L=25-54.
DR   PDB; 2C8Q; X-ray; 1.95 A; A=90-110, B=25-53.
DR   PDB; 2C8R; X-ray; 1.50 A; A=90-110, B=25-53.
DR   PDB; 2CEU; X-ray; 1.80 A; A/C=90-110, B/D=25-49.
DR   PDB; 2G54; X-ray; 2.25 A; C/D=25-54.
DR   PDB; 2G56; X-ray; 2.20 A; C/D=25-54.
DR   PDB; 2H67; NMR; -; A=90-110, B=25-54.
DR   PDB; 2HH4; NMR; -; A=90-110, B=25-54.
DR   PDB; 2HHO; NMR; -; A=90-110, B=25-54.
DR   PDB; 2HIU; NMR; -; A=90-110, B=25-54.
DR   PDB; 2JMN; NMR; -; A=90-110, B=25-54.
DR   PDB; 2JUM; NMR; -; A=90-110, B=25-54.
DR   PDB; 2JUU; NMR; -; A=90-110, B=25-54.
DR   PDB; 2JUV; NMR; -; A=90-110, B=25-54.
DR   PDB; 2JV1; NMR; -; A=90-110, B=25-54.
DR   PDB; 2JZQ; NMR; -; A=25-54, A=90-110.
DR   PDB; 2K91; NMR; -; A=90-110, B=25-54.
DR   PDB; 2K9R; NMR; -; A=90-110, B=25-54.
DR   PDB; 2KJJ; NMR; -; A=90-110, B=25-54.
DR   PDB; 2KJU; NMR; -; A=90-110, B=25-54.
DR   PDB; 2KQP; NMR; -; A=25-110.
DR   PDB; 2KQQ; NMR; -; A=90-110, B=25-54.
DR   PDB; 2KXK; NMR; -; A=90-110, B=25-54.
DR   PDB; 2L1Y; NMR; -; A=90-110, B=25-54.
DR   PDB; 2L1Z; NMR; -; A=90-110, B=25-54.
DR   PDB; 2LGB; NMR; -; A=90-110, B=25-55.
DR   PDB; 2LWZ; NMR; -; A=25-54, A=89-110.
DR   PDB; 2M1D; NMR; -; A=90-110, B=25-54.
DR   PDB; 2M1E; NMR; -; A=90-110, B=25-54.
DR   PDB; 2M2M; NMR; -; A=90-110, B=25-54.
DR   PDB; 2M2N; NMR; -; A=90-110, B=25-54.
DR   PDB; 2M2O; NMR; -; A=90-110, B=25-54.
DR   PDB; 2M2P; NMR; -; A=90-110, B=25-54.
DR   PDB; 2MLI; NMR; -; A=90-110, B=25-54.
DR   PDB; 2MPG; NMR; -; A=90-110, B=25-54.
DR   PDB; 2MPI; NMR; -; A=90-110, B=25-54.
DR   PDB; 2MVC; NMR; -; A=90-110, B=25-54.
DR   PDB; 2MVD; NMR; -; A=90-110, B=25-54.
DR   PDB; 2OLY; X-ray; 1.70 A; A/C/E/G/I/K=90-110, B/D/F/H/J/L=25-54.
DR   PDB; 2OLZ; X-ray; 1.70 A; A/C/E/G/I/K=90-110, B/D/F/H/J/L=25-54.
DR   PDB; 2OM0; X-ray; 2.05 A; 1/3/A/C/E/G/I/K/Q/S/U/X/a/c/e/g/i/k=90-110, 2/4/B/D/F/H/J/L/R/T/V/Y/b/d/f/h/j/l=25-54.
DR   PDB; 2OM1; X-ray; 1.97 A; 1/3/A/C/E/G/I/K/Q/S/U/X/a/c/e/g/i/k=90-110, 2/4/B/D/F/H/J/L/R/T/V/Y/b/d/f/h/j/l=25-54.
DR   PDB; 2OMG; X-ray; 1.52 A; A/C/E=90-110, B/D/F=25-54.
DR   PDB; 2OMH; X-ray; 1.36 A; A/C/E=90-110, B/D/F=25-54.
DR   PDB; 2OMI; X-ray; 2.24 A; A/C/E/G/I/K=90-110, B/D/F/H/J/L=25-54.
DR   PDB; 2OMQ; X-ray; 2.00 A; A/B/C/D=36-41.
DR   PDB; 2QIU; X-ray; 2.00 A; A/C=89-110, B/D=25-54.
DR   PDB; 2R34; X-ray; 2.25 A; A/C=89-110, B/D=25-54.
DR   PDB; 2R35; X-ray; 2.08 A; A/C=89-110, B/D=25-54.
DR   PDB; 2R36; X-ray; 2.00 A; A/C=89-110, B/D=25-54.
DR   PDB; 2RN5; NMR; -; A=90-110, B=25-54.
DR   PDB; 2VJZ; X-ray; 1.80 A; A/C=90-110, B/D=25-54.
DR   PDB; 2VK0; X-ray; 2.20 A; A/C=90-110, B/D=25-54.
DR   PDB; 2W44; X-ray; 2.00 A; A/C/E=94-110, B/D/F=25-53.
DR   PDB; 2WBY; X-ray; 2.60 A; C/E=90-109, D/F=25-43.
DR   PDB; 2WC0; X-ray; 2.80 A; C/E=90-110, D/F=25-54.
DR   PDB; 2WRU; X-ray; 1.57 A; A=90-110, B=25-50.
DR   PDB; 2WRV; X-ray; 2.15 A; A=90-110, B=25-50.
DR   PDB; 2WRW; X-ray; 2.41 A; A=90-110, B=25-50.
DR   PDB; 2WRX; X-ray; 1.50 A; A/C=90-110, B/D=25-54.
DR   PDB; 2WS0; X-ray; 2.10 A; A=90-110, B=25-54.
DR   PDB; 2WS1; X-ray; 1.60 A; A=90-110, B=25-54.
DR   PDB; 2WS4; X-ray; 1.90 A; A=90-110, B=25-50.
DR   PDB; 2WS6; X-ray; 1.50 A; A/C/E/G/I/K=90-110, B/D/F/H/J/L=25-54.
DR   PDB; 2WS7; X-ray; 2.59 A; A/C/E/G/I/K=90-110, B/D/F/H/J/L=25-50.
DR   PDB; 3AIY; NMR; -; A/C/E/G/I/K=90-110, B/D/F/H/J/L=25-54.
DR   PDB; 3BXQ; X-ray; 1.30 A; A/C=90-110, B/D=25-54.
DR   PDB; 3E7Y; X-ray; 1.60 A; A/C=90-110, B/D=25-53.
DR   PDB; 3E7Z; X-ray; 1.70 A; A/C=90-110, B/D=25-53.
DR   PDB; 3EXX; X-ray; 1.35 A; A/C=90-110, B/D=25-54.
DR   PDB; 3FQ9; X-ray; 1.35 A; A/C=91-110, B/D=25-54.
DR   PDB; 3HYD; X-ray; 1.00 A; A=35-41.
DR   PDB; 3I3Z; X-ray; 1.60 A; A=90-110, B=25-54.
DR   PDB; 3I40; X-ray; 1.85 A; A=90-110, B=25-54.
DR   PDB; 3ILG; X-ray; 1.90 A; A/C=90-110, B/D=25-54.
DR   PDB; 3INC; X-ray; 1.85 A; A/C=90-110, B/D=25-54.
DR   PDB; 3IR0; X-ray; 2.20 A; A/C/E/G/I/K/M/O/R/T/V/X=90-110, B/D/F/H/J/L/N/P/S/U/W/Y=25-54.
DR   PDB; 3JSD; X-ray; 2.50 A; A/C=90-110, B/D=25-54.
DR   PDB; 3KQ6; X-ray; 1.90 A; A/C=90-110, B/D=25-54.
DR   PDB; 3P2X; X-ray; 2.00 A; A/C=90-110, B/D=25-54.
DR   PDB; 3P33; X-ray; 2.30 A; A/C/E/G=90-110, B/D/F/H=25-54.
DR   PDB; 3Q6E; X-ray; 2.05 A; A/C=90-110, B/D=25-54.
DR   PDB; 3ROV; X-ray; 2.30 A; A/C/E/G/I/K=90-110, B/D/F/H/J/L=25-54.
DR   PDB; 3TT8; X-ray; 1.12 A; A/C=90-110, B/D=25-54.
DR   PDB; 3U4N; X-ray; 1.98 A; A=90-110, B=25-53.
DR   PDB; 3UTQ; X-ray; 1.67 A; C=15-24.
DR   PDB; 3UTS; X-ray; 2.71 A; C/H=15-24.
DR   PDB; 3UTT; X-ray; 2.60 A; C/H=15-24.
DR   PDB; 3V19; X-ray; 2.00 A; A/C=90-110, B/D=25-54.
DR   PDB; 3V1G; X-ray; 2.20 A; A/C=90-110, B/D=25-54.
DR   PDB; 3W11; X-ray; 3.90 A; A=90-110, B=25-54.
DR   PDB; 3W12; X-ray; 4.30 A; A=90-110, B=25-50.
DR   PDB; 3W13; X-ray; 4.30 A; A=90-110, B=25-50.
DR   PDB; 3W7Y; X-ray; 0.92 A; A/C=90-110, B/D=25-54.
DR   PDB; 3W7Z; X-ray; 1.15 A; A/C=90-110, B/D=25-54.
DR   PDB; 3W80; X-ray; 1.40 A; A/C/E/G=90-110, B/D/F/H=25-54.
DR   PDB; 3ZI3; X-ray; 1.70 A; A=90-110, B=25-54.
DR   PDB; 3ZQR; X-ray; 1.90 A; A/C/E/G/I/K=90-110, B/D/F/H/J/L=25-54.
DR   PDB; 3ZS2; X-ray; 1.97 A; A/C/E/G/I/K=90-110, B/D/F/H/J/L=25-54.
DR   PDB; 3ZU1; X-ray; 1.60 A; A/C=90-110, B/D=25-54.
DR   PDB; 4AIY; NMR; -; A/C/E/G/I/K=90-110, B/D/F/H/J/L=25-54.
DR   PDB; 4AJX; X-ray; 1.20 A; A/C/E/G/I/K=90-110, B/D/F/H/J/L=25-53.
DR   PDB; 4AJZ; X-ray; 1.80 A; A/C=90-110, B/D=25-53.
DR   PDB; 4AK0; X-ray; 2.28 A; A=90-110, B=25-53.
DR   PDB; 4AKJ; X-ray; 2.01 A; A/C=90-110, B/D=25-53.
DR   PDB; 4CXL; X-ray; 1.50 A; A=90-110, B=25-54.
DR   PDB; 4CXN; X-ray; 1.70 A; A=90-110, B=25-54.
DR   PDB; 4CY7; X-ray; 1.40 A; A/C=90-110, B/D=25-54.
DR   PDB; 4EFX; X-ray; 1.98 A; A/C=90-110, B/D=25-52.
DR   PDB; 4EWW; X-ray; 2.30 A; A/C=90-110, B/D=25-54.
DR   PDB; 4EWX; X-ray; 2.20 A; A/C=90-110, B/D=25-54.
DR   PDB; 4EWZ; X-ray; 1.79 A; A/C=90-110, B/D=25-54.
DR   PDB; 4EX0; X-ray; 1.86 A; A/C=90-110, B/D=25-54.
DR   PDB; 4EX1; X-ray; 1.66 A; A/C=90-110, B/D=25-54.
DR   PDB; 4EXX; X-ray; 1.55 A; A/C=90-110, B/D=25-54.
DR   PDB; 4EY1; X-ray; 1.47 A; A/C=90-110, B/D=25-54.
DR   PDB; 4EY9; X-ray; 1.47 A; A/C=90-110, B/D=25-54.
DR   PDB; 4EYD; X-ray; 1.47 A; A/C=90-110, B/D=25-54.
DR   PDB; 4EYN; X-ray; 1.53 A; A/C=90-110, B/D=25-54.
DR   PDB; 4EYP; X-ray; 1.59 A; A/C=90-110, B/D=25-54.
DR   PDB; 4F0N; X-ray; 1.68 A; A/C=90-110, B/D=25-54.
DR   PDB; 4F0O; X-ray; 1.67 A; A/C=90-110, B/D=25-54.
DR   PDB; 4F1A; X-ray; 1.80 A; A/C=90-110, B/D=25-54.
DR   PDB; 4F1B; X-ray; 1.59 A; A/C=90-110, B/D=25-54.
DR   PDB; 4F1C; X-ray; 1.70 A; A/C=90-110, B/D=25-54.
DR   PDB; 4F1D; X-ray; 1.64 A; A/C=90-110, B/D=25-54.
DR   PDB; 4F1F; X-ray; 1.68 A; A/C=90-110, B/D=25-54.
DR   PDB; 4F1G; X-ray; 1.64 A; A/C=90-110, B/D=25-54.
DR   PDB; 4F4T; X-ray; 1.64 A; A/C=90-110, B/D=25-54.
DR   PDB; 4F4V; X-ray; 1.64 A; A/C=90-110, B/D=25-54.
DR   PDB; 4F51; X-ray; 1.64 A; A/C=90-110, B/D=25-54.
DR   PDB; 4F8F; X-ray; 1.68 A; A/C=90-110, B/D=25-54.
DR   PDB; 4FG3; X-ray; 2.00 A; A/C=90-110, B/D=25-54.
DR   PDB; 4FKA; X-ray; 1.08 A; A/C=90-110, B/D=25-54.
DR   PDB; 4GBC; X-ray; 1.78 A; A/C=90-110, B/D=25-54.
DR   PDB; 4GBI; X-ray; 2.50 A; A/C=90-110, B/D=25-54.
DR   PDB; 4GBK; X-ray; 2.40 A; A/C=90-110, B/D=25-54.
DR   PDB; 4GBL; X-ray; 2.50 A; A/C=90-110, B/D=25-54.
DR   PDB; 4GBN; X-ray; 1.87 A; A/C=90-110, B/D=25-54.
DR   PDB; 4IUZ; X-ray; 1.60 A; A=90-110, B=25-54.
DR   PDB; 4IYD; X-ray; 1.66 A; A=90-109, B=25-53.
DR   PDB; 4IYF; X-ray; 1.80 A; A=90-109, B=25-53.
DR   PDB; 4NIB; X-ray; 1.40 A; A=90-110, B=25-54.
DR   PDB; 4OGA; X-ray; 3.50 A; A=90-110, B=25-54.
DR   PDB; 4P65; X-ray; 1.50 A; A/C/E/G/I/K=90-110, B/D/F/H/J/L=25-54.
DR   PDB; 4Q5Z; X-ray; 3.93 A; a/b/c/d/e/f/g/h=90-109, x=25-43.
DR   PDB; 4RXW; X-ray; 1.73 A; A/C=90-110, B/D=25-54.
DR   PDB; 4UNE; X-ray; 1.59 A; A/C=90-110, B/D=25-54.
DR   PDB; 4UNG; X-ray; 1.81 A; A/C=90-110, B/D=25-54.
DR   PDB; 4UNH; X-ray; 2.75 A; A=90-110, B=25-54.
DR   PDB; 4WDI; X-ray; 2.31 A; C/F=39-47.
DR   PDB; 4XC4; X-ray; 1.50 A; A/C=90-110, B/D=25-54.
DR   PDB; 4Y19; X-ray; 2.50 A; C=75-90.
DR   PDB; 4Y1A; X-ray; 4.00 A; C=75-90.
DR   PDB; 4Z76; X-ray; 1.88 A; C/F=39-46.
DR   PDB; 4Z77; X-ray; 1.85 A; C/F=39-47.
DR   PDB; 4Z78; X-ray; 2.30 A; C/F/I=39-48.
DR   PDB; 5AIY; NMR; -; A/C/E/G/I/K=90-110, B/D/F/H/J/L=25-54.
DR   PDB; 5CNY; X-ray; 1.70 A; A/C=90-110, B/D=25-54.
DR   PDB; 5CO2; X-ray; 1.70 A; A/C=90-110, B/D=25-54.
DR   PDB; 5CO6; X-ray; 1.80 A; A/C=90-110, B/D=25-54.
DR   PDB; 5CO9; X-ray; 1.92 A; A/C=90-110, B/D=25-54.
DR   PDBsum; 1A7F; -.
DR   PDBsum; 1AI0; -.
DR   PDBsum; 1AIY; -.
DR   PDBsum; 1B9E; -.
DR   PDBsum; 1BEN; -.
DR   PDBsum; 1EFE; -.
DR   PDBsum; 1EV3; -.
DR   PDBsum; 1EV6; -.
DR   PDBsum; 1EVR; -.
DR   PDBsum; 1FU2; -.
DR   PDBsum; 1FUB; -.
DR   PDBsum; 1G7A; -.
DR   PDBsum; 1G7B; -.
DR   PDBsum; 1GUJ; -.
DR   PDBsum; 1HIQ; -.
DR   PDBsum; 1HIS; -.
DR   PDBsum; 1HIT; -.
DR   PDBsum; 1HLS; -.
DR   PDBsum; 1HTV; -.
DR   PDBsum; 1HUI; -.
DR   PDBsum; 1IOG; -.
DR   PDBsum; 1IOH; -.
DR   PDBsum; 1J73; -.
DR   PDBsum; 1JCA; -.
DR   PDBsum; 1JCO; -.
DR   PDBsum; 1JK8; -.
DR   PDBsum; 1K3M; -.
DR   PDBsum; 1KMF; -.
DR   PDBsum; 1LKQ; -.
DR   PDBsum; 1LPH; -.
DR   PDBsum; 1MHI; -.
DR   PDBsum; 1MHJ; -.
DR   PDBsum; 1MSO; -.
DR   PDBsum; 1OS3; -.
DR   PDBsum; 1OS4; -.
DR   PDBsum; 1Q4V; -.
DR   PDBsum; 1QIY; -.
DR   PDBsum; 1QIZ; -.
DR   PDBsum; 1QJ0; -.
DR   PDBsum; 1RWE; -.
DR   PDBsum; 1SF1; -.
DR   PDBsum; 1SJT; -.
DR   PDBsum; 1SJU; -.
DR   PDBsum; 1T0C; -.
DR   PDBsum; 1T1K; -.
DR   PDBsum; 1T1P; -.
DR   PDBsum; 1T1Q; -.
DR   PDBsum; 1TRZ; -.
DR   PDBsum; 1TYL; -.
DR   PDBsum; 1TYM; -.
DR   PDBsum; 1UZ9; -.
DR   PDBsum; 1VKT; -.
DR   PDBsum; 1W8P; -.
DR   PDBsum; 1XDA; -.
DR   PDBsum; 1XGL; -.
DR   PDBsum; 1XW7; -.
DR   PDBsum; 1ZEG; -.
DR   PDBsum; 1ZEH; -.
DR   PDBsum; 1ZNJ; -.
DR   PDBsum; 2AIY; -.
DR   PDBsum; 2C8Q; -.
DR   PDBsum; 2C8R; -.
DR   PDBsum; 2CEU; -.
DR   PDBsum; 2G54; -.
DR   PDBsum; 2G56; -.
DR   PDBsum; 2H67; -.
DR   PDBsum; 2HH4; -.
DR   PDBsum; 2HHO; -.
DR   PDBsum; 2HIU; -.
DR   PDBsum; 2JMN; -.
DR   PDBsum; 2JUM; -.
DR   PDBsum; 2JUU; -.
DR   PDBsum; 2JUV; -.
DR   PDBsum; 2JV1; -.
DR   PDBsum; 2JZQ; -.
DR   PDBsum; 2K91; -.
DR   PDBsum; 2K9R; -.
DR   PDBsum; 2KJJ; -.
DR   PDBsum; 2KJU; -.
DR   PDBsum; 2KQP; -.
DR   PDBsum; 2KQQ; -.
DR   PDBsum; 2KXK; -.
DR   PDBsum; 2L1Y; -.
DR   PDBsum; 2L1Z; -.
DR   PDBsum; 2LGB; -.
DR   PDBsum; 2LWZ; -.
DR   PDBsum; 2M1D; -.
DR   PDBsum; 2M1E; -.
DR   PDBsum; 2M2M; -.
DR   PDBsum; 2M2N; -.
DR   PDBsum; 2M2O; -.
DR   PDBsum; 2M2P; -.
DR   PDBsum; 2MLI; -.
DR   PDBsum; 2MPG; -.
DR   PDBsum; 2MPI; -.
DR   PDBsum; 2MVC; -.
DR   PDBsum; 2MVD; -.
DR   PDBsum; 2OLY; -.
DR   PDBsum; 2OLZ; -.
DR   PDBsum; 2OM0; -.
DR   PDBsum; 2OM1; -.
DR   PDBsum; 2OMG; -.
DR   PDBsum; 2OMH; -.
DR   PDBsum; 2OMI; -.
DR   PDBsum; 2OMQ; -.
DR   PDBsum; 2QIU; -.
DR   PDBsum; 2R34; -.
DR   PDBsum; 2R35; -.
DR   PDBsum; 2R36; -.
DR   PDBsum; 2RN5; -.
DR   PDBsum; 2VJZ; -.
DR   PDBsum; 2VK0; -.
DR   PDBsum; 2W44; -.
DR   PDBsum; 2WBY; -.
DR   PDBsum; 2WC0; -.
DR   PDBsum; 2WRU; -.
DR   PDBsum; 2WRV; -.
DR   PDBsum; 2WRW; -.
DR   PDBsum; 2WRX; -.
DR   PDBsum; 2WS0; -.
DR   PDBsum; 2WS1; -.
DR   PDBsum; 2WS4; -.
DR   PDBsum; 2WS6; -.
DR   PDBsum; 2WS7; -.
DR   PDBsum; 3AIY; -.
DR   PDBsum; 3BXQ; -.
DR   PDBsum; 3E7Y; -.
DR   PDBsum; 3E7Z; -.
DR   PDBsum; 3EXX; -.
DR   PDBsum; 3FQ9; -.
DR   PDBsum; 3HYD; -.
DR   PDBsum; 3I3Z; -.
DR   PDBsum; 3I40; -.
DR   PDBsum; 3ILG; -.
DR   PDBsum; 3INC; -.
DR   PDBsum; 3IR0; -.
DR   PDBsum; 3JSD; -.
DR   PDBsum; 3KQ6; -.
DR   PDBsum; 3P2X; -.
DR   PDBsum; 3P33; -.
DR   PDBsum; 3Q6E; -.
DR   PDBsum; 3ROV; -.
DR   PDBsum; 3TT8; -.
DR   PDBsum; 3U4N; -.
DR   PDBsum; 3UTQ; -.
DR   PDBsum; 3UTS; -.
DR   PDBsum; 3UTT; -.
DR   PDBsum; 3V19; -.
DR   PDBsum; 3V1G; -.
DR   PDBsum; 3W11; -.
DR   PDBsum; 3W12; -.
DR   PDBsum; 3W13; -.
DR   PDBsum; 3W7Y; -.
DR   PDBsum; 3W7Z; -.
DR   PDBsum; 3W80; -.
DR   PDBsum; 3ZI3; -.
DR   PDBsum; 3ZQR; -.
DR   PDBsum; 3ZS2; -.
DR   PDBsum; 3ZU1; -.
DR   PDBsum; 4AIY; -.
DR   PDBsum; 4AJX; -.
DR   PDBsum; 4AJZ; -.
DR   PDBsum; 4AK0; -.
DR   PDBsum; 4AKJ; -.
DR   PDBsum; 4CXL; -.
DR   PDBsum; 4CXN; -.
DR   PDBsum; 4CY7; -.
DR   PDBsum; 4EFX; -.
DR   PDBsum; 4EWW; -.
DR   PDBsum; 4EWX; -.
DR   PDBsum; 4EWZ; -.
DR   PDBsum; 4EX0; -.
DR   PDBsum; 4EX1; -.
DR   PDBsum; 4EXX; -.
DR   PDBsum; 4EY1; -.
DR   PDBsum; 4EY9; -.
DR   PDBsum; 4EYD; -.
DR   PDBsum; 4EYN; -.
DR   PDBsum; 4EYP; -.
DR   PDBsum; 4F0N; -.
DR   PDBsum; 4F0O; -.
DR   PDBsum; 4F1A; -.
DR   PDBsum; 4F1B; -.
DR   PDBsum; 4F1C; -.
DR   PDBsum; 4F1D; -.
DR   PDBsum; 4F1F; -.
DR   PDBsum; 4F1G; -.
DR   PDBsum; 4F4T; -.
DR   PDBsum; 4F4V; -.
DR   PDBsum; 4F51; -.
DR   PDBsum; 4F8F; -.
DR   PDBsum; 4FG3; -.
DR   PDBsum; 4FKA; -.
DR   PDBsum; 4GBC; -.
DR   PDBsum; 4GBI; -.
DR   PDBsum; 4GBK; -.
DR   PDBsum; 4GBL; -.
DR   PDBsum; 4GBN; -.
DR   PDBsum; 4IUZ; -.
DR   PDBsum; 4IYD; -.
DR   PDBsum; 4IYF; -.
DR   PDBsum; 4NIB; -.
DR   PDBsum; 4OGA; -.
DR   PDBsum; 4P65; -.
DR   PDBsum; 4Q5Z; -.
DR   PDBsum; 4RXW; -.
DR   PDBsum; 4UNE; -.
DR   PDBsum; 4UNG; -.
DR   PDBsum; 4UNH; -.
DR   PDBsum; 4WDI; -.
DR   PDBsum; 4XC4; -.
DR   PDBsum; 4Y19; -.
DR   PDBsum; 4Y1A; -.
DR   PDBsum; 4Z76; -.
DR   PDBsum; 4Z77; -.
DR   PDBsum; 4Z78; -.
DR   PDBsum; 5AIY; -.
DR   PDBsum; 5CNY; -.
DR   PDBsum; 5CO2; -.
DR   PDBsum; 5CO6; -.
DR   PDBsum; 5CO9; -.
DR   ProteinModelPortal; P01308; -.
DR   SMR; P01308; 25-110.
DR   BioGrid; 109842; 12.
DR   DIP; DIP-6024N; -.
DR   IntAct; P01308; 3.
DR   MINT; MINT-106847; -.
DR   STRING; 9606.ENSP00000250971; -.
DR   ChEMBL; CHEMBL5881; -.
DR   Allergome; 2121; Hom s Insulin.
DR   PhosphoSite; P01308; -.
DR   BioMuta; INS; -.
DR   DMDM; 124617; -.
DR   PaxDb; P01308; -.
DR   PeptideAtlas; P01308; -.
DR   PRIDE; P01308; -.
DR   DNASU; 3630; -.
DR   Ensembl; ENST00000250971; ENSP00000250971; ENSG00000254647. [P01308-1]
DR   Ensembl; ENST00000381330; ENSP00000370731; ENSG00000254647. [P01308-1]
DR   Ensembl; ENST00000397262; ENSP00000380432; ENSG00000254647. [P01308-1]
DR   GeneID; 3630; -.
DR   KEGG; hsa:3630; -.
DR   UCSC; uc001lvn.2; human. [P01308-1]
DR   CTD; 3630; -.
DR   GeneCards; INS; -.
DR   GeneReviews; INS; -.
DR   HGNC; HGNC:6081; INS.
DR   HPA; CAB000048; -.
DR   HPA; CAB012098; -.
DR   HPA; CAB053843; -.
DR   HPA; HPA004932; -.
DR   MalaCards; INS; -.
DR   MIM; 125852; phenotype.
DR   MIM; 176730; gene.
DR   MIM; 606176; phenotype.
DR   MIM; 613370; phenotype.
DR   MIM; 616214; phenotype.
DR   neXtProt; NX_P01308; -.
DR   Orphanet; 552; MODY.
DR   Orphanet; 99885; Permanent neonatal diabetes mellitus.
DR   PharmGKB; PA201; -.
DR   eggNOG; ENOG410J0XC; Eukaryota.
DR   eggNOG; ENOG4111VJB; LUCA.
DR   GeneTree; ENSGT00390000015440; -.
DR   HOGENOM; HOG000261669; -.
DR   HOVERGEN; HBG006137; -.
DR   InParanoid; P01308; -.
DR   KO; K04526; -.
DR   OMA; GFFYSPK; -.
DR   PhylomeDB; P01308; -.
DR   TreeFam; TF332820; -.
DR   BioCyc; MetaCyc:MONOMER-16190; -.
DR   Reactome; R-HSA-210745; Regulation of gene expression in beta cells.
DR   Reactome; R-HSA-264876; Insulin processing.
DR   Reactome; R-HSA-422085; Synthesis, secretion, and deacylation of Ghrelin.
DR   Reactome; R-HSA-422356; Regulation of insulin secretion.
DR   Reactome; R-HSA-6807878; COPI-mediated anterograde transport.
DR   Reactome; R-HSA-74713; IRS activation.
DR   Reactome; R-HSA-74749; Signal attenuation.
DR   Reactome; R-HSA-74751; Insulin receptor signalling cascade.
DR   Reactome; R-HSA-74752; Signaling by Insulin receptor.
DR   Reactome; R-HSA-77387; Insulin receptor recycling.
DR   SignaLink; P01308; -.
DR   EvolutionaryTrace; P01308; -.
DR   GeneWiki; Insulin; -.
DR   GenomeRNAi; 3630; -.
DR   NextBio; 14203; -.
DR   PMAP-CutDB; P01308; -.
DR   PRO; PR:P01308; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; P01308; -.
DR   ExpressionAtlas; P01308; baseline and differential.
DR   Genevisible; P01308; HS.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0031904; C:endosome lumen; TAS:Reactome.
DR   GO; GO:0005576; C:extracellular region; IC:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0005796; C:Golgi lumen; TAS:Reactome.
DR   GO; GO:0034774; C:secretory granule lumen; TAS:Reactome.
DR   GO; GO:0005179; F:hormone activity; NAS:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0005158; F:insulin receptor binding; IDA:UniProtKB.
DR   GO; GO:0005159; F:insulin-like growth factor receptor binding; IPI:BHF-UCL.
DR   GO; GO:0002020; F:protease binding; IPI:UniProtKB.
DR   GO; GO:0032148; P:activation of protein kinase B activity; IDA:BHF-UCL.
DR   GO; GO:0006953; P:acute-phase response; IDA:BHF-UCL.
DR   GO; GO:0046631; P:alpha-beta T cell activation; IDA:UniProtKB.
DR   GO; GO:0007267; P:cell-cell signaling; IC:UniProtKB.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0031018; P:endocrine pancreas development; TAS:Reactome.
DR   GO; GO:0006112; P:energy reserve metabolic process; TAS:Reactome.
DR   GO; GO:0055089; P:fatty acid homeostasis; IMP:BHF-UCL.
DR   GO; GO:0007186; P:G-protein coupled receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0042593; P:glucose homeostasis; IMP:BHF-UCL.
DR   GO; GO:0006006; P:glucose metabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0015758; P:glucose transport; IDA:UniProtKB.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0000165; P:MAPK cascade; IDA:BHF-UCL.
DR   GO; GO:0002674; P:negative regulation of acute inflammatory response; IDA:BHF-UCL.
DR   GO; GO:0045922; P:negative regulation of fatty acid metabolic process; IMP:BHF-UCL.
DR   GO; GO:2000252; P:negative regulation of feeding behavior; IDA:DFLAT.
DR   GO; GO:0045721; P:negative regulation of gluconeogenesis; NAS:BHF-UCL.
DR   GO; GO:0045818; P:negative regulation of glycogen catabolic process; IMP:BHF-UCL.
DR   GO; GO:0050995; P:negative regulation of lipid catabolic process; IMP:AgBase.
DR   GO; GO:0033861; P:negative regulation of NAD(P)H oxidase activity; IDA:BHF-UCL.
DR   GO; GO:1902176; P:negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway; NAS:BHF-UCL.
DR   GO; GO:0042177; P:negative regulation of protein catabolic process; IDA:UniProtKB.
DR   GO; GO:0032460; P:negative regulation of protein oligomerization; IDA:UniProtKB.
DR   GO; GO:0050709; P:negative regulation of protein secretion; IDA:BHF-UCL.
DR   GO; GO:0045861; P:negative regulation of proteolysis; IMP:BHF-UCL.
DR   GO; GO:0060266; P:negative regulation of respiratory burst involved in inflammatory response; IDA:BHF-UCL.
DR   GO; GO:0045908; P:negative regulation of vasodilation; NAS:UniProtKB.
DR   GO; GO:0090336; P:positive regulation of brown fat cell differentiation; TAS:BHF-UCL.
DR   GO; GO:0045597; P:positive regulation of cell differentiation; NAS:BHF-UCL.
DR   GO; GO:0030307; P:positive regulation of cell growth; NAS:BHF-UCL.
DR   GO; GO:0030335; P:positive regulation of cell migration; ISS:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0032270; P:positive regulation of cellular protein metabolic process; IMP:BHF-UCL.
DR   GO; GO:0050715; P:positive regulation of cytokine secretion; IDA:UniProtKB.
DR   GO; GO:0045740; P:positive regulation of DNA replication; IDA:BHF-UCL.
DR   GO; GO:0046326; P:positive regulation of glucose import; IDA:BHF-UCL.
DR   GO; GO:0045725; P:positive regulation of glycogen biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0045821; P:positive regulation of glycolytic process; IDA:BHF-UCL.
DR   GO; GO:0046628; P:positive regulation of insulin receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0046889; P:positive regulation of lipid biosynthetic process; NAS:BHF-UCL.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:BHF-UCL.
DR   GO; GO:0045840; P:positive regulation of mitotic nuclear division; IDA:UniProtKB.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IDA:BHF-UCL.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; NAS:UniProtKB.
DR   GO; GO:0051000; P:positive regulation of nitric-oxide synthase activity; NAS:UniProtKB.
DR   GO; GO:0090277; P:positive regulation of peptide hormone secretion; TAS:BHF-UCL.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; IDA:BHF-UCL.
DR   GO; GO:0031954; P:positive regulation of protein autophosphorylation; ISS:BHF-UCL.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IDA:BHF-UCL.
DR   GO; GO:1900182; P:positive regulation of protein localization to nucleus; IDA:BHF-UCL.
DR   GO; GO:0060267; P:positive regulation of respiratory burst; IDA:BHF-UCL.
DR   GO; GO:0045909; P:positive regulation of vasodilation; NAS:UniProtKB.
DR   GO; GO:0006521; P:regulation of cellular amino acid metabolic process; IMP:BHF-UCL.
DR   GO; GO:0050796; P:regulation of insulin secretion; TAS:Reactome.
DR   GO; GO:0032880; P:regulation of protein localization; IDA:BHF-UCL.
DR   GO; GO:0050708; P:regulation of protein secretion; IDA:UniProtKB.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; NAS:BHF-UCL.
DR   GO; GO:0022898; P:regulation of transmembrane transporter activity; IDA:BHF-UCL.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   GO; GO:0042060; P:wound healing; IDA:BHF-UCL.
DR   Gene3D; 1.10.100.10; -; 2.
DR   InterPro; IPR004825; Insulin.
DR   InterPro; IPR016179; Insulin-like.
DR   InterPro; IPR022353; Insulin_CS.
DR   InterPro; IPR022352; Insulin_family.
DR   Pfam; PF00049; Insulin; 1.
DR   PRINTS; PR00277; INSULIN.
DR   PRINTS; PR00276; INSULINFAMLY.
DR   SMART; SM00078; IlGF; 1.
DR   SUPFAM; SSF56994; SSF56994; 1.
DR   PROSITE; PS00262; INSULIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Carbohydrate metabolism;
KW   Cleavage on pair of basic residues; Complete proteome;
KW   Diabetes mellitus; Direct protein sequencing; Disease mutation;
KW   Disulfide bond; Glucose metabolism; Hormone; Pharmaceutical;
KW   Polymorphism; Reference proteome; Secreted; Signal.
FT   SIGNAL        1     24       {ECO:0000269|PubMed:14426955}.
FT   PEPTIDE      25     54       Insulin B chain.
FT                                /FTId=PRO_0000015819.
FT   PROPEP       57     87       C peptide.
FT                                /FTId=PRO_0000015820.
FT   PEPTIDE      90    110       Insulin A chain.
FT                                /FTId=PRO_0000015821.
FT   DISULFID     31     96       Interchain (between B and A chains).
FT   DISULFID     43    109       Interchain (between B and A chains).
FT   DISULFID     95    100       {ECO:0000269|PubMed:5101771}.
FT   VARIANT       6      6       R -> C (in MODY10; dbSNP:rs121908278).
FT                                {ECO:0000269|PubMed:18162506}.
FT                                /FTId=VAR_063721.
FT   VARIANT       6      6       R -> H (in MODY10; dbSNP:rs121908259).
FT                                {ECO:0000269|PubMed:20226046}.
FT                                /FTId=VAR_063722.
FT   VARIANT      24     24       A -> D (in PNDM; dbSNP:rs80356663).
FT                                {ECO:0000269|PubMed:17855560,
FT                                ECO:0000269|PubMed:18162506}.
FT                                /FTId=VAR_063723.
FT   VARIANT      29     29       H -> D (in PNDM; dbSNP:rs121908272).
FT                                {ECO:0000269|PubMed:18162506}.
FT                                /FTId=VAR_063724.
FT   VARIANT      32     32       G -> R (in PNDM; dbSNP:rs80356664).
FT                                {ECO:0000269|PubMed:17855560,
FT                                ECO:0000269|PubMed:18162506}.
FT                                /FTId=VAR_063725.
FT   VARIANT      32     32       G -> S (in PNDM; dbSNP:rs80356664).
FT                                {ECO:0000269|PubMed:17855560,
FT                                ECO:0000269|PubMed:18162506}.
FT                                /FTId=VAR_063726.
FT   VARIANT      34     34       H -> D (in HPRI; Providence).
FT                                {ECO:0000269|PubMed:3470784}.
FT                                /FTId=VAR_003971.
FT   VARIANT      35     35       L -> P (in PNDM; dbSNP:rs121908273).
FT                                {ECO:0000269|PubMed:18162506}.
FT                                /FTId=VAR_063727.
FT   VARIANT      43     43       C -> G (in PNDM; dbSNP:rs80356666).
FT                                {ECO:0000269|PubMed:17855560,
FT                                ECO:0000269|PubMed:18162506}.
FT                                /FTId=VAR_063728.
FT   VARIANT      46     46       R -> Q (in MODY10; dbSNP:rs121908260).
FT                                {ECO:0000269|PubMed:18192540,
FT                                ECO:0000269|PubMed:20226046}.
FT                                /FTId=VAR_063729.
FT   VARIANT      47     47       G -> V (in PNDM; dbSNP:rs80356667).
FT                                {ECO:0000269|PubMed:17855560,
FT                                ECO:0000269|PubMed:18162506}.
FT                                /FTId=VAR_063730.
FT   VARIANT      48     48       F -> C (in PNDM; dbSNP:rs80356668).
FT                                {ECO:0000269|PubMed:17855560,
FT                                ECO:0000269|PubMed:18162506}.
FT                                /FTId=VAR_063731.
FT   VARIANT      48     48       F -> S (associated with diabetes mellitus
FT                                type-II; Los-Angeles).
FT                                {ECO:0000269|PubMed:6312455,
FT                                ECO:0000269|PubMed:6424111,
FT                                ECO:0000269|PubMed:8421693}.
FT                                /FTId=VAR_003972.
FT   VARIANT      49     49       F -> L (in Chicago).
FT                                {ECO:0000269|PubMed:6424111}.
FT                                /FTId=VAR_003973.
FT   VARIANT      55     55       R -> C (in IDDM2; dbSNP:rs121908261).
FT                                {ECO:0000269|PubMed:18192540}.
FT                                /FTId=VAR_063732.
FT   VARIANT      68     68       L -> M (in dbSNP:rs121908279).
FT                                {ECO:0000269|PubMed:18162506}.
FT                                /FTId=VAR_063733.
FT   VARIANT      84     84       G -> R (in PNDM; uncertain pathological
FT                                significance; dbSNP:rs121908274).
FT                                {ECO:0000269|PubMed:18162506}.
FT                                /FTId=VAR_063734.
FT   VARIANT      89     89       R -> C (in PNDM; dbSNP:rs80356669).
FT                                {ECO:0000269|PubMed:17855560,
FT                                ECO:0000269|PubMed:18162506}.
FT                                /FTId=VAR_063735.
FT   VARIANT      89     89       R -> H (in HPRI; impairs
FT                                posttranslational cleavage;
FT                                dbSNP:rs28933985).
FT                                {ECO:0000269|PubMed:2196279,
FT                                ECO:0000269|PubMed:4019786}.
FT                                /FTId=VAR_003974.
FT   VARIANT      89     89       R -> L (in HPRI; Kyoto).
FT                                {ECO:0000269|PubMed:1601997}.
FT                                /FTId=VAR_003975.
FT   VARIANT      90     90       G -> C (in PNDM; dbSNP:rs80356670).
FT                                {ECO:0000269|PubMed:17855560,
FT                                ECO:0000269|PubMed:18162506}.
FT                                /FTId=VAR_063736.
FT   VARIANT      92     92       V -> L (in Wakayama).
FT                                {ECO:0000269|PubMed:3537011}.
FT                                /FTId=VAR_003976.
FT   VARIANT      96     96       C -> S (in PNDM; dbSNP:rs80356671).
FT                                {ECO:0000269|PubMed:18162506}.
FT                                /FTId=VAR_063737.
FT   VARIANT      96     96       C -> Y (in PNDM; dbSNP:rs80356671).
FT                                {ECO:0000269|PubMed:17855560,
FT                                ECO:0000269|PubMed:18162506}.
FT                                /FTId=VAR_063738.
FT   VARIANT     101    101       S -> C (in PNDM; dbSNP:rs121908276).
FT                                {ECO:0000269|PubMed:18162506}.
FT                                /FTId=VAR_063739.
FT   VARIANT     103    103       Y -> C (in PNDM; dbSNP:rs121908277).
FT                                {ECO:0000269|PubMed:18162506}.
FT                                /FTId=VAR_063740.
FT   VARIANT     108    108       Y -> C (in PNDM; dbSNP:rs80356672).
FT                                {ECO:0000269|PubMed:17855560,
FT                                ECO:0000269|PubMed:18162506}.
FT                                /FTId=VAR_063741.
FT   STRAND       26     29       {ECO:0000244|PDB:4EFX}.
FT   HELIX        33     43       {ECO:0000244|PDB:3W7Y}.
FT   HELIX        44     46       {ECO:0000244|PDB:3W7Y}.
FT   STRAND       48     50       {ECO:0000244|PDB:3W7Y}.
FT   TURN         59     66       {ECO:0000244|PDB:1T0C}.
FT   STRAND       74     76       {ECO:0000244|PDB:1T0C}.
FT   HELIX        79     81       {ECO:0000244|PDB:1T0C}.
FT   TURN         84     86       {ECO:0000244|PDB:1T0C}.
FT   HELIX        91     97       {ECO:0000244|PDB:3W7Y}.
FT   STRAND       98    101       {ECO:0000244|PDB:4EFX}.
FT   HELIX       102    106       {ECO:0000244|PDB:3W7Y}.
FT   TURN        107    109       {ECO:0000244|PDB:1HIQ}.
SQ   SEQUENCE   110 AA;  11981 MW;  C2C3B23B85E520E5 CRC64;
     MALWMRLLPL LALLALWGPD PAAAFVNQHL CGSHLVEALY LVCGERGFFY TPKTRREAED
     LQVGQVELGG GPGAGSLQPL ALEGSLQKRG IVEQCCTSIC SLYQLENYCN
//
ID   NTRK1_HUMAN             Reviewed;         796 AA.
AC   P04629; B2R6T5; B7ZM34; P08119; Q15655; Q15656; Q5D056; Q5VZS2;
AC   Q7Z5C3; Q9UIU7;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   02-MAY-2006, sequence version 4.
DT   17-FEB-2016, entry version 211.
DE   RecName: Full=High affinity nerve growth factor receptor;
DE            EC=2.7.10.1;
DE   AltName: Full=Neurotrophic tyrosine kinase receptor type 1;
DE   AltName: Full=TRK1-transforming tyrosine kinase protein;
DE   AltName: Full=Tropomyosin-related kinase A;
DE   AltName: Full=Tyrosine kinase receptor;
DE   AltName: Full=Tyrosine kinase receptor A;
DE            Short=Trk-A;
DE   AltName: Full=gp140trk;
DE   AltName: Full=p140-TrkA;
DE   Flags: Precursor;
GN   Name=NTRK1; Synonyms=MTC, TRK, TRKA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TRKA-I).
RC   TISSUE=Colon;
RX   PubMed=2927393;
RA   Martin-Zanca D., Oskam R., Mitra G., Copeland T.D., Barbacid M.;
RT   "Molecular and biochemical characterization of the human trk proto-
RT   oncogene.";
RL   Mol. Cell. Biol. 9:24-33(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   PubMed=7823156;
RA   Shelton D.L., Sutherland J., Gripp J., Camerato T., Armanini M.P.,
RA   Phillips H.S., Carroll K., Spencer S.D., Levinson A.D.;
RT   "Human trks: molecular cloning, tissue distribution, and expression of
RT   extracellular domain immunoadhesins.";
RL   J. Neurosci. 15:477-491(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9290260; DOI=10.1007/BF02766957;
RA   Indo Y., Mardy S., Tsuruta M., Karim M.A., Matsuda I.;
RT   "Structure and organization of the human TRKA gene encoding a high
RT   affinity receptor for nerve growth factor.";
RL   Jpn. J. Hum. Genet. 42:343-351(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM TRKA-II), AND
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-175 (ISOFORM 3).
RC   TISSUE=Uterus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS TRKA-I AND TRKA-II).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-71.
RX   PubMed=15870692; DOI=10.1038/sj.onc.1208697;
RA   Fujimoto M., Kitazawa R., Maeda S., Kitazawa S.;
RT   "Methylation adjacent to negatively regulating AP-1 site reactivates
RT   TrkA gene expression during cancer progression.";
RL   Oncogene 24:5108-5118(2005).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 399-796, AND CHROMOSOMAL TRANSLOCATION
RP   WITH TPM3.
RX   PubMed=2869410; DOI=10.1038/319743a0;
RA   Martin-Zanca D., Hughes S.H., Barbacid M.;
RT   "A human oncogene formed by the fusion of truncated tropomyosin and
RT   protein tyrosine kinase sequences.";
RL   Nature 319:743-748(1986).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 399-796.
RX   PubMed=2966065;
RA   Kozma S.C., Redmond S.M.S., Saurer S.M., Groner B., Hynes N.E.;
RT   "Activation of the receptor kinase domain of the trk oncogene by
RT   recombination with two different cellular sequences.";
RL   EMBO J. 7:147-154(1988).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 399-796, AND CHROMOSOMAL TRANSLOCATION
RP   WITH TFG.
RX   PubMed=7565764;
RA   Greco A., Mariani C., Miranda C., Lupas A., Pagliardini S., Pomati M.,
RA   Pierotti M.A.;
RT   "The DNA rearrangement that generates the TRK-T3 oncogene involves a
RT   novel gene on chromosome 3 whose product has a potential coiled-coil
RT   domain.";
RL   Mol. Cell. Biol. 15:6118-6127(1995).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 486-796, AND CHROMOSOMAL REARRANGEMENT
RP   WITH TPR.
RX   PubMed=1532241;
RA   Greco A., Pierotti M.A., Bongarzone I., Pagliardini S., Lanzi C.,
RA   Della Porta G.;
RT   "TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes
RT   in human papillary thyroid carcinomas.";
RL   Oncogene 7:237-242(1992).
RN   [12]
RP   FUNCTION AS RECEPTOR FOR NGF.
RX   PubMed=1850821; DOI=10.1038/350678a0;
RA   Hempstead B.L., Martin-Zanca D., Kaplan D.R., Parada L.F., Chao M.V.;
RT   "High-affinity NGF binding requires coexpression of the trk proto-
RT   oncogene and the low-affinity NGF receptor.";
RL   Nature 350:678-683(1991).
RN   [13]
RP   FUNCTION IN NGF SIGNALING, AND IDENTIFICATION AS THE HIGH AFFINITY NGF
RP   RECEPTOR.
RX   PubMed=1849459; DOI=10.1016/0092-8674(91)90419-Y;
RA   Klein R., Jing S., Nanduri V., O'Rourke E., Barbacid M.;
RT   "The trk proto-oncogene encodes a receptor for nerve growth factor.";
RL   Cell 65:189-197(1991).
RN   [14]
RP   ALTERNATIVE SPLICING (ISOFORMS TRKA-I AND TRKA-II), FUNCTION IN CELL
RP   SURVIVAL, NGF-BINDING, PHOSPHORYLATION, AND TISSUE SPECIFICITY.
RX   PubMed=8325889;
RA   Barker P.A., Lomen-Hoerth C., Gensch E.M., Meakin S.O., Glass D.J.,
RA   Shooter E.M.;
RT   "Tissue-specific alternative splicing generates two isoforms of the
RT   trkA receptor.";
RL   J. Biol. Chem. 268:15150-15157(1993).
RN   [15]
RP   PHOSPHORYLATION AT TYR-791, INTERACTION WITH PLCG1, AND MUTAGENESIS OF
RP   TYR-791.
RX   PubMed=7510697;
RA   Loeb D.M., Stephens R.M., Copeland T.D., Kaplan D.R., Greene L.A.;
RT   "A Trk nerve growth factor (NGF) receptor point mutation affecting
RT   interaction with phospholipase C-gamma 1 abolishes NGF-promoted
RT   peripherin induction but not neurite outgrowth.";
RL   J. Biol. Chem. 269:8901-8910(1994).
RN   [16]
RP   FUNCTION IN NEURONAL DIFFERENTIATION, FUNCTION IN PHOSPHORYLATION OF
RP   SHC1 AND PLCG1, INTERACTION WITH SHC1, MUTAGENESIS OF TYR-496; LYS-544
RP   AND TYR-791, AND PHOSPHORYLATION AT TYR-496 AND TYR-791.
RX   PubMed=8155326; DOI=10.1016/0896-6273(94)90223-2;
RA   Stephens R.M., Loeb D.M., Copeland T.D., Pawson T., Greene L.A.,
RA   Kaplan D.R.;
RT   "Trk receptors use redundant signal transduction pathways involving
RT   SHC and PLC-gamma 1 to mediate NGF responses.";
RL   Neuron 12:691-705(1994).
RN   [17]
RP   FUNCTION IN NF-KAPPA-B ACTIVATION, AND INTERACTION WITH SQSTM1.
RX   PubMed=11244088; DOI=10.1074/jbc.C000869200;
RA   Wooten M.W., Seibenhener M.L., Mamidipudi V., Diaz-Meco M.T.,
RA   Barker P.A., Moscat J.;
RT   "The atypical protein kinase C-interacting protein p62 is a scaffold
RT   for NF-kappaB activation by nerve growth factor.";
RL   J. Biol. Chem. 276:7709-7712(2001).
RN   [18]
RP   FUNCTION IN NEURONAL CELL PROLIFERATION AND DIFFERENTIATION, FUNCTION
RP   IN SIGNALING CASCADE ACTIVATION, NGF-BINDING, SUBCELLULAR LOCATION,
RP   ALTERNATIVE SPLICING (ISOFORM TRKA-III), CHARACTERIZATION OF ISOFORM
RP   TRKA-III, PHOSPHORYLATION AT TYR-496; TYR-680; TYR-681 AND TYR-791,
RP   INTERACTION WITH FRS2; GRB2; PIK3R1; PLCG1; SHC1, GLYCOSYLATION,
RP   TISSUE SPECIFICITY, AND INDUCTION BY HYPOXIA.
RX   PubMed=15488758; DOI=10.1016/j.ccr.2004.09.011;
RA   Tacconelli A., Farina A.R., Cappabianca L., Desantis G., Tessitore A.,
RA   Vetuschi A., Sferra R., Rucci N., Argenti B., Screpanti I., Gulino A.,
RA   Mackay A.R.;
RT   "TrkA alternative splicing: a regulated tumor-promoting switch in
RT   human neuroblastoma.";
RL   Cancer Cell 6:347-360(2004).
RN   [19]
RP   INTERACTION WITH SORT1, AND ENZYME REGULATION.
RX   PubMed=21102451; DOI=10.1038/nn.2689;
RA   Vaegter C.B., Jansen P., Fjorback A.W., Glerup S., Skeldal S.,
RA   Kjolby M., Richner M., Erdmann B., Nyengaard J.R., Tessarollo L.,
RA   Lewin G.R., Willnow T.E., Chao M.V., Nykjaer A.;
RT   "Sortilin associates with Trk receptors to enhance anterograde
RT   transport and neurotrophin signaling.";
RL   Nat. Neurosci. 14:54-61(2011).
RN   [20]
RP   STRUCTURE BY NMR OF 489-500.
RX   PubMed=8524391; DOI=10.1038/378584a0;
RA   Zhou M.-M., Ravichandran K.S., Olejniczak E.F., Petros A.M.,
RA   Meadows R.P., Sattler M., Harlan J.E., Wade W.S., Burakoff S.J.,
RA   Fesik S.W.;
RT   "Structure and ligand recognition of the phosphotyrosine binding
RT   domain of Shc.";
RL   Nature 378:584-592(1995).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 278-386.
RX   PubMed=10388563; DOI=10.1006/jmbi.1999.2816;
RA   Ultsch M.H., Wiesmann C., Simmons L.C., Henrich J., Yang M.,
RA   Reilly D., Bass S.H., de Vos A.M.;
RT   "Crystal structures of the neurotrophin-binding domain of TrkA, TrkB
RT   and TrkC.";
RL   J. Mol. Biol. 290:149-159(1999).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 282-382.
RX   PubMed=10490030; DOI=10.1038/43705;
RA   Wiesmann C., Ultsch M.H., Bass S.H., de Vos A.M.;
RT   "Crystal structure of nerve growth factor in complex with the ligand-
RT   binding domain of the TrkA receptor.";
RL   Nature 401:184-188(1999).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (3.4 ANGSTROMS) OF 36-382 IN COMPLEX WITH NGF,
RP   HOMODIMERIZATION, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-95;
RP   ASN-121; ASN-188; ASN-262; ASN-281 AND ASN-358.
RX   PubMed=17196528; DOI=10.1016/j.neuron.2006.09.034;
RA   Wehrman T., He X., Raab B., Dukipatti A., Blau H., Garcia K.C.;
RT   "Structural and mechanistic insights into nerve growth factor
RT   interactions with the TrkA and p75 receptors.";
RL   Neuron 53:25-38(2007).
RN   [24]
RP   VARIANT CIPA ARG-577.
RX   PubMed=8696348; DOI=10.1038/ng0896-485;
RA   Indo Y., Tsuruta M., Hayashida Y., Karim M.A., Ohta K., Kawano T.,
RA   Mitsubuchi H., Tonoki H., Awaya Y., Matsuda I.;
RT   "Mutations in the TRKA/NGF receptor gene in patients with congenital
RT   insensitivity to pain with anhidrosis.";
RL   Nat. Genet. 13:485-488(1996).
RN   [25]
RP   VARIANT CIPA PRO-780.
RX   PubMed=10090906; DOI=10.1086/302319;
RA   Greco A., Villa R., Tubino B., Romano L., Penso D., Pierotti M.A.;
RT   "A novel NTRK1 mutation associated with congenital insensitivity to
RT   pain with anhidrosis.";
RL   Am. J. Hum. Genet. 64:1207-1210(1999).
RN   [26]
RP   VARIANTS CIPA PRO-213; TRP-649 AND SER-714, AND VARIANTS SER-85;
RP   TYR-604 AND VAL-613.
RX   PubMed=10330344; DOI=10.1086/302422;
RA   Mardy S., Miura Y., Endo F., Matsuda I., Sztriha L., Frossard P.,
RA   Moosa A., Ismail E.A.R., Macaya A., Andria G., Toscano E., Gibson W.,
RA   Graham G.E., Indo Y.;
RT   "Congenital insensitivity to pain with anhidrosis: novel mutations in
RT   the TRKA (NTRK1) gene encoding a high-affinity receptor for nerve
RT   growth factor.";
RL   Am. J. Hum. Genet. 64:1570-1579(1999).
RN   [27]
RP   VARIANTS TYR-604; VAL-613 AND GLN-780.
RX   PubMed=10443680; DOI=10.1210/jc.84.8.2784;
RA   Gimm O., Greco A., Hoang-Vu C., Dralle H., Pierotti M.A., Eng C.;
RT   "Mutation analysis reveals novel sequence variants in NTRK1 in
RT   sporadic human medullary thyroid carcinoma.";
RL   J. Clin. Endocrinol. Metab. 84:2784-2787(1999).
RN   [28]
RP   VARIANT CIPA VAL-587.
RX   PubMed=10233776; DOI=10.1046/j.1523-1747.1999.00569.x;
RA   Yotsumoto S., Setoyama M., Hozumi H., Mizoguchi S., Fukumaru S.,
RA   Kobayashi K., Saheki T., Kanzaki T.;
RT   "A novel point mutation affecting the tyrosine kinase domain of the
RT   TRKA gene in a family with congenital insensitivity to pain with
RT   anhidrosis.";
RL   J. Invest. Dermatol. 112:810-814(1999).
RN   [29]
RP   VARIANTS TYR-604 AND VAL-613.
RX   PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions
RT   of human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [30]
RP   ERRATUM.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
RN   [31]
RP   VARIANT CIPA LEU-695, AND VARIANT VAL-613.
RC   TISSUE=Peripheral blood;
RX   PubMed=10861667;
RX   DOI=10.1002/1096-8628(20000619)92:5<353::AID-AJMG12>3.0.CO;2-C;
RA   Shatzky S., Moses S., Levy J., Pinsk V., Hershkovitz E., Herzog L.,
RA   Shorer Z., Luder A., Parvari R.;
RT   "Congenital insensitivity to pain with anhidrosis (CIPA) in Israeli-
RT   Bedouins: genetic heterogeneity, novel mutations in the TRKA/NGF
RT   receptor gene, clinical findings, and results of nerve conduction
RT   studies.";
RL   Am. J. Med. Genet. 92:353-360(2000).
RN   [32]
RP   VARIANTS CIPA PRO-93; ARG-522; ARG-577; CYS-654 AND TYR-674.
RX   PubMed=10982191; DOI=10.1007/s004390051018;
RA   Miura Y., Mardy S., Awaya Y., Nihei K., Endo F., Matsuda I., Indo Y.;
RT   "Mutation and polymorphism analysis of the TRKA (NTRK1) gene encoding
RT   a high-affinity receptor for nerve growth factor in congenital
RT   insensitivity to pain with anhidrosis (CIPA) families.";
RL   Hum. Genet. 106:116-124(2000).
RN   [33]
RP   VARIANT CIPA ARG-577.
RX   PubMed=10567924;
RX   DOI=10.1002/(SICI)1097-4652(200001)182:1<127::AID-JCP14>3.0.CO;2-0;
RA   Greco A., Villa R., Fusetti L., Orlandi R., Pierotti M.A.;
RT   "The Gly571Arg mutation, associated with the autonomic and sensory
RT   disorder congenital insensitivity to pain with anhidrosis, causes the
RT   inactivation of the NTRK1/nerve growth factor receptor.";
RL   J. Cell. Physiol. 182:127-133(2000).
RN   [34]
RP   VARIANT CIPA CYS-359, AND VARIANTS TYR-604 AND VAL-613.
RX   PubMed=11310631; DOI=10.1002/ana.103;
RA   Houlden H., King R.H., Hashemi-Nejad A., Wood N.W., Mathias C.J.,
RA   Reilly M., Thomas P.K.;
RT   "A novel TRK A (NTRK1) mutation associated with hereditary sensory and
RT   autonomic neuropathy type V.";
RL   Ann. Neurol. 49:521-525(2001).
RN   [35]
RP   CHARACTERIZATION OF VARIANTS CIPA PRO-93; PRO-213; ARG-522; ARG-577;
RP   TRP-649; CYS-654 AND SER-714, AND CHARACTERIZATION OF VARIANTS SER-85;
RP   TYR-604; VAL-613 AND TYR-674.
RX   PubMed=11159935; DOI=10.1093/hmg/10.3.179;
RA   Mardy S., Miura Y., Endo F., Matsuda I., Indo Y.;
RT   "Congenital insensitivity to pain with anhidrosis (CIPA): effect of
RT   TRKA (NTRK1) missense mutations on autophosphorylation of the receptor
RT   tyrosine kinase for nerve growth factor.";
RL   Hum. Mol. Genet. 10:179-188(2001).
RN   [36]
RP   VARIANTS [LARGE SCALE ANALYSIS] ARG-80; VAL-107; MET-237; GLY-238;
RP   GLY-260; GLN-444; CYS-452; THR-566; TYR-604; VAL-613; GLN-780 AND
RP   ILE-790.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [37]
RP   VARIANTS CIPA LYS-492 AND CYS-654, AND VARIANT TRP-6.
RX   PubMed=22302274; DOI=10.1007/s00415-011-6397-y;
RA   Davidson G.L., Murphy S.M., Polke J.M., Laura M., Salih M.A.,
RA   Muntoni F., Blake J., Brandner S., Davies N., Horvath R., Price S.,
RA   Donaghy M., Roberts M., Foulds N., Ramdharry G., Soler D., Lunn M.P.,
RA   Manji H., Davis M.B., Houlden H., Reilly M.M.;
RT   "Frequency of mutations in the genes associated with hereditary
RT   sensory and autonomic neuropathy in a UK cohort.";
RL   J. Neurol. 259:1673-1685(2012).
CC   -!- FUNCTION: Receptor tyrosine kinase involved in the development and
CC       the maturation of the central and peripheral nervous systems
CC       through regulation of proliferation, differentiation and survival
CC       of sympathetic and nervous neurons. High affinity receptor for NGF
CC       which is its primary ligand, it can also bind and be activated by
CC       NTF3/neurotrophin-3. However, NTF3 only supports axonal extension
CC       through NTRK1 but has no effect on neuron survival. Upon dimeric
CC       NGF ligand-binding, undergoes homodimerization,
CC       autophosphorylation and activation. Recruits, phosphorylates
CC       and/or activates several downstream effectors including SHC1,
CC       FRS2, SH2B1, SH2B2 and PLCG1 that regulate distinct overlapping
CC       signaling cascades driving cell survival and differentiation.
CC       Through SHC1 and FRS2 activates a GRB2-Ras-MAPK cascade that
CC       regulates cell differentiation and survival. Through PLCG1
CC       controls NF-Kappa-B activation and the transcription of genes
CC       involved in cell survival. Through SHC1 and SH2B1 controls a Ras-
CC       PI3 kinase-AKT1 signaling cascade that is also regulating
CC       survival. In absence of ligand and activation, may promote cell
CC       death, making the survival of neurons dependent on trophic
CC       factors.
CC   -!- FUNCTION: Isoform TrkA-III is resistant to NGF, constitutively
CC       activates AKT1 and NF-kappa-B and is unable to activate the Ras-
CC       MAPK signaling cascade. Antagonizes the anti-proliferative NGF-
CC       NTRK1 signaling that promotes neuronal precursors differentiation.
CC       Isoform TrkA-III promotes angiogenesis and has oncogenic activity
CC       when overexpressed.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- ENZYME REGULATION: The pro-survival signaling effect of NTRK1 in
CC       neurons requires its endocytosis into signaling early endosomes
CC       and its retrograde axonal transport. This is regulated by
CC       different proteins including CFL1, RAC1 and SORT1. NTF3 is unable
CC       to induce this signaling probably due to the lability of the NTF3-
CC       NTRK1 complex in endosomes. SH2D1A inhibits the
CC       autophosphorylation of the receptor, and alters the recruitment
CC       and activation of downstream effectors and signaling cascades (By
CC       similarity). Regulated by NGFR (By similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Exists in a dynamic equilibrium between monomeric (low
CC       affinity) and dimeric (high affinity) structures. Homodimerization
CC       is induced by binding of a NGF dimer. Interacts with SQSTM1;
CC       bridges NTRK1 to NGFR. Forms a ternary complex with NGFR and
CC       KIDINS220; this complex is affected by the expression levels of
CC       KIDINS220 and an increase in KIDINS220 expression leads to a
CC       decreased association of NGFR and NTRK1 (By similarity). Interacts
CC       with SH2D1A; regulates NTRK1 (By similarity). Interacts
CC       (phosphorylated upon activation by NGF) with SHC1; mediates SHC1
CC       phosphorylation and activation. Interacts (phosphorylated upon
CC       activation by NGF) with PLCG1; mediates PLCG1 phosphorylation and
CC       activation. Interacts (phosphorylated) with SH2B1 and SH2B2.
CC       Interacts with GRB2. Interacts with PIK3R1. Interacts with FRS2.
CC       Interacts with SORT1; may regulate NTRK1 anterograde axonal
CC       transport. Interacts with RAB7A (By similarity). Found in a
CC       complex, at least composed of KIDINS220, MAGI2, NTRK1 and RAPGEF2;
CC       the complex is mainly formed at late endosomes in a nerve growth
CC       factor (NGF)-dependent manner (By similarity). Interacts with
CC       RAPGEF2; the interaction is strengthened after NGF stimulation (By
CC       similarity). {ECO:0000250}.
CC   -!- INTERACTION:
CC       P22681:CBL; NbExp=2; IntAct=EBI-1028226, EBI-518228;
CC       P01138:NGF; NbExp=2; IntAct=EBI-1028226, EBI-1028250;
CC       Q8K4V6:Pirb (xeno); NbExp=2; IntAct=EBI-1028226, EBI-8602514;
CC       P18031:PTPN1; NbExp=2; IntAct=EBI-1028226, EBI-968788;
CC       Q99523:SORT1; NbExp=3; IntAct=EBI-1028226, EBI-1057058;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:15488758};
CC       Single-pass type I membrane protein {ECO:0000269|PubMed:15488758}.
CC       Early endosome membrane {ECO:0000250}; Single-pass type I membrane
CC       protein {ECO:0000250}. Late endosome membrane {ECO:0000250};
CC       Single-pass type I membrane protein {ECO:0000250}.
CC       Note=Internalized to endosomes upon binding of NGF or NTF3 and
CC       further transported to the cell body via a retrograde axonal
CC       transport. Localized at cell membrane and early endosomes before
CC       nerve growth factor (NGF) stimulation. Recruited to late endosomes
CC       after NGF stimulation. Colocalized with RAPGEF2 at late endosomes
CC       (By similarity). {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC         Comment=TrkA-I and TrkA-II isoforms have similar biological
CC         properties but are differentially expressed.;
CC       Name=TrkA-II; Synonyms=TrkAII;
CC         IsoId=P04629-1; Sequence=Displayed;
CC         Note=Major isoform.;
CC       Name=TrkA-I; Synonyms=TrkAI;
CC         IsoId=P04629-2; Sequence=VSP_002899;
CC         Note=Has enhanced responsiveness to NTF3 neurotrophin.;
CC       Name=3;
CC         IsoId=P04629-3; Sequence=VSP_041905, VSP_002899;
CC       Name=TrkA-III; Synonyms=TrkAIII;
CC         IsoId=P04629-4; Sequence=VSP_042152, VSP_002899;
CC         Note=Constitutively active. Does not bind NGF and does not
CC         interact with GRB2 and FRS2.;
CC   -!- TISSUE SPECIFICITY: Isoform TrkA-I is found in most non-neuronal
CC       tissues. Isoform TrkA-II is primarily expressed in neuronal cells.
CC       TrkA-III is specifically expressed by pluripotent neural stem and
CC       neural crest progenitors. {ECO:0000269|PubMed:15488758,
CC       ECO:0000269|PubMed:8325889}.
CC   -!- INDUCTION: Isoform TrkA-III is up-regulated upon hypoxia in cells
CC       normally expressing it. {ECO:0000269|PubMed:15488758}.
CC   -!- DOMAIN: The transmembrane domain mediates interaction with
CC       KIDINS220. {ECO:0000250}.
CC   -!- DOMAIN: The extracellular domain mediates interaction with NGFR.
CC       {ECO:0000250}.
CC   -!- PTM: Ligand-mediated autophosphorylation. Interaction with SQSTM1
CC       is phosphotyrosine-dependent. Autophosphorylation at Tyr-496
CC       mediates interaction and phosphorylation of SHC1.
CC       {ECO:0000269|PubMed:15488758, ECO:0000269|PubMed:7510697,
CC       ECO:0000269|PubMed:8155326, ECO:0000269|PubMed:8325889}.
CC   -!- PTM: N-glycosylated (Probable). Isoform TrkA-I is N-glycosylated.
CC       {ECO:0000269|PubMed:15488758, ECO:0000269|PubMed:17196528,
CC       ECO:0000305}.
CC   -!- PTM: Ubiquitinated. Undergoes polyubiquitination upon activation;
CC       regulated by NGFR. Ubiquitination regulates the internalization of
CC       the receptor (By similarity). {ECO:0000250}.
CC   -!- DISEASE: Congenital insensitivity to pain with anhidrosis (CIPA)
CC       [MIM:256800]: Characterized by a congenital insensitivity to pain,
CC       anhidrosis (absence of sweating), absence of reaction to noxious
CC       stimuli, self-mutilating behavior, and mental retardation. This
CC       rare autosomal recessive disorder is also known as congenital
CC       sensory neuropathy with anhidrosis or hereditary sensory and
CC       autonomic neuropathy type IV or familial dysautonomia type II.
CC       {ECO:0000269|PubMed:10090906, ECO:0000269|PubMed:10233776,
CC       ECO:0000269|PubMed:10330344, ECO:0000269|PubMed:10567924,
CC       ECO:0000269|PubMed:10861667, ECO:0000269|PubMed:10982191,
CC       ECO:0000269|PubMed:11310631, ECO:0000269|PubMed:22302274,
CC       ECO:0000269|PubMed:8696348}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Note=Chromosomal aberrations involving NTRK1 are found in
CC       papillary thyroid carcinomas (PTCs) (PubMed:2869410,
CC       PubMed:7565764, PubMed:1532241). Translocation t(1;3)(q21;q11)
CC       with TFG generates the TRKT3 (TRK-T3) transcript by fusing TFG to
CC       the 3'-end of NTRK1 (PubMed:7565764). A rearrangement with TPM3
CC       generates the TRK transcript by fusing TPM3 to the 3'-end of NTRK1
CC       (PubMed:2869410). An intrachromosomal rearrangement that links the
CC       protein kinase domain of NTRK1 to the 5'-end of the TPR gene forms
CC       the fusion protein TRK-T1. TRK-T1 is a 55 kDa protein reacting
CC       with antibodies against the C-terminus of the NTRK1 protein
CC       (PubMed:1532241). {ECO:0000269|PubMed:1532241,
CC       ECO:0000269|PubMed:2869410, ECO:0000269|PubMed:7565764}.
CC   -!- MISCELLANEOUS: Trk also stands for tropomyosin-related kinase
CC       since it was first isolated as an oncogenic protein which was the
CC       result of a fusion between the tropomyosin gene TPM3 and NTRK1.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 2 Ig-like C2-type (immunoglobulin-like)
CC       domains. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 2 LRR (leucine-rich) repeats. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 LRRCT domain. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA27243.1; Type=Erroneous termination; Positions=786; Note=Translated as Gln.; Evidence={ECO:0000305};
CC       Sequence=CAA27243.1; Type=Frameshift; Positions=769; Evidence={ECO:0000305};
CC       Sequence=CAA27243.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the N-terminal part.; Evidence={ECO:0000305};
CC       Sequence=CAA29888.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the N-terminal part.; Evidence={ECO:0000305};
CC       Sequence=CAA44719.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the N-terminal part.; Evidence={ECO:0000305};
CC       Sequence=CAA59936.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the N-terminal part.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M23102; AAA36770.1; -; mRNA.
DR   EMBL; AB019488; BAA34355.1; -; Genomic_DNA.
DR   EMBL; AK312704; BAG35582.1; -; mRNA.
DR   EMBL; DB265639; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AL158169; CAH70010.1; -; Genomic_DNA.
DR   EMBL; BC062580; AAH62580.1; -; mRNA.
DR   EMBL; BC136554; AAI36555.1; -; mRNA.
DR   EMBL; BC144239; AAI44240.1; -; mRNA.
DR   EMBL; AY321513; AAP88292.1; -; Genomic_DNA.
DR   EMBL; X03541; CAA27243.1; ALT_SEQ; mRNA.
DR   EMBL; X06704; CAA29888.1; ALT_SEQ; mRNA.
DR   EMBL; X85960; CAA59936.1; ALT_SEQ; mRNA.
DR   EMBL; X62947; CAA44719.1; ALT_SEQ; mRNA.
DR   CCDS; CCDS1161.1; -. [P04629-1]
DR   CCDS; CCDS30890.1; -. [P04629-3]
DR   CCDS; CCDS30891.1; -. [P04629-2]
DR   PIR; A30124; TVHUTT.
DR   PIR; S23741; S23741.
DR   RefSeq; NP_001007793.1; NM_001007792.1. [P04629-3]
DR   RefSeq; NP_001012331.1; NM_001012331.1. [P04629-2]
DR   RefSeq; NP_002520.2; NM_002529.3. [P04629-1]
DR   UniGene; Hs.406293; -.
DR   PDB; 1HE7; X-ray; 2.00 A; A=285-413.
DR   PDB; 1SHC; NMR; -; B=489-500.
DR   PDB; 1WWA; X-ray; 2.50 A; X/Y=278-386.
DR   PDB; 1WWW; X-ray; 2.20 A; X/Y=282-382.
DR   PDB; 2IFG; X-ray; 3.40 A; A/B=36-382.
DR   PDB; 4AOJ; X-ray; 2.75 A; A/B/C=473-796.
DR   PDB; 4CRP; NMR; -; A=282-383.
DR   PDB; 4F0I; X-ray; 2.30 A; A/B=498-796.
DR   PDB; 4GT5; X-ray; 2.40 A; A=498-796.
DR   PDB; 4PMM; X-ray; 2.00 A; A=501-787.
DR   PDB; 4PMP; X-ray; 1.80 A; A=501-787.
DR   PDB; 4PMS; X-ray; 2.80 A; A=501-787.
DR   PDB; 4PMT; X-ray; 2.10 A; A=501-787.
DR   PDB; 4YNE; X-ray; 2.02 A; A=502-796.
DR   PDB; 4YPS; X-ray; 2.10 A; A=502-796.
DR   PDBsum; 1HE7; -.
DR   PDBsum; 1SHC; -.
DR   PDBsum; 1WWA; -.
DR   PDBsum; 1WWW; -.
DR   PDBsum; 2IFG; -.
DR   PDBsum; 4AOJ; -.
DR   PDBsum; 4CRP; -.
DR   PDBsum; 4F0I; -.
DR   PDBsum; 4GT5; -.
DR   PDBsum; 4PMM; -.
DR   PDBsum; 4PMP; -.
DR   PDBsum; 4PMS; -.
DR   PDBsum; 4PMT; -.
DR   PDBsum; 4YNE; -.
DR   PDBsum; 4YPS; -.
DR   ProteinModelPortal; P04629; -.
DR   SMR; P04629; 36-382, 459-794.
DR   BioGrid; 110969; 1941.
DR   DIP; DIP-5714N; -.
DR   IntAct; P04629; 17.
DR   MINT; MINT-124106; -.
DR   STRING; 9606.ENSP00000431418; -.
DR   BindingDB; P04629; -.
DR   ChEMBL; CHEMBL2815; -.
DR   DrugBank; DB00321; Amitriptyline.
DR   DrugBank; DB00619; Imatinib.
DR   DrugBank; DB08896; Regorafenib.
DR   GuidetoPHARMACOLOGY; 1817; -.
DR   iPTMnet; P04629; -.
DR   PhosphoSite; P04629; -.
DR   BioMuta; NTRK1; -.
DR   DMDM; 94730402; -.
DR   PaxDb; P04629; -.
DR   PRIDE; P04629; -.
DR   Ensembl; ENST00000368196; ENSP00000357179; ENSG00000198400. [P04629-2]
DR   Ensembl; ENST00000392302; ENSP00000376120; ENSG00000198400. [P04629-3]
DR   Ensembl; ENST00000524377; ENSP00000431418; ENSG00000198400. [P04629-1]
DR   GeneID; 4914; -.
DR   KEGG; hsa:4914; -.
DR   UCSC; uc001fqf.1; human. [P04629-3]
DR   UCSC; uc001fqh.1; human. [P04629-1]
DR   UCSC; uc001fqi.1; human. [P04629-2]
DR   UCSC; uc009wsi.1; human. [P04629-4]
DR   CTD; 4914; -.
DR   GeneCards; NTRK1; -.
DR   GeneReviews; NTRK1; -.
DR   HGNC; HGNC:8031; NTRK1.
DR   HPA; CAB004606; -.
DR   HPA; HPA035799; -.
DR   MalaCards; NTRK1; -.
DR   MIM; 164970; gene.
DR   MIM; 191315; gene.
DR   MIM; 256800; phenotype.
DR   neXtProt; NX_P04629; -.
DR   Orphanet; 99361; Familial medullary thyroid carcinoma.
DR   Orphanet; 642; Hereditary sensory and autonomic neuropathy type 4.
DR   Orphanet; 64752; Hereditary sensory and autonomic neuropathy type 5.
DR   Orphanet; 146; Papillary or follicular thyroid carcinoma.
DR   PharmGKB; PA31817; -.
DR   eggNOG; ENOG410IMMI; Eukaryota.
DR   eggNOG; ENOG410XTGG; LUCA.
DR   GeneTree; ENSGT00760000118818; -.
DR   HOVERGEN; HBG056735; -.
DR   InParanoid; P04629; -.
DR   KO; K03176; -.
DR   OMA; KNVTCWA; -.
DR   OrthoDB; EOG7GTT32; -.
DR   PhylomeDB; P04629; -.
DR   TreeFam; TF106465; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-167021; PLC-gamma1 signalling.
DR   Reactome; R-HSA-167044; Signalling to RAS.
DR   Reactome; R-HSA-170968; Frs2-mediated activation.
DR   Reactome; R-HSA-170984; ARMS-mediated activation.
DR   Reactome; R-HSA-177504; Retrograde neurotrophin signalling.
DR   Reactome; R-HSA-187024; NGF-independant TRKA activation.
DR   Reactome; R-HSA-187042; TRKA activation by NGF.
DR   Reactome; R-HSA-187706; Signalling to p38 via RIT and RIN.
DR   Reactome; R-HSA-198203; PI3K/AKT activation.
DR   Reactome; R-HSA-198745; Signalling to STAT3.
DR   SignaLink; P04629; -.
DR   ChiTaRS; NTRK1; human.
DR   EvolutionaryTrace; P04629; -.
DR   GenomeRNAi; 4914; -.
DR   NextBio; 18907; -.
DR   PRO; PR:P04629; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; P04629; -.
DR   ExpressionAtlas; P04629; baseline and differential.
DR   Genevisible; P04629; HS.
DR   GO; GO:0030424; C:axon; IEA:Ensembl.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IEA:Ensembl.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0005769; C:early endosome; ISS:UniProtKB.
DR   GO; GO:0031901; C:early endosome membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005768; C:endosome; TAS:Reactome.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005770; C:late endosome; ISS:UniProtKB.
DR   GO; GO:0031902; C:late endosome membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; ISS:UniProtKB.
DR   GO; GO:0043234; C:protein complex; ISS:UniProtKB.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005004; F:GPI-linked ephrin receptor activity; IEA:Ensembl.
DR   GO; GO:0048406; F:nerve growth factor binding; IDA:UniProtKB.
DR   GO; GO:0010465; F:nerve growth factor receptor activity; IDA:UniProtKB.
DR   GO; GO:0043121; F:neurotrophin binding; TAS:ProtInc.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0007190; P:activation of adenylate cyclase activity; TAS:Reactome.
DR   GO; GO:0000186; P:activation of MAPKK activity; TAS:Reactome.
DR   GO; GO:0007202; P:activation of phospholipase C activity; TAS:Reactome.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0007411; P:axon guidance; IEA:Ensembl.
DR   GO; GO:0060385; P:axonogenesis involved in innervation; ISS:UniProtKB.
DR   GO; GO:0030183; P:B cell differentiation; IEA:Ensembl.
DR   GO; GO:0061368; P:behavioral response to formalin induced pain; IEA:Ensembl.
DR   GO; GO:1990090; P:cellular response to nerve growth factor stimulus; ISS:UniProtKB.
DR   GO; GO:0071316; P:cellular response to nicotine; IEA:Ensembl.
DR   GO; GO:0007623; P:circadian rhythm; IEA:Ensembl.
DR   GO; GO:0050966; P:detection of mechanical stimulus involved in sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0050965; P:detection of temperature stimulus involved in sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0010623; P:developmental programmed cell death; ISS:UniProtKB.
DR   GO; GO:0007611; P:learning or memory; IEA:Ensembl.
DR   GO; GO:0042490; P:mechanoreceptor differentiation; IEA:Ensembl.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IDA:UniProtKB.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; ISS:UniProtKB.
DR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0021553; P:olfactory nerve development; IEA:Ensembl.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:GOC.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; TAS:Reactome.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IDA:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0043547; P:positive regulation of GTPase activity; IDA:UniProtKB.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IDA:UniProtKB.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0043068; P:positive regulation of programmed cell death; ISS:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; TAS:BHF-UCL.
DR   GO; GO:0046579; P:positive regulation of Ras protein signal transduction; IDA:UniProtKB.
DR   GO; GO:0051965; P:positive regulation of synapse assembly; IEA:Ensembl.
DR   GO; GO:0051968; P:positive regulation of synaptic transmission, glutamatergic; IEA:Ensembl.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0007265; P:Ras protein signal transduction; TAS:Reactome.
DR   GO; GO:0014823; P:response to activity; IEA:Ensembl.
DR   GO; GO:0048678; P:response to axon injury; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0051602; P:response to electrical stimulus; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0051599; P:response to hydrostatic pressure; IEA:Ensembl.
DR   GO; GO:0031667; P:response to nutrient levels; IEA:Ensembl.
DR   GO; GO:0009314; P:response to radiation; IEA:Ensembl.
DR   GO; GO:0060009; P:Sertoli cell development; IEA:Ensembl.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; TAS:Reactome.
DR   GO; GO:0048485; P:sympathetic nervous system development; ISS:UniProtKB.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; TAS:Reactome.
DR   Gene3D; 2.60.40.10; -; 2.
DR   Gene3D; 3.80.10.10; -; 1.
DR   InterPro; IPR000483; Cys-rich_flank_reg_C.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR031635; NTRK_C2.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR020461; Tyr_kinase_neurotrophic_rcpt_1.
DR   InterPro; IPR020777; Tyr_kinase_NGF_rcpt.
DR   InterPro; IPR002011; Tyr_kinase_rcpt_2_CS.
DR   Pfam; PF13855; LRR_8; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF16920; TPKR_C2; 1.
DR   PRINTS; PR01939; NTKRECEPTOR.
DR   PRINTS; PR01940; NTKRECEPTOR1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00409; IG; 1.
DR   SMART; SM00082; LRRCT; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 2.
DR   SUPFAM; SSF52058; SSF52058; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Chromosomal rearrangement; Complete proteome; Developmental protein;
KW   Differentiation; Disease mutation; Disulfide bond; Endosome;
KW   Glycoprotein; Immunoglobulin domain; Kinase; Leucine-rich repeat;
KW   Membrane; Neurogenesis; Nucleotide-binding; Phosphoprotein;
KW   Polymorphism; Proto-oncogene; Receptor; Reference proteome; Repeat;
KW   Signal; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL        1     32       {ECO:0000255}.
FT   CHAIN        33    796       High affinity nerve growth factor
FT                                receptor.
FT                                /FTId=PRO_0000016724.
FT   TOPO_DOM     33    423       Extracellular. {ECO:0000255}.
FT   TRANSMEM    424    439       Helical. {ECO:0000255}.
FT   TOPO_DOM    440    796       Cytoplasmic. {ECO:0000255}.
FT   REPEAT       90    113       LRR 1.
FT   REPEAT      116    137       LRR 2.
FT   DOMAIN      148    193       LRRCT.
FT   DOMAIN      194    283       Ig-like C2-type 1.
FT   DOMAIN      299    365       Ig-like C2-type 2.
FT   DOMAIN      510    781       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     516    524       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      469    490       Interaction with SQSTM1. {ECO:0000250}.
FT   ACT_SITE    650    650       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     544    544       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   SITE        398    399       Breakpoint for translocation to form TRK
FT                                and TRK-T3.
FT   SITE        486    486       Breakpoint for translocation to form TRK-
FT                                T1.
FT   SITE        496    496       Interaction with SHC1.
FT   SITE        791    791       Interaction with PLCG1.
FT   MOD_RES     496    496       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:15488758,
FT                                ECO:0000269|PubMed:8155326}.
FT   MOD_RES     676    676       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000305|PubMed:8325889}.
FT   MOD_RES     680    680       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:15488758}.
FT   MOD_RES     681    681       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:15488758}.
FT   MOD_RES     791    791       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:15488758,
FT                                ECO:0000269|PubMed:7510697,
FT                                ECO:0000269|PubMed:8155326}.
FT   CARBOHYD     67     67       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD     95     95       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:17196528}.
FT   CARBOHYD    121    121       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:17196528}.
FT   CARBOHYD    188    188       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:17196528}.
FT   CARBOHYD    202    202       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    253    253       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    262    262       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:17196528}.
FT   CARBOHYD    281    281       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:17196528}.
FT   CARBOHYD    318    318       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    323    323       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    338    338       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    358    358       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:17196528}.
FT   CARBOHYD    401    401       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID    154    191       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:17196528}.
FT   DISULFID    215    265       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:17196528}.
FT   VAR_SEQ       1     71       MLRGGRRGQLGWHSWAAGPGSLLAWLILASAGAAPCPDACC
FT                                PHGSSGLRCTRDGALDSLHHLPGAENLTEL -> MKEAALI
FT                                CLAPSVPPILTVKSWDTMQLRAARSRCTNLLAAS (in
FT                                isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_041905.
FT   VAR_SEQ     192    284       GVPTLKVQVPNASVDVGDDVLLRCQVEGRGLEQAGWILTEL
FT                                EQSATVMKSGGLPSLGLTLANVTSDLNRKNVTCWAENDVGR
FT                                AEVSVQVNVSF -> V (in isoform TrkA-III).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_042152.
FT   VAR_SEQ     393    398       Missing (in isoform TrkA-I, isoform 3 and
FT                                isoform TrkA-III).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:2927393}.
FT                                /FTId=VSP_002899.
FT   VARIANT       6      6       R -> W. {ECO:0000269|PubMed:22302274}.
FT                                /FTId=VAR_068480.
FT   VARIANT      18     18       G -> E (in dbSNP:rs1007211).
FT                                /FTId=VAR_049714.
FT   VARIANT      80     80       Q -> R (in dbSNP:rs55891455).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041461.
FT   VARIANT      85     85       R -> S. {ECO:0000269|PubMed:10330344,
FT                                ECO:0000269|PubMed:11159935}.
FT                                /FTId=VAR_009623.
FT   VARIANT      93     93       L -> P (in CIPA; aberrantly processed;
FT                                shows diminished autophosphorylation in
FT                                neuronal cells).
FT                                {ECO:0000269|PubMed:10982191,
FT                                ECO:0000269|PubMed:11159935}.
FT                                /FTId=VAR_009624.
FT   VARIANT     107    107       A -> V (in an ovarian serous carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041462.
FT   VARIANT     213    213       L -> P (in CIPA; aberrantly processed;
FT                                shows diminished autophosphorylation in
FT                                neuronal cells).
FT                                {ECO:0000269|PubMed:10330344,
FT                                ECO:0000269|PubMed:11159935}.
FT                                /FTId=VAR_009625.
FT   VARIANT     237    237       T -> M (in dbSNP:rs55909005).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041463.
FT   VARIANT     238    238       V -> G (in dbSNP:rs56000394).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041464.
FT   VARIANT     260    260       R -> G (in dbSNP:rs35116695).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041465.
FT   VARIANT     359    359       Y -> C (in CIPA).
FT                                {ECO:0000269|PubMed:11310631}.
FT                                /FTId=VAR_068481.
FT   VARIANT     444    444       R -> Q (in dbSNP:rs56320207).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041466.
FT   VARIANT     452    452       R -> C (in dbSNP:rs34900547).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041467.
FT   VARIANT     492    492       E -> K (in CIPA).
FT                                {ECO:0000269|PubMed:22302274}.
FT                                /FTId=VAR_068482.
FT   VARIANT     522    522       G -> R (in CIPA; processed as wild-type
FT                                but shows significantly diminished
FT                                autophosphorylation in both neuronal and
FT                                non-neuronal cells).
FT                                {ECO:0000269|PubMed:10982191,
FT                                ECO:0000269|PubMed:11159935}.
FT                                /FTId=VAR_009626.
FT   VARIANT     566    566       M -> T (in dbSNP:rs55892037).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041468.
FT   VARIANT     577    577       G -> R (in CIPA; loss of function;
FT                                processed as wild-type but shows
FT                                significantly diminished
FT                                autophosphorylation in both neuronal and
FT                                non-neuronal cells).
FT                                {ECO:0000269|PubMed:10567924,
FT                                ECO:0000269|PubMed:10982191,
FT                                ECO:0000269|PubMed:11159935,
FT                                ECO:0000269|PubMed:8696348}.
FT                                /FTId=VAR_004103.
FT   VARIANT     587    587       M -> V (in CIPA).
FT                                {ECO:0000269|PubMed:10233776}.
FT                                /FTId=VAR_009627.
FT   VARIANT     604    604       H -> Y (in dbSNP:rs6336).
FT                                {ECO:0000269|PubMed:10330344,
FT                                ECO:0000269|PubMed:10391209,
FT                                ECO:0000269|PubMed:10443680,
FT                                ECO:0000269|PubMed:11159935,
FT                                ECO:0000269|PubMed:11310631,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_009628.
FT   VARIANT     613    613       G -> V (in dbSNP:rs6339).
FT                                {ECO:0000269|PubMed:10330344,
FT                                ECO:0000269|PubMed:10391209,
FT                                ECO:0000269|PubMed:10443680,
FT                                ECO:0000269|PubMed:10861667,
FT                                ECO:0000269|PubMed:11159935,
FT                                ECO:0000269|PubMed:11310631,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_009629.
FT   VARIANT     649    649       R -> W (in CIPA; processed as wild-type
FT                                but shows significantly diminished
FT                                autophosphorylation in both neuronal and
FT                                non-neuronal cells).
FT                                {ECO:0000269|PubMed:10330344,
FT                                ECO:0000269|PubMed:11159935}.
FT                                /FTId=VAR_009630.
FT   VARIANT     654    654       R -> C (in CIPA; processed as wild-type
FT                                but shows significantly diminished
FT                                autophosphorylation in both neuronal and
FT                                non-neuronal cells).
FT                                {ECO:0000269|PubMed:10982191,
FT                                ECO:0000269|PubMed:11159935,
FT                                ECO:0000269|PubMed:22302274}.
FT                                /FTId=VAR_009631.
FT   VARIANT     674    674       D -> Y (in CIPA; unknown pathological
FT                                significance; might impair the function
FT                                of the enzyme without compromising
FT                                autophosphorylation).
FT                                {ECO:0000269|PubMed:10982191,
FT                                ECO:0000269|PubMed:11159935}.
FT                                /FTId=VAR_009632.
FT   VARIANT     695    695       P -> L (in CIPA).
FT                                {ECO:0000269|PubMed:10861667}.
FT                                /FTId=VAR_009633.
FT   VARIANT     714    714       G -> S (in CIPA; processed as wild-type
FT                                but shows significantly diminished
FT                                autophosphorylation in both neuronal and
FT                                non-neuronal cells).
FT                                {ECO:0000269|PubMed:10330344,
FT                                ECO:0000269|PubMed:11159935}.
FT                                /FTId=VAR_009634.
FT   VARIANT     780    780       R -> P (in CIPA; loss of function;
FT                                dbSNP:rs35669708).
FT                                {ECO:0000269|PubMed:10090906}.
FT                                /FTId=VAR_009635.
FT   VARIANT     780    780       R -> Q (in dbSNP:rs35669708).
FT                                {ECO:0000269|PubMed:10443680,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_009636.
FT   VARIANT     790    790       V -> I (in dbSNP:rs55948542).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041469.
FT   MUTAGEN     496    496       Y->F: Loss of interaction with SHC1 and
FT                                altered phosphorylation of SHC1. Altered
FT                                neurite outgrowth and altered activation
FT                                of the MAPK pathway; when associated with
FT                                F-791. {ECO:0000269|PubMed:8155326}.
FT   MUTAGEN     544    544       K->N: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:8155326}.
FT   MUTAGEN     791    791       Y->F: Loss of interaction with PLCG1 and
FT                                altered phosphorylation of PLCG1. Altered
FT                                neurite outgrowth and altered activation
FT                                of the MAPK pathway; when associated with
FT                                F-496. {ECO:0000269|PubMed:7510697,
FT                                ECO:0000269|PubMed:8155326}.
FT   CONFLICT    263    263       V -> L (in Ref. 1; AAA36770).
FT                                {ECO:0000305}.
FT   CONFLICT    300    300       C -> S (in Ref. 1; AAA36770).
FT                                {ECO:0000305}.
FT   CONFLICT    529    529       C -> S (in Ref. 10; CAA59936).
FT                                {ECO:0000305}.
FT   STRAND       38     40       {ECO:0000244|PDB:2IFG}.
FT   STRAND       43     46       {ECO:0000244|PDB:2IFG}.
FT   TURN         57     61       {ECO:0000244|PDB:2IFG}.
FT   STRAND       69     72       {ECO:0000244|PDB:2IFG}.
FT   HELIX        84     86       {ECO:0000244|PDB:2IFG}.
FT   STRAND       94     97       {ECO:0000244|PDB:2IFG}.
FT   HELIX       110    112       {ECO:0000244|PDB:2IFG}.
FT   STRAND      119    121       {ECO:0000244|PDB:2IFG}.
FT   TURN        133    135       {ECO:0000244|PDB:2IFG}.
FT   STRAND      142    144       {ECO:0000244|PDB:2IFG}.
FT   HELIX       154    156       {ECO:0000244|PDB:2IFG}.
FT   HELIX       157    164       {ECO:0000244|PDB:2IFG}.
FT   HELIX       171    173       {ECO:0000244|PDB:2IFG}.
FT   STRAND      178    181       {ECO:0000244|PDB:2IFG}.
FT   STRAND      195    199       {ECO:0000244|PDB:2IFG}.
FT   STRAND      211    218       {ECO:0000244|PDB:2IFG}.
FT   STRAND      227    230       {ECO:0000244|PDB:2IFG}.
FT   STRAND      234    238       {ECO:0000244|PDB:2IFG}.
FT   STRAND      244    253       {ECO:0000244|PDB:2IFG}.
FT   TURN        257    260       {ECO:0000244|PDB:2IFG}.
FT   STRAND      263    265       {ECO:0000244|PDB:2IFG}.
FT   STRAND      276    278       {ECO:0000244|PDB:2IFG}.
FT   STRAND      284    290       {ECO:0000244|PDB:1WWW}.
FT   STRAND      298    305       {ECO:0000244|PDB:1HE7}.
FT   STRAND      312    317       {ECO:0000244|PDB:1HE7}.
FT   STRAND      326    333       {ECO:0000244|PDB:1HE7}.
FT   STRAND      342    350       {ECO:0000244|PDB:1HE7}.
FT   HELIX       353    355       {ECO:0000244|PDB:1HE7}.
FT   STRAND      357    365       {ECO:0000244|PDB:1HE7}.
FT   STRAND      368    376       {ECO:0000244|PDB:1HE7}.
FT   TURN        494    496       {ECO:0000244|PDB:1SHC}.
FT   HELIX       507    509       {ECO:0000244|PDB:4PMP}.
FT   STRAND      510    518       {ECO:0000244|PDB:4PMP}.
FT   STRAND      520    531       {ECO:0000244|PDB:4PMP}.
FT   STRAND      540    546       {ECO:0000244|PDB:4PMP}.
FT   HELIX       553    566       {ECO:0000244|PDB:4PMP}.
FT   STRAND      575    579       {ECO:0000244|PDB:4PMP}.
FT   STRAND      581    584       {ECO:0000244|PDB:4PMP}.
FT   STRAND      586    590       {ECO:0000244|PDB:4PMP}.
FT   HELIX       597    603       {ECO:0000244|PDB:4PMP}.
FT   STRAND      605    607       {ECO:0000244|PDB:4F0I}.
FT   HELIX       608    611       {ECO:0000244|PDB:4PMP}.
FT   STRAND      615    617       {ECO:0000244|PDB:4YNE}.
FT   STRAND      619    621       {ECO:0000244|PDB:4YNE}.
FT   HELIX       624    643       {ECO:0000244|PDB:4PMP}.
FT   HELIX       653    655       {ECO:0000244|PDB:4PMP}.
FT   STRAND      656    659       {ECO:0000244|PDB:4PMP}.
FT   TURN        660    662       {ECO:0000244|PDB:4PMP}.
FT   STRAND      663    666       {ECO:0000244|PDB:4PMP}.
FT   HELIX       672    675       {ECO:0000244|PDB:4PMM}.
FT   HELIX       677    679       {ECO:0000244|PDB:4PMP}.
FT   STRAND      681    684       {ECO:0000244|PDB:4PMM}.
FT   STRAND      687    689       {ECO:0000244|PDB:4PMM}.
FT   HELIX       691    693       {ECO:0000244|PDB:4PMP}.
FT   HELIX       696    701       {ECO:0000244|PDB:4PMP}.
FT   HELIX       706    721       {ECO:0000244|PDB:4PMP}.
FT   TURN        727    730       {ECO:0000244|PDB:4PMP}.
FT   HELIX       733    742       {ECO:0000244|PDB:4PMP}.
FT   HELIX       754    763       {ECO:0000244|PDB:4PMP}.
FT   HELIX       768    770       {ECO:0000244|PDB:4PMP}.
FT   HELIX       774    787       {ECO:0000244|PDB:4PMP}.
SQ   SEQUENCE   796 AA;  87497 MW;  6C15C721E336B601 CRC64;
     MLRGGRRGQL GWHSWAAGPG SLLAWLILAS AGAAPCPDAC CPHGSSGLRC TRDGALDSLH
     HLPGAENLTE LYIENQQHLQ HLELRDLRGL GELRNLTIVK SGLRFVAPDA FHFTPRLSRL
     NLSFNALESL SWKTVQGLSL QELVLSGNPL HCSCALRWLQ RWEEEGLGGV PEQKLQCHGQ
     GPLAHMPNAS CGVPTLKVQV PNASVDVGDD VLLRCQVEGR GLEQAGWILT ELEQSATVMK
     SGGLPSLGLT LANVTSDLNR KNVTCWAEND VGRAEVSVQV NVSFPASVQL HTAVEMHHWC
     IPFSVDGQPA PSLRWLFNGS VLNETSFIFT EFLEPAANET VRHGCLRLNQ PTHVNNGNYT
     LLAANPFGQA SASIMAAFMD NPFEFNPEDP IPVSFSPVDT NSTSGDPVEK KDETPFGVSV
     AVGLAVFACL FLSTLLLVLN KCGRRNKFGI NRPAVLAPED GLAMSLHFMT LGGSSLSPTE
     GKGSGLQGHI IENPQYFSDA CVHHIKRRDI VLKWELGEGA FGKVFLAECH NLLPEQDKML
     VAVKALKEAS ESARQDFQRE AELLTMLQHQ HIVRFFGVCT EGRPLLMVFE YMRHGDLNRF
     LRSHGPDAKL LAGGEDVAPG PLGLGQLLAV ASQVAAGMVY LAGLHFVHRD LATRNCLVGQ
     GLVVKIGDFG MSRDIYSTDY YRVGGRTMLP IRWMPPESIL YRKFTTESDV WSFGVVLWEI
     FTYGKQPWYQ LSNTEAIDCI TQGRELERPR ACPPEVYAIM RGCWQREPQQ RHSIKDVHAR
     LQALAQAPPV YLDVLG
//
ID   PKHD1_HUMAN             Reviewed;        4074 AA.
AC   P08F94; Q5VUA2; Q5VUA3; Q5VWV1; Q86Z26; Q8TCZ9;
DT   18-MAY-2010, integrated into UniProtKB/Swiss-Prot.
DT   18-MAY-2010, sequence version 1.
DT   20-JAN-2016, entry version 57.
DE   RecName: Full=Fibrocystin;
DE   AltName: Full=Polycystic kidney and hepatic disease 1 protein;
DE   AltName: Full=Polyductin;
DE   AltName: Full=Tigmin;
DE   Flags: Precursor;
GN   Name=PKHD1; Synonyms=FCYT, TIGM1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANTS ARPKD MET-36;
RP   VAL-222; TRP-1249; ARG-1407; PHE-1664; MET-1741; ARG-1917; GLY-1995;
RP   LYS-2331; THR-2957; PHE-3018 AND THR-3553, AND VARIANTS VAL-25;
RP   MET-752; CYS-760; ARG-852; VAL-1262; MET-2938; TYR-3139; ILE-3960 AND
RP   ARG-4048.
RC   TISSUE=Kidney;
RX   PubMed=11919560; DOI=10.1038/ng833;
RA   Ward C.J., Hogan M.C., Rossetti S., Walker D., Sneddon T., Wang X.,
RA   Kubly V., Cunningham J.M., Bacallao R., Ishibashi M., Milliner D.S.,
RA   Torres V.E., Harris P.C.;
RT   "The gene mutated in autosomal recessive polycystic kidney disease
RT   encodes a large, receptor-like protein.";
RL   Nat. Genet. 30:259-269(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), ALTERNATIVE
RP   SPLICING, VARIANTS ARPKD MET-36; VAL-222; LEU-253; HIS-760; SER-1122;
RP   TRP-1624 AND THR-2957, AND VARIANTS VAL-1870 AND TYR-3139.
RC   TISSUE=Kidney;
RX   PubMed=11898128; DOI=10.1086/340448;
RA   Onuchic L.F., Furu L., Nagasawa Y., Hou X., Eggermann T., Ren Z.,
RA   Bergmann C., Senderek J., Esquivel E., Zeltner R.,
RA   Rudnik-Schoeneborn S., Mrug M., Sweeney W., Avner E.D., Zerres K.,
RA   Guay-Woodford L.M., Somlo S., Germino G.G.;
RT   "PKHD1, the polycystic kidney and hepatic disease 1 gene, encodes a
RT   novel large protein containing multiple immunoglobulin-like-plexin-
RT   transcription-factor domains and parallel beta-helix 1 repeats.";
RL   Am. J. Hum. Genet. 70:1305-1317(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND VARIANT TYR-1204.
RC   TISSUE=Fetal kidney;
RX   PubMed=12079288; DOI=10.1006/geno.2002.6802;
RA   Xiong H., Chen Y., Yi Y., Tsuchiya K., Moeckel G., Cheung J.,
RA   Liang D., Tham K., Xu X., Chen X.-Z., Pei Y., Zhao Z.J., Wu G.;
RT   "A novel gene encoding a TIG multiple domain protein is a positional
RT   candidate for autosomal recessive polycystic kidney disease.";
RL   Genomics 80:96-104(2002).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   REVIEW ON VARIANTS.
RX   PubMed=15108277; DOI=10.1002/humu.20029;
RA   Bergmann C., Senderek J., Kuepper F., Schneider F., Dornia C.,
RA   Windelen E., Eggermann T., Rudnik-Schoeneborn S., Kirfel J., Furu L.,
RA   Onuchic L.F., Rossetti S., Harris P.C., Somlo S., Guay-Woodford L.,
RA   Germino G.G., Moser M., Buettner R., Zerres K.;
RT   "PKHD1 mutations in autosomal recessive polycystic kidney disease
RT   (ARPKD).";
RL   Hum. Mutat. 23:453-463(2004).
RN   [7]
RP   TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
RX   PubMed=14978161; DOI=10.1097/01.ASN.0000113793.12558.1D;
RA   Wang S., Luo Y., Wilson P.D., Witman G.B., Zhou J.;
RT   "The autosomal recessive polycystic kidney disease protein is
RT   localized to primary cilia, with concentration in the basal body
RT   area.";
RL   J. Am. Soc. Nephrol. 15:592-602(2004).
RN   [8]
RP   TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
RX   PubMed=15458427; DOI=10.1111/j.1523-1755.2004.00844.x;
RA   Menezes L.F., Cai Y., Nagasawa Y., Silva A.M., Watkins M.L.,
RA   Da Silva A.M., Somlo S., Guay-Woodford L.M., Germino G.G.,
RA   Onuchic L.F.;
RT   "Polyductin, the PKHD1 gene product, comprises isoforms expressed in
RT   plasma membrane, primary cilium, and cytoplasm.";
RL   Kidney Int. 66:1345-1355(2004).
RN   [9]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=20554582; DOI=10.1093/hmg/ddq233;
RA   Zhang J., Wu M., Wang S., Shah J.V., Wilson P.D., Zhou J.;
RT   "Polycystic kidney disease protein fibrocystin localizes to the
RT   mitotic spindle and regulates spindle bipolarity.";
RL   Hum. Mol. Genet. 19:3306-3319(2010).
RN   [10]
RP   VARIANTS ARPKD MET-36; SER-223; LEU-253; SER-473; PRO-496; CYS-656;
RP   ASN-703; HIS-760; LEU-805; LYS-997; GLU-1030; SER-1122; SER-1123;
RP   TRP-1249; ARG-1407; LEU-1486; TRP-1624; PHE-1664; MET-1741; ARG-1917;
RP   GLY-1995; THR-1998; PRO-2134; LYS-2331; TYR-2761; THR-2957; PHE-3018;
RP   VAL-3081; VAL-3293; GLY-3471; CYS-3482 AND THR-3553, AND VARIANTS
RP   MET-579; SER-830 AND TYR-3139.
RX   PubMed=12506140; DOI=10.1097/01.ASN.0000039578.55705.6E;
RA   Bergmann C., Senderek J., Sedlacek B., Pegiazoglou I., Puglia P.,
RA   Eggermann T., Rudnik-Schoeneborn S., Furu L., Onuchic L.F.,
RA   De Baca M., Germino G.G., Guay-Woodford L., Somlo S., Moser M.,
RA   Buettner R., Zerres K.;
RT   "Spectrum of mutations in the gene for autosomal recessive polycystic
RT   kidney disease (ARPKD/PKHD1).";
RL   J. Am. Soc. Nephrol. 14:76-89(2003).
RN   [11]
RP   VARIANTS ARPKD MET-36; VAL-326; ASN-387 DEL; PRO-899; SER-1123;
RP   ILE-1584; ILE-1781; LEU-1789; GLY-1942; ASP-1971; LEU-2032; GLY-2422;
RP   ALA-2641; PRO-2772; GLY-2861; CYS-2863; THR-2957; LEU-2983; GLY-3036;
RP   TYR-3124; LEU-3167; ASP-3175; SER-3175; THR-3177; VAL-3293 AND
RP   SER-3783, AND VARIANTS ASP-457; PHE-732; CYS-760; PRO-1150; LEU-1283;
RP   PHE-1709; VAL-1870; GLY-2615; LYS-2869; TYR-3139; ILE-3143; ASP-3440;
RP   LYS-3551; ARG-3899 AND ILE-3960.
RX   PubMed=12874454; DOI=10.1097/01.ASN.0000078805.87038.05;
RA   Furu L., Onuchic L.F., Gharavi A., Hou X., Esquivel E.L., Nagasawa Y.,
RA   Bergmann C., Senderek J., Avner E., Zerres K., Germino G.G.,
RA   Guay-Woodford L.M., Somlo S.;
RT   "Milder presentation of recessive polycystic kidney disease requires
RT   presence of amino acid substitution mutations.";
RL   J. Am. Soc. Nephrol. 14:2004-2014(2003).
RN   [12]
RP   VARIANTS ARPKD VAL-17; MET-36; VAL-222; LEU-739; LEU-757; LEU-805;
RP   THR-1389; MET-1741; LEU-1833; CYS-1838; ASN-1867; GLY-1942; PHE-2688;
RP   THR-2957; THR-3177; ARG-3346; VAL-3468; VAL-3502; GLN-3529 AND
RP   TYR-3622, AND VARIANTS CYS-760; SER-830; VAL-1262; PHE-1709; VAL-1870;
RP   LYS-2869; TYR-3139; ARG-3505; ARG-3899; ILE-3960 AND ARG-4048.
RX   PubMed=12846734; DOI=10.1046/j.1523-1755.2003.00111.x;
RA   Rossetti S., Torra R., Coto E., Consugar M., Kubly V., Malaga S.,
RA   Navarro M., El-Youssef M., Torres V.E., Harris P.C.;
RT   "A complete mutation screen of PKHD1 in autosomal-recessive polycystic
RT   kidney disease (ARPKD) pedigrees.";
RL   Kidney Int. 64:391-403(2003).
RN   [13]
RP   VARIANTS ARPKD MET-36; THR-307; HIS-486; LEU-805; TYR-1472; PHE-2303;
RP   THR-2957; GLY-2962; TYR-3124; THR-3177 AND CYS-3482, AND VARIANTS
RP   LYS-2869 AND TYR-3139.
RX   PubMed=15108281; DOI=10.1002/humu.20019;
RA   Bergmann C., Senderek J., Schneider F., Dornia C., Kuepper F.,
RA   Eggermann T., Rudnik-Schoeneborn S., Kirfel J., Moser M., Buettner R.,
RA   Zerres K.;
RT   "PKHD1 mutations in families requesting prenatal diagnosis for
RT   autosomal recessive polycystic kidney disease (ARPKD).";
RL   Hum. Mutat. 23:487-495(2004).
RN   [14]
RP   VARIANT ARPKD LEU-372.
RX   PubMed=16677362; DOI=10.1111/j.1399-3046.2005.00464.x;
RA   Prelog M., Bergmann C., Ausserlechner M.J., Fischer H., Margreiter R.,
RA   Gassner I., Brunner A., Jungraithmayr T.C., Zerres K., Sergi E.C.,
RA   Zimmerhackl L.B.;
RT   "Successful transplantation in a child with rapid progression of
RT   autosomal recessive polycystic kidney disease associated with a novel
RT   mutation.";
RL   Pediatr. Transplant. 10:362-366(2006).
RN   [15]
RP   VARIANTS [LARGE SCALE ANALYSIS] HIS-19; CYS-1081; ARG-1096; TRP-1624
RP   AND LYS-1806.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [16]
RP   VARIANTS ARPKD TRP-92; THR-246; CYS-255; VAL-293; GLU-466; VAL-470;
RP   THR-539; PRO-686; ARG-724; ARG-1712; GLY-1817; GLY-1875; LEU-1928;
RP   THR-2009; ARG-2106; GLU-2210; LEU-2219; ARG-2224; ARG-2422; VAL-2431;
RP   CYS-2573; GLY-2798; ARG-2803; LYS-2804; ARG-3049; THR-3207 AND
RP   CYS-3957, AND VARIANTS VAL-292; CYS-723; HIS-2661 AND ALA-3219.
RX   PubMed=19914852; DOI=10.1016/j.ymgme.2009.10.010;
RA   Gunay-Aygun M., Tuchman M., Font-Montgomery E., Lukose L., Edwards H.,
RA   Garcia A., Ausavarat S., Ziegler S.G., Piwnica-Worms K., Bryant J.,
RA   Bernardini I., Fischer R., Huizing M., Guay-Woodford L., Gahl W.A.;
RT   "PKHD1 sequence variations in 78 children and adults with autosomal
RT   recessive polycystic kidney disease and congenital hepatic fibrosis.";
RL   Mol. Genet. Metab. 99:160-173(2010).
CC   -!- FUNCTION: May be required for correct bipolar cell division
CC       through the regulation of centrosome duplication and mitotic
CC       spindle assembly. May be a receptor protein that acts in
CC       collecting-duct and biliary differentiation.
CC       {ECO:0000269|PubMed:20554582}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:15458427};
CC       Single-pass type I membrane protein {ECO:0000255}. Cytoplasm
CC       {ECO:0000269|PubMed:15458427}. Cell projection, cilium
CC       {ECO:0000269|PubMed:14978161, ECO:0000269|PubMed:15458427}.
CC       Cytoplasm, cytoskeleton, cilium basal body
CC       {ECO:0000269|PubMed:14978161}. Cytoplasm, cytoskeleton, spindle
CC       {ECO:0000269|PubMed:20554582}. Chromosome, centromere
CC       {ECO:0000269|PubMed:20554582}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC         Comment=Additional isoforms seem to exist. As a matter of fact,
CC         alternatively spliced products seem to fall into two broad
CC         groups: one group, which includes the longest continuous ORF but
CC         which may also include molecules lacking some middle domains,
CC         has a single TM element and is likely to be associated with the
CC         plasma membrane. The other group lacks a TM domain and thus its
CC         members may be secreted.;
CC       Name=1;
CC         IsoId=P08F94-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P08F94-2; Sequence=VSP_003947, VSP_003948;
CC   -!- TISSUE SPECIFICITY: Predominantly expressed in fetal and adult
CC       kidney. In the kidney, it is found in the cortical and medullary
CC       collecting ducts. Also present in the adult pancreas, but at much
CC       lower levels. Detectable in fetal and adult liver. Rather
CC       indistinct signal in fetal brain. {ECO:0000269|PubMed:14978161,
CC       ECO:0000269|PubMed:15458427}.
CC   -!- DISEASE: Polycystic kidney disease, autosomal recessive (ARPKD)
CC       [MIM:263200]: A severe form of polycystic kidney disease affecting
CC       the kidneys and the hepatic biliary tract. The clinical spectrum
CC       is widely variable, with most cases presenting during infancy. The
CC       fetal phenotypic features classically include enlarged and
CC       echogenic kidneys, as well as oligohydramnios secondary to a poor
CC       urine output. Up to 50% of the affected neonates die shortly after
CC       birth, as a result of severe pulmonary hypoplasia and secondary
CC       respiratory insufficiency. In the subset that survives the
CC       perinatal period, morbidity and mortality are mainly related to
CC       severe systemic hypertension, renal insufficiency, and portal
CC       hypertension due to portal-tract fibrosis.
CC       {ECO:0000269|PubMed:11898128, ECO:0000269|PubMed:11919560,
CC       ECO:0000269|PubMed:12506140, ECO:0000269|PubMed:12846734,
CC       ECO:0000269|PubMed:12874454, ECO:0000269|PubMed:15108281,
CC       ECO:0000269|PubMed:16677362, ECO:0000269|PubMed:19914852}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Contains 2 G8 domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00817}.
CC   -!- SIMILARITY: Contains 12 IPT/TIG domains. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 9 PbH1 repeats. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Mutation Database Autosomal Recessive
CC       Polycystic Kidney Disease (ARPKD/PKHD1);
CC       URL="http://www.humgen.rwth-aachen.de/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY074797; AAL74290.1; -; mRNA.
DR   EMBL; AY129465; AAM93492.1; -; Genomic_DNA.
DR   EMBL; AF480064; AAM44232.1; -; mRNA.
DR   EMBL; AY092083; AAM18186.1; -; mRNA.
DR   EMBL; AL590391; CAH72781.1; -; Genomic_DNA.
DR   EMBL; AL121946; CAH72781.1; JOINED; Genomic_DNA.
DR   EMBL; AL157774; CAH72781.1; JOINED; Genomic_DNA.
DR   EMBL; AL355997; CAH72781.1; JOINED; Genomic_DNA.
DR   EMBL; AL391221; CAH72781.1; JOINED; Genomic_DNA.
DR   EMBL; AL590391; CAH72782.1; -; Genomic_DNA.
DR   EMBL; AL121946; CAH72782.1; JOINED; Genomic_DNA.
DR   EMBL; AL157774; CAH72782.1; JOINED; Genomic_DNA.
DR   EMBL; AL391221; CAH72782.1; JOINED; Genomic_DNA.
DR   EMBL; AL157774; CAH73867.1; -; Genomic_DNA.
DR   EMBL; AL121946; CAH73867.1; JOINED; Genomic_DNA.
DR   EMBL; AL355997; CAH73867.1; JOINED; Genomic_DNA.
DR   EMBL; AL391221; CAH73867.1; JOINED; Genomic_DNA.
DR   EMBL; AL590391; CAH73867.1; JOINED; Genomic_DNA.
DR   EMBL; AL157774; CAH73868.1; -; Genomic_DNA.
DR   EMBL; AL121946; CAH73868.1; JOINED; Genomic_DNA.
DR   EMBL; AL391221; CAH73868.1; JOINED; Genomic_DNA.
DR   EMBL; AL590391; CAH73868.1; JOINED; Genomic_DNA.
DR   EMBL; AL391221; CAI16676.1; -; Genomic_DNA.
DR   EMBL; AL121946; CAI16676.1; JOINED; Genomic_DNA.
DR   EMBL; AL157774; CAI16676.1; JOINED; Genomic_DNA.
DR   EMBL; AL355997; CAI16676.1; JOINED; Genomic_DNA.
DR   EMBL; AL590391; CAI16676.1; JOINED; Genomic_DNA.
DR   EMBL; AL391221; CAI16677.1; -; Genomic_DNA.
DR   EMBL; AL121946; CAI16677.1; JOINED; Genomic_DNA.
DR   EMBL; AL157774; CAI16677.1; JOINED; Genomic_DNA.
DR   EMBL; AL590391; CAI16677.1; JOINED; Genomic_DNA.
DR   EMBL; AL355997; CAI20233.1; -; Genomic_DNA.
DR   EMBL; AL121946; CAI20233.1; JOINED; Genomic_DNA.
DR   EMBL; AL157774; CAI20233.1; JOINED; Genomic_DNA.
DR   EMBL; AL391221; CAI20233.1; JOINED; Genomic_DNA.
DR   EMBL; AL590391; CAI20233.1; JOINED; Genomic_DNA.
DR   EMBL; AL121946; CAI20324.1; -; Genomic_DNA.
DR   EMBL; AL157774; CAI20324.1; JOINED; Genomic_DNA.
DR   EMBL; AL355997; CAI20324.1; JOINED; Genomic_DNA.
DR   EMBL; AL391221; CAI20324.1; JOINED; Genomic_DNA.
DR   EMBL; AL590391; CAI20324.1; JOINED; Genomic_DNA.
DR   EMBL; AL121946; CAI20325.1; -; Genomic_DNA.
DR   EMBL; AL157774; CAI20325.1; JOINED; Genomic_DNA.
DR   EMBL; AL391221; CAI20325.1; JOINED; Genomic_DNA.
DR   EMBL; AL590391; CAI20325.1; JOINED; Genomic_DNA.
DR   EMBL; CH471081; EAX04359.1; -; Genomic_DNA.
DR   CCDS; CCDS4935.1; -. [P08F94-1]
DR   CCDS; CCDS4936.1; -. [P08F94-2]
DR   RefSeq; NP_619639.3; NM_138694.3. [P08F94-1]
DR   RefSeq; NP_733842.2; NM_170724.2. [P08F94-2]
DR   RefSeq; XP_011512981.1; XM_011514679.1. [P08F94-1]
DR   RefSeq; XP_011512982.1; XM_011514680.1. [P08F94-1]
DR   UniGene; Hs.662050; -.
DR   ProteinModelPortal; P08F94; -.
DR   SMR; P08F94; 1198-1253, 1301-1338, 1389-1414, 1573-1628.
DR   BioGrid; 111331; 1.
DR   STRING; 9606.ENSP00000360158; -.
DR   iPTMnet; P08F94; -.
DR   PhosphoSite; P08F94; -.
DR   BioMuta; PKHD1; -.
DR   DMDM; 296439717; -.
DR   PaxDb; P08F94; -.
DR   PRIDE; P08F94; -.
DR   Ensembl; ENST00000340994; ENSP00000341097; ENSG00000170927. [P08F94-2]
DR   Ensembl; ENST00000371117; ENSP00000360158; ENSG00000170927. [P08F94-1]
DR   GeneID; 5314; -.
DR   KEGG; hsa:5314; -.
DR   UCSC; uc003pah.1; human. [P08F94-1]
DR   UCSC; uc003pai.3; human. [P08F94-2]
DR   CTD; 5314; -.
DR   GeneCards; PKHD1; -.
DR   GeneReviews; PKHD1; -.
DR   H-InvDB; HIX0005949; -.
DR   HGNC; HGNC:9016; PKHD1.
DR   HPA; HPA031227; -.
DR   MalaCards; PKHD1; -.
DR   MIM; 263200; phenotype.
DR   MIM; 606702; gene.
DR   neXtProt; NX_P08F94; -.
DR   Orphanet; 731; Autosomal recessive polycystic kidney disease.
DR   PharmGKB; PA33348; -.
DR   eggNOG; ENOG410IEIF; Eukaryota.
DR   eggNOG; ENOG410XQ01; LUCA.
DR   GeneTree; ENSGT00780000121902; -.
DR   HOGENOM; HOG000115555; -.
DR   InParanoid; P08F94; -.
DR   OMA; SERLGFH; -.
DR   OrthoDB; EOG78WKQS; -.
DR   PhylomeDB; P08F94; -.
DR   TreeFam; TF329582; -.
DR   GenomeRNAi; 5314; -.
DR   NextBio; 20548; -.
DR   PRO; PR:P08F94; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; P08F94; -.
DR   Genevisible; P08F94; HS.
DR   GO; GO:0031362; C:anchored component of external side of plasma membrane; TAS:UniProtKB.
DR   GO; GO:0016324; C:apical plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0036064; C:ciliary basal body; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0072686; C:mitotic spindle; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0072372; C:primary cilium; IDA:UniProtKB.
DR   GO; GO:0004872; F:receptor activity; NAS:UniProtKB.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; IMP:UniProtKB.
DR   GO; GO:0042384; P:cilium assembly; ISS:UniProtKB.
DR   GO; GO:0042592; P:homeostatic process; NAS:UniProtKB.
DR   GO; GO:0001822; P:kidney development; ISS:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0051271; P:negative regulation of cellular component movement; ISS:UniProtKB.
DR   GO; GO:0032088; P:negative regulation of NF-kappaB transcription factor activity; IMP:UniProtKB.
DR   GO; GO:0051898; P:negative regulation of protein kinase B signaling; IMP:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IMP:UniProtKB.
DR   GO; GO:0010824; P:regulation of centrosome duplication; IMP:UniProtKB.
DR   GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:0032006; P:regulation of TOR signaling; IMP:UniProtKB.
DR   GO; GO:0016337; P:single organismal cell-cell adhesion; ISS:UniProtKB.
DR   Gene3D; 2.160.20.10; -; 3.
DR   Gene3D; 2.60.40.10; -; 7.
DR   InterPro; IPR019316; G8_domain.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR014756; Ig_E-set.
DR   InterPro; IPR002909; IPT.
DR   InterPro; IPR006626; PbH1.
DR   InterPro; IPR012334; Pectin_lyas_fold.
DR   InterPro; IPR011050; Pectin_lyase_fold/virulence.
DR   InterPro; IPR028839; PKHD1.
DR   PANTHER; PTHR11915:SF299; PTHR11915:SF299; 1.
DR   Pfam; PF10162; G8; 2.
DR   Pfam; PF01833; TIG; 8.
DR   SMART; SM00429; IPT; 6.
DR   SMART; SM00710; PbH1; 10.
DR   SUPFAM; SSF51126; SSF51126; 3.
DR   SUPFAM; SSF81296; SSF81296; 6.
DR   PROSITE; PS51484; G8; 2.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell membrane; Cell projection; Centromere;
KW   Chromosome; Ciliopathy; Cilium; Complete proteome; Cytoplasm;
KW   Cytoskeleton; Disease mutation; Glycoprotein; Membrane; Polymorphism;
KW   Receptor; Reference proteome; Repeat; Signal; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL        1     23       {ECO:0000255}.
FT   CHAIN        24   4074       Fibrocystin.
FT                                /FTId=PRO_0000022062.
FT   TOPO_DOM     24   3858       Extracellular. {ECO:0000255}.
FT   TRANSMEM   3859   3879       Helical. {ECO:0000255}.
FT   TOPO_DOM   3880   4074       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       24    111       IPT/TIG 1; atypical.
FT   DOMAIN      137    232       IPT/TIG 2.
FT   DOMAIN      259    335       IPT/TIG 3.
FT   DOMAIN      931   1015       IPT/TIG 4.
FT   DOMAIN     1019   1103       IPT/TIG 5.
FT   DOMAIN     1108   1192       IPT/TIG 6; atypical.
FT   DOMAIN     1196   1289       IPT/TIG 7.
FT   DOMAIN     1301   1382       IPT/TIG 8; atypical.
FT   DOMAIN     1389   1481       IPT/TIG 9.
FT   DOMAIN     1486   1570       IPT/TIG 10.
FT   DOMAIN     1573   1659       IPT/TIG 11.
FT   DOMAIN     1658   1742       IPT/TIG 12; atypical.
FT   DOMAIN     1932   2053       G8 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00817}.
FT   REPEAT     2226   2248       PbH1 1.
FT   REPEAT     2249   2271       PbH1 2.
FT   REPEAT     2292   2325       PbH1 3.
FT   REPEAT     2326   2347       PbH1 4.
FT   REPEAT     2409   2431       PbH1 5.
FT   REPEAT     2469   2502       PbH1 6.
FT   DOMAIN     2747   2873       G8 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00817}.
FT   REPEAT     3010   3032       PbH1 7.
FT   REPEAT     3033   3055       PbH1 8.
FT   REPEAT     3086   3108       PbH1 9.
FT   CARBOHYD     54     54       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    226    226       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    276    276       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    357    357       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    387    387       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    507    507       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    520    520       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    529    529       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    641    641       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    711    711       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    830    830       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    869    869       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    967    967       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    977    977       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1065   1065       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1084   1084       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1116   1116       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1135   1135       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1234   1234       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1241   1241       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1312   1312       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1323   1323       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1346   1346       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1377   1377       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1460   1460       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1475   1475       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1494   1494       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1527   1527       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1532   1532       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1564   1564       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1582   1582       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1602   1602       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1631   1631       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1698   1698       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1764   1764       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1779   1779       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1879   1879       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1883   1883       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1919   1919       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1945   1945       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1959   1959       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2034   2034       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2115   2115       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2144   2144       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2350   2350       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2385   2385       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2435   2435       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2471   2471       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2509   2509       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2535   2535       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2553   2553       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2595   2595       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2633   2633       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2753   2753       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2768   2768       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   3008   3008       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   3140   3140       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   3169   3169       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   3225   3225       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   3488   3488       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   3528   3528       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   3707   3707       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   3726   3726       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   3838   3838       N-linked (GlcNAc...). {ECO:0000255}.
FT   VAR_SEQ    3386   3396       GTFREEQKCTY -> VTTEQALKISE (in isoform
FT                                2). {ECO:0000303|PubMed:12079288}.
FT                                /FTId=VSP_003947.
FT   VAR_SEQ    3397   4074       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:12079288}.
FT                                /FTId=VSP_003948.
FT   VARIANT      17     17       A -> V (in ARPKD).
FT                                {ECO:0000269|PubMed:12846734}.
FT                                /FTId=VAR_018520.
FT   VARIANT      19     19       R -> H (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036228.
FT   VARIANT      25     25       I -> V. {ECO:0000269|PubMed:11919560}.
FT                                /FTId=VAR_018521.
FT   VARIANT      36     36       T -> M (in ARPKD; common mutation;
FT                                dbSNP:rs28939383).
FT                                {ECO:0000269|PubMed:11898128,
FT                                ECO:0000269|PubMed:11919560,
FT                                ECO:0000269|PubMed:12506140,
FT                                ECO:0000269|PubMed:12846734,
FT                                ECO:0000269|PubMed:12874454,
FT                                ECO:0000269|PubMed:15108281}.
FT                                /FTId=VAR_014039.
FT   VARIANT      92     92       R -> W (in ARPKD).
FT                                {ECO:0000269|PubMed:19914852}.
FT                                /FTId=VAR_066416.
FT   VARIANT     222    222       I -> V (in ARPKD).
FT                                {ECO:0000269|PubMed:11898128,
FT                                ECO:0000269|PubMed:11919560,
FT                                ECO:0000269|PubMed:12846734}.
FT                                /FTId=VAR_014040.
FT   VARIANT     223    223       G -> S (in ARPKD).
FT                                {ECO:0000269|PubMed:12506140}.
FT                                /FTId=VAR_018522.
FT   VARIANT     246    246       I -> T (in ARPKD).
FT                                {ECO:0000269|PubMed:19914852}.
FT                                /FTId=VAR_066417.
FT   VARIANT     253    253       F -> L (in ARPKD).
FT                                {ECO:0000269|PubMed:11898128,
FT                                ECO:0000269|PubMed:12506140}.
FT                                /FTId=VAR_014041.
FT   VARIANT     255    255       Y -> C (in ARPKD).
FT                                {ECO:0000269|PubMed:19914852}.
FT                                /FTId=VAR_066418.
FT   VARIANT     292    292       I -> V (in a patient with polycystic
FT                                kidney disease).
FT                                {ECO:0000269|PubMed:19914852}.
FT                                /FTId=VAR_066419.
FT   VARIANT     293    293       A -> V (in ARPKD).
FT                                {ECO:0000269|PubMed:19914852}.
FT                                /FTId=VAR_066420.
FT   VARIANT     307    307       I -> T (in ARPKD).
FT                                {ECO:0000269|PubMed:15108281}.
FT                                /FTId=VAR_018523.
FT   VARIANT     326    326       G -> V (in ARPKD).
FT                                {ECO:0000269|PubMed:12874454}.
FT                                /FTId=VAR_018524.
FT   VARIANT     372    372       F -> L (in ARPKD).
FT                                {ECO:0000269|PubMed:16677362}.
FT                                /FTId=VAR_027439.
FT   VARIANT     387    387       Missing (in ARPKD).
FT                                {ECO:0000269|PubMed:12874454}.
FT                                /FTId=VAR_018525.
FT   VARIANT     457    457       E -> D. {ECO:0000269|PubMed:12874454}.
FT                                /FTId=VAR_018526.
FT   VARIANT     466    466       G -> E (in ARPKD).
FT                                {ECO:0000269|PubMed:19914852}.
FT                                /FTId=VAR_066421.
FT   VARIANT     470    470       G -> V (in ARPKD).
FT                                {ECO:0000269|PubMed:19914852}.
FT                                /FTId=VAR_066422.
FT   VARIANT     473    473       I -> S (in ARPKD).
FT                                {ECO:0000269|PubMed:12506140}.
FT                                /FTId=VAR_018527.
FT   VARIANT     486    486       Y -> H (in ARPKD).
FT                                {ECO:0000269|PubMed:15108281}.
FT                                /FTId=VAR_018528.
FT   VARIANT     488    488       R -> P.
FT                                /FTId=VAR_018529.
FT   VARIANT     496    496       R -> P (in ARPKD).
FT                                {ECO:0000269|PubMed:12506140}.
FT                                /FTId=VAR_018530.
FT   VARIANT     539    539       I -> T (in ARPKD).
FT                                {ECO:0000269|PubMed:19914852}.
FT                                /FTId=VAR_066423.
FT   VARIANT     579    579       T -> M (in dbSNP:rs45500692).
FT                                {ECO:0000269|PubMed:12506140}.
FT                                /FTId=VAR_018531.
FT   VARIANT     656    656       W -> C (in ARPKD).
FT                                {ECO:0000269|PubMed:12506140}.
FT                                /FTId=VAR_018532.
FT   VARIANT     686    686       H -> P (in ARPKD).
FT                                {ECO:0000269|PubMed:19914852}.
FT                                /FTId=VAR_066424.
FT   VARIANT     703    703       D -> N (in ARPKD).
FT                                {ECO:0000269|PubMed:12506140}.
FT                                /FTId=VAR_018533.
FT   VARIANT     723    723       R -> C. {ECO:0000269|PubMed:19914852}.
FT                                /FTId=VAR_066425.
FT   VARIANT     724    724       P -> R (in ARPKD).
FT                                {ECO:0000269|PubMed:19914852}.
FT                                /FTId=VAR_066426.
FT   VARIANT     732    732       V -> F (in dbSNP:rs201432731).
FT                                {ECO:0000269|PubMed:12874454}.
FT                                /FTId=VAR_018534.
FT   VARIANT     739    739       P -> L (in ARPKD).
FT                                {ECO:0000269|PubMed:12846734}.
FT                                /FTId=VAR_018535.
FT   VARIANT     752    752       T -> M. {ECO:0000269|PubMed:11919560}.
FT                                /FTId=VAR_014042.
FT   VARIANT     757    757       I -> L (in ARPKD).
FT                                {ECO:0000269|PubMed:12846734}.
FT                                /FTId=VAR_018536.
FT   VARIANT     760    760       R -> C (in dbSNP:rs9370096).
FT                                {ECO:0000269|PubMed:11919560,
FT                                ECO:0000269|PubMed:12846734,
FT                                ECO:0000269|PubMed:12874454}.
FT                                /FTId=VAR_014043.
FT   VARIANT     760    760       R -> H (in ARPKD).
FT                                {ECO:0000269|PubMed:11898128,
FT                                ECO:0000269|PubMed:12506140}.
FT                                /FTId=VAR_014044.
FT   VARIANT     760    760       R -> W (in dbSNP:rs9370096).
FT                                /FTId=VAR_051282.
FT   VARIANT     805    805       P -> L (in ARPKD).
FT                                {ECO:0000269|PubMed:12506140,
FT                                ECO:0000269|PubMed:12846734,
FT                                ECO:0000269|PubMed:15108281}.
FT                                /FTId=VAR_018537.
FT   VARIANT     830    830       N -> S. {ECO:0000269|PubMed:12506140,
FT                                ECO:0000269|PubMed:12846734}.
FT                                /FTId=VAR_018538.
FT   VARIANT     852    852       W -> R. {ECO:0000269|PubMed:11919560}.
FT                                /FTId=VAR_014045.
FT   VARIANT     899    899       T -> P (in ARPKD).
FT                                {ECO:0000269|PubMed:12874454}.
FT                                /FTId=VAR_018539.
FT   VARIANT     997    997       M -> K (in ARPKD).
FT                                {ECO:0000269|PubMed:12506140}.
FT                                /FTId=VAR_018540.
FT   VARIANT    1030   1030       A -> E (in ARPKD).
FT                                {ECO:0000269|PubMed:12506140}.
FT                                /FTId=VAR_018541.
FT   VARIANT    1081   1081       R -> C (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036229.
FT   VARIANT    1096   1096       L -> R (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036230.
FT   VARIANT    1122   1122       G -> S (in ARPKD).
FT                                {ECO:0000269|PubMed:11898128,
FT                                ECO:0000269|PubMed:12506140}.
FT                                /FTId=VAR_014046.
FT   VARIANT    1123   1123       G -> S (in ARPKD).
FT                                {ECO:0000269|PubMed:12506140,
FT                                ECO:0000269|PubMed:12874454}.
FT                                /FTId=VAR_018542.
FT   VARIANT    1136   1136       Y -> C (in dbSNP:rs41273726).
FT                                /FTId=VAR_018543.
FT   VARIANT    1150   1150       A -> P. {ECO:0000269|PubMed:12874454}.
FT                                /FTId=VAR_018544.
FT   VARIANT    1204   1204       C -> Y. {ECO:0000269|PubMed:12079288}.
FT                                /FTId=VAR_014047.
FT   VARIANT    1249   1249       C -> W (in ARPKD).
FT                                {ECO:0000269|PubMed:11919560,
FT                                ECO:0000269|PubMed:12506140}.
FT                                /FTId=VAR_014048.
FT   VARIANT    1262   1262       A -> V (in dbSNP:rs9296669).
FT                                {ECO:0000269|PubMed:11919560,
FT                                ECO:0000269|PubMed:12846734}.
FT                                /FTId=VAR_014049.
FT   VARIANT    1283   1283       S -> L. {ECO:0000269|PubMed:12874454}.
FT                                /FTId=VAR_018545.
FT   VARIANT    1389   1389       P -> T (in ARPKD).
FT                                {ECO:0000269|PubMed:12846734}.
FT                                /FTId=VAR_018546.
FT   VARIANT    1407   1407       L -> R (in ARPKD).
FT                                {ECO:0000269|PubMed:11919560,
FT                                ECO:0000269|PubMed:12506140}.
FT                                /FTId=VAR_014050.
FT   VARIANT    1472   1472       C -> Y (in ARPKD).
FT                                {ECO:0000269|PubMed:15108281}.
FT                                /FTId=VAR_018547.
FT   VARIANT    1486   1486       P -> L (in ARPKD).
FT                                {ECO:0000269|PubMed:12506140}.
FT                                /FTId=VAR_018548.
FT   VARIANT    1584   1584       S -> I (in ARPKD).
FT                                {ECO:0000269|PubMed:12874454}.
FT                                /FTId=VAR_018549.
FT   VARIANT    1624   1624       R -> W (in ARPKD).
FT                                {ECO:0000269|PubMed:11898128,
FT                                ECO:0000269|PubMed:12506140,
FT                                ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_014051.
FT   VARIANT    1664   1664       S -> F (in ARPKD; dbSNP:rs28937907).
FT                                {ECO:0000269|PubMed:11919560,
FT                                ECO:0000269|PubMed:12506140}.
FT                                /FTId=VAR_014052.
FT   VARIANT    1709   1709       L -> F (in dbSNP:rs45517932).
FT                                {ECO:0000269|PubMed:12846734,
FT                                ECO:0000269|PubMed:12874454}.
FT                                /FTId=VAR_018550.
FT   VARIANT    1712   1712       G -> R (in a patient with polycystic
FT                                kidney disease; dbSNP:rs141103838).
FT                                {ECO:0000269|PubMed:19914852}.
FT                                /FTId=VAR_066427.
FT   VARIANT    1741   1741       V -> M (in ARPKD; dbSNP:rs28939099).
FT                                {ECO:0000269|PubMed:11919560,
FT                                ECO:0000269|PubMed:12506140,
FT                                ECO:0000269|PubMed:12846734}.
FT                                /FTId=VAR_014053.
FT   VARIANT    1781   1781       T -> I (in ARPKD).
FT                                {ECO:0000269|PubMed:12874454}.
FT                                /FTId=VAR_018551.
FT   VARIANT    1789   1789       V -> L (in ARPKD).
FT                                {ECO:0000269|PubMed:12874454}.
FT                                /FTId=VAR_018552.
FT   VARIANT    1806   1806       E -> K (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036231.
FT   VARIANT    1817   1817       V -> G (in ARPKD).
FT                                {ECO:0000269|PubMed:19914852}.
FT                                /FTId=VAR_066428.
FT   VARIANT    1833   1833       S -> L (in ARPKD).
FT                                {ECO:0000269|PubMed:12846734}.
FT                                /FTId=VAR_018553.
FT   VARIANT    1838   1838       Y -> C (in ARPKD).
FT                                {ECO:0000269|PubMed:12846734}.
FT                                /FTId=VAR_018554.
FT   VARIANT    1867   1867       S -> N (in ARPKD).
FT                                {ECO:0000269|PubMed:12846734}.
FT                                /FTId=VAR_018555.
FT   VARIANT    1870   1870       L -> V (in dbSNP:rs2435322).
FT                                {ECO:0000269|PubMed:11898128,
FT                                ECO:0000269|PubMed:12846734,
FT                                ECO:0000269|PubMed:12874454}.
FT                                /FTId=VAR_018556.
FT   VARIANT    1875   1875       V -> G (in ARPKD).
FT                                {ECO:0000269|PubMed:19914852}.
FT                                /FTId=VAR_066429.
FT   VARIANT    1917   1917       Q -> R (in ARPKD).
FT                                {ECO:0000269|PubMed:11919560,
FT                                ECO:0000269|PubMed:12506140}.
FT                                /FTId=VAR_014054.
FT   VARIANT    1928   1928       W -> L (in ARPKD).
FT                                {ECO:0000269|PubMed:19914852}.
FT                                /FTId=VAR_066430.
FT   VARIANT    1942   1942       D -> G (in ARPKD).
FT                                {ECO:0000269|PubMed:12846734,
FT                                ECO:0000269|PubMed:12874454}.
FT                                /FTId=VAR_018557.
FT   VARIANT    1971   1971       G -> D (in ARPKD; dbSNP:rs180675584).
FT                                {ECO:0000269|PubMed:12874454}.
FT                                /FTId=VAR_018558.
FT   VARIANT    1995   1995       E -> G (in ARPKD).
FT                                {ECO:0000269|PubMed:11919560,
FT                                ECO:0000269|PubMed:12506140}.
FT                                /FTId=VAR_014055.
FT   VARIANT    1998   1998       I -> T (in ARPKD).
FT                                {ECO:0000269|PubMed:12506140}.
FT                                /FTId=VAR_018559.
FT   VARIANT    2009   2009       A -> T (in ARPKD).
FT                                {ECO:0000269|PubMed:19914852}.
FT                                /FTId=VAR_066431.
FT   VARIANT    2032   2032       V -> L (in ARPKD).
FT                                {ECO:0000269|PubMed:12874454}.
FT                                /FTId=VAR_018560.
FT   VARIANT    2106   2106       L -> R (in ARPKD).
FT                                {ECO:0000269|PubMed:19914852}.
FT                                /FTId=VAR_066432.
FT   VARIANT    2134   2134       L -> P (in ARPKD).
FT                                {ECO:0000269|PubMed:12506140}.
FT                                /FTId=VAR_018561.
FT   VARIANT    2210   2210       G -> E (in ARPKD).
FT                                {ECO:0000269|PubMed:19914852}.
FT                                /FTId=VAR_066433.
FT   VARIANT    2219   2219       S -> L (in ARPKD).
FT                                {ECO:0000269|PubMed:19914852}.
FT                                /FTId=VAR_066434.
FT   VARIANT    2224   2224       G -> R (in ARPKD; may affect splicing).
FT                                {ECO:0000269|PubMed:19914852}.
FT                                /FTId=VAR_066435.
FT   VARIANT    2303   2303       I -> F (in ARPKD).
FT                                {ECO:0000269|PubMed:15108281}.
FT                                /FTId=VAR_018562.
FT   VARIANT    2331   2331       I -> K (in ARPKD).
FT                                {ECO:0000269|PubMed:11919560,
FT                                ECO:0000269|PubMed:12506140}.
FT                                /FTId=VAR_014056.
FT   VARIANT    2422   2422       C -> G (in ARPKD).
FT                                {ECO:0000269|PubMed:12874454}.
FT                                /FTId=VAR_018563.
FT   VARIANT    2422   2422       C -> R (in ARPKD).
FT                                {ECO:0000269|PubMed:19914852}.
FT                                /FTId=VAR_066436.
FT   VARIANT    2431   2431       E -> V (in ARPKD; may affect splicing).
FT                                {ECO:0000269|PubMed:19914852}.
FT                                /FTId=VAR_066437.
FT   VARIANT    2573   2573       R -> C (in ARPKD).
FT                                {ECO:0000269|PubMed:19914852}.
FT                                /FTId=VAR_066438.
FT   VARIANT    2615   2615       A -> G. {ECO:0000269|PubMed:12874454}.
FT                                /FTId=VAR_018564.
FT   VARIANT    2641   2641       T -> A (in ARPKD; dbSNP:rs7766366).
FT                                {ECO:0000269|PubMed:12874454}.
FT                                /FTId=VAR_018565.
FT   VARIANT    2661   2661       Y -> H (in a patient with polycystic
FT                                kidney disease).
FT                                {ECO:0000269|PubMed:19914852}.
FT                                /FTId=VAR_066439.
FT   VARIANT    2688   2688       C -> F (in ARPKD).
FT                                {ECO:0000269|PubMed:12846734}.
FT                                /FTId=VAR_018566.
FT   VARIANT    2761   2761       D -> Y (in ARPKD).
FT                                {ECO:0000269|PubMed:12506140}.
FT                                /FTId=VAR_018567.
FT   VARIANT    2772   2772       L -> P (in ARPKD).
FT                                {ECO:0000269|PubMed:12874454}.
FT                                /FTId=VAR_018568.
FT   VARIANT    2798   2798       V -> G (in ARPKD).
FT                                {ECO:0000269|PubMed:19914852}.
FT                                /FTId=VAR_066440.
FT   VARIANT    2803   2803       C -> R (in ARPKD).
FT                                {ECO:0000269|PubMed:19914852}.
FT                                /FTId=VAR_066441.
FT   VARIANT    2804   2804       M -> K (in ARPKD).
FT                                {ECO:0000269|PubMed:19914852}.
FT                                /FTId=VAR_066442.
FT   VARIANT    2861   2861       S -> G (in ARPKD; dbSNP:rs150925674).
FT                                {ECO:0000269|PubMed:12874454}.
FT                                /FTId=VAR_018569.
FT   VARIANT    2863   2863       Y -> C (in ARPKD).
FT                                {ECO:0000269|PubMed:12874454}.
FT                                /FTId=VAR_018570.
FT   VARIANT    2869   2869       T -> K (in dbSNP:rs142522748).
FT                                {ECO:0000269|PubMed:12846734,
FT                                ECO:0000269|PubMed:12874454,
FT                                ECO:0000269|PubMed:15108281}.
FT                                /FTId=VAR_018571.
FT   VARIANT    2938   2938       T -> M. {ECO:0000269|PubMed:11919560}.
FT                                /FTId=VAR_014057.
FT   VARIANT    2957   2957       I -> T (in ARPKD).
FT                                {ECO:0000269|PubMed:11898128,
FT                                ECO:0000269|PubMed:11919560,
FT                                ECO:0000269|PubMed:12506140,
FT                                ECO:0000269|PubMed:12846734,
FT                                ECO:0000269|PubMed:12874454,
FT                                ECO:0000269|PubMed:15108281}.
FT                                /FTId=VAR_014058.
FT   VARIANT    2962   2962       D -> G (in ARPKD).
FT                                {ECO:0000269|PubMed:15108281}.
FT                                /FTId=VAR_018572.
FT   VARIANT    2983   2983       S -> L (in ARPKD).
FT                                {ECO:0000269|PubMed:12874454}.
FT                                /FTId=VAR_018573.
FT   VARIANT    3018   3018       S -> F (in ARPKD).
FT                                {ECO:0000269|PubMed:11919560,
FT                                ECO:0000269|PubMed:12506140}.
FT                                /FTId=VAR_014059.
FT   VARIANT    3036   3036       V -> G (in ARPKD).
FT                                {ECO:0000269|PubMed:12874454}.
FT                                /FTId=VAR_018574.
FT   VARIANT    3049   3049       H -> R (in ARPKD).
FT                                {ECO:0000269|PubMed:19914852}.
FT                                /FTId=VAR_066443.
FT   VARIANT    3052   3052       D -> Y (in dbSNP:rs765526).
FT                                /FTId=VAR_027440.
FT   VARIANT    3072   3072       A -> V (in dbSNP:rs139306706).
FT                                /FTId=VAR_018575.
FT   VARIANT    3081   3081       I -> V (in ARPKD).
FT                                {ECO:0000269|PubMed:12506140}.
FT                                /FTId=VAR_018576.
FT   VARIANT    3088   3088       D -> N.
FT                                /FTId=VAR_018577.
FT   VARIANT    3107   3107       R -> P.
FT                                /FTId=VAR_018578.
FT   VARIANT    3124   3124       H -> Y (in ARPKD).
FT                                {ECO:0000269|PubMed:12874454,
FT                                ECO:0000269|PubMed:15108281}.
FT                                /FTId=VAR_018579.
FT   VARIANT    3139   3139       D -> Y (in dbSNP:rs45503297).
FT                                {ECO:0000269|PubMed:11898128,
FT                                ECO:0000269|PubMed:11919560,
FT                                ECO:0000269|PubMed:12506140,
FT                                ECO:0000269|PubMed:12846734,
FT                                ECO:0000269|PubMed:12874454,
FT                                ECO:0000269|PubMed:15108281}.
FT                                /FTId=VAR_014060.
FT   VARIANT    3143   3143       R -> I. {ECO:0000269|PubMed:12874454}.
FT                                /FTId=VAR_018580.
FT   VARIANT    3167   3167       I -> L (in ARPKD).
FT                                {ECO:0000269|PubMed:12874454}.
FT                                /FTId=VAR_018581.
FT   VARIANT    3175   3175       N -> D (in ARPKD).
FT                                {ECO:0000269|PubMed:12874454}.
FT                                /FTId=VAR_018582.
FT   VARIANT    3175   3175       N -> S (in ARPKD).
FT                                {ECO:0000269|PubMed:12874454}.
FT                                /FTId=VAR_018583.
FT   VARIANT    3177   3177       I -> T (in ARPKD).
FT                                {ECO:0000269|PubMed:12846734,
FT                                ECO:0000269|PubMed:12874454,
FT                                ECO:0000269|PubMed:15108281}.
FT                                /FTId=VAR_018584.
FT   VARIANT    3207   3207       A -> T (in ARPKD).
FT                                {ECO:0000269|PubMed:19914852}.
FT                                /FTId=VAR_066444.
FT   VARIANT    3219   3219       V -> A (in a patient with polycystic
FT                                kidney disease).
FT                                {ECO:0000269|PubMed:19914852}.
FT                                /FTId=VAR_066445.
FT   VARIANT    3289   3289       S -> I (in dbSNP:rs148932323).
FT                                /FTId=VAR_018585.
FT   VARIANT    3293   3293       D -> V (in ARPKD).
FT                                {ECO:0000269|PubMed:12506140,
FT                                ECO:0000269|PubMed:12874454}.
FT                                /FTId=VAR_018586.
FT   VARIANT    3346   3346       C -> R (in ARPKD).
FT                                {ECO:0000269|PubMed:12846734}.
FT                                /FTId=VAR_018587.
FT   VARIANT    3440   3440       V -> D. {ECO:0000269|PubMed:12874454}.
FT                                /FTId=VAR_018588.
FT   VARIANT    3468   3468       I -> V (in ARPKD).
FT                                {ECO:0000269|PubMed:12846734}.
FT                                /FTId=VAR_018589.
FT   VARIANT    3471   3471       V -> G (in ARPKD).
FT                                {ECO:0000269|PubMed:12506140}.
FT                                /FTId=VAR_018590.
FT   VARIANT    3482   3482       R -> C (in ARPKD).
FT                                {ECO:0000269|PubMed:12506140,
FT                                ECO:0000269|PubMed:15108281}.
FT                                /FTId=VAR_018591.
FT   VARIANT    3502   3502       E -> V (in ARPKD).
FT                                {ECO:0000269|PubMed:12846734}.
FT                                /FTId=VAR_018592.
FT   VARIANT    3505   3505       S -> R (in dbSNP:rs139014478).
FT                                {ECO:0000269|PubMed:12846734}.
FT                                /FTId=VAR_018593.
FT   VARIANT    3529   3529       E -> Q (in ARPKD; dbSNP:rs145184792).
FT                                {ECO:0000269|PubMed:12846734}.
FT                                /FTId=VAR_018594.
FT   VARIANT    3551   3551       E -> K. {ECO:0000269|PubMed:12874454}.
FT                                /FTId=VAR_018595.
FT   VARIANT    3553   3553       I -> T (in ARPKD).
FT                                {ECO:0000269|PubMed:11919560,
FT                                ECO:0000269|PubMed:12506140}.
FT                                /FTId=VAR_014061.
FT   VARIANT    3622   3622       C -> Y (in ARPKD).
FT                                {ECO:0000269|PubMed:12846734}.
FT                                /FTId=VAR_018596.
FT   VARIANT    3783   3783       P -> S (in ARPKD).
FT                                {ECO:0000269|PubMed:12874454}.
FT                                /FTId=VAR_018597.
FT   VARIANT    3837   3837       V -> I (in dbSNP:rs9474034).
FT                                /FTId=VAR_027441.
FT   VARIANT    3842   3842       R -> L (in dbSNP:rs76572975).
FT                                /FTId=VAR_018598.
FT   VARIANT    3899   3899       Q -> R (in dbSNP:rs4715227).
FT                                {ECO:0000269|PubMed:12846734,
FT                                ECO:0000269|PubMed:12874454}.
FT                                /FTId=VAR_018599.
FT   VARIANT    3905   3905       I -> N (in dbSNP:rs2661488).
FT                                /FTId=VAR_027442.
FT   VARIANT    3913   3913       R -> H (in dbSNP:rs2661487).
FT                                /FTId=VAR_027443.
FT   VARIANT    3957   3957       R -> C (in ARPKD; dbSNP:rs146680689).
FT                                {ECO:0000269|PubMed:19914852}.
FT                                /FTId=VAR_066446.
FT   VARIANT    3960   3960       V -> I (in dbSNP:rs34548196).
FT                                {ECO:0000269|PubMed:11919560,
FT                                ECO:0000269|PubMed:12846734,
FT                                ECO:0000269|PubMed:12874454}.
FT                                /FTId=VAR_014062.
FT   VARIANT    4048   4048       Q -> R (in dbSNP:rs9381994).
FT                                {ECO:0000269|PubMed:11919560,
FT                                ECO:0000269|PubMed:12846734}.
FT                                /FTId=VAR_014063.
SQ   SEQUENCE   4074 AA;  446702 MW;  719AA72F1203EDE1 CRC64;
     MTAWLISLMS IEVLLLAVRH LSLHIEPEEG SLAGGTWITV IFDGLELGVL YPNNGSQLEI
     HLVNVNMVVP ALRSVPCDVF PVFLDLPVVT CRTRSVLSEA HEGLYFLEAY FGGQLVSSPN
     PGPRDSCTFK FSKAQTPIVH QVYPPSGVPG KLIHVYGWII TGRLETFDFD AEYIDSPVIL
     EAQGDKWVTP CSLINRQMGS CYPIQEDHGL GTLQCHVEGD YIGSQNVSFS VFNKGKSMVH
     KKAWLISAKQ DLFLYQTHSE ILSVFPETGS LGGRTNITIT GDFFDNSAQV TIAGIPCDIR
     HVSPRKIECT TRAPGKDVRL TTPQPGNRGL LFEVGDAVEG LELTEATPGY RWQIVPNASS
     PFGFWSQEGQ PFRARLSGFF VAPETNNYTF WIQADSQASL HFSWSEEPRT KVKVASISVG
     TADWFDSWEQ NRDEGTWQQK TPKLELLGGA MYYLEAEHHG IAPSRGMRIG VQIHNTWLNP
     DVVTTYLREK HQIRVRAQRL PEVQVLNVSG RGNFFLTWDN VSSQPIPANA TAHLIQTTIE
     ELLAVKCKLE PLWSNILLRL GFERGPEVSN SDGDLTSGTE PFCGRFSLRQ PRHLVLTPPA
     AQKGYRLDQY THLCLAYKGH MNKILKMIVS FTIGFQNMVK NTTCDWSLTR TSPESWQFDC
     TDLWETCVRC FGDLQPPPAN SPVLVHQINL LPLAQETGLF YVDEIIIADT NVTVSQADSG
     TARPGGNLVE SVSVVGSPPV YSVTSWLAGC GTELPLITAR SVPTEGTEEG SGLVLVTTQR
     RQRTSPPLGG HFRIQLPNTV ISDVPVQISA HHLHQLLQNN ADDFTSRYLN ASDFTVKEDL
     YTCYEHVWTL SWSTQIGDLP NFIRVSDENL TGVNPAAATR VVYDGGVFLG PIFGDMLATA
     NQHTQVVVRV NDVPAHCPGS CSFQYLQGST PCVHSVWYSI DGDINLMIYI TGTGFSGDSQ
     FLQVTVNKTS CKVIFSNQTN VVCQTDLLPV GMHRILMLVR PSGLAISATG EDLFLNVKPR
     LDMVEPSRAA DIGGLWATIR GSSLEGVSLI LFGSYSCAIN VATSNSSRIQ CKVPPRGKDG
     RIVNVTVIRG DYSAVLPRAF TYVSSLNPVI VTLSRNISNI AGGETLVIGV ARLMNYTDLD
     VEVHVQDALA PVHTQSAWGL EVALPPLPAG LHRISVSING VSIHSQGVDL HIQYLTEVFS
     IEPCCGSLLG GTILSISGIG FSRDPALVWV LVGNRSCDIV NLTEASIWCE TLPAPQIPDA
     GAPTVPAAVE VWAGNRFFAR GPSPSLVGKG FTFMYEAAAT PVVTAMQGEI TNSSLSLHVG
     GSNLSNSVIL LGNLNCDVET QSFQGNVSLS GCSIPLHSLE AGIYPLQVRQ KQMGFANMSV
     VLQQFAVMPR IMAIFPSQGS ACGGTILTVR GLLLNSRRRS VRVDLSGPFT CVILSLGDHT
     ILCQVSLEGD PLPGASFSLN VTVLVNGLTS ECQGNCTLFI REEASPVMDA LSTNTSGSLT
     TVLIRGQRLA TTADEPMVFV DDQLPCNVTF FNASHVVCQT RDLAPGPHYL SVFYTRNGYA
     CSGNVSRHFY IMPQVFHYFP KNFSLHGGSL LTIEGTGLRG QNTTSVYIDQ QTCLTVNIGA
     ELIRCIVPTG NGSVALEIEV DGLWYHIGVI GYNKAFTPEL ISISQSDDIL TFAVAQISGA
     ANIDIFIGMS PCVGVSGNHT VLQCVVPSLP AGEYHVRGYD CIRGWASSAL VFTSRVIITA
     VTENFGCLGG RLVHVFGAGF SPGNVSAAVC GAPCRVLANA TVSAFSCLVL PLDVSLAFLC
     GLKREEDSCE AARHTYVQCD LTVAMATEQL LESWPYLYIC EESSQCLFVP DHWAESMFPS
     FSGLFISPKL ERDEVLIYNS SCNITMETEA EMECETPNQP ITVKITEIRK RWGQNTQGNF
     SLQFCRRWSR THSWFPERLP QDGDNVTVEN GQLLLLDTNT SILNLLHIKG GKLIFMAPGP
     IELRAHAILV SDGGELRIGS EDKPFQGRAQ ITLYGSSYST PFFPYGVKFL AVRNGTLSLH
     GSLPEVIVTC LRATAHALDT VLALEDAVDW NPGDEVVIIS GTGVKGAKPM EEIVTVETVQ
     DTDLYLKSPL RYSHNFTENW VAGEHHILKA TVALLSRSIT IQGNLTNERE KLLVSCQEAN
     APEGNLQHCL YSMSEKMLGS RDMGARVIVQ SFPEEPSQVQ LKGVQFQVLG QAFHKHLSSL
     TLVGAMRESF IQGCTVRNSF SRGLSMCGTL GLKVDSNVFY NILGHALLVG TCTEMRYISW
     EAIHGRKDDW SGHGNIIRNN VIIQVSGAEG LSNPEMLTPS GIYICSPTNV IEGNRVCGAG
     YGYFFHLMTN QTSQAPLLSF TQNIAHSCTR YGLFVYPKFQ PPWDNVTGTT LFQSFTVWES
     AGGAQIFRSS NLRLKNFKVY SCRDFGIDVL ESDANTSVTD SLLLGHFAHK GSLCMSSGIK
     TPKRWELMVS NTTFVNFDLI NCVAIRTCSD CSQGQGGFTV KTSQLKFTNS SNLVAFPFPH
     AAILEDLDGS LSGKNRSHIL ASMETLSASC LVNSSFGRVV HGSACGGGVL FHRMSIGLAN
     TPEVSYDLTM TDSRNKTTTV NYVRDTLSNP RGWMALLLDQ ETYSLQSENL WINRSLQYSA
     TFDNFAPGNY LLLVHTDLPP YPDILLRCGS RVGLSFPFLP SPGQNQGCDW FFNSQLRQLT
     YLVSGEGQVQ VILRVKEGMP PTISASTSAP ESALKWSLPE TWQGVEEGWG GYNNTIPGPG
     DDVLILPNRT VLVDTDLPFF KGLYVMGTLD FPVDRSNVLS VACMVIAGGE LKVGTLENPL
     EKEQKLLILL RASEGVFCDR MNGIHIDPGT IGVYGKVHLY SAYPKNSWTH LGADIASGNE
     RIIVEDAVDW RPHDKIVLSS SSYEPHEAEV LTVKEVKGHH VRIYERLKHR HIGSVHVTED
     GRHIRLAAEV GLLTRNIQIQ PDVSCRGRLF VGSFRKSSRE EFSGVLQLLN VEIQNFGSPL
     YSSVEFSNVS AGSWIISSTL HQSCGGGIHA AASHGVLLND NIVFGTAGHG IDLEGQAYTV
     TNNLVVLMTQ PAWSTIWVAG IKVNQVKDIN LHGNVVAGSE RLGFHIRGHK CSSCELLWSD
     NVAHSSLHGL HLYKESGLDN CTRISGFLAF KNFDYGAMLH VENSVEIENI TLVDNTIGLL
     AVVYVFSAPQ NSVKKVQIVL RNSVIVATSS SFDCIQDKVK PHSANLTSTD RAPSNPRGGR
     IGILWPVFTS EPNQWPQEPW HKVRNDHSIS GIMKLQDVTF SSFVKSCYSD DLDVCILPNA
     ENSGIMHPIT AERTRMLKIK DKNKFYFPSL QPRKDLGKVV CPELDCASPR KYLFKDLDGR
     ALGLPPPVSV FPKTEAEWTA SFFNAGTFRE EQKCTYQFLM QGFICKQTDQ VVLILDSADA
     IWAIQKLYPV VSVTSGFVDV FSSVNANIPC STSGSVSTFY SILPIRQITK VCFMDQTPQV
     LRFFLLGNKS TSKLLLAVFY HELQSPHVFL GESFIPPTLV QSASLLLNES IGANYFNIMD
     NLLYVVLQGE EPIEIRSGVS IHLALTVMVS VLEKGWEIVI LERLTNFLQI GQNQIRFIHE
     MPGHEETLKA IADSRAKRKR NCPTVTCTSH YRRVGQRRPL MMEMNSHRAS PPMTVETISK
     VIVIEIGDSP TVRSTGMISS LSSNKLQNLA HRVITAQQTG VLENVLNMTI GALLVTQSKG
     VIGYGNTSSF KTGNLIYIRP YALSILVQPS DGEVGNELPV QPQLVFLDEQ NRRVESLGPP
     SEPWTISASL EGASDSVLKG CTQAETQDGY VSFYNLAVLI SGSNWHFIFT VTSPPGVNFT
     ARSKPFAVLP VTRKEKSTII LAASLSSVAS WLALSCLVCC WLKRSKSRKT KPEEIPESQT
     NNQNIHIHIS SKRRESQGPK KEDTVVGEDM RMKVMLGKVN QCPHQLMNGV SRRKVSRHIV
     REEEAAVPAP GTTGITSHGH ICAPGAPAQQ VYLQETGNWK EGQEQLLRYQ LAGQNQLLLL
     CPDFRQERQQ LPGQSRLSKQ SGSLGLSQEK KASCGATEAF CLHSVHPETI QEQL
//
ID   FGF10_HUMAN             Reviewed;         208 AA.
AC   O15520; C7FDY0; Q6FHR3; Q6FHT6; Q96P59;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   09-DEC-2015, entry version 146.
DE   RecName: Full=Fibroblast growth factor 10;
DE            Short=FGF-10;
DE   AltName: Full=Keratinocyte growth factor 2;
DE   Flags: Precursor;
GN   Name=FGF10;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Lung;
RX   PubMed=9287324; DOI=10.1074/jbc.272.37.23191;
RA   Emoto H., Tagashira S., Mattei M.-G., Yamasaki M., Hashimoto G.,
RA   Katsumata T., Negoro T., Nakatsuka M., Birnbaum D., Coulier F.,
RA   Itoh N.;
RT   "Structure and expression of human fibroblast growth factor-10.";
RL   J. Biol. Chem. 272:23191-23194(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Lung;
RA   Jimenez P.A., Gruber J.R., Liu B., Feng P., Florence C., Blunt A.,
RA   Huddleston K.A., Teliska M., Alfonso P., Coleman T.A., Ornitz D.M.,
RA   Dillon P.A., Duan R.D.;
RT   "Cutaneous wound healing by keratinocyte growth factor 2.";
RL   Submitted (JUL-1997) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Zhang Y., Zhang B., Zhou Y., Peng X., Yuan J., Qiang B.;
RL   Submitted (AUG-2001) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Nakhla A.M., Hryb D.J., Kahn S.M., Romas N.A., Rosner W.;
RT   "Expression of FGF10 in human prostate stromal cells.";
RL   Submitted (JUL-2009) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Halleck A., Ebert L., Mkoundinya M., Schick M., Eisenstein S.,
RA   Neubert P., Kstrang K., Schatten R., Shen B., Henze S., Mar W.,
RA   Korn B., Zuo D., Hu Y., LaBaer J.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (APR-2004) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   INTERACTION WITH FGFBP1.
RX   PubMed=15806171; DOI=10.1038/sj.onc.1208560;
RA   Beer H.-D., Bittner M., Niklaus G., Munding C., Max N., Goppelt A.,
RA   Werner S.;
RT   "The fibroblast growth factor binding protein is a novel interaction
RT   partner of FGF-7, FGF-10 and FGF-22 and regulates FGF activity:
RT   implications for epithelial repair.";
RL   Oncogene 24:5269-5277(2005).
RN   [10]
RP   INTERACTION WITH FGFR1 AND FGFR2, AND FUNCTION IN STIMULATION OF CELL
RP   PROLIFERATION.
RX   PubMed=16597617; DOI=10.1074/jbc.M601252200;
RA   Zhang X., Ibrahimi O.A., Olsen S.K., Umemori H., Mohammadi M.,
RA   Ornitz D.M.;
RT   "Receptor specificity of the fibroblast growth factor family. The
RT   complete mammalian FGF family.";
RL   J. Biol. Chem. 281:15694-15700(2006).
RN   [11]
RP   REVIEW.
RX   PubMed=20094046; DOI=10.1038/nrc2780;
RA   Turner N., Grose R.;
RT   "Fibroblast growth factor signalling: from development to cancer.";
RL   Nat. Rev. Cancer 10:116-129(2010).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 69-208 IN COMPLEX WITH FGFR2.
RX   PubMed=12591959; DOI=10.1073/pnas.0436500100;
RA   Yeh B.K., Igarashi M., Eliseenkova A.V., Plotnikov A.N., Sher I.,
RA   Ron D., Aaronson S.A., Mohammadi M.;
RT   "Structural basis by which alternative splicing confers specificity in
RT   fibroblast growth factor receptors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:2266-2271(2003).
RN   [13]
RP   INVOLVEMENT IN ALSG.
RX   PubMed=15654336; DOI=10.1038/ng1507;
RA   Entesarian M., Matsson H., Klar J., Bergendal B., Olson L.,
RA   Arakaki R., Hayashi Y., Ohuchi H., Falahat B., Bolstad A.I.,
RA   Jonsson R., Wahren-Herlenius M., Dahl N.;
RT   "Mutations in the gene encoding fibroblast growth factor 10 are
RT   associated with aplasia of lacrimal and salivary glands.";
RL   Nat. Genet. 37:125-127(2005).
RN   [14]
RP   VARIANT LADDS ARG-156.
RX   PubMed=16630169; DOI=10.1111/j.1399-0004.2006.00597.x;
RA   Milunsky J.M., Zhao G., Maher T.A., Colby R., Everman D.B.;
RT   "LADD syndrome is caused by FGF10 mutations.";
RL   Clin. Genet. 69:349-354(2006).
RN   [15]
RP   VARIANT LADDS PHE-106.
RX   PubMed=16501574; DOI=10.1038/ng1757;
RA   Rohmann E., Brunner H.G., Kayserili H., Uyguner O., Nuernberg G.,
RA   Lew E.D., Dobbie A., Eswarakumar V.P., Uzumcu A., Ulubil-Emeroglu M.,
RA   Leroy J.G., Li Y., Becker C., Lehnerdt K., Cremers C.W.R.J.,
RA   Yueksel-Apak M., Nuernberg P., Kubisch C., Schlessinger J.,
RA   van Bokhoven H., Wollnik B.;
RT   "Mutations in different components of FGF signaling in LADD
RT   syndrome.";
RL   Nat. Genet. 38:414-417(2006).
CC   -!- FUNCTION: Plays an important role in the regulation of embryonic
CC       development, cell proliferation and cell differentiation. Required
CC       for normal branching morphogenesis. May play a role in wound
CC       healing. {ECO:0000269|PubMed:16597617}.
CC   -!- SUBUNIT: Interacts with FGFR1 and FGFR2. Interacts with FGFBP1.
CC       {ECO:0000269|PubMed:12591959, ECO:0000269|PubMed:15806171,
CC       ECO:0000269|PubMed:16597617}.
CC   -!- INTERACTION:
CC       P21802:FGFR2; NbExp=2; IntAct=EBI-1035684, EBI-1028658;
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000305}.
CC   -!- DISEASE: Aplasia of lacrimal and salivary glands (ALSG)
CC       [MIM:180920]: A rare condition characterized by dry conjunctival
CC       mucosae, irritable eyes, epiphora (constant tearing), and
CC       xerostomia (dryness of the mouth), which increases risk of dental
CC       erosion, dental caries, periodontal disease, and oral infections.
CC       ALSG has variable expressivity, and affected individuals may have
CC       aplasia or hypoplasia of the lacrimal, parotid, submandibular, and
CC       sublingual glands and absence of the lacrimal puncta.
CC       {ECO:0000269|PubMed:15654336}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Lacrimo-auriculo-dento-digital syndrome (LADDS)
CC       [MIM:149730]: An autosomal dominant ectodermal dysplasia, a
CC       heterogeneous group of disorders due to abnormal development of
CC       two or more ectodermal structures. Lacrimo-auriculo-dento-digital
CC       syndrome is characterized by aplastic/hypoplastic lacrimal and
CC       salivary glands and ducts, cup-shaped ears, hearing loss,
CC       hypodontia and enamel hypoplasia, and distal limb segments
CC       anomalies. In addition to these cardinal features, facial
CC       dysmorphism, malformations of the kidney and respiratory system
CC       and abnormal genitalia have been reported. Craniosynostosis and
CC       severe syndactyly are not observed. {ECO:0000269|PubMed:16501574,
CC       ECO:0000269|PubMed:16630169}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the heparin-binding growth factors family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/fgf10/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB002097; BAA22331.1; -; mRNA.
DR   EMBL; U67918; AAB61991.1; -; mRNA.
DR   EMBL; AF411527; AAL05875.1; -; mRNA.
DR   EMBL; GQ351295; ACU00617.1; -; mRNA.
DR   EMBL; CR541665; CAG46466.1; -; mRNA.
DR   EMBL; CR541688; CAG46489.1; -; mRNA.
DR   EMBL; AY604046; AAS99733.1; -; Genomic_DNA.
DR   EMBL; CH471119; EAW56075.1; -; Genomic_DNA.
DR   EMBL; BC069561; AAH69561.1; -; mRNA.
DR   EMBL; BC105021; AAI05022.1; -; mRNA.
DR   EMBL; BC105023; AAI05024.1; -; mRNA.
DR   CCDS; CCDS3950.1; -.
DR   RefSeq; NP_004456.1; NM_004465.1.
DR   RefSeq; XP_005248321.1; XM_005248264.2.
DR   UniGene; Hs.664499; -.
DR   PDB; 1NUN; X-ray; 2.90 A; A=64-208.
DR   PDBsum; 1NUN; -.
DR   ProteinModelPortal; O15520; -.
DR   SMR; O15520; 69-207.
DR   BioGrid; 108546; 6.
DR   DIP; DIP-6037N; -.
DR   IntAct; O15520; 1.
DR   MINT; MINT-257957; -.
DR   STRING; 9606.ENSP00000264664; -.
DR   PhosphoSite; O15520; -.
DR   BioMuta; FGF10; -.
DR   PaxDb; O15520; -.
DR   PRIDE; O15520; -.
DR   DNASU; 2255; -.
DR   Ensembl; ENST00000264664; ENSP00000264664; ENSG00000070193.
DR   GeneID; 2255; -.
DR   KEGG; hsa:2255; -.
DR   UCSC; uc003jog.1; human.
DR   CTD; 2255; -.
DR   GeneCards; FGF10; -.
DR   HGNC; HGNC:3666; FGF10.
DR   HPA; CAB010315; -.
DR   MalaCards; FGF10; -.
DR   MIM; 149730; phenotype.
DR   MIM; 180920; phenotype.
DR   MIM; 602115; gene.
DR   neXtProt; NX_O15520; -.
DR   Orphanet; 86815; Aplasia of lacrimal and salivary glands.
DR   Orphanet; 2363; Lacrimoauriculodentodigital syndrome.
DR   PharmGKB; PA28106; -.
DR   eggNOG; KOG3885; Eukaryota.
DR   eggNOG; ENOG4111IPH; LUCA.
DR   GeneTree; ENSGT00760000118859; -.
DR   HOGENOM; HOG000236341; -.
DR   HOVERGEN; HBG007580; -.
DR   InParanoid; O15520; -.
DR   KO; K04358; -.
DR   OMA; SSIPVTC; -.
DR   OrthoDB; EOG7992S1; -.
DR   PhylomeDB; O15520; -.
DR   TreeFam; TF317805; -.
DR   Reactome; R-HSA-109704; PI3K Cascade.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-190370; FGFR1b ligand binding and activation.
DR   Reactome; R-HSA-190377; FGFR2b ligand binding and activation.
DR   Reactome; R-HSA-2033519; Activated point mutants of FGFR2.
DR   Reactome; R-HSA-210747; Regulation of gene expression in early pancreatic precursor cells.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-5654219; Phospholipase C-mediated cascade: FGFR1.
DR   Reactome; R-HSA-5654221; Phospholipase C-mediated cascade, FGFR2.
DR   Reactome; R-HSA-5654688; SHC-mediated cascade:FGFR1.
DR   Reactome; R-HSA-5654689; PI-3K cascade:FGFR1.
DR   Reactome; R-HSA-5654693; FRS-mediated FGFR1 signaling.
DR   Reactome; R-HSA-5654695; PI-3K cascade:FGFR2.
DR   Reactome; R-HSA-5654699; SHC-mediated cascade:FGFR2.
DR   Reactome; R-HSA-5654700; FRS-mediated FGFR2 signaling.
DR   Reactome; R-HSA-5654726; Negative regulation of FGFR1 signaling.
DR   Reactome; R-HSA-5654727; Negative regulation of FGFR2 signaling.
DR   Reactome; R-HSA-5655253; Signaling by FGFR2 in disease.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   SignaLink; O15520; -.
DR   EvolutionaryTrace; O15520; -.
DR   GeneWiki; FGF10; -.
DR   GenomeRNAi; 2255; -.
DR   NextBio; 9135; -.
DR   PRO; PR:O15520; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; O15520; -.
DR   CleanEx; HS_FGF10; -.
DR   ExpressionAtlas; O15520; baseline and differential.
DR   Genevisible; O15520; HS.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0042056; F:chemoattractant activity; IDA:UniProtKB.
DR   GO; GO:0005104; F:fibroblast growth factor receptor binding; IDA:UniProtKB.
DR   GO; GO:0008083; F:growth factor activity; IDA:UniProtKB.
DR   GO; GO:0008201; F:heparin binding; IDA:UniProtKB.
DR   GO; GO:0005111; F:type 2 fibroblast growth factor receptor binding; IPI:UniProtKB.
DR   GO; GO:0031532; P:actin cytoskeleton reorganization; IDA:UniProtKB.
DR   GO; GO:0000187; P:activation of MAPK activity; IDA:UniProtKB.
DR   GO; GO:0000186; P:activation of MAPKK activity; TAS:Reactome.
DR   GO; GO:0001525; P:angiogenesis; IEA:Ensembl.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0001974; P:blood vessel remodeling; IEA:Ensembl.
DR   GO; GO:0060667; P:branch elongation involved in salivary gland morphogenesis; IEA:Ensembl.
DR   GO; GO:0048754; P:branching morphogenesis of an epithelial tube; IDA:UniProtKB.
DR   GO; GO:0060436; P:bronchiole morphogenesis; IEA:Ensembl.
DR   GO; GO:0060449; P:bud elongation involved in lung branching; IEA:Ensembl.
DR   GO; GO:0060447; P:bud outgrowth involved in lung branching; IDA:MGI.
DR   GO; GO:0007368; P:determination of left/right symmetry; IEA:Ensembl.
DR   GO; GO:0031076; P:embryonic camera-type eye development; IEA:Ensembl.
DR   GO; GO:0048557; P:embryonic digestive tract morphogenesis; IEA:Ensembl.
DR   GO; GO:0030538; P:embryonic genitalia morphogenesis; IEA:Ensembl.
DR   GO; GO:0009880; P:embryonic pattern specification; IEA:Ensembl.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0010631; P:epithelial cell migration; IEA:Ensembl.
DR   GO; GO:0050673; P:epithelial cell proliferation; IDA:UniProtKB.
DR   GO; GO:0060664; P:epithelial cell proliferation involved in salivary gland morphogenesis; IEA:Ensembl.
DR   GO; GO:0070371; P:ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0000132; P:establishment of mitotic spindle orientation; IEA:Ensembl.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0048807; P:female genitalia morphogenesis; IEA:Ensembl.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0060595; P:fibroblast growth factor receptor signaling pathway involved in mammary gland specification; IDA:MGI.
DR   GO; GO:0031069; P:hair follicle morphogenesis; IEA:Ensembl.
DR   GO; GO:0070384; P:Harderian gland development; IEA:Ensembl.
DR   GO; GO:0050930; P:induction of positive chemotaxis; IEA:Ensembl.
DR   GO; GO:0045087; P:innate immune response; TAS:Reactome.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0043616; P:keratinocyte proliferation; IEA:Ensembl.
DR   GO; GO:0032808; P:lacrimal gland development; IMP:UniProtKB.
DR   GO; GO:0060174; P:limb bud formation; IEA:Ensembl.
DR   GO; GO:0060428; P:lung epithelium development; IDA:MGI.
DR   GO; GO:0061115; P:lung proximal/distal axis specification; IEA:Ensembl.
DR   GO; GO:0060430; P:lung saccule development; IMP:UniProtKB.
DR   GO; GO:0048808; P:male genitalia morphogenesis; IEA:Ensembl.
DR   GO; GO:0060615; P:mammary gland bud formation; IEA:Ensembl.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0060915; P:mesenchymal cell differentiation involved in lung development; IEA:Ensembl.
DR   GO; GO:0060496; P:mesenchymal-epithelial cell signaling involved in lung development; IEA:Ensembl.
DR   GO; GO:0001823; P:mesonephros development; IEP:UniProtKB.
DR   GO; GO:0001656; P:metanephros development; IEP:UniProtKB.
DR   GO; GO:0003338; P:metanephros morphogenesis; IEA:Ensembl.
DR   GO; GO:0042693; P:muscle cell fate commitment; IEA:Ensembl.
DR   GO; GO:0071157; P:negative regulation of cell cycle arrest; IDA:UniProtKB.
DR   GO; GO:0045596; P:negative regulation of cell differentiation; IEA:Ensembl.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:2001240; P:negative regulation of extrinsic apoptotic signaling pathway in absence of ligand; IEA:Ensembl.
DR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IEA:Ensembl.
DR   GO; GO:0001759; P:organ induction; IEA:Ensembl.
DR   GO; GO:0030916; P:otic vesicle formation; IEA:Ensembl.
DR   GO; GO:0031016; P:pancreas development; IEA:Ensembl.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; TAS:Reactome.
DR   GO; GO:0021983; P:pituitary gland development; IEA:Ensembl.
DR   GO; GO:0050918; P:positive chemotaxis; IDA:UniProtKB.
DR   GO; GO:0032781; P:positive regulation of ATPase activity; IDA:UniProtKB.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:0031659; P:positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle; IDA:UniProtKB.
DR   GO; GO:0045739; P:positive regulation of DNA repair; IDA:UniProtKB.
DR   GO; GO:0045740; P:positive regulation of DNA replication; IMP:UniProtKB.
DR   GO; GO:0010634; P:positive regulation of epithelial cell migration; IDA:UniProtKB.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IDA:UniProtKB.
DR   GO; GO:0060054; P:positive regulation of epithelial cell proliferation involved in wound healing; NAS:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0048146; P:positive regulation of fibroblast proliferation; IEA:Ensembl.
DR   GO; GO:0071338; P:positive regulation of hair follicle cell proliferation; IDA:UniProtKB.
DR   GO; GO:0051549; P:positive regulation of keratinocyte migration; IDA:UniProtKB.
DR   GO; GO:0010838; P:positive regulation of keratinocyte proliferation; IDA:UniProtKB.
DR   GO; GO:0050671; P:positive regulation of lymphocyte proliferation; IDA:UniProtKB.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:UniProtKB.
DR   GO; GO:0045931; P:positive regulation of mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:0045747; P:positive regulation of Notch signaling pathway; IEA:Ensembl.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0046579; P:positive regulation of Ras protein signal transduction; IDA:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0050677; P:positive regulation of urothelial cell proliferation; IDA:UniProtKB.
DR   GO; GO:0030949; P:positive regulation of vascular endothelial growth factor receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0070352; P:positive regulation of white fat cell proliferation; IEA:Ensembl.
DR   GO; GO:0060513; P:prostatic bud formation; IEA:Ensembl.
DR   GO; GO:0034394; P:protein localization to cell surface; IDA:UniProtKB.
DR   GO; GO:0060019; P:radial glial cell differentiation; ISS:UniProtKB.
DR   GO; GO:0007265; P:Ras protein signal transduction; TAS:Reactome.
DR   GO; GO:0032925; P:regulation of activin receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0060665; P:regulation of branching involved in salivary gland morphogenesis by mesenchymal-epithelial signaling; IEA:Ensembl.
DR   GO; GO:0046877; P:regulation of saliva secretion; IMP:UniProtKB.
DR   GO; GO:0008589; P:regulation of smoothened signaling pathway; IEA:Ensembl.
DR   GO; GO:0032355; P:response to estradiol; IEA:Ensembl.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0007431; P:salivary gland development; IMP:UniProtKB.
DR   GO; GO:0061033; P:secretion by lung epithelial cell involved in lung growth; IDA:UniProtKB.
DR   GO; GO:0060879; P:semicircular canal fusion; IEA:Ensembl.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; TAS:Reactome.
DR   GO; GO:0051145; P:smooth muscle cell differentiation; IEA:Ensembl.
DR   GO; GO:0035019; P:somatic stem cell population maintenance; IEA:Ensembl.
DR   GO; GO:0048536; P:spleen development; IEA:Ensembl.
DR   GO; GO:0060661; P:submandibular salivary gland formation; IEA:Ensembl.
DR   GO; GO:0070075; P:tear secretion; IMP:UniProtKB.
DR   GO; GO:0048538; P:thymus development; IDA:UniProtKB.
DR   GO; GO:0030878; P:thyroid gland development; IEA:Ensembl.
DR   GO; GO:0042246; P:tissue regeneration; IEA:Ensembl.
DR   GO; GO:0060510; P:Type II pneumocyte differentiation; IEA:Ensembl.
DR   GO; GO:0050674; P:urothelial cell proliferation; IDA:UniProtKB.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0050872; P:white fat cell differentiation; IEA:Ensembl.
DR   GO; GO:0042060; P:wound healing; IDA:UniProtKB.
DR   InterPro; IPR008996; Cytokine_IL1-like.
DR   InterPro; IPR028252; FGF10.
DR   InterPro; IPR002209; Fibroblast_GF_fam.
DR   InterPro; IPR028142; IL-1_fam/FGF_fam.
DR   PANTHER; PTHR11486; PTHR11486; 1.
DR   PANTHER; PTHR11486:SF21; PTHR11486:SF21; 1.
DR   Pfam; PF00167; FGF; 1.
DR   PRINTS; PR00263; HBGFFGF.
DR   PRINTS; PR00262; IL1HBGF.
DR   SMART; SM00442; FGF; 1.
DR   SUPFAM; SSF50353; SSF50353; 1.
DR   PROSITE; PS00247; HBGF_FGF; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Disease mutation;
KW   Ectodermal dysplasia; Glycoprotein; Growth factor;
KW   Lacrimo-auriculo-dento-digital syndrome; Reference proteome; Secreted;
KW   Signal.
FT   SIGNAL        1     37       {ECO:0000255}.
FT   CHAIN        38    208       Fibroblast growth factor 10.
FT                                /FTId=PRO_0000008981.
FT   COMPBIAS     52     62       Poly-Ser.
FT   CARBOHYD     51     51       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    196    196       N-linked (GlcNAc...). {ECO:0000255}.
FT   VARIANT     106    106       C -> F (in LADDS).
FT                                {ECO:0000269|PubMed:16501574}.
FT                                /FTId=VAR_029888.
FT   VARIANT     156    156       I -> R (in LADDS).
FT                                {ECO:0000269|PubMed:16630169}.
FT                                /FTId=VAR_029889.
FT   CONFLICT     43     43       D -> V (in Ref. 5; CAG46489).
FT                                {ECO:0000305}.
FT   CONFLICT    120    120       V -> A (in Ref. 3; AAL05875).
FT                                {ECO:0000305}.
FT   CONFLICT    134    134       M -> R (in Ref. 3; AAL05875).
FT                                {ECO:0000305}.
FT   HELIX        70     73       {ECO:0000244|PDB:1NUN}.
FT   STRAND       76     84       {ECO:0000244|PDB:1NUN}.
FT   STRAND       89     92       {ECO:0000244|PDB:1NUN}.
FT   STRAND       98    101       {ECO:0000244|PDB:1NUN}.
FT   STRAND      111    117       {ECO:0000244|PDB:1NUN}.
FT   STRAND      120    125       {ECO:0000244|PDB:1NUN}.
FT   TURN        126    129       {ECO:0000244|PDB:1NUN}.
FT   STRAND      130    134       {ECO:0000244|PDB:1NUN}.
FT   STRAND      138    145       {ECO:0000244|PDB:1NUN}.
FT   STRAND      150    156       {ECO:0000244|PDB:1NUN}.
FT   STRAND      162    171       {ECO:0000244|PDB:1NUN}.
FT   STRAND      174    177       {ECO:0000244|PDB:1NUN}.
FT   HELIX       189    191       {ECO:0000244|PDB:1NUN}.
FT   HELIX       197    199       {ECO:0000244|PDB:1NUN}.
FT   STRAND      201    205       {ECO:0000244|PDB:1NUN}.
SQ   SEQUENCE   208 AA;  23436 MW;  C0A0705C108680B3 CRC64;
     MWKWILTHCA SAFPHLPGCC CCCFLLLFLV SSVPVTCQAL GQDMVSPEAT NSSSSSFSSP
     SSAGRHVRSY NHLQGDVRWR KLFSFTKYFL KIEKNGKVSG TKKENCPYSI LEITSVEIGV
     VAVKAINSNY YLAMNKKGKL YGSKEFNNDC KLKERIEENG YNTYASFNWQ HNGRQMYVAL
     NGKGAPRRGQ KTRRKNTSAH FLPMVVHS
//
ID   IL6_HUMAN               Reviewed;         212 AA.
AC   P05231; Q9UCU2; Q9UCU3; Q9UCU4;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   13-AUG-1987, sequence version 1.
DT   20-JAN-2016, entry version 192.
DE   RecName: Full=Interleukin-6;
DE            Short=IL-6;
DE   AltName: Full=B-cell stimulatory factor 2;
DE            Short=BSF-2;
DE   AltName: Full=CTL differentiation factor;
DE            Short=CDF;
DE   AltName: Full=Hybridoma growth factor;
DE   AltName: Full=Interferon beta-2;
DE            Short=IFN-beta-2;
DE   Flags: Precursor;
GN   Name=IL6; Synonyms=IFNB2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PARTIAL PROTEIN SEQUENCE.
RX   PubMed=3491322; DOI=10.1038/324073a0;
RA   Hirano T., Yasukawa K., Harada H., Taga T., Watanabe Y., Matsuda T.,
RA   Kashiwamura S., Nakajima K., Koyama K., Iwamatsu A., Tsunasawa S.,
RA   Sakiyama F., Matsui H., Takahara Y., Taniguchi T., Kishimoto T.;
RT   "Complementary DNA for a novel human interleukin (BSF-2) that induces
RT   B lymphocytes to produce immunoglobulin.";
RL   Nature 324:73-76(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=3500852;
RA   Yasukawa K., Hirano T., Watanabe Y., Muratani K., Matsuda T.,
RA   Nakai S., Kishimoto T.;
RT   "Structure and expression of human B cell stimulatory factor-2 (BSF-
RT   2/IL-6) gene.";
RL   EMBO J. 6:2939-2945(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3538015; DOI=10.1073/pnas.83.23.8957;
RA   May L.T., Helfgott D.C., Sehgal P.B.;
RT   "Anti-beta-interferon antibodies inhibit the increased expression of
RT   HLA-B7 mRNA in tumor necrosis factor-treated human fibroblasts:
RT   structural studies of the beta 2 interferon involved.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:8957-8961(1986).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3023045;
RA   Zilberstein A., Ruggieri R., Korn J.H., Revel M.;
RT   "Structure and expression of cDNA and genes for human interferon-beta-
RT   2, a distinct species inducible by growth-stimulatory cytokines.";
RL   EMBO J. 5:2529-2537(1986).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3320204;
RA   Brakenhoff J.P.J., de Groot E.R., Evers R.F., Pannekoek H.,
RA   Aarden L.A.;
RT   "Molecular cloning and expression of hybridoma growth factor in
RT   Escherichia coli.";
RL   J. Immunol. 139:4116-4121(1987).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2789513; DOI=10.1016/0006-291X(89)92328-0;
RA   Tonouchi N., Miwa K., Karasuyama H., Matsui H.;
RT   "Deletion of 3' untranslated region of human BSF-2 mRNA causes
RT   stabilization of the mRNA and high-level expression in mouse NIH3T3
RT   cells.";
RL   Biochem. Biophys. Res. Commun. 163:1056-1062(1989).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA].
RC   TISSUE=Fibroblast;
RX   PubMed=3758081; DOI=10.1111/j.1432-1033.1986.tb09931.x;
RA   Haegeman G., Content J., Volckaert G., Derynck R., Tavernier J.,
RA   Fiers W.;
RT   "Structural analysis of the sequence coding for an inducible 26-kDa
RT   protein in human fibroblasts.";
RL   Eur. J. Biochem. 159:625-632(1986).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3266463;
RA   Wong G., Witek-Giannotti J., Hewick R., Clark S., Ogawa M.;
RT   "Interleukin 6: identification as a hematopoietic colony-stimulating
RT   factor.";
RL   Behring Inst. Mitt. 83:40-47(1988).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=1291290;
RA   Chen Q.Y.;
RT   "Stable and efficient expression of human interleukin-6 cDNA in
RT   mammalian cells after gene transfer.";
RL   Zhonghua Zhong Liu Za Zhi 14:340-344(1992).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-32 AND VAL-162.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JUN-2001) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [12]
RP   PROTEIN SEQUENCE OF 30-63.
RX   PubMed=3279116;
RA   van Damme J., van Beeumen J., Decock B., van Snick J., de Ley M.,
RA   Billiau A.;
RT   "Separation and comparison of two monokines with lymphocyte-activating
RT   factor activity: IL-1 beta and hybridoma growth factor (HGF).
RT   Identification of leukocyte-derived HGF as IL-6.";
RL   J. Immunol. 140:1534-1541(1988).
RN   [13]
RP   PROTEIN SEQUENCE OF 30-50.
RX   PubMed=2610854;
RA   Ming J.E., Cernetti C., Steinman R.M., Granelli-Piperno A.;
RT   "Interleukin 6 is the principal cytolytic T lymphocyte differentiation
RT   factor for thymocytes in human leukocyte conditioned medium.";
RL   J. Mol. Cell. Immunol. 4:203-211(1989).
RN   [14]
RP   PROTEIN SEQUENCE OF 30-40, AND GLYCOSYLATION.
RX   PubMed=1883960; DOI=10.1016/1043-4666(91)90018-9;
RA   May L.T., Shaw J.E., Khanna A.K., Zabriskie J.B., Sehgal P.B.;
RT   "Marked cell-type-specific differences in glycosylation of human
RT   interleukin-6.";
RL   Cytokine 3:204-211(1991).
RN   [15]
RP   PROTEIN SEQUENCE OF 50-212 OF RECOMBINANT FORM LACKING FIRST DISULFIDE
RP   BOND.
RX   PubMed=7851440; DOI=10.1111/j.1432-1033.1995.tb20427.x;
RA   Breton J., la Fiura A., Bertolero F., Orsini G., Valsasina B.,
RA   Ziliotto R., de Filippis V., Polverino de Laureto P., Fontana A.;
RT   "Structure, stability and biological properties of a N-terminally
RT   truncated form of recombinant human interleukin-6 containing a single
RT   disulfide bond.";
RL   Eur. J. Biochem. 227:573-581(1995).
RN   [16]
RP   DISULFIDE BONDS.
RX   PubMed=2472117; DOI=10.1016/0003-9861(89)90205-1;
RA   Clogston C.L., Boone T.C., Crandall B.C., Mendiaz E.A., Lu H.S.;
RT   "Disulfide structures of human interleukin-6 are similar to those of
RT   human granulocyte colony stimulating factor.";
RL   Arch. Biochem. Biophys. 272:144-151(1989).
RN   [17]
RP   MUTAGENESIS.
RX   PubMed=2037043; DOI=10.1016/0014-5793(91)80491-K;
RA   Luetticken C., Kruettgen A., Moeller C., Heinrich P.C., Rose-John S.;
RT   "Evidence for the importance of a positive charge and an alpha-helical
RT   structure of the C-terminus for biological activity of human IL-6.";
RL   FEBS Lett. 282:265-267(1991).
RN   [18]
RP   STRUCTURE BY NMR.
RX   PubMed=8555185; DOI=10.1021/bi951949e;
RA   Nishimura C., Watanabe A., Gouda H., Shimada I., Arata Y.;
RT   "Folding topologies of human interleukin-6 and its mutants as studied
RT   by NMR spectroscopy.";
RL   Biochemistry 35:273-281(1996).
RN   [19]
RP   STRUCTURE BY NMR.
RX   PubMed=9159484; DOI=10.1006/jmbi.1997.0933;
RA   Xu G.-Y., Yu H.-A., Hong J., Stahl M., McDonagh T., Kay L.E.,
RA   Cumming D.A.;
RT   "Solution structure of recombinant human interleukin-6.";
RL   J. Mol. Biol. 268:468-481(1997).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS).
RX   PubMed=9118960; DOI=10.1093/emboj/16.5.989;
RA   Somers W., Stahl M., Seehra J.S.;
RT   "1.9-A crystal structure of interleukin 6: implications for a novel
RT   mode of receptor dimerization and signaling.";
RL   EMBO J. 16:989-997(1997).
RN   [21]
RP   INVOLVEMENT IN RASJ.
RX   PubMed=9769329; DOI=10.1172/JCI2629;
RA   Fishman D., Faulds G., Jeffery R., Mohamed-Ali V., Yudkin J.S.,
RA   Humphries S., Woo P.;
RT   "The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on
RT   IL-6 transcription and plasma IL-6 levels, and an association with
RT   systemic-onset juvenile chronic arthritis.";
RL   J. Clin. Invest. 102:1369-1376(1998).
RN   [22]
RP   INVOLVEMENT IN SUSCEPTIBILITY TO KAPOSI SARCOMA.
RX   PubMed=11001912;
RA   Foster C.B., Lehrnbecher T., Samuels S., Stein S., Mol F.,
RA   Metcalf J.A., Wyvill K., Steinberg S.M., Kovacs J., Blauvelt A.,
RA   Yarchoan R., Chanock S.J.;
RT   "An IL6 promoter polymorphism is associated with a lifetime risk of
RT   development of Kaposi sarcoma in men infected with human
RT   immunodeficiency virus.";
RL   Blood 96:2562-2567(2000).
RN   [23]
RP   INVOLVEMENT IN BMD.
RX   PubMed=11355017; DOI=10.1007/s100380170077;
RA   Ota N., Nakajima T., Nakazawa I., Suzuki T., Hosoi T., Orimo H.,
RA   Inoue S., Shirai Y., Emi M.;
RT   "A nucleotide variant in the promoter region of the interleukin-6 gene
RT   associated with decreased bone mineral density.";
RL   J. Hum. Genet. 46:267-272(2001).
RN   [24]
RP   INVOLVEMENT IN BMD.
RX   PubMed=12768442; DOI=10.1007/s10038-003-0020-8;
RA   Chung H.W., Seo J.-S., Hur S.E., Kim H.L., Kim J.Y., Jung J.H.,
RA   Kim L.H., Park B.L., Shin H.D.;
RT   "Association of interleukin-6 promoter variant with bone mineral
RT   density in pre-menopausal women.";
RL   J. Hum. Genet. 48:243-248(2003).
RN   [25]
RP   PHOSPHORYLATION AT SER-81.
RX   PubMed=26091039; DOI=10.1016/j.cell.2015.05.028;
RA   Tagliabracci V.S., Wiley S.E., Guo X., Kinch L.N., Durrant E., Wen J.,
RA   Xiao J., Cui J., Nguyen K.B., Engel J.L., Coon J.J., Grishin N.,
RA   Pinna L.A., Pagliarini D.J., Dixon J.E.;
RT   "A single kinase generates the majority of the secreted
RT   phosphoproteome.";
RL   Cell 161:1619-1632(2015).
CC   -!- FUNCTION: Cytokine with a wide variety of biological functions. It
CC       is a potent inducer of the acute phase response. Plays an
CC       essential role in the final differentiation of B-cells into Ig-
CC       secreting cells Involved in lymphocyte and monocyte
CC       differentiation. Acts on B-cells, T-cells, hepatocytes,
CC       hematopoietic progenitor cells and cells of the CNS. Required for
CC       the generation of T(H)17 cells. Also acts as a myokine. It is
CC       discharged into the bloodstream after muscle contraction and acts
CC       to increase the breakdown of fats and to improve insulin
CC       resistance. It induces myeloma and plasmacytoma growth and induces
CC       nerve cells differentiation.
CC   -!- INTERACTION:
CC       P08887:IL6R; NbExp=5; IntAct=EBI-720533, EBI-299383;
CC       Q05516:ZBTB16; NbExp=2; IntAct=EBI-720533, EBI-711925;
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- PTM: N- and O-glycosylated. {ECO:0000269|PubMed:1883960}.
CC   -!- POLYMORPHISM: Genetic variations in IL6 may be correlated with
CC       bone mineral density (BMD). Low BMD is a risk factor for
CC       osteoporotic fracture. Osteoporosis is characterized by reduced
CC       bone mineral density, disrutption of bone microarchitecture, and
CC       the alteration of the amount and variety of non-collagenous
CC       proteins in bone. Osteoporotic bones are more at risk of fracture.
CC       {ECO:0000269|PubMed:11355017, ECO:0000269|PubMed:12768442}.
CC   -!- DISEASE: Rheumatoid arthritis systemic juvenile (RASJ)
CC       [MIM:604302]: An inflammatory articular disorder with systemic-
CC       onset beginning before the age of 16. It represents a subgroup of
CC       juvenile arthritis associated with severe extraarticular features
CC       and occasionally fatal complications. During active phases of the
CC       disorder, patients display a typical daily spiking fever, an
CC       evanescent macular rash, lymphadenopathy, hepatosplenomegaly,
CC       serositis, myalgia and arthritis. {ECO:0000269|PubMed:9769329}.
CC       Note=Disease susceptibility is associated with variations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Note=A IL6 promoter polymorphism is associated with a
CC       lifetime risk of development of Kaposi sarcoma in HIV-infected
CC       men. {ECO:0000269|PubMed:11001912}.
CC   -!- SIMILARITY: Belongs to the IL-6 superfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=R&D Systems' cytokine mini-reviews: IL-6;
CC       URL="http://www.rndsystems.com/molecule_detail.aspx?m=1648";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Interleukin-6 entry;
CC       URL="https://en.wikipedia.org/wiki/Interleukin_6";
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/il6/";
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=IL6";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/IL6ID519ch7p15.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X04430; CAA28026.1; -; mRNA.
DR   EMBL; M14584; AAA52728.1; -; mRNA.
DR   EMBL; X04602; CAA28268.1; -; mRNA.
DR   EMBL; Y00081; CAA68278.1; -; Genomic_DNA.
DR   EMBL; M18403; AAA52729.1; -; mRNA.
DR   EMBL; M29150; AAA59154.1; -; mRNA.
DR   EMBL; X04402; CAA27990.1; -; Genomic_DNA.
DR   EMBL; X04403; CAA27991.1; -; mRNA.
DR   EMBL; M54894; AAC41704.1; -; mRNA.
DR   EMBL; S56892; AAD13886.1; -; mRNA.
DR   EMBL; AF372214; AAK48987.1; -; Genomic_DNA.
DR   EMBL; BC015511; AAH15511.1; -; mRNA.
DR   CCDS; CCDS5375.1; -.
DR   PIR; A32648; IVHUB2.
DR   RefSeq; NP_000591.1; NM_000600.3.
DR   RefSeq; XP_011513692.1; XM_011515390.1.
DR   UniGene; Hs.654458; -.
DR   PDB; 1ALU; X-ray; 1.90 A; A=28-212.
DR   PDB; 1IL6; NMR; -; A=28-212.
DR   PDB; 1N2Q; Model; -; E/F=30-212.
DR   PDB; 1P9M; X-ray; 3.65 A; B=29-212.
DR   PDB; 2IL6; NMR; -; A=28-212.
DR   PDB; 4CNI; X-ray; 2.20 A; C/D=42-212.
DR   PDB; 4J4L; X-ray; 2.30 A; C/D=47-212.
DR   PDB; 4NI7; X-ray; 2.40 A; A=28-212.
DR   PDB; 4NI9; X-ray; 2.55 A; A/C=28-212.
DR   PDB; 4O9H; X-ray; 2.42 A; A=28-212.
DR   PDBsum; 1ALU; -.
DR   PDBsum; 1IL6; -.
DR   PDBsum; 1N2Q; -.
DR   PDBsum; 1P9M; -.
DR   PDBsum; 2IL6; -.
DR   PDBsum; 4CNI; -.
DR   PDBsum; 4J4L; -.
DR   PDBsum; 4NI7; -.
DR   PDBsum; 4NI9; -.
DR   PDBsum; 4O9H; -.
DR   ProteinModelPortal; P05231; -.
DR   SMR; P05231; 42-212.
DR   BioGrid; 109783; 2.
DR   DIP; DIP-482N; -.
DR   IntAct; P05231; 5.
DR   MINT; MINT-190042; -.
DR   STRING; 9606.ENSP00000258743; -.
DR   ChEMBL; CHEMBL1795129; -.
DR   DrugBank; DB01404; Ginseng.
DR   DrugBank; DB09036; Siltuximab.
DR   iPTMnet; P05231; -.
DR   PhosphoSite; P05231; -.
DR   BioMuta; IL6; -.
DR   DMDM; 124347; -.
DR   MaxQB; P05231; -.
DR   PaxDb; P05231; -.
DR   PRIDE; P05231; -.
DR   DNASU; 3569; -.
DR   Ensembl; ENST00000258743; ENSP00000258743; ENSG00000136244.
DR   Ensembl; ENST00000404625; ENSP00000385675; ENSG00000136244.
DR   GeneID; 3569; -.
DR   KEGG; hsa:3569; -.
DR   UCSC; uc003svj.4; human.
DR   CTD; 3569; -.
DR   GeneCards; IL6; -.
DR   H-InvDB; HIX0167872; -.
DR   HGNC; HGNC:6018; IL6.
DR   HPA; CAB023406; -.
DR   MalaCards; IL6; -.
DR   MIM; 147620; gene.
DR   MIM; 148000; phenotype.
DR   MIM; 604302; phenotype.
DR   neXtProt; NX_P05231; -.
DR   Orphanet; 206; Crohn disease.
DR   Orphanet; 85414; Systemic-onset juvenile idiopathic arthritis.
DR   PharmGKB; PA198; -.
DR   eggNOG; ENOG410IW11; Eukaryota.
DR   eggNOG; ENOG4112BXV; LUCA.
DR   HOGENOM; HOG000236330; -.
DR   HOVERGEN; HBG000471; -.
DR   InParanoid; P05231; -.
DR   KO; K05405; -.
DR   OMA; FNQETCL; -.
DR   OrthoDB; EOG7QG453; -.
DR   PhylomeDB; P05231; -.
DR   TreeFam; TF335984; -.
DR   Reactome; R-HSA-1059683; Interleukin-6 signaling.
DR   Reactome; R-HSA-110056; MAPK3 (ERK1) activation.
DR   Reactome; R-HSA-112411; MAPK1 (ERK2) activation.
DR   Reactome; R-HSA-2559582; Senescence-Associated Secretory Phenotype (SASP).
DR   SignaLink; P05231; -.
DR   ChiTaRS; IL6; human.
DR   EvolutionaryTrace; P05231; -.
DR   GeneWiki; Interleukin_6; -.
DR   GenomeRNAi; 3569; -.
DR   NextBio; 13950; -.
DR   PMAP-CutDB; P05231; -.
DR   PRO; PR:P05231; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   Bgee; P05231; -.
DR   CleanEx; HS_IL6; -.
DR   ExpressionAtlas; P05231; baseline and differential.
DR   Genevisible; P05231; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:Ensembl.
DR   GO; GO:0009897; C:external side of plasma membrane; IEA:Ensembl.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0005896; C:interleukin-6 receptor complex; IDA:BHF-UCL.
DR   GO; GO:0005125; F:cytokine activity; IDA:BHF-UCL.
DR   GO; GO:0008083; F:growth factor activity; IDA:BHF-UCL.
DR   GO; GO:0005138; F:interleukin-6 receptor binding; NAS:UniProtKB.
DR   GO; GO:0006953; P:acute-phase response; TAS:BHF-UCL.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0046849; P:bone remodeling; IEA:Ensembl.
DR   GO; GO:0060445; P:branching involved in salivary gland morphogenesis; IEA:Ensembl.
DR   GO; GO:0016049; P:cell growth; IEA:Ensembl.
DR   GO; GO:0045454; P:cell redox homeostasis; IEA:Ensembl.
DR   GO; GO:0071549; P:cellular response to dexamethasone stimulus; IEA:Ensembl.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; IDA:BHF-UCL.
DR   GO; GO:0071347; P:cellular response to interleukin-1; IEA:Ensembl.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IMP:MGI.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IEA:Ensembl.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0050829; P:defense response to Gram-negative bacterium; TAS:BHF-UCL.
DR   GO; GO:0050830; P:defense response to Gram-positive bacterium; TAS:BHF-UCL.
DR   GO; GO:0042832; P:defense response to protozoan; IEA:Ensembl.
DR   GO; GO:0051607; P:defense response to virus; IDA:BHF-UCL.
DR   GO; GO:0031018; P:endocrine pancreas development; ISS:BHF-UCL.
DR   GO; GO:0060664; P:epithelial cell proliferation involved in salivary gland morphogenesis; IEA:Ensembl.
DR   GO; GO:0070091; P:glucagon secretion; ISS:BHF-UCL.
DR   GO; GO:0042593; P:glucose homeostasis; IEA:Ensembl.
DR   GO; GO:0002384; P:hepatic immune response; IDA:BHF-UCL.
DR   GO; GO:0006959; P:humoral immune response; IC:BHF-UCL.
DR   GO; GO:0006954; P:inflammatory response; IDA:BHF-UCL.
DR   GO; GO:0070102; P:interleukin-6-mediated signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0002548; P:monocyte chemotaxis; IC:BHF-UCL.
DR   GO; GO:0046716; P:muscle cell cellular homeostasis; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; TAS:ProtInc.
DR   GO; GO:0045079; P:negative regulation of chemokine biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0032966; P:negative regulation of collagen biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; IEA:Ensembl.
DR   GO; GO:0050710; P:negative regulation of cytokine secretion; IEA:Ensembl.
DR   GO; GO:0045599; P:negative regulation of fat cell differentiation; NAS:BHF-UCL.
DR   GO; GO:0045721; P:negative regulation of gluconeogenesis; IEA:Ensembl.
DR   GO; GO:0046888; P:negative regulation of hormone secretion; IEA:Ensembl.
DR   GO; GO:0010888; P:negative regulation of lipid storage; NAS:BHF-UCL.
DR   GO; GO:0048635; P:negative regulation of muscle organ development; IEA:Ensembl.
DR   GO; GO:1901215; P:negative regulation of neuron death; IEA:Ensembl.
DR   GO; GO:0006469; P:negative regulation of protein kinase activity; IEA:Ensembl.
DR   GO; GO:0031175; P:neuron projection development; IMP:BHF-UCL.
DR   GO; GO:0001781; P:neutrophil apoptotic process; IDA:UniProtKB.
DR   GO; GO:0002446; P:neutrophil mediated immunity; TAS:BHF-UCL.
DR   GO; GO:0030168; P:platelet activation; TAS:BHF-UCL.
DR   GO; GO:0002675; P:positive regulation of acute inflammatory response; IDA:BHF-UCL.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0050871; P:positive regulation of B cell activation; IDA:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0032722; P:positive regulation of chemokine production; IDA:BHF-UCL.
DR   GO; GO:0045740; P:positive regulation of DNA replication; IEA:Ensembl.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IEA:Ensembl.
DR   GO; GO:0051024; P:positive regulation of immunoglobulin secretion; IDA:BHF-UCL.
DR   GO; GO:0032755; P:positive regulation of interleukin-6 production; IDA:BHF-UCL.
DR   GO; GO:0046427; P:positive regulation of JAK-STAT cascade; IDA:BHF-UCL.
DR   GO; GO:0002690; P:positive regulation of leukocyte chemotaxis; TAS:BHF-UCL.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:BHF-UCL.
DR   GO; GO:0045666; P:positive regulation of neuron differentiation; IEA:Ensembl.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IEA:Ensembl.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; TAS:BHF-UCL.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:MGI.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IDA:MGI.
DR   GO; GO:0033160; P:positive regulation of protein import into nucleus, translocation; IEA:Ensembl.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IEA:Ensembl.
DR   GO; GO:0051091; P:positive regulation of sequence-specific DNA binding transcription factor activity; IDA:BHF-UCL.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IDA:BHF-UCL.
DR   GO; GO:2000366; P:positive regulation of STAT protein import into nucleus; IC:BHF-UCL.
DR   GO; GO:0042102; P:positive regulation of T cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0045630; P:positive regulation of T-helper 2 cell differentiation; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:BHF-UCL.
DR   GO; GO:0045727; P:positive regulation of translation; IDA:UniProtKB.
DR   GO; GO:0051971; P:positive regulation of transmission of nerve impulse; IEA:Ensembl.
DR   GO; GO:2000676; P:positive regulation of type B pancreatic cell apoptotic process; TAS:BHF-UCL.
DR   GO; GO:0042517; P:positive regulation of tyrosine phosphorylation of Stat3 protein; IDA:BHF-UCL.
DR   GO; GO:0045765; P:regulation of angiogenesis; IC:BHF-UCL.
DR   GO; GO:0008360; P:regulation of cell shape; IEA:Ensembl.
DR   GO; GO:0045188; P:regulation of circadian sleep/wake cycle, non-REM sleep; IEA:Ensembl.
DR   GO; GO:0010574; P:regulation of vascular endothelial growth factor production; IDA:BHF-UCL.
DR   GO; GO:0043200; P:response to amino acid; IEA:Ensembl.
DR   GO; GO:0046677; P:response to antibiotic; IEA:Ensembl.
DR   GO; GO:0010996; P:response to auditory stimulus; IEA:Ensembl.
DR   GO; GO:0031000; P:response to caffeine; IEA:Ensembl.
DR   GO; GO:0051592; P:response to calcium ion; IEA:Ensembl.
DR   GO; GO:0009409; P:response to cold; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0051602; P:response to electrical stimulus; IEA:Ensembl.
DR   GO; GO:0051384; P:response to glucocorticoid; IDA:BHF-UCL.
DR   GO; GO:0009408; P:response to heat; IEA:Ensembl.
DR   GO; GO:0032868; P:response to insulin; IEA:Ensembl.
DR   GO; GO:0031667; P:response to nutrient levels; IEA:Ensembl.
DR   GO; GO:0032494; P:response to peptidoglycan; NAS:BHF-UCL.
DR   GO; GO:0001878; P:response to yeast; IEA:Ensembl.
DR   GO; GO:0072540; P:T-helper 17 cell lineage commitment; ISS:UniProtKB.
DR   Gene3D; 1.20.1250.10; -; 1.
DR   InterPro; IPR009079; 4_helix_cytokine-like_core.
DR   InterPro; IPR012351; 4_helix_cytokine_core.
DR   InterPro; IPR003574; IL-6.
DR   InterPro; IPR030474; IL-6/GCSF/MGF.
DR   InterPro; IPR030473; IL6/GCSF/MGF_CS.
DR   PANTHER; PTHR11457; PTHR11457; 1.
DR   Pfam; PF00489; IL6; 1.
DR   PIRSF; PIRSF001935; IL6_MGF_GCSF; 1.
DR   PRINTS; PR00433; IL6GCSFMGF.
DR   SMART; SM00126; IL6; 1.
DR   SUPFAM; SSF47266; SSF47266; 1.
DR   PROSITE; PS00254; INTERLEUKIN_6; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acute phase; Complete proteome; Cytokine;
KW   Direct protein sequencing; Disulfide bond; Glycoprotein;
KW   Growth factor; Phosphoprotein; Polymorphism; Reference proteome;
KW   Secreted; Signal.
FT   SIGNAL        1     29       {ECO:0000269|PubMed:1883960,
FT                                ECO:0000269|PubMed:2610854,
FT                                ECO:0000269|PubMed:3279116}.
FT   CHAIN        30    212       Interleukin-6.
FT                                /FTId=PRO_0000015582.
FT   MOD_RES      81     81       Phosphoserine; by FAM20C.
FT                                {ECO:0000269|PubMed:26091039}.
FT   CARBOHYD     73     73       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:1883960}.
FT   DISULFID     72     78       {ECO:0000269|PubMed:2472117}.
FT   DISULFID    101    111       {ECO:0000269|PubMed:2472117}.
FT   VARIANT      32     32       P -> S (in dbSNP:rs2069830).
FT                                {ECO:0000269|Ref.10}.
FT                                /FTId=VAR_013075.
FT   VARIANT     162    162       D -> E (in dbSNP:rs13306435).
FT                                /FTId=VAR_029266.
FT   VARIANT     162    162       D -> V (in dbSNP:rs2069860).
FT                                {ECO:0000269|Ref.10}.
FT                                /FTId=VAR_013076.
FT   MUTAGEN     173    173       A->V: Almost no loss of activity.
FT                                {ECO:0000269|PubMed:2037043}.
FT   MUTAGEN     185    185       W->R: No loss of activity.
FT                                {ECO:0000269|PubMed:2037043}.
FT   MUTAGEN     204    204       S->P: 87% loss of activity.
FT                                {ECO:0000269|PubMed:2037043}.
FT   MUTAGEN     210    210       R->K,E,Q,T,A,P: Loss of activity.
FT                                {ECO:0000269|PubMed:2037043}.
FT   MUTAGEN     212    212       M->T,N,S,R: Loss of activity.
FT                                {ECO:0000269|PubMed:2037043}.
FT   HELIX        49     75       {ECO:0000244|PDB:1ALU}.
FT   STRAND       76     79       {ECO:0000244|PDB:2IL6}.
FT   TURN         81     83       {ECO:0000244|PDB:4CNI}.
FT   HELIX        84     87       {ECO:0000244|PDB:4CNI}.
FT   HELIX        97     99       {ECO:0000244|PDB:1ALU}.
FT   STRAND      102    105       {ECO:0000244|PDB:4J4L}.
FT   HELIX       108    132       {ECO:0000244|PDB:1ALU}.
FT   STRAND      134    136       {ECO:0000244|PDB:4J4L}.
FT   HELIX       137    157       {ECO:0000244|PDB:1ALU}.
FT   STRAND      159    161       {ECO:0000244|PDB:1ALU}.
FT   HELIX       169    180       {ECO:0000244|PDB:1ALU}.
FT   HELIX       184    209       {ECO:0000244|PDB:1ALU}.
SQ   SEQUENCE   212 AA;  23718 MW;  1F1ED1FE1B734079 CRC64;
     MNSFSTSAFG PVAFSLGLLL VLPAAFPAPV PPGEDSKDVA APHRQPLTSS ERIDKQIRYI
     LDGISALRKE TCNKSNMCES SKEALAENNL NLPKMAEKDG CFQSGFNEET CLVKIITGLL
     EFEVYLEYLQ NRFESSEEQA RAVQMSTKVL IQFLQKKAKN LDAITTPDPT TNASLLTKLQ
     AQNQWLQDMT THLILRSFKE FLQSSLRALR QM
//
ID   CCL2_HUMAN              Reviewed;          99 AA.
AC   P13500; B2R4V3; Q9UDF3;
DT   01-JAN-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1990, sequence version 1.
DT   17-FEB-2016, entry version 197.
DE   RecName: Full=C-C motif chemokine 2;
DE   AltName: Full=HC11;
DE   AltName: Full=Monocyte chemoattractant protein 1;
DE   AltName: Full=Monocyte chemotactic and activating factor;
DE            Short=MCAF;
DE   AltName: Full=Monocyte chemotactic protein 1;
DE            Short=MCP-1;
DE   AltName: Full=Monocyte secretory protein JE;
DE   AltName: Full=Small-inducible cytokine A2;
DE   Flags: Precursor;
GN   Name=CCL2; Synonyms=MCP1, SCYA2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2923622; DOI=10.1016/0006-291X(89)92430-3;
RA   Furutani Y., Nomura H., Notake M., Oyamada Y., Fukui T., Yamada M.,
RA   Larsen C.G., Oppenheim J.J., Matsushima K.;
RT   "Cloning and sequencing of the cDNA for human monocyte chemotactic and
RT   activating factor (MCAF).";
RL   Biochem. Biophys. Res. Commun. 159:249-255(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA].
RX   PubMed=2513477;
RA   Rollins B.J., Stier P., Ernst T., Wong G.G.;
RT   "The human homolog of the JE gene encodes a monocyte secretory
RT   protein.";
RL   Mol. Cell. Biol. 9:4687-4695(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Glial tumor;
RX   PubMed=2465924; DOI=10.1016/0014-5793(89)80590-3;
RA   Yoshimura T., Yuhki N., Moore S.K., Appella E., Lerman M.I.,
RA   Leonard E.J.;
RT   "Human monocyte chemoattractant protein-1 (MCP-1). Full-length cDNA
RT   cloning, expression in mitogen-stimulated blood mononuclear
RT   leukocytes, and sequence similarity to mouse competence gene JE.";
RL   FEBS Lett. 244:487-493(1989).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2518726; DOI=10.1093/intimm/1.4.388;
RA   Chang H.C., Hsu F., Freeman G.J., Griffin J.D., Reinherz E.L.;
RT   "Cloning and expression of a gamma-interferon-inducible gene in
RT   monocytes: a new member of a cytokine gene family.";
RL   Int. Immunol. 1:388-397(1989).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2357211; DOI=10.1016/0006-291X(90)90338-N;
RA   Shyy Y.J., Li Y.S., Kolattukudy P.E.;
RT   "Structure of human monocyte chemotactic protein gene and its
RT   regulation by TPA.";
RL   Biochem. Biophys. Res. Commun. 169:346-351(1990).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=1661560;
RA   Yoshimura T., Leonard E.J.;
RT   "Human monocyte chemoattractant protein-1 (MCP-1).";
RL   Adv. Exp. Med. Biol. 305:47-56(1991).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8107690; DOI=10.1007/BF01772208;
RA   Li Y.S., Shyy Y.J., Wright J.G., Valente A.J., Cornhill J.F.,
RA   Kolattukudy P.E.;
RT   "The expression of monocyte chemotactic protein (MCP-1) in human
RT   vascular endothelium in vitro and in vivo.";
RL   Mol. Cell. Biochem. 126:61-68(1993).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=10918580; DOI=10.1038/sj.onc.1203643;
RA   Finzer P., Soto U., Delius H., Patzelt A., Poustka A., Coy J.F.,
RA   zur Hausen H., Roesl F.;
RT   "Differential transcriptional regulation of the monocyte-
RT   chemoattractant protein-1 (MCP-1) gene in tumorigenic and non-
RT   tumorigenic HPV 18 positive cells: the role of the chromatin structure
RT   and AP-1 composition.";
RL   Oncogene 19:3235-3244(2000).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Caput D., Ferrara P., Miloux B., Minty A., Vita N.;
RT   "Protein with cytokine activity, recombinant DNA, expression vector
RT   and hosts for obtaining it.";
RL   Patent number EP0488900, 03-JUN-1992.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JUN-2002) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Urinary bladder;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [15]
RP   PROTEIN SEQUENCE OF 24-99, AND PYROGLUTAMATE FORMATION AT GLN-24.
RX   PubMed=2648385; DOI=10.1073/pnas.86.6.1850;
RA   Robinson E.A., Yoshimura T., Leonard E.J., Tanaka S., Griffin P.R.,
RA   Shabanowitz J., Hunt D.F., Appella E.;
RT   "Complete amino acid sequence of a human monocyte chemoattractant, a
RT   putative mediator of cellular immune reactions.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:1850-1854(1989).
RN   [16]
RP   PROTEIN SEQUENCE OF 29-53 AND 82-92.
RX   PubMed=2322286; DOI=10.1016/0006-291X(90)90609-Q;
RA   Decock B., Conings R., Lenaerts J.-P., Biliau A., van Damme J.;
RT   "Identification of the monocyte chemotactic protein from human
RT   osteosarcoma cells and monocytes: detection of a novel N-terminally
RT   processed form.";
RL   Biochem. Biophys. Res. Commun. 167:904-909(1990).
RN   [17]
RP   GENE STRUCTURE.
RX   PubMed=2071154; DOI=10.1016/0888-7543(91)90338-F;
RA   Rollins B.J., Morton C.C., Ledbetter D.H., Eddy R.L. Jr., Shows T.B.;
RT   "Assignment of the human small inducible cytokine A2 gene, SCYA2
RT   (encoding JE or MCP-1), to 17q11.2-12: evolutionary relatedness of
RT   cytokines clustered at the same locus.";
RL   Genomics 10:489-492(1991).
RN   [18]
RP   MUTAGENESIS.
RX   PubMed=8195247;
RA   Zhang Y.J., Rutledge B.J., Rollins B.J.;
RT   "Structure/activity analysis of human monocyte chemoattractant
RT   protein-1 (MCP-1) by mutagenesis. Identification of a mutated protein
RT   that inhibits MCP-1-mediated monocyte chemotaxis.";
RL   J. Biol. Chem. 269:15918-15924(1994).
RN   [19]
RP   EFFECT OF DELETION OF N-TERMINAL RESIDUES.
RX   PubMed=8627182; DOI=10.1084/jem.183.2.681;
RA   Weber M., Uguccioni M., Baggiolini M., Clark-Lewis I., Dahinden C.A.;
RT   "Deletion of the NH2-terminal residue converts monocyte chemotactic
RT   protein 1 from an activator of basophil mediator release to an
RT   eosinophil chemoattractant.";
RL   J. Exp. Med. 183:681-685(1996).
RN   [20]
RP   SUBUNIT.
RX   PubMed=8898111; DOI=10.1016/0014-5793(96)01024-1;
RA   Kim K.-S., Rajarathnam K., Clark-Lewis I., Sykes B.D.;
RT   "Structural characterization of a monomeric chemokine: monocyte
RT   chemoattractant protein-3.";
RL   FEBS Lett. 395:277-282(1996).
RN   [21]
RP   GAG BINDING SITES LYS-81 AND HIS-89, AND MUTAGENESIS OF LYS-81; HIS-89
RP   AND 95-GLN--THR-99.
RX   PubMed=9792674; DOI=10.1074/jbc.273.45.29641;
RA   Chakravarty L., Rogers L., Quach T., Breckenridge S.,
RA   Kolattukudy P.E.;
RT   "Lysine 58 and histidine 66 at the C-terminal alpha-helix of monocyte
RT   chemoattractant protein-1 are essential for glycosaminoglycan
RT   binding.";
RL   J. Biol. Chem. 273:29641-29647(1998).
RN   [22]
RP   HOMODIMERIZATION, AND MUTAGENESIS OF PRO-31; VAL-32; THR-33 AND
RP   TYR-36.
RX   PubMed=9837883; DOI=10.1074/jbc.273.50.33157;
RA   Paavola C.D., Hemmerich S., Grunberger D., Polsky I., Bloom A.,
RA   Freedman R., Mulkins M., Bhakta S., McCarley D., Wiesent L., Wong B.,
RA   Jarnagin K., Handel T.M.;
RT   "Monomeric monocyte chemoattractant protein-1 (MCP-1) binds and
RT   activates the MCP-1 receptor CCR2B.";
RL   J. Biol. Chem. 273:33157-33165(1998).
RN   [23]
RP   MUTAGENESIS OF 25-PRO--PRO-31; ASP-26; ILE-28; ASN-29; PRO-31; VAL-32
RP   AND THR-33.
RX   PubMed=10587439; DOI=10.1021/bi9912239;
RA   Jarnagin K., Grunberger D., Mulkins M., Wong B., Hemmerich S.,
RA   Paavola C., Bloom A., Bhakta S., Diehl F., Freedman R., McCarley D.,
RA   Polsky I., Ping-Tsou A., Kosaka A., Handel T.M.;
RT   "Identification of surface residues of the monocyte chemotactic
RT   protein 1 that affect signaling through the receptor CCR2.";
RL   Biochemistry 38:16167-16177(1999).
RN   [24]
RP   IMPORTANCE OF TYR-36; ARG-47; LYS-58; LYS-61 AND LYS-72 FOR RECEPTOR
RP   BINDING, AND MUTAGENESIS.
RX   PubMed=10529171; DOI=10.1021/bi991029m;
RA   Hemmerich S., Paavola C., Bloom A., Bhakta S., Freedman R.,
RA   Grunberger D., Krstenansky J., Lee S., McCarley D., Mulkins M.,
RA   Wong B., Pease J., Mizoue L., Mirzadegan T., Polsky I., Thompson K.,
RA   Handel T.M., Jarnagin K.;
RT   "Identification of residues in the monocyte chemotactic protein-1 that
RT   contact the MCP-1 receptor, CCR2.";
RL   Biochemistry 38:13013-13025(1999).
RN   [25]
RP   GAG BINDING SITES ARG-41; LYS-42 AND ARG-47, AND MUTAGENESIS.
RX   PubMed=15033992; DOI=10.1074/jbc.M311224200;
RA   Lau E.K., Paavola C.D., Johnson Z., Gaudry J.-P., Geretti E.,
RA   Borlat F., Kungl A.J., Proudfoot A.E., Handel T.M.;
RT   "Identification of the glycosaminoglycan binding site of the CC
RT   chemokine, MCP-1: implications for structure and function in vivo.";
RL   J. Biol. Chem. 279:22294-22305(2004).
RN   [26]
RP   INDUCTION BY OSMOTIC STRESS.
RX   PubMed=23233732; DOI=10.1194/jlr.M033365;
RA   Ueno M., Shen W.J., Patel S., Greenberg A.S., Azhar S., Kraemer F.B.;
RT   "Fat-specific protein 27 modulates nuclear factor of activated T cells
RT   5 and the cellular response to stress.";
RL   J. Lipid Res. 54:734-743(2013).
RN   [27]
RP   3D-STRUCTURE MODELING.
RX   PubMed=1857712; DOI=10.1093/protein/4.3.263;
RA   Gronenborn A.M., Clore G.M.;
RT   "Modeling the three-dimensional structure of the monocyte chemo-
RT   attractant and activating protein MCAF/MCP-1 on the basis of the
RT   solution structure of interleukin-8.";
RL   Protein Eng. 4:263-269(1991).
RN   [28]
RP   STRUCTURE BY NMR.
RX   PubMed=8639605; DOI=10.1021/bi9602270;
RA   Handel T.M., Domaille P.J.;
RT   "Heteronuclear (1H, 13C, 15N) NMR assignments and solution structure
RT   of the monocyte chemoattractant protein-1 (MCP-1) dimer.";
RL   Biochemistry 35:6569-6584(1996).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS).
RX   PubMed=8989326; DOI=10.1038/nsb0197-64;
RA   Lubkowski J., Bujacz G., Domaille P.J., Handel T.M., Wlodawer A.;
RT   "The structure of MCP-1 in two crystal forms provides a rare example
RT   of variable quaternary interactions.";
RL   Nat. Struct. Biol. 4:64-69(1997).
RN   [30]
RP   INVOLVEMENT IN MYCOBACTERIUM TUBERCULOSIS SUSCEPTIBILITY.
RX   PubMed=16352737; DOI=10.1084/jem.20050126;
RA   Flores-Villanueva P.O., Ruiz-Morales J.A., Song C.-H., Flores L.M.,
RA   Jo E.-K., Montano M., Barnes P.F., Selman M., Granados J.;
RT   "A functional promoter polymorphism in monocyte chemoattractant
RT   protein-1 is associated with increased susceptibility to pulmonary
RT   tuberculosis.";
RL   J. Exp. Med. 202:1649-1658(2005).
CC   -!- FUNCTION: Chemotactic factor that attracts monocytes and basophils
CC       but not neutrophils or eosinophils. Augments monocyte anti-tumor
CC       activity. Has been implicated in the pathogenesis of diseases
CC       characterized by monocytic infiltrates, like psoriasis, rheumatoid
CC       arthritis or atherosclerosis. May be involved in the recruitment
CC       of monocytes into the arterial wall during the disease process of
CC       atherosclerosis.
CC   -!- SUBUNIT: Monomer or homodimer; in equilibrium. Binds to CCR2 and
CC       CCR4. Is tethered on endothelial cells by glycosaminoglycan (GAG)
CC       side chains of proteoglycans. {ECO:0000269|PubMed:8898111}.
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- INDUCTION: Up-regulated upon hypertonic conditions.
CC       {ECO:0000269|PubMed:23233732}.
CC   -!- PTM: Processing at the N-terminus can regulate receptor and target
CC       cell selectivity. Deletion of the N-terminal residue converts it
CC       from an activator of basophil to an eosinophil chemoattractant.
CC   -!- POLYMORPHISM: Genetic variations in CCL2 determine Mycobacterium
CC       tuberculosis susceptibility [MIM:607948].
CC       {ECO:0000269|PubMed:16352737}.
CC   -!- SIMILARITY: Belongs to the intercrine beta (chemokine CC) family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=CCL2 entry;
CC       URL="https://en.wikipedia.org/wiki/CCL2";
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/scya2/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M24545; AAA18164.1; -; mRNA.
DR   EMBL; M28225; AAA60308.1; -; Genomic_DNA.
DR   EMBL; M28223; AAA60308.1; JOINED; Genomic_DNA.
DR   EMBL; M28224; AAA60308.1; JOINED; Genomic_DNA.
DR   EMBL; M28226; AAA60309.1; -; mRNA.
DR   EMBL; M31626; AAA36330.1; -; Genomic_DNA.
DR   EMBL; M30816; AAA36330.1; JOINED; Genomic_DNA.
DR   EMBL; M31625; AAA36330.1; JOINED; Genomic_DNA.
DR   EMBL; X14768; CAA32876.1; -; mRNA.
DR   EMBL; M37719; AAA18102.1; -; Genomic_DNA.
DR   EMBL; S71513; AAB20651.1; -; mRNA.
DR   EMBL; S69738; AAB29926.1; -; mRNA.
DR   EMBL; Y18933; CAC14049.1; -; Genomic_DNA.
DR   EMBL; A17786; CAA01352.1; -; mRNA.
DR   EMBL; BT007329; AAP35993.1; -; mRNA.
DR   EMBL; AF519531; AAM54046.1; -; Genomic_DNA.
DR   EMBL; AK311960; BAG34900.1; -; mRNA.
DR   EMBL; CH471147; EAW80212.1; -; Genomic_DNA.
DR   EMBL; BC009716; AAH09716.1; -; mRNA.
DR   CCDS; CCDS11277.1; -.
DR   PIR; A35474; A60299.
DR   RefSeq; NP_002973.1; NM_002982.3.
DR   UniGene; Hs.303649; -.
DR   PDB; 1DOK; X-ray; 1.85 A; A/B=24-99.
DR   PDB; 1DOL; X-ray; 2.40 A; A=24-99.
DR   PDB; 1DOM; NMR; -; A/B=24-99.
DR   PDB; 1DON; NMR; -; A/B=24-99.
DR   PDB; 1MCA; Model; -; A/B=24-96.
DR   PDB; 1ML0; X-ray; 2.80 A; D=24-99.
DR   PDB; 2BDN; X-ray; 2.53 A; A=24-99.
DR   PDB; 2NZ1; X-ray; 2.50 A; D/E/Y=24-99.
DR   PDB; 3IFD; X-ray; 1.90 A; A=24-99.
DR   PDB; 4DN4; X-ray; 2.80 A; M=24-99.
DR   PDB; 4R8I; X-ray; 2.05 A; A=24-99.
DR   PDB; 4ZK9; X-ray; 2.60 A; B=24-99.
DR   PDBsum; 1DOK; -.
DR   PDBsum; 1DOL; -.
DR   PDBsum; 1DOM; -.
DR   PDBsum; 1DON; -.
DR   PDBsum; 1MCA; -.
DR   PDBsum; 1ML0; -.
DR   PDBsum; 2BDN; -.
DR   PDBsum; 2NZ1; -.
DR   PDBsum; 3IFD; -.
DR   PDBsum; 4DN4; -.
DR   PDBsum; 4R8I; -.
DR   PDBsum; 4ZK9; -.
DR   ProteinModelPortal; P13500; -.
DR   SMR; P13500; 24-94.
DR   BioGrid; 112251; 14.
DR   DIP; DIP-5838N; -.
DR   IntAct; P13500; 1.
DR   MINT; MINT-103269; -.
DR   STRING; 9606.ENSP00000225831; -.
DR   BindingDB; P13500; -.
DR   ChEMBL; CHEMBL1649052; -.
DR   DrugBank; DB01406; Danazol.
DR   DrugBank; DB01055; Mimosine.
DR   BioMuta; CCL2; -.
DR   DMDM; 126842; -.
DR   PaxDb; P13500; -.
DR   PRIDE; P13500; -.
DR   DNASU; 6347; -.
DR   Ensembl; ENST00000225831; ENSP00000225831; ENSG00000108691.
DR   GeneID; 6347; -.
DR   KEGG; hsa:6347; -.
DR   UCSC; uc002hhy.3; human.
DR   CTD; 6347; -.
DR   GeneCards; CCL2; -.
DR   HGNC; HGNC:10618; CCL2.
DR   HPA; CAB013676; -.
DR   HPA; HPA019163; -.
DR   MalaCards; CCL2; -.
DR   MIM; 158105; gene.
DR   MIM; 607948; phenotype.
DR   neXtProt; NX_P13500; -.
DR   PharmGKB; PA130413151; -.
DR   eggNOG; ENOG410J1ST; Eukaryota.
DR   eggNOG; ENOG410YXJU; LUCA.
DR   GeneTree; ENSGT00730000110714; -.
DR   HOGENOM; HOG000036686; -.
DR   HOVERGEN; HBG017871; -.
DR   InParanoid; P13500; -.
DR   KO; K14624; -.
DR   OMA; NKEICAD; -.
DR   PhylomeDB; P13500; -.
DR   TreeFam; TF334888; -.
DR   Reactome; R-HSA-380108; Chemokine receptors bind chemokines.
DR   Reactome; R-HSA-380994; ATF4 activates genes.
DR   EvolutionaryTrace; P13500; -.
DR   GeneWiki; CCL2; -.
DR   GenomeRNAi; 6347; -.
DR   NextBio; 24660; -.
DR   PMAP-CutDB; P13500; -.
DR   PRO; PR:P13500; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; P13500; -.
DR   CleanEx; HS_CCL2; -.
DR   ExpressionAtlas; P13500; baseline and differential.
DR   Genevisible; P13500; HS.
DR   GO; GO:0043679; C:axon terminus; IEA:Ensembl.
DR   GO; GO:0044299; C:C-fiber; IEA:Ensembl.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0030139; C:endocytic vesicle; IEA:Ensembl.
DR   GO; GO:0005576; C:extracellular region; IDA:BHF-UCL.
DR   GO; GO:0005615; C:extracellular space; TAS:ProtInc.
DR   GO; GO:0043204; C:perikaryon; IEA:Ensembl.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl.
DR   GO; GO:0005791; C:rough endoplasmic reticulum; IEA:Ensembl.
DR   GO; GO:0045202; C:synapse; IEA:Ensembl.
DR   GO; GO:0031727; F:CCR2 chemokine receptor binding; ISS:BHF-UCL.
DR   GO; GO:0008009; F:chemokine activity; TAS:ProtInc.
DR   GO; GO:0008201; F:heparin binding; IEA:Ensembl.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0005102; F:receptor binding; TAS:ProtInc.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0001525; P:angiogenesis; TAS:BHF-UCL.
DR   GO; GO:0043615; P:astrocyte cell migration; IDA:BHF-UCL.
DR   GO; GO:0007155; P:cell adhesion; TAS:ProtInc.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; IEA:Ensembl.
DR   GO; GO:0019725; P:cellular homeostasis; TAS:BHF-UCL.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0071318; P:cellular response to ATP; IEA:Ensembl.
DR   GO; GO:0071549; P:cellular response to dexamethasone stimulus; IEA:Ensembl.
DR   GO; GO:0035690; P:cellular response to drug; IEA:Ensembl.
DR   GO; GO:0044344; P:cellular response to fibroblast growth factor stimulus; IEP:UniProtKB.
DR   GO; GO:0071403; P:cellular response to high density lipoprotein particle stimulus; IEA:Ensembl.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; IEA:Ensembl.
DR   GO; GO:0071346; P:cellular response to interferon-gamma; IEP:UniProtKB.
DR   GO; GO:0071347; P:cellular response to interleukin-1; IEP:UniProtKB.
DR   GO; GO:0071354; P:cellular response to interleukin-6; IEA:Ensembl.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; ISS:BHF-UCL.
DR   GO; GO:0036006; P:cellular response to macrophage colony-stimulating factor stimulus; IEA:Ensembl.
DR   GO; GO:0071407; P:cellular response to organic cyclic compound; IDA:UniProtKB.
DR   GO; GO:0036120; P:cellular response to platelet-derived growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0071300; P:cellular response to retinoic acid; IEA:Ensembl.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IEP:UniProtKB.
DR   GO; GO:0070098; P:chemokine-mediated signaling pathway; IBA:GO_Central.
DR   GO; GO:0006935; P:chemotaxis; TAS:ProtInc.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0007010; P:cytoskeleton organization; IDA:UniProtKB.
DR   GO; GO:0030968; P:endoplasmic reticulum unfolded protein response; TAS:Reactome.
DR   GO; GO:0007186; P:G-protein coupled receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0007187; P:G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger; TAS:ProtInc.
DR   GO; GO:0035684; P:helper T cell extravasation; ISS:BHF-UCL.
DR   GO; GO:0006959; P:humoral immune response; TAS:ProtInc.
DR   GO; GO:0006954; P:inflammatory response; IDA:UniProtKB.
DR   GO; GO:0007259; P:JAK-STAT cascade; TAS:ProtInc.
DR   GO; GO:0002523; P:leukocyte migration involved in inflammatory response; IEA:Ensembl.
DR   GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; IDA:UniProtKB.
DR   GO; GO:0048247; P:lymphocyte chemotaxis; IBA:GO_Central.
DR   GO; GO:0048246; P:macrophage chemotaxis; IDA:BHF-UCL.
DR   GO; GO:0000165; P:MAPK cascade; IMP:UniProtKB.
DR   GO; GO:0060135; P:maternal process involved in female pregnancy; IEA:Ensembl.
DR   GO; GO:0060137; P:maternal process involved in parturition; IEA:Ensembl.
DR   GO; GO:0002548; P:monocyte chemotaxis; IDA:BHF-UCL.
DR   GO; GO:0016525; P:negative regulation of angiogenesis; IEA:Ensembl.
DR   GO; GO:0034351; P:negative regulation of glial cell apoptotic process; IDA:UniProtKB.
DR   GO; GO:2000502; P:negative regulation of natural killer cell chemotaxis; IDA:UniProtKB.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IDA:UniProtKB.
DR   GO; GO:0030593; P:neutrophil chemotaxis; IBA:GO_Central.
DR   GO; GO:0009887; P:organ morphogenesis; TAS:ProtInc.
DR   GO; GO:0031100; P:organ regeneration; IEA:Ensembl.
DR   GO; GO:0036499; P:PERK-mediated unfolded protein response; TAS:Reactome.
DR   GO; GO:2000427; P:positive regulation of apoptotic cell clearance; ISS:BHF-UCL.
DR   GO; GO:0090280; P:positive regulation of calcium ion import; IDA:BHF-UCL.
DR   GO; GO:0002693; P:positive regulation of cellular extravasation; IEA:Ensembl.
DR   GO; GO:0032967; P:positive regulation of collagen biosynthetic process; IEA:Ensembl.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IBA:GO_Central.
DR   GO; GO:0043547; P:positive regulation of GTPase activity; IBA:GO_Central.
DR   GO; GO:0090265; P:positive regulation of immune complex clearance by monocytes and macrophages; IEA:Ensembl.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; IBA:GO_Central.
DR   GO; GO:0001912; P:positive regulation of leukocyte mediated cytotoxicity; IEA:Ensembl.
DR   GO; GO:0010759; P:positive regulation of macrophage chemotaxis; IEA:Ensembl.
DR   GO; GO:0090026; P:positive regulation of monocyte chemotaxis; IEA:Ensembl.
DR   GO; GO:0051770; P:positive regulation of nitric-oxide synthase biosynthetic process; ISS:BHF-UCL.
DR   GO; GO:0090314; P:positive regulation of protein targeting to membrane; IEA:Ensembl.
DR   GO; GO:0050806; P:positive regulation of synaptic transmission; IEA:Ensembl.
DR   GO; GO:0050870; P:positive regulation of T cell activation; ISS:BHF-UCL.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; IEA:Ensembl.
DR   GO; GO:0043491; P:protein kinase B signaling; IMP:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0008360; P:regulation of cell shape; IDA:UniProtKB.
DR   GO; GO:0010574; P:regulation of vascular endothelial growth factor production; IEA:Ensembl.
DR   GO; GO:0014823; P:response to activity; IEA:Ensembl.
DR   GO; GO:0043200; P:response to amino acid; IEA:Ensembl.
DR   GO; GO:0046677; P:response to antibiotic; IEA:Ensembl.
DR   GO; GO:0009617; P:response to bacterium; NAS:BHF-UCL.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0010332; P:response to gamma radiation; IEA:Ensembl.
DR   GO; GO:0009408; P:response to heat; IEA:Ensembl.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0009612; P:response to mechanical stimulus; IEA:Ensembl.
DR   GO; GO:0032570; P:response to progesterone; IEA:Ensembl.
DR   GO; GO:0033552; P:response to vitamin B3; IEA:Ensembl.
DR   GO; GO:0009611; P:response to wounding; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; NAS:ProtInc.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0019079; P:viral genome replication; TAS:ProtInc.
DR   InterPro; IPR000827; Chemokine_CC_CS.
DR   InterPro; IPR001811; Chemokine_IL8-like_dom.
DR   Pfam; PF00048; IL8; 1.
DR   SMART; SM00199; SCY; 1.
DR   SUPFAM; SSF54117; SSF54117; 1.
DR   PROSITE; PS00472; SMALL_CYTOKINES_CC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Chemotaxis; Complete proteome; Cytokine;
KW   Direct protein sequencing; Disulfide bond; Glycoprotein;
KW   Inflammatory response; Pyrrolidone carboxylic acid;
KW   Reference proteome; Secreted; Signal.
FT   SIGNAL        1     23       {ECO:0000269|PubMed:2648385}.
FT   CHAIN        24     99       C-C motif chemokine 2.
FT                                /FTId=PRO_0000005146.
FT   SITE         31     31       Involved in dimerization.
FT   SITE         36     36       Involved in dimerization, receptor
FT                                binding and signaling.
FT   SITE         41     41       Involved in GAG binding.
FT   SITE         42     42       Involved in GAG binding.
FT   SITE         47     47       Involved in GAG binding and receptor
FT                                binding.
FT   SITE         58     58       Involved in dimerization.
FT   SITE         61     61       Involved in dimerization.
FT   SITE         72     72       Involved in GAG binding and receptor
FT                                binding.
FT   SITE         81     81       Involved in GAG binding.
FT   SITE         89     89       Involved in GAG binding.
FT   MOD_RES      24     24       Pyrrolidone carboxylic acid.
FT                                {ECO:0000269|PubMed:1661560,
FT                                ECO:0000269|PubMed:2648385}.
FT   CARBOHYD     37     37       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     34     59
FT   DISULFID     35     75
FT   MUTAGEN      24     91       Missing: 83% reduction in activity.
FT   MUTAGEN      24     85       Missing: 90% reduction in activity.
FT   MUTAGEN      24     24       Missing: Loss of activity.
FT   MUTAGEN      25     31       Missing: Loss of signaling.
FT                                {ECO:0000269|PubMed:10587439}.
FT   MUTAGEN      26     26       D->A: Reduction in activity.
FT                                {ECO:0000269|PubMed:10587439}.
FT   MUTAGEN      28     28       I->A: Slight reduction in activity.
FT                                {ECO:0000269|PubMed:10587439}.
FT   MUTAGEN      29     29       N->A: 50% reduction in activity.
FT                                {ECO:0000269|PubMed:10587439}.
FT   MUTAGEN      31     31       P->A: Loss of dimerization; slight
FT                                reduction of activity.
FT                                {ECO:0000269|PubMed:10587439,
FT                                ECO:0000269|PubMed:9837883}.
FT   MUTAGEN      32     32       V->A: Slight reduction in activity.
FT                                {ECO:0000269|PubMed:10587439,
FT                                ECO:0000269|PubMed:9837883}.
FT   MUTAGEN      32     32       V->E: Slight reduction in affinity.
FT                                {ECO:0000269|PubMed:10587439,
FT                                ECO:0000269|PubMed:9837883}.
FT   MUTAGEN      33     33       T->A: Slight reduction in activity.
FT                                {ECO:0000269|PubMed:10587439,
FT                                ECO:0000269|PubMed:9837883}.
FT   MUTAGEN      33     33       T->E: Slight reduction in affinity.
FT                                {ECO:0000269|PubMed:10587439,
FT                                ECO:0000269|PubMed:9837883}.
FT   MUTAGEN      36     36       Y->A: Loss of activity.
FT                                {ECO:0000269|PubMed:9837883}.
FT   MUTAGEN      47     47       R->F: 95% reduction in activity; strong
FT                                reduction of receptor binding.
FT   MUTAGEN      50     50       S->Q: 40% reduction in activity.
FT   MUTAGEN      51     51       Y->D: Loss of activity.
FT   MUTAGEN      53     53       R->L: Loss of activity.
FT   MUTAGEN      79     79       K->A: No effect on heparin binding.
FT   MUTAGEN      81     81       K->A: Strongly reduces heparin binding.
FT                                {ECO:0000269|PubMed:9792674}.
FT   MUTAGEN      89     89       H->A: Strongly reduces heparin binding.
FT                                {ECO:0000269|PubMed:9792674}.
FT   MUTAGEN      91     91       D->L: 90% reduction in activity.
FT   MUTAGEN      95     99       Missing: No effect on heparin binding.
FT                                {ECO:0000269|PubMed:9792674}.
FT   HELIX        25     29       {ECO:0000244|PDB:1DOK}.
FT   STRAND       32     34       {ECO:0000244|PDB:1DOK}.
FT   HELIX        45     47       {ECO:0000244|PDB:1DOK}.
FT   STRAND       48     54       {ECO:0000244|PDB:1DOK}.
FT   STRAND       59     61       {ECO:0000244|PDB:1DOK}.
FT   STRAND       63     68       {ECO:0000244|PDB:1DOK}.
FT   STRAND       73     76       {ECO:0000244|PDB:1DOK}.
FT   STRAND       78     80       {ECO:0000244|PDB:4ZK9}.
FT   HELIX        81     92       {ECO:0000244|PDB:1DOK}.
FT   STRAND       93     95       {ECO:0000244|PDB:1DON}.
SQ   SEQUENCE   99 AA;  11025 MW;  45EC72361435302F CRC64;
     MKVSAALLCL LLIAATFIPQ GLAQPDAINA PVTCCYNFTN RKISVQRLAS YRRITSSKCP
     KEAVIFKTIV AKEICADPKQ KWVQDSMDHL DKQTQTPKT
//
ID   BMP2_HUMAN              Reviewed;         396 AA.
AC   P12643;
DT   01-OCT-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1989, sequence version 1.
DT   17-FEB-2016, entry version 186.
DE   RecName: Full=Bone morphogenetic protein 2;
DE            Short=BMP-2;
DE   AltName: Full=Bone morphogenetic protein 2A;
DE            Short=BMP-2A;
DE   Flags: Precursor;
GN   Name=BMP2; Synonyms=BMP2A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION.
RX   PubMed=3201241; DOI=10.1126/science.3201241;
RA   Wozney J.M., Rosen V., Celeste A.J., Mitsock L.M., Whitters M.J.,
RA   Kriz R.W., Hewick R.M., Wang E.A.;
RT   "Novel regulators of bone formation: molecular clones and
RT   activities.";
RL   Science 242:1528-1534(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Shore E.M., Xu M.-Q., Calvert G., Moriatis J., Kaplan F.S.;
RT   "Human bone morphogenetic protein 2 (BMP-2) genomic DNA sequence.";
RL   Submitted (DEC-1997) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M.,
RA   Beasley O.P., Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J.,
RA   Buck D., Burrill W.D., Butler A.P., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M., Clark G., Clark L.N., Clark S.Y., Clee C.M.,
RA   Clegg S., Cobley V.E., Collier R.E., Connor R.E., Corby N.R.,
RA   Coulson A., Coville G.J., Deadman R., Dhami P.D., Dunn M.,
RA   Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H.,
RA   Rice C.M., Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S.,
RA   Skuce C.D., Smith M.L., Soderlund C., Steward C.A., Sulston J.E.,
RA   Swann R.M., Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A.,
RA   Tracey A., Tromans A.C., Vaudin M., Wall M., Wallis J.M.,
RA   Whitehead S.L., Whittaker P., Willey D.L., Williams L., Williams S.A.,
RA   Wilming L., Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S.,
RA   Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [4]
RP   GLYCOSYLATION AT ASN-338.
RX   PubMed=9265423; DOI=10.1021/ac9611172;
RA   Yeung B., Porter T.J., Vath J.E.;
RT   "Direct isoform analysis of high-mannose-containing glycoproteins by
RT   on-line capillary electrophoresis electrospray mass spectrometry.";
RL   Anal. Chem. 69:2510-2516(1997).
RN   [5]
RP   INTERACTION WITH SOSTDC1.
RX   PubMed=15020244; DOI=10.1016/j.bbrc.2004.02.075;
RA   Yanagita M., Oka M., Watabe T., Iguchi H., Niida A., Takahashi S.,
RA   Akiyama T., Miyazono K., Yanagisawa M., Sakurai T.;
RT   "USAG-1: a bone morphogenetic protein antagonist abundantly expressed
RT   in the kidney.";
RL   Biochem. Biophys. Res. Commun. 316:490-500(2004).
RN   [6]
RP   PROTEOLYTIC PROCESSING, AND PROPEPTIDE.
RX   PubMed=20555025; DOI=10.1210/en.2010-0326;
RA   Heng S., Paule S., Hardman B., Li Y., Singh H., Rainczuk A.,
RA   Stephens A.N., Nie G.;
RT   "Posttranslational activation of bone morphogenetic protein 2 is
RT   mediated by proprotein convertase 6 during decidualization for
RT   pregnancy establishment.";
RL   Endocrinology 151:3909-3917(2010).
RN   [7]
RP   FUNCTION.
RX   PubMed=24362451; DOI=10.1007/s00223-013-9828-1;
RA   Tanaka K., Kaji H., Yamaguchi T., Kanazawa I., Canaff L., Hendy G.N.,
RA   Sugimoto T.;
RT   "Involvement of the osteoinductive factors, Tmem119 and BMP-2, and the
RT   ER stress response PERK-eIF2alpha-ATF4 pathway in the commitment of
RT   myoblastic into osteoblastic cells.";
RL   Calcif. Tissue Int. 94:454-464(2014).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 292-396, AND SUBUNIT.
RX   PubMed=10074410; DOI=10.1006/jmbi.1999.2590;
RA   Scheufler C., Sebald W., Huelsmeyer M.;
RT   "Crystal structure of human bone morphogenetic protein-2 at 2.7 A
RT   resolution.";
RL   J. Mol. Biol. 287:103-115(1999).
CC   -!- FUNCTION: Induces cartilage and bone formation (PubMed:3201241).
CC       Stimulates the differentiation of myoblasts into osteoblasts via
CC       the EIF2AK3-EIF2A- ATF4 pathway. BMP2 activation of EIF2AK3
CC       stimulates phosphorylation of EIF2A which leads to increased
CC       expression of ATF4 which plays a central role in osteoblast
CC       differentiation. In addition stimulates TMEM119, which upregulates
CC       the expression of ATF4 (PubMed:24362451).
CC       {ECO:0000269|PubMed:24362451, ECO:0000269|PubMed:3201241}.
CC   -!- SUBUNIT: Homodimer; disulfide-linked (PubMed:10074410). Interacts
CC       with SOSTDC1 (PubMed:15020244). Interacts with GREM2, RGMA, RGMB
CC       and RGMC. Interacts with ASPN (By similarity). Interacts with
CC       MAFP5 (By similarity). {ECO:0000250|UniProtKB:P21274,
CC       ECO:0000269|PubMed:10074410, ECO:0000269|PubMed:15020244}.
CC   -!- INTERACTION:
CC       P36894:BMPR1A; NbExp=11; IntAct=EBI-1029262, EBI-1029237;
CC       O00238:BMPR1B; NbExp=3; IntAct=EBI-1029262, EBI-7527193;
CC       Q12841:FSTL1; NbExp=2; IntAct=EBI-1029262, EBI-2349801;
CC       Q13253:NOG; NbExp=2; IntAct=EBI-1029262, EBI-1035205;
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- TISSUE SPECIFICITY: Particularly abundant in lung, spleen and
CC       colon and in low but significant levels in heart, brain, placenta,
CC       liver, skeletal muscle, kidney, pancreas, prostate, ovary and
CC       small intestine.
CC   -!- PHARMACEUTICAL: Available under the name Infuse (Medtronic Sofamor
CC       Danek). Used for treating open tibial shaft fractures.
CC   -!- SIMILARITY: Belongs to the TGF-beta family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Bone morphogenetic protein 2
CC       entry;
CC       URL="https://en.wikipedia.org/wiki/Bone_morphogenetic_protein_2";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M22489; AAA51834.1; -; mRNA.
DR   EMBL; AF040249; AAF21646.1; -; Genomic_DNA.
DR   EMBL; AL035668; CAB82007.1; -; Genomic_DNA.
DR   CCDS; CCDS13099.1; -.
DR   PIR; B37278; BMHU2.
DR   RefSeq; NP_001191.1; NM_001200.3.
DR   UniGene; Hs.73853; -.
DR   PDB; 1ES7; X-ray; 2.90 A; A/C=283-396.
DR   PDB; 1REU; X-ray; 2.65 A; A=294-396.
DR   PDB; 1REW; X-ray; 1.86 A; A/B=283-396.
DR   PDB; 2GOO; X-ray; 2.20 A; A/D=283-396.
DR   PDB; 2H62; X-ray; 1.85 A; A/B=283-396.
DR   PDB; 2H64; X-ray; 1.92 A; A=283-396.
DR   PDB; 2QJ9; X-ray; 2.44 A; A/B=283-396.
DR   PDB; 2QJA; X-ray; 2.60 A; A/B=283-396.
DR   PDB; 2QJB; X-ray; 2.50 A; A/B=283-396.
DR   PDB; 3BK3; X-ray; 2.70 A; A/B=283-396.
DR   PDB; 3BMP; X-ray; 2.70 A; A=283-396.
DR   PDB; 4MID; X-ray; 2.14 A; A=283-312.
DR   PDB; 4N1D; X-ray; 1.91 A; A=283-305, A=362-396.
DR   PDB; 4UHY; X-ray; 3.20 A; A/B=283-396.
DR   PDB; 4UHZ; X-ray; 2.85 A; A=283-396.
DR   PDB; 4UI0; X-ray; 2.80 A; A/B=283-396.
DR   PDB; 4UI1; X-ray; 2.35 A; A/B=283-396.
DR   PDB; 4UI2; X-ray; 3.15 A; B=283-396.
DR   PDBsum; 1ES7; -.
DR   PDBsum; 1REU; -.
DR   PDBsum; 1REW; -.
DR   PDBsum; 2GOO; -.
DR   PDBsum; 2H62; -.
DR   PDBsum; 2H64; -.
DR   PDBsum; 2QJ9; -.
DR   PDBsum; 2QJA; -.
DR   PDBsum; 2QJB; -.
DR   PDBsum; 3BK3; -.
DR   PDBsum; 3BMP; -.
DR   PDBsum; 4MID; -.
DR   PDBsum; 4N1D; -.
DR   PDBsum; 4UHY; -.
DR   PDBsum; 4UHZ; -.
DR   PDBsum; 4UI0; -.
DR   PDBsum; 4UI1; -.
DR   PDBsum; 4UI2; -.
DR   ProteinModelPortal; P12643; -.
DR   SMR; P12643; 76-216, 293-396.
DR   BioGrid; 107118; 8.
DR   DIP; DIP-5792N; -.
DR   IntAct; P12643; 8.
DR   MINT; MINT-6772716; -.
DR   STRING; 9606.ENSP00000368104; -.
DR   BindingDB; P12643; -.
DR   ChEMBL; CHEMBL1926496; -.
DR   PhosphoSite; P12643; -.
DR   BioMuta; BMP2; -.
DR   DMDM; 115068; -.
DR   PaxDb; P12643; -.
DR   PRIDE; P12643; -.
DR   DNASU; 650; -.
DR   Ensembl; ENST00000378827; ENSP00000368104; ENSG00000125845.
DR   GeneID; 650; -.
DR   KEGG; hsa:650; -.
DR   UCSC; uc002wmu.1; human.
DR   CTD; 650; -.
DR   GeneCards; BMP2; -.
DR   HGNC; HGNC:1069; BMP2.
DR   MalaCards; BMP2; -.
DR   MIM; 112261; gene.
DR   neXtProt; NX_P12643; -.
DR   Orphanet; 261295; 20p12.3 microdeletion syndrome.
DR   Orphanet; 93396; Brachydactyly type A2.
DR   PharmGKB; PA25379; -.
DR   eggNOG; KOG3900; Eukaryota.
DR   eggNOG; ENOG410XT8Z; LUCA.
DR   GeneTree; ENSGT00760000118883; -.
DR   HOGENOM; HOG000249478; -.
DR   HOVERGEN; HBG004860; -.
DR   InParanoid; P12643; -.
DR   KO; K04662; -.
DR   OMA; DEHSWSQ; -.
DR   OrthoDB; EOG7WHH9D; -.
DR   PhylomeDB; P12643; -.
DR   TreeFam; TF351789; -.
DR   Reactome; R-HSA-201451; Signaling by BMP.
DR   Reactome; R-HSA-2129379; Molecules associated with elastic fibres.
DR   SignaLink; P12643; -.
DR   ChiTaRS; BMP2; human.
DR   EvolutionaryTrace; P12643; -.
DR   GeneWiki; Bone_morphogenetic_protein_2; -.
DR   GenomeRNAi; 650; -.
DR   NextBio; 2640; -.
DR   PRO; PR:P12643; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   Bgee; P12643; -.
DR   CleanEx; HS_BMP2; -.
DR   ExpressionAtlas; P12643; baseline and differential.
DR   Genevisible; P12643; HS.
DR   GO; GO:0070724; C:BMP receptor complex; IDA:BHF-UCL.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0070700; F:BMP receptor binding; IDA:MGI.
DR   GO; GO:0039706; F:co-receptor binding; IPI:BHF-UCL.
DR   GO; GO:0005125; F:cytokine activity; IBA:GO_Central.
DR   GO; GO:0019211; F:phosphatase activator activity; IDA:MGI.
DR   GO; GO:0046982; F:protein heterodimerization activity; IDA:MGI.
DR   GO; GO:0005102; F:receptor binding; TAS:ProtInc.
DR   GO; GO:0004745; F:retinol dehydrogenase activity; ISS:UniProtKB.
DR   GO; GO:0046332; F:SMAD binding; IDA:BHF-UCL.
DR   GO; GO:0005160; F:transforming growth factor beta receptor binding; IBA:GO_Central.
DR   GO; GO:0000187; P:activation of MAPK activity; IDA:AgBase.
DR   GO; GO:0003181; P:atrioventricular valve morphogenesis; ISS:UniProtKB.
DR   GO; GO:0030509; P:BMP signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0003130; P:BMP signaling pathway involved in heart induction; IDA:BHF-UCL.
DR   GO; GO:0030282; P:bone mineralization; ISS:UniProtKB.
DR   GO; GO:0035630; P:bone mineralization involved in bone maturation; IDA:BHF-UCL.
DR   GO; GO:0001658; P:branching involved in ureteric bud morphogenesis; ISS:UniProtKB.
DR   GO; GO:0060317; P:cardiac epithelial to mesenchymal transition; IDA:BHF-UCL.
DR   GO; GO:0055007; P:cardiac muscle cell differentiation; IMP:BHF-UCL.
DR   GO; GO:0055008; P:cardiac muscle tissue morphogenesis; ISS:UniProtKB.
DR   GO; GO:0035051; P:cardiocyte differentiation; IMP:BHF-UCL.
DR   GO; GO:0045165; P:cell fate commitment; ISS:UniProtKB.
DR   GO; GO:0007267; P:cell-cell signaling; TAS:ProtInc.
DR   GO; GO:0071773; P:cellular response to BMP stimulus; IDA:BHF-UCL.
DR   GO; GO:0071407; P:cellular response to organic cyclic compound; IEA:Ensembl.
DR   GO; GO:0002062; P:chondrocyte differentiation; IDA:AgBase.
DR   GO; GO:0060128; P:corticotropin hormone secreting cell differentiation; ISS:UniProtKB.
DR   GO; GO:0009790; P:embryo development; ISS:UniProtKB.
DR   GO; GO:0035054; P:embryonic heart tube anterior/posterior pattern specification; ISS:UniProtKB.
DR   GO; GO:0003203; P:endocardial cushion morphogenesis; ISS:UniProtKB.
DR   GO; GO:0001837; P:epithelial to mesenchymal transition; IDA:BHF-UCL.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0040007; P:growth; IEA:InterPro.
DR   GO; GO:0007507; P:heart development; ISS:UniProtKB.
DR   GO; GO:0001701; P:in utero embryonic development; ISS:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; ISS:UniProtKB.
DR   GO; GO:0048839; P:inner ear development; ISS:UniProtKB.
DR   GO; GO:0048762; P:mesenchymal cell differentiation; IDA:UniProtKB.
DR   GO; GO:0072138; P:mesenchymal cell proliferation involved in ureteric bud development; ISS:UniProtKB.
DR   GO; GO:0060485; P:mesenchyme development; IMP:BHF-UCL.
DR   GO; GO:0032348; P:negative regulation of aldosterone biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0051042; P:negative regulation of calcium-independent cell-cell adhesion; IDA:AgBase.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IEP:AgBase.
DR   GO; GO:2000726; P:negative regulation of cardiac muscle cell differentiation; IDA:BHF-UCL.
DR   GO; GO:0045786; P:negative regulation of cell cycle; IDA:HGNC.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IDA:BHF-UCL.
DR   GO; GO:2000065; P:negative regulation of cortisol biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0043569; P:negative regulation of insulin-like growth factor receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0010894; P:negative regulation of steroid biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:BHF-UCL.
DR   GO; GO:0003308; P:negative regulation of Wnt signaling pathway involved in heart development; IDA:BHF-UCL.
DR   GO; GO:0007219; P:Notch signaling pathway; ISS:UniProtKB.
DR   GO; GO:0042475; P:odontogenesis of dentin-containing tooth; ISS:UniProtKB.
DR   GO; GO:0009887; P:organ morphogenesis; ISS:UniProtKB.
DR   GO; GO:0001649; P:osteoblast differentiation; IDA:MGI.
DR   GO; GO:0060389; P:pathway-restricted SMAD protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0060039; P:pericardium development; ISS:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:MGI.
DR   GO; GO:0048711; P:positive regulation of astrocyte differentiation; ISS:UniProtKB.
DR   GO; GO:0030501; P:positive regulation of bone mineralization; IDA:BHF-UCL.
DR   GO; GO:0061036; P:positive regulation of cartilage development; IDA:MGI.
DR   GO; GO:0030335; P:positive regulation of cell migration; ISS:UniProtKB.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IDA:UniProtKB.
DR   GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; IDA:BHF-UCL.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:DFLAT.
DR   GO; GO:0045600; P:positive regulation of fat cell differentiation; ISS:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; IDA:UniProtKB.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:DFLAT.
DR   GO; GO:0045666; P:positive regulation of neuron differentiation; ISS:UniProtKB.
DR   GO; GO:0042482; P:positive regulation of odontogenesis; ISS:UniProtKB.
DR   GO; GO:0045778; P:positive regulation of ossification; IDA:MGI.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; IDA:BHF-UCL.
DR   GO; GO:0033690; P:positive regulation of osteoblast proliferation; ISS:UniProtKB.
DR   GO; GO:1900745; P:positive regulation of p38MAPK cascade; IDA:DFLAT.
DR   GO; GO:0010862; P:positive regulation of pathway-restricted SMAD protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0010922; P:positive regulation of phosphatase activity; IDA:MGI.
DR   GO; GO:0032092; P:positive regulation of protein binding; IDA:BHF-UCL.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:MGI.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:1901522; P:positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus; IDA:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0030177; P:positive regulation of Wnt signaling pathway; ISS:UniProtKB.
DR   GO; GO:0060804; P:positive regulation of Wnt signaling pathway by BMP signaling pathway; ISS:UniProtKB.
DR   GO; GO:0031648; P:protein destabilization; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:DFLAT.
DR   GO; GO:0006029; P:proteoglycan metabolic process; IEA:Ensembl.
DR   GO; GO:0042487; P:regulation of odontogenesis of dentin-containing tooth; IEA:Ensembl.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IDA:HGNC.
DR   GO; GO:0001666; P:response to hypoxia; ISS:UniProtKB.
DR   GO; GO:0001501; P:skeletal system development; TAS:ProtInc.
DR   GO; GO:0060395; P:SMAD protein signal transduction; IDA:UniProtKB.
DR   GO; GO:0021537; P:telencephalon development; IDA:MGI.
DR   GO; GO:0021978; P:telencephalon regionalization; ISS:UniProtKB.
DR   GO; GO:0060129; P:thyroid-stimulating hormone-secreting cell differentiation; ISS:UniProtKB.
DR   Gene3D; 2.10.90.10; -; 1.
DR   InterPro; IPR029034; Cystine-knot_cytokine.
DR   InterPro; IPR002405; Inhibin_asu.
DR   InterPro; IPR001839; TGF-b_C.
DR   InterPro; IPR001111; TGF-b_N.
DR   InterPro; IPR015615; TGF-beta-rel.
DR   InterPro; IPR017948; TGFb_CS.
DR   PANTHER; PTHR11848; PTHR11848; 1.
DR   Pfam; PF00019; TGF_beta; 1.
DR   Pfam; PF00688; TGFb_propeptide; 1.
DR   PRINTS; PR00669; INHIBINA.
DR   SMART; SM00204; TGFB; 1.
DR   SUPFAM; SSF57501; SSF57501; 1.
DR   PROSITE; PS00250; TGF_BETA_1; 1.
DR   PROSITE; PS51362; TGF_BETA_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Chondrogenesis; Cleavage on pair of basic residues;
KW   Complete proteome; Cytokine; Developmental protein; Differentiation;
KW   Disulfide bond; Glycoprotein; Growth factor; Osteogenesis;
KW   Pharmaceutical; Phosphoprotein; Polymorphism; Reference proteome;
KW   Secreted; Signal.
FT   SIGNAL        1     23       {ECO:0000255}.
FT   PROPEP       24    282       Cleaved by PCSK5.
FT                                /FTId=PRO_0000033824.
FT   CHAIN       283    396       Bone morphogenetic protein 2.
FT                                /FTId=PRO_0000033825.
FT   MOD_RES      87     87       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P12644}.
FT   CARBOHYD    135    135       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    163    163       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    164    164       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    200    200       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    338    338       N-linked (GlcNAc...) (high mannose).
FT                                {ECO:0000269|PubMed:9265423}.
FT   DISULFID    296    361
FT   DISULFID    325    393
FT   DISULFID    329    395
FT   DISULFID    360    360       Interchain.
FT   VARIANT      37     37       S -> A (in dbSNP:rs2273073).
FT                                /FTId=VAR_020061.
FT   VARIANT      77     77       P -> S (in dbSNP:rs36105541).
FT                                /FTId=VAR_052568.
FT   VARIANT     106    106       A -> T (in dbSNP:rs2273074).
FT                                /FTId=VAR_020062.
FT   VARIANT     161    161       L -> S (in dbSNP:rs34183594).
FT                                /FTId=VAR_052569.
FT   VARIANT     190    190       R -> S (in dbSNP:rs235768).
FT                                /FTId=VAR_024232.
FT   VARIANT     387    387       D -> G (in dbSNP:rs11545591).
FT                                /FTId=VAR_052570.
FT   STRAND      295    299       {ECO:0000244|PDB:2H62}.
FT   STRAND      302    304       {ECO:0000244|PDB:2H62}.
FT   HELIX       305    308       {ECO:0000244|PDB:2H62}.
FT   TURN        311    313       {ECO:0000244|PDB:2H62}.
FT   STRAND      314    316       {ECO:0000244|PDB:2H62}.
FT   STRAND      318    321       {ECO:0000244|PDB:2H62}.
FT   STRAND      324    326       {ECO:0000244|PDB:2H62}.
FT   HELIX       333    336       {ECO:0000244|PDB:4UI2}.
FT   STRAND      337    339       {ECO:0000244|PDB:2H62}.
FT   HELIX       341    352       {ECO:0000244|PDB:2H62}.
FT   STRAND      354    356       {ECO:0000244|PDB:1REU}.
FT   STRAND      360    374       {ECO:0000244|PDB:2H62}.
FT   HELIX       376    378       {ECO:0000244|PDB:4UI1}.
FT   STRAND      380    396       {ECO:0000244|PDB:2H62}.
SQ   SEQUENCE   396 AA;  44702 MW;  20653A3987B25E60 CRC64;
     MVAGTRCLLA LLLPQVLLGG AAGLVPELGR RKFAAASSGR PSSQPSDEVL SEFELRLLSM
     FGLKQRPTPS RDAVVPPYML DLYRRHSGQP GSPAPDHRLE RAASRANTVR SFHHEESLEE
     LPETSGKTTR RFFFNLSSIP TEEFITSAEL QVFREQMQDA LGNNSSFHHR INIYEIIKPA
     TANSKFPVTR LLDTRLVNQN ASRWESFDVT PAVMRWTAQG HANHGFVVEV AHLEEKQGVS
     KRHVRISRSL HQDEHSWSQI RPLLVTFGHD GKGHPLHKRE KRQAKHKQRK RLKSSCKRHP
     LYVDFSDVGW NDWIVAPPGY HAFYCHGECP FPLADHLNST NHAIVQTLVN SVNSKIPKAC
     CVPTELSAIS MLYLDENEKV VLKNYQDMVV EGCGCR
//
ID   A4_RAT                  Reviewed;         770 AA.
AC   P08592; Q547B7;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-1992, sequence version 2.
DT   17-FEB-2016, entry version 192.
DE   RecName: Full=Amyloid beta A4 protein;
DE   AltName: Full=ABPP;
DE            Short=APP;
DE   AltName: Full=Alzheimer disease amyloid A4 protein homolog;
DE   AltName: Full=Amyloid precursor protein {ECO:0000305};
DE   AltName: Full=Amyloidogenic glycoprotein;
DE            Short=AG;
DE   AltName: Full=Beta-amyloid precursor protein {ECO:0000305};
DE   Contains:
DE     RecName: Full=N-APP;
DE   Contains:
DE     RecName: Full=Soluble APP-alpha;
DE              Short=S-APP-alpha;
DE   Contains:
DE     RecName: Full=Soluble APP-beta;
DE              Short=S-APP-beta;
DE   Contains:
DE     RecName: Full=C99;
DE   Contains:
DE     RecName: Full=Beta-amyloid protein 42;
DE     AltName: Full=Beta-APP42;
DE   Contains:
DE     RecName: Full=Beta-amyloid protein 40;
DE     AltName: Full=Beta-APP40;
DE   Contains:
DE     RecName: Full=C83;
DE   Contains:
DE     RecName: Full=P3(42);
DE   Contains:
DE     RecName: Full=P3(40);
DE   Contains:
DE     RecName: Full=C80;
DE   Contains:
DE     RecName: Full=Gamma-secretase C-terminal fragment 59;
DE     AltName: Full=Gamma-CTF(59);
DE   Contains:
DE     RecName: Full=Gamma-secretase C-terminal fragment 57;
DE     AltName: Full=Gamma-CTF(57);
DE   Contains:
DE     RecName: Full=Gamma-secretase C-terminal fragment 50;
DE     AltName: Full=Gamma-CTF(50);
DE   Contains:
DE     RecName: Full=C31;
DE   Flags: Precursor;
GN   Name=App;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM APP695).
RC   TISSUE=Brain;
RX   PubMed=2900758;
RA   Shivers B.D., Hilbich C., Multhaup G., Salbaum J.M., Beyreuther K.,
RA   Seeburg P.H.;
RT   "Alzheimer's disease amyloidogenic glycoprotein: expression pattern in
RT   rat brain suggests a role in cell contact.";
RL   EMBO J. 7:1365-1370(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM APP770).
RA   Feng J., Song S., Zheng J.;
RT   "A new beta amyloid precursor protein cDNA found in Rat6 embryo
RT   fibroblasts.";
RL   Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   PROTEIN SEQUENCE OF 18-44.
RX   PubMed=2968652; DOI=10.1126/science.2968652;
RA   Schubert D., Schroeder R., LaCorbiere M., Saitoh T., Cole G.;
RT   "Amyloid beta protein precursor is possibly a heparan sulfate
RT   proteoglycan core protein.";
RL   Science 241:223-226(1988).
RN   [4]
RP   PROTEIN SEQUENCE OF 18-32.
RX   PubMed=1673681;
RA   Potempska A., Styles J., Mehta P., Kim K.S., Miller D.L.;
RT   "Purification and tissue level of the beta-amyloid peptide precursor
RT   of rat brain.";
RL   J. Biol. Chem. 266:8464-8469(1991).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 289-364.
RC   TISSUE=Liver;
RX   PubMed=2648331; DOI=10.1093/nar/17.5.2130;
RA   Kang J., Mueller-Hill B.;
RT   "The sequence of the two extra exons in rat preA4.";
RL   Nucleic Acids Res. 17:2130-2130(1989).
RN   [6]
RP   PROTEIN SEQUENCE OF 720-730, AND MASS SPECTROMETRY.
RX   PubMed=11483588; DOI=10.1074/jbc.C100357200;
RA   Gu Y., Misonou H., Sato T., Dohmae N., Takio K., Ihara Y.;
RT   "Distinct intramembrane cleavage of the beta-amyloid precursor protein
RT   family resembling gamma-secretase-like cleavage of Notch.";
RL   J. Biol. Chem. 276:35235-35238(2001).
RN   [7]
RP   ALTERNATIVE SPLICING.
RX   PubMed=8624099; DOI=10.1111/j.1749-6632.1996.tb34433.x;
RA   Sandbrink R., Masters C.L., Beyreuther K.;
RT   "APP gene family. Alternative splicing generates functionally related
RT   isoforms.";
RL   Ann. N. Y. Acad. Sci. 777:281-287(1996).
RN   [8]
RP   TISSUE SPECIFICITY OF APPICAN.
RX   PubMed=7744833; DOI=10.1074/jbc.270.20.11839;
RA   Shioi J., Pangalos M.N., Ripellino J.A., Vassilacopoulou D.,
RA   Mytilineou C., Margolis R.U., Robakis N.K.;
RT   "The Alzheimer amyloid precursor proteoglycan (appican) is present in
RT   brain and is produced by astrocytes but not by neurons in primary
RT   neural cultures.";
RL   J. Biol. Chem. 270:11839-11844(1995).
RN   [9]
RP   TISSUE SPECIFICITY OF ISOFORMS.
RX   PubMed=8996834;
RA   Sandbrink R., Monning U., Masters C.L., Beyreuther K.;
RT   "Expression of the APP gene family in brain cells, brain development
RT   and aging.";
RL   Gerontology 43:119-131(1997).
RN   [10]
RP   INTERACTION WITH DDB1, AND MUTAGENESIS OF TYR-757; ASN-759 AND
RP   TYR-762.
RX   PubMed=9930726; DOI=10.1046/j.1471-4159.1999.0720549.x;
RA   Watanabe T., Sukegawa J., Tomita S., Iijima K., Oguchi S., Suzuki T.,
RA   Nairn A.C., Greengard P.;
RT   "A 127-kDa protein (UV-DDB) binds to the cytoplasmic domain of the
RT   Alzheimer's amyloid precursor protein.";
RL   J. Neurochem. 72:549-556(1999).
RN   [11]
RP   INTERACTION WITH GNAO1, AND MUTAGENESIS OF 732-HIS-HIS-733.
RX   PubMed=10024358;
RA   Brouillet E., Trembleau A., Galanaud D., Volovitch M., Bouillot C.,
RA   Valenza C., Prochiantz A., Allinquant B.;
RT   "The amyloid precursor protein interacts with Go heterotrimeric
RT   protein within a cell compartment specialized in signal
RT   transduction.";
RL   J. Neurosci. 19:1717-1727(1999).
RN   [12]
RP   COPPER-BINDING.
RX   PubMed=7913895; DOI=10.1016/0014-5793(94)00658-X;
RA   Hesse L., Beher D., Masters C.L., Multhaup G.;
RT   "The beta A4 amyloid precursor protein binding to copper.";
RL   FEBS Lett. 349:109-116(1994).
RN   [13]
RP   CHARACTERISTICS OF APPICAN, AND MUTAGENESIS OF SER-656.
RX   PubMed=7737970; DOI=10.1074/jbc.270.18.10388;
RA   Pangalos M.N., Efthimiopoulos S., Shioi J., Robakis N.K.;
RT   "The chondroitin sulfate attachment site of appican is formed by
RT   splicing out exon 15 of the amyloid precursor gene.";
RL   J. Biol. Chem. 270:10388-10391(1995).
RN   [14]
RP   BETA-AMYLOID METAL-BINDING.
RX   PubMed=10386999; DOI=10.1021/bi990438f;
RA   Huang X., Atwood C.S., Hartshorn M.A., Multhaup G., Goldstein L.E.,
RA   Scarpa R.C., Cuajungco M.P., Gray D.N., Lim J., Moir R.D., Tanzi R.E.,
RA   Bush A.I.;
RT   "The A beta peptide of Alzheimer's disease directly produces hydrogen
RT   peroxide through metal ion reduction.";
RL   Biochemistry 38:7609-7616(1999).
RN   [15]
RP   BETA-AMYLOID ZINC-BINDING.
RX   PubMed=10413512; DOI=10.1021/bi990205o;
RA   Liu S.T., Howlett G., Barrow C.J.;
RT   "Histidine-13 is a crucial residue in the zinc ion-induced aggregation
RT   of the A beta peptide of Alzheimer's disease.";
RL   Biochemistry 38:9373-9378(1999).
RN   [16]
RP   IMPORTANCE OF GLY-704 IN FREE RADICAL PROPAGATION, AND MUTAGENESIS OF
RP   GLY-704.
RX   PubMed=11959460; DOI=10.1016/S0925-4439(01)00097-7;
RA   Kanski J., Varadarajan S., Aksenova M., Butterfield D.A.;
RT   "Role of glycine-33 and methionine-35 in Alzheimer's amyloid beta-
RT   peptide 1-42-associated oxidative stress and neurotoxicity.";
RL   Biochim. Biophys. Acta 1586:190-198(2002).
RN   [17]
RP   PHOSPHORYLATION AT THR-729; SER-730 AND THR-743.
RX   PubMed=9085254;
RA   Oishi M., Nairn A.C., Czernik A.J., Lim G.S., Isohara T., Gandy S.E.,
RA   Greengard P., Suzuki T.;
RT   "The cytoplasmic domain of Alzheimer's amyloid precursor protein is
RT   phosphorylated at Thr654, Ser655, and Thr668 in adult rat brain and
RT   cultured cells.";
RL   Mol. Med. 3:111-123(1997).
RN   [18]
RP   PHOSPHORYLATION AT SER-730.
RX   PubMed=10329382; DOI=10.1006/bbrc.1999.0637;
RA   Isohara T., Horiuchi A., Watanabe T., Ando K., Czernik A.J., Uno I.,
RA   Greengard P., Nairn A.C., Suzuki T.;
RT   "Phosphorylation of the cytoplasmic domain of Alzheimer's beta-amyloid
RT   precursor protein at Ser655 by a novel protein kinase.";
RL   Biochem. Biophys. Res. Commun. 258:300-305(1999).
RN   [19]
RP   PHOSPHORYLATION, INDUCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   THR-743.
RX   PubMed=10341243;
RA   Ando K., Oishi M., Takeda S., Iijima K., Isohara T., Nairn A.C.,
RA   Kirino Y., Greengard P., Suzuki T.;
RT   "Role of phosphorylation of Alzheimer's amyloid precursor protein
RT   during neuronal differentiation.";
RL   J. Neurosci. 19:4421-4427(1999).
RN   [20]
RP   PHOSPHORYLATION AT THR-743.
RX   PubMed=10936190; DOI=10.1046/j.1471-4159.2000.0751085.x;
RA   Iijima K., Ando K., Takeda S., Satoh Y., Seki T., Itohara S.,
RA   Greengard P., Kirino Y., Nairn A.C., Suzuki T.;
RT   "Neuron-specific phosphorylation of Alzheimer's beta-amyloid precursor
RT   protein by cyclin-dependent kinase 5.";
RL   J. Neurochem. 75:1085-1091(2000).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-441, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A.,
RA   Lundby C., Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14
RT   different rat organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
RN   [22]
RP   UBIQUITINATION AT LYS-763, AND MUTAGENESIS OF LYS-763.
RX   PubMed=22847417; DOI=10.1073/pnas.1206786109;
RA   El Ayadi A., Stieren E.S., Barral J.M., Boehning D.;
RT   "Ubiquilin-1 regulates amyloid precursor protein maturation and
RT   degradation by stimulating K63-linked polyubiquitination of lysine
RT   688.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:13416-13421(2012).
RN   [23]
RP   STRUCTURE OF CARBOHYDRATE IN APPICAN.
RX   PubMed=11479316; DOI=10.1074/jbc.M105818200;
RA   Tsuchida K., Shioi J., Yamada S., Boghosian G., Wu A., Cai H.,
RA   Sugahara K., Robakis N.K.;
RT   "Appican, the proteoglycan form of the amyloid precursor protein,
RT   contains chondroitin sulfate E in the repeating disaccharide region
RT   and 4-O-sulfated galactose in the linkage region.";
RL   J. Biol. Chem. 276:37155-37160(2001).
CC   -!- FUNCTION: Functions as a cell surface receptor and performs
CC       physiological functions on the surface of neurons relevant to
CC       neurite growth, neuronal adhesion and axonogenesis. Involved in
CC       cell mobility and transcription regulation through protein-protein
CC       interactions (By similarity). Can promote transcription activation
CC       through binding to APBB1-KAT5 and inhibit Notch signaling through
CC       interaction with Numb (By similarity). Couples to apoptosis-
CC       inducing pathways such as those mediated by G(O) and JIP. Inhibits
CC       G(o) alpha ATPase activity. Acts as a kinesin I membrane receptor,
CC       mediating the axonal transport of beta-secretase and presenilin 1
CC       (By similarity). May be involved in copper homeostasis/oxidative
CC       stress through copper ion reduction. Can regulate neurite
CC       outgrowth through binding to components of the extracellular
CC       matrix such as heparin and collagen I and IV (By similarity). The
CC       splice isoforms that contain the BPTI domain possess protease
CC       inhibitor activity. Induces a AGER-dependent pathway that involves
CC       activation of p38 MAPK, resulting in internalization of amyloid-
CC       beta peptide and leading to mitochondrial dysfunction in cultured
CC       mitochondrial dysfunction in cultured cortical neurons. Provides
CC       Cu(2+) ions for GPC1 which are required for release of nitric
CC       oxide (NO) and subsequent degradation of the heparan sulfate
CC       chains on GPC1 (By similarity). {ECO:0000250}.
CC   -!- FUNCTION: Beta-amyloid peptides are lipophilic metal chelators
CC       with metal-reducing activity. Binds transient metals such as
CC       copper, zinc and iron. Rat and mouse beta-amyloid peptides bind
CC       only weakly transient metals and have little reducing activity due
CC       to substitutions of transient metal chelating residues. Beta-APP42
CC       may activate mononuclear phagocytes in the brain and elicits
CC       inflammatory responses. Promotes both tau aggregation and TPK II-
CC       mediated phosphorylation. Also binds GPC1 in lipid rafts (By
CC       similarity). {ECO:0000250}.
CC   -!- FUNCTION: Appicans elicit adhesion of neural cells to the
CC       extracellular matrix and may regulate neurite outgrowth in the
CC       brain.
CC   -!- FUNCTION: The gamma-CTF peptides as well as the caspase-cleaved
CC       peptides, including C31, are potent enhancers of neuronal
CC       apoptosis. {ECO:0000250}.
CC   -!- FUNCTION: N-APP binds TNFRSF21 triggering caspase activation and
CC       degeneration of both neuronal cell bodies (via caspase-3) and
CC       axons (via caspase-6). {ECO:0000250}.
CC   -!- SUBUNIT: Binds, via its C-terminus, to the PID domain of several
CC       cytoplasmic proteins, including APBB family members, the APBA
CC       family, MAPK8IP1, SHC1 and NUMB and DAB1 (By similarity). Binding
CC       to DAB1 inhibits its serine phosphorylation (By similarity).
CC       Interacts (via NPXY motif) with DAB2 (via PID domain); the
CC       interaction is impaired by tyrosine phosphorylation of the NPXY
CC       motif. Also interacts with GPCR-like protein BPP, FPRL1, APPBP1,
CC       IB1, KNS2 (via its TPR domains), APPBP2 (via BaSS) (By similarity)
CC       and DDB1. In vitro, it binds MAPT via the MT-binding domains (By
CC       similarity). Associates with microtubules in the presence of ATP
CC       and in a kinesin-dependent manner (By similarity). Interacts,
CC       through a C-terminal domain, with GNAO1. Amyloid beta-42 binds
CC       CHRNA7 in hippocampal neurons (By similarity). Beta-amyloid
CC       associates with HADH2 (By similarity). Interacts with CPEB1,
CC       ANKS1B, TNFRSF21 and AGER (By similarity). Interacts with ITM2B.
CC       Interacts with ITM2C. Interacts with IDE. Can form homodimers;
CC       this is promoted by heparin binding (By similarity). Beta-amyloid
CC       protein 40 interacts with S100A9 (By similarity). CTF-alpha
CC       product of APP interacts with GSAP (By similarity). Interacts with
CC       SORL1 (By similarity). Interacts with PLD3 (By similarity).
CC       Interacts with VDAC1 (By similarity). {ECO:0000250,
CC       ECO:0000250|UniProtKB:P05067}.
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000269|PubMed:10341243};
CC       Single-pass type I membrane protein {ECO:0000269|PubMed:10341243}.
CC       Membrane, clathrin-coated pit {ECO:0000269|PubMed:10341243}.
CC       Note=Cell surface protein that rapidly becomes internalized via
CC       clathrin-coated pits. During maturation, the immature APP (N-
CC       glycosylated in the endoplasmic reticulum) moves to the Golgi
CC       complex where complete maturation occurs (O-glycosylated and
CC       sulfated). After alpha-secretase cleavage, soluble APP is released
CC       into the extracellular space and the C-terminal is internalized to
CC       endosomes and lysosomes. Some APP accumulates in secretory
CC       transport vesicles leaving the late Golgi compartment and returns
CC       to the cell surface. Gamma-CTF(59) peptide is located to both the
CC       cytoplasm and nuclei of neurons. It can be translocated to the
CC       nucleus through association with APBB1 (Fe65). Associates with
CC       GPC1 in perinuclear compartments (By similarity). Beta-APP42
CC       associates with FPRL1 at the cell surface and the complex is then
CC       rapidly internalized (By similarity). APP sorts to the basolateral
CC       surface in epithelial cells (By similarity). During neuronal
CC       differentiation, the Thr-742 phosphorylated form is located mainly
CC       in growth cones, moderately in neurites and sparingly in the cell
CC       body. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=8;
CC       Name=APP770;
CC         IsoId=P08592-1; Sequence=Displayed;
CC       Name=APP695;
CC         IsoId=P08592-2; Sequence=VSP_000015, VSP_000016;
CC       Name=L-APP677;
CC         IsoId=P08592-3; Sequence=Not described;
CC         Note=L-isoforms are referred to as appicans.;
CC       Name=L-APP696;
CC         IsoId=P08592-4; Sequence=Not described;
CC         Note=L-isoforms are referred to as appicans.;
CC       Name=APP714;
CC         IsoId=P08592-5; Sequence=Not described;
CC       Name=L-APP733;
CC         IsoId=P08592-6; Sequence=Not described;
CC         Note=L-isoforms are referred to as appicans.;
CC       Name=APP751;
CC         IsoId=P08592-7; Sequence=Not described;
CC       Name=L-APP752;
CC         IsoId=P08592-8; Sequence=Not described;
CC         Note=L-isoforms are referred to as appicans.;
CC   -!- TISSUE SPECIFICITY: In the brain, non-L-APP isoforms are expressed
CC       in neurons, isoform APP695 being the predominant form. In
CC       astrocytes and microglial cells, almost 50% is L-isoform
CC       (appican). {ECO:0000269|PubMed:7744833,
CC       ECO:0000269|PubMed:8996834}.
CC   -!- DEVELOPMENTAL STAGE: From 6 days to 7 months, levels of KPI-
CC       containing isoforms increase in the brain cortex and hippocampus.
CC       Levels of L-APP increase in all brain regions during the same
CC       period, but levels are low compared to non-L-APP isoforms.
CC   -!- INDUCTION: Phosphorylation of mature, glycosylated APP occurs 48-
CC       72 hours after treatment of neuronal cells with nerve growth
CC       factor which correlates with the timing of neurite outgrowth.
CC       {ECO:0000269|PubMed:10341243}.
CC   -!- DOMAIN: The basolateral sorting signal (BaSS) is required for
CC       sorting of membrane proteins to the basolateral surface of
CC       epithelial cells.
CC   -!- DOMAIN: The NPXY sequence motif found in many tyrosine-
CC       phosphorylated proteins is required for the specific binding of
CC       the PID domain. However, additional amino acids either N- or C-
CC       terminal to the NPXY motif are often required for complete
CC       interaction. The PID domain-containing proteins which bind APP
CC       require the YENPTY motif for full interaction. These interactions
CC       are independent of phosphorylation on the terminal tyrosine
CC       residue. The NPXY site is also involved in clathrin-mediated
CC       endocytosis.
CC   -!- PTM: Proteolytically processed under normal cellular conditions.
CC       Cleavage either by alpha-secretase, beta-secretase or theta-
CC       secretase leads to generation and extracellular release of soluble
CC       APP peptides, S-APP-alpha and S-APP-beta, and the retention of
CC       corresponding membrane-anchored C-terminal fragments, C80, C83 and
CC       C99. Subsequent processing of C80 and C83 by gamma-secretase
CC       yields P3 peptides. This is the major secretory pathway and is
CC       non-amyloidogenic. Alternatively, presenilin/nicastrin-mediated
CC       gamma-secretase processing of C99 releases the amyloid beta
CC       proteins, amyloid-beta 40 (Abeta40) and amyloid-beta 42 (Abeta42),
CC       major components of amyloid plaques, and the cytotoxic C-terminal
CC       fragments, gamma-CTF(50), gamma-CTF(57) and gamma-CTF(59) (By
CC       similarity). {ECO:0000250}.
CC   -!- PTM: Proteolytically cleaved by caspases during neuronal
CC       apoptosis. Cleavage at Asp-739 by either caspase-3, -8 or -9
CC       results in the production of the neurotoxic C31 peptide and the
CC       increased production of beta-amyloid peptides. {ECO:0000250}.
CC   -!- PTM: N-glycosylated.
CC   -!- PTM: O-glycosylated. O-linkage of chondroitin sulfate to the L-APP
CC       isoforms produces the APP proteoglycan core proteins, the
CC       appicans. The chondroitin sulfate chain of appicans contains 4-O-
CC       sulfated galactose in the linkage region and chondroitin sulfate E
CC       in the repeated disaccharide region.
CC   -!- PTM: Phosphorylation in the C-terminal on tyrosine, threonine and
CC       serine residues is neuron-specific. Phosphorylation can affect APP
CC       processing, neuronal differentiation and interaction with other
CC       proteins. The Thr-743 phosphorylated form causes a conformational
CC       change which reduces binding of Fe65 family members.
CC       Phosphorylation on Tyr-757 is required for SHC binding.
CC       Phosphorylated in the extracellular domain by casein kinases on
CC       both soluble and membrane-bound APP. This phosphorylation is
CC       inhibited by heparin. {ECO:0000269|PubMed:10329382,
CC       ECO:0000269|PubMed:10341243, ECO:0000269|PubMed:10936190,
CC       ECO:0000269|PubMed:9085254}.
CC   -!- PTM: Extracellular binding and reduction of copper, results in a
CC       corresponding oxidation of Cys-144 and Cys-158, and the formation
CC       of a disulfide bond. {ECO:0000250}.
CC   -!- PTM: Trophic-factor deprivation triggers the cleavage of surface
CC       APP by beta-secretase to release sAPP-beta which is further
CC       cleaved to release an N-terminal fragment of APP (N-APP).
CC       {ECO:0000250}.
CC   -!- PTM: Beta-amyloid peptides are degraded by IDE. {ECO:0000250}.
CC   -!- MASS SPECTROMETRY: Mass=5911.3; Method=MALDI; Range=721-770;
CC       Evidence={ECO:0000269|PubMed:11483588};
CC   -!- MASS SPECTROMETRY: Mass=6024.4; Method=MALDI; Range=720-770;
CC       Evidence={ECO:0000269|PubMed:11483588};
CC   -!- MISCELLANEOUS: Chelation of metal ions, notably copper, iron and
CC       zinc, can induce histidine-bridging between beta-amyloid molecules
CC       resulting in beta-amyloid-metal aggregates. Rat and mouse beta-
CC       amyloid peptides have an arginine residue substituted for the
CC       bridging histidine residue and are thus less capable of forming
CC       amyloid aggregates. Extracellular zinc-binding increases binding
CC       of heparin to APP and inhibits collagen-binding (By similarity).
CC       {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the APP family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 BPTI/Kunitz inhibitor domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00031}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X07648; CAA30488.1; -; mRNA.
DR   EMBL; AF513015; AAM90259.1; -; mRNA.
DR   EMBL; X14066; CAA32229.1; -; mRNA.
DR   PIR; S00550; S00550.
DR   PIR; S03607; S03607.
DR   PIR; S23094; S23094.
DR   RefSeq; NP_062161.1; NM_019288.2. [P08592-1]
DR   RefSeq; XP_006248073.1; XM_006248011.2. [P08592-2]
DR   UniGene; Rn.2104; -.
DR   PDB; 1M7E; X-ray; 2.45 A; D/E/F=755-763.
DR   PDB; 1NMJ; NMR; -; A=672-699.
DR   PDB; 1OQN; X-ray; 2.30 A; C/D=755-763.
DR   PDB; 2LI9; NMR; -; A/B=672-687.
DR   PDBsum; 1M7E; -.
DR   PDBsum; 1NMJ; -.
DR   PDBsum; 1OQN; -.
DR   PDBsum; 2LI9; -.
DR   ProteinModelPortal; P08592; -.
DR   SMR; P08592; 28-189, 287-342, 374-565, 672-699, 739-770.
DR   BioGrid; 248450; 3.
DR   DIP; DIP-6114N; -.
DR   DIP; DIP-618N; -.
DR   DIP; DIP-685N; -.
DR   IntAct; P08592; 7.
DR   MINT; MINT-1521802; -.
DR   STRING; 10116.ENSRNOP00000041613; -.
DR   MEROPS; I02.015; -.
DR   TCDB; 1.C.50.1.1; the amyloid Beta-protein peptide (aBetapp) family.
DR   iPTMnet; P08592; -.
DR   PhosphoSite; P08592; -.
DR   PaxDb; P08592; -.
DR   PRIDE; P08592; -.
DR   Ensembl; ENSRNOT00000048854; ENSRNOP00000041613; ENSRNOG00000006997. [P08592-1]
DR   GeneID; 54226; -.
DR   KEGG; rno:54226; -.
DR   UCSC; RGD:2139; rat. [P08592-1]
DR   CTD; 351; -.
DR   RGD; 2139; App.
DR   eggNOG; KOG3540; Eukaryota.
DR   eggNOG; ENOG410ZTKC; LUCA.
DR   GeneTree; ENSGT00530000063252; -.
DR   HOGENOM; HOG000232190; -.
DR   HOVERGEN; HBG000051; -.
DR   InParanoid; P08592; -.
DR   KO; K04520; -.
DR   OMA; TKTCIGT; -.
DR   OrthoDB; EOG7RNJZP; -.
DR   PhylomeDB; P08592; -.
DR   TreeFam; TF317274; -.
DR   Reactome; R-RNO-114608; Platelet degranulation.
DR   Reactome; R-RNO-1810476; RIP-mediated NFkB activation via ZBP1.
DR   Reactome; R-RNO-3000178; ECM proteoglycans.
DR   Reactome; R-RNO-3134963; DEx/H-box helicases activate type I IFN and inflammatory cytokines production.
DR   Reactome; R-RNO-416476; G alpha (q) signalling events.
DR   Reactome; R-RNO-418594; G alpha (i) signalling events.
DR   Reactome; R-RNO-432720; Lysosome Vesicle Biogenesis.
DR   Reactome; R-RNO-444473; Formyl peptide receptors bind formyl peptides and many other ligands.
DR   Reactome; R-RNO-445989; TAK1 activates NFkB by phosphorylation and activation of IKKs complex.
DR   Reactome; R-RNO-879415; Advanced glycosylation endproduct receptor signaling.
DR   Reactome; R-RNO-933542; TRAF6 mediated NF-kB activation.
DR   EvolutionaryTrace; P08592; -.
DR   NextBio; 610648; -.
DR   PRO; PR:P08592; -.
DR   Proteomes; UP000002494; Chromosome 11.
DR   ExpressionAtlas; P08592; baseline and differential.
DR   Genevisible; P08592; RN.
DR   GO; GO:0045177; C:apical part of cell; IEA:Ensembl.
DR   GO; GO:0097449; C:astrocyte projection; IDA:RGD.
DR   GO; GO:0030424; C:axon; ISS:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IDA:AgBase.
DR   GO; GO:0005911; C:cell-cell junction; IEA:Ensembl.
DR   GO; GO:0035253; C:ciliary rootlet; IEA:Ensembl.
DR   GO; GO:0005905; C:coated pit; IEA:UniProtKB-SubCell.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0043198; C:dendritic shaft; IEA:Ensembl.
DR   GO; GO:0043197; C:dendritic spine; IEA:Ensembl.
DR   GO; GO:0005768; C:endosome; IEA:Ensembl.
DR   GO; GO:0030134; C:ER to Golgi transport vesicle; IEA:Ensembl.
DR   GO; GO:0070062; C:extracellular exosome; IEA:Ensembl.
DR   GO; GO:0005615; C:extracellular space; IDA:RGD.
DR   GO; GO:0005794; C:Golgi apparatus; ISS:UniProtKB.
DR   GO; GO:0030426; C:growth cone; IDA:RGD.
DR   GO; GO:1990812; C:growth cone filopodium; IDA:RGD.
DR   GO; GO:1990761; C:growth cone lamellipodium; IDA:RGD.
DR   GO; GO:0016021; C:integral component of membrane; ISS:UniProtKB.
DR   GO; GO:0044304; C:main axon; IDA:RGD.
DR   GO; GO:0045121; C:membrane raft; IEA:Ensembl.
DR   GO; GO:0031594; C:neuromuscular junction; IEA:Ensembl.
DR   GO; GO:0043005; C:neuron projection; IDA:RGD.
DR   GO; GO:0005641; C:nuclear envelope lumen; IEA:Ensembl.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:RGD.
DR   GO; GO:0043235; C:receptor complex; IEA:Ensembl.
DR   GO; GO:0005791; C:rough endoplasmic reticulum; IDA:RGD.
DR   GO; GO:0005790; C:smooth endoplasmic reticulum; IEA:Ensembl.
DR   GO; GO:0051233; C:spindle midzone; IEA:Ensembl.
DR   GO; GO:0043195; C:terminal bouton; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0003677; F:DNA binding; ISS:UniProtKB.
DR   GO; GO:0070851; F:growth factor receptor binding; IPI:RGD.
DR   GO; GO:0008201; F:heparin binding; IEA:UniProtKB-KW.
DR   GO; GO:0016504; F:peptidase activator activity; IDA:RGD.
DR   GO; GO:0004867; F:serine-type endopeptidase inhibitor activity; IEA:UniProtKB-KW.
DR   GO; GO:0046914; F:transition metal ion binding; IEA:InterPro.
DR   GO; GO:0008344; P:adult locomotory behavior; ISS:UniProtKB.
DR   GO; GO:0019731; P:antibacterial humoral response; IDA:UniProtKB.
DR   GO; GO:0019732; P:antifungal humoral response; IDA:UniProtKB.
DR   GO; GO:0008088; P:axon cargo transport; ISS:UniProtKB.
DR   GO; GO:0016199; P:axon midline choice point recognition; ISS:UniProtKB.
DR   GO; GO:0007409; P:axonogenesis; ISS:UniProtKB.
DR   GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW.
DR   GO; GO:0006878; P:cellular copper ion homeostasis; ISS:UniProtKB.
DR   GO; GO:0071320; P:cellular response to cAMP; IEP:RGD.
DR   GO; GO:1990090; P:cellular response to nerve growth factor stimulus; IEP:RGD.
DR   GO; GO:0071874; P:cellular response to norepinephrine stimulus; IMP:RGD.
DR   GO; GO:0008203; P:cholesterol metabolic process; IEA:Ensembl.
DR   GO; GO:0048669; P:collateral sprouting in absence of injury; ISS:UniProtKB.
DR   GO; GO:0050829; P:defense response to Gram-negative bacterium; IDA:UniProtKB.
DR   GO; GO:0050830; P:defense response to Gram-positive bacterium; IDA:UniProtKB.
DR   GO; GO:0016358; P:dendrite development; ISS:UniProtKB.
DR   GO; GO:0006897; P:endocytosis; ISS:UniProtKB.
DR   GO; GO:0030198; P:extracellular matrix organization; ISS:UniProtKB.
DR   GO; GO:0030900; P:forebrain development; IEA:Ensembl.
DR   GO; GO:0045087; P:innate immune response; IDA:UniProtKB.
DR   GO; GO:0035235; P:ionotropic glutamate receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0007626; P:locomotory behavior; ISS:UniProtKB.
DR   GO; GO:0007617; P:mating behavior; ISS:UniProtKB.
DR   GO; GO:0006378; P:mRNA polyadenylation; ISS:UniProtKB.
DR   GO; GO:0045665; P:negative regulation of neuron differentiation; IEA:Ensembl.
DR   GO; GO:0050885; P:neuromuscular process controlling balance; IEA:Ensembl.
DR   GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0031175; P:neuron projection development; ISS:UniProtKB.
DR   GO; GO:0016322; P:neuron remodeling; ISS:UniProtKB.
DR   GO; GO:0007219; P:Notch signaling pathway; IEA:UniProtKB-KW.
DR   GO; GO:0010971; P:positive regulation of G2/M transition of mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:0045931; P:positive regulation of mitotic cell cycle; ISS:UniProtKB.
DR   GO; GO:0010952; P:positive regulation of peptidase activity; IDA:GOC.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0007176; P:regulation of epidermal growth factor-activated receptor activity; ISS:UniProtKB.
DR   GO; GO:0040014; P:regulation of multicellular organism growth; ISS:UniProtKB.
DR   GO; GO:0043393; P:regulation of protein binding; IEA:Ensembl.
DR   GO; GO:0050803; P:regulation of synapse structure or activity; ISS:UniProtKB.
DR   GO; GO:0006417; P:regulation of translation; ISS:UniProtKB.
DR   GO; GO:0010288; P:response to lead ion; IEP:RGD.
DR   GO; GO:0006979; P:response to oxidative stress; IEA:Ensembl.
DR   GO; GO:0001878; P:response to yeast; IDA:UniProtKB.
DR   GO; GO:0051563; P:smooth endoplasmic reticulum calcium ion homeostasis; IEA:Ensembl.
DR   GO; GO:0001967; P:suckling behavior; IEA:Ensembl.
DR   GO; GO:0051124; P:synaptic growth at neuromuscular junction; IEA:Ensembl.
DR   GO; GO:0008542; P:visual learning; ISS:UniProtKB.
DR   Gene3D; 3.30.1490.140; -; 1.
DR   Gene3D; 3.90.570.10; -; 1.
DR   Gene3D; 4.10.230.10; -; 1.
DR   Gene3D; 4.10.410.10; -; 1.
DR   InterPro; IPR008155; Amyloid_glyco.
DR   InterPro; IPR013803; Amyloid_glyco_Abeta.
DR   InterPro; IPR011178; Amyloid_glyco_Cu-bd.
DR   InterPro; IPR024329; Amyloid_glyco_E2_domain.
DR   InterPro; IPR008154; Amyloid_glyco_extra.
DR   InterPro; IPR019744; Amyloid_glyco_extracell_CS.
DR   InterPro; IPR015849; Amyloid_glyco_heparin-bd.
DR   InterPro; IPR019745; Amyloid_glyco_intracell_CS.
DR   InterPro; IPR028866; APP.
DR   InterPro; IPR019543; APP_amyloid_C.
DR   InterPro; IPR002223; Kunitz_BPTI.
DR   InterPro; IPR020901; Prtase_inh_Kunz-CS.
DR   PANTHER; PTHR23103:SF7; PTHR23103:SF7; 2.
DR   Pfam; PF10515; APP_amyloid; 1.
DR   Pfam; PF12924; APP_Cu_bd; 1.
DR   Pfam; PF12925; APP_E2; 1.
DR   Pfam; PF02177; APP_N; 1.
DR   Pfam; PF03494; Beta-APP; 1.
DR   Pfam; PF00014; Kunitz_BPTI; 1.
DR   PRINTS; PR00203; AMYLOIDA4.
DR   PRINTS; PR00759; BASICPTASE.
DR   PRINTS; PR00204; BETAAMYLOID.
DR   SMART; SM00006; A4_EXTRA; 1.
DR   SMART; SM00131; KU; 1.
DR   SUPFAM; SSF109843; SSF109843; 1.
DR   SUPFAM; SSF56491; SSF56491; 1.
DR   SUPFAM; SSF57362; SSF57362; 1.
DR   SUPFAM; SSF89811; SSF89811; 1.
DR   PROSITE; PS00319; A4_EXTRA; 1.
DR   PROSITE; PS00320; A4_INTRA; 1.
DR   PROSITE; PS00280; BPTI_KUNITZ_1; 1.
DR   PROSITE; PS50279; BPTI_KUNITZ_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Amyloid; Apoptosis; Cell adhesion;
KW   Coated pit; Complete proteome; Copper; Direct protein sequencing;
KW   Disulfide bond; Endocytosis; Glycoprotein; Heparin-binding; Iron;
KW   Isopeptide bond; Membrane; Metal-binding; Notch signaling pathway;
KW   Phosphoprotein; Protease inhibitor; Proteoglycan; Reference proteome;
KW   Serine protease inhibitor; Signal; Transmembrane; Transmembrane helix;
KW   Ubl conjugation; Zinc.
FT   SIGNAL        1     17       {ECO:0000250}.
FT   CHAIN        18    770       Amyloid beta A4 protein.
FT                                /FTId=PRO_0000000159.
FT   CHAIN        18    687       Soluble APP-alpha. {ECO:0000250}.
FT                                /FTId=PRO_0000000160.
FT   CHAIN        18    671       Soluble APP-beta. {ECO:0000255}.
FT                                /FTId=PRO_0000000161.
FT   CHAIN        18    286       N-APP. {ECO:0000250}.
FT                                /FTId=PRO_0000381971.
FT   CHAIN       672    770       C99. {ECO:0000255}.
FT                                /FTId=PRO_0000000162.
FT   CHAIN       672    713       Beta-amyloid protein 42. {ECO:0000250}.
FT                                /FTId=PRO_0000000163.
FT   CHAIN       672    711       Beta-amyloid protein 40. {ECO:0000250}.
FT                                /FTId=PRO_0000000164.
FT   CHAIN       688    770       C83. {ECO:0000250}.
FT                                /FTId=PRO_0000000165.
FT   PEPTIDE     688    713       P3(42). {ECO:0000250}.
FT                                /FTId=PRO_0000000166.
FT   PEPTIDE     688    711       P3(40). {ECO:0000250}.
FT                                /FTId=PRO_0000000167.
FT   CHAIN       691    770       C80.
FT                                /FTId=PRO_0000384579.
FT   CHAIN       712    770       Gamma-secretase C-terminal fragment 59.
FT                                /FTId=PRO_0000000168.
FT   CHAIN       714    770       Gamma-secretase C-terminal fragment 57.
FT                                /FTId=PRO_0000000169.
FT   CHAIN       721    770       Gamma-secretase C-terminal fragment 50.
FT                                /FTId=PRO_0000000170.
FT   CHAIN       740    770       C31. {ECO:0000250}.
FT                                /FTId=PRO_0000000171.
FT   TOPO_DOM     18    699       Extracellular. {ECO:0000255}.
FT   TRANSMEM    700    723       Helical. {ECO:0000255}.
FT   TOPO_DOM    724    770       Cytoplasmic. {ECO:0000250}.
FT   DOMAIN      291    341       BPTI/Kunitz inhibitor.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00031}.
FT   REGION       96    110       Heparin-binding. {ECO:0000250}.
FT   REGION      135    155       Copper-binding. {ECO:0000250}.
FT   REGION      181    188       Zinc-binding. {ECO:0000250}.
FT   REGION      391    423       Heparin-binding. {ECO:0000250}.
FT   REGION      491    522       Heparin-binding. {ECO:0000250}.
FT   REGION      523    540       Collagen-binding. {ECO:0000250}.
FT   REGION      732    751       Interaction with G(o)-alpha.
FT   MOTIF       724    734       Basolateral sorting signal.
FT                                {ECO:0000250}.
FT   MOTIF       759    762       NPXY motif; contains endocytosis signal.
FT   COMPBIAS    230    260       Asp/Glu-rich (acidic).
FT   COMPBIAS    274    280       Poly-Thr.
FT   METAL       147    147       Copper 1. {ECO:0000250}.
FT   METAL       151    151       Copper 1. {ECO:0000250}.
FT   METAL       168    168       Copper 1. {ECO:0000250}.
FT   METAL       677    677       Copper or zinc 2. {ECO:0000250}.
FT   METAL       685    685       Copper or zinc 2. {ECO:0000250}.
FT   SITE        144    144       Required for Cu(2+) reduction.
FT                                {ECO:0000250}.
FT   SITE        301    302       Reactive bond. {ECO:0000250}.
FT   SITE        671    672       Cleavage; by beta-secretase.
FT                                {ECO:0000250}.
FT   SITE        672    673       Cleavage; by caspase-6.
FT   SITE        687    688       Cleavage; by alpha-secretase.
FT                                {ECO:0000250}.
FT   SITE        690    691       Cleavage; by theta-secretase.
FT                                {ECO:0000250}.
FT   SITE        711    712       Cleavage; by gamma-secretase; site 1.
FT                                {ECO:0000250}.
FT   SITE        713    714       Cleavage; by gamma-secretase; site 2.
FT                                {ECO:0000250}.
FT   SITE        720    721       Cleavage; by gamma-secretase; site 3.
FT                                {ECO:0000250}.
FT   SITE        739    740       Cleavage; by caspase-6, caspase-8 or
FT                                caspase-9. {ECO:0000250}.
FT   MOD_RES     198    198       Phosphoserine; by CK2. {ECO:0000250}.
FT   MOD_RES     206    206       Phosphoserine; by CK1. {ECO:0000250}.
FT   MOD_RES     441    441       Phosphoserine.
FT                                {ECO:0000244|PubMed:22673903}.
FT   MOD_RES     497    497       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P05067}.
FT   MOD_RES     729    729       Phosphothreonine.
FT                                {ECO:0000269|PubMed:9085254}.
FT   MOD_RES     730    730       Phosphoserine; by APP-kinase I.
FT                                {ECO:0000269|PubMed:10329382,
FT                                ECO:0000269|PubMed:9085254}.
FT   MOD_RES     743    743       Phosphothreonine; by CDK5 and MAPK10.
FT                                {ECO:0000269|PubMed:10936190,
FT                                ECO:0000269|PubMed:9085254}.
FT   MOD_RES     757    757       Phosphotyrosine; by ABL1. {ECO:0000250}.
FT   CARBOHYD    542    542       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    571    571       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    656    656       O-linked (Xyl...) (chondroitin sulfate);
FT                                in L-APP isoforms.
FT   DISULFID     38     62       {ECO:0000255|PROSITE-ProRule:PRU00031}.
FT   DISULFID     73    117       {ECO:0000255|PROSITE-ProRule:PRU00031}.
FT   DISULFID     98    105       {ECO:0000255|PROSITE-ProRule:PRU00031}.
FT   DISULFID    133    187       {ECO:0000255|PROSITE-ProRule:PRU00031}.
FT   DISULFID    144    174       {ECO:0000255|PROSITE-ProRule:PRU00031}.
FT   DISULFID    158    186       {ECO:0000255|PROSITE-ProRule:PRU00031}.
FT   DISULFID    291    341       {ECO:0000255|PROSITE-ProRule:PRU00031}.
FT   DISULFID    300    324       {ECO:0000255|PROSITE-ProRule:PRU00031}.
FT   DISULFID    316    337       {ECO:0000255|PROSITE-ProRule:PRU00031}.
FT   CROSSLNK    763    763       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:22847417}.
FT   VAR_SEQ     289    289       E -> V (in isoform APP695).
FT                                {ECO:0000303|PubMed:2900758}.
FT                                /FTId=VSP_000015.
FT   VAR_SEQ     290    364       Missing (in isoform APP695).
FT                                {ECO:0000303|PubMed:2900758}.
FT                                /FTId=VSP_000016.
FT   MUTAGEN     656    656       S->A: No chondroitin sulfate linkage to
FT                                isoform L-APP733.
FT                                {ECO:0000269|PubMed:7737970}.
FT   MUTAGEN     704    704       G->V: Little oxidized neuronal proteins.
FT                                Scarce beta-APP42 peptide aggregation. No
FT                                neurotoxicity.
FT                                {ECO:0000269|PubMed:11959460}.
FT   MUTAGEN     732    733       HH->GL,GP: Almost complete loss of
FT                                binding to GNAO1. No inhibition of GTPase
FT                                activity. {ECO:0000269|PubMed:10024358}.
FT   MUTAGEN     743    743       T->A: No effect on neurite growth and
FT                                maturation.
FT                                {ECO:0000269|PubMed:10341243}.
FT   MUTAGEN     743    743       T->E: Inhibits neurite growth and
FT                                maturation.
FT                                {ECO:0000269|PubMed:10341243}.
FT   MUTAGEN     757    757       Y->G: No DBB1 binding.
FT                                {ECO:0000269|PubMed:9930726}.
FT   MUTAGEN     759    759       N->A: Some DBB1 binding.
FT                                {ECO:0000269|PubMed:9930726}.
FT   MUTAGEN     762    762       Y->A: Some DBB1 binding.
FT                                {ECO:0000269|PubMed:9930726}.
FT   MUTAGEN     763    763       K->R: Loss of ubiquitination.
FT                                {ECO:0000269|PubMed:22847417}.
FT   TURN        674    676       {ECO:0000244|PDB:2LI9}.
FT   TURN        679    686       {ECO:0000244|PDB:1NMJ}.
FT   HELIX       687    695       {ECO:0000244|PDB:1NMJ}.
SQ   SEQUENCE   770 AA;  86704 MW;  C26C9D6BB2D929A7 CRC64;
     MLPSLALLLL AAWTVRALEV PTDGNAGLLA EPQIAMFCGK LNMHMNVQNG KWESDPSGTK
     TCIGTKEGIL QYCQEVYPEL QITNVVEANQ PVTIQNWCKR GRKQCKTHTH IVIPYRCLVG
     EFVSDALLVP DKCKFLHQER MDVCETHLHW HTVAKETCSE KSTNLHDYGM LLPCGIDKFR
     GVEFVCCPLA EESDSIDSAD AEEDDSDVWW GGADTDYADG GEDKVVEVAE EEEVADVEEE
     EAEDDEDVED GDEVEEEAEE PYEEATERTT SIATTTTTTT ESVEEVVREV CSEQAETGPC
     RAMISRWYFD VTEGKCAPFF YGGCGGNRNN FDTEEYCMAV CGSVSSQSLL KTTSEPLPQD
     PVKLPTTAAS TPDAVDKYLE TPGDENEHAH FQKAKERLEA KHRERMSQVM REWEEAERQA
     KNLPKADKKA VIQHFQEKVE SLEQEAANER QQLVETHMAR VEAMLNDRRR LALENYITAL
     QAVPPRPHHV FNMLKKYVRA EQKDRQHTLK HFEHVRMVDP KKAAQIRSQV MTHLRVIYER
     MNQSLSLLYN VPAVAEEIQD EVDELLQKEQ NYSDDVLANM ISEPRISYGN DALMPSLTET
     KTTVELLPVN GEFSLDDLQP WHPFGVDSVP ANTENEVEPV DARPAADRGL TTRPGSGLTN
     IKTEEISEVK MDAEFGHDSG FEVRHQKLVF FAEDVGSNKG AIIGLMVGGV VIATVIVITL
     VMLKKKQYTS IHHGVVEVDA AVTPEERHLS KMQQNGYENP TYKFFEQMQN
//
ID   ACE_HUMAN               Reviewed;        1306 AA.
AC   P12821; B0LPF0; B4DXI3; E7EU16; P22966; Q53YX9; Q59GY8; Q7M4L4;
DT   01-OCT-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1989, sequence version 1.
DT   20-JAN-2016, entry version 203.
DE   RecName: Full=Angiotensin-converting enzyme;
DE            Short=ACE;
DE            EC=3.2.1.-;
DE            EC=3.4.15.1;
DE   AltName: Full=Dipeptidyl carboxypeptidase I;
DE   AltName: Full=Kininase II;
DE   AltName: CD_antigen=CD143;
DE   Contains:
DE     RecName: Full=Angiotensin-converting enzyme, soluble form;
DE   Flags: Precursor;
GN   Name=ACE; Synonyms=DCP, DCP1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SOMATIC-1).
RX   PubMed=2849100; DOI=10.1073/pnas.85.24.9386;
RA   Soubrier F., Alhenc-Gelas F., Hubert C., Allegrini J., John M.,
RA   Tregear G., Corbol P.;
RT   "Two putative active centers in human angiotensin I-converting enzyme
RT   revealed by molecular cloning.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:9386-9390(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TESTIS-SPECIFIC).
RX   PubMed=2547653; DOI=10.1016/0014-5793(89)80897-X;
RA   Lattion A.L., Soubrier F., Allegrini J., Hubert C., Corvol P.,
RA   Alhenc-Gelas F.;
RT   "The testicular transcript of the angiotensin I-converting enzyme
RT   encodes for the ancestral, non-duplicated form of the enzyme.";
RL   FEBS Lett. 252:99-104(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TESTIS-SPECIFIC).
RX   PubMed=2554286; DOI=10.1073/pnas.86.20.7741;
RA   Ehlers M.R.W., Fox E.A., Strydom D.J., Riordan J.F.;
RT   "Molecular cloning of human testicular angiotensin-converting enzyme:
RT   the testis isozyme is identical to the C-terminal half of endothelial
RT   angiotensin-converting enzyme.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:7741-7745(1989).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-261; TRP-561 AND
RP   SER-1286.
RX   PubMed=10319862; DOI=10.1038/8760;
RA   Rieder M.J., Taylor S.L., Clark A.G., Nickerson D.A.;
RT   "Sequence variation in the human angiotensin converting enzyme.";
RL   Nat. Genet. 22:59-62(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-1239 (ISOFORM SOMATIC-1).
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R.,
RA   Gnerre S., Goldstein S., Grafham D.V., Grocock R., Hafez N.,
RA   Hagopian D.S., Hart E., Norman C.H., Humphray S., Jaffe D.B.,
RA   Jones M., Kamal M., Khodiyar V.K., LaButti K., Laird G., Lehoczky J.,
RA   Liu X., Lokyitsang T., Loveland J., Lui A., Macdonald P., Major J.E.,
RA   Matthews L., Mauceli E., McCarroll S.A., Mihalev A.H., Mudge J.,
RA   Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., Schwartz D.C.,
RA   Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in
RT   the human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [9]
RP   PROTEIN SEQUENCE OF 30-46.
RC   TISSUE=Lung;
RX   PubMed=2558109;
RA   Takeuchi K., Shimizu T., Ohishi N., Seyama Y., Takaku F.,
RA   Yotsumoto H.;
RT   "Purification of human lung angiotensin-converting enzyme by high-
RT   performance liquid chromatography: properties and N-terminal amino
RT   acid sequence.";
RL   J. Biochem. 106:442-445(1989).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1114-1306 (ISOFORM SOMATIC-2), AND
RP   ALTERNATIVE SPLICING.
RC   TISSUE=Umbilical vein endothelial cell;
RX   PubMed=9642152; DOI=10.1006/bbrc.1998.8813;
RA   Sugimura K., Tian X.-L., Hoffmann S., Ganten D., Bader M.;
RT   "Alternative splicing of the mRNA coding for the human endothelial
RT   angiotensin-converting enzyme: a new mechanism for solubilization.";
RL   Biochem. Biophys. Res. Commun. 247:466-472(1998).
RN   [11]
RP   ZINC-BINDING.
RX   PubMed=1649623; DOI=10.1021/bi00243a012;
RA   Ehlers M.R.W., Riordan J.F.;
RT   "Angiotensin-converting enzyme: zinc- and inhibitor-binding
RT   stoichiometries of the somatic and testis isozymes.";
RL   Biochemistry 30:7118-7126(1991).
RN   [12]
RP   DISULFIDE BONDS.
RX   PubMed=8755737; DOI=10.1021/bi960243x;
RA   Sturrock E.D., Yu X.C., Wu Z., Biemann K., Riordan J.F.;
RT   "Assignment of free and disulfide-bonded cysteine residues in testis
RT   angiotensin-converting enzyme: functional implications.";
RL   Biochemistry 35:9560-9566(1996).
RN   [13]
RP   GLYCOSYLATION AT ASN-38; ASN-54; ASN-111; ASN-146; ASN-509; ASN-695;
RP   ASN-714; ASN-760; ASN-942 AND ASN-1191, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=9013598; DOI=10.1074/jbc.272.6.3511;
RA   Yu X.C., Sturrock E.D., Wu Z., Biemann K., Ehlers M.R.W.,
RA   Riordan J.F.;
RT   "Identification of N-linked glycosylation sites in human testis
RT   angiotensin-converting enzyme and expression of an active
RT   deglycosylated form.";
RL   J. Biol. Chem. 272:3511-3519(1997).
RN   [14]
RP   CLEAVAGE SITE, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=10769174; DOI=10.1042/0264-6021:3470711;
RA   Woodman Z.L., Oppong S.Y., Cook S., Hooper N.M., Schwager S.L.U.,
RA   Brandt W.F., Ehlers M.R.W., Sturrock E.D.;
RT   "Shedding of somatic angiotensin-converting enzyme (ACE) is
RT   inefficient compared with testis ACE despite cleavage at identical
RT   stalk sites.";
RL   Biochem. J. 347:711-718(2000).
RN   [15]
RP   TISSUE SPECIFICITY.
RX   PubMed=10969042; DOI=10.1161/01.RES.87.5.e1;
RA   Donoghue M., Hsieh F., Baronas E., Godbout K., Gosselin M.,
RA   Stagliano N., Donovan M., Woolf B., Robison K., Jeyaseelan R.,
RA   Breitbart R.E., Acton S.;
RT   "A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2)
RT   converts angiotensin I to angiotensin 1-9.";
RL   Circ. Res. 87:E1-E9(2000).
RN   [16]
RP   TISSUE SPECIFICITY.
RX   PubMed=10924499; DOI=10.1074/jbc.M002615200;
RA   Tipnis S.R., Hooper N.M., Hyde R., Karran E., Christie G.,
RA   Turner A.J.;
RT   "A human homolog of angiotensin-converting enzyme. Cloning and
RT   functional expression as a captopril-insensitive carboxypeptidase.";
RL   J. Biol. Chem. 275:33238-33243(2000).
RN   [17]
RP   BIOPHYSICOCHEMICAL PROPERTIES, AND CHARACTERIZATION OF VARIANT
RP   LEU-1228.
RX   PubMed=11076943; DOI=10.1074/jbc.M007706200;
RA   Eyries M., Michaud A., Deinum J., Agrapart M., Chomilier J.,
RA   Kramers C., Soubrier F.;
RT   "Increased shedding of angiotensin-converting enzyme by a mutation
RT   identified in the stalk region.";
RL   J. Biol. Chem. 276:5525-5532(2001).
RN   [18]
RP   PHOSPHORYLATION AT SER-1299, AND MUTAGENESIS OF SER-1299.
RX   PubMed=12386153; DOI=10.1161/01.RES.0000038114.17939.C8;
RA   Kohlstedt K., Shoghi F., Mueller-Esterl W., Busse R., Fleming I.;
RT   "CK2 phosphorylates the angiotensin-converting enzyme and regulates
RT   its retention in the endothelial cell plasma membrane.";
RL   Circ. Res. 91:749-756(2002).
RN   [19]
RP   TISSUE SPECIFICITY.
RX   PubMed=12459472; DOI=10.1016/S0014-5793(02)03640-2;
RA   Harmer D., Gilbert M., Borman R., Clark K.L.;
RT   "Quantitative mRNA expression profiling of ACE 2, a novel homologue of
RT   angiotensin converting enzyme.";
RL   FEBS Lett. 532:107-110(2002).
RN   [20]
RP   BIOPHYSICOCHEMICAL PROPERTIES, AND CLEAVAGE SITE.
RX   PubMed=12542396; DOI=10.1042/BJ20021842;
RA   Gordon K., Redelinghuys P., Schwager S.L.U., Ehlers M.R.W.,
RA   Papageorgiou A.C., Natesh R., Acharya K.R., Sturrock E.D.;
RT   "Deglycosylation, processing and crystallization of human testis
RT   angiotensin-converting enzyme.";
RL   Biochem. J. 371:437-442(2003).
RN   [21]
RP   INDUCTION.
RX   PubMed=15151696; DOI=10.1186/1741-7015-2-19;
RA   Goulter A.B., Goddard M.J., Allen J.C., Clark K.L.;
RT   "ACE2 gene expression is up-regulated in the human failing heart.";
RL   BMC Med. 2:19-19(2004).
RN   [22]
RP   TISSUE SPECIFICITY, AND INDUCTION.
RX   PubMed=15671045; DOI=10.1093/eurheartj/ehi114;
RA   Burrell L.M., Risvanis J., Kubota E., Dean R.G., MacDonald P.S.,
RA   Lu S., Tikellis C., Grant S.L., Lew R.A., Smith A.I., Cooper M.E.,
RA   Johnston C.I.;
RT   "Myocardial infarction increases ACE2 expression in rat and humans.";
RL   Eur. Heart J. 26:369-375(2005).
RN   [23]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-509; ASN-695 AND ASN-714.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [24]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-111; ASN-445 AND ASN-714.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 642-1230, AND X-RAY
RP   CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 642-1230 IN COMPLEX WITH
RP   LISINOPRIL.
RX   PubMed=12540854; DOI=10.1038/nature01370;
RA   Natesh R., Schwager S.L.U., Sturrock E.D., Acharya K.R.;
RT   "Crystal structure of the human angiotensin-converting enzyme-
RT   lisinopril complex.";
RL   Nature 421:551-554(2003).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 642-1230 IN COMPLEX WITH
RP   ENALAPRILAT, AND X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 642-1230 IN
RP   COMPLEX WITH CAPTOPRIL.
RX   PubMed=15236580; DOI=10.1021/bi049480n;
RA   Natesh R., Schwager S.L.U., Evans H.R., Sturrock E.D., Acharya K.R.;
RT   "Structural details on the binding of antihypertensive drugs captopril
RT   and enalaprilat to human testicular angiotensin I-converting enzyme.";
RL   Biochemistry 43:8718-8724(2004).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 30-641 IN COMPLEX WITH
RP   LISINOPRIL; ZINC AND CHLORIDE IONS, AND GLYCOSYLATION AT ASN-54;
RP   ASN-74; ASN-146; ASN-318 AND ASN-509.
RX   PubMed=16476442; DOI=10.1016/j.jmb.2006.01.048;
RA   Corradi H.R., Schwager S.L.U., Nchinda A.T., Sturrock E.D.,
RA   Acharya K.R.;
RT   "Crystal structure of the N domain of human somatic angiotensin I-
RT   converting enzyme provides a structural basis for domain-specific
RT   inhibitor design.";
RL   J. Mol. Biol. 357:964-974(2006).
RN   [29]
RP   INVOLVEMENT IN MVCD3.
RX   PubMed=10099885;
RA   Vleming L.J., van der Pijl J.W., Lemkes H.H.P.J., Westendorp R.G.J.,
RA   Maassen J.A., Daha M.R., van Es L.A., van Kooten C.;
RT   "The DD genotype of the ACE gene polymorphism is associated with
RT   progression of diabetic nephropathy to end stage renal failure in
RT   IDDM.";
RL   Clin. Nephrol. 51:133-140(1999).
RN   [30]
RP   VARIANTS THR-1018; VAL-1051; GLN-1279; SER-1286 AND PRO-1296.
RX   PubMed=10391210; DOI=10.1038/10297;
RA   Halushka M.K., Fan J.-B., Bentley K., Hsie L., Shen N., Weder A.,
RA   Cooper R., Lipshutz R., Chakravarti A.;
RT   "Patterns of single-nucleotide polymorphisms in candidate genes for
RT   blood-pressure homeostasis.";
RL   Nat. Genet. 22:239-247(1999).
RN   [31]
RP   VARIANT LEU-1228, AND ASSOCIATION WITH BENIGN SERUM INCREASE OF
RP   ANGIOTENSIN-CONVERTING ENZYME.
RX   PubMed=11551873; DOI=10.1161/hc3601.095932;
RA   Kramers C., Danilov S.M., Deinum J., Balyasnikova I.V.,
RA   Scharenborg N., Looman M., Boomsma F., de Keijzer M.H., van Duijn C.,
RA   Martin S., Soubrier F., Adema G.J.;
RT   "Point mutation in the stalk of angiotensin-converting enzyme causes a
RT   dramatic increase in serum angiotensin-converting enzyme but no
RT   cardiovascular disease.";
RL   Circulation 104:1236-1240(2001).
RN   [32]
RP   VARIANT LEU-1228, AND ASSOCIATION WITH BENIGN SERUM INCREASE OF
RP   ANGIOTENSIN-CONVERTING ENZYME.
RX   PubMed=14694062; DOI=10.1212/01.WNL.0000098990.12845.DA;
RA   Linnebank M., Kesper K., Jeub M., Urbach H., Wuellner U.,
RA   Klockgether T., Schmidt S.;
RT   "Hereditary elevation of angiotensin converting enzyme suggesting
RT   neurosarcoidosis.";
RL   Neurology 61:1819-1820(2003).
RN   [33]
RP   INVOLVEMENT IN SUSCEPTIBILITY TO ISCHSTR.
RX   PubMed=15534175; DOI=10.1001/archneur.61.11.1652;
RA   Casas J.P., Hingorani A.D., Bautista L.E., Sharma P.;
RT   "Meta-analysis of genetic studies in ischemic stroke: thirty-two genes
RT   involving approximately 18,000 cases and 58,000 controls.";
RL   Arch. Neurol. 61:1652-1661(2004).
RN   [34]
RP   INVOLVEMENT IN SUSCEPTIBILITY TO ICH.
RX   PubMed=15277638; DOI=10.1212/01.WNL.0000130200.12993.0C;
RA   Slowik A., Turaj W., Dziedzic T., Haefele A., Pera J., Malecki M.T.,
RA   Glodzik-Sobanska L., Szermer P., Figlewicz D.A., Szczudlik A.;
RT   "DD genotype of ACE gene is a risk factor for intracerebral
RT   hemorrhage.";
RL   Neurology 63:359-361(2004).
RN   [35]
RP   INVOLVEMENT IN RTD, AND VARIANT ARG-354.
RX   PubMed=16116425; DOI=10.1038/ng1623;
RA   Gribouval O., Gonzales M., Neuhaus T., Aziza J., Bieth E., Laurent N.,
RA   Bouton J.M., Feuillet F., Makni S., Ben Amar H., Laube G.,
RA   Delezoide A.-L., Bouvier R., Dijoud F., Ollagnon-Roman E., Roume J.,
RA   Joubert M., Antignac C., Gubler M.-C.;
RT   "Mutations in genes in the renin-angiotensin system are associated
RT   with autosomal recessive renal tubular dysgenesis.";
RL   Nat. Genet. 37:964-968(2005).
RN   [36]
RP   VARIANT ASN-295.
RX   PubMed=25787250; DOI=10.1073/pnas.1503696112;
RA   Cromer M.K., Choi M., Nelson-Williams C., Fonseca A.L., Kunstman J.W.,
RA   Korah R.M., Overton J.D., Mane S., Kenney B., Malchoff C.D.,
RA   Stalberg P., Akerstroem G., Westin G., Hellman P., Carling T.,
RA   Bjoerklund P., Lifton R.P.;
RT   "Neomorphic effects of recurrent somatic mutations in Yin Yang 1 in
RT   insulin-producing adenomas.";
RL   Proc. Natl. Acad. Sci. U.S.A. 112:4062-4067(2015).
CC   -!- FUNCTION: Converts angiotensin I to angiotensin II by release of
CC       the terminal His-Leu, this results in an increase of the
CC       vasoconstrictor activity of angiotensin. Also able to inactivate
CC       bradykinin, a potent vasodilator. Has also a glycosidase activity
CC       which releases GPI-anchored proteins from the membrane by cleaving
CC       the mannose linkage in the GPI moiety.
CC   -!- CATALYTIC ACTIVITY: Release of a C-terminal dipeptide,
CC       oligopeptide-|-Xaa-Yaa, when Xaa is not Pro, and Yaa is neither
CC       Asp nor Glu. Thus, conversion of angiotensin I to angiotensin II,
CC       with increase in vasoconstrictor activity, but no action on
CC       angiotensin II.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC       Note=Binds 2 Zn(2+) ions per subunit.;
CC   -!- COFACTOR: Isoform Testis-specific:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC       Note=Isoform Testis-specific only binds 1 Zn(2+) ion per subunit.;
CC   -!- COFACTOR:
CC       Name=chloride; Xref=ChEBI:CHEBI:17996;
CC       Note=Binds 3 chloride ions per subunit.;
CC   -!- ENZYME REGULATION: Strongly activated by chloride. Specifically
CC       inhibited by lisinopril, captopril and enalaprilat.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=2.51 mM for Hip-His-Leu {ECO:0000269|PubMed:11076943,
CC         ECO:0000269|PubMed:12542396};
CC   -!- SUBCELLULAR LOCATION: Angiotensin-converting enzyme, soluble form:
CC       Secreted.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein. Cytoplasm {ECO:0000250}. Note=Detected in both cell
CC       membrane and cytoplasm in neurons. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=Somatic-1;
CC         IsoId=P12821-1; Sequence=Displayed;
CC       Name=Somatic-2; Synonyms=Soluble;
CC         IsoId=P12821-2; Sequence=VSP_029932, VSP_029933;
CC         Note=Incomplete sequence.;
CC       Name=Testis-specific; Synonyms=ACE-T;
CC         IsoId=P12821-3, P22966-1;
CC         Sequence=VSP_035120, VSP_035121;
CC         Note=Variant in position: 32:S->P (in dbSNP:rs4317). Variant in
CC         position: 49:S->G (in dbSNP:rs4318).;
CC       Name=4;
CC         IsoId=P12821-4; Sequence=VSP_054836, VSP_054837;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed, with highest levels in
CC       lung, kidney, heart, gastrointestinal system and prostate. Isoform
CC       Testis-specific is expressed in spermatocytes and adult testis.
CC       {ECO:0000269|PubMed:10924499, ECO:0000269|PubMed:10969042,
CC       ECO:0000269|PubMed:12459472, ECO:0000269|PubMed:15671045}.
CC   -!- INDUCTION: Up-regulated in failing heart.
CC       {ECO:0000269|PubMed:15151696, ECO:0000269|PubMed:15671045}.
CC   -!- PTM: Phosphorylated by CK2 on Ser-1299; which allows membrane
CC       retention. {ECO:0000269|PubMed:12386153}.
CC   -!- DISEASE: Ischemic stroke (ISCHSTR) [MIM:601367]: A stroke is an
CC       acute neurologic event leading to death of neural tissue of the
CC       brain and resulting in loss of motor, sensory and/or cognitive
CC       function. Ischemic strokes, resulting from vascular occlusion, is
CC       considered to be a highly complex disease consisting of a group of
CC       heterogeneous disorders with multiple genetic and environmental
CC       risk factors. {ECO:0000269|PubMed:15534175}. Note=Disease
CC       susceptibility is associated with variations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Renal tubular dysgenesis (RTD) [MIM:267430]: Autosomal
CC       recessive severe disorder of renal tubular development
CC       characterized by persistent fetal anuria and perinatal death,
CC       probably due to pulmonary hypoplasia from early-onset
CC       oligohydramnios (the Potter phenotype).
CC       {ECO:0000269|PubMed:16116425}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Microvascular complications of diabetes 3 (MVCD3)
CC       [MIM:612624]: Pathological conditions that develop in numerous
CC       tissues and organs as a consequence of diabetes mellitus. They
CC       include diabetic retinopathy, diabetic nephropathy leading to end-
CC       stage renal disease, and diabetic neuropathy. Diabetic retinopathy
CC       remains the major cause of new-onset blindness among diabetic
CC       adults. It is characterized by vascular permeability and increased
CC       tissue ischemia and angiogenesis. {ECO:0000269|PubMed:10099885}.
CC       Note=Disease susceptibility is associated with variations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Intracerebral hemorrhage (ICH) [MIM:614519]: A
CC       pathological condition characterized by bleeding into one or both
CC       cerebral hemispheres including the basal ganglia and the cerebral
CC       cortex. It is often associated with hypertension and
CC       craniocerebral trauma. Intracerebral bleeding is a common cause of
CC       stroke. {ECO:0000269|PubMed:15277638}. Note=Disease susceptibility
CC       is associated with variations affecting the gene represented in
CC       this entry.
CC   -!- MISCELLANEOUS: Inhibitors of ACE are commonly used to treat
CC       hypertension and some types of renal and cardiac dysfunction.
CC   -!- MISCELLANEOUS: The glycosidase activity probably uses different
CC       active site residues than the metalloprotease activity.
CC   -!- SIMILARITY: Belongs to the peptidase M2 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAD92208.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=ACE";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J04144; AAA51684.1; -; mRNA.
DR   EMBL; M26657; AAA60611.1; -; mRNA.
DR   EMBL; X16295; CAA34362.1; -; mRNA.
DR   EMBL; AF118569; AAD28560.1; -; Genomic_DNA.
DR   EMBL; AY436326; AAR03504.1; -; Genomic_DNA.
DR   EMBL; AK301988; BAG63395.1; -; mRNA.
DR   EMBL; EU332840; ABY87529.1; -; Genomic_DNA.
DR   EMBL; AB208971; BAD92208.1; ALT_INIT; mRNA.
DR   EMBL; AC113554; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS11637.1; -. [P12821-1]
DR   CCDS; CCDS45755.1; -. [P12821-3]
DR   CCDS; CCDS54155.1; -. [P12821-4]
DR   PIR; A31759; A31759.
DR   PIR; PW0053; PW0053.
DR   PIR; S05238; S05238.
DR   RefSeq; NP_000780.1; NM_000789.3. [P12821-1]
DR   RefSeq; NP_001171528.1; NM_001178057.1. [P12821-4]
DR   RefSeq; NP_690043.1; NM_152830.2. [P12821-3]
DR   UniGene; Hs.298469; -.
DR   PDB; 1O86; X-ray; 2.00 A; A=642-1230.
DR   PDB; 1O8A; X-ray; 2.00 A; A=642-1230.
DR   PDB; 1UZE; X-ray; 1.82 A; A=642-1230.
DR   PDB; 1UZF; X-ray; 2.00 A; A=642-1230.
DR   PDB; 2C6F; X-ray; 3.01 A; A/B=30-641.
DR   PDB; 2C6N; X-ray; 3.00 A; A/B=30-641.
DR   PDB; 2IUL; X-ray; 2.01 A; A=642-1232.
DR   PDB; 2IUX; X-ray; 2.80 A; A=642-1232.
DR   PDB; 2OC2; X-ray; 2.25 A; A=642-1232.
DR   PDB; 2XY9; X-ray; 1.97 A; A=645-1228.
DR   PDB; 2XYD; X-ray; 2.15 A; A/B=30-639.
DR   PDB; 2YDM; X-ray; 2.44 A; A=642-1230.
DR   PDB; 3BKK; X-ray; 2.17 A; A=642-1232.
DR   PDB; 3BKL; X-ray; 2.18 A; A=642-1232.
DR   PDB; 3L3N; X-ray; 2.30 A; A=642-1232.
DR   PDB; 3NXQ; X-ray; 1.99 A; A/B=30-658.
DR   PDB; 4APH; X-ray; 1.99 A; A=642-1230.
DR   PDB; 4APJ; X-ray; 2.60 A; A=642-1230.
DR   PDB; 4BXK; X-ray; 2.20 A; A/B=30-657.
DR   PDB; 4BZR; X-ray; 1.84 A; A=642-1230.
DR   PDB; 4BZS; X-ray; 2.10 A; A/B=30-657.
DR   PDB; 4C2N; X-ray; 2.59 A; A=642-1230.
DR   PDB; 4C2O; X-ray; 1.80 A; A=642-1230.
DR   PDB; 4C2P; X-ray; 1.99 A; A=642-1230.
DR   PDB; 4C2Q; X-ray; 2.40 A; A=642-1230.
DR   PDB; 4C2R; X-ray; 2.30 A; A=642-1230.
DR   PDB; 4CA5; X-ray; 1.85 A; A=642-1230.
DR   PDB; 4CA6; X-ray; 1.91 A; A/B=30-639.
DR   PDB; 4UFA; X-ray; 1.80 A; A/B=30-657.
DR   PDB; 4UFB; X-ray; 1.80 A; A/B/C/D=30-657.
DR   PDBsum; 1O86; -.
DR   PDBsum; 1O8A; -.
DR   PDBsum; 1UZE; -.
DR   PDBsum; 1UZF; -.
DR   PDBsum; 2C6F; -.
DR   PDBsum; 2C6N; -.
DR   PDBsum; 2IUL; -.
DR   PDBsum; 2IUX; -.
DR   PDBsum; 2OC2; -.
DR   PDBsum; 2XY9; -.
DR   PDBsum; 2XYD; -.
DR   PDBsum; 2YDM; -.
DR   PDBsum; 3BKK; -.
DR   PDBsum; 3BKL; -.
DR   PDBsum; 3L3N; -.
DR   PDBsum; 3NXQ; -.
DR   PDBsum; 4APH; -.
DR   PDBsum; 4APJ; -.
DR   PDBsum; 4BXK; -.
DR   PDBsum; 4BZR; -.
DR   PDBsum; 4BZS; -.
DR   PDBsum; 4C2N; -.
DR   PDBsum; 4C2O; -.
DR   PDBsum; 4C2P; -.
DR   PDBsum; 4C2Q; -.
DR   PDBsum; 4C2R; -.
DR   PDBsum; 4CA5; -.
DR   PDBsum; 4CA6; -.
DR   PDBsum; 4UFA; -.
DR   PDBsum; 4UFB; -.
DR   ProteinModelPortal; P12821; -.
DR   SMR; P12821; 30-641, 645-1230.
DR   BioGrid; 108004; 6.
DR   IntAct; P12821; 1.
DR   MINT; MINT-127316; -.
DR   STRING; 9606.ENSP00000290866; -.
DR   BindingDB; P12821; -.
DR   ChEMBL; CHEMBL1808; -.
DR   DrugBank; DB00542; Benazepril.
DR   DrugBank; DB00616; Candoxatril.
DR   DrugBank; DB01197; Captopril.
DR   DrugBank; DB01340; Cilazapril.
DR   DrugBank; DB00584; Enalapril.
DR   DrugBank; DB00492; Fosinopril.
DR   DrugBank; DB00722; Lisinopril.
DR   DrugBank; DB00691; Moexipril.
DR   DrugBank; DB00790; Perindopril.
DR   DrugBank; DB00881; Quinapril.
DR   DrugBank; DB00178; Ramipril.
DR   DrugBank; DB01180; Rescinnamine.
DR   DrugBank; DB01348; Spirapril.
DR   DrugBank; DB00519; Trandolapril.
DR   GuidetoPHARMACOLOGY; 1613; -.
DR   MEROPS; M02.001; -.
DR   iPTMnet; P12821; -.
DR   PhosphoSite; P12821; -.
DR   BioMuta; ACE; -.
DR   DMDM; 113045; -.
DR   MaxQB; P12821; -.
DR   PaxDb; P12821; -.
DR   PeptideAtlas; P12821; -.
DR   PRIDE; P12821; -.
DR   Ensembl; ENST00000290863; ENSP00000290863; ENSG00000159640. [P12821-3]
DR   Ensembl; ENST00000290866; ENSP00000290866; ENSG00000159640. [P12821-1]
DR   Ensembl; ENST00000413513; ENSP00000392247; ENSG00000159640. [P12821-4]
DR   GeneID; 1636; -.
DR   KEGG; hsa:1636; -.
DR   UCSC; uc002jau.2; human. [P12821-1]
DR   UCSC; uc002jav.2; human. [P12821-3]
DR   CTD; 1636; -.
DR   GeneCards; ACE; -.
DR   HGNC; HGNC:2707; ACE.
DR   HPA; CAB002426; -.
DR   HPA; CAB002921; -.
DR   HPA; HPA029298; -.
DR   MalaCards; ACE; -.
DR   MIM; 106180; gene+phenotype.
DR   MIM; 267430; phenotype.
DR   MIM; 601367; phenotype.
DR   MIM; 612624; phenotype.
DR   MIM; 614519; phenotype.
DR   neXtProt; NX_P12821; -.
DR   Orphanet; 97369; Renal tubular dysgenesis of genetic origin.
DR   PharmGKB; PA139; -.
DR   eggNOG; KOG3690; Eukaryota.
DR   eggNOG; ENOG410XPJ3; LUCA.
DR   GeneTree; ENSGT00520000055576; -.
DR   HOGENOM; HOG000007838; -.
DR   HOVERGEN; HBG000264; -.
DR   InParanoid; P12821; -.
DR   KO; K01283; -.
DR   OMA; VTMEQLF; -.
DR   OrthoDB; EOG76HQ13; -.
DR   PhylomeDB; P12821; -.
DR   TreeFam; TF312861; -.
DR   BioCyc; MetaCyc:HS08412-MONOMER; -.
DR   BRENDA; 3.4.15.1; 2681.
DR   Reactome; R-HSA-2022377; Metabolism of Angiotensinogen to Angiotensins.
DR   SABIO-RK; P12821; -.
DR   SignaLink; P12821; -.
DR   EvolutionaryTrace; P12821; -.
DR   GeneWiki; Angiotensin-converting_enzyme; -.
DR   GenomeRNAi; 1636; -.
DR   NextBio; 6722; -.
DR   PMAP-CutDB; P12821; -.
DR   PRO; PR:P12821; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; P12821; -.
DR   CleanEx; HS_ACE; -.
DR   ExpressionAtlas; P12821; baseline and differential.
DR   Genevisible; P12821; HS.
DR   GO; GO:0005768; C:endosome; IDA:BHF-UCL.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005764; C:lysosome; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0003779; F:actin binding; IDA:UniProtKB.
DR   GO; GO:0031711; F:bradykinin receptor binding; IPI:BHF-UCL.
DR   GO; GO:0004180; F:carboxypeptidase activity; IEA:UniProtKB-KW.
DR   GO; GO:0031404; F:chloride ion binding; IDA:BHF-UCL.
DR   GO; GO:0008144; F:drug binding; IDA:BHF-UCL.
DR   GO; GO:0004175; F:endopeptidase activity; IDA:UniProtKB.
DR   GO; GO:0008238; F:exopeptidase activity; IDA:BHF-UCL.
DR   GO; GO:0008237; F:metallopeptidase activity; IDA:UniProtKB.
DR   GO; GO:0051019; F:mitogen-activated protein kinase binding; IPI:BHF-UCL.
DR   GO; GO:0031434; F:mitogen-activated protein kinase kinase binding; IPI:BHF-UCL.
DR   GO; GO:0008241; F:peptidyl-dipeptidase activity; IDA:UniProtKB.
DR   GO; GO:0008240; F:tripeptidyl-peptidase activity; IDA:BHF-UCL.
DR   GO; GO:0008270; F:zinc ion binding; IDA:BHF-UCL.
DR   GO; GO:0002005; P:angiotensin catabolic process in blood; IC:UniProtKB.
DR   GO; GO:0002003; P:angiotensin maturation; TAS:Reactome.
DR   GO; GO:0002474; P:antigen processing and presentation of peptide antigen via MHC class I; TAS:BHF-UCL.
DR   GO; GO:0050482; P:arachidonic acid secretion; IDA:BHF-UCL.
DR   GO; GO:0050435; P:beta-amyloid metabolic process; IDA:BHF-UCL.
DR   GO; GO:0001974; P:blood vessel remodeling; IC:BHF-UCL.
DR   GO; GO:0071838; P:cell proliferation in bone marrow; ISS:BHF-UCL.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0060047; P:heart contraction; ISS:BHF-UCL.
DR   GO; GO:0060218; P:hematopoietic stem cell differentiation; IC:BHF-UCL.
DR   GO; GO:0042447; P:hormone catabolic process; IDA:BHF-UCL.
DR   GO; GO:0001822; P:kidney development; IMP:BHF-UCL.
DR   GO; GO:0032943; P:mononuclear cell proliferation; IC:BHF-UCL.
DR   GO; GO:1903597; P:negative regulation of gap junction assembly; ISS:BHF-UCL.
DR   GO; GO:0002446; P:neutrophil mediated immunity; ISS:BHF-UCL.
DR   GO; GO:0043171; P:peptide catabolic process; IDA:BHF-UCL.
DR   GO; GO:2000170; P:positive regulation of peptidyl-cysteine S-nitrosylation; ISS:BHF-UCL.
DR   GO; GO:1900086; P:positive regulation of peptidyl-tyrosine autophosphorylation; ISS:BHF-UCL.
DR   GO; GO:0061098; P:positive regulation of protein tyrosine kinase activity; ISS:BHF-UCL.
DR   GO; GO:0060177; P:regulation of angiotensin metabolic process; IDA:BHF-UCL.
DR   GO; GO:0008217; P:regulation of blood pressure; ISS:BHF-UCL.
DR   GO; GO:1902033; P:regulation of hematopoietic stem cell proliferation; ISS:BHF-UCL.
DR   GO; GO:0002019; P:regulation of renal output by angiotensin; IC:BHF-UCL.
DR   GO; GO:0014910; P:regulation of smooth muscle cell migration; ISS:BHF-UCL.
DR   GO; GO:0003081; P:regulation of systemic arterial blood pressure by renin-angiotensin; IC:UniProtKB.
DR   GO; GO:0019229; P:regulation of vasoconstriction; IC:UniProtKB.
DR   GO; GO:0042312; P:regulation of vasodilation; IC:BHF-UCL.
DR   GO; GO:0007283; P:spermatogenesis; ISS:BHF-UCL.
DR   InterPro; IPR001548; Peptidase_M2.
DR   PANTHER; PTHR10514; PTHR10514; 1.
DR   Pfam; PF01401; Peptidase_M2; 2.
DR   PRINTS; PR00791; PEPDIPTASEA.
DR   PROSITE; PS00142; ZINC_PROTEASE; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Carboxypeptidase; Cell membrane;
KW   Complete proteome; Cytoplasm; Direct protein sequencing;
KW   Disulfide bond; Glycoprotein; Hydrolase; Membrane; Metal-binding;
KW   Metalloprotease; Phosphoprotein; Polymorphism; Protease;
KW   Reference proteome; Repeat; Secreted; Signal; Transmembrane;
KW   Transmembrane helix; Zinc.
FT   SIGNAL        1     29       {ECO:0000269|PubMed:2558109}.
FT   CHAIN        30   1306       Angiotensin-converting enzyme.
FT                                /FTId=PRO_0000028530.
FT   CHAIN        30   1232       Angiotensin-converting enzyme, soluble
FT                                form.
FT                                /FTId=PRO_0000028531.
FT   PROPEP     1233   1306       Removed in soluble form.
FT                                /FTId=PRO_0000028532.
FT   TOPO_DOM     30   1256       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1257   1277       Helical. {ECO:0000255}.
FT   TOPO_DOM   1278   1306       Cytoplasmic. {ECO:0000255}.
FT   REGION       30    630       Peptidase M2 1.
FT   REGION      631   1232       Peptidase M2 2.
FT   ACT_SITE    391    391       1.
FT   ACT_SITE    989    989       2.
FT   METAL       390    390       Zinc 1; catalytic.
FT                                {ECO:0000269|PubMed:16476442}.
FT   METAL       394    394       Zinc 1; catalytic.
FT                                {ECO:0000269|PubMed:16476442}.
FT   METAL       418    418       Zinc 1; catalytic.
FT                                {ECO:0000269|PubMed:16476442}.
FT   METAL       988    988       Zinc 2; catalytic.
FT                                {ECO:0000269|PubMed:16476442}.
FT   METAL       992    992       Zinc 2; catalytic.
FT                                {ECO:0000269|PubMed:16476442}.
FT   METAL      1016   1016       Zinc 2; catalytic.
FT                                {ECO:0000269|PubMed:16476442}.
FT   BINDING     231    231       Chloride 1.
FT   BINDING     529    529       Chloride 1.
FT   BINDING     791    791       Chloride 2.
FT   BINDING     829    829       Chloride 3.
FT   BINDING    1090   1090       Chloride 2.
FT   BINDING    1094   1094       Chloride 2.
FT   BINDING    1127   1127       Chloride 3.
FT   SITE       1225   1225       Not glycosylated.
FT   MOD_RES    1299   1299       Phosphoserine.
FT                                {ECO:0000269|PubMed:12386153}.
FT   CARBOHYD     38     38       N-linked (GlcNAc...).
FT                                {ECO:0000305|PubMed:9013598}.
FT   CARBOHYD     54     54       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16476442,
FT                                ECO:0000269|PubMed:9013598}.
FT   CARBOHYD     74     74       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16476442}.
FT   CARBOHYD    111    111       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:9013598}.
FT   CARBOHYD    146    146       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16476442,
FT                                ECO:0000269|PubMed:9013598}.
FT   CARBOHYD    160    160       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    318    318       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16476442}.
FT   CARBOHYD    445    445       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    509    509       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:16476442,
FT                                ECO:0000269|PubMed:9013598}.
FT   CARBOHYD    677    677       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    695    695       N-linked (GlcNAc...) (complex).
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:9013598}.
FT   CARBOHYD    714    714       N-linked (GlcNAc...) (complex).
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:9013598}.
FT   CARBOHYD    760    760       N-linked (GlcNAc...); partial.
FT                                {ECO:0000269|PubMed:9013598}.
FT   CARBOHYD    942    942       N-linked (GlcNAc...); partial.
FT                                {ECO:0000269|PubMed:9013598}.
FT   CARBOHYD   1191   1191       N-linked (GlcNAc...); partial.
FT                                {ECO:0000269|PubMed:9013598}.
FT   DISULFID    157    165       {ECO:0000269|PubMed:8755737}.
FT   DISULFID    757    763       {ECO:0000269|PubMed:8755737}.
FT   DISULFID    957    975       {ECO:0000269|PubMed:8755737}.
FT   DISULFID   1143   1155       {ECO:0000269|PubMed:8755737}.
FT   VAR_SEQ       1    641       MGAASGRRGPGLLLPLPLLLLLPPQPALALDPGLQPGNFSA
FT                                DEAGAQLFAQSYNSSAEQVLFQSVAASWAHDTNITAENARR
FT                                QEEAALLSQEFAEAWGQKAKELYEPIWQNFTDPQLRRIIGA
FT                                VRTLGSANLPLAKRQQYNALLSNMSRIYSTAKVCLPNKTAT
FT                                CWSLDPDLTNILASSRSYAMLLFAWEGWHNAAGIPLKPLYE
FT                                DFTALSNEAYKQDGFTDTGAYWRSWYNSPTFEDDLEHLYQQ
FT                                LEPLYLNLHAFVRRALHRRYGDRYINLRGPIPAHLLGDMWA
FT                                QSWENIYDMVVPFPDKPNLDVTSTMLQQGWNATHMFRVAEE
FT                                FFTSLELSPMPPEFWEGSMLEKPADGREVVCHASAWDFYNR
FT                                KDFRIKQCTRVTMDQLSTVHHEMGHIQYYLQYKDLPVSLRR
FT                                GANPGFHEAIGDVLALSVSTPEHLHKIGLLDRVTNDTESDI
FT                                NYLLKMALEKIAFLPFGYLVDQWRWGVFSGRTPPSRYNFDW
FT                                WYLRTKYQGICPPVTRNETHFDAGAKFHVPNVTPYIRYFVS
FT                                FVLQFQFHEALCKEAGYEGPLHQCDIYRSTKAGAKLRKVLQ
FT                                AGSSRPWQEVLKDMVGLDALDAQPLLKYFQPVTQWLQEQNQ
FT                                QNGEVLGWPEYQWHPPLPDNYPEGID -> MGQGWATAGLP
FT                                SLLFLLLCYGHPLLVPSQEASQQVTVTHGTSSQATTSSQTT
FT                                THQATAHQTSAQSPN (in isoform 4).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_054836.
FT   VAR_SEQ       1    574       Missing (in isoform Testis-specific).
FT                                {ECO:0000303|PubMed:2547653,
FT                                ECO:0000303|PubMed:2554286}.
FT                                /FTId=VSP_035120.
FT   VAR_SEQ     575    641       AGSSRPWQEVLKDMVGLDALDAQPLLKYFQPVTQWLQEQNQ
FT                                QNGEVLGWPEYQWHPPLPDNYPEGID -> MGQGWATAGLP
FT                                SLLFLLLCYGHPLLVPSQEASQQVTVTHGTSSQATTSSQTT
FT                                THQATAHQTSAQSPN (in isoform Testis-
FT                                specific). {ECO:0000303|PubMed:2547653,
FT                                ECO:0000303|PubMed:2554286}.
FT                                /FTId=VSP_035121.
FT   VAR_SEQ    1128   1168       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_054837.
FT   VAR_SEQ    1137   1145       QFHEALCQA -> HPFSQHTAA (in isoform
FT                                Somatic-2). {ECO:0000303|PubMed:9642152}.
FT                                /FTId=VSP_029932.
FT   VAR_SEQ    1146   1306       Missing (in isoform Somatic-2).
FT                                {ECO:0000303|PubMed:9642152}.
FT                                /FTId=VSP_029933.
FT   VARIANT     154    154       A -> T (in dbSNP:rs13306087).
FT                                /FTId=VAR_029139.
FT   VARIANT     183    183       A -> T (in dbSNP:rs12720754).
FT                                /FTId=VAR_029140.
FT   VARIANT     244    244       Y -> C (in dbSNP:rs3730025).
FT                                /FTId=VAR_023430.
FT   VARIANT     260    260       R -> C (in dbSNP:rs4302).
FT                                /FTId=VAR_054000.
FT   VARIANT     260    260       R -> L (in dbSNP:rs4303).
FT                                /FTId=VAR_054001.
FT   VARIANT     261    261       A -> S (in dbSNP:rs4303).
FT                                {ECO:0000269|PubMed:10319862}.
FT                                /FTId=VAR_011707.
FT   VARIANT     295    295       D -> N. {ECO:0000269|PubMed:25787250}.
FT                                /FTId=VAR_074173.
FT   VARIANT     351    351       P -> L (in dbSNP:rs2229839).
FT                                /FTId=VAR_023431.
FT   VARIANT     354    354       G -> R (in dbSNP:rs56394458).
FT                                {ECO:0000269|PubMed:16116425}.
FT                                /FTId=VAR_035434.
FT   VARIANT     379    379       R -> Q (in dbSNP:rs13306085).
FT                                /FTId=VAR_029141.
FT   VARIANT     524    524       V -> A (in dbSNP:rs12720746).
FT                                /FTId=VAR_029142.
FT   VARIANT     561    561       R -> W (in dbSNP:rs4314).
FT                                {ECO:0000269|PubMed:10319862}.
FT                                /FTId=VAR_011708.
FT   VARIANT     592    592       D -> G (in dbSNP:rs12709426).
FT                                /FTId=VAR_020053.
FT   VARIANT     828    828       M -> T (in dbSNP:rs13306091).
FT                                /FTId=VAR_034602.
FT   VARIANT     916    916       T -> M (in dbSNP:rs3730043).
FT                                /FTId=VAR_023432.
FT   VARIANT    1018   1018       I -> T (in dbSNP:rs4976).
FT                                {ECO:0000269|PubMed:10391210}.
FT                                /FTId=VAR_014189.
FT   VARIANT    1051   1051       F -> V (in dbSNP:rs4977).
FT                                {ECO:0000269|PubMed:10391210}.
FT                                /FTId=VAR_014190.
FT   VARIANT    1187   1187       T -> M (in dbSNP:rs12709442).
FT                                /FTId=VAR_023433.
FT   VARIANT    1228   1228       P -> L (no effect on activity; increases
FT                                secretion; rate of solubilization is 2.5-
FT                                fold higher than wild-type).
FT                                {ECO:0000269|PubMed:11076943,
FT                                ECO:0000269|PubMed:11551873,
FT                                ECO:0000269|PubMed:14694062}.
FT                                /FTId=VAR_023434.
FT   VARIANT    1279   1279       R -> Q (in dbSNP:rs4980).
FT                                {ECO:0000269|PubMed:10391210}.
FT                                /FTId=VAR_014191.
FT   VARIANT    1286   1286       R -> S (in dbSNP:rs4364).
FT                                {ECO:0000269|PubMed:10319862,
FT                                ECO:0000269|PubMed:10391210}.
FT                                /FTId=VAR_011709.
FT   VARIANT    1296   1296       Q -> P (in dbSNP:rs4981).
FT                                {ECO:0000269|PubMed:10391210}.
FT                                /FTId=VAR_014192.
FT   MUTAGEN    1299   1299       S->A: Abolishes phosphorylation and
FT                                decreases membrane retention.
FT                                {ECO:0000269|PubMed:12386153}.
FT   CONFLICT     35     35       Q -> E (in Ref. 9; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT     42     42       D -> R (in Ref. 9; AA sequence).
FT                                {ECO:0000305}.
FT   HELIX        32     34       {ECO:0000244|PDB:4UFA}.
FT   HELIX        43     72       {ECO:0000244|PDB:4UFA}.
FT   HELIX        77    105       {ECO:0000244|PDB:4UFA}.
FT   TURN        106    108       {ECO:0000244|PDB:4UFA}.
FT   HELIX       109    111       {ECO:0000244|PDB:4UFA}.
FT   HELIX       115    124       {ECO:0000244|PDB:4UFA}.
FT   HELIX       128    131       {ECO:0000244|PDB:4UFA}.
FT   HELIX       134    153       {ECO:0000244|PDB:4UFA}.
FT   STRAND      155    157       {ECO:0000244|PDB:4UFA}.
FT   STRAND      159    161       {ECO:0000244|PDB:4BZS}.
FT   STRAND      165    167       {ECO:0000244|PDB:4UFA}.
FT   TURN        168    170       {ECO:0000244|PDB:4UFA}.
FT   HELIX       171    178       {ECO:0000244|PDB:4UFA}.
FT   HELIX       182    216       {ECO:0000244|PDB:4UFA}.
FT   TURN        217    219       {ECO:0000244|PDB:4UFA}.
FT   HELIX       223    229       {ECO:0000244|PDB:4UFA}.
FT   HELIX       236    266       {ECO:0000244|PDB:4UFA}.
FT   TURN        268    270       {ECO:0000244|PDB:4UFA}.
FT   STRAND      281    284       {ECO:0000244|PDB:4UFA}.
FT   HELIX       291    293       {ECO:0000244|PDB:4UFA}.
FT   HELIX       294    297       {ECO:0000244|PDB:4UFA}.
FT   HELIX       309    315       {ECO:0000244|PDB:4UFA}.
FT   HELIX       319    332       {ECO:0000244|PDB:4UFA}.
FT   HELIX       340    345       {ECO:0000244|PDB:4UFA}.
FT   STRAND      352    354       {ECO:0000244|PDB:4CA6}.
FT   STRAND      362    365       {ECO:0000244|PDB:4UFA}.
FT   STRAND      367    370       {ECO:0000244|PDB:4UFA}.
FT   STRAND      372    375       {ECO:0000244|PDB:4UFA}.
FT   HELIX       382    401       {ECO:0000244|PDB:4UFA}.
FT   HELIX       406    408       {ECO:0000244|PDB:4UFA}.
FT   HELIX       414    429       {ECO:0000244|PDB:4UFA}.
FT   HELIX       431    436       {ECO:0000244|PDB:4UFA}.
FT   HELIX       447    461       {ECO:0000244|PDB:4UFA}.
FT   HELIX       464    479       {ECO:0000244|PDB:4UFA}.
FT   HELIX       485    487       {ECO:0000244|PDB:4UFA}.
FT   HELIX       488    500       {ECO:0000244|PDB:4UFA}.
FT   HELIX       514    517       {ECO:0000244|PDB:4UFA}.
FT   TURN        519    524       {ECO:0000244|PDB:4UFA}.
FT   HELIX       528    547       {ECO:0000244|PDB:4UFA}.
FT   HELIX       554    556       {ECO:0000244|PDB:4UFA}.
FT   HELIX       563    575       {ECO:0000244|PDB:4UFA}.
FT   HELIX       581    589       {ECO:0000244|PDB:4UFA}.
FT   HELIX       597    616       {ECO:0000244|PDB:4UFA}.
FT   TURN        634    637       {ECO:0000244|PDB:4CA6}.
FT   HELIX       646    675       {ECO:0000244|PDB:4C2O}.
FT   HELIX       680    704       {ECO:0000244|PDB:4C2O}.
FT   HELIX       709    711       {ECO:0000244|PDB:4C2O}.
FT   HELIX       715    724       {ECO:0000244|PDB:4C2O}.
FT   HELIX       728    731       {ECO:0000244|PDB:4C2O}.
FT   HELIX       734    753       {ECO:0000244|PDB:4C2O}.
FT   STRAND      755    757       {ECO:0000244|PDB:4C2O}.
FT   STRAND      759    761       {ECO:0000244|PDB:1UZE}.
FT   STRAND      763    765       {ECO:0000244|PDB:4C2O}.
FT   TURN        766    768       {ECO:0000244|PDB:4C2O}.
FT   HELIX       769    776       {ECO:0000244|PDB:4C2O}.
FT   HELIX       780    793       {ECO:0000244|PDB:4C2O}.
FT   HELIX       795    799       {ECO:0000244|PDB:4C2O}.
FT   HELIX       802    815       {ECO:0000244|PDB:4C2O}.
FT   HELIX       821    827       {ECO:0000244|PDB:4C2O}.
FT   HELIX       834    844       {ECO:0000244|PDB:4C2O}.
FT   HELIX       846    864       {ECO:0000244|PDB:4C2O}.
FT   HELIX       866    868       {ECO:0000244|PDB:4C2O}.
FT   STRAND      879    882       {ECO:0000244|PDB:4C2O}.
FT   HELIX       889    891       {ECO:0000244|PDB:4C2O}.
FT   HELIX       892    895       {ECO:0000244|PDB:4C2O}.
FT   HELIX       906    912       {ECO:0000244|PDB:4C2O}.
FT   HELIX       917    930       {ECO:0000244|PDB:4C2O}.
FT   HELIX       938    943       {ECO:0000244|PDB:4C2O}.
FT   STRAND      945    947       {ECO:0000244|PDB:4APJ}.
FT   STRAND      950    952       {ECO:0000244|PDB:4BZR}.
FT   STRAND      960    963       {ECO:0000244|PDB:4C2O}.
FT   STRAND      965    968       {ECO:0000244|PDB:4C2O}.
FT   STRAND      970    973       {ECO:0000244|PDB:4C2O}.
FT   HELIX       980    998       {ECO:0000244|PDB:4C2O}.
FT   TURN        999   1001       {ECO:0000244|PDB:4C2O}.
FT   HELIX      1004   1006       {ECO:0000244|PDB:4C2O}.
FT   HELIX      1012   1026       {ECO:0000244|PDB:4C2O}.
FT   HELIX      1029   1034       {ECO:0000244|PDB:4C2O}.
FT   HELIX      1045   1077       {ECO:0000244|PDB:4C2O}.
FT   TURN       1083   1085       {ECO:0000244|PDB:4C2O}.
FT   HELIX      1086   1098       {ECO:0000244|PDB:4C2O}.
FT   HELIX      1112   1115       {ECO:0000244|PDB:4C2O}.
FT   TURN       1117   1122       {ECO:0000244|PDB:4C2O}.
FT   HELIX      1126   1145       {ECO:0000244|PDB:4C2O}.
FT   HELIX      1152   1154       {ECO:0000244|PDB:4C2O}.
FT   HELIX      1161   1171       {ECO:0000244|PDB:4C2O}.
FT   TURN       1172   1175       {ECO:0000244|PDB:4C2O}.
FT   HELIX      1179   1187       {ECO:0000244|PDB:4C2O}.
FT   STRAND     1188   1191       {ECO:0000244|PDB:3BKL}.
FT   HELIX      1195   1215       {ECO:0000244|PDB:4C2O}.
SQ   SEQUENCE   1306 AA;  149715 MW;  1B33BCA7301A26AA CRC64;
     MGAASGRRGP GLLLPLPLLL LLPPQPALAL DPGLQPGNFS ADEAGAQLFA QSYNSSAEQV
     LFQSVAASWA HDTNITAENA RRQEEAALLS QEFAEAWGQK AKELYEPIWQ NFTDPQLRRI
     IGAVRTLGSA NLPLAKRQQY NALLSNMSRI YSTAKVCLPN KTATCWSLDP DLTNILASSR
     SYAMLLFAWE GWHNAAGIPL KPLYEDFTAL SNEAYKQDGF TDTGAYWRSW YNSPTFEDDL
     EHLYQQLEPL YLNLHAFVRR ALHRRYGDRY INLRGPIPAH LLGDMWAQSW ENIYDMVVPF
     PDKPNLDVTS TMLQQGWNAT HMFRVAEEFF TSLELSPMPP EFWEGSMLEK PADGREVVCH
     ASAWDFYNRK DFRIKQCTRV TMDQLSTVHH EMGHIQYYLQ YKDLPVSLRR GANPGFHEAI
     GDVLALSVST PEHLHKIGLL DRVTNDTESD INYLLKMALE KIAFLPFGYL VDQWRWGVFS
     GRTPPSRYNF DWWYLRTKYQ GICPPVTRNE THFDAGAKFH VPNVTPYIRY FVSFVLQFQF
     HEALCKEAGY EGPLHQCDIY RSTKAGAKLR KVLQAGSSRP WQEVLKDMVG LDALDAQPLL
     KYFQPVTQWL QEQNQQNGEV LGWPEYQWHP PLPDNYPEGI DLVTDEAEAS KFVEEYDRTS
     QVVWNEYAEA NWNYNTNITT ETSKILLQKN MQIANHTLKY GTQARKFDVN QLQNTTIKRI
     IKKVQDLERA ALPAQELEEY NKILLDMETT YSVATVCHPN GSCLQLEPDL TNVMATSRKY
     EDLLWAWEGW RDKAGRAILQ FYPKYVELIN QAARLNGYVD AGDSWRSMYE TPSLEQDLER
     LFQELQPLYL NLHAYVRRAL HRHYGAQHIN LEGPIPAHLL GNMWAQTWSN IYDLVVPFPS
     APSMDTTEAM LKQGWTPRRM FKEADDFFTS LGLLPVPPEF WNKSMLEKPT DGREVVCHAS
     AWDFYNGKDF RIKQCTTVNL EDLVVAHHEM GHIQYFMQYK DLPVALREGA NPGFHEAIGD
     VLALSVSTPK HLHSLNLLSS EGGSDEHDIN FLMKMALDKI AFIPFSYLVD QWRWRVFDGS
     ITKENYNQEW WSLRLKYQGL CPPVPRTQGD FDPGAKFHIP SSVPYIRYFV SFIIQFQFHE
     ALCQAAGHTG PLHKCDIYQS KEAGQRLATA MKLGFSRPWP EAMQLITGQP NMSASAMLSY
     FKPLLDWLRT ENELHGEKLG WPQYNWTPNS ARSEGPLPDS GRVSFLGLDL DAQQARVGQW
     LLLFLGIALL VATLGLSQRL FSIRHRSLHR HSHGPQFGSE VELRHS
//
ID   HH_DROME                Reviewed;         471 AA.
AC   Q02936; A4V396; Q9VCQ4;
DT   01-FEB-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-SEP-2009, sequence version 4.
DT   20-JAN-2016, entry version 177.
DE   RecName: Full=Protein hedgehog;
DE   Contains:
DE     RecName: Full=Protein hedgehog N-product;
DE              Short=Hh-Np;
DE              Short=N-Hh;
DE   Contains:
DE     RecName: Full=Protein hedgehog C-product;
DE              Short=Hh-Cp;
DE     AltName: Full=C-Hh;
DE   Flags: Precursor;
GN   Name=hh; ORFNames=CG4637;
OS   Drosophila melanogaster (Fruit fly).
OC   Eukaryota; Metazoa; Ecdysozoa; Arthropoda; Hexapoda; Insecta;
OC   Pterygota; Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC   Ephydroidea; Drosophilidae; Drosophila; Sophophora.
OX   NCBI_TaxID=7227;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM LONG), FUNCTION,
RP   DEVELOPMENTAL STAGE, AND TISSUE SPECIFICITY.
RC   STRAIN=Canton-S; TISSUE=Embryo;
RX   PubMed=8166882; DOI=10.1016/0378-1119(93)90392-G;
RA   Tashiro S., Michiue T., Higashijima S., Zenno S., Ishimaru S.,
RA   Takahashi F., Orihara M., Kojima T., Saigo K.;
RT   "Structure and expression of hedgehog, a Drosophila segment-polarity
RT   gene required for cell-cell communication.";
RL   Gene 124:183-189(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, DEVELOPMENTAL STAGE, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=1394430; DOI=10.1016/0092-8674(92)90264-D;
RA   Lee J.J., von Kessler D.P., Parks S., Beachy P.A.;
RT   "Secretion and localized transcription suggest a role in positional
RT   signaling for products of the segmentation gene hedgehog.";
RL   Cell 71:33-50(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING, SUBCELLULAR
RP   LOCATION, DEVELOPMENTAL STAGE, AND TISSUE SPECIFICITY.
RC   STRAIN=Oregon-R; TISSUE=Embryo;
RX   PubMed=1280560;
RA   Mohler J., Vani K.;
RT   "Molecular organization and embryonic expression of the hedgehog gene
RT   involved in cell-cell communication in segmental patterning of
RT   Drosophila.";
RL   Development 115:957-971(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG), FUNCTION, DEVELOPMENTAL
RP   STAGE, AND TISSUE SPECIFICITY.
RC   STRAIN=Oregon-R; TISSUE=Embryo;
RX   PubMed=1340474; DOI=10.1101/gad.6.12b.2635;
RA   Tabata T., Eaton S., Kornberg T.B.;
RT   "The Drosophila hedgehog gene is expressed specifically in posterior
RT   compartment cells and is a target of engrailed regulation.";
RL   Genes Dev. 6:2635-2645(1992).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Berkeley;
RX   PubMed=10731132; DOI=10.1126/science.287.5461.2185;
RA   Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D.,
RA   Amanatides P.G., Scherer S.E., Li P.W., Hoskins R.A., Galle R.F.,
RA   George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,
RA   Sutton G.G., Wortman J.R., Yandell M.D., Zhang Q., Chen L.X.,
RA   Brandon R.C., Rogers Y.-H.C., Blazej R.G., Champe M., Pfeiffer B.D.,
RA   Wan K.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Miklos G.L.G.,
RA   Abril J.F., Agbayani A., An H.-J., Andrews-Pfannkoch C., Baldwin D.,
RA   Ballew R.M., Basu A., Baxendale J., Bayraktaroglu L., Beasley E.M.,
RA   Beeson K.Y., Benos P.V., Berman B.P., Bhandari D., Bolshakov S.,
RA   Borkova D., Botchan M.R., Bouck J., Brokstein P., Brottier P.,
RA   Burtis K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I.,
RA   Cherry J.M., Cawley S., Dahlke C., Davenport L.B., Davies P.,
RA   de Pablos B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,
RA   Dodson K., Doup L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,
RA   Durbin K.J., Evangelista C.C., Ferraz C., Ferriera S., Fleischmann W.,
RA   Fosler C., Gabrielian A.E., Garg N.S., Gelbart W.M., Glasser K.,
RA   Glodek A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,
RA   Harris N.L., Harvey D.A., Heiman T.J., Hernandez J.R., Houck J.,
RA   Hostin D., Houston K.A., Howland T.J., Wei M.-H., Ibegwam C.,
RA   Jalali M., Kalush F., Karpen G.H., Ke Z., Kennison J.A., Ketchum K.A.,
RA   Kimmel B.E., Kodira C.D., Kraft C.L., Kravitz S., Kulp D., Lai Z.,
RA   Lasko P., Lei Y., Levitsky A.A., Li J.H., Li Z., Liang Y., Lin X.,
RA   Liu X., Mattei B., McIntosh T.C., McLeod M.P., McPherson D.,
RA   Merkulov G., Milshina N.V., Mobarry C., Morris J., Moshrefi A.,
RA   Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.M., Nelson D.L.,
RA   Nelson D.R., Nelson K.A., Nixon K., Nusskern D.R., Pacleb J.M.,
RA   Palazzolo M., Pittman G.S., Pan S., Pollard J., Puri V., Reese M.G.,
RA   Reinert K., Remington K., Saunders R.D.C., Scheeler F., Shen H.,
RA   Shue B.C., Siden-Kiamos I., Simpson M., Skupski M.P., Smith T.J.,
RA   Spier E., Spradling A.C., Stapleton M., Strong R., Sun E.,
RA   Svirskas R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,
RA   Wang Z.-Y., Wassarman D.A., Weinstock G.M., Weissenbach J.,
RA   Williams S.M., Woodage T., Worley K.C., Wu D., Yang S., Yao Q.A.,
RA   Ye J., Yeh R.-F., Zaveri J.S., Zhan M., Zhang G., Zhao Q., Zheng L.,
RA   Zheng X.H., Zhong F.N., Zhong W., Zhou X., Zhu S.C., Zhu X.,
RA   Smith H.O., Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.;
RT   "The genome sequence of Drosophila melanogaster.";
RL   Science 287:2185-2195(2000).
RN   [6]
RP   GENOME REANNOTATION.
RC   STRAIN=Berkeley;
RX   PubMed=12537572; DOI=10.1186/gb-2002-3-12-research0083;
RA   Misra S., Crosby M.A., Mungall C.J., Matthews B.B., Campbell K.S.,
RA   Hradecky P., Huang Y., Kaminker J.S., Millburn G.H., Prochnik S.E.,
RA   Smith C.D., Tupy J.L., Whitfield E.J., Bayraktaroglu L., Berman B.P.,
RA   Bettencourt B.R., Celniker S.E., de Grey A.D.N.J., Drysdale R.A.,
RA   Harris N.L., Richter J., Russo S., Schroeder A.J., Shu S.Q.,
RA   Stapleton M., Yamada C., Ashburner M., Gelbart W.M., Rubin G.M.,
RA   Lewis S.E.;
RT   "Annotation of the Drosophila melanogaster euchromatic genome: a
RT   systematic review.";
RL   Genome Biol. 3:RESEARCH0083.1-RESEARCH0083.22(2002).
RN   [7]
RP   AUTOCATALYTIC CLEAVAGE, AND PROTEOLYTIC PROCESSING.
RX   PubMed=7885476; DOI=10.1038/374363a0;
RA   Porter J.A., von Kessler D.P., Ekker S.C., Young K.E., Lee J.J.,
RA   Moses K., Beachy P.A.;
RT   "The product of hedgehog autoproteolytic cleavage active in local and
RT   long-range signalling.";
RL   Nature 374:363-366(1995).
RN   [8]
RP   FUNCTION, AND MUTAGENESIS OF CYS-85.
RX   PubMed=11319862; DOI=10.1006/dbio.2001.0218;
RA   Lee J.D., Kraus P., Gaiano N., Nery S., Kohtz J., Fishell G.,
RA   Loomis C.A., Treisman J.E.;
RT   "An acylatable residue of Hedgehog is differentially required in
RT   Drosophila and mouse limb development.";
RL   Dev. Biol. 233:122-136(2001).
RN   [9]
RP   PALMITOYLATION AT CYS-85, MUTAGENESIS OF CYS-85, AND MASS
RP   SPECTROMETRY.
RX   PubMed=11486055; DOI=10.1126/science.1064437;
RA   Chamoun Z., Mann R.K., Nellen D., von Kessler D.P., Bellotto M.,
RA   Beachy P.A., Basler K.;
RT   "Skinny hedgehog, an acyltransferase required for palmitoylation and
RT   activity of the hedgehog signal.";
RL   Science 293:2080-2084(2001).
RN   [10]
RP   ROLE OF CHOLESTEROL, AND SUBCELLULAR LOCATION.
RX   PubMed=12586063; DOI=10.1016/S1534-5807(03)00031-5;
RA   Gallet A., Rodriguez R., Ruel L., Therond P.P.;
RT   "Cholesterol modification of hedgehog is required for trafficking and
RT   movement, revealing an asymmetric cellular response to hedgehog.";
RL   Dev. Cell 4:191-204(2003).
RN   [11]
RP   INTERACTION WITH SHF.
RX   PubMed=15691765; DOI=10.1016/j.devcel.2004.12.018;
RA   Gorfinkiel N., Sierra J., Callejo A., Ibanez C., Guerrero I.;
RT   "The Drosophila ortholog of the human wnt inhibitor factor shifted
RT   controls the diffusion of lipid-modified hedgehog.";
RL   Dev. Cell 8:241-253(2005).
RN   [12]
RP   ROLE OF LIPOPHORIN IN MOVEMENT.
RX   PubMed=15875013; DOI=10.1038/nature03504;
RA   Panakova D., Sprong H., Marois E., Thiele C., Eaton S.;
RT   "Lipoprotein particles are required for Hedgehog and Wingless
RT   signalling.";
RL   Nature 435:58-65(2005).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 258-402, AND MUTAGENESIS.
RX   PubMed=9335337; DOI=10.1016/S0092-8674(01)80011-8;
RA   Hall T.M.T., Porter J.A., Young K.E., Koonin E.V., Beachy P.A.,
RA   Leahy D.J.;
RT   "Crystal structure of a Hedgehog autoprocessing domain: homology
RT   between Hedgehog and self-splicing proteins.";
RL   Cell 91:85-97(1997).
CC   -!- FUNCTION: Intercellular signal essential for a variety of
CC       patterning events during development. Establishes the anterior-
CC       posterior axis of the embryonic segments and patterns the larval
CC       imaginal disks. Binds to the patched (ptc) receptor, which
CC       functions in association with smoothened (smo), to activate the
CC       transcription of target genes wingless (wg), decapentaplegic (dpp)
CC       and ptc. In the absence of hh, ptc represses the constitutive
CC       signaling activity of smo through fused (fu).
CC   -!- FUNCTION: The hedgehog protein N-product constitutes the active
CC       species in both local and long-range signaling, whereas the C-
CC       terminal product has no signaling activity. It acts as a
CC       morphogen, and diffuses long distances despite its lipidation.
CC       Heparan sulfate proteoglycans of the extracellular matrix play an
CC       essential role in diffusion. Lipophorin is required for diffusion,
CC       probably by acting as vehicle for its movement, explaining how it
CC       can spread over long distances despite its lipidation.
CC   -!- FUNCTION: The hedgehog protein C-product, which mediates the
CC       autocatalytic activity, has no signaling activity.
CC   -!- SUBUNIT: Interacts with shf. {ECO:0000269|PubMed:15691765}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:1280560}.
CC       Cytoplasm {ECO:0000269|PubMed:1280560}. Note=Nuclear up to
CC       embryonic stage 10 and then at stage 11 shifts to the cytoplasm
CC       (PubMed:1280560). Also secreted in either cleaved or uncleaved
CC       form to mediate signaling to other cells (PubMed:1280560).
CC   -!- SUBCELLULAR LOCATION: Protein hedgehog N-product: Cell membrane
CC       {ECO:0000269|PubMed:12586063}; Lipid-anchor
CC       {ECO:0000269|PubMed:12586063}. Note=The N-terminal peptide remains
CC       associated with the cell surface (PubMed:12586063).
CC   -!- SUBCELLULAR LOCATION: Protein hedgehog C-product: Secreted,
CC       extracellular space {ECO:0000269|PubMed:12586063}. Note=The C-
CC       terminal peptide diffuses from the cell (PubMed:12586063).
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=Long; Synonyms=A, B;
CC         IsoId=Q02936-1; Sequence=Displayed;
CC       Name=Short;
CC         IsoId=Q02936-2; Sequence=VSP_002065, VSP_002066;
CC   -!- TISSUE SPECIFICITY: In embryos, expression starts at stage 5 as a
CC       few stripes at the anterior and posterior ends, this expands to 17
CC       stripes during stages 8-11. Expression is also seen in CNS and
CC       some PNS cells until stage 13-14, and in foregut, hindgut and
CC       salivary glands. In larvae, expression is seen in the posterior
CC       compartment of the wing imaginal disk.
CC       {ECO:0000269|PubMed:1280560, ECO:0000269|PubMed:1340474,
CC       ECO:0000269|PubMed:1394430, ECO:0000269|PubMed:8166882}.
CC   -!- DEVELOPMENTAL STAGE: Expressed in embryos, larvae and pupae at
CC       high levels with maximum expression in 6-12 hours embryos and 0-24
CC       hours pupae. Low levels of expression are seen in adults.
CC       {ECO:0000269|PubMed:1280560, ECO:0000269|PubMed:1340474,
CC       ECO:0000269|PubMed:1394430, ECO:0000269|PubMed:8166882}.
CC   -!- PTM: The C-terminal domain displays autoproteolytic activity.
CC       Cleavage of the full-length hedgehog protein is followed by the
CC       covalent attachment of a cholesterol moiety to the C-terminus of
CC       the newly generated N-terminal fragment (N-product).
CC   -!- PTM: Cholesterol attachment plays an essential role in restricting
CC       the spatial distribution of hedgehog activity to the cell surface.
CC   -!- PTM: N-terminal palmitoylation of the hedgehog N-product is
CC       required for the embryonic and larval patterning activities of the
CC       hedgehog signal. Rasp acts within the secretory pathway to
CC       catalyze the N-terminal palmitoylation of Hh.
CC       {ECO:0000269|PubMed:11486055}.
CC   -!- MASS SPECTROMETRY: Mass=20238.44; Method=MALDI; Range=85-257;
CC       Evidence={ECO:0000269|PubMed:11486055};
CC   -!- SIMILARITY: Belongs to the hedgehog family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA28604.1; Type=Frameshift; Positions=21, 48; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L05404; AAA28604.1; ALT_FRAME; mRNA.
DR   EMBL; L05405; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; L02793; AAA16458.1; -; Unassigned_DNA.
DR   EMBL; Z11840; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; S66384; AAB28646.1; -; mRNA.
DR   EMBL; AE014297; AAF56102.1; -; Genomic_DNA.
DR   EMBL; AE014297; ABC66186.1; -; Genomic_DNA.
DR   PIR; A46400; A46400.
DR   RefSeq; NP_001034065.1; NM_001038976.1. [Q02936-1]
DR   UniGene; Dm.2371; -.
DR   PDB; 1AT0; X-ray; 1.90 A; A=258-402.
DR   PDB; 2IBG; X-ray; 2.20 A; E/F/G/H=99-248.
DR   PDBsum; 1AT0; -.
DR   PDBsum; 2IBG; -.
DR   ProteinModelPortal; Q02936; -.
DR   SMR; Q02936; 100-248, 258-402.
DR   BioGrid; 67682; 37.
DR   DIP; DIP-51313N; -.
DR   IntAct; Q02936; 2.
DR   STRING; 7227.FBpp0099945; -.
DR   MEROPS; C46.001; -.
DR   PaxDb; Q02936; -.
DR   EnsemblMetazoa; FBtr0100506; FBpp0099945; FBgn0004644. [Q02936-1]
DR   GeneID; 42737; -.
DR   KEGG; dme:Dmel_CG4637; -.
DR   UCSC; CG4637-RA; d. melanogaster. [Q02936-1]
DR   CTD; 42737; -.
DR   FlyBase; FBgn0004644; hh.
DR   eggNOG; KOG3638; Eukaryota.
DR   eggNOG; ENOG410XQA3; LUCA.
DR   GeneTree; ENSGT00390000001117; -.
DR   InParanoid; Q02936; -.
DR   KO; K06224; -.
DR   OMA; PSMPERT; -.
DR   OrthoDB; EOG779NZ5; -.
DR   PhylomeDB; Q02936; -.
DR   Reactome; R-DME-5358346; Hedgehog ligand biogenesis.
DR   Reactome; R-DME-5362798; Release of Hh-Np from the secreting cell.
DR   Reactome; R-DME-5632681; Ligand-receptor interactions.
DR   SignaLink; Q02936; -.
DR   EvolutionaryTrace; Q02936; -.
DR   GenomeRNAi; 42737; -.
DR   NextBio; 830301; -.
DR   PMAP-CutDB; Q02936; -.
DR   PRO; PR:Q02936; -.
DR   Proteomes; UP000000803; Chromosome 3R.
DR   Bgee; Q02936; -.
DR   Genevisible; Q02936; DM.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0016023; C:cytoplasmic membrane-bounded vesicle; IDA:FlyBase.
DR   GO; GO:0030139; C:endocytic vesicle; IDA:FlyBase.
DR   GO; GO:0005768; C:endosome; IDA:FlyBase.
DR   GO; GO:0005576; C:extracellular region; NAS:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:FlyBase.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; NAS:UniProtKB.
DR   GO; GO:0016015; F:morphogen activity; TAS:FlyBase.
DR   GO; GO:0005113; F:patched binding; NAS:UniProtKB.
DR   GO; GO:0008233; F:peptidase activity; IEA:UniProtKB-KW.
DR   GO; GO:0005119; F:smoothened binding; NAS:UniProtKB.
DR   GO; GO:0007487; P:analia development; TAS:FlyBase.
DR   GO; GO:0021960; P:anterior commissure morphogenesis; IMP:FlyBase.
DR   GO; GO:0035288; P:anterior head segmentation; TAS:FlyBase.
DR   GO; GO:0008595; P:anterior/posterior axis specification, embryo; NAS:FlyBase.
DR   GO; GO:0048099; P:anterior/posterior lineage restriction, imaginal disc; TAS:FlyBase.
DR   GO; GO:0001746; P:Bolwig's organ morphogenesis; IMP:FlyBase.
DR   GO; GO:0045168; P:cell-cell signaling involved in cell fate commitment; IMP:UniProtKB.
DR   GO; GO:0007386; P:compartment pattern specification; TAS:FlyBase.
DR   GO; GO:0001745; P:compound eye morphogenesis; TAS:FlyBase.
DR   GO; GO:0001751; P:compound eye photoreceptor cell differentiation; TAS:FlyBase.
DR   GO; GO:0035231; P:cytoneme assembly; IMP:FlyBase.
DR   GO; GO:0048066; P:developmental pigmentation; TAS:FlyBase.
DR   GO; GO:0007398; P:ectoderm development; NAS:FlyBase.
DR   GO; GO:0009880; P:embryonic pattern specification; IEP:UniProtKB.
DR   GO; GO:0008544; P:epidermis development; TAS:FlyBase.
DR   GO; GO:0007427; P:epithelial cell migration, open tracheal system; IMP:FlyBase.
DR   GO; GO:0048592; P:eye morphogenesis; IMP:FlyBase.
DR   GO; GO:0007440; P:foregut morphogenesis; TAS:FlyBase.
DR   GO; GO:0035224; P:genital disc anterior/posterior pattern formation; IEP:FlyBase.
DR   GO; GO:0035215; P:genital disc development; IMP:FlyBase.
DR   GO; GO:0035232; P:germ cell attraction; TAS:FlyBase.
DR   GO; GO:0008354; P:germ cell migration; IMP:FlyBase.
DR   GO; GO:0042078; P:germ-line stem cell division; TAS:FlyBase.
DR   GO; GO:0008347; P:glial cell migration; IMP:FlyBase.
DR   GO; GO:0007506; P:gonadal mesoderm development; IMP:FlyBase.
DR   GO; GO:0040007; P:growth; NAS:FlyBase.
DR   GO; GO:0007507; P:heart development; NAS:FlyBase.
DR   GO; GO:0060914; P:heart formation; IMP:FlyBase.
DR   GO; GO:0007442; P:hindgut morphogenesis; IMP:FlyBase.
DR   GO; GO:0007446; P:imaginal disc growth; TAS:FlyBase.
DR   GO; GO:0007447; P:imaginal disc pattern formation; NAS:FlyBase.
DR   GO; GO:0007474; P:imaginal disc-derived wing vein specification; TAS:FlyBase.
DR   GO; GO:0016539; P:intein-mediated protein splicing; IEA:InterPro.
DR   GO; GO:0035217; P:labial disc development; IMP:FlyBase.
DR   GO; GO:0007478; P:leg disc morphogenesis; TAS:FlyBase.
DR   GO; GO:0007498; P:mesoderm development; NAS:FlyBase.
DR   GO; GO:0016335; P:morphogenesis of larval imaginal disc epithelium; IMP:FlyBase.
DR   GO; GO:0002385; P:mucosal immune response; IMP:FlyBase.
DR   GO; GO:0031397; P:negative regulation of protein ubiquitination; IDA:FlyBase.
DR   GO; GO:0045861; P:negative regulation of proteolysis; IMP:FlyBase.
DR   GO; GO:0007424; P:open tracheal system development; TAS:FlyBase.
DR   GO; GO:0030707; P:ovarian follicle cell development; TAS:FlyBase.
DR   GO; GO:0030713; P:ovarian follicle cell stalk formation; TAS:FlyBase.
DR   GO; GO:0007280; P:pole cell migration; IGI:FlyBase.
DR   GO; GO:0045743; P:positive regulation of fibroblast growth factor receptor signaling pathway; IMP:FlyBase.
DR   GO; GO:0007228; P:positive regulation of hh target transcription factor activity; IGI:FlyBase.
DR   GO; GO:0045880; P:positive regulation of smoothened signaling pathway; TAS:FlyBase.
DR   GO; GO:0042993; P:positive regulation of transcription factor import into nucleus; IMP:FlyBase.
DR   GO; GO:0035289; P:posterior head segmentation; TAS:FlyBase.
DR   GO; GO:0007458; P:progression of morphogenetic furrow involved in compound eye morphogenesis; IMP:FlyBase.
DR   GO; GO:0016540; P:protein autoprocessing; IDA:UniProtKB.
DR   GO; GO:0045464; P:R8 cell fate specification; NAS:FlyBase.
DR   GO; GO:0042127; P:regulation of cell proliferation; NAS:FlyBase.
DR   GO; GO:2000274; P:regulation of epithelial cell migration, open tracheal system; IMP:FlyBase.
DR   GO; GO:0007346; P:regulation of mitotic cell cycle; IMP:FlyBase.
DR   GO; GO:0046620; P:regulation of organ growth; TAS:FlyBase.
DR   GO; GO:0042306; P:regulation of protein import into nucleus; IMP:FlyBase.
DR   GO; GO:0006357; P:regulation of transcription from RNA polymerase II promoter; TAS:FlyBase.
DR   GO; GO:0007367; P:segment polarity determination; IEP:UniProtKB.
DR   GO; GO:0007224; P:smoothened signaling pathway; IGI:FlyBase.
DR   GO; GO:0048103; P:somatic stem cell division; TAS:FlyBase.
DR   GO; GO:0035277; P:spiracle morphogenesis, open tracheal system; IMP:FlyBase.
DR   GO; GO:0035290; P:trunk segmentation; TAS:FlyBase.
DR   GO; GO:0007418; P:ventral midline development; IMP:FlyBase.
DR   GO; GO:0048100; P:wing disc anterior/posterior pattern formation; TAS:FlyBase.
DR   GO; GO:0007473; P:wing disc proximal/distal pattern formation; TAS:FlyBase.
DR   Gene3D; 2.170.16.10; -; 1.
DR   Gene3D; 3.30.1380.10; -; 1.
DR   InterPro; IPR001657; Hedgehog.
DR   InterPro; IPR028992; Hedgehog/Intein_dom.
DR   InterPro; IPR009045; Hedgehog_sig/DD-Pept_Zn-bd_dom.
DR   InterPro; IPR000320; Hedgehog_signalling_dom.
DR   InterPro; IPR001767; Hint_dom.
DR   InterPro; IPR003586; Hint_dom_C.
DR   InterPro; IPR003587; Hint_dom_N.
DR   InterPro; IPR006141; Intein_N.
DR   Pfam; PF01085; HH_signal; 1.
DR   Pfam; PF01079; Hint; 1.
DR   PIRSF; PIRSF009400; Peptidase_C46; 1.
DR   PRINTS; PR00632; SONICHHOG.
DR   SMART; SM00305; HintC; 1.
DR   SMART; SM00306; HintN; 1.
DR   SUPFAM; SSF51294; SSF51294; 1.
DR   SUPFAM; SSF55166; SSF55166; 1.
DR   PROSITE; PS50817; INTEIN_N_TER; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Autocatalytic cleavage; Calcium;
KW   Cell membrane; Complete proteome; Cytoplasm; Developmental protein;
KW   Hydrolase; Lipoprotein; Membrane; Metal-binding; Morphogen; Nucleus;
KW   Palmitate; Protease; Reference proteome; Secreted;
KW   Segmentation polarity protein; Signal.
FT   SIGNAL        1      ?       {ECO:0000255}.
FT   PROPEP        ?     84       {ECO:0000255}.
FT                                /FTId=PRO_0000383048.
FT   CHAIN        85    471       Protein hedgehog.
FT                                /FTId=PRO_0000013202.
FT   CHAIN        85    257       Protein hedgehog N-product.
FT                                /FTId=PRO_0000013203.
FT   CHAIN       258    471       Protein hedgehog C-product.
FT                                /FTId=PRO_0000013204.
FT   COMPBIAS      5     41       Ser-rich.
FT   METAL       149    149       Calcium 1.
FT                                {ECO:0000250|UniProtKB:Q15465}.
FT   METAL       150    150       Calcium 1.
FT                                {ECO:0000250|UniProtKB:Q15465}.
FT   METAL       150    150       Calcium 2.
FT                                {ECO:0000250|UniProtKB:Q15465}.
FT   METAL       155    155       Calcium 1.
FT                                {ECO:0000250|UniProtKB:Q15465}.
FT   METAL       185    185       Calcium 1; via carbonyl oxygen.
FT                                {ECO:0000250|UniProtKB:Q15465}.
FT   METAL       186    186       Calcium 1.
FT                                {ECO:0000250|UniProtKB:Q15465}.
FT   METAL       186    186       Calcium 2.
FT                                {ECO:0000250|UniProtKB:Q15465}.
FT   METAL       189    189       Calcium 2.
FT                                {ECO:0000250|UniProtKB:Q15465}.
FT   METAL       191    191       Calcium 2.
FT                                {ECO:0000250|UniProtKB:Q15465}.
FT   SITE        257    258       Cleavage; by autolysis.
FT   SITE        303    303       Involved in cholesterol transfer.
FT   SITE        326    326       Involved in auto-cleavage.
FT   SITE        329    329       Essential for auto-cleavage.
FT   LIPID        85     85       N-palmitoyl cysteine.
FT                                {ECO:0000269|PubMed:11486055}.
FT   LIPID       257    257       Cholesterol glycine ester.
FT   VAR_SEQ     161    192       RCKEKLNVLAYSVMNEWPGIRLLVTESWDEDY -> VRKTL
FT                                KHRKLVTKFVIHHWESFAYRNHCDKVT (in isoform
FT                                Short). {ECO:0000305}.
FT                                /FTId=VSP_002065.
FT   VAR_SEQ     193    471       Missing (in isoform Short).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_002066.
FT   MUTAGEN      85     85       C->S: N-product is made but fails to
FT                                undergo palmitoylation.
FT                                {ECO:0000269|PubMed:11319862,
FT                                ECO:0000269|PubMed:11486055}.
FT   MUTAGEN     303    303       D->A: No cholesterol transfer.
FT                                {ECO:0000269|PubMed:9335337}.
FT   MUTAGEN     326    326       T->A: Greatly reduced autoprocessing
FT                                activity. {ECO:0000269|PubMed:9335337}.
FT   MUTAGEN     329    329       H->A: No autoprocessing activity.
FT                                {ECO:0000269|PubMed:9335337}.
FT   CONFLICT    156    156       R -> G (in Ref. 1; AAA28604).
FT                                {ECO:0000305}.
FT   CONFLICT    347    347       D -> H (in Ref. 1; AAA28604).
FT                                {ECO:0000305}.
FT   CONFLICT    373    373       V -> L (in Ref. 1; AAA28604).
FT                                {ECO:0000305}.
FT   CONFLICT    407    407       Q -> P (in Ref. 3; Z11840).
FT                                {ECO:0000305}.
FT   STRAND      107    111       {ECO:0000244|PDB:2IBG}.
FT   TURN        116    119       {ECO:0000244|PDB:2IBG}.
FT   HELIX       131    135       {ECO:0000244|PDB:2IBG}.
FT   STRAND      144    146       {ECO:0000244|PDB:2IBG}.
FT   HELIX       160    176       {ECO:0000244|PDB:2IBG}.
FT   STRAND      182    188       {ECO:0000244|PDB:2IBG}.
FT   HELIX       199    202       {ECO:0000244|PDB:2IBG}.
FT   STRAND      205    210       {ECO:0000244|PDB:2IBG}.
FT   HELIX       215    217       {ECO:0000244|PDB:2IBG}.
FT   HELIX       218    228       {ECO:0000244|PDB:2IBG}.
FT   STRAND      231    234       {ECO:0000244|PDB:2IBG}.
FT   STRAND      241    244       {ECO:0000244|PDB:2IBG}.
FT   STRAND      264    267       {ECO:0000244|PDB:1AT0}.
FT   STRAND      272    274       {ECO:0000244|PDB:1AT0}.
FT   HELIX       275    277       {ECO:0000244|PDB:1AT0}.
FT   STRAND      283    287       {ECO:0000244|PDB:1AT0}.
FT   STRAND      293    317       {ECO:0000244|PDB:1AT0}.
FT   STRAND      322    325       {ECO:0000244|PDB:1AT0}.
FT   STRAND      330    335       {ECO:0000244|PDB:1AT0}.
FT   TURN        336    339       {ECO:0000244|PDB:1AT0}.
FT   STRAND      340    345       {ECO:0000244|PDB:1AT0}.
FT   HELIX       346    348       {ECO:0000244|PDB:1AT0}.
FT   STRAND      354    358       {ECO:0000244|PDB:1AT0}.
FT   TURN        360    362       {ECO:0000244|PDB:1AT0}.
FT   STRAND      365    393       {ECO:0000244|PDB:1AT0}.
FT   STRAND      396    400       {ECO:0000244|PDB:1AT0}.
SQ   SEQUENCE   471 AA;  52150 MW;  8ECD796A92FE7043 CRC64;
     MDNHSSVPWA SAASVTCLSL DAKCHSSSSS SSSKSAASSI SAIPQEETQT MRHIAHTQRC
     LSRLTSLVAL LLIVLPMVFS PAHSCGPGRG LGRHRARNLY PLVLKQTIPN LSEYTNSASG
     PLEGVIRRDS PKFKDLVPNY NRDILFRDEE GTGADRLMSK RCKEKLNVLA YSVMNEWPGI
     RLLVTESWDE DYHHGQESLH YEGRAVTIAT SDRDQSKYGM LARLAVEAGF DWVSYVSRRH
     IYCSVKSDSS ISSHVHGCFT PESTALLESG VRKPLGELSI GDRVLSMTAN GQAVYSEVIL
     FMDRNLEQMQ NFVQLHTDGG AVLTVTPAHL VSVWQPESQK LTFVFADRIE EKNQVLVRDV
     ETGELRPQRV VKVGSVRSKG VVAPLTREGT IVVNSVAASC YAVINSQSLA HWGLAPMRLL
     STLEAWLPAK EQLHSSPKVV SSAQQQNGIH WYANALYKVK DYVLPQSWRH D
//
ID   CLUS_HUMAN              Reviewed;         449 AA.
AC   P10909; B2R9Q1; B3KSE6; P11380; P11381; Q2TU75; Q5HYC1; Q7Z5B9;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1989, sequence version 1.
DT   17-FEB-2016, entry version 186.
DE   RecName: Full=Clusterin;
DE   AltName: Full=Aging-associated gene 4 protein;
DE   AltName: Full=Apolipoprotein J;
DE            Short=Apo-J;
DE   AltName: Full=Complement cytolysis inhibitor;
DE            Short=CLI;
DE   AltName: Full=Complement-associated protein SP-40,40;
DE   AltName: Full=Ku70-binding protein 1;
DE   AltName: Full=NA1/NA2;
DE   AltName: Full=Testosterone-repressed prostate message 2;
DE            Short=TRPM-2;
DE   Contains:
DE     RecName: Full=Clusterin beta chain;
DE     AltName: Full=ApoJalpha;
DE     AltName: Full=Complement cytolysis inhibitor a chain;
DE   Contains:
DE     RecName: Full=Clusterin alpha chain;
DE     AltName: Full=ApoJbeta;
DE     AltName: Full=Complement cytolysis inhibitor b chain;
DE   Flags: Precursor;
GN   Name=CLU; Synonyms=APOJ, CLI, KUB1; ORFNames=AAG4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF
RP   N-TERMINUS, SUBUNIT, DISULFIDE BONDS, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Liver;
RX   PubMed=2780565; DOI=10.1073/pnas.86.18.7123;
RA   Jenne D.E., Tschopp J.;
RT   "Molecular structure and functional characterization of a human
RT   complement cytolysis inhibitor found in blood and seminal plasma:
RT   identity to sulfated glycoprotein 2, a constituent of rat testis
RT   fluid.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:7123-7127(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], PARTIAL NUCLEOTIDE SEQUENCE [MRNA]
RP   (ISOFORM 2), AND TISSUE SPECIFICITY.
RX   PubMed=8181474; DOI=10.1111/j.1432-1033.1994.tb18807.x;
RA   Wong P., Taillefer D., Lakins J., Pineault J., Chader G.,
RA   Tenniswood M.;
RT   "Molecular characterization of human TRPM-2/clusterin, a gene
RT   associated with sperm maturation, apoptosis and neurodegeneration.";
RL   Eur. J. Biochem. 221:917-925(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND PARTIAL
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Stomach, and Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RA   Li W.B., Gruber C., Jessee J., Polayes D.;
RT   "Full-length cDNA libraries and normalization.";
RL   Submitted (JUL-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Small intestine;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS HIS-317; ASN-328 AND
RP   LEU-396.
RG   NIEHS SNPs program;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S.,
RA   Garber M., Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A.,
RA   Chang J.L., Cuomo C.A., Dewar K., FitzGerald M.G., Yang X.,
RA   Allen N.R., Anderson S., Asakawa T., Blechschmidt K., Bloom T.,
RA   Borowsky M.L., Butler J., Cook A., Corum B., DeArellano K.,
RA   DeCaprio D., Dooley K.T., Dorris L. III, Engels R., Gloeckner G.,
RA   Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., Jaffe D.B.,
RA   Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C.,
RA   O'Leary S.B., O'Neill K., Parker S.C.J., Polley A., Raymond C.K.,
RA   Reichwald K., Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R.,
RA   Smith C.L., Sneddon T.P., Talamas J.A., Tenzin P., Topham K.,
RA   Venkataraman V., Wen G., Yamazaki S., Young S.K., Zeng Q.,
RA   Zimmer A.R., Rosenthal A., Birren B.W., Platzer M., Shimizu N.,
RA   Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5), AND PARTIAL
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain, and Spinal ganglion;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   PROTEIN SEQUENCE OF 23-33; 229-242; 303-317 AND 397-403, SUBUNIT, AND
RP   INTERACTION WITH APOA1.
RX   PubMed=1903064;
RA   James R.W., Hochstrasser A.-C., Borghini I., Martin B.M., Pometta D.,
RA   Hochstrasser D.F.;
RT   "Characterization of a human high density lipoprotein-associated
RT   protein, NA1/NA2. Identity with SP-40,40, an inhibitor of complement-
RT   mediated cytolysis.";
RL   Arterioscler. Thromb. 11:645-652(1991).
RN   [10]
RP   PROTEIN SEQUENCE OF 23-52 AND 228-257, SUBUNIT, DISULFIDE BOND,
RP   PROTEOLYTIC PROCESSING, GLYCOSYLATION, SUBCELLULAR LOCATION, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=2387851;
RA   de Silva H., Stuart W.D., Park Y.B., Mao S.J.T., Gil C.M.,
RA   Wetterau J.R., Busch S.J., Harmony J.A.K.;
RT   "Purification and characterization of apolipoprotein J.";
RL   J. Biol. Chem. 265:14292-14297(1990).
RN   [11]
RP   PROTEIN SEQUENCE OF 23-41 AND 228-246, INTERACTION WITH APP,
RP   SUBCELLULAR LOCATION, DISULFIDE BOND, AND TISSUE SPECIFICITY.
RX   PubMed=8328966;
RA   Ghiso J., Matsubara E., Koudinov A., Choi-Miura N.-H., Tomita M.,
RA   Wisniewski T., Frangione B.;
RT   "The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is
RT   complexed to SP-40,40 (apolipoprotein J), an inhibitor of the
RT   complement membrane-attack complex.";
RL   Biochem. J. 293:27-30(1993).
RN   [12]
RP   PROTEIN SEQUENCE OF 23-37 AND 228-242.
RX   PubMed=2601725; DOI=10.1016/0161-5890(89)90139-9;
RA   Choi N.H., Mazda T., Tomita M.;
RT   "A serum protein SP40,40 modulates the formation of membrane attack
RT   complex of complement on erythrocytes.";
RL   Mol. Immunol. 26:835-840(1989).
RN   [13]
RP   PROTEIN SEQUENCE OF 23-33 AND 228-240, SUBCELLULAR LOCATION, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=3154963;
RA   Hochstrasser A.-C., James R.W., Martin B.M., Harrington M.,
RA   Hochstrasser D.F., Pometta D., Merril C.R.;
RT   "HDL particle associated proteins in plasma and cerebrospinal fluid:
RT   identification and partial sequencing.";
RL   Appl. Theor. Electrophor. 1:73-76(1988).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 34-449 (ISOFORMS 1/2/4), PARTIAL PROTEIN
RP   SEQUENCE, SUBUNIT, AND TISSUE SPECIFICITY.
RX   PubMed=1974459; DOI=10.1021/bi00474a025;
RA   de Silva H.V., Harmony J.A.K., Stuart W.D., Gil C.M., Robbins J.;
RT   "Apolipoprotein J: structure and tissue distribution.";
RL   Biochemistry 29:5380-5389(1990).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 61-449.
RC   TISSUE=Astrocytoma;
RX   PubMed=1924317; DOI=10.1073/pnas.88.19.8577;
RA   Danik M., Chabot J.G., Mercier C., Benabid A.L., Chauvin C.,
RA   Quirion R., Suh M.;
RT   "Human gliomas and epileptic foci express high levels of a mRNA
RT   related to rat testicular sulfated glycoprotein 2, a purported marker
RT   of cell death.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:8577-8581(1991).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 140-449.
RC   TISSUE=Fetal liver;
RA   Glew M.D., Kirszbaum L., Bozas S.E., Walker I.D.;
RL   Submitted (JAN-1993) to the EMBL/GenBank/DDBJ databases.
RN   [17]
RP   PARTIAL NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND PARTIAL PROTEIN
RP   SEQUENCE.
RC   TISSUE=Liver;
RX   PubMed=2721499;
RA   Kirszbaum L., Sharpe J.A., Murphy B., D'Apice J.F.A., Classon B.,
RA   Hudson P., Walker I.D.;
RT   "Molecular cloning and characterization of the novel, human
RT   complement-associated protein, SP-40,40: a link between the complement
RT   and reproductive systems.";
RL   EMBO J. 8:711-718(1989).
RN   [18]
RP   PARTIAL PROTEIN SEQUENCE, DISULFIDE BONDS, AND GLYCOSYLATION AT
RP   ASN-86; ASN-103; ASN-145; ASN-291; ASN-354 AND ASN-374.
RX   PubMed=1551440; DOI=10.1016/0014-5793(92)80330-J;
RA   Kirszbaum L., Bozas S.E., Walker I.D.;
RT   "SP-40,40, a protein involved in the control of the complement
RT   pathway, possesses a unique array of disulphide bridges.";
RL   FEBS Lett. 297:70-76(1992).
RN   [19]
RP   PARTIAL NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RA   Kim J.W.;
RT   "Identification of human aging-associated gene.";
RL   Submitted (DEC-2003) to the EMBL/GenBank/DDBJ databases.
RN   [20]
RP   INTERACTION WITH APOA1.
RX   PubMed=1742316; DOI=10.1016/0005-2760(91)90167-G;
RA   Ehnholm C., Bozas S.E., Tenkanen H., Kirszbaum L., Metso J.,
RA   Murphy B., Walker I.D.;
RT   "The apolipoprotein A-I binding protein of placenta and the SP-40,40
RT   protein of human blood are different proteins which both bind to
RT   apolipoprotein A-I.";
RL   Biochim. Biophys. Acta 1086:255-260(1991).
RN   [21]
RP   DISULFIDE BONDS.
RX   PubMed=1491011;
RA   Choi-Miura N.H., Takahashi Y., Nakano Y., Tobe T., Tomita M.;
RT   "Identification of the disulfide bonds in human plasma protein SP-
RT   40,40 (apolipoprotein-J).";
RL   J. Biochem. 112:557-561(1992).
RN   [22]
RP   INTERACTION WITH PON1, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=8292612; DOI=10.1021/bi00169a026;
RA   Kelso G.J., Stuart W.D., Richter R.J., Furlong C.E.,
RA   Jordan-Starck T.C., Harmony J.A.K.;
RT   "Apolipoprotein J is associated with paraoxonase in human plasma.";
RL   Biochemistry 33:832-839(1994).
RN   [23]
RP   GLYCOSYLATION AT ASN-86; ASN-103; ASN-145; ASN-291; ASN-354 AND
RP   ASN-374.
RC   TISSUE=Serum;
RX   PubMed=9336835; DOI=10.1002/pro.5560061007;
RA   Kapron J.T., Hilliard G.M., Lakins J.N., Tenniswood M.P., West K.A.,
RA   Carr S.A., Crabb J.W.;
RT   "Identification and characterization of glycosylation sites in human
RT   serum clusterin.";
RL   Protein Sci. 6:2120-2133(1997).
RN   [24]
RP   FUNCTION, SUBCELLULAR LOCATION, ABSENCE OF ATPASE ACTIVITY, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=11123922; DOI=10.1021/bi002189x;
RA   Poon S., Easterbrook-Smith S.B., Rybchyn M.S., Carver J.A.,
RA   Wilson M.R.;
RT   "Clusterin is an ATP-independent chaperone with very broad substrate
RT   specificity that stabilizes stressed proteins in a folding-competent
RT   state.";
RL   Biochemistry 39:15953-15960(2000).
RN   [25]
RP   FUNCTION, AND SUBUNIT.
RX   PubMed=12047389; DOI=10.1046/j.1432-1033.2002.02957.x;
RA   Hatters D.M., Wilson M.R., Easterbrook-Smith S.B., Howlett G.J.;
RT   "Suppression of apolipoprotein C-II amyloid formation by the
RT   extracellular chaperone, clusterin.";
RL   Eur. J. Biochem. 269:2789-2794(2002).
RN   [26]
RP   FUNCTION, SUBUNIT, AND CIRCULAR DICHROISM.
RX   PubMed=12176985; DOI=10.1074/jbc.M204855200;
RA   Poon S., Rybchyn M.S., Easterbrook-Smith S.B., Carver J.A.,
RA   Pankhurst G.J., Wilson M.R.;
RT   "Mildly acidic pH activates the extracellular molecular chaperone
RT   clusterin.";
RL   J. Biol. Chem. 277:39532-39540(2002).
RN   [27]
RP   ALTERNATIVE SPLICING, IDENTIFICATION OF ISOFORM 4, FUNCTION,
RP   INTERACTION WITH XRCC6, AND SUBCELLULAR LOCATION.
RX   PubMed=12551933; DOI=10.1074/jbc.M209233200;
RA   Leskov K.S., Klokov D.Y., Li J., Kinsella T.J., Boothman D.A.;
RT   "Synthesis and functional analyses of nuclear clusterin, a cell death
RT   protein.";
RL   J. Biol. Chem. 278:11590-11600(2003).
RN   [28]
RP   FUNCTION.
RX   PubMed=12882985; DOI=10.1074/jbc.C300252200;
RA   Santilli G., Aronow B.J., Sala A.;
RT   "Essential requirement of apolipoprotein J (clusterin) signaling for
RT   IkappaB expression and regulation of NF-kappaB activity.";
RL   J. Biol. Chem. 278:38214-38219(2003).
RN   [29]
RP   GLYCOSYLATION AT ASN-354.
RC   TISSUE=Serum;
RX   PubMed=12754519; DOI=10.1038/nbt827;
RA   Zhang H., Li X.-J., Martin D.B., Aebersold R.;
RT   "Identification and quantification of N-linked glycoproteins using
RT   hydrazide chemistry, stable isotope labeling and mass spectrometry.";
RL   Nat. Biotechnol. 21:660-666(2003).
RN   [30]
RP   INTERACTION WITH CLUAP1.
RX   PubMed=15480429; DOI=10.1038/sj.onc.1208100;
RA   Takahashi M., Lin Y.-M., Nakamura Y., Furukawa Y.;
RT   "Isolation and characterization of a novel gene CLUAP1 whose
RT   expression is frequently upregulated in colon cancer.";
RL   Oncogene 23:9289-9294(2004).
RN   [31]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-354 AND ASN-374.
RC   TISSUE=Plasma;
RX   PubMed=14760718; DOI=10.1002/pmic.200300556;
RA   Bunkenborg J., Pilch B.J., Podtelejnikov A.V., Wisniewski J.R.;
RT   "Screening for N-glycosylated proteins by liquid chromatography mass
RT   spectrometry.";
RL   Proteomics 4:454-465(2004).
RN   [32]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-86; ASN-103; ASN-145;
RP   ASN-291; ASN-354 AND ASN-374.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [33]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH BAX.
RX   PubMed=16113678; DOI=10.1038/ncb1291;
RA   Zhang H., Kim J.K., Edwards C.A., Xu Z., Taichman R., Wang C.Y.;
RT   "Clusterin inhibits apoptosis by interacting with activated Bax.";
RL   Nat. Cell Biol. 7:909-915(2005).
RN   [34]
RP   INDUCTION, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=16548883; DOI=10.1111/j.1462-5822.2005.00644.x;
RA   Leong W.F., Chow V.T.;
RT   "Transcriptomic and proteomic analyses of rhabdomyosarcoma cells
RT   reveal differential cellular gene expression in response to
RT   enterovirus 71 infection.";
RL   Cell. Microbiol. 8:565-580(2006).
RN   [35]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-374.
RC   TISSUE=Saliva;
RX   PubMed=16740002; DOI=10.1021/pr050492k;
RA   Ramachandran P., Boontheung P., Xie Y., Sondej M., Wong D.T.,
RA   Loo J.A.;
RT   "Identification of N-linked glycoproteins in human saliva by
RT   glycoprotein capture and mass spectrometry.";
RL   J. Proteome Res. 5:1493-1503(2006).
RN   [36]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-374.
RC   TISSUE=Platelet;
RX   PubMed=16263699; DOI=10.1074/mcp.M500324-MCP200;
RA   Lewandrowski U., Moebius J., Walter U., Sickmann A.;
RT   "Elucidation of N-glycosylation sites on human platelet proteins: a
RT   glycoproteomic approach.";
RL   Mol. Cell. Proteomics 5:226-233(2006).
RN   [37]
RP   FUNCTION, SUBUNIT, INTERACTION WITH LRP2, GLYCOSYLATION, SUBCELLULAR
RP   LOCATION, IDENTIFICATION BY MASS SPECTROMETRY, CIRCULAR DICHROISM, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=17260971; DOI=10.1021/bi062082v;
RA   Stewart E.M., Aquilina J.A., Easterbrook-Smith S.B.,
RA   Murphy-Durland D., Jacobsen C., Moestrup S., Wilson M.R.;
RT   "Effects of glycosylation on the structure and function of the
RT   extracellular chaperone clusterin.";
RL   Biochemistry 46:1412-1422(2007).
RN   [38]
RP   FUNCTION, INDUCTION, PROTEASOMAL DEGRADATION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=17689225; DOI=10.1016/j.bbadis.2007.06.004;
RA   Ranney M.K., Ahmed I.S., Potts K.R., Craven R.J.;
RT   "Multiple pathways regulating the anti-apoptotic protein clusterin in
RT   breast cancer.";
RL   Biochim. Biophys. Acta 1772:1103-1111(2007).
RN   [39]
RP   IDENTIFICATION IN A COMPLEX WITH LTF; SEMG1 AND EPPIN.
RX   PubMed=17567961; DOI=10.1095/biolreprod.107.060194;
RA   Wang Z., Widgren E.E., Richardson R.T., O'Rand M.G.;
RT   "Characterization of an eppin protein complex from human semen and
RT   spermatozoa.";
RL   Biol. Reprod. 77:476-484(2007).
RN   [40]
RP   FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=17412999; DOI=10.1096/fj.06-7986com;
RA   Yerbury J.J., Poon S., Meehan S., Thompson B., Kumita J.R.,
RA   Dobson C.M., Wilson M.R.;
RT   "The extracellular chaperone clusterin influences amyloid formation
RT   and toxicity by interacting with prefibrillar structures.";
RL   FASEB J. 21:2312-2322(2007).
RN   [41]
RP   ALTERNATIVE SPLICING, IDENTIFICATION OF ISOFORMS 1 AND 2, AND
RP   INDUCTION BY ANDROGEN.
RX   PubMed=17148459; DOI=10.1074/jbc.M608162200;
RA   Cochrane D.R., Wang Z., Muramaki M., Gleave M.E., Nelson C.C.;
RT   "Differential regulation of clusterin and its isoforms by androgens in
RT   prostate cells.";
RL   J. Biol. Chem. 282:2278-2287(2007).
RN   [42]
RP   FUNCTION, AND SUBUNIT.
RX   PubMed=17407782; DOI=10.1016/j.jmb.2007.02.095;
RA   Kumita J.R., Poon S., Caddy G.L., Hagan C.L., Dumoulin M.,
RA   Yerbury J.J., Stewart E.M., Robinson C.V., Wilson M.R., Dobson C.M.;
RT   "The extracellular chaperone clusterin potently inhibits human
RT   lysozyme amyloid formation by interacting with prefibrillar species.";
RL   J. Mol. Biol. 369:157-167(2007).
RN   [43]
RP   ALTERNATIVE SPLICING, IDENTIFICATION OF ISOFORMS 1; 2 AND 5, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=17322305; DOI=10.1074/mcp.M600261-MCP200;
RA   Andersen C.L., Schepeler T., Thorsen K., Birkenkamp-Demtroder K.,
RA   Mansilla F., Aaltonen L.A., Laurberg S., Orntoft T.F.;
RT   "Clusterin expression in normal mucosa and colorectal cancer.";
RL   Mol. Cell. Proteomics 6:1039-1048(2007).
RN   [44]
RP   SUBCELLULAR LOCATION, INTERACTION WITH SYVN1, AND UBIQUITINATION.
RX   PubMed=17451556; DOI=10.1111/j.1600-0854.2007.00549.x;
RA   Nizard P., Tetley S., Le Drean Y., Watrin T., Le Goff P., Wilson M.R.,
RA   Michel D.;
RT   "Stress-induced retrotranslocation of clusterin/ApoJ into the
RT   cytosol.";
RL   Traffic 8:554-565(2007).
RN   [45]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-291; ASN-317 AND ASN-374.
RC   TISSUE=Milk;
RX   PubMed=18780401; DOI=10.1002/pmic.200701057;
RA   Picariello G., Ferranti P., Mamone G., Roepstorff P., Addeo F.;
RT   "Identification of N-linked glycoproteins in human milk by hydrophilic
RT   interaction liquid chromatography and mass spectrometry.";
RL   Proteomics 8:3833-3847(2008).
RN   [46]
RP   FUNCTION, AND SUBUNIT.
RX   PubMed=19535339; DOI=10.1074/jbc.M109.033688;
RA   Wyatt A.R., Yerbury J.J., Wilson M.R.;
RT   "Structural characterization of clusterin-chaperone client protein
RT   complexes.";
RL   J. Biol. Chem. 284:21920-21927(2009).
RN   [47]
RP   FUNCTION, SUBCELLULAR LOCATION, AND UBIQUITINATION.
RX   PubMed=19137541; DOI=10.1002/jcp.21671;
RA   Rizzi F., Caccamo A.E., Belloni L., Bettuzzi S.;
RT   "Clusterin is a short half-life, poly-ubiquitinated protein, which
RT   controls the fate of prostate cancer cells.";
RL   J. Cell. Physiol. 219:314-323(2009).
RN   [48]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-86; ASN-103; ASN-145;
RP   ASN-354 AND ASN-374.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [49]
RP   GLYCOSYLATION AT ASN-86 AND ASN-374.
RX   PubMed=19139490; DOI=10.1074/mcp.M800504-MCP200;
RA   Jia W., Lu Z., Fu Y., Wang H.P., Wang L.H., Chi H., Yuan Z.F.,
RA   Zheng Z.B., Song L.N., Han H.H., Liang Y.M., Wang J.L., Cai Y.,
RA   Zhang Y.K., Deng Y.L., Ying W.T., He S.M., Qian X.H.;
RT   "A strategy for precise and large scale identification of core
RT   fucosylated glycoproteins.";
RL   Mol. Cell. Proteomics 8:913-923(2009).
RN   [50]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-374, AND STRUCTURE OF
RP   CARBOHYDRATES.
RC   TISSUE=Cerebrospinal fluid;
RX   PubMed=19838169; DOI=10.1038/nmeth.1392;
RA   Nilsson J., Rueetschi U., Halim A., Hesse C., Carlsohn E.,
RA   Brinkmalm G., Larson G.;
RT   "Enrichment of glycopeptides for glycan structure and attachment site
RT   identification.";
RL   Nat. Methods 6:809-811(2009).
RN   [51]
RP   FUNCTION.
RX   PubMed=19996109; DOI=10.1074/jbc.M109.079566;
RA   Wyatt A.R., Wilson M.R.;
RT   "Identification of human plasma proteins as major clients for the
RT   extracellular chaperone clusterin.";
RL   J. Biol. Chem. 285:3532-3539(2010).
RN   [52]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH COMMD1; UBIQUITIN;
RP   CUL1 ANDBTRC, AND IDENTIFICATION IN A E3 UBIQUITIN-PROTEIN LIGASE
RP   COMPLEX.
RX   PubMed=20068069; DOI=10.1158/1541-7786.MCR-09-0277;
RA   Zoubeidi A., Ettinger S., Beraldi E., Hadaschik B., Zardan A.,
RA   Klomp L.W., Nelson C.C., Rennie P.S., Gleave M.E.;
RT   "Clusterin facilitates COMMD1 and I-kappaB degradation to enhance NF-
RT   kappaB activity in prostate cancer cells.";
RL   Mol. Cancer Res. 8:119-130(2010).
RN   [53]
RP   FUNCTION.
RX   PubMed=21505792; DOI=10.1007/s00018-011-0684-8);
RA   Wyatt A.R., Yerbury J.J., Berghofer P., Greguric I., Katsifis A.,
RA   Dobson C.M., Wilson M.R.;
RT   "Clusterin facilitates in vivo clearance of extracellular misfolded
RT   proteins.";
RL   Cell. Mol. Life Sci. 68:3919-3931(2011).
RN   [54]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-133 AND SER-396, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
CC   -!- FUNCTION: Isoform 1 functions as extracellular chaperone that
CC       prevents aggregation of nonnative proteins. Prevents stress-
CC       induced aggregation of blood plasma proteins. Inhibits formation
CC       of amyloid fibrils by APP, APOC2, B2M, CALCA, CSN3, SNCA and
CC       aggregation-prone LYZ variants (in vitro). Does not require ATP.
CC       Maintains partially unfolded proteins in a state appropriate for
CC       subsequent refolding by other chaperones, such as HSPA8/HSC70.
CC       Does not refold proteins by itself. Binding to cell surface
CC       receptors triggers internalization of the chaperone-client complex
CC       and subsequent lysosomal or proteasomal degradation. Secreted
CC       isoform 1 protects cells against apoptosis and against cytolysis
CC       by complement. Intracellular isoforms interact with ubiquitin and
CC       SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase
CC       complexes and promote the ubiquitination and subsequent
CC       proteasomal degradation of target proteins. Promotes proteasomal
CC       degradation of COMMD1 and IKBKB. Modulates NF-kappa-B
CC       transcriptional activity. Nuclear isoforms promote apoptosis.
CC       Mitochondrial isoforms suppress BAX-dependent release of
CC       cytochrome c into the cytoplasm and inhibit apoptosis. Plays a
CC       role in the regulation of cell proliferation.
CC       {ECO:0000269|PubMed:11123922, ECO:0000269|PubMed:12047389,
CC       ECO:0000269|PubMed:12176985, ECO:0000269|PubMed:12551933,
CC       ECO:0000269|PubMed:12882985, ECO:0000269|PubMed:16113678,
CC       ECO:0000269|PubMed:17260971, ECO:0000269|PubMed:17407782,
CC       ECO:0000269|PubMed:17412999, ECO:0000269|PubMed:17689225,
CC       ECO:0000269|PubMed:19137541, ECO:0000269|PubMed:19535339,
CC       ECO:0000269|PubMed:19996109, ECO:0000269|PubMed:20068069,
CC       ECO:0000269|PubMed:21505792}.
CC   -!- SUBUNIT: Antiparallel disulfide-linked heterodimer of an alpha
CC       chain and a beta chain. Self-associates and forms higher
CC       oligomers. Interacts with a broad range of misfolded proteins,
CC       including APP, APOC2 and LYZ. Slightly acidic pH promotes
CC       interaction with misfolded proteins. Forms high-molecular weight
CC       oligomers upon interaction with misfolded proteins. Interacts with
CC       APOA1, LRP2, CLUAP1 AND PON1. Interacts with the complement
CC       complex. Interacts (via alpha chain) with XRCC6. Interacts with
CC       SYVN1, COMMD1, BTRC, CUL1 and with ubiquitin and SCF (SKP1-CUL1-F-
CC       box protein) E3 ubiquitin-protein ligase complexes. Interacts (via
CC       alpha chain) with BAX in stressed cells, where BAX undergoes a
CC       conformation change leading to association with the mitochondrial
CC       membrane. Does not interact with BAX in unstressed cells. Found in
CC       a complex with LTF, CLU, EPPIN and SEMG1.
CC       {ECO:0000269|PubMed:12047389, ECO:0000269|PubMed:12176985,
CC       ECO:0000269|PubMed:12551933, ECO:0000269|PubMed:1491011,
CC       ECO:0000269|PubMed:15480429, ECO:0000269|PubMed:1551440,
CC       ECO:0000269|PubMed:16113678, ECO:0000269|PubMed:17260971,
CC       ECO:0000269|PubMed:17407782, ECO:0000269|PubMed:17412999,
CC       ECO:0000269|PubMed:1742316, ECO:0000269|PubMed:17451556,
CC       ECO:0000269|PubMed:17567961, ECO:0000269|PubMed:1903064,
CC       ECO:0000269|PubMed:19535339, ECO:0000269|PubMed:1974459,
CC       ECO:0000269|PubMed:20068069, ECO:0000269|PubMed:2387851,
CC       ECO:0000269|PubMed:2780565, ECO:0000269|PubMed:8292612,
CC       ECO:0000269|PubMed:8328966}.
CC   -!- INTERACTION:
CC       P18509:ADCYAP1; NbExp=4; IntAct=EBI-1104674, EBI-8588930;
CC       Q07817-1:BCL2L1; NbExp=6; IntAct=EBI-4322678, EBI-287195;
CC       Q9NRI5:DISC1; NbExp=4; IntAct=EBI-1104674, EBI-529989;
CC       P01100:FOS; NbExp=2; IntAct=EBI-1104674, EBI-852851;
CC       P30101:PDIA3; NbExp=2; IntAct=EBI-1104674, EBI-979862;
CC       P37231:PPARG; NbExp=3; IntAct=EBI-1104674, EBI-781384;
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Secreted. Note=Can
CC       retrotranslocate from the secretory compartments to the cytosol
CC       upon cellular stress.
CC   -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Mitochondrion membrane;
CC       Peripheral membrane protein; Cytoplasmic side. Cytoplasm, cytosol.
CC       Microsome. Endoplasmic reticulum. Cytoplasmic vesicle, secretory
CC       vesicle, chromaffin granule {ECO:0000250}. Note=Isoforms lacking
CC       the N-terminal signal sequence have been shown to be cytoplasmic
CC       and/or nuclear. Secreted isoforms can retrotranslocate from the
CC       secretory compartments to the cytosol upon cellular stress.
CC       Detected in perinuclear foci that may be aggresomes containing
CC       misfolded, ubiquitinated proteins. Detected at the mitochondrion
CC       membrane upon induction of apoptosis.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1; Synonyms=2, CLU35, sCLU;
CC         IsoId=P10909-1; Sequence=Displayed;
CC         Note=Major isoform.;
CC       Name=2; Synonyms=1, CLU34;
CC         IsoId=P10909-2; Sequence=VSP_037661;
CC       Name=3;
CC         IsoId=P10909-3; Sequence=VSP_041475;
CC       Name=4; Synonyms=nCLU;
CC         IsoId=P10909-4; Sequence=VSP_041476;
CC         Note=Minor isoform that has been detected in a breast cancer
CC         cell line, but not in any other tissues or cell lines.;
CC       Name=5; Synonyms=CLU36;
CC         IsoId=P10909-5; Sequence=VSP_041477;
CC   -!- TISSUE SPECIFICITY: Detected in blood plasma, cerebrospinal fluid,
CC       milk, seminal plasma and colon mucosa. Detected in the germinal
CC       center of colon lymphoid nodules and in colon parasympathetic
CC       ganglia of the Auerbach plexus (at protein level). Ubiquitous.
CC       Detected in brain, testis, ovary, liver and pancreas, and at lower
CC       levels in kidney, heart, spleen and lung.
CC       {ECO:0000269|PubMed:11123922, ECO:0000269|PubMed:17260971,
CC       ECO:0000269|PubMed:17322305, ECO:0000269|PubMed:17412999,
CC       ECO:0000269|PubMed:1974459, ECO:0000269|PubMed:2387851,
CC       ECO:0000269|PubMed:2780565, ECO:0000269|PubMed:3154963,
CC       ECO:0000269|PubMed:8181474, ECO:0000269|PubMed:8292612,
CC       ECO:0000269|PubMed:8328966}.
CC   -!- INDUCTION: Up-regulated in response to enterovirus 71 (EV71)
CC       infection (at protein level). Up-regulated by agents that induce
CC       apoptosis, both at mRNA and protein level. Isoform 1 is up-
CC       regulated by androgen. Isoform 2 is down-regulated by androgen.
CC       {ECO:0000269|PubMed:16548883, ECO:0000269|PubMed:17148459,
CC       ECO:0000269|PubMed:17689225}.
CC   -!- PTM: Isoform 1 is proteolytically cleaved on its way through the
CC       secretory system, probably within the Golgi lumen.
CC       {ECO:0000269|PubMed:2387851}.
CC   -!- PTM: Polyubiquitinated, leading to proteasomal degradation.
CC       {ECO:0000269|PubMed:17451556, ECO:0000269|PubMed:19137541}.
CC   -!- PTM: Heavily N-glycosylated. About 30% of the protein mass is
CC       comprised of complex N-linked carbohydrate.
CC       {ECO:0000269|PubMed:12754519, ECO:0000269|PubMed:14760718,
CC       ECO:0000269|PubMed:1551440, ECO:0000269|PubMed:16263699,
CC       ECO:0000269|PubMed:16335952, ECO:0000269|PubMed:16740002,
CC       ECO:0000269|PubMed:17260971, ECO:0000269|PubMed:18780401,
CC       ECO:0000269|PubMed:19139490, ECO:0000269|PubMed:19159218,
CC       ECO:0000269|PubMed:19838169, ECO:0000269|PubMed:2387851,
CC       ECO:0000269|PubMed:9336835}.
CC   -!- SIMILARITY: Belongs to the clusterin family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA35692.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=AAB06508.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=AAB06508.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence.; Evidence={ECO:0000305};
CC       Sequence=AAH10514.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=AAH19588.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=AAP88927.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=AAP88927.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=AAT08041.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=BAG36598.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=CAA32847.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/clu/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/CLUID40107ch8p21.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M25915; AAA35692.1; ALT_INIT; mRNA.
DR   EMBL; M63379; AAB06507.1; -; Genomic_DNA.
DR   EMBL; M63376; AAB06507.1; JOINED; Genomic_DNA.
DR   EMBL; M63377; AAB06507.1; JOINED; Genomic_DNA.
DR   EMBL; M63378; AAB06507.1; JOINED; Genomic_DNA.
DR   EMBL; M64722; AAB06508.1; ALT_SEQ; mRNA.
DR   EMBL; AK093399; BAG52708.1; -; mRNA.
DR   EMBL; AK313870; BAG36598.1; ALT_INIT; mRNA.
DR   EMBL; CR599675; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; BX648414; CAI45990.1; -; mRNA.
DR   EMBL; AY341244; AAP88927.1; ALT_INIT; Genomic_DNA.
DR   EMBL; AF311103; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC010514; AAH10514.1; ALT_INIT; mRNA.
DR   EMBL; BC019588; AAH19588.1; ALT_INIT; mRNA.
DR   EMBL; BU150467; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; J02908; AAA51765.1; -; mRNA.
DR   EMBL; M74816; AAA60321.1; -; mRNA.
DR   EMBL; L00974; AAA60567.1; -; Genomic_DNA.
DR   EMBL; X14723; CAA32847.1; ALT_INIT; mRNA.
DR   EMBL; AY513288; AAT08041.1; ALT_INIT; mRNA.
DR   CCDS; CCDS47832.1; -. [P10909-1]
DR   PIR; S43646; A41386.
DR   RefSeq; NP_001822.3; NM_001831.3. [P10909-1]
DR   RefSeq; XP_006716347.1; XM_006716284.1. [P10909-2]
DR   UniGene; Hs.436657; -.
DR   ProteinModelPortal; P10909; -.
DR   BioGrid; 107603; 123.
DR   DIP; DIP-37546N; -.
DR   IntAct; P10909; 44.
DR   MINT; MINT-3007494; -.
DR   STRING; 9606.ENSP00000315130; -.
DR   iPTMnet; P10909; -.
DR   PhosphoSite; P10909; -.
DR   BioMuta; CLU; -.
DR   DMDM; 116533; -.
DR   DOSAC-COBS-2DPAGE; P10909; -.
DR   OGP; P10909; -.
DR   REPRODUCTION-2DPAGE; IPI00291262; -.
DR   SWISS-2DPAGE; P10909; -.
DR   MaxQB; P10909; -.
DR   PaxDb; P10909; -.
DR   PRIDE; P10909; -.
DR   DNASU; 1191; -.
DR   Ensembl; ENST00000316403; ENSP00000315130; ENSG00000120885. [P10909-1]
DR   Ensembl; ENST00000405140; ENSP00000385419; ENSG00000120885. [P10909-1]
DR   Ensembl; ENST00000523500; ENSP00000429620; ENSG00000120885. [P10909-1]
DR   GeneID; 1191; -.
DR   KEGG; hsa:1191; -.
DR   UCSC; uc003xfw.2; human. [P10909-1]
DR   UCSC; uc003xfy.2; human. [P10909-5]
DR   CTD; 1191; -.
DR   GeneCards; CLU; -.
DR   HGNC; HGNC:2095; CLU.
DR   HPA; CAB000476; -.
DR   HPA; CAB016253; -.
DR   HPA; HPA000572; -.
DR   MIM; 185430; gene.
DR   neXtProt; NX_P10909; -.
DR   PharmGKB; PA26620; -.
DR   eggNOG; ENOG410IHRB; Eukaryota.
DR   eggNOG; ENOG410YYKB; LUCA.
DR   GeneTree; ENSGT00530000063668; -.
DR   HOVERGEN; HBG006908; -.
DR   InParanoid; P10909; -.
DR   KO; K17252; -.
DR   OMA; MKFYARV; -.
DR   OrthoDB; EOG7K6PV4; -.
DR   PhylomeDB; P10909; -.
DR   TreeFam; TF333030; -.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   ChiTaRS; CLU; human.
DR   GeneWiki; Clusterin; -.
DR   GenomeRNAi; 1191; -.
DR   NextBio; 4922; -.
DR   PMAP-CutDB; P10909; -.
DR   PRO; PR:P10909; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   Bgee; P10909; -.
DR   CleanEx; HS_CLU; -.
DR   ExpressionAtlas; P10909; baseline and differential.
DR   Genevisible; P10909; HS.
DR   GO; GO:0016235; C:aggresome; IEA:Ensembl.
DR   GO; GO:0097440; C:apical dendrite; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0072562; C:blood microparticle; IDA:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0042583; C:chromaffin granule; IEA:UniProtKB-SubCell.
DR   GO; GO:0005737; C:cytoplasm; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0005829; C:cytosol; IEA:UniProtKB-SubCell.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:UniProtKB-SubCell.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0031012; C:extracellular matrix; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0030426; C:growth cone; IEA:Ensembl.
DR   GO; GO:0005622; C:intracellular; IDA:GOC.
DR   GO; GO:0031966; C:mitochondrial membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; IDA:BHF-UCL.
DR   GO; GO:0097418; C:neurofibrillary tangle; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0031093; C:platelet alpha granule lumen; TAS:Reactome.
DR   GO; GO:0043234; C:protein complex; IDA:UniProtKB.
DR   GO; GO:0034366; C:spherical high-density lipoprotein particle; IDA:BHF-UCL.
DR   GO; GO:0051087; F:chaperone binding; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0051787; F:misfolded protein binding; IDA:UniProtKB.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IDA:UniProtKB.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0000902; P:cell morphogenesis; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0032286; P:central nervous system myelin maintenance; IMP:Alzheimers_University_of_Toronto.
DR   GO; GO:0051131; P:chaperone-mediated protein complex assembly; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0061077; P:chaperone-mediated protein folding; IDA:UniProtKB.
DR   GO; GO:0006956; P:complement activation; TAS:ProtInc.
DR   GO; GO:0006958; P:complement activation, classical pathway; IEA:UniProtKB-KW.
DR   GO; GO:0031018; P:endocrine pancreas development; IEA:Ensembl.
DR   GO; GO:0044849; P:estrous cycle; IEA:Ensembl.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0097193; P:intrinsic apoptotic signaling pathway; IDA:UniProtKB.
DR   GO; GO:0006629; P:lipid metabolic process; NAS:ProtInc.
DR   GO; GO:0001774; P:microglial cell activation; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0061518; P:microglial cell proliferation; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:1902430; P:negative regulation of beta-amyloid formation; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:1902230; P:negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage; IMP:BHF-UCL.
DR   GO; GO:0032463; P:negative regulation of protein homooligomerization; IMP:BHF-UCL.
DR   GO; GO:0048812; P:neuron projection morphogenesis; IEA:Ensembl.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0002576; P:platelet degranulation; TAS:Reactome.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:1902004; P:positive regulation of beta-amyloid formation; ISS:Alzheimers_University_of_Toronto.
DR   GO; GO:0045597; P:positive regulation of cell differentiation; IEA:Ensembl.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:2001244; P:positive regulation of intrinsic apoptotic signaling pathway; IMP:UniProtKB.
DR   GO; GO:1902998; P:positive regulation of neurofibrillary tangle assembly; IMP:Alzheimers_University_of_Toronto.
DR   GO; GO:1901216; P:positive regulation of neuron death; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IMP:UniProtKB.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IMP:UniProtKB.
DR   GO; GO:2000060; P:positive regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process; IMP:UniProtKB.
DR   GO; GO:1902949; P:positive regulation of tau-protein kinase activity; IMP:Alzheimers_University_of_Toronto.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0017038; P:protein import; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0050821; P:protein stabilization; IDA:UniProtKB.
DR   GO; GO:1900221; P:regulation of beta-amyloid clearance; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:1901214; P:regulation of neuron death; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:1902847; P:regulation of neuronal signal transduction; IMP:Alzheimers_University_of_Toronto.
DR   GO; GO:0001836; P:release of cytochrome c from mitochondria; IC:BHF-UCL.
DR   GO; GO:0009416; P:response to light stimulus; IEA:Ensembl.
DR   GO; GO:0051788; P:response to misfolded protein; IDA:BHF-UCL.
DR   GO; GO:0035864; P:response to potassium ion; IEA:Ensembl.
DR   GO; GO:0009615; P:response to virus; IEP:UniProtKB.
DR   GO; GO:0043691; P:reverse cholesterol transport; TAS:BHF-UCL.
DR   InterPro; IPR016016; Clusterin.
DR   InterPro; IPR000753; Clusterin-like.
DR   InterPro; IPR016015; Clusterin_C.
DR   InterPro; IPR016014; Clusterin_N.
DR   PANTHER; PTHR10970:SF1; PTHR10970:SF1; 1.
DR   Pfam; PF01093; Clusterin; 1.
DR   PIRSF; PIRSF002368; Clusterin; 1.
DR   SMART; SM00035; CLa; 1.
DR   SMART; SM00030; CLb; 1.
DR   PROSITE; PS00492; CLUSTERIN_1; 1.
DR   PROSITE; PS00493; CLUSTERIN_2; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Apoptosis; Chaperone; Complement pathway;
KW   Complete proteome; Cytoplasm; Cytoplasmic vesicle;
KW   Direct protein sequencing; Disulfide bond; Endoplasmic reticulum;
KW   Glycoprotein; Immunity; Innate immunity; Membrane; Microsome;
KW   Mitochondrion; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Secreted; Signal; Ubl conjugation.
FT   SIGNAL        1     22       {ECO:0000269|PubMed:1903064,
FT                                ECO:0000269|PubMed:2387851,
FT                                ECO:0000269|PubMed:2601725,
FT                                ECO:0000269|PubMed:2780565,
FT                                ECO:0000269|PubMed:3154963,
FT                                ECO:0000269|PubMed:8328966}.
FT   CHAIN        23    449       Clusterin.
FT                                /FTId=PRO_0000005529.
FT   CHAIN        23    227       Clusterin beta chain.
FT                                {ECO:0000269|PubMed:1974459}.
FT                                /FTId=PRO_0000005530.
FT   CHAIN       228    449       Clusterin alpha chain.
FT                                {ECO:0000269|PubMed:1974459}.
FT                                /FTId=PRO_0000005531.
FT   MOTIF        78     81       Nuclear localization signal.
FT                                {ECO:0000250}.
FT   MOTIF       443    447       Nuclear localization signal.
FT                                {ECO:0000250}.
FT   MOD_RES     133    133       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     396    396       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   CARBOHYD     86     86       N-linked (GlcNAc...) (complex).
FT                                {ECO:0000269|PubMed:1551440,
FT                                ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19139490,
FT                                ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:9336835}.
FT   CARBOHYD    103    103       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:1551440,
FT                                ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:2721499,
FT                                ECO:0000269|PubMed:9336835}.
FT   CARBOHYD    145    145       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:1551440,
FT                                ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:2721499,
FT                                ECO:0000269|PubMed:9336835}.
FT   CARBOHYD    291    291       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:1551440,
FT                                ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:18780401,
FT                                ECO:0000269|PubMed:2721499,
FT                                ECO:0000269|PubMed:9336835}.
FT   CARBOHYD    317    317       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:18780401}.
FT   CARBOHYD    354    354       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:12754519,
FT                                ECO:0000269|PubMed:14760718,
FT                                ECO:0000269|PubMed:1551440,
FT                                ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:9336835}.
FT   CARBOHYD    374    374       N-linked (GlcNAc...) (complex).
FT                                {ECO:0000269|PubMed:14760718,
FT                                ECO:0000269|PubMed:1551440,
FT                                ECO:0000269|PubMed:16263699,
FT                                ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:16740002,
FT                                ECO:0000269|PubMed:18780401,
FT                                ECO:0000269|PubMed:19139490,
FT                                ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:19838169,
FT                                ECO:0000269|PubMed:9336835}.
FT   DISULFID    102    313       Interchain (between beta and alpha
FT                                chains).
FT   DISULFID    113    305       Interchain (between beta and alpha
FT                                chains).
FT   DISULFID    116    302       Interchain (between beta and alpha
FT                                chains).
FT   DISULFID    121    295       Interchain (between beta and alpha
FT                                chains).
FT   DISULFID    129    285       Interchain (between beta and alpha
FT                                chains).
FT   VAR_SEQ       1    175       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_041475.
FT   VAR_SEQ       1     33       Missing (in isoform 4). {ECO:0000305}.
FT                                /FTId=VSP_041476.
FT   VAR_SEQ       1      1       M -> MQVCSQPQRGCVREQSAINTAPPSAHNAASPGGARG
FT                                HRVPLTEACKDSRIGGM (in isoform 2).
FT                                {ECO:0000303|PubMed:17974005,
FT                                ECO:0000303|PubMed:2780565,
FT                                ECO:0000303|Ref.4}.
FT                                /FTId=VSP_037661.
FT   VAR_SEQ       1      1       M -> MEACKDSRIGGM (in isoform 5).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_041477.
FT   VARIANT     317    317       N -> H (in dbSNP:rs9331936).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_019366.
FT   VARIANT     328    328       D -> N (in dbSNP:rs9331938).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_019367.
FT   VARIANT     396    396       S -> L (in dbSNP:rs13494).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_019368.
FT   CONFLICT     28     28       D -> S (in Ref. 9; AA sequence and 13; AA
FT                                sequence). {ECO:0000305}.
FT   CONFLICT     47     47       Q -> H (in Ref. 10; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT     52     52       G -> Q (in Ref. 10; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    172    172       M -> V (in Ref. 5; CAI45990).
FT                                {ECO:0000305}.
FT   CONFLICT    224    224       R -> L (in Ref. 3; BAG36598).
FT                                {ECO:0000305}.
FT   CONFLICT    305    305       C -> M (in Ref. 9; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    388    388       T -> M (in Ref. 5; CAI45990).
FT                                {ECO:0000305}.
FT   CONFLICT    411    411       D -> G (in Ref. 3; BAG36598).
FT                                {ECO:0000305}.
SQ   SEQUENCE   449 AA;  52495 MW;  9583DE4CCECC169F CRC64;
     MMKTLLLFVG LLLTWESGQV LGDQTVSDNE LQEMSNQGSK YVNKEIQNAV NGVKQIKTLI
     EKTNEERKTL LSNLEEAKKK KEDALNETRE SETKLKELPG VCNETMMALW EECKPCLKQT
     CMKFYARVCR SGSGLVGRQL EEFLNQSSPF YFWMNGDRID SLLENDRQQT HMLDVMQDHF
     SRASSIIDEL FQDRFFTREP QDTYHYLPFS LPHRRPHFFF PKSRIVRSLM PFSPYEPLNF
     HAMFQPFLEM IHEAQQAMDI HFHSPAFQHP PTEFIREGDD DRTVCREIRH NSTGCLRMKD
     QCDKCREILS VDCSTNNPSQ AKLRRELDES LQVAERLTRK YNELLKSYQW KMLNTSSLLE
     QLNEQFNWVS RLANLTQGED QYYLRVTTVA SHTSDSDVPS GVTEVVVKLF DSDPITVTVP
     VEVSRKNPKF METVAEKALQ EYRKKHREE
//
ID   ALBU_HUMAN              Reviewed;         609 AA.
AC   P02768; E7ESS9; O95574; P04277; Q13140; Q645G4; Q68DN5; Q6UXK4;
AC   Q86YG0; Q8IUK7; Q9P157; Q9P1I7; Q9UHS3; Q9UJZ0;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1990, sequence version 2.
DT   17-FEB-2016, entry version 226.
DE   RecName: Full=Serum albumin;
DE   Flags: Precursor;
GN   Name=ALB;
GN   ORFNames=GIG20, GIG42, PRO0903, PRO1708, PRO2044, PRO2619, PRO2675,
GN   UNQ696/PRO1341;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT LYS-420.
RX   PubMed=6171778; DOI=10.1093/nar/9.22.6103;
RA   Lawn R.M., Adelman J., Bock S.C., Franke A.E., Houck C.M.,
RA   Najarian R.C., Seeburg P.H., Wion K.L.;
RT   "The sequence of human serum albumin cDNA and its expression in E.
RT   coli.";
RL   Nucleic Acids Res. 9:6103-6114(1981).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT GLY-121.
RX   PubMed=6275391; DOI=10.1073/pnas.79.1.71;
RA   Dugaiczyk A., Law S.W., Dennison O.E.;
RT   "Nucleotide sequence and the encoded amino acids of human serum
RT   albumin mRNA.";
RL   Proc. Natl. Acad. Sci. U.S.A. 79:71-75(1982).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=3009475;
RA   Minghetti P.P., Ruffner D.E., Kuang W.J., Dennison O.E., Hawkins J.W.,
RA   Beattie W.G., Dugaiczyk A.;
RT   "Molecular structure of the human albumin gene is revealed by
RT   nucleotide sequence within q11-22 of chromosome 4.";
RL   J. Biol. Chem. 261:6747-6757(1986).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RA   Yang S., Zhang R.A., Qi Z.W., Yuan Z.Y.;
RT   "Human serum albumin.";
RL   Submitted (SEP-1999) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT HIROSHIMA-1
RP   LYS-378.
RA   Huang M.C., Wu H.T.;
RT   "The cDNA sequences of human serum albumin.";
RL   Submitted (AUG-2002) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Hinchliffe E.;
RT   "Induction of galactose regulated gene expression in yeast.";
RL   Patent number EP0248637, 09-DEC-1987.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RA   Yu Z., Fu Y.;
RT   "High expression HSA in Pichia for Pharmaceutical Use.";
RL   Submitted (AUG-2004) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Wang F., Huang L.;
RT   "Cloning and sequence analysis of human albumin gene.";
RL   Submitted (SEP-2006) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RA   Kim J.W.;
RT   "Identification of a human cell growth inhibition gene.";
RL   Submitted (FEB-2004) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Fetal liver;
RX   PubMed=11483580; DOI=10.1101/gr.175501;
RA   Yu Y., Zhang C., Zhou G., Wu S., Qu X., Wei H., Xing G., Dong C.,
RA   Zhai Y., Wan J., Ouyang S., Li L., Zhang S., Zhou K., Zhang Y., Wu C.,
RA   He F.;
RT   "Gene expression profiling in human fetal liver and identification of
RT   tissue- and developmental-stage-specific genes through compiled
RT   expression profiles and efficient cloning of full-length cDNAs.";
RL   Genome Res. 11:1392-1403(2001).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   TYR-27.
RC   TISSUE=Liver;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JUN-2007) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [15]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3).
RC   TISSUE=Liver, and Skeletal muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-455.
RC   TISSUE=Liver;
RA   Menaya J., Parrilla R., Ayuso M.S.;
RL   Submitted (MAR-1995) to the EMBL/GenBank/DDBJ databases.
RN   [17]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-167.
RX   PubMed=12975309; DOI=10.1101/gr.1293003;
RA   Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J.,
RA   Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA   Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S.,
RA   Huang A., Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J.,
RA   Lewis L., Liao D., Mark M.R., Robbie E., Sanchez C., Schoenfeld J.,
RA   Seshagiri S., Simmons L., Singh J., Smith V., Stinson J., Vagts A.,
RA   Vandlen R.L., Watanabe C., Wieand D., Woods K., Xie M.-H.,
RA   Yansura D.G., Yi S., Yu G., Yuan J., Zhang M., Zhang Z., Goddard A.D.,
RA   Wood W.I., Godowski P.J., Gray A.M.;
RT   "The secreted protein discovery initiative (SPDI), a large-scale
RT   effort to identify novel human secreted and transmembrane proteins: a
RT   bioinformatics assessment.";
RL   Genome Res. 13:2265-2270(2003).
RN   [18]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-26.
RX   PubMed=2419329;
RA   Urano Y., Watanabe K., Sakai M., Tamaoki T.;
RT   "The human albumin gene. Characterization of the 5' and 3' flanking
RT   regions and the polymorphic gene transcripts.";
RL   J. Biol. Chem. 261:3244-3251(1986).
RN   [19]
RP   PROTEIN SEQUENCE OF 25-609.
RX   PubMed=1225573; DOI=10.1016/0014-5793(75)80242-0;
RA   Meloun B., Moravek L., Kostka V.;
RT   "Complete amino acid sequence of human serum albumin.";
RL   FEBS Lett. 58:134-137(1975).
RN   [20]
RP   PROTEIN SEQUENCE OF 25-609.
RA   Brown J.R., Shockley P., Behrens P.Q.;
RL   (In) Bing D.H. (eds.);
RL   The chemistry and physiology of the human plasma proteins, pp.23-40,
RL   Pergamon Press, New York (1979).
RN   [21]
RP   PROTEIN SEQUENCE OF 25-44 AND 480-499.
RC   TISSUE=Heart;
RX   PubMed=7895732; DOI=10.1002/elps.11501501209;
RA   Corbett J.M., Wheeler C.H., Baker C.S., Yacoub M.H., Dunn M.J.;
RT   "The human myocardial two-dimensional gel protein database: update
RT   1994.";
RL   Electrophoresis 15:1459-1465(1994).
RN   [22]
RP   PROTEIN SEQUENCE OF 25-34.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A.,
RA   Thomas G.R., Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass
RT   spectrometric identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [23]
RP   PROTEIN SEQUENCE OF 45-75; 98-130; 162-183; 239-254; 265-281; 287-298;
RP   348-372; 397-434; 438-452; 500-543; 550-558; 570-581 AND 599-609, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Brain, Cajal-Retzius cell, and Fetal brain cortex;
RA   Lubec G., Vishwanath V., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [24]
RP   PROTEIN SEQUENCE OF 166-174.
RX   PubMed=3087352; DOI=10.1016/0006-291X(86)90429-8;
RA   Mogard M.H., Kobayashi R., Chen C.F., Lee T.D., Reeve J.R. Jr.,
RA   Shively J.E., Walsh J.H.;
RT   "The amino acid sequence of kinetensin, a novel peptide isolated from
RT   pepsin-treated human plasma: homology with human serum albumin,
RT   neurotensin and angiotensin.";
RL   Biochem. Biophys. Res. Commun. 136:983-988(1986).
RN   [25]
RP   PROTEIN SEQUENCE OF 166-174.
RX   PubMed=2437111;
RA   Carraway R.E., Mitra S.P., Cochrane D.E.;
RT   "Structure of a biologically active neurotensin-related peptide
RT   obtained from pepsin-treated albumin(s).";
RL   J. Biol. Chem. 262:5968-5973(1987).
RN   [26]
RP   PROTEIN SEQUENCE OF 222-229, AND ASPIRIN-ACETYLATION AT LYS-223.
RX   PubMed=955075; DOI=10.1016/0014-5793(76)80496-6;
RA   Walker J.E.;
RT   "Lysine residue 199 of human serum albumin is modified by
RT   acetylsalicylic acid.";
RL   FEBS Lett. 66:173-175(1976).
RN   [27]
RP   PROTEIN SEQUENCE OF 250-264, GLYCATION AT LYS-75; LYS-161; LYS-186;
RP   LYS-249; LYS-257; LYS-300; LYS-337; LYS-347; LYS-375; LYS-402;
RP   LYS-437; LYS-468; LYS-560; LYS-549; LYS-569 AND LYS-597, LACK OF
RP   GLYCATION AT LYS-28; LYS-44; LYS-65; LYS-88; LYS-97; LYS-117; LYS-130;
RP   LYS-160; LYS-183; LYS-198; LYS-205; LYS-214; LYS-219; LYS-229;
RP   LYS-236; LYS-264; LYS-286; LYS-298; LYS-310; LYS-383; LYS-396;
RP   LYS-413; LYS-426; LYS-438; LYS-456; LYS-460; LYS-490; LYS-499;
RP   LYS-524; LYS-543; LYS-548; LYS-562; LYS-565; LYS-581; LYS-584; LYS-588
RP   AND LYS-598, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=15047055; DOI=10.1016/j.jasms.2003.11.014;
RA   Lapolla A., Fedele D., Reitano R., Arico N.C., Seraglia R., Traldi P.,
RA   Marotta E., Tonani R.;
RT   "Enzymatic digestion and mass spectrometry in the study of advanced
RT   glycation end products/peptides.";
RL   J. Am. Soc. Mass Spectrom. 15:496-509(2004).
RN   [28]
RP   DISULFIDE BONDS.
RA   Saber M.A., Stockbauer P., Moravek L., Meloun B.;
RT   "Disulfide bonds in human serum albumin.";
RL   Collect. Czech. Chem. Commun. 42:564-579(1977).
RN   [29]
RP   BILIRUBIN-BINDING SITE.
RX   PubMed=656055;
RA   Jacobsen C.;
RT   "Lysine residue 240 of human serum albumin is involved in high-
RT   affinity binding of bilirubin.";
RL   Biochem. J. 171:453-459(1978).
RN   [30]
RP   GLYCATION AT LYS-223 AND LYS-549.
RX   PubMed=6853480;
RA   Garlick R.L., Mazer J.S.;
RT   "The principal site of nonenzymatic glycosylation of human serum
RT   albumin in vivo.";
RL   J. Biol. Chem. 258:6142-6146(1983).
RN   [31]
RP   GLYCATION AT LYS-549.
RX   PubMed=6706980;
RA   Shaklai N., Garlick R.L., Bunn H.F.;
RT   "Nonenzymatic glycosylation of human serum albumin alters its
RT   conformation and function.";
RL   J. Biol. Chem. 259:3812-3817(1984).
RN   [32]
RP   GLYCATION AT LYS-36; LYS-223; LYS-257; LYS-305; LYS-341; LYS-375;
RP   LYS-463; LYS-549 AND LYS-558.
RX   PubMed=3759977;
RA   Iberg N., Fluckiger R.;
RT   "Nonenzymatic glycosylation of albumin in vivo. Identification of
RT   multiple glycosylated sites.";
RL   J. Biol. Chem. 261:13542-13545(1986).
RN   [33]
RP   INVOLVEMENT IN ANALBA.
RX   PubMed=8134387; DOI=10.1073/pnas.91.6.2275;
RA   Watkins S., Madison J., Galliano M., Minchiotti L., Putnam F.W.;
RT   "A nucleotide insertion and frameshift cause analbuminemia in an
RT   Italian family.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:2275-2279(1994).
RN   [34]
RP   FUNCTION, AND ZINC-BINDING SITES.
RX   PubMed=19021548; DOI=10.1042/BST0361317;
RA   Lu J., Stewart A.J., Sadler P.J., Pinheiro T.J., Blindauer C.A.;
RT   "Albumin as a zinc carrier: properties of its high-affinity zinc-
RT   binding site.";
RL   Biochem. Soc. Trans. 36:1317-1321(2008).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-82, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=18318008; DOI=10.1002/pmic.200700884;
RA   Han G., Ye M., Zhou H., Jiang X., Feng S., Jiang X., Tian R., Wan D.,
RA   Zou H., Gu J.;
RT   "Large-scale phosphoproteome analysis of human liver tissue by
RT   enrichment and fractionation of phosphopeptides with strong anion
RT   exchange chromatography.";
RL   Proteomics 8:1346-1361(2008).
RN   [36]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-443; THR-444 AND
RP   THR-446, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [37]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [38]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-82; SER-89 AND SER-513,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [39]
RP   PHOSPHORYLATION AT SER-29; SER-82; SER-89 AND THR-107.
RX   PubMed=26091039; DOI=10.1016/j.cell.2015.05.028;
RA   Tagliabracci V.S., Wiley S.E., Guo X., Kinch L.N., Durrant E., Wen J.,
RA   Xiao J., Cui J., Nguyen K.B., Engel J.L., Coon J.J., Grishin N.,
RA   Pinna L.A., Pagliarini D.J., Dixon J.E.;
RT   "A single kinase generates the majority of the secreted
RT   phosphoproteome.";
RL   Cell 161:1619-1632(2015).
RN   [40]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [41]
RP   X-RAY CRYSTALLOGRAPHY (6.0 ANGSTROMS).
RX   PubMed=2727704; DOI=10.1126/science.2727704;
RA   Carter D.C., He X.-M., Munson S.H., Twigg P.D., Gernert K.M.,
RA   Broom M.B., Miller T.Y.;
RT   "Three-dimensional structure of human serum albumin.";
RL   Science 244:1195-1198(1989).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (4.0 ANGSTROMS).
RX   PubMed=2374930; DOI=10.1126/science.2374930;
RA   Carter D.C., He X.-M.;
RT   "Structure of human serum albumin.";
RL   Science 249:302-303(1990).
RN   [43]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS).
RX   PubMed=1630489; DOI=10.1038/358209a0;
RA   He X.-M., Carter D.C.;
RT   "Atomic structure and chemistry of human serum albumin.";
RL   Nature 358:209-215(1992).
RN   [44]
RP   ERRATUM.
RA   He X.-M., Carter D.C.;
RL   Nature 364:362-362(1993).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS).
RX   PubMed=9731778; DOI=10.1038/1869;
RA   Curry S., Mandelkow H., Brick P., Franks N.;
RT   "Crystal structure of human serum albumin complexed with fatty acid
RT   reveals an asymmetric distribution of binding sites.";
RL   Nat. Struct. Biol. 5:827-835(1998).
RN   [46]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS).
RX   PubMed=10388840; DOI=10.1093/protein/12.6.439;
RA   Sugio S., Kashima A., Mochizuki S., Noda M., Kobayashi K.;
RT   "Crystal structure of human serum albumin at 2.5-A resolution.";
RL   Protein Eng. 12:439-446(1999).
RN   [47]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 25-609.
RX   PubMed=10940303; DOI=10.1074/jbc.M005460200;
RA   Bhattacharya A.A., Curry S., Franks N.P.;
RT   "Binding of the general anesthetics propofol and halothane to human
RT   serum albumin. High resolution crystal structures.";
RL   J. Biol. Chem. 275:38731-38738(2000).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS).
RX   PubMed=11743713; DOI=10.1006/jmbi.2000.5208;
RA   Petitpas I., Grune T., Bhattacharya A.A., Curry S.;
RT   "Crystal structures of human serum albumin complexed with
RT   monounsaturated and polyunsaturated fatty acids.";
RL   J. Mol. Biol. 314:955-960(2001).
RN   [49]
RP   VARIANT CANTERBURY ASN-337.
RX   PubMed=3828358; DOI=10.1016/0167-4838(87)90088-4;
RA   Brennan S.O., Herbert P.;
RT   "Albumin Canterbury (313 Lys-->Asn). A point mutation in the second
RT   domain of serum albumin.";
RL   Biochim. Biophys. Acta 912:191-197(1987).
RN   [50]
RP   VARIANTS NASKAPI/MERSIN GLU-396 AND MEXICO GLY-574.
RX   PubMed=3474609; DOI=10.1073/pnas.84.13.4413;
RA   Takahashi N., Takahashi Y., Blumberg B.S., Putnam F.W.;
RT   "Amino acid substitutions in genetic variants of human serum albumin
RT   and in sequences inferred from molecular cloning.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:4413-4417(1987).
RN   [51]
RP   VARIANTS NAGASAKI-3 GLN-27 YANOMAMA-2 GLU-396; NAGASAKI-2 ASN-399 AND
RP   MAKU GLU-565.
RX   PubMed=3479777; DOI=10.1073/pnas.84.22.8001;
RA   Takshashi N., Takahashi Y., Isobe T., Putnam F.W., Fujita M.,
RA   Satoh C., Neel J.V.;
RT   "Amino acid substitutions in inherited albumin variants from
RT   Amerindian and Japanese populations.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:8001-8005(1987).
RN   [52]
RP   VARIANTS FUKUOKA-2 HIS-23; CHRISTCHURCH/HONOLULU-2 GLN-24; TAGLIACOZZO
RP   ASN-337 AND ALBUMIN B/OSAKA-2/PHNOM PHEN LYS-594.
RX   PubMed=2911589; DOI=10.1073/pnas.86.2.434;
RA   Arai K., Ishioka N., Huss K., Madison J., Putnam F.W.;
RT   "Identical structural changes in inherited albumin variants from
RT   different populations.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:434-438(1989).
RN   [53]
RP   VARIANTS HONOLULU-2 GLN-24; NAGASAKI-1 GLY-293; HIROSHIMA-1 LYS-378;
RP   TOCHIGI LYS-400; HIROSHIMA-2 LYS-406 AND OSAKA-2 LYS-594.
RX   PubMed=2762316; DOI=10.1073/pnas.86.16.6092;
RA   Arai K., Madison J., Huss K., Ishioka N., Satoh C., Fujita M.,
RA   Neel J.V., Sakurabayashi I., Putnam F.W.;
RT   "Point substitutions in Japanese alloalbumins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:6092-6096(1989).
RN   [54]
RP   VARIANTS HONOLULU-1 PRO-24; HONOLULU-2 GLN-24; NAGOYA LYS-143; NEW
RP   GUINEA ASN-337; MANAUS-1/LAMBADI LYS-525; FUKUOKA-1 ASN-587; OSAKA-1
RP   LYS-589 AND OSAKA-2 LYS-594.
RX   PubMed=2404284; DOI=10.1073/pnas.87.1.497;
RA   Arai K., Madison J., Shimuzu A., Putnam F.W.;
RT   "Point substitutions in albumin genetic variants from Asia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:497-501(1990).
RN   [55]
RP   CHARACTERIZATION OF VARIANT REDHILL.
RX   PubMed=2104980; DOI=10.1073/pnas.87.1.26;
RA   Brennan S.O., Myles T., Peach R.J., Donaldson D., George P.M.;
RT   "Albumin Redhill (-1 Arg, 320 Ala-->Thr): a glycoprotein variant of
RT   human serum albumin whose precursor has an aberrant signal peptidase
RT   cleavage site.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:26-30(1990).
RN   [56]
RP   VARIANTS VARESE HIS-23; TORINO LYS-84 AND VIBO VALENTIA LYS-106.
RX   PubMed=2247440; DOI=10.1073/pnas.87.22.8721;
RA   Galliano M., Minchiotti L., Porta F., Rossi A., Ferri G., Madison J.,
RA   Watkins S., Putnam F.W.;
RT   "Mutations in genetic variants of human serum albumin found in
RT   Italy.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:8721-8725(1990).
RN   [57]
RP   CHARACTERIZATION OF VARIANT VENEZIA.
RX   PubMed=2068071; DOI=10.1073/pnas.88.14.5959;
RA   Watkins S., Madison J., Davis E., Sakamoto Y., Galliano M.,
RA   Minchiotti L., Putnam F.W.;
RT   "A donor splice mutation and a single-base deletion produce two
RT   carboxyl-terminal variants of human serum albumin.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:5959-5963(1991).
RN   [58]
RP   VARIANTS KOMAGOME-3 HIS-23; IOWA CITY-2 VAL-25; KOMAGOME-2 ARG-152;
RP   IOWA CITY-1 VAL-389 AND KOMAGOME-1 GLU-396.
RX   PubMed=1946412; DOI=10.1073/pnas.88.21.9853;
RA   Madison J., Arai K., Feld R.D., Kyle R.A., Watkins S., Davis E.,
RA   Matsuda Y., Amaki I., Putnam F.W.;
RT   "Genetic variants of serum albumin in Americans and Japanese.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:9853-9857(1991).
RN   [59]
RP   VARIANT CASEBROOK ASN-518.
RX   PubMed=1859851; DOI=10.1016/0925-4439(91)90023-3;
RA   Peach R.J., Brennan S.O.;
RT   "Structural characterization of a glycoprotein variant of human serum
RT   albumin: albumin Casebrook (494 Asp-->Asn).";
RL   Biochim. Biophys. Acta 1097:49-54(1991).
RN   [60]
RP   VARIANTS SONDRIO LYS-357 AND PARIS-2 ASN-587.
RX   PubMed=1347703; DOI=10.1016/0167-4838(92)90207-T;
RA   Minchiotti L., Galliano M., Stoppini M., Ferri G., Crespeau H.,
RA   Rochu D., Porta F.;
RT   "Two alloalbumins with identical electrophoretic mobility are produced
RT   by differently charged amino acid substitutions.";
RL   Biochim. Biophys. Acta 1119:232-238(1992).
RN   [61]
RP   VARIANTS MALMO-I CYS-23; MALMO-95 ASN-87; MALMO-10 ARG-292; MALMO-47
RP   LYS-342; MALMO-5 GLN-400 AND MALMO-61 ALA-574.
RX   PubMed=1518850; DOI=10.1073/pnas.89.17.8225;
RA   Carlson J., Sakamoto Y., Laurell C.-B., Madison J., Watkins S.,
RA   Putnam F.W.;
RT   "Alloalbuminemia in Sweden: structural study and phenotypic
RT   distribution of nine albumin variants.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:8225-8229(1992).
RN   [62]
RP   VARIANT HERBORN GLU-264.
RX   PubMed=8513793; DOI=10.1111/j.1432-1033.1993.tb17939.x;
RA   Minchiotti L., Galliano M., Zapponi M.C., Tenni R.;
RT   "The structural characterization and bilirubin-binding properties of
RT   albumin Herborn, a [Lys240-->Glu] albumin mutant.";
RL   Eur. J. Biochem. 214:437-444(1993).
RN   [63]
RP   VARIANT HAWKES BAY PHE-201.
RX   PubMed=8347685; DOI=10.1016/0925-4439(93)90151-P;
RA   Brennan S.O., Fellowes A.P.;
RT   "Albumin Hawkes Bay; a low level variant caused by loss of a
RT   sulphydryl group at position 177.";
RL   Biochim. Biophys. Acta 1182:46-50(1993).
RN   [64]
RP   VARIANT ORTONOVO LYS-529.
RX   PubMed=7902134; DOI=10.1016/0925-4439(93)90117-J;
RA   Galliano M., Minchiotti L., Iadarola P., Stoppini M., Giagnoni P.,
RA   Watkins S., Madison J., Putnam F.W.;
RT   "Protein and DNA sequence analysis of a 'private' genetic variant:
RT   albumin Ortonovo (Glu-505-->Lys).";
RL   Biochim. Biophys. Acta 1225:27-32(1993).
RN   [65]
RP   VARIANTS LARINO TYR-27; TRADATE-2 GLN-249 AND CASERTA ASN-300.
RX   PubMed=8022807; DOI=10.1073/pnas.91.14.6476;
RA   Madison J., Galliano M., Watkins S., Minchiotti L., Porta F.,
RA   Rossi A., Putnam F.W.;
RT   "Genetic variants of human serum albumin in Italy: point mutants and a
RT   carboxyl-terminal variant.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:6476-6480(1994).
RN   [66]
RP   VARIANT DH HIS-242.
RX   PubMed=8048949; DOI=10.1006/bbrc.1994.1998;
RA   Sunthornthepvarakul T., Angkeow P., Weiss R.E., Hayashi Y.,
RA   Retetoff S.;
RT   "An identical missense mutation in the albumin gene results in
RT   familial dysalbuminemic hyperthyroxinemia in 8 unrelated families.";
RL   Biochem. Biophys. Res. Commun. 202:781-787(1994).
RN   [67]
RP   VARIANT DH HIS-242, AND PROTEIN SEQUENCE OF 25-51.
RX   PubMed=7852505; DOI=10.1210/jc.80.2.461;
RA   Rushbrook J.I., Becker E., Schussler G.C., Divino C.M.;
RT   "Identification of a human serum albumin species associated with
RT   familial dysalbuminemic hyperthyroxinemia.";
RL   J. Clin. Endocrinol. Metab. 80:461-467(1995).
RN   [68]
RP   VARIANT DH HIS-242.
RX   PubMed=9329347; DOI=10.1210/jc.82.10.3246;
RA   Wada N., Chiba H., Shimizu C., Kijima H., Kubo M., Koike T.;
RT   "A novel missense mutation in codon 218 of the albumin gene in a
RT   distinct phenotype of familial dysalbuminemic hyperthyroxinemia in a
RT   Japanese kindred.";
RL   J. Clin. Endocrinol. Metab. 82:3246-3250(1997).
RN   [69]
RP   VARIANT DH PRO-90.
RX   PubMed=9589637; DOI=10.1210/jc.83.5.1448;
RA   Sunthornthepvarakul T., Likitmaskul S., Ngowngarmratana S.,
RA   Angsusingha K., Kitvitayasak S., Scherberg N.H., Refetoff S.;
RT   "Familial dysalbuminemic hypertriiodothyroninemia: a new, dominantly
RT   inherited albumin defect.";
RL   J. Clin. Endocrinol. Metab. 83:1448-1454(1998).
RN   [70]
RP   VARIANT TYR-73, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Urine;
RX   PubMed=11680902;
RX   DOI=10.1002/1615-9861(200101)1:1<93::AID-PROT93>3.3.CO;2-V;
RA   Spahr C.S., Davis M.T., McGinley M.D., Robinson J.H., Bures E.J.,
RA   Beierle J., Mort J., Courchesne P.L., Chen K., Wahl R.C., Yu W.,
RA   Luethy R., Patterson S.D.;
RT   "Towards defining the urinary proteome using liquid chromatography-
RT   tandem mass spectrometry I. Profiling an unfractionated tryptic
RT   digest.";
RL   Proteomics 1:93-107(2001).
RN   [71]
RP   CHARACTERIZATION OF VARIANT KENITRA.
RX   PubMed=11168369; DOI=10.1046/j.1432-1033.2001.01899.x;
RA   Minchiotti L., Campagnoli M., Rossi A., Cosulich M.E., Monti M.,
RA   Pucci P., Kragh-Hansen U., Granel B., Disdier P., Weiller P.J.,
RA   Galliano M.;
RT   "A nucleotide insertion and frameshift cause albumin Kenitra, an
RT   extended and O-glycosylated mutant of human serum albumin with two
RT   additional disulfide bridges.";
RL   Eur. J. Biochem. 268:344-352(2001).
CC   -!- FUNCTION: Serum albumin, the main protein of plasma, has a good
CC       binding capacity for water, Ca(2+), Na(+), K(+), fatty acids,
CC       hormones, bilirubin and drugs. Its main function is the regulation
CC       of the colloidal osmotic pressure of blood. Major zinc transporter
CC       in plasma, typically binds about 80% of all plasma zinc.
CC       {ECO:0000269|PubMed:19021548}.
CC   -!- INTERACTION:
CC       P02786:TFRC; NbExp=2; IntAct=EBI-714423, EBI-355727;
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P02768-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P02768-2; Sequence=VSP_021275;
CC       Name=3;
CC         IsoId=P02768-3; Sequence=VSP_057389;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Plasma.
CC   -!- PTM: Kenitra variant is partially O-glycosylated at Thr-620. It
CC       has two new disulfide bonds Cys-600 to Cys-602 and Cys-601 to Cys-
CC       606.
CC   -!- PTM: Glycated in diabetic patients.
CC   -!- PTM: Phosphorylated by FAM20C in the extracellular medium.
CC       {ECO:0000269|PubMed:26091039}.
CC   -!- PTM: Acetylated on Lys-223 by acetylsalicylic acid.
CC   -!- POLYMORPHISM: A variant structure of albumin could lead to
CC       increased binding of zinc resulting in an asymptomatic
CC       augmentation of zinc concentration in the blood. The sequence
CC       shown is that of variant albumin A.
CC   -!- DISEASE: Hyperthyroxinemia, familial dysalbuminemic (FDAH)
CC       [MIM:615999]: A disorder characterized by abnormally elevated
CC       levels of total serum thyroxine (T4) in euthyroid patients. It is
CC       due to abnormal serum albumin that binds T4 with enhanced
CC       affinity. {ECO:0000269|PubMed:7852505, ECO:0000269|PubMed:8048949,
CC       ECO:0000269|PubMed:9329347, ECO:0000269|PubMed:9589637}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Analbuminemia (ANALBA) [MIM:616000]: A rare autosomal
CC       recessive disorder manifested by the presence of a very low amount
CC       of circulating serum albumin. Affected individuals manifest mild
CC       edema, hypotension, fatigue, and, occasionally, lower body
CC       lipodystrophy (mainly in adult females). The most common
CC       biochemical finding is hyperlipidemia, with a significant increase
CC       in the total and LDL cholesterol concentrations, but normal
CC       concentrations of HDL cholesterol and triglycerides.
CC       {ECO:0000269|PubMed:8134387}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the ALB/AFP/VDB family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00769}.
CC   -!- SIMILARITY: Contains 3 albumin domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00769}.
CC   -!- CAUTION: A peptide arising from positions 166 to 174 was
CC       originally (PubMed:3087352 and PubMed:2437111) termed neurotensin-
CC       related peptide (NRP) or kinetensin and was thought to regulate
CC       fat digestion, lipid absorption, and blood flow. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAF22034.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=AAF69644.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=AAG35503.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Albumin Website;
CC       URL="http://www.albumin.org";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Serum albumin entry;
CC       URL="https://en.wikipedia.org/wiki/Serum_albumin";
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/alb/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; V00494; CAA23753.1; -; mRNA.
DR   EMBL; V00495; CAA23754.1; -; mRNA.
DR   EMBL; M12523; AAA98797.1; -; Genomic_DNA.
DR   EMBL; M12523; AAA98798.1; -; Genomic_DNA.
DR   EMBL; AF190168; AAF01333.1; -; mRNA.
DR   EMBL; AF542069; AAN17825.1; -; mRNA.
DR   EMBL; A06977; CAA00606.1; -; mRNA.
DR   EMBL; AY728024; AAU21642.1; -; mRNA.
DR   EMBL; DQ986150; ABJ16448.1; -; mRNA.
DR   EMBL; AY544124; AAT11155.1; -; mRNA.
DR   EMBL; AY550967; AAT52213.1; -; mRNA.
DR   EMBL; AF116645; AAF71067.1; -; mRNA.
DR   EMBL; AF118090; AAF22034.1; ALT_INIT; mRNA.
DR   EMBL; AF119840; AAF69594.1; -; mRNA.
DR   EMBL; AF119890; AAF69644.1; ALT_INIT; mRNA.
DR   EMBL; AF130077; AAG35503.1; ALT_INIT; mRNA.
DR   EMBL; CR749331; CAH18185.1; -; mRNA.
DR   EMBL; EF649953; ABS29264.1; -; Genomic_DNA.
DR   EMBL; AC108157; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471057; EAX05676.1; -; Genomic_DNA.
DR   EMBL; BC014308; AAH14308.1; -; mRNA.
DR   EMBL; BC034023; AAH34023.1; -; mRNA.
DR   EMBL; BC035969; AAH35969.1; -; mRNA.
DR   EMBL; BC036003; AAH36003.1; -; mRNA.
DR   EMBL; BC041789; AAH41789.1; -; mRNA.
DR   EMBL; U22961; AAA64922.1; -; mRNA.
DR   EMBL; AY358313; AAQ89947.1; -; mRNA.
DR   EMBL; AH002596; AAA51688.1; -; Genomic_DNA.
DR   CCDS; CCDS3555.1; -. [P02768-1]
DR   PIR; A93743; ABHUS.
DR   RefSeq; NP_000468.1; NM_000477.5. [P02768-1]
DR   UniGene; Hs.418167; -.
DR   UniGene; Hs.592379; -.
DR   PDB; 1AO6; X-ray; 2.50 A; A/B=25-609.
DR   PDB; 1BJ5; X-ray; 2.50 A; A=25-609.
DR   PDB; 1BKE; X-ray; 3.15 A; A=28-608.
DR   PDB; 1BM0; X-ray; 2.50 A; A/B=25-609.
DR   PDB; 1E78; X-ray; 2.60 A; A/B=25-609.
DR   PDB; 1E7A; X-ray; 2.20 A; A/B=25-609.
DR   PDB; 1E7B; X-ray; 2.38 A; A/B=25-609.
DR   PDB; 1E7C; X-ray; 2.40 A; A=25-609.
DR   PDB; 1E7E; X-ray; 2.50 A; A=25-609.
DR   PDB; 1E7F; X-ray; 2.43 A; A=25-609.
DR   PDB; 1E7G; X-ray; 2.50 A; A=25-609.
DR   PDB; 1E7H; X-ray; 2.43 A; A=25-609.
DR   PDB; 1E7I; X-ray; 2.70 A; A=25-609.
DR   PDB; 1GNI; X-ray; 2.40 A; A=25-609.
DR   PDB; 1GNJ; X-ray; 2.60 A; A=25-609.
DR   PDB; 1H9Z; X-ray; 2.50 A; A=25-609.
DR   PDB; 1HA2; X-ray; 2.50 A; A=25-609.
DR   PDB; 1HK1; X-ray; 2.65 A; A=25-609.
DR   PDB; 1HK2; X-ray; 2.80 A; A=25-609.
DR   PDB; 1HK3; X-ray; 2.80 A; A=25-609.
DR   PDB; 1HK4; X-ray; 2.40 A; A=25-609.
DR   PDB; 1HK5; X-ray; 2.70 A; A=25-609.
DR   PDB; 1N5U; X-ray; 1.90 A; A=25-609.
DR   PDB; 1O9X; X-ray; 3.20 A; A=25-609.
DR   PDB; 1TF0; X-ray; 2.70 A; A=25-596.
DR   PDB; 1UOR; X-ray; 2.80 A; A=25-609.
DR   PDB; 1YSX; NMR; -; A=409-609.
DR   PDB; 2BX8; X-ray; 2.70 A; A/B=25-609.
DR   PDB; 2BXA; X-ray; 2.35 A; A/B=25-609.
DR   PDB; 2BXB; X-ray; 3.20 A; A/B=25-609.
DR   PDB; 2BXC; X-ray; 3.10 A; A/B=25-609.
DR   PDB; 2BXD; X-ray; 3.05 A; A/B=25-609.
DR   PDB; 2BXE; X-ray; 2.95 A; A/B=25-609.
DR   PDB; 2BXF; X-ray; 2.95 A; A/B=25-609.
DR   PDB; 2BXG; X-ray; 2.70 A; A/B=25-609.
DR   PDB; 2BXH; X-ray; 2.25 A; A/B=25-609.
DR   PDB; 2BXI; X-ray; 2.50 A; A=25-609.
DR   PDB; 2BXK; X-ray; 2.40 A; A=25-609.
DR   PDB; 2BXL; X-ray; 2.60 A; A=25-609.
DR   PDB; 2BXM; X-ray; 2.50 A; A=25-609.
DR   PDB; 2BXN; X-ray; 2.65 A; A=25-609.
DR   PDB; 2BXO; X-ray; 2.60 A; A=25-609.
DR   PDB; 2BXP; X-ray; 2.30 A; A=25-609.
DR   PDB; 2BXQ; X-ray; 2.60 A; A=25-609.
DR   PDB; 2ESG; X-ray; -; C=25-609.
DR   PDB; 2I2Z; X-ray; 2.70 A; A=25-609.
DR   PDB; 2I30; X-ray; 2.90 A; A=25-609.
DR   PDB; 2N0X; NMR; -; A=432-447.
DR   PDB; 2VDB; X-ray; 2.52 A; A=30-608.
DR   PDB; 2VUE; X-ray; 2.42 A; A/B=25-609.
DR   PDB; 2VUF; X-ray; 3.05 A; A/B=25-609.
DR   PDB; 2XSI; X-ray; 2.70 A; A=25-609.
DR   PDB; 2XVQ; X-ray; 2.90 A; A/B=25-609.
DR   PDB; 2XVU; X-ray; 2.60 A; A/B=25-609.
DR   PDB; 2XVV; X-ray; 2.40 A; A=25-609.
DR   PDB; 2XVW; X-ray; 2.65 A; A=25-609.
DR   PDB; 2XW0; X-ray; 2.40 A; A/B=25-609.
DR   PDB; 2XW1; X-ray; 2.50 A; A/B=25-609.
DR   PDB; 2YDF; X-ray; 2.75 A; A/B=25-609.
DR   PDB; 3A73; X-ray; 2.19 A; A/B=25-609.
DR   PDB; 3B9L; X-ray; 2.60 A; A=25-609.
DR   PDB; 3B9M; X-ray; 2.70 A; A=25-609.
DR   PDB; 3CX9; X-ray; 2.80 A; A=27-608.
DR   PDB; 3JQZ; X-ray; 3.30 A; A/B=25-609.
DR   PDB; 3JRY; X-ray; 2.30 A; A/B=25-609.
DR   PDB; 3LU6; X-ray; 2.70 A; A/B=25-609.
DR   PDB; 3LU7; X-ray; 2.80 A; A/B=25-609.
DR   PDB; 3LU8; X-ray; 2.60 A; A/B=25-609.
DR   PDB; 3SQJ; X-ray; 2.05 A; A/B=27-608.
DR   PDB; 3TDL; X-ray; 2.60 A; A=25-609.
DR   PDB; 3UIV; X-ray; 2.20 A; A/H=25-609.
DR   PDB; 4BKE; X-ray; 2.35 A; A=1-609.
DR   PDB; 4E99; X-ray; 2.30 A; A=25-609.
DR   PDB; 4EMX; X-ray; 2.30 A; A/B=25-609.
DR   PDB; 4G03; X-ray; 2.22 A; A/B=25-609.
DR   PDB; 4G04; X-ray; 2.30 A; A/B=25-609.
DR   PDB; 4HGK; X-ray; 3.04 A; A/B=25-609.
DR   PDB; 4HGM; X-ray; 2.34 A; B=25-609.
DR   PDB; 4IW1; X-ray; 2.56 A; A=25-609.
DR   PDB; 4IW2; X-ray; 2.41 A; A=25-609.
DR   PDB; 4K2C; X-ray; 3.23 A; A/B=25-609.
DR   PDB; 4K71; X-ray; 2.40 A; A/D=25-609.
DR   PDB; 4L8U; X-ray; 2.01 A; A=25-609.
DR   PDB; 4L9K; X-ray; 2.40 A; A/B=25-609.
DR   PDB; 4L9Q; X-ray; 2.70 A; A/B=25-609.
DR   PDB; 4LA0; X-ray; 2.40 A; A/B=25-609.
DR   PDB; 4LB2; X-ray; 2.80 A; A/B=25-609.
DR   PDB; 4LB9; X-ray; 2.70 A; A=25-609.
DR   PDB; 4N0F; X-ray; 3.02 A; D/G/J/M=25-609.
DR   PDB; 4N0U; X-ray; 3.80 A; D=27-609.
DR   PDB; 4S1Y; X-ray; 3.16 A; A=25-609.
DR   PDBsum; 1AO6; -.
DR   PDBsum; 1BJ5; -.
DR   PDBsum; 1BKE; -.
DR   PDBsum; 1BM0; -.
DR   PDBsum; 1E78; -.
DR   PDBsum; 1E7A; -.
DR   PDBsum; 1E7B; -.
DR   PDBsum; 1E7C; -.
DR   PDBsum; 1E7E; -.
DR   PDBsum; 1E7F; -.
DR   PDBsum; 1E7G; -.
DR   PDBsum; 1E7H; -.
DR   PDBsum; 1E7I; -.
DR   PDBsum; 1GNI; -.
DR   PDBsum; 1GNJ; -.
DR   PDBsum; 1H9Z; -.
DR   PDBsum; 1HA2; -.
DR   PDBsum; 1HK1; -.
DR   PDBsum; 1HK2; -.
DR   PDBsum; 1HK3; -.
DR   PDBsum; 1HK4; -.
DR   PDBsum; 1HK5; -.
DR   PDBsum; 1N5U; -.
DR   PDBsum; 1O9X; -.
DR   PDBsum; 1TF0; -.
DR   PDBsum; 1UOR; -.
DR   PDBsum; 1YSX; -.
DR   PDBsum; 2BX8; -.
DR   PDBsum; 2BXA; -.
DR   PDBsum; 2BXB; -.
DR   PDBsum; 2BXC; -.
DR   PDBsum; 2BXD; -.
DR   PDBsum; 2BXE; -.
DR   PDBsum; 2BXF; -.
DR   PDBsum; 2BXG; -.
DR   PDBsum; 2BXH; -.
DR   PDBsum; 2BXI; -.
DR   PDBsum; 2BXK; -.
DR   PDBsum; 2BXL; -.
DR   PDBsum; 2BXM; -.
DR   PDBsum; 2BXN; -.
DR   PDBsum; 2BXO; -.
DR   PDBsum; 2BXP; -.
DR   PDBsum; 2BXQ; -.
DR   PDBsum; 2ESG; -.
DR   PDBsum; 2I2Z; -.
DR   PDBsum; 2I30; -.
DR   PDBsum; 2N0X; -.
DR   PDBsum; 2VDB; -.
DR   PDBsum; 2VUE; -.
DR   PDBsum; 2VUF; -.
DR   PDBsum; 2XSI; -.
DR   PDBsum; 2XVQ; -.
DR   PDBsum; 2XVU; -.
DR   PDBsum; 2XVV; -.
DR   PDBsum; 2XVW; -.
DR   PDBsum; 2XW0; -.
DR   PDBsum; 2XW1; -.
DR   PDBsum; 2YDF; -.
DR   PDBsum; 3A73; -.
DR   PDBsum; 3B9L; -.
DR   PDBsum; 3B9M; -.
DR   PDBsum; 3CX9; -.
DR   PDBsum; 3JQZ; -.
DR   PDBsum; 3JRY; -.
DR   PDBsum; 3LU6; -.
DR   PDBsum; 3LU7; -.
DR   PDBsum; 3LU8; -.
DR   PDBsum; 3SQJ; -.
DR   PDBsum; 3TDL; -.
DR   PDBsum; 3UIV; -.
DR   PDBsum; 4BKE; -.
DR   PDBsum; 4E99; -.
DR   PDBsum; 4EMX; -.
DR   PDBsum; 4G03; -.
DR   PDBsum; 4G04; -.
DR   PDBsum; 4HGK; -.
DR   PDBsum; 4HGM; -.
DR   PDBsum; 4IW1; -.
DR   PDBsum; 4IW2; -.
DR   PDBsum; 4K2C; -.
DR   PDBsum; 4K71; -.
DR   PDBsum; 4L8U; -.
DR   PDBsum; 4L9K; -.
DR   PDBsum; 4L9Q; -.
DR   PDBsum; 4LA0; -.
DR   PDBsum; 4LB2; -.
DR   PDBsum; 4LB9; -.
DR   PDBsum; 4N0F; -.
DR   PDBsum; 4N0U; -.
DR   PDBsum; 4S1Y; -.
DR   DisProt; DP00515; -.
DR   ProteinModelPortal; P02768; -.
DR   SMR; P02768; 26-608.
DR   BioGrid; 106715; 170.
DR   DIP; DIP-29902N; -.
DR   IntAct; P02768; 170.
DR   MINT; MINT-3004222; -.
DR   STRING; 9606.ENSP00000295897; -.
DR   BindingDB; P02768; -.
DR   ChEMBL; CHEMBL3253; -.
DR   DrugBank; DB05812; Abiraterone.
DR   DrugBank; DB01418; Acenocoumarol.
DR   DrugBank; DB01614; Acepromazine.
DR   DrugBank; DB00945; Acetylsalicylic acid.
DR   DrugBank; DB00459; Acitretin.
DR   DrugBank; DB00802; Alfentanil.
DR   DrugBank; DB00321; Amitriptyline.
DR   DrugBank; DB00415; Ampicillin.
DR   DrugBank; DB00995; Auranofin.
DR   DrugBank; DB01294; Bismuth Subsalicylate.
DR   DrugBank; DB08907; Canagliflozin.
DR   DrugBank; DB01197; Captopril.
DR   DrugBank; DB00456; Cefalotin.
DR   DrugBank; DB01327; Cefazolin.
DR   DrugBank; DB00274; Cefmetazole.
DR   DrugBank; DB01328; Cefonicid.
DR   DrugBank; DB01329; Cefoperazone.
DR   DrugBank; DB00493; Cefotaxime.
DR   DrugBank; DB01330; Cefotetan.
DR   DrugBank; DB00430; Cefpiramide.
DR   DrugBank; DB01212; Ceftriaxone.
DR   DrugBank; DB00482; Celecoxib.
DR   DrugBank; DB00567; Cephalexin.
DR   DrugBank; DB00477; Chlorpromazine.
DR   DrugBank; DB01242; Clomipramine.
DR   DrugBank; DB01068; Clonazepam.
DR   DrugBank; DB01147; Cloxacillin.
DR   DrugBank; DB01189; Desflurane.
DR   DrugBank; DB00829; Diazepam.
DR   DrugBank; DB00586; Diclofenac.
DR   DrugBank; DB00861; Diflunisal.
DR   DrugBank; DB01396; Digitoxin.
DR   DrugBank; DB04855; Dronedarone.
DR   DrugBank; DB00228; Enflurane.
DR   DrugBank; DB08899; Enzalutamide.
DR   DrugBank; DB00530; Erlotinib.
DR   DrugBank; DB00199; Erythromycin.
DR   DrugBank; DB00783; Estradiol.
DR   DrugBank; DB00655; Estrone.
DR   DrugBank; DB04574; Estropipate.
DR   DrugBank; DB00903; Ethacrynic acid.
DR   DrugBank; DB00749; Etodolac.
DR   DrugBank; DB00573; Fenoprofen.
DR   DrugBank; DB00544; Fluorouracil.
DR   DrugBank; DB00472; Fluoxetine.
DR   DrugBank; DB00712; Flurbiprofen.
DR   DrugBank; DB01320; Fosphenytoin.
DR   DrugBank; DB06716; Fospropofol.
DR   DrugBank; DB00695; Furosemide.
DR   DrugBank; DB00743; Gadobenate Dimeglumine.
DR   DrugBank; DB06705; Gadofosveset trisodium.
DR   DrugBank; DB01044; Gatifloxacin.
DR   DrugBank; DB00317; Gefitinib.
DR   DrugBank; DB01120; Gliclazide.
DR   DrugBank; DB01016; Glyburide.
DR   DrugBank; DB01159; Halothane.
DR   DrugBank; DB00070; Hyaluronidase.
DR   DrugBank; DB06205; Hyaluronidase (Human Recombinant).
DR   DrugBank; DB01050; Ibuprofen.
DR   DrugBank; DB00619; Imatinib.
DR   DrugBank; DB00328; Indomethacin.
DR   DrugBank; DB01307; Insulin Detemir.
DR   DrugBank; DB04711; Iodipamide.
DR   DrugBank; DB00762; Irinotecan.
DR   DrugBank; DB00753; Isoflurane.
DR   DrugBank; DB08820; Ivacaftor.
DR   DrugBank; DB01587; Ketazolam.
DR   DrugBank; DB01009; Ketoprofen.
DR   DrugBank; DB00451; Levothyroxine.
DR   DrugBank; DB00279; Liothyronine.
DR   DrugBank; DB01583; Liotrix.
DR   DrugBank; DB00678; Losartan.
DR   DrugBank; DB08932; MACITENTAN.
DR   DrugBank; DB01397; Magnesium salicylate.
DR   DrugBank; DB00931; Methacycline.
DR   DrugBank; DB00563; Methotrexate.
DR   DrugBank; DB06710; Methyltestosterone.
DR   DrugBank; DB08893; Mirabegron.
DR   DrugBank; DB00688; Mycophenolate mofetil.
DR   DrugBank; DB01183; Naloxone.
DR   DrugBank; DB00788; Naproxen.
DR   DrugBank; DB00731; Nateglinide.
DR   DrugBank; DB00717; Norethindrone.
DR   DrugBank; DB00540; Nortriptyline.
DR   DrugBank; DB00334; Olanzapine.
DR   DrugBank; DB00776; Oxcarbazepine.
DR   DrugBank; DB00454; Pethidine.
DR   DrugBank; DB00946; Phenprocoumon.
DR   DrugBank; DB00252; Phenytoin.
DR   DrugBank; DB01621; Pipotiazine.
DR   DrugBank; DB00554; Piroxicam.
DR   DrugBank; DB08860; Pitavastatin.
DR   DrugBank; DB06209; Prasugrel.
DR   DrugBank; DB00635; Prednisone.
DR   DrugBank; DB01032; Probenecid.
DR   DrugBank; DB00818; Propofol.
DR   DrugBank; DB00912; Repaglinide.
DR   DrugBank; DB01045; Rifampicin.
DR   DrugBank; DB00412; Rosiglitazone.
DR   DrugBank; DB01098; Rosuvastatin.
DR   DrugBank; DB06201; Rufinamide.
DR   DrugBank; DB00936; Salicylic acid.
DR   DrugBank; DB01232; Saquinavir.
DR   DrugBank; DB01236; Sevoflurane.
DR   DrugBank; DB06290; Simeprevir.
DR   DrugBank; DB00815; Sodium lauryl sulfate.
DR   DrugBank; DB00364; Sucralfate.
DR   DrugBank; DB01581; Sulfamerazine.
DR   DrugBank; DB01582; Sulfamethazine.
DR   DrugBank; DB00576; Sulfamethizole.
DR   DrugBank; DB01015; Sulfamethoxazole.
DR   DrugBank; DB00605; Sulindac.
DR   DrugBank; DB00864; Tacrolimus.
DR   DrugBank; DB05521; Telaprevir.
DR   DrugBank; DB00624; Testosterone.
DR   DrugBank; DB00759; Tetracycline.
DR   DrugBank; DB01622; Thioproperazine.
DR   DrugBank; DB01623; Thiothixene.
DR   DrugBank; DB01056; Tocainide.
DR   DrugBank; DB08895; Tofacitinib.
DR   DrugBank; DB00177; Valsartan.
DR   DrugBank; DB00512; Vancomycin.
DR   DrugBank; DB05294; Vandetanib.
DR   DrugBank; DB08881; Vemurafenib.
DR   DrugBank; DB08828; Vismodegib.
DR   DrugBank; DB00682; Warfarin.
DR   DrugBank; DB00137; Xanthophyll.
DR   DrugBank; DB00495; Zidovudine.
DR   Allergome; 763; Hom s HSA.
DR   iPTMnet; P02768; -.
DR   PhosphoSite; P02768; -.
DR   SwissPalm; P02768; -.
DR   UniCarbKB; P02768; -.
DR   BioMuta; ALB; -.
DR   DMDM; 113576; -.
DR   DOSAC-COBS-2DPAGE; P02768; -.
DR   OGP; P02768; -.
DR   REPRODUCTION-2DPAGE; IPI00384697; -.
DR   REPRODUCTION-2DPAGE; IPI00745872; -.
DR   REPRODUCTION-2DPAGE; P02768; -.
DR   SWISS-2DPAGE; P02768; -.
DR   UCD-2DPAGE; P02768; -.
DR   MaxQB; P02768; -.
DR   PaxDb; P02768; -.
DR   PRIDE; P02768; -.
DR   DNASU; 213; -.
DR   Ensembl; ENST00000295897; ENSP00000295897; ENSG00000163631. [P02768-1]
DR   Ensembl; ENST00000621085; ENSP00000483421; ENSG00000163631. [P02768-3]
DR   GeneID; 213; -.
DR   KEGG; hsa:213; -.
DR   UCSC; uc003hgs.4; human. [P02768-1]
DR   CTD; 213; -.
DR   GeneCards; ALB; -.
DR   HGNC; HGNC:399; ALB.
DR   HPA; CAB006262; -.
DR   HPA; HPA031024; -.
DR   HPA; HPA031025; -.
DR   MalaCards; ALB; -.
DR   MIM; 103600; gene.
DR   MIM; 615999; phenotype.
DR   MIM; 616000; phenotype.
DR   neXtProt; NX_P02768; -.
DR   Orphanet; 86816; Congenital analbuminemia.
DR   Orphanet; 276271; Familial dysalbuminemic hyperthyroxinemia.
DR   PharmGKB; PA24690; -.
DR   eggNOG; ENOG410IIRZ; Eukaryota.
DR   eggNOG; ENOG410Z40H; LUCA.
DR   GeneTree; ENSGT00390000000113; -.
DR   HOGENOM; HOG000293137; -.
DR   HOVERGEN; HBG004207; -.
DR   InParanoid; P02768; -.
DR   KO; K16141; -.
DR   OMA; EPERNEC; -.
DR   OrthoDB; EOG7S4X5C; -.
DR   PhylomeDB; P02768; -.
DR   TreeFam; TF335561; -.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   Reactome; R-HSA-159418; Recycling of bile acids and salts.
DR   Reactome; R-HSA-194223; HDL-mediated lipid transport.
DR   Reactome; R-HSA-2168880; Scavenging of heme from plasma.
DR   Reactome; R-HSA-5619058; Defective SLCO1B3 causes hyperbilirubinemia, Rotor type (HBLRR).
DR   Reactome; R-HSA-5619110; Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR).
DR   Reactome; R-HSA-879518; Transport of organic anions.
DR   ChiTaRS; ALB; human.
DR   EvolutionaryTrace; P02768; -.
DR   GeneWiki; Serum_albumin; -.
DR   GenomeRNAi; 213; -.
DR   NextBio; 20804896; -.
DR   PMAP-CutDB; P02768; -.
DR   PRO; PR:P02768; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   Bgee; P02768; -.
DR   ExpressionAtlas; P02768; baseline and differential.
DR   Genevisible; P02768; HS.
DR   GO; GO:0005604; C:basement membrane; IEA:Ensembl.
DR   GO; GO:0072562; C:blood microparticle; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; NAS:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0043209; C:myelin sheath; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0031093; C:platelet alpha granule lumen; TAS:Reactome.
DR   GO; GO:0043234; C:protein complex; IDA:UniProtKB.
DR   GO; GO:0016209; F:antioxidant activity; NAS:UniProtKB.
DR   GO; GO:0051087; F:chaperone binding; IPI:BHF-UCL.
DR   GO; GO:0005507; F:copper ion binding; NAS:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0008144; F:drug binding; IDA:UniProtKB.
DR   GO; GO:0005504; F:fatty acid binding; IDA:UniProtKB.
DR   GO; GO:0030170; F:pyridoxal phosphate binding; IDA:UniProtKB.
DR   GO; GO:0015643; F:toxic substance binding; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:Ensembl.
DR   GO; GO:0015721; P:bile acid and bile salt transport; TAS:Reactome.
DR   GO; GO:0008206; P:bile acid metabolic process; TAS:Reactome.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0098869; P:cellular oxidant detoxification; NAS:GOC.
DR   GO; GO:0009267; P:cellular response to starvation; IDA:UniProtKB.
DR   GO; GO:0019836; P:hemolysis by symbiont of host erythrocytes; IDA:UniProtKB.
DR   GO; GO:0042157; P:lipoprotein metabolic process; TAS:Reactome.
DR   GO; GO:0051659; P:maintenance of mitochondrion location; IDA:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0043069; P:negative regulation of programmed cell death; NAS:UniProtKB.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0002576; P:platelet degranulation; TAS:Reactome.
DR   GO; GO:0046010; P:positive regulation of circadian sleep/wake cycle, non-REM sleep; IEA:Ensembl.
DR   GO; GO:0006898; P:receptor-mediated endocytosis; TAS:Reactome.
DR   GO; GO:0046689; P:response to mercury ion; IEA:Ensembl.
DR   GO; GO:0007584; P:response to nutrient; IEA:Ensembl.
DR   GO; GO:0010033; P:response to organic substance; IEA:Ensembl.
DR   GO; GO:0070541; P:response to platinum ion; IEA:Ensembl.
DR   GO; GO:0001895; P:retina homeostasis; IEP:UniProtKB.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   GO; GO:0043252; P:sodium-independent organic anion transport; TAS:Reactome.
DR   GO; GO:0055085; P:transmembrane transport; TAS:Reactome.
DR   GO; GO:0006810; P:transport; TAS:UniProtKB.
DR   InterPro; IPR000264; ALB/AFP/VDB.
DR   InterPro; IPR020858; Serum_albumin-like.
DR   InterPro; IPR021177; Serum_albumin/AFP/Afamin.
DR   InterPro; IPR020857; Serum_albumin_CS.
DR   InterPro; IPR014760; Serum_albumin_N.
DR   Pfam; PF00273; Serum_albumin; 3.
DR   PIRSF; PIRSF002520; Serum_albumin_subgroup; 1.
DR   PRINTS; PR00802; SERUMALBUMIN.
DR   SMART; SM00103; ALBUMIN; 3.
DR   SUPFAM; SSF48552; SSF48552; 3.
DR   PROSITE; PS00212; ALBUMIN_1; 3.
DR   PROSITE; PS51438; ALBUMIN_2; 3.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing;
KW   Cleavage on pair of basic residues; Complete proteome; Copper;
KW   Direct protein sequencing; Disease mutation; Disulfide bond;
KW   Glycation; Glycoprotein; Lipid-binding; Metal-binding; Phosphoprotein;
KW   Polymorphism; Reference proteome; Repeat; Secreted; Signal; Zinc.
FT   SIGNAL        1     18
FT   PROPEP       19     24
FT                                /FTId=PRO_0000001067.
FT   CHAIN        25    609       Serum albumin.
FT                                /FTId=PRO_0000001068.
FT   DOMAIN       19    210       Albumin 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00769}.
FT   DOMAIN      211    403       Albumin 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00769}.
FT   DOMAIN      404    601       Albumin 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00769}.
FT   METAL        27     27       Copper. {ECO:0000250}.
FT   METAL        91     91       Zinc.
FT   METAL       123    123       Zinc.
FT   METAL       271    271       Zinc.
FT   METAL       273    273       Zinc.
FT   BINDING     264    264       Bilirubin.
FT   SITE         28     28       Not glycated.
FT   SITE         44     44       Not glycated.
FT   SITE         65     65       Not glycated.
FT   SITE         88     88       Not glycated.
FT   SITE         97     97       Not glycated.
FT   SITE        117    117       Not glycated.
FT   SITE        130    130       Not glycated.
FT   SITE        160    160       Not glycated.
FT   SITE        183    183       Not glycated.
FT   SITE        198    198       Not glycated.
FT   SITE        205    205       Not glycated.
FT   SITE        214    214       Not glycated.
FT   SITE        219    219       Not glycated.
FT   SITE        223    223       Aspirin-acetylated lysine.
FT   SITE        229    229       Not glycated.
FT   SITE        236    236       Not glycated.
FT   SITE        264    264       Not glycated.
FT   SITE        286    286       Not glycated.
FT   SITE        298    298       Not glycated.
FT   SITE        310    310       Not glycated.
FT   SITE        383    383       Not glycated.
FT   SITE        396    396       Not glycated.
FT   SITE        413    413       Not glycated.
FT   SITE        426    426       Not glycated.
FT   SITE        438    438       Not glycated.
FT   SITE        456    456       Not glycated.
FT   SITE        460    460       Not glycated.
FT   SITE        490    490       Not glycated.
FT   SITE        499    499       Not glycated.
FT   SITE        524    524       Not glycated.
FT   SITE        543    543       Not glycated.
FT   SITE        548    548       Not glycated.
FT   SITE        562    562       Not glycated.
FT   SITE        565    565       Not glycated.
FT   SITE        581    581       Not glycated.
FT   SITE        584    584       Not glycated.
FT   SITE        588    588       Not glycated.
FT   SITE        598    598       Not glycated.
FT   MOD_RES      29     29       Phosphoserine; by FAM20C.
FT                                {ECO:0000269|PubMed:26091039}.
FT   MOD_RES      82     82       Phosphoserine; by FAM20C.
FT                                {ECO:0000244|PubMed:18318008,
FT                                ECO:0000244|PubMed:24275569,
FT                                ECO:0000269|PubMed:26091039}.
FT   MOD_RES      89     89       Phosphoserine; by FAM20C.
FT                                {ECO:0000244|PubMed:24275569,
FT                                ECO:0000269|PubMed:26091039}.
FT   MOD_RES     107    107       Phosphothreonine; by FAM20C.
FT                                {ECO:0000269|PubMed:26091039}.
FT   MOD_RES     229    229       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:P07724}.
FT   MOD_RES     297    297       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P07724}.
FT   MOD_RES     443    443       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     444    444       Phosphothreonine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     446    446       Phosphothreonine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     460    460       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:P07724}.
FT   MOD_RES     513    513       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     543    543       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:P07724}.
FT   MOD_RES     588    588       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:P07724}.
FT   CARBOHYD     36     36       N-linked (Glc) (glycation).
FT                                {ECO:0000305}.
FT   CARBOHYD     75     75       N-linked (Glc) (glycation); in vitro.
FT   CARBOHYD    161    161       N-linked (Glc) (glycation); in vitro.
FT   CARBOHYD    186    186       N-linked (Glc) (glycation); in vitro.
FT   CARBOHYD    223    223       N-linked (Glc) (glycation); in vitro.
FT   CARBOHYD    249    249       N-linked (Glc) (glycation); in vitro.
FT   CARBOHYD    257    257       N-linked (Glc) (glycation).
FT                                {ECO:0000305}.
FT   CARBOHYD    300    300       N-linked (Glc) (glycation); in vitro.
FT   CARBOHYD    305    305       N-linked (Glc) (glycation).
FT   CARBOHYD    337    337       N-linked (Glc) (glycation); in vitro.
FT   CARBOHYD    341    341       N-linked (Glc) (glycation).
FT                                {ECO:0000305}.
FT   CARBOHYD    342    342       N-linked (GlcNAc...); in variant Redhill.
FT                                /FTId=CAR_000226.
FT   CARBOHYD    347    347       N-linked (Glc) (glycation); in vitro.
FT   CARBOHYD    375    375       N-linked (Glc) (glycation).
FT                                {ECO:0000305}.
FT   CARBOHYD    402    402       N-linked (Glc) (glycation); in vitro.
FT   CARBOHYD    437    437       N-linked (Glc) (glycation); in vitro.
FT   CARBOHYD    463    463       N-linked (Glc) (glycation).
FT   CARBOHYD    468    468       N-linked (Glc) (glycation); in vitro.
FT   CARBOHYD    518    518       N-linked (GlcNAc...); in variant
FT                                Casebrook.
FT                                /FTId=CAR_000069.
FT   CARBOHYD    549    549       N-linked (Glc) (glycation).
FT   CARBOHYD    558    558       N-linked (Glc) (glycation).
FT                                {ECO:0000305}.
FT   CARBOHYD    560    560       N-linked (Glc) (glycation); in vitro.
FT   CARBOHYD    569    569       N-linked (Glc) (glycation); in vitro.
FT   CARBOHYD    597    597       N-linked (Glc) (glycation); in vitro.
FT   DISULFID     77     86       {ECO:0000255|PROSITE-ProRule:PRU00769,
FT                                ECO:0000269|Ref.28}.
FT   DISULFID     99    115       {ECO:0000255|PROSITE-ProRule:PRU00769,
FT                                ECO:0000269|Ref.28}.
FT   DISULFID    114    125       {ECO:0000255|PROSITE-ProRule:PRU00769,
FT                                ECO:0000269|Ref.28}.
FT   DISULFID    148    193       {ECO:0000255|PROSITE-ProRule:PRU00769,
FT                                ECO:0000269|Ref.28}.
FT   DISULFID    192    201       {ECO:0000255|PROSITE-ProRule:PRU00769,
FT                                ECO:0000269|Ref.28}.
FT   DISULFID    224    270       {ECO:0000255|PROSITE-ProRule:PRU00769,
FT                                ECO:0000269|Ref.28}.
FT   DISULFID    269    277       {ECO:0000255|PROSITE-ProRule:PRU00769,
FT                                ECO:0000269|Ref.28}.
FT   DISULFID    289    303       {ECO:0000255|PROSITE-ProRule:PRU00769,
FT                                ECO:0000269|Ref.28}.
FT   DISULFID    302    313       {ECO:0000255|PROSITE-ProRule:PRU00769,
FT                                ECO:0000269|Ref.28}.
FT   DISULFID    340    385       {ECO:0000255|PROSITE-ProRule:PRU00769,
FT                                ECO:0000269|Ref.28}.
FT   DISULFID    384    393       {ECO:0000255|PROSITE-ProRule:PRU00769,
FT                                ECO:0000269|Ref.28}.
FT   DISULFID    416    462       {ECO:0000255|PROSITE-ProRule:PRU00769,
FT                                ECO:0000269|Ref.28}.
FT   DISULFID    461    472       {ECO:0000255|PROSITE-ProRule:PRU00769,
FT                                ECO:0000269|Ref.28}.
FT   DISULFID    485    501       {ECO:0000255|PROSITE-ProRule:PRU00769,
FT                                ECO:0000269|Ref.28}.
FT   DISULFID    500    511       {ECO:0000255|PROSITE-ProRule:PRU00769,
FT                                ECO:0000269|Ref.28}.
FT   DISULFID    538    583       {ECO:0000255|PROSITE-ProRule:PRU00769,
FT                                ECO:0000269|Ref.28}.
FT   DISULFID    582    591       {ECO:0000255|PROSITE-ProRule:PRU00769,
FT                                ECO:0000269|Ref.28}.
FT   VAR_SEQ      43    234       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|Ref.9}.
FT                                /FTId=VSP_021275.
FT   VAR_SEQ     164    376       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_057389.
FT   VARIANT      23     23       R -> C (in Redhill/Malmo-I/Tradate;
FT                                associated with T-344 in Redhill).
FT                                {ECO:0000269|PubMed:1518850}.
FT                                /FTId=VAR_000499.
FT   VARIANT      23     23       R -> H (in Fukuoka-2/Lille/Taipei/Varese/
FT                                Komagome-3). {ECO:0000269|PubMed:1946412,
FT                                ECO:0000269|PubMed:2247440,
FT                                ECO:0000269|PubMed:2911589}.
FT                                /FTId=VAR_000500.
FT   VARIANT      24     24       R -> L (in Jaffna).
FT                                /FTId=VAR_000501.
FT   VARIANT      24     24       R -> P (in Takefu/Honolulu-1).
FT                                {ECO:0000269|PubMed:2404284}.
FT                                /FTId=VAR_000502.
FT   VARIANT      24     24       R -> Q (in Christchurch/Honolulu-2).
FT                                {ECO:0000269|PubMed:2404284,
FT                                ECO:0000269|PubMed:2762316,
FT                                ECO:0000269|PubMed:2911589}.
FT                                /FTId=VAR_000503.
FT   VARIANT      25     25       D -> V (in Bleinheim/Iowa city-2).
FT                                {ECO:0000269|PubMed:1946412}.
FT                                /FTId=VAR_000504.
FT   VARIANT      27     27       H -> Q (in Nagasaki-3).
FT                                /FTId=VAR_000505.
FT   VARIANT      27     27       H -> Y (in Larino).
FT                                {ECO:0000269|PubMed:17974005,
FT                                ECO:0000269|PubMed:8022807}.
FT                                /FTId=VAR_000506.
FT   VARIANT      73     73       F -> Y. {ECO:0000269|PubMed:11680902}.
FT                                /FTId=VAR_010657.
FT   VARIANT      84     84       E -> K (in Torino).
FT                                {ECO:0000269|PubMed:2247440}.
FT                                /FTId=VAR_000507.
FT   VARIANT      87     87       D -> N (in Malmo-95/Dalakarlia).
FT                                {ECO:0000269|PubMed:1518850}.
FT                                /FTId=VAR_000508.
FT   VARIANT      90     90       L -> P (in DH).
FT                                {ECO:0000269|PubMed:9589637}.
FT                                /FTId=VAR_013011.
FT   VARIANT     106    106       E -> K (in Vibo Valentia).
FT                                {ECO:0000269|PubMed:2247440}.
FT                                /FTId=VAR_000509.
FT   VARIANT     121    121       E -> G. {ECO:0000269|PubMed:6275391}.
FT                                /FTId=VAR_014290.
FT   VARIANT     138    138       R -> G (in Yanomama-2).
FT                                /FTId=VAR_000510.
FT   VARIANT     143    143       E -> K (in Nagoya).
FT                                {ECO:0000269|PubMed:2404284}.
FT                                /FTId=VAR_000511.
FT   VARIANT     146    146       V -> E (in Tregasio).
FT                                /FTId=VAR_013012.
FT   VARIANT     152    152       H -> R (in Komagome-2).
FT                                {ECO:0000269|PubMed:1946412}.
FT                                /FTId=VAR_000512.
FT   VARIANT     201    201       C -> F (in Hawkes bay).
FT                                {ECO:0000269|PubMed:8347685}.
FT                                /FTId=VAR_000513.
FT   VARIANT     215    215       A -> T (in dbSNP:rs3210154).
FT                                /FTId=VAR_014291.
FT   VARIANT     215    215       A -> V (in dbSNP:rs3204504).
FT                                /FTId=VAR_014292.
FT   VARIANT     220    220       Q -> L (in dbSNP:rs3210163).
FT                                /FTId=VAR_014293.
FT   VARIANT     242    242       R -> H (in DH).
FT                                {ECO:0000269|PubMed:7852505,
FT                                ECO:0000269|PubMed:8048949,
FT                                ECO:0000269|PubMed:9329347}.
FT                                /FTId=VAR_000514.
FT   VARIANT     242    242       R -> P (in DH).
FT                                /FTId=VAR_013013.
FT   VARIANT     249    249       K -> Q (in Tradate-2).
FT                                {ECO:0000269|PubMed:8022807}.
FT                                /FTId=VAR_000515.
FT   VARIANT     264    264       K -> E (in Herborn).
FT                                {ECO:0000269|PubMed:8513793}.
FT                                /FTId=VAR_000516.
FT   VARIANT     292    292       Q -> R (in Malmo-10).
FT                                {ECO:0000269|PubMed:1518850}.
FT                                /FTId=VAR_000517.
FT   VARIANT     293    293       D -> G (in Nagasaki-1).
FT                                {ECO:0000269|PubMed:2762316}.
FT                                /FTId=VAR_000518.
FT   VARIANT     300    300       K -> N (in Caserta).
FT                                {ECO:0000269|PubMed:8022807}.
FT                                /FTId=VAR_000519.
FT   VARIANT     337    337       K -> N (in Canterbury/New Guinea/
FT                                Tagliacozzo/Cuneo/Cooperstown).
FT                                {ECO:0000269|PubMed:2404284,
FT                                ECO:0000269|PubMed:2911589,
FT                                ECO:0000269|PubMed:3828358}.
FT                                /FTId=VAR_000520.
FT   VARIANT     338    338       D -> G (in Bergamo).
FT                                /FTId=VAR_013014.
FT   VARIANT     338    338       D -> V (in Brest).
FT                                /FTId=VAR_013015.
FT   VARIANT     342    342       N -> K (in Malmo-47).
FT                                {ECO:0000269|PubMed:1518850}.
FT                                /FTId=VAR_000521.
FT   VARIANT     344    344       A -> T (in Redhill; associated with C-
FT                                23).
FT                                /FTId=VAR_000522.
FT   VARIANT     345    345       E -> K (in Roma).
FT                                /FTId=VAR_000523.
FT   VARIANT     357    357       E -> K (in Sondrio).
FT                                {ECO:0000269|PubMed:1347703}.
FT                                /FTId=VAR_000524.
FT   VARIANT     378    378       E -> K (in Hiroshima-1).
FT                                {ECO:0000269|PubMed:2762316,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_000525.
FT   VARIANT     382    382       E -> K (in Coari I/Porto Alegre).
FT                                /FTId=VAR_000526.
FT   VARIANT     383    383       K -> N (in Trieste).
FT                                /FTId=VAR_013016.
FT   VARIANT     389    389       D -> H (in Parklands).
FT                                /FTId=VAR_000527.
FT   VARIANT     389    389       D -> V (in Iowa city-1).
FT                                {ECO:0000269|PubMed:1946412}.
FT                                /FTId=VAR_000528.
FT   VARIANT     396    396       K -> E (in Naskapi/Mersin/Komagome-1).
FT                                {ECO:0000269|PubMed:1946412,
FT                                ECO:0000269|PubMed:3474609,
FT                                ECO:0000269|PubMed:3479777}.
FT                                /FTId=VAR_000529.
FT   VARIANT     399    399       D -> N (in Nagasaki-2).
FT                                {ECO:0000269|PubMed:3479777}.
FT                                /FTId=VAR_000530.
FT   VARIANT     400    400       E -> K (in Tochigi).
FT                                {ECO:0000269|PubMed:2762316}.
FT                                /FTId=VAR_000531.
FT   VARIANT     400    400       E -> Q (in Malmo-5).
FT                                {ECO:0000269|PubMed:1518850}.
FT                                /FTId=VAR_000532.
FT   VARIANT     406    406       E -> K (in Hiroshima-2).
FT                                {ECO:0000269|PubMed:2762316}.
FT                                /FTId=VAR_000533.
FT   VARIANT     420    420       E -> K. {ECO:0000269|PubMed:6171778}.
FT                                /FTId=VAR_014294.
FT   VARIANT     434    434       R -> C (in Liprizzi).
FT                                /FTId=VAR_013017.
FT   VARIANT     490    490       K -> E (in dbSNP:rs1063469).
FT                                /FTId=VAR_014295.
FT   VARIANT     503    503       E -> K (in Dublin).
FT                                /FTId=VAR_000534.
FT   VARIANT     518    518       D -> N (in Casebrook).
FT                                {ECO:0000269|PubMed:1859851}.
FT                                /FTId=VAR_000535.
FT   VARIANT     525    525       E -> K (in Manaus-1/Adana/Lambadi/
FT                                Vancouver). {ECO:0000269|PubMed:2404284}.
FT                                /FTId=VAR_000536.
FT   VARIANT     529    529       E -> K (in Ortonovo).
FT                                {ECO:0000269|PubMed:7902134}.
FT                                /FTId=VAR_000537.
FT   VARIANT     557    557       V -> M (in Maddaloni; dbSNP:rs78284052).
FT                                /FTId=VAR_013018.
FT   VARIANT     560    560       K -> E (in Castel di Sangro).
FT                                /FTId=VAR_000538.
FT   VARIANT     565    565       K -> E (in Maku).
FT                                {ECO:0000269|PubMed:3479777}.
FT                                /FTId=VAR_000539.
FT   VARIANT     574    574       D -> A (in Malmo-61).
FT                                {ECO:0000269|PubMed:1518850}.
FT                                /FTId=VAR_000541.
FT   VARIANT     574    574       D -> G (in Mexico).
FT                                {ECO:0000269|PubMed:3474609}.
FT                                /FTId=VAR_000540.
FT   VARIANT     584    584       K -> E (in Church bay).
FT                                /FTId=VAR_013019.
FT   VARIANT     587    587       D -> N (in Fukuoka-1/Paris-2).
FT                                {ECO:0000269|PubMed:1347703,
FT                                ECO:0000269|PubMed:2404284}.
FT                                /FTId=VAR_000542.
FT   VARIANT     589    589       E -> K (in Osaka-1).
FT                                {ECO:0000269|PubMed:2404284}.
FT                                /FTId=VAR_000543.
FT   VARIANT     594    594       E -> K (in Osaka-2/Phnom Phen/albumin B/
FT                                Verona). {ECO:0000269|PubMed:2404284,
FT                                ECO:0000269|PubMed:2762316,
FT                                ECO:0000269|PubMed:2911589}.
FT                                /FTId=VAR_000544.
FT   VARIANT     596    609       GKKLVAASQAALGL -> PTMRIRERK (in Venezia).
FT                                /FTId=VAR_000547.
FT   VARIANT     597    597       K -> E (in Gent/Milano Fast).
FT                                /FTId=VAR_000545.
FT   VARIANT     598    598       K -> N (in Vanves).
FT                                /FTId=VAR_000546.
FT   VARIANT     599    609       LVAASQAALGL -> TCCCKSSCLRLITSHLKASQPTMRIR
FT                                ERK (in Kenitra).
FT                                /FTId=VAR_012981.
FT   CONFLICT     55     55       L -> P (in Ref. 11; CAH18185).
FT                                {ECO:0000305}.
FT   CONFLICT    122    122       R -> S (in Ref. 4; AAF01333).
FT                                {ECO:0000305}.
FT   CONFLICT    155    155       E -> Q (in Ref. 19; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    174    174       Y -> L (in Ref. 24; AA sequence and 25;
FT                                AA sequence). {ECO:0000305}.
FT   CONFLICT    194    194       Q -> E (in Ref. 19; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    327    332       PSLAAD -> MFVLLC (in Ref. 10; AAF71067).
FT                                {ECO:0000305}.
FT   CONFLICT    405    405       V -> A (in Ref. 10; AAF71067).
FT                                {ECO:0000305}.
FT   CONFLICT    409    409       Q -> E (in Ref. 15; AAH14308).
FT                                {ECO:0000305}.
FT   CONFLICT    441    441       Q -> E (in Ref. 2; CAA23753).
FT                                {ECO:0000305}.
FT   CONFLICT    466    466       E -> G (in Ref. 4; AAF01333).
FT                                {ECO:0000305}.
FT   CONFLICT    488    489       HE -> EH (in Ref. 19; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    490    490       K -> R (in Ref. 11; CAH18185).
FT                                {ECO:0000305}.
FT   CONFLICT    525    525       E -> Q (in Ref. 19; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    551    551       T -> A (in Ref. 11; CAH18185).
FT                                {ECO:0000305}.
FT   CONFLICT    560    560       K -> R (in Ref. 11; CAH18185).
FT                                {ECO:0000305}.
FT   CONFLICT    604    604       Q -> R (in Ref. 5; AAN17825).
FT                                {ECO:0000305}.
FT   HELIX        30     38       {ECO:0000244|PDB:1N5U}.
FT   HELIX        40     54       {ECO:0000244|PDB:1N5U}.
FT   STRAND       55     58       {ECO:0000244|PDB:2BXH}.
FT   HELIX        60     79       {ECO:0000244|PDB:1N5U}.
FT   TURN         84     87       {ECO:0000244|PDB:1N5U}.
FT   HELIX        90     99       {ECO:0000244|PDB:1N5U}.
FT   TURN        101    103       {ECO:0000244|PDB:2BXH}.
FT   HELIX       104    108       {ECO:0000244|PDB:1N5U}.
FT   HELIX       109    116       {ECO:0000244|PDB:1N5U}.
FT   HELIX       119    128       {ECO:0000244|PDB:1N5U}.
FT   STRAND      130    132       {ECO:0000244|PDB:4N0F}.
FT   HELIX       144    153       {ECO:0000244|PDB:1N5U}.
FT   HELIX       155    169       {ECO:0000244|PDB:1N5U}.
FT   STRAND      170    173       {ECO:0000244|PDB:3TDL}.
FT   HELIX       175    192       {ECO:0000244|PDB:1N5U}.
FT   STRAND      195    197       {ECO:0000244|PDB:4L8U}.
FT   HELIX       198    230       {ECO:0000244|PDB:1N5U}.
FT   HELIX       232    246       {ECO:0000244|PDB:1N5U}.
FT   STRAND      248    250       {ECO:0000244|PDB:1BJ5}.
FT   HELIX       252    271       {ECO:0000244|PDB:1N5U}.
FT   HELIX       274    289       {ECO:0000244|PDB:1N5U}.
FT   HELIX       290    294       {ECO:0000244|PDB:1N5U}.
FT   HELIX       297    299       {ECO:0000244|PDB:1GNI}.
FT   HELIX       300    303       {ECO:0000244|PDB:1N5U}.
FT   HELIX       307    315       {ECO:0000244|PDB:1N5U}.
FT   HELIX       330    333       {ECO:0000244|PDB:1N5U}.
FT   STRAND      336    338       {ECO:0000244|PDB:2BXP}.
FT   HELIX       339    345       {ECO:0000244|PDB:1N5U}.
FT   HELIX       347    360       {ECO:0000244|PDB:1N5U}.
FT   STRAND      363    365       {ECO:0000244|PDB:4N0F}.
FT   HELIX       367    384       {ECO:0000244|PDB:1N5U}.
FT   STRAND      387    389       {ECO:0000244|PDB:1N5U}.
FT   HELIX       390    394       {ECO:0000244|PDB:1N5U}.
FT   HELIX       397    422       {ECO:0000244|PDB:1N5U}.
FT   HELIX       424    438       {ECO:0000244|PDB:1N5U}.
FT   STRAND      440    442       {ECO:0000244|PDB:2BXC}.
FT   HELIX       444    461       {ECO:0000244|PDB:1N5U}.
FT   STRAND      462    464       {ECO:0000244|PDB:2BXH}.
FT   HELIX       466    488       {ECO:0000244|PDB:1N5U}.
FT   STRAND      489    491       {ECO:0000244|PDB:4G03}.
FT   HELIX       495    502       {ECO:0000244|PDB:1N5U}.
FT   TURN        505    507       {ECO:0000244|PDB:1N5U}.
FT   HELIX       508    513       {ECO:0000244|PDB:1N5U}.
FT   STRAND      519    521       {ECO:0000244|PDB:4E99}.
FT   HELIX       529    531       {ECO:0000244|PDB:1N5U}.
FT   HELIX       535    538       {ECO:0000244|PDB:1N5U}.
FT   HELIX       542    559       {ECO:0000244|PDB:1N5U}.
FT   STRAND      561    563       {ECO:0000244|PDB:1E7A}.
FT   HELIX       565    583       {ECO:0000244|PDB:1N5U}.
FT   STRAND      584    587       {ECO:0000244|PDB:1N5U}.
FT   HELIX       588    590       {ECO:0000244|PDB:2BXG}.
FT   TURN        591    593       {ECO:0000244|PDB:1N5U}.
FT   HELIX       594    606       {ECO:0000244|PDB:1N5U}.
SQ   SEQUENCE   609 AA;  69367 MW;  F88FF61DD242E818 CRC64;
     MKWVTFISLL FLFSSAYSRG VFRRDAHKSE VAHRFKDLGE ENFKALVLIA FAQYLQQCPF
     EDHVKLVNEV TEFAKTCVAD ESAENCDKSL HTLFGDKLCT VATLRETYGE MADCCAKQEP
     ERNECFLQHK DDNPNLPRLV RPEVDVMCTA FHDNEETFLK KYLYEIARRH PYFYAPELLF
     FAKRYKAAFT ECCQAADKAA CLLPKLDELR DEGKASSAKQ RLKCASLQKF GERAFKAWAV
     ARLSQRFPKA EFAEVSKLVT DLTKVHTECC HGDLLECADD RADLAKYICE NQDSISSKLK
     ECCEKPLLEK SHCIAEVEND EMPADLPSLA ADFVESKDVC KNYAEAKDVF LGMFLYEYAR
     RHPDYSVVLL LRLAKTYETT LEKCCAAADP HECYAKVFDE FKPLVEEPQN LIKQNCELFE
     QLGEYKFQNA LLVRYTKKVP QVSTPTLVEV SRNLGKVGSK CCKHPEAKRM PCAEDYLSVV
     LNQLCVLHEK TPVSDRVTKC CTESLVNRRP CFSALEVDET YVPKEFNAET FTFHADICTL
     SEKERQIKKQ TALVELVKHK PKATKEQLKA VMDDFAAFVE KCCKADDKET CFAEEGKKLV
     AASQAALGL
//